ࡱ> (  h S k q kosBl[ _+bjbj ΐΐ\))!7!7777;;;8AI!;ykp txxx5@8u<<>>>>>>=ߘ.>701>!7!7xx$S;;;P!7Rx7x<;<;;BRs7"lx ˪U;X-f(i0^ V ll 7Q3X;QQQ>>j5QQQ QQQQQQQQQ) 5:   PHARMACY DATA MANAGEMENT USER MANUAL Version 1.0 September 1997 (Revised December 2008) Department of Veterans Affairs Office of Information & Technology Office of Enterprise Development Revision History XE "Revision History" \b  Each time this manual is updated, the Title Page lists the new revised date and this page describes the changes. If the Revised Pages column lists All, replace the existing manual with the reissued manual. If the Revised Pages column lists individual entries (e.g., 25, 32), either update the existing manual with the Change Pages Document or print the entire new manual. DateRevised PagesPatch NumberDescription12/08 HYPERLINK \l "P131_19a" 19a-19d, HYPERLINK \l "P131_149"149-150PSS*1*139Add ed explanations of DEA special handling code N for Nutritional Supplement. (M. Anthony, PM; G. OConnor, Tech. Writer)08/0855PSS*1*94Added text clarifying administration times and frequency. (S. Templeton, PM; G. OConnor, Tech. Writer)07/07i-iii, 33, 34, 149, 151PSS*1*88- Prompts for injection site in BCMA and Display ON IVP/IVPB TAB IN BCMA added to the PSS MEDICATION ROUTES input template. - Updated index to include BCMA prompts (R. Singer, PM; E. Phelps, Tech. Writer)01/07v, 19a, 53PSS*1*120Added new prompts for warning label source for Consolidated Mail Outpatient Pharmacy (CMOP) and Outpatient Pharmacy Automation Interface (OPAI) to the Pharmacy System Parameters Edit section. Updated formatting on pages iii and 19a. (E. Williamson, PM; S. Krakosky, Tech. Writer)06/0624gPSS*1*92Added Service Code field to Drug Enter/Edit option. (R. Hardy, PM; M. Rentachintala, Tech. Writer)04/06i-iii, 19-19d, 20, 24, 24b, 24e-f, 29PSS*1*90HIPAA NCPDP Global Project. In Drug Enter/Edit section: - Added description of a new code ("E") added to the DEA, SPECIAL HDLG field, as well as a list of DEA, SPECIAL HDLG field effects on ePharmacy Billing. - Added description of the new Dispense As Written DAW CODE field and how it is used in ePharmacy Billing. Updated existing Drug Enter/Edit screen capture examples to include the DAW CODE prompt. - Added new screen capture example: Drug Enter/Edit Dispense As Written (DAW) Code Editing. (S. Spense, PM; M. Newman, Tech. Writer)03/05i vi, 3, 20 - 24f, 29, 53, 58a - 58h, 149-152 PSS*1*87Laser Labels II project. Added Warning Builder option and section. Added Warning Mapping option and section. Added Warning Label and Gender-Specific Warnings prompts to the Drug Enter/Edit option. Added Warning Label Source prompt to the Pharmacy System Parameters Edit option. Updated the Table of Contents and Index to reflect the new options. Cleaned up footers, misspelled words, etc. on many pages. (H. Whitley, PM; L. Woodson, Tech. Writer)01/0555PSS*1*59- Added text about odd schedules and note regarding schedule name of OTHER to Standard Schedule Edit, section 1.15. (S. Templeton, PM, R. Singer, PM, M. Newman, Tech. Writer)10/04i, iii, 3, 58a-b, 153PSS*1*82- Added Send Entire Drug File to External Interface option to menu list. -Added new section for Send Entire Drug File to External Interface option. - Updated the Table of Contents and the Index to reflect the new option.07/03i-iii 3, 19-24d 29-30 58PSS*1*61- Described functionality change for deriving the DEA, SPECIAL HDLG code. - Added description of changes to Drug Enter/Edit option and included the related screen capture, resulting in pages 19-24 being renumbered to pages 19-24d. - Added new Controlled Substances/PKI Reports menu and related reports to the PDM options list, and updated the Table of Contents to reflect this addition. - Noted additional code (F=NON REFILLABLE) for DEA, SPECIAL HDLG field. - Updated screen captures for Lookup into Dispense Drug File option to include CS FEDERAL SCHEDULE field in drug details.04/03i 10-12a,19-23a,36 23b-24,30 150PSS*1*68-Updated the Revision History Page. -Added Non-VA Med messages to the examples in the Enter/Edit Dosages, Drug Enter/Edit, and Edit Orderable Items sections. -Added Non-VA Med examples to the Drug Enter/Edit and Lookup into Dispense Drug File sections. -Updated the index to cover Non-VA Meds.03/03i-ii iii iv 1 3 9-12b 19-23b 31 33-38 55 57-58 97-152 PSS*1*47-Updated the Revision History Pages. -Added Other Language Translation Setup option to the table of contents. -Added appendices on Spanish terms to the TOC. -Added information about PDM now allowing users to enter SIG components in another language. -Added Other Language Translation Setup to the list of options. -Updated Dosage Form File Enter/ Edit section to show the new Other Language options. -Updated Enter/Edit Dosages section to show new Other Language Dosage Name field. -Updated Drug Enter/Edit section to show new Other Language Dosage Name field. -Updated Medication Instruction File Add/Edit section to show Other Language Expansion field. -Updated Medication Route File Enter/Edit section to show new Other Language Expansion field. -Updated Orderable Item Management and Dispense Drug/Orderable Item Maintenance sections to show new Other Language Instructions field. -Updated Standard Schedule Edit section to show Other Language Expansion field. -Added the stand-alone Other Language Translation Setup option. -Updated the index. - Added appendices with Spanish equivalents for common terms, moved appendices after the Glossary, and renumbered pages from Glossary through the Index.10/02i, (ii) iii, (iv) 3, (4) 51-52 52a-52b 53, (54) 55, (56) 57, (58) 104a-104b 109-112PSS*1*55- Updated this Revision History Page. - Changed Table of Contents to include new menu option. - Added new Drug Text File Report option to menu item list. - Updated Drug Text Enter/Edit section to show the new Drug Text File Report option. - Added new section for new menu option Drug Text File Report. Adding this section changed the section numbering for remaining sections in Chapter 1. - Added Appendix B. - Updated the Index.09/01AllPSS*1*38Added this Revision History Page. Added Patch Release changes and Pharmacy Ordering Enhancements (POE) enhancements edits. Updated manual to comply with current documentation standards.09/97Original Release of User Manual Table of Contents XE "Table of Contents" \b   TOC \o "1-3" \h \z  HYPERLINK \l "_Toc95131161" Introduction  PAGEREF _Toc95131161 \h 1  HYPERLINK \l "_Toc95131162" Chapter One Pharmacy Data Management Options  PAGEREF _Toc95131162 \h 3  HYPERLINK \l "_Toc95131163" Dosage Form File Enter/Edit  PAGEREF _Toc95131163 \h 3  HYPERLINK \l "_Toc95131164" 1.1 CMOP Mark/Unmark (Single drug)  PAGEREF _Toc95131164 \h 5  HYPERLINK \l "_Toc95131165" 1.2 Dosages  PAGEREF _Toc95131165 \h 7  HYPERLINK \l "_Toc95131166" 1.2.1 Auto Create Dosages  PAGEREF _Toc95131166 \h 7  HYPERLINK \l "_Toc95131167" 1.2.2 Dosage Form File Enter/Edit  PAGEREF _Toc95131167 \h 9  HYPERLINK \l "_Toc95131168" 1.2.3 Enter/Edit Dosages  PAGEREF _Toc95131168 \h 10  HYPERLINK \l "_Toc95131169" 1.2.4 Most Common Dosages Report  PAGEREF _Toc95131169 \h 13  HYPERLINK \l "_Toc95131170" 1.2.5 Noun/Dosage Form Report  PAGEREF _Toc95131170 \h 15  HYPERLINK \l "_Toc95131171" 1.2.6 Review Dosages Report  PAGEREF _Toc95131171 \h 17  HYPERLINK \l "_Toc95131172" 1.3 Drug Enter/Edit  PAGEREF _Toc95131172 \h 19  HYPERLINK \l "_Toc95131173" 1.4 Drug Interaction Management  PAGEREF _Toc95131173 \h 25  HYPERLINK \l "_Toc95131174" 1.4.1 Enter/Edit Local Drug Interaction  PAGEREF _Toc95131174 \h 25  HYPERLINK \l "_Toc95131175" 1.4.2 Report of Locally Entered Interactions  PAGEREF _Toc95131175 \h 26  HYPERLINK \l "_Toc95131176" 1.5 Electrolyte File (IV)  PAGEREF _Toc95131176 \h 27  HYPERLINK \l "_Toc95131177" 1.6 Lookup into Dispense Drug File  PAGEREF _Toc95131177 \h 29  HYPERLINK \l "_Toc95131178" 1.7 Medication Instruction File Add/Edit  PAGEREF _Toc95131178 \h 31  HYPERLINK \l "_Toc95131179" 1.8 Medication Route File Enter/Edit  PAGEREF _Toc95131179 \h 33  HYPERLINK \l "_Toc95131180" 1.9 Orderable Item Management  PAGEREF _Toc95131180 \h 35  HYPERLINK \l "_Toc95131181" 1.9.1 Edit Orderable Items  PAGEREF _Toc95131181 \h 35  HYPERLINK \l "_Toc95131182" 1.9.2 Dispense Drug/Orderable Item Maintenance  PAGEREF _Toc95131182 \h 37  HYPERLINK \l "_Toc95131183" 1.9.3 Orderable Item/Dosages Report  PAGEREF _Toc95131183 \h 39  HYPERLINK \l "_Toc95131184" 1.9.4 Patient Instructions Report  PAGEREF _Toc95131184 \h 43  HYPERLINK \l "_Toc95131185" 1.10 Orderable Item Report  PAGEREF _Toc95131185 \h 45  HYPERLINK \l "_Toc95131186" 1.11 Formulary Information Report  PAGEREF _Toc95131186 \h 49  HYPERLINK \l "_Toc95131187" 1.12 Drug Text Enter/Edit  PAGEREF _Toc95131187 \h 51  HYPERLINK \l "DrugTextFileReport" 1.13 Drug Text File Report 52a  HYPERLINK \l "_Toc95131189" 1.14 Pharmacy System Parameters Edit  PAGEREF _Toc95131189 \h 53  HYPERLINK \l "_Toc95131190" 1.15 Standard Schedule Edit  PAGEREF _Toc95131190 \h 55  HYPERLINK \l "_Toc95131191" 1.16 Synonym Enter/Edit  PAGEREF _Toc95131191 \h 57  HYPERLINK \l "_Toc95131192" 1.17 Other Language Translation Setup  PAGEREF _Toc95131192 \h 57  HYPERLINK \l "_Toc95131193" 1.18 Controlled Substances/PKI Reports  PAGEREF _Toc95131193 \h 58  HYPERLINK \l "_Toc95131194" 1.19 Send Entire Drug File to External Interface 58 PAGEREF _Toc95131194 \h a  HYPERLINK \l "_Toc95131195" 1.20 Warning Builder 58 PAGEREF _Toc95131195 \h a  HYPERLINK \l "_Toc95131196" 1.21 Warning Mapping 58 PAGEREF _Toc95131196 \h f  HYPERLINK \l "_Toc95131197" Chapter Two Understanding Dosages  PAGEREF _Toc95131197 \h 59  HYPERLINK \l "_Toc95131198" 2.1 Possible Dosages  PAGEREF _Toc95131198 \h 59  HYPERLINK \l "_Toc95131199" 2.2 Local Possible Dosages  PAGEREF _Toc95131199 \h 73  HYPERLINK \l "_Toc95131200" 2.3 Possible Dosages and Local Possible Dosages  PAGEREF _Toc95131200 \h 79  HYPERLINK \l "_Toc95131201" 2.4 Multi-Ingredient Drugs  PAGEREF _Toc95131201 \h 83  HYPERLINK \l "_Toc95131202" Chapter Three Creating the Sig  PAGEREF _Toc95131202 \h 85  HYPERLINK \l "_Toc95131203" 3.1 SIG Formulas  PAGEREF _Toc95131203 \h 89  HYPERLINK \l "_Toc95131204" Glossary  PAGEREF _Toc95131204 \h 97  HYPERLINK \l "_Toc95131205" Appendix A Convertible Dosage Form/Unit Combinations  PAGEREF _Toc95131205 \h 101  HYPERLINK \l "_Toc95131206" Appendix B Original Drug Text File Entries Combinations  PAGEREF _Toc95131206 \h 109  HYPERLINK \l "_Toc95131207" Appendix C Administration Schedules - Spanish Translations  PAGEREF _Toc95131207 \h 111  HYPERLINK \l "_Toc95131208" Appendix D Dosage Forms - Spanish Translations  PAGEREF _Toc95131208 \h 117  HYPERLINK \l "_Toc95131209" Appendix E Local Possible Dosages - Spanish Translations  PAGEREF _Toc95131209 \h 125  HYPERLINK \l "_Toc95131210" Appendix F Medication Instructions - Spanish Translations  PAGEREF _Toc95131210 \h 131  HYPERLINK \l "_Toc95131211" Appendix G Medication Routes Spanish Translations  PAGEREF _Toc95131211 \h 145  HYPERLINK \l "_Toc95131212" Index  PAGEREF _Toc95131212 \h 149  Introduction XE "Introduction" \b  Pharmacy Data Management (PDM) provides tools for managing Pharmacy data. It includes tools for creating Pharmacy Orderable Items and maintaining files necessary for the Computerized Patient Record System (CPRS). PDM consolidates tools for managing the various Pharmacy software products. It provides Pharmacy Supervisors, in one location, the capability to enter and edit data from the local DRUG file (#50) for all Pharmacy related packages. PDM now allows users to enter medication instruction components (e.g., dosage, noun, verb, expansion) in a language other than English. However, at this time, the Patient Medication Information Sheets only allow patient data to be in English or Spanish. The PDM user manual is designed to acquaint the user with the various PDM options and offer specific guidance on the maintenance and use of the PDM package. Documentation concerning the PDM package, including any subsequent change pages affecting this documentation, can be found at the VistA documentation library on the Internet at HYPERLINK "http://www.va.gov/vdl"http://www.va.gov/vdl. Notations that will be used consistently throughout this PDM user manual are outlined below. Menu options XE "Menu Options" \b  will be italicized. Example: The Drug Enter/Edit option permits you to enter or edit a drug. Screen prompts XE "Screen prompts" \b  will be denoted with quotation marks around them. Example: the select drug prompt will display next. Responses in bold face indicate user input. Example: DRUG INTERACTION SEVERITY: CRITICAL Text centered between bent parentheses represents a keyboard key that needs to be pressed in order for the system to capture a user response or move the cursor to another field. indicates that the Enter key (or Return key on some keyboards) must be pressed. Example: Type Y for Yes or N for No and press indicates that the Tab key must be pressed. Example: Press to move the cursor to the next field.  Indicates especially important or helpful information.  Options are locked with a particular security key. The user must hold the particular security key to be able to perform the menu option. Example:  Without the PSXCOMPMGR key,  XE "PSXCOMPMGR key" \b the Consolidated Mail Outpatient Pharmacy options cannot be accessed. ( The page symbol indicates a referral to a diagram. ?, ??, ??? One, two or three question marks can be entered at any of the prompts for online help. One question mark elicits a brief statement of what information is appropriate for the prompt. Two question marks provide more help, plus the hidden actions, and three question marks will provide more detailed help, including a list of possible answers, if appropriate. ^ Up arrow (caret or a circumflex) and pressing can be used to exit the present option. Chapter One Pharmacy Data Management Options The PDM options  XE "Pharmacy Data Management options" \b are listed below. Each of these options is explained in detail later in this user manual.   CMOP Mark/Unmark (Single XE "CMOP Mark/Unmark (Single drug) option" \b  drug) Dosages ... Auto Create Dosages Dosage Form File Enter/Edit Enter/Edit Dosages Most Common Dosages Report Noun/Dosage Form Report Review Dosages Report Drug Enter/Edit Drug Interaction Management ... Enter/Edit Local Drug Interaction Report of Locally Entered Interactions Electrolyte File (IV) Lookup into Dispense Drug File Medication Instruction File Add/Edit Medication Route File Enter/Edit Orderable Item Management ... Edit Orderable Items Dispense Drug/Orderable Item Maintenance Orderable Item/Dosages Report Patient Instructions Report Orderable Item Report Formulary Information Report Drug Text Enter/Edit Drug Text File Report Pharmacy System Parameters Edit Standard Schedule Edit Synonym Enter/Edit Other Language Translation* Controlled Substances/PKI Reports DEA Spec Hdlg & CS Fed Sch Discrepancy Controlled Substances Not Matched to NDF CS (DRUGS) Inconsistent with DEA Spec Hdlg CS (Ord. Item) Inconsistent with DEA Spec Hdlg Send Entire Drug File to External Interface Warning Builder Warning Mapping *Other Language Translation Setup is a stand-alone option that must be assigned to the person(s) responsible for maintaining it. CMOP Mark/Unmark (Single drug) XE "CMOP Mark/Unmark (Single drug) option" \b  [PSSXX MARK] The CMOP Mark/Unmark (Single drug) option  XE "CMOP Mark/Unmark (Single drug) option" \b allows the user to mark/unmark a single drug for transmission to the Consolidated Mail Outpatient Pharmacy (CMOP). Pertinent DRUG file (#50) and VA PRODUCT file (#50.68) fields shall be displayed to the user for review whenever a drug is marked or unmarked for CMOP transmission. If the user marks the entry to transmit to CMOP, it will replace the Dispense Unit with the VA Dispense Unit. In addition, if the user overwrites the local drug name with the VA Print Name, the entry may not be edited. The VA Print Name will be displayed on all profiles and prescription labels if the local drug name is overwritten with the VA Print Name. The local drug name will no longer be selectable during order entry. If the user chooses not to overwrite the local drug name with the VA Print Name, the local drug name will continue to be displayed on all profiles and can be used for drug selection during order entry. The VA Print Name will be displayed on all prescription labels regardless of the local drug name. A drug cannot be marked for CMOP if: It is inactive in DRUG file (#50) or VA PRODUCT file (#50.68). It is not marked for Outpatient Medications use. It is not matched to National Drug File. It is a Schedule I or II narcotic. It is not marked for CMOP in National Drug File. The ability to mark/unmark a singe drug for CMOP transmission is also available utilizing the Drug Enter/Edit option.  Locked: PSXCMOPMGR Without the PSXCMOPMGR key,  XE "PSXCMOPMGR key" \b the CMOP Mark/Unmark (Single drug) XE "CMOP Mark/Unmark (Single drug) option" \b  option will not appear on your menu. When using the CMOP Mark/Unmark (Single drug) XE "CMOP Mark/Unmark (Single drug) option" \b option to mark a drug for CMOP the user must update the cost information in the DRUG file (#50) to ensure the cost data for each prescription fill will be correct. Use the Drug Enter/Edit option XE "Drug Enter/Edit option" \b to edit the price per order unit and the dispense units per order unit when appropriate. Example 1: Marking a CMOP Drug (Single drug)  XE "Marking a CMOP Drug (Single drug)" \b Select Pharmacy Data Management Option: CMOP Mark/Unmark (Single drug) XE "CMOP Mark/Unmark (Single drug) option" \b This option allows you to choose entries from your drug file and helps you review your NDF matches and mark individual entries to send to CMOP. If you mark the entry to transmit to CMOP, it will replace your Dispense Unit with the VA Dispense Unit. In addition, you may overwrite the local drug name with the VA Print Name and the entry will remain uneditable. Select DRUG GENERIC NAME: GUAIFENESIN 100MG/5ML LIQUID RE302 Local Drug Generic Name: GUAIFENESIN 100MG/5ML LIQUID ORDER UNIT: 120ML DISPENSE UNITS/ORDER UNITS: 120 DISPENSE UNIT: EA PRICE PER DISPENSE UNIT: 0.01 VA Print Name: GUAIFENESIN 100MG/5ML SYRUP VA Dispense Unit: ML VA Drug Class: RE302 CMOP ID: G0035 Do you wish to mark this drug to transmit to CMOP? Enter Yes or No: YES QUANTITY DISPENSE MESSAGE: ENTER IN MULTIPLES OF 120. Your old Dispense Unit EA does not match the new one ML. You may wish to edit the Price Per Order Unit and/or The Dispense Units Per Order Unit. Do you wish to overwrite your local name? Enter Yes or No: YES Select DRUG GENERIC NAME: Example 2: Unmarking a CMOP Drug (Single drug) XE "Unmarking a CMOP Drug (Single drug)" \b Select DRUG GENERIC NAME: GUAIFENESIN 100MG/5ML SYRUP RE302 Local Drug Generic Name: GUAIFENESIN 100MG/5ML SYRUP ORDER UNIT: 120ML DISPENSE UNITS/ORDER UNITS: 120 DISPENSE UNIT: ML PRICE PER DISPENSE UNIT: 0.01 VA Print Name: GUAIFENESIN 100MG/5ML SYRUP VA Dispense Unit: ML VA Drug Class: RE302 CMOP ID: G0035 Do you wish to UNmark this drug to transmit to CMOP? Enter Yes or No: YES Select DRUG GENERIC NAME: Dosages [PSS DOSAGES MANAGEMENT] The Dosages XE "Dosages" \b option controls the entering and editing of dosages. The six dosages sub-options are explained in more detail below. Auto Create Dosages [PSS DOSAGE CONVERSION] The Auto Create Dosages option will queue the conversion that populates the Possible Dosages and Local Possible Dosages in the DRUG file (#50). When the Auto Create Dosages XE "Auto Create Dosages" \b job is complete, a mail message is sent to the user. The initial creation of these dosages occurred after the setup of patch PSS*1*34; therefore, all subsequent executions of this option are considered a rerun. Example: Rerun Auto Create Dosages  XE "Rerun Auto Create Dosages" \b This option will queue the conversion that populates the Possible Dosages and Local Possible Dosages in the Drug file. Select Systems Manager Menu Option: PDM Pharmacy Data Management Select Pharmacy Data Management Option: DOSages Select Dosages Option: AUTo Create Dosages This option will queue the conversion that populates the Possible Dosages and Local Possible Dosages in the Drug file. The dosage conversion was last run by PDMPHARMACIST,ONE It started on DEC 07, 2000@15:09:20 and ended on DEC 07, 2000@15:09:34 Are you sure you want to run the Dosage conversion again? N// Example: Mail Message following completion of Auto Create Dosages  XE "Mail Message following completion of Auto Create Dosages" \b Subj: PDM DOSAGE CONVERSION [#81907] 07 Dec 00 15:09 2 lines From: PHARMACY DATA MANAGEMENT In 'IN' basket. Page 1 *New* ------------------------------------------------------------------------------- The PDM Auto Create Dosages Job has run to completion. Please use the Dosages Review Report to print out results. Enter message action (in IN basket): Ignore// Dosage Form File Enter/Edit [PSS DOSAGE FORM EDIT] The Dosage Form File Enter/Edit XE "Dosage Form Enter/Edit" \b option provides the ability to edit data in the DOSAGE FORM file (#50.606). Changes made using this option may affect the way CPRS and Outpatient Pharmacy SIGs display and how Local Possible Dosages are created. The Noun entries are used to populate the Local Possible Dosages for DRUG file (#50) entries, when these entries are matched to National Drug File. These Nouns may be package specific (i.e. Outpatient Pharmacy, Inpatient Medications, or both). Entries in this file will be used as default values in the construction of the Outpatient Pharmacy prescription SIG. The conjunction will be used to provide a connector between the Local Possible Dosage and the strength and units or Dispense Drug name when displaying the dosage list through CPRS. For example, the dosage 1 TEASPOONFUL GUAIFENESIN WITH DEXTROMETHORPHAN SYRUP would display as 1 TEASPOONFUL OF GUAIFENESIN WITH DEXTROMETHORPHAN SYRUP in CPRS after the conjunction OF was provided using the Dosage Form File Enter/Edit option. The Dosage Form File Enter/Edit option allows the user to enter a noun, verb, or preposition in a language other than English. PDM does not translate English terms into another language; instead, it allows the user to enter a translation of a term. If a value has not been entered in the OTHER LANGUAGE VERB, OTHER LANGUAGE PREPOSITION, or OTHER LANGUAGE NOUN fields, PDM defaults to the values entered in the VERB, PREPOSITION, or NOUN fields. If the VERB, PREPOSITION, or NOUN fields do not contain data for the selected item, the system will not display default values for those fields during CPRS or Outpatient Pharmacy prescription order entry processing. However, when building the SIG, Outpatient Pharmacy will default to the values the user input during order entry. See Appendix D for a list of Spanish equivalents for some of the more common dosage forms. Example: Dosage Form File Enter/Edit Select Dosages Option: DOSage Form File Enter/Edit Select DOSAGE FORM NAME: TAB NAME: TAB Select MED ROUTE FOR DOSAGE FORM: ORAL// VERB: TAKE// OTHER LANGUAGE VERB: TOMAR PREPOSITION: BY// OTHER LANGUAGE PREPOSITION: POR Select NOUN: TABLET(S)// NOUN: TABLET(S)// OTHER LANGUAGE NOUN: TABLETAS// TABLETA(S) PACKAGE: Both// Select NOUN: CONJUNCTION: OF// Enter/Edit Dosages [PSS EDIT DOSAGES] The Enter/Edit Dosages XE "Enter/Edit Dosages" \b option allows you to edit Possible Dosages and Local Possible Dosages for a selected Dispense Drug. These dosages may be specified for Inpatient Medications, Outpatient Pharmacy, or both packages. The BCMA UNITS PER DOSE field is used by Inpatient Medications to populate the Units Per Dose information for Unit Dose orders. This value will determine the number of times a medication must be scanned in order to document a medication administration through Bar Code Medication Administration (BCMA). This field is not required and an entry should be made only when multiple scans through BCMA appear to document erroneous dosages. The Enter/Edit Dosages option allows the user to enter a dosage in a language other than English. PDM does not translate English terms into another language; instead, it allows the user to enter a translation of a term. If a value has not been entered in the OTHER LANGUAGE DOSAGE NAME field, PDM defaults to the value entered in the LOCAL POSSIBLE DOSAGE field. If no values exist in the LOCAL POSSIBLE DOSAGE and OTHER LANGUAGE DOSAGE NAME fields, the system will not display default values for those fields during CPRS or Outpatient Pharmacy prescription order entry processing. However, when building the SIG, Outpatient Pharmacy will default to the value the user input during order entry. See Appendix E for a list of Spanish equivalents for some of the more common Local Possible Dosages. Example 1: Enter/Edit Dosages Simple Possible Dosage Select Drug: ACETAMIN 1 ACETAMINOPHEN 160MG/5ML LIQUID CN103 NATL FORM; 480 ML/BT (NDC) 2 ACETAMINOPHEN 300MG/CODEINE 30MG TAB CN101 VISN FORM 3 ACETAMINOPHEN 300MG/CODEINE 30MG TB U.D. CN101 VISN FORM (NDC) 4 ACETAMINOPHEN 325MG TAB CN103 NATL FORM 5 ACETAMINOPHEN 325MG TAB U.D. CN103 NATL FORM (IEN) Press to see more, '^' to exit this list, OR CHOOSE 1-5: 4 ACETAMINOPHEN 325MG TAB CN103 NATL FORM This entry is marked for the following PHARMACY packages: Outpatient Non-VA Med ACETAMINOPHEN 325MG TAB Inactive Date: Strength from National Drug File match => 325 MG Strength currently in the Drug File => 325 MG Edit Strength? N// O Strength => 325 Unit => MG Select DISPENSE UNITS PER DOSE: ? Answer with POSSIBLE DOSAGES DISPENSE UNITS PER DOSE Choose from: 1 325 IO 2 650 IO You may enter a new POSSIBLE DOSAGES, if you wish Type a Number between 0 and 99999999, 4 Decimal Digits Select DISPENSE UNITS PER DOSE: 3 Example 1: Enter/Edit Dosages Simple Possible Dosage (continued) Are you adding '3' as a new POSSIBLE DOSAGES (the 3RD for this DRUG)? No// Y (Yes) Dosage = 975MG POSSIBLE DOSAGES DOSE: 975// (No Editing) DISPENSE UNITS PER DOSE: 3// PACKAGE: O Strength => 325 Unit => MG Select DISPENSE UNITS PER DOSE: Enter/Edit Local Possible Dosages? N// O Select Drug: Example 2: Enter/Edit Dosages Create a Local Possible Dosage Select Dosages Option: ENter/Edit Dosages Select Drug: GUAIFENESIN 100MG/5ML SYRUP RE302 DISP BY ML(120 ML MAX/NON-REFILLABLE)mpr 1BT=120ML *OTC DRUG* $ 6/02 This entry is marked for the following PHARMACY packages: Outpatient Unit Dose Non-VA Med GUAIFENESIN 100MG/5ML SYRUP Inactive Date: Strength from National Drug File match => 100 MG/5ML Strength currently in the Drug File => 100 Edit Strength? N// O Strength => 100 Unit => Select DISPENSE UNITS PER DOSE: ? Answer with POSSIBLE DOSAGES DISPENSE UNITS PER DOSE Choose from: 1 100 I 2 200 I You may enter a new POSSIBLE DOSAGES, if you wish Type a Number between 0 and 99999999, 4 Decimal Digits Select DISPENSE UNITS PER DOSE: This drug has the following Local Possible Dosages: 2 TEASPOONFULS PACKAGE: O 10 MLS PACKAGE: I Do you want to merge new Local Possible Dosages? Y// YES Setting Local Possible Dosages.. Strength: 100 Unit: MG/5ML Select LOCAL POSSIBLE DOSAGE: 2 TEASPOONFULS O LOCAL POSSIBLE DOSAGE: 2 TEASPOONFULS// OTHER LANGUAGE DOSAGE NAME: 2 CUCHARADITAS PACKAGE: Outpatient// Strength: 100 Unit: MG/5ML Example 3: Enter/Edit Dosages Editing the Dispense Units Per Dose Select Dosages Option: ENter/Edit Dosages Select Drug: PROPR 1 PROPRANOLOL 10MG S.T. CV100 2 PROPRANOLOL 40MG S.T. CV100 3 PROPRANOLOL 80MG S.T. CV100 4 PROPRANOLOL TABS,80MG.PINACIDIL STUDY STUDY DRUG CHOOSE 1-4: 2 PROPRANOLOL 40MG S.T. CV100 This entry is marked for the following PHARMACY packages: Outpatient Unit Dose Non-VA Med PROPRANOLOL 40MG S.T. Inactive Date: Strength from National Drug File match => 40 MG Strength currently in the Drug File => 40 MG Edit Strength? N// O Strength => 40 Unit => MG Select DISPENSE UNITS PER DOSE: 0.5 Are you adding '.5' as a new POSSIBLE DOSAGES (the 3RD for this DRUG)? No// Y (Yes) Dosage = 20MG POSSIBLE DOSAGES DOSE: 20// (No Editing) DISPENSE UNITS PER DOSE: 0.5// PACKAGE: IO BCMA UNITS PER DOSE: Strength => 40 Unit => MG Select DISPENSE UNITS PER DOSE: Enter/Edit Local Possible Dosages? N// O Select Drug: Example 4: Enter/Edit Dosages Creating Possible Dosages Select Dosages Option: ENter/Edit Dosages Select Drug: GRISEOFULVIN 500MG S.T. AM700 This entry is marked for the following PHARMACY packages: Outpatient Unit Dose Non-VA Med GRISEOFULVIN 500MG S.T. Inactive Date: This drug can have Possible Dosages, but currently does not have any. Create Possible Dosages for this drug? N// ? This drug meets the criteria to have Possible Dosages, but it currently does not have any. If you answer 'YES', Possible Dosages will be created for this drug, based on the match to the National Drug File. Create Possible Dosages for this drug? N// YES Resetting Possible Dosages.. Press Return to continue: Strength from National Drug File match => 500 MG Strength currently in the Drug File => 500 MG Edit Strength? N// O Strength => 500 Unit => MG Select DISPENSE UNITS PER DOSE: ? Answer with POSSIBLE DOSAGES DISPENSE UNITS PER DOSE Choose from: 1 500 IO 2 1000 IO You may enter a new POSSIBLE DOSAGES, if you wish Type a Number between 0 and 99999999, 4 Decimal Digits Select DISPENSE UNITS PER DOSE: Enter/Edit Local Possible Dosages? N// O Select Drug: Most Common Dosages Report [PSS COMMON DOSAGES] The Most Common Dosages Report XE "Most Common Dosages Report" \b option displays the most common dosages administered over a specified time period for Unit Dose orders. Example: Most Common Dosages Report Select Dosages Option: MOst Common Dosages Report This report displays common dosages of Dispense Drugs for Unit Dose orders based on the time frame entered. Unit Dose orders without a Dosage Ordered are not included on this report. If there are multiple Dispense Drugs associated with an order, only the first Dispense Drug of the order will print with the Dosage Ordered. Press Return to continue, '^' to exit: Enter start date for gathering Dosages: T-365 (JAN 23, 2000) Do not print Dosage if frequency is less than: (1-100): 1// 10 Because of the length of this report, and the time needed to gather the information, this report must be queued to a printer. DEVICE: HOME// QUEUED DEVICE: HOME// PRINTER 1 (This report must be sent a printer) COMMON DOSAGES REPORT STARTING FROM 01/23/00 PAGE: 1 DRUG DOSAGE FREQUENCY ------------------------------------------------------------------------------ ACETAMINOPHEN 325MG TAB U.D. 325-650MG TAB 12 650 mg 16 650MG 25 650MG TAB 66 650mg 33 ACETAMINOPHEN 500MG TAB U.D. 1000 mg 20 1000MG 11 1000MG TAB 33 1000mg 12 500-1000MG TAB 17 ALBUTEROL 0.5% INHL SOLN 0.5% NEB SOLN 10 0.5CC SOLN 40 0.5ML SOLN 12 ALBUTEROL 90MCG 200D ORAL INHL 2 PUFFS 52 2 puffs 17 ALLOPURINOL 300MG TAB U.D. 300MG TAB 12 ALOH/MGOH/SIMTH XTRA STRENGTH LIQ 30CC 11 30CC SUSP 15 30cc 25 AMOXICILLIN 500/CLAV K 125MG TAB 500/125MG TAB 13 Example: Most Common Dosages Report (continued) ASPIRIN 325MG EC TAB U.D. 325 MG 11 325MG EC TAB 80 ASPIRIN 325MG TAB U.D. 325 MG 10 325 mg 10 325MG TAB 17 ASPIRIN 81MG CHEW TAB 81MG TAB 16 ATENOLOL 25MG TAB 25MG TAB 17 ATENOLOL 50MG TAB 50MG TAB 14 AZITHROMYCIN 250MG TAB 250MG TAB 11 BISACODYL 10MG RTL SUPP 10MG SUPP 19 CARBAMAZEPINE (TEGRETOL) 100MG CHEW TAB 100MG TAB 11 CARBAMAZEPINE (TEGRETOL) 200MG TAB 200MG TAB 11 CASANTHRANOL 30/DOCUSATE 100MG CAP U.D. 30/100MG CAP 24 CLOPIDOGREL BISULFATE 75MG TAB 75 mg 14 DEXAMETHASONE 4MG TAB U.D. 4MG 13 DIGOXIN (LANOXIN) 0.125MG TAB 0.125 mg 10 0.125MG 10 0.125MG TAB 23 DIGOXIN (LANOXIN) 0.25MG TAB 0.25MG 13 0.25MG TAB 27 DOCUSATE NA 100MG CAP U.D. 100 MG 11 100 mg 19 100MG 11 100MG CAP 40 DROPERIDOL 5MG/2ML INJ 1/4-1/2CC INJ 19 FELODIPINE 5MG SA TAB U.D. 5MG SA TAB 10 FERROUS SULFATE 325MG TAB 325MG TAB 31 FLUNISOLIDE 250MCG 100D ORAL INHL 2 PUFFS 18 2 puffs 12 FOLIC ACID 1MG TAB U.D. 1 mg 21 1MG TAB 19 (Report continues) Noun/Dosage Form Report [PSS DOSE FORM/NOUN REPORT] The Noun/Dosage Form Report XE "Noun/Dosage Form Report" \b option displays the Dosage Forms, along with their associated Nouns and package use identifiers. It also displays the Local Possible Dosage created by the software based on the Nouns and Instructions of each Dosage Form. Example: Noun/Dosage Form Report Select Dosages Option: NOUN/Dosage Form Report This report shows the Dosage Forms and Nouns, along with the package use for each Noun and the resulting Local Possible Dosage. DEVICE: HOME// TELNET DEVICE Dosage Form Dispense Units per Dose PAGE: 1 Noun(s) Package-->Local Possible Dosage ----------------------------------------------------------------------------- ADAPTER (1) ADAPTER IO--> 1 ADAPTER AEROSOL (1) PUFF(S) IO--> 1 PUFF SPRAY(S) IO--> 1 SPRAY AEROSOL,ORAL (1,2) PUFF(S) IO--> 1 PUFF IO--> 2 PUFFS SPRAY(S) IO--> 1 SPRAY IO--> 2 SPRAYS AEROSOL,RTL (1,2) APPLICATORFUL(S) IO--> 1 APPLICATORFUL IO--> 2 APPLICATORFULS AEROSOL,TOP (1,2) SPRAY(S) IO--> 1 SPRAY IO--> 2 SPRAYS AEROSOL,VAG (1,2) SPRAY(S) IO--> 1 SPRAY IO--> 2 SPRAYS APPLICATOR (1,2) APPLICATOR IO--> 1 APPLICATOR IO--> 2 APPLICATOR BAG BAG IO--> BAG BANDAGE IO--> BANDAGE BAR,CHEWABLE (1) BAR(S) IO--> 1 BAR BAR,TOP (No Nouns) BARRIER BARRIER IO--> BARRIER Example: Noun/Dosage Form Report (continued) BEADS,TOP BEADS IO--> BEADS BELT BELT OI--> BELT BLOCK IO--> BLOCK CAP,EC (1,2) CAPSULE(S) IO--> 1 CAPSULE IO--> 2 CAPSULES CAP,INHL (1,2) CAPSULE(S) IO--> 1 CAPSULE IO--> 2 CAPSULES CAP,ORAL (1,2) CAPSULE(S) IO--> 1 CAPSULE IO--> 2 CAPSULES CAP,SA (1,2) CAPSULE(S) IO--> 1 CAPSULE IO--> 2 CAPSULES CAP,SPRINKLE (1,2) CAPSULE(S) IO--> 1 CAPSULE IO--> 2 CAPSULES CAP,SPRINKLE,SA (1,2) CAPSULE(S) IO--> 1 CAPSULE IO--> 2 CAPSULES CAP/INJ (1,2) (No Nouns) CATHETER CATHETER O--> CATHETER CHAMBER CHAMBER IO--> CHAMBER (Report Continues) Review Dosages Report [PSS DOSAGE REVIEW REPORT] The Review Dosages Report XE "Review Dosages Report" \b option shows the Possible Dosages and Local Possible Dosages for selected Dispense Drugs. Example: Review Dosages Report Select Dosages Option: REView Dosages Report Select one of the following: A ALL S SELECT A RANGE Print Report for (A)ll or (S)elect a Range: S// ELECT A RANGE To see drugs beginning with the letter 'A', enter 'A', or whichever letter you wish to see. To see drugs in a range, for example drugs starting with the letters 'G', 'H', 'I' and 'J', enter in the format 'G-J'. Select a Range: G Report will be for drugs starting with the letter G, and ending with drugs starting with the letter G. Is this correct? Y// ES This report is designed for 132 column format! DEVICE: HOME// ;C-VT132 TELNET DEVICE Dosage report for drugs from G through G Outpatient Expansion PAGE: 1 ------------------------------------------------------------------------------------------------- (2281) G U BAGS Inactive Date: Strength: Units: Application Package: O Possible Dosages: (None) Local Possible Dosages: BAG Package: IO (3383) GABAPENTIN 100MG CAP Inactive Date: Strength: 100 Units: MG Application Package: O Possible Dosages: Dispense Units Per Dose: 1 Dose: 100MG Package: IO 1 CAPSULE Dispense Units Per Dose: 2 Dose: 200MG Package: IO 2 CAPSULES Local Possible Dosages: 1 CAPSULE Package: O 2 CAPSULES Package: O (3386) GABAPENTIN 100MG CAP UD Inactive Date: Strength: 100 Units: MG Application Package: U Possible Dosages: Dispense Units Per Dose: 1 Dose: 100MG Package: IO 1 CAPSULE Example: Review Dosages Report (continued) Dispense Units Per Dose: 2 Dose: 200MG Package: IO 2 CAPSULES Local Possible Dosages: (None) (3384) GABAPENTIN 300MG CAP Inactive Date: Strength: 300 Units: MG Application Package: O Possible Dosages: Dispense Units Per Dose: 1 Dose: 300MG Package: IO 1 CAPSULE Dispense Units Per Dose: 2 Dose: 600MG Package: IO 2 CAPSULES Local Possible Dosages: 1 CAPSULE Package: O (3387) GABAPENTIN 300MG CAP UD Inactive Date: Strength: 300 Units: MG Application Package: U Possible Dosages: Dispense Units Per Dose: 1 Dose: 300MG Package: IO 1 CAPSULE Dispense Units Per Dose: 2 Dose: 600MG Package: IO 2 CAPSULES Local Possible Dosages: (None) (3385) GABAPENTIN 400MG CAP Inactive Date: Strength: 400 Units: MG Application Package: O Possible Dosages: Dispense Units Per Dose: 1 Dose: 400MG Package: IO 1 CAPSULE Dispense Units Per Dose: 2 Dose: 800MG Package: IO 2 CAPSULES Local Possible Dosages: 1 CAPSULE Package: O (3388) GABAPENTIN 400MG CAP UD Inactive Date: Strength: 400 Units: MG Application Package: U Possible Dosages: Dispense Units Per Dose: 1 Dose: 400MG Package: IO 1 CAPSULE Dispense Units Per Dose: 2 Dose: 800MG Package: IO 2 CAPSULES Local Possible Dosages: (None) (4425) GABAPENTIN 600MG TAB Inactive Date: Strength: 600 Units: MG Application Package: OU Possible Dosages: Dispense Units Per Dose: 1 Dose: 600MG Package: IO 1 TABLET Dispense Units Per Dose: 2 Dose: 1200MG Package: IO 2 TABLETS Local Possible Dosages: 1 TABLET Package: O (4426) GABAPENTIN 800MG TAB Inactive Date: Strength: 800 Units: MG Application Package: OU Possible Dosages: Dispense Units Per Dose: 1 Dose: 800MG Package: IO 1 TABLET Dispense Units Per Dose: 2 Dose: 1600MG Package: IO 2 TABLETS Local Possible Dosages: 1 TABLET Package: O (3858) GANCICLOVIR 250MG CAP Inactive Date: Strength: 250 Units: MG Application Package: O Possible Dosages: Dispense Units Per Dose: 1 Dose: 250MG Package: IO 1 CAPSULE Dispense Units Per Dose: 2 Dose: 500MG Package: IO 2 CAPSULES Local Possible Dosages: (None) (4033) GANCICLOVIR 4.5MG IMPLANT,OPH Inactive Date: Strength: 4.5 Units: MG Application Package: OU Possible Dosages: Dispense Units Per Dose: 1 Dose: 4.5MG Package: I Dispense Units Per Dose: 2 Dose: 9MG Package: I Local Possible Dosages: (Report Continues) Drug Enter/Edit [PSS DRUG ENTER/EDIT] The Drug Enter/Edit XE "Drug Enter/Edit" \b option allows users to make a new Dispense Drug entry into the DRUG file (#50) or to make changes to existing DRUG file (#50) Dispense Drug entries. This option consolidates entries for all Pharmacy packages if the user possesses the proper package key. It will also allow the user to match Dispense Drugs to corresponding NATIONAL DRUG file (#50.6) and Pharmacy Orderable Item entries and to tie the Dispense Drug to a DRUG TEXT file (#51.7) entry. Dispense Drug formulary status is designated via this option and formulary alternatives may be designated for non-formulary Dispense Drug entries. Dosages created as the result of National Drug File matching or auto creation of dosages may be reviewed and edited via this option. Outpatient Pharmacy designated Dispense Drug entries may be marked or unmarked as a LAB MONITOR or CLOZAPINE DRUG. This will allow lab values to print on the Outpatient Action Profile for the designated drug and provide lab monitor checks for Clozapine drugs during the medication order entry process. The Drug Enter/Edit option allows the user to enter a dosage in a language other than English. PDM does not translate English terms into another language; instead, it allows the user to enter a translation of a term. If a value has not been entered in the OTHER LANGUAGE DOSAGE NAME field, PDM defaults to the value entered in the LOCAL POSSIBLE DOSAGE field. If no values exist in the LOCAL POSSIBLE DOSAGE and OTHER LANGUAGE DOSAGE NAME fields, the system will not display default values for those fields during CPRS or Outpatient Pharmacy prescription order entry processing. However, when building the SIG, Outpatient Pharmacy will default to the value the user input during order entry. Patch PSS*1*61 adds a new code F for NON REFILLABLE to the DEA, SPECIAL HDLG field of the DRUG file (#50), which will allow sites to mark drugs other than controlled substances or clozapine drugs as NON REFILLABLE. Patch PSS*1*81 adds a new code E to the DEA, SPECIAL HDLG field of the DRUG file (#50) to indicate that the drug is electronically billable. This will allow OTC drugs, supply items, and other drugs that are usually not billable to be marked for electronic billing. DEA Special Handling Code XE "DEA Special Handling Code"  Sites will need to determine all the nutritional supplements in their drug file and mark the DEA, SPECIAL HDLG field entry for all of their nutritional supplements drug file entries with an N. They will also need to append any entries that may be third party reimbursable with an E. Usually only Rx Only nutritional supplements are third party reimbursable. Select OPTION NAME: DRUG ENTER/EDIT PSS DRUG ENTER/EDIT Drug Enter/Edit Drug Enter/Edit Select DRUG GENERIC NAME: TRAZO Lookup: GENERIC NAME 1 TRAZODONE 100MG TAB N/F 2 TRAZODONE 50MG TAB CHOOSE 1-2: 1 TRAZODONE 100MG TAB N/F ******************************************************************************* This entry is marked for the following PHARMACY packages: Outpatient Non-VA Med GENERIC NAME: TRAZODONE 100MG TAB// VA CLASSIFICATION: DEA, SPECIAL HDLG: 6// ? ANSWER MUST BE 1-6 CHARACTERS IN LENGTH THE SPECIAL HANDLING CODE IS A 2 TO 6 POSTION FIELD. IF APPLICABLE, A SCHEDULE CODE MUST APPEAR IN THE FIRST POSITION. FOR EXAMPLE, A SCHEDULE 3 NARCOTIC WILL BE CODED '3A', A SCHEDULE 3 NON-NARCOTIC WILL BE CODED '3C' AND A SCHEDULE 2 DEPRESSANT WILL BE CODED '2L'. THE CODES ARE: 0 MANUFACTURED IN PHARMACY 1 SCHEDULE 1 ITEM 2 SCHEDULE 2 ITEM 3 SCHEDULE 3 ITEM 4 SCHEDULE 4 ITEM 5 SCHEDULE 5 ITEM 6 LEGEND ITEM 9 OVER-THE-COUNTER L DEPRESSANTS AND STIMULANTS A NARCOTICS AND ALCOHOLS P DATED DRUGS I INVESTIGATIONAL DRUGS M BULK COMPOUND ITEMS C CONTROLLED SUBSTANCES - NON NARCOTIC R RESTRICTED ITEMS S SUPPLY ITEMS B ALLOW REFILL (SCH. 3, 4, 5 ONLY) W NOT RENEWABLE F NON REFILLABLE E ELECTRONICALLY BILLABLE N NUTRITIONAL SUPPLEMENT DEA, SPECIAL HDLG: N// DEA, SPECIAL HDLG field effects on ePharmacy Billing: If the DEA, SPECIAL HDLG field contains an I (Investigational), S (Supply), N (Nutritional Supplement), or 9 (OTC), the drug is NOT billable. However, if the same drug also contains the E (electronically billable), the drug becomes BILLABLE. If the DEA, SPECIAL HDLG field contains an M or 0 (both designating a Compound Drug), the drug is NOT billable. If the same drug contains the E (electronically billable), the drug is STILL NOT billable. If the DEA, SPECIAL HDLG field is NULL (empty), the drug is NOT billable . Note that ALL other drugs are billable. Follow these guidelines to ensure proper electronic billing: If an item is to be billed, then there must be an entry in the DEA, SPECIAL HDLG field. It is not necessary to include a numeric value; any value (other than the non-billable codes listed above) will allow ePharmacy to submit a bill. Add an E to all items that contain 9, N, I, or S, but are actually billable. This will most often occur with Insulin and Glucose test strips, which are usually marked with a 9 but are, in fact, billable for most insurance companies. Add a non-billable code (0 (zero), 9, or M) to all items that should NOT be billed. Specifically, the VA may not disclose any information on the following diseases: HIV, drug abuse, alcohol abuse, or sickle cell anemia. In order to avoid disclosing these diagnoses, it has been decided that the VA will not bill for any drug that is used exclusively or almost exclusively for these conditions. Drugs to mark as non-billable include Antiretrovirals, Disulfiram, Naltrexone, and Methadone for maintenance or detox. Note: The NDF option, Rematch/Match Single Drugs, screens out those items with a DEA, SPECIAL HDLG code of 0, I, or M. When sites receive NDF data updates that cause one of these items to be unmatched from NDF, they cannot use the Rematch/Match Single Drugs option to rematch if they have added 0, I, or M to drugs like Antiretrovirals, Disulfiram, Naltrexone, or Methadone for maintenance or detox. Sites can either: Rematch to NDF using another option, or Remove the DEA, SPECIAL HDLG code, use the Rematch/Match Single Drugs option, and then add the DEA, SPECIAL HDLG code back in. Patch PSS*1*90 adds a new multiple field to the DRUG file (#50) to store the latest National Drug Code (NDC) numbers that have been dispensed at window as well as by CMOP for a specific division. This way, when the next prescription is entered by the division for the same drug, the last used NDC is automatically retrieved from this new multiple, saved in the PRESCRIPTION file (#52), and sent to the third party payer through ECME. This field is populated automatically and does not require user input. Below is the multiple field and the fields under it: 32 NDC BY OUTPATIENT SITE .01 -OUTPATIENT SITE 1 -LAST LOCAL NDC 2 -LAST CMOP NDC DAW CODE field effects on ePharmacy Billing: Patch PSS*1*90 adds a new DAW CODE field to the DRUG file (#50). DAW stands for Dispense as Written, and refers to a set of ten NCPDP codes (0-9) that tells third party payers why a brand or generic product was selected to fill a prescription. See table below. DAW Code DAW Description 0 No Product Selection Indicated 1 Substitution Not Allowed by Prescriber 2 Substitution Allowed-Patient Requested Product Dispensed 3 Substitution Allowed-Pharmacist Selected Product Dispensed 4 Substitution Allowed-Generic Drug Not in Stock 5 Substitution Allowed-Brand Drug Dispensed as a Generic 6 Override 7 Substitution Not Allowed-Brand Drug Mandated by Law 8 Substitution Allowed-Generic Drug Not Available in Marketplace 9 Other Since the VA primarily uses generic products, this has not been a major issue to date. The DAW CODE field default is 0, which means the physician did not specify whether to dispense a generic or brand name product. We anticipate getting some rejections from third parties for cases where we still dispense branded products, even though a generic is available in the marketplace. Our use of Coumadin instead of generic Warfarin is one example. DAW codes are typically set for individual prescriptions, but can be set at the DRUG file (#50) level as well. An example scenario of each is given below. Example: Setting the DAW CODE at the Prescription Level If you are informed that a prescription for Coumadin was rejected for DAW reasons, you might try changing the DAW CODE of the prescription and resubmitting. The change can be made through the Patient Prescription Processing option or the Edit Prescriptions option in Outpatient Pharmacy V. 7.0. The DAW CODE will display for ePharmacy prescriptions. For original fills, this information can be edited by selecting screen field 21. For refills, the user must select screen field 20 (Refill Data), then select the refill numberto be edited;the DAW CODE: prompt displays after the DIVISION: prompt. In the case of the Coumadin reject, you may try changing the field to a 5 or a 1, then resubmitting to see if the claim gets processed. Both 5 and 1 are appropriate choices for the VA setting. Whether or not a claim will get rejected for these reasons and which code to use will vary from third party to third party. We are using brand name products, but are not charging for brand name products. The most common DAW codes are explained as follows: #1: Physician stipulates that a particular brand be used. #5: A brand name product is dispensed even though a generic product exists. Patient will be charged at the generic price. Example: Setting the DAW CODE at the Drug File Level If you are told that almost every prescription for Coumadin is being rejected, you may choose to make the change at the DRUG file (#50) level. Editing the DAW Code field in the DRUG file (#50) for the Coumadin entry will make a global change, such that each ePharmacy prescription filled for that product will use the DAW code you specify. Note: Ask your Pharmacy ADPAC to make the change at the DRUG file (#50) level. When using the Drug Enter/Edit option, a warning message is displayed if a discrepancy is found between the CS FEDERAL SCHEDULE field (#19) of the VA PRODUCT file (#50.68) and the DEA, SPECIAL HDLG field (#3) of the DRUG file (#50). The warning message says, "The CS Federal Schedule associated with this drug in the VA Product file represents a DEA, Special Handling code of XX", where XX is the DEA, SPECIAL HDLG code mapped to corresponding CS FEDERAL SCHEDULE code defined as follows (schedule I, IV and V are identical): CS FEDERAL DEA, SPECIAL SCHEDULE HDLG Schedule I narcotics 1 1 Schedule II narcotics 2 2A Schedule II non-narcotics 2n 2C Schedule III narcotics 3 3A Schedule III non-narcotics 3n 3C Schedule IV narcotics 4 4 Schedule V narcotics 5 5 Example 1: Drug Enter/Edit Select Pharmacy Data Management Option: DRUG 1 Drug Enter/Edit 2 Drug Interaction Management 3 Drug Text Enter/Edit CHOOSE 1-3: 1 Drug Enter/Edit Select DRUG GENERIC NAME: PROPRA 1 PROPRANOLOL 10MG S.T. CV100 2 PROPRANOLOL 40MG S.T. CV100 3 PROPRANOLOL 80MG S.T. CV100 4 PROPRANOLOL TABS,80MG.PINACIDIL STUDY STUDY DRUG CHOOSE 1-4: 2 PROPRANOLOL 40MG S.T. CV100 ******************************************************************************* This entry is marked for the following PHARMACY packages: Outpatient Unit Dose Non-VA Med GENERIC NAME: PROPRANOLOL 40MG S.T. Replace VA CLASSIFICATION: CV100// DEA, SPECIAL HDLG: 6P// NATIONAL FORMULARY INDICATOR: YES LOCAL NON-FORMULARY: VISN NON-FORMULARY: Select DRUG TEXT ENTRY: Select FORMULARY ALTERNATIVE: Select SYNONYM: 000719179613// SYNONYM: 000719179613// INTENDED USE: DRUG ACCOUNTABILITY// NDC CODE: 000719-1796-13// Select SYNONYM: MESSAGE: RESTRICTION: FSN: 6505-00-221-3393A// NDC: 719-1796-13// INACTIVE DATE: WARNING LABEL SOURCE is 'NEW'. The following WARNING LABEL may continue to be used for a limited time for some external interfaces. WARNING LABEL: Current Warning labels for PROPRANOLOL 40MG S.T. Labels will print in the order in which they appear for local and CMOP fills: 13N It is very important that you take or use this exactly as directed. Do not skip doses or discontinue unless directed by your doctor. 9N Some non-prescription drugs may aggravate your condition. Read all labels carefully. If a warning appears, check with your doctor. Pharmacy fill card display: DRUG WARNING 13N,9N NOTE: Because the NEW WARNING LABEL LIST field is empty, the warnings above are the warnings that our national data source distributes for this drug. Would you like to edit this list of warnings? N// O ORDER UNIT: BT// PRICE PER ORDER UNIT: 50.34// DISPENSE UNIT: DISPENSE UNITS PER ORDER UNIT: 1000// PRICE PER DISPENSE UNIT: 0.050 DAW CODE: 0// - NO PRODUCT SELECTION INDICATED points to PROPRANOLOL HCL 40MG TAB in the National Drug file. This drug has already been matched and classified with the National Drug file. In addition, if the dosage form changes as a result of rematching, you will have to match/rematch to Orderable Item. Example 1: Drug Enter/Edit (continued) Do you wish to match/rematch to NATIONAL DRUG file? No// (No) Just a reminder...you are editing PROPRANOLOL 40MG S.T.. Strength from National Drug File match => 40 MG Strength currently in the Drug File => 40 MG Strength => 40 Unit => MG POSSIBLE DOSAGES: DISPENSE UNITS PER DOSE: 1 DOSE: 40 PACKAGE: IO DISPENSE UNITS PER DOSE: 2 DOSE: 80 PACKAGE: IO DISPENSE UNITS PER DOSE: .5 DOSE: 20 PACKAGE: IO LOCAL POSSIBLE DOSAGES: OTHER LANGUAGE DOSAGE NAME Do you want to edit the dosages? N// YES Changing the strength will update all possible dosages for this Drug. STRENGTH: 40// Select DISPENSE UNITS PER DOSE: 0.5 20 IO DISPENSE UNITS PER DOSE: 0.5// @ SURE YOU WANT TO DELETE THE ENTIRE '.5' DISPENSE UNITS PER DOSE? Y (Yes) Select DISPENSE UNITS PER DOSE: Enter/Edit Local Possible Dosages? N// O ******************************************************************************* This entry is marked for the following PHARMACY packages: Outpatient Unit Dose Non-VA Med MARK THIS DRUG AND EDIT IT FOR: O - Outpatient U - Unit Dose X - Non-VA Med Enter your choice(s) separated by commas : O ** You are NOW editing OUTPATIENT fields. ** AN Outpatient Pharmacy ITEM? Yes// (Yes) CORRESPONDING INPATIENT DRUG: MAXIMUM DOSE PER DAY: LOCAL NON-FORMULARY: NORMAL AMOUNT TO ORDER: 4// SOURCE OF SUPPLY: 1P// CURRENT INVENTORY: -3822// ACTION PROFILE MESSAGE (OP): MESSAGE: QUANTITY DISPENSE MESSAGE: OP EXTERNAL DISPENSE: Do you wish to mark to transmit to CMOP? Enter Yes or No: NO Do you wish to mark/unmark as a LAB MONITOR or CLOZAPINE DRUG? Enter Yes or No: NO ** You are NOW in the ORDERABLE ITEM matching for the dispense drug. ** PROPRANOLOL 40MG S.T. is already matched to PROPRANOLOL TAB Do you want to match to a different Orderable Item? NO// Select DRUG GENERIC NAME: Example 2: Drug Enter/Edit Marking of an Outpatient Drug for Clozapine or Lab Monitor MARK THIS DRUG AND EDIT IT FOR: O - Outpatient U - Unit Dose I - IV X - Non-VA Med Enter your choice(s) separated by commas : O ** You are NOW editing OUTPATIENT fields. ** AN Outpatient Pharmacy ITEM? Yes// (Yes) CORRESPONDING INPATIENT DRUG: CLOZAPINE 100MG TAB // MAXIMUM DOSE PER DAY: LOCAL NON-FORMULARY: NORMAL AMOUNT TO ORDER: 1// SOURCE OF SUPPLY: CURRENT INVENTORY: 1000// ACTION PROFILE MESSAGE (OP): RESTRICTED TO NATIONALLY REGISTERED PATIENTS. Replace MESSAGE: NATL RESTRICTED (IEN) Replace QUANTITY DISPENSE MESSAGE: Do you wish to mark/unmark as a LAB MONITOR or CLOZAPINE DRUG? Enter Yes or No: YES Mark/Unmark for Lab Monitor or Clozapine: Select one of the following: L LAB MONITOR C CLOZAPINE Enter response: CLOZAPINE ** You are NOW editing CLOZAPINE fields. ** Prescription of Clozapine requires identification of two laboratory tests, WBC and Absolute Neutrophil Count (ANC). You currently have both laboratory tests identified. Type of Test Lab Test Monitor Specimen Type ------- ---------------- ------------- 1. WBC WBC SERUM 2. ANC ABSOLUTE GRANULOCYTE COUNT SERUM (E)dit or (D)elete entry? ** You are NOW in the ORDERABLE ITEM matching for the dispense drug. ** CLOZAPINE 100MG TAB is already matched to CLOZAPINE TAB Do you want to match to a different Orderable Item? NO// Example 3: Drug Enter/Edit Editing Local Possible Dosages and Orderable Item Select Pharmacy Data Management Option: DRUG 1 Drug Enter/Edit 2 Drug Interaction Management 3 Drug Text Enter/Edit CHOOSE 1-3: 1 Drug Enter/Edit Select DRUG GENERIC NAME: CLOTRIMAZOLE 1% TOP CREAM-15 DE102 15GM-DISP BY GM ...OK? Yes// (Yes) *********************************************************************** This entry is marked for the following PHARMACY packages: Outpatient Unit Dose Ward Stock Non-VA Med GENERIC NAME: CLOTRIMAZOLE 1% TOP CREAM-15 Replace VA CLASSIFICATION: DE102// DEA, SPECIAL HDLG: 6P// NATIONAL FORMULARY INDICATOR: YES LOCAL NON-FORMULARY: VISN NON-FORMULARY: Select DRUG TEXT ENTRY: Select FORMULARY ALTERNATIVE: Select SYNONYM: CLOTRIMAZOLE 1% TOP CREAM-15 // SYNONYM: CLOTRIMAZOLE 1% TOP CREAM-15 Replace INTENDED USE: NDC CODE: Select SYNONYM: MESSAGE: 15GM-DISP BY GM* Replace RESTRICTION: FSN: 6505-01-023-5011// NDC: 0085-0613-02// INACTIVE DATE: WARNING LABEL SOURCE is 'NEW'. The following WARNING LABEL may continue to be used for a limited time for some external interfaces. WARNING LABEL: 8,2 // Current Warning labels for CLOTRIMAZOLE 1% TOP CREAM-15 Labels will print in the order in which they appear for local and CMOP fills: 20N For external use only. Pharmacy fill card display: DRUG WARNING 20N NOTE: Because the NEW WARNING LABEL LIST field is empty, the warnings above are the warnings that our national data source distributes for this drug. Would you like to edit this list of warnings? N// YES NEW WARNING LABEL LIST: 8,2,20N Current Warning labels for CLOTRIMAZOLE 1% TOP CREAM-15 Labels will print in the order in which they appear for local and CMOP fills: 8 DO NOT DRINK ALCOHOLIC BEVERAGES when taking this medication. 2 IMPORTANT: Finish all this medication unless otherwise directed by prescriber. 20N For external use only. Pharmacy fill card display: DRUG WARNING 8,2,20N NEW WARNING LABEL LIST: 8,2,20N Would you like to edit this list of warnings? N// O Example 3: Drug Enter/Edit Editing Local Possible Dosages and Orderable Item (continued) ORDER UNIT: TU// PRICE PER ORDER UNIT: 9.77// DISPENSE UNIT: GM// DISPENSE UNITS PER ORDER UNIT: 15// PRICE PER DISPENSE UNIT: 0.651 DAW CODE: 0// - NO PRODUCT SELECTION INDICATED points to CLOTRIMAZOLE 1% TOP CREAM-15 in the National Drug file. This drug has already been matched and classified with the National Drug file. In addition, if the dosage form changes as a result of rematching, you will have to match/rematch to Orderable Item. Do you wish to match/rematch to NATIONAL DRUG file? No// (No) Just a reminder...you are editing CLOTRIMAZOLE 1% TOP CREAM-15. LOCAL POSSIBLE DOSAGES: A THIN FILM PACKAGE: OI Do you want to edit Local Possible Dosages? N// YES This drug has the following Local Possible Dosages: A THIN FILM PACKAGE: OI Do you want to merge new Local Possible Dosages? Y// NO Strength: 1 Unit: % Select LOCAL POSSIBLE DOSAGE: A THIN FILM OI LOCAL POSSIBLE DOSAGE: A THIN FILM// OTHER LANGUAGE DOSAGE NAME: UNA CAPA FINA PACKAGE: Both// BCMA UNITS PER DOSE: Strength: 1 Unit: % Select LOCAL POSSIBLE DOSAGE: *********************************************************************** This entry is marked for the following PHARMACY packages: Outpatient Unit Dose Ward Stock Non-VA Med MARK THIS DRUG AND EDIT IT FOR: O - Outpatient U - Unit Dose I - IV W - Ward Stock D - Drug Accountability C - Controlled Substances X - Non-VA Med A - ALL Enter your choice(s) separated by commas : O ** You are NOW editing OUTPATIENT fields. ** AN Outpatient Pharmacy ITEM? Yes// (Yes) CORRESPONDING INPATIENT DRUG: MAXIMUM DOSE PER DAY: STANDARD SIG: AP TAA BID LOCAL NON-FORMULARY: NORMAL AMOUNT TO ORDER: // SOURCE OF SUPPLY: 1P// CURRENT INVENTORY: // ACTION PROFILE MESSAGE (OP): MESSAGE: 15GM-DISP BY GM* Replace QUANTITY DISPENSE MESSAGE: DISP BY GM (MULTIPLES OF 15)// Example 3: Drug Enter/Edit Editing Local Possible Dosages and Orderable Item (continued) Replace OP EXTERNAL DISPENSE: Do you wish to mark to transmit to CMOP? Enter Yes or No: YES This option allows you to choose entries from your drug file and helps you review your NDF matches and mark individual entries to send to CMOP. If you mark the entry to transmit to CMOP, it will replace your Dispense Unit with the VA Dispense Unit. In addition, you may overwrite the local drug name with the VA Print Name and the entry will remain uneditable. Local Drug Generic Name: CLOTRIMAZOLE 1% TOP CREAM-15 ORDER UNIT: TU DISPENSE UNITS/ORDER UNITS: 15 DISPENSE UNIT: GM PRICE PER DISPENSE UNIT: 0.651 VA Print Name: CLOTRIMAZOLE 1% TOP CREAM-15 VA Dispense Unit: GM VA Drug Class: DE102 CMOP ID: C0298 Do you wish to mark this drug to transmit to CMOP? Enter Yes or No: YES QUANTITY DISPENSE MESSAGE: DISP BY GM (MULTIPLES OF 15) Replace Do you wish to overwrite your local name? Enter Yes or No: NO Do you wish to mark/unmark as a LAB MONITOR or CLOZAPINE DRUG? Enter Yes or No: NO ** You are NOW in the ORDERABLE ITEM matching for the dispense drug. ** CLOTRIMAZOLE 1% TOP CREAM-15 is already matched to CLOTRIMAZOLE CREAM,TOP Do you want to match to a different Orderable Item? NO// YES Dosage Form -> CREAM,TOP Match to another Orderable Item with same Dosage Form? NO// Dosage Form -> CREAM,TOP Dispense Drug -> CLOTRIMAZOLE 1% TOP CREAM-15 Orderable Item Name: CLOTRIMAZOLE// Matching CLOTRIMAZOLE 1% TOP CREAM-15 to CLOTRIMAZOLE CREAM,TOP Is this OK? YES// Match Complete! Now editing Orderable Item: CLOTRIMAZOLE CREAM,TOP This Orderable Item is Formulary. Select OI-DRUG TEXT ENTRY: INACTIVE DATE: DAY (nD) or DOSE (nL) LIMIT: MED ROUTE: Example 3: Drug Enter/Edit Editing Local Possible Dosages and Orderable Item (continued) SCHEDULE TYPE: SCHEDULE: PATIENT INSTRUCTIONS: OTHER LANGUAGE INSTRUCTIONS: Select SYNONYM: Example 4: Drug Enter/Edit Editing Non-VA Medications XE "Non-VA Meds, Drug Enter/Edit" \b  Select DRUG GENERIC NAME: GINGER ROOT TAB/CAP Are you adding 'GINGER ROOT' as a new DRUG (the 1756TH)? No// Y (Yes) DRUG NUMBER: 112// DRUG VA CLASSIFICATION: DRUG FSN: DRUG NATIONAL DRUG CLASS: DRUG LOCAL NON-FORMULARY: N N/F DRUG INACTIVE DATE: DRUG MESSAGE: DRUG RESTRICTION: GENERIC NAME: GINGER ROOT TAB/CAP// ^DI 1 DISPENSE UNIT 2 DISPENSE UNITS PER ORDER UNIT CHOOSE 1-2: 2 DISPENSE UNITS PER ORDER UNIT DISPENSE UNITS PER ORDER UNIT: PRICE PER DISPENSE UNIT: 0.0000 DAW CODE: 0// - NO PRODUCT SELECTION INDICATED Do you wish to match/rematch to NATIONAL DRUG file? Yes// (Yes) Deleting Possible Dosages... Match local drug GINGER ROOT ORDER UNIT: DISPENSE UNITS/ORDER UNITS: 2 DISPENSE UNIT: No NDC to match... I will attempt to match the NDCs from your SYNONYMS. No match by Synonym NDC... now first word Match made with GINGER ROOT TAB/CAP Now select VA Product Name 1 GINGER CAP/TAB CAP/TAB HA000 G0226 Enter your choice: 1 Is this a match < Reply Y, N or press return to continue > : Y CHOOSE FROM: 1 60 BOTTLE 2 OTHER OTHER Enter Package Size & Type Combination: 1 Local drug ginger root matches GINGER CAP/TAB PACKAGE SIZE: OTHER PACKAGE TYPE: OTHER < Enter "Y" for yes > < Enter "N" for no > OK? : Y LOCAL DRUG NAME: GINGER ROOT TAB/CAP ORDER UNIT: DISPENSE UNITS/ORDER UNITS: DISPENSE UNIT: VA PRODUCT NAME: GINGER CAP/TAB VA PRINT NAME: GINGER CAP/TAB CMOP ID: G0226 Example 4: Drug Enter/Edit Editing Non-VA Medications (continued) XE "Non-VA Meds, Drug Enter/Edit" \b  VA DISPENSE UNIT: CAP/TAB MARKABLE FOR CMOP: NO PACKAGE SIZE: BOTTLE PACKAGE TYPE: OTHER VA CLASS: HA000 HERBS/ALTERNATIVE THERAPIES INGREDIENTS: NATIONAL FORMULARY INDICATOR: NO NATIONAL FORMULARY RESTRICTION: < Enter "Y" for yes, "N" for no > Is this a match ? Y You have just VERIFIED this match and MERGED the entry. Resetting Possible Dosages.. Press Return to continue: Just a reminder...you are editing GINGER ROOT. LOCAL POSSIBLE DOSAGES: Do you want to edit Local Possible Dosages? N// MARK THIS DRUG AND EDIT IT FOR: O - Outpatient X - Non-VA Med Enter your choice(s) separated by commas : X X - Non-VA Med ** You are NOW Marking/Unmarking for NON-VA MEDS. ** A Non-VA Med ITEM? No// Y (Yes) ** You are NOW in the ORDERABLE ITEM matching for the dispense drug. ** Dosage Form -> CAP/TAB Match to another Orderable Item with same Dosage Form? NO// Dosage Form -> CAP/TAB Dispense Drug -> ginger root Orderable Item Name: GINGER// Matching GINGER ROOT TAB/CAP to GINGER CAP/TAB Is this OK? YES// Match Complete! Now editing Orderable Item: GINGER CAP/TAB  FORMULARY STATUS: Select OI-DRUG TEXT ENTRY: INACTIVE DATE: DAY (nD) or DOSE (nL) LIMIT: MED ROUTE: SCHEDULE TYPE: SCHEDULE: PATIENT INSTRUCTIONS: OTHER LANGUAGE INSTRUCTIONS: Select SYNONYM: Example 5: Drug Enter/Edit Editing Controlled Substances Select DRUG GENERIC NAME: morphine sulf 15mg cr tab MORPHINE SULF 15MG CR TAB CN101 WRITTEN RX REQUIRED ******************************************************************************* This entry is marked for the following PHARMACY packages: Outpatient Unit Dose Controlled Substances GENERIC NAME: MORPHINE SULF 15MG CR TAB Replace VA CLASSIFICATION: CN101// DEA, SPECIAL HDLG: 2C// The CS Federal Schedule associated with this drug in the VA Product File represents a DEA, Special Handling code of 2A. DEA, SPECIAL HDLG: 2C// 2A NATIONAL FORMULARY INDICATOR: YES Example 6: Drug Enter/Edit Gender-Specific Warnings XE "Gender-Specific Warnings"  Select DRUG GENERIC NAME: AMYL Lookup: GENERIC NAME AMYL NITRITE 0.3ML INHALENT CV250 ...OK? Yes// (Yes) ******************************************************************************* This entry is marked for the following PHARMACY packages: Outpatient Unit Dose Non-VA Med GENERIC NAME: AMYL NITRITE 0.3ML INHALENT Replace VA CLASSIFICATION: CV250// DEA, SPECIAL HDLG: 6P// NATIONAL FORMULARY INDICATOR: YES LOCAL NON-FORMULARY: VISN NON-FORMULARY: Select DRUG TEXT ENTRY: Select FORMULARY ALTERNATIVE: Select SYNONYM: 000223700212// SYNONYM: 000223700212// INTENDED USE: DRUG ACCOUNTABILITY// NDC CODE: 000223-7002-12// Select SYNONYM: MESSAGE: RESTRICTION: FSN: NDC: 223-7002-12// INACTIVE DATE: WARNING LABEL SOURCE is 'NEW'. The following WARNING LABEL may continue to be used for a limited time for some external interfaces. WARNING LABEL: Current Warning labels for AMYL NITRITE 0.3ML INHALENT Labels will print in the order in which they appear for local and CMOP fills: 31N Do not take this drug if you become pregnant. Pharmacy fill card display: DRUG WARNING 31N NOTE: Because the NEW WARNING LABEL LIST field is empty, the warnings above are the warnings that our national data source distributes for this drug. Would you like to edit this list of warnings? N// O Example 6: Drug Enter/Edit Gender-Specific Warnings (continued) GENDER SPECIFIC LBLS ON ALL RX: YES// ? If a new warning is specific to one gender, set this field to "N" to print the warning only for patients of that gender. Choose from: Y YES N NO GENDER SPECIFIC LBLS ON ALL RX: YES// ORDER UNIT: BX// PRICE PER ORDER UNIT: 4.95// Example 7: Drug Enter/Edit Dispense As Written (DAW) Code Editing Select OPTION NAME: PSS DRUG 1 PSS DRUG ENTER/EDIT Drug Enter/Edit 2 PSS DRUG TEXT FILE REPORT Drug Text File Report CHOOSE 1-2: 1 PSS DRUG ENTER/EDIT Drug Enter/Edit Drug Enter/Edit Select DRUG GENERIC NAME: METAPROTERENOL 5% SOLUTION 10ML RE102 ...OK? Yes// (Yes) ******************************************************************************* This entry is marked for the following PHARMACY packages: Outpatient Unit Dose Non-VA Med GENERIC NAME: METAPROTERENOL 5% SOLUTION 10ML Replace VA CLASSIFICATION: RE102// DEA, SPECIAL HDLG: NATIONAL FORMULARY INDICATOR: YES LOCAL NON-FORMULARY: VISN NON-FORMULARY: Select DRUG TEXT ENTRY: Select FORMULARY ALTERNATIVE: Select SYNONYM: METAPROTERENOL SULFATE 5% INHL SOLN // SYNONYM: METAPROTERENOL SULFATE 5% INHL SOLN Replace INTENDED USE: NDC CODE: Select SYNONYM: MESSAGE: RESTRICTION: FSN: NDC: 597-0071-75// INACTIVE DATE: WARNING LABEL SOURCE is 'NEW'. The following WARNING LABEL may continue to be used for a limited time for some external interfaces. WARNING LABEL: Current Warning labels for METAPROTERENOL 5% SOLUTION 10ML No warnings from the new data source exist for this drug. Verify that the drug is matched to the National Drug File. Would you like to edit this list of warnings? N// O ORDER UNIT: PRICE PER ORDER UNIT: DISPENSE UNIT: ML// DISPENSE UNITS PER ORDER UNIT: PRICE PER DISPENSE UNIT: 2.461 Example 7: Drug Enter/Edit Dispense As Written (DAW) Code Editing (continued) DAW CODE: 0// ? Enter the Dispensed As Written (DAW) code for this Drug. This information will be used when submitting electronic claims to 3rd party payers (ePharmacy). Select one of the following: 0 - NO PRODUCT SELECTION INDICATED 1 - SUBSTITUTION NOT ALLOWED BY PRESCRIBER 2 - SUBSTITUTION ALLOWED-PATIENT REQUESTED PRODUCT DISPENSED 3 - SUBSTITUTION ALLOWED-PHARMACIST SELECTED PRODUCT DISPENSED 4 - SUBSTITUTION ALLOWED-GENERIC DRUG NOT IN STOCK 5 - SUBSTITUTION ALLOWED-BRAND DRUG DISPENSED AS A GENERIC 6 - OVERRIDE 7 - SUBSTITUTION NOT ALLOWED-BRAND DRUG MANDATED BY LAW 8 - SUBSTITUTION ALLOWED-GENERIC DRUG NOT AVAILABLE IN MARKETPLACE 9 - OTHER DAW CODE: 0// - NO PRODUCT SELECTION INDICATED points to METAPROTERENOL SO4 5% SOLN,INHL in the National Drug file. This drug has already been matched and classified with the National Drug file. In addition, if the dosage form changes as a result of rematching, you will have to match/rematch to Orderable Item. This drug has also been marked to transmit to CMOP. If you choose to rematch it, the drug will be marked NOT TO TRANSMIT to CMOP. Do you wish to match/rematch to NATIONAL DRUG file? No// (No) Just a reminder...you are editing METAPROTERENOL 5% SOLUTION 10ML. LOCAL POSSIBLE DOSAGES: Do you want to edit Local Possible Dosages? N// O ******************************************************************************* This entry is marked for the following PHARMACY packages: Outpatient Unit Dose Non-VA Med MARK THIS DRUG AND EDIT IT FOR: O - Outpatient I - IV D - Drug Accountability C - Controlled Substances X - Non-VA Med Enter your choice(s) separated by commas : ** You are NOW in the ORDERABLE ITEM matching for the dispense drug. ** METAPROTERENOL 5% SOLUTION 10ML is already matched to METAPROTERENOL SOLN,INHL Do you want to match to a different Orderable Item? NO// With Patch PSS*1*92, the Drug Enter/Edit option is modified to allow the user to enter a Service Code in the DRUG file (#50). Note: Service Codes are assigned by the Charge Description Master Change Control Board. No entry should be made without coordination of the Change Control Board to assign the code. If a drug is matched to an entry in the VA PRODUCT file of the NDF package, a Service Code need not be entered in the DRUG file. If a Service Code is defined for drugs of this type in the DRUG file and is matched in the VA PRODUCT file, the value defined in the VA PRODUCT file takes precedence. The PSSCOMMON input template portion of the Drug Enter/Edit [PSS DRUG ENTER/EDIT] option is modified to allow entry of the new SERVICE CODE field. The following is an incomplete example showing only the display when the drug is matched to NDF so there is no prompt for a Service Code. Example 7: Drug Enter/Edit Drug matched to NDF, no prompt for Service Code NDC: INACTIVE DATE: <-----( Note: here between inactive date and warning label is where the Service Code prompt would have been displayed if the drug had not been matched to NDF. WARNING LABEL SOURCE is not 'NEW'. WARNING LABEL will be used until the WARNING LABEL SOURCE is set to 'NEW'. The following is an incomplete example showing only the display when the drug is not matched to NDF so a Service Code is entered. Example 8: Drug Enter/Edit Drug not matched to NDF, entering a Service Code NDC: INACTIVE DATE: If you are planning to match to a NDF entry later or have no plan of using the external billing function, you may skip the Service Code entry. SERVICE CODE: ? This is required for external billing purposes only. Answer must be between 600001-699999. SERVICE CODE: ?? The Charge Description Master (CDM) Change Control board assigns value for this field. The value should be a number between 600001-699999. SERVICE CODE: 699991 Drug Interaction Management [PSS DRG INTER MANAGEMENT] The Drug Interaction Management XE "Drug Interaction Management" \b sub-menu provides options through which local drug interactions may be entered or edited in the DRUG INTERACTION file (#56) or the severity of any interaction in the file may be changed from significant to critical. Enter/Edit Local Drug Interaction [PSS INTERACTION LOCAL ADD] The Enter/Edit Local Drug Interaction XE "Enter/Edit Local Drug Interaction" \b option allows Pharmacy sites to add local drug interactions to the DRUG INTERACTION file (#56) or edit only local drug interactions already in the file. The national entries in the DRUG INTERACTION file (#56) cannot be edited. When a prescription is filled, this information displays on the screen during the order checking process of medication order entry or prints whenever a prescription is filled. Example 1: Enter a Local Drug Interaction Select Pharmacy Data Management Option: DRUG INTeraction Management Select Drug Interaction Management Option: Enter/Edit Local Drug Interaction Select Drug Interaction: LOCALLY/TEST INTERACTION ARE YOU ADDING LOCALLY/TEST INTERACTION AS A NEW DRUG INTERACTION? Y (YES) DRUG INTERACTION INGREDIENT 1: CODEINE DRUG INTERACTION INGREDIENT 2: ACETAMINOPHEN DRUG INTERACTION SEVERITY: CRITICAL NAME: LOCALLY/TEST INTERACTION Replace INGREDIENT 1: CODEINE// INGREDIENT 2: ACETAMINOPHEN// SEVERITY: CRITICAL// TOTAL INDEXES: 30752// (No Editing) Example 2: Edit a Local Drug Interaction Select Pharmacy Data Management Option: DRUG INTeraction Management Select Drug Interaction Management Option: Enter/Edit Local Drug Interaction Select Drug Interaction: LOCALLY/TEST INTERACTION Primary Ingre.: CODEINE and ACETAMINOPHEN severity: CRITICAL NAME: LOCALLY/TEST INTERACTION Replace @ SURE YOU WANT TO DELETE THE ENTIRE LOCALLY/TEST INTERACTION DRUG INTERACTION? Y (YES) Select Drug Interaction: Report of Locally Entered Interactions [PSS REPORT LOCAL INTERACTIONS] The Report of Locally Entered Interactions option allows sites to print a report of locally entered drug interactions and their severity. Example: Report of Locally Entered Interactions Select Drug Interaction Management Option: ? Enter/Edit Local Drug Interaction Report of Locally Entered Interactions Enter ?? for more options, ??? for brief descriptions, ?OPTION for help text. Select Drug Interaction Management Option: REPort of Locally Entered Interactions This report gives you a printed copy of locally added drug interactions and their severity. You may queue the report to print, if you wish. DEVICE: VIRTUAL Right Margin: 80// LOCALLY ADDED DRUG INTERACTION LIST APR 13,2001 13:29 PAGE 1 NAME SEVERITY -------------------------------------------------------------------------------- DIGITALIS/DIPHENHYDRAMINE SIGNIFICANT ALPRAZOLAM/COLCHCINE CRITICAL AMOXICILLIN/CISAPRIDE CRITICAL AMINOPHYLLINE/AZITHROMYCIN CRITICAL AZITHROMYCIN/THEOPHYLLINE CRITICAL AZITHROMYCIN/OXTRIPHYLLINE CRITICAL AMPICILLIN/ASCORBIC ACID CRITICAL ASCORBIC ACID/ATENOLOL SIGNIFICANT ACACIA/ACETIC ACID SIGNIFICANT AMIKACIN/ASPIRIN SIGNIFICANT ASCORBIC ACID/ASPIRIN CRITICAL AMIKACIN/FLUORESCEIN SIGNIFICANT Select Drug Interaction Management Option: Electrolyte File (IV) [PSSJI ELECTROLYTE FILE] The Electrolyte File (IV) option allows the contents of the DRUG ELECTROLYTES file (#50.4) to be altered. This file contains the names of anions/cations and their concentration units. The file provides the ability for sites to enter intravenous (IV) orders for electrolytes as individual ingredients so that the IV label will print the total of individual electrolytes rather than the additive names. The ELECTROLYTES sub-file in the IV ADDITIVES file (#52.6) and IV SOLUTIONS file (#52.7) point to this Electrolyte file. Example 1: Electrolyte File (Adding) Select Pharmacy Data Management Option: ELectrolyte File (IV) Select DRUG ELECTROYTES NAME: CHLORIDE MEQ/ML ARE YOU ADDING CHLORIDE AS A NEW DRUG ELECTROLYTES (THE 9TH)? Y (YES) DRUG ELECTROLYTES CONCENTRATION UNITS: MEQ/ML NAME: CHLORIDE// CONCENTRATION UNITS: Select DRUG ELECTROLYTES NAME: Example 2: Electrolyte File (Deleting) Select Pharmacy Data Management Option: ELectrolyte File (IV) Select DRUG ELECTROLYTES NAME: CHLORIDE NAME: CHLORIDE// @ SURE YOU WANT TO DELETE THE ENTIRE CHLORIDE DRUG ELECTROLYTES? Y (YES) Lookup into Dispense Drug File [PSS LOOK] The Lookup into Dispense Drug File XE "Lookup into Dispense Drug File" \b option provides a lookup into the DRUG file (#50) and displays fields that are commonly edited. It is not possible to edit entries in the DRUG file (#50) from this option. Edits can be made through the use of the Drug Enter/Edit option. Patch PSS*1*61 ensures that the newly populated CS FEDERAL SCHEDULE field of the VA PRODUCT file (#50.68) is also included as part of the drug details in the Lookup into Dispense Drug File option. Example 1: Lookup Drug Select DRUG GENERIC NAME: TIMOLOL 1 TIMOLOL MALEATE 0.25% OPH GEL OP101 N/F NATL N/F; 2.5 ML/TUBE 2 TIMOLOL MALEATE 0.25% OPH SOLN OP101 NATL REVIEW; 5 ML/BT (IEN) 3 TIMOLOL MALEATE 0.5% OPH GEL OP101 N/F NATL N/F; 2.5 ML/TUBE (IEN) 4 TIMOLOL MALEATE 0.5% OPH SOLN OP101 NATL REVIEW; 5 ML/BT (IEN) CHOOSE 1-4: 4 TIMOLOL MALEATE 0.5% OPH SOLN OP101 NATL REVIEW; 5 ML/BT (IEN) TIMOLOL MALEATE 0.5% OPH SOLN ============================================================================= VA PRINT NAME: TIMOLOL MALEATE 0.5% OPH SOLN CMOP ID#: T0056 VA PRODUCT NAME: TIMOLOL MALEATE 0.5% SOLN,OPH CMOP DISPENSE: NO ORDERABLE ITEM: TIMOLOL SOLN,OPH NDF DF: SOLN,OPH ORDERABLE ITEM TEXT: SYNONYM(S): TIMOPTIC 0.5% Trade Name T/5 Quick Code T.5 Quick Code 024208032405 Drug Accountability 1677 Quick Code MESSAGE: NATL REVIEW; 5 ML/BT (IEN) ----------------------------------------------------------------------------- DEA, SPECIAL HDLG: 6P NDC: 61314-227-05 DAW CODE: 5 SUBSTITUTION ALLOWED-BRAND DRUG DISPENSED AS A GENERIC CS FEDERAL SCHEDULE: INACTIVE DATE: QUANTITY DISPENSE MESSAGE: ML (5/BT) WARNING LABEL SOURCE is set to 'NEW' NEW WARNING LABEL: 22N For the eye. Pharmacy fill card display: DRUG WARNING 22N ----------------------------------------------------------------------------- ORDER UNIT: BT PRICE/ORDER UNIT: 1.45 DISPENSE UNIT: ML VA DISPENSE UNIT: ML DISPENSE UNITS/ORDER UNIT: 5 PRICE/DISPENSE UNIT: 0.2900 APPL PKG USE: Outpatient Unit Dose STRENGTH: UNIT: POSSIBLE DOSAGES: LOCAL POSSIBLE DOSAGES: LOCAL POSSIBLE DOSAGE: 1 DROP PACKAGE: IO BCMA UNITS PER DOSE: 1 LOCAL POSSIBLE DOSAGE: 2 DROPS PACKAGE: IO BCMA UNITS PER DOSE: 1 ----------------------------------------------------------------------------- VA CLASS: OP101 BETA-BLOCKERS,TOPICAL OPHTHALMIC LOCAL NON-FORMULARY: VISN NON-FORMULARY: National Formulary Indicator: YES National Restriction: Local Drug Text: Example 2: Lookup into Dispense Drug File Select Pharmacy Data Management Option: LOOKUP INTO Dispense Drug File Select DRUG GENERIC NAME: LOVASTATIN 20MG TAB CV350 N/F RESTRICTED TO CARDIOLOGY SERVICE LOVASTATIN 20MG TAB ============================================================================ VA PRINT NAME: LOVASTATIN 20MG TAB CMOP ID#: L0060 VA PRODUCT NAME: LOVASTATIN 20MG TAB CMOP DISPENSE: YES ORDERABLE ITEM: LOVASTATIN TAB (N/F) NDF DF: TAB ORDERABLE ITEM TEXT: Refer to PBM/MAP Hyperlipidemia treatment guidelines for use. SYNONYM (S): MEVACOR Trade Name MESSAGE: THIS IS RESTRICTED TO CARDIOLOGY SERVICE ----------------------------------------------------------------------------- DEA, SPECIAL HDLG: 6 NDC: 000006-0731-82 CS FEDERAL SCHEDULE: INACTIVE DATE: QUANTITY DISPENSE MESSAGE: DISPENSE IN 30'S WARNING LABEL: WITH FOOD ----------------------------------------------------------------------------- ORDER UNIT: BT PRICE/ORDER UNIT: 50 DISPENSE UNIT: TAB VA DISPENSE UNIT: TAB DISPENSE UNITS/ORDER UNIT: 100 PRICE/DISPENSE UNIT: 0.500 APPL PKG USE: Outpatient Unit Dose ----------------------------------------------------------------------------- VA CLASS: CV350 ANTILIPEMIC AGENTS LOCAL NON-FORMULARY: N/F VISN NON-FORMULARY: N/F National Formulary Indicator: YES FORMULARY ALTERNATIVES: SIMVASTATIN 20MG TAB PRAVASTATIN 20MG TAB National Restriction: (Refer to PBM/MAP Hyperlipidemia treatment guidelines for use) Local Drug Text: Example 3: Lookup Drug - Looking Up a Non-VA Med Select DRUG GENERIC NAME: GINKO TAB/CAP HA000 N/F ginko tab/cap ============================================================================= VA PRODUCT NAME: GINKGO EXT 60MG TAB ORDERABLE ITEM: ginko TAB (N/F) NDF DF: TAB ORDERABLE ITEM TEXT: SYNONYM(S): MESSAGE: ----------------------------------------------------------------------------- DEA, SPECIAL HDLG: NDC: CS FEDERAL SCHEDULE: INACTIVE DATE: ----------------------------------------------------------------------------- ORDER UNIT: PRICE/ORDER UNIT: DISPENSE UNIT: DISPENSE UNITS/ORDER UNIT: PRICE/DISPENSE UNIT: APPL PKG USE: Non-VA Med STRENGTH: UNIT: POSSIBLE DOSAGES: LOCAL POSSIBLE DOSAGES: ----------------------------------------------------------------------------- VA CLASS: LOCAL NON-FORMULARY: N/F VISN NON-FORMULARY: National Formulary Indicator: Not Matched to NDF Medication Instruction File Add/Edit [PSSJU MI] The Medication Instruction File Add/Edit XE "Medication Instruction File Add/Edit" \b option allows the user to enter and edit abbreviations and expansions in the MEDICATION INSTRUCTION file (#51) and to flag those entries for use by the Inpatient Medications package only, Outpatient Pharmacy package only, or both. The expansions in the MEDICATION INSTRUCTION file (#51) expand the Schedule and Patient Instructions when building the SIG. The Inpatient Medications package contains a field called SPECIAL INSTRUCTIONS that utilizes these abbreviations and expansions when printing various reports. Additionally, the Outpatient Pharmacy package utilizes these abbreviations for expansions when building the prescription SIG. The Medication Instruction File Add/Edit option allows the user to enter the expansion in a language other than English. PDM does not translate English terms into another language; instead, it allows the user to enter a translation of a term. If a value has not been entered in the OTHER LANGUAGE EXPANSION field, PDM defaults to the value entered in the EXPANSION field. If no values exist in the EXPANSION and OTHER LANGUAGE EXPANSION fields, an EXPANSION value will not print when Outpatient Pharmacy builds the SIG. See Appendix F for a list of Spanish equivalents for some of the more common medication instructions. Example: Edit Frequency in Medication Instruction File Select Pharmacy Data Management Option: MEDICATION INStruction File Add/Edit Select MEDICATION INSTRUCTION NAME: HS AT BEDTIME NAME: HS// SYNONYM: QHS// EXPANSION: AT BEDTIME// OTHER LANGUAGE EXPANSION: AL ACOSTARSE PLURAL: INTENDED USE: IN & OUTPATIENT// FREQUENCY (IN MINUTES): 1440// Medication Route File Enter/Edit [PSS MEDICATION ROUTES EDIT] The Medication Route File Enter/Edit XE "Medication Route File Enter/Edit" \b option provides the ability to enter and edit data in the MEDICATION ROUTES file (#51.2). Medication routes may be designated for use in all packages or for use only in the National Drug File package. If an Outpatient Pharmacy expansion has been entered at the OUTPATIENT EXPANSION prompt, the Outpatient Pharmacy expansion portion of the medication route will appear as part of the SIG on the prescription label exactly as the Outpatient Pharmacy expansion was entered in MEDICATION ROUTES file (#51.2). The IV FLAG field (#6) in the MEDICATION ROUTES file (#51.2) is used to determine that the order can be processed through the IV portion of the Inpatient Medications package. The PROMPT FOR INJ. SITE IN BCMA XE "BCMA prompts:PROMPT FOR INJ. SITE IN BCMA"  XE "PROMPT FOR INJ. SITE IN BCMA"  field (#8) in the MEDICATION ROUTES file (#51.2) is used to send information to be displayed on the BCMA Virtual Due List and Coversheet and to verify whether the user should be prompted for an injection site. The DSPLY ON IVP/IVPB TAB IN BCMA? XE "BCMA prompts::DSPLY ON IVP/IVPB TAB IN BCMA?"  XE "DSPLY ON IVP/IVPB TAB IN BCMA?"  field (#9) in the MEDICATION ROUTES file (#51.2) is used to send information to be displayed on the BCMA IVP/IVPB Tab and Coversheet. The Medication Route File Enter/Edit option allows the user to enter an interpretation of the OUTPATIENT EXPANSION field in a language other than English. PDM does not translate English terms into another language; instead, it allows the user to enter a translation of a term. If a value has not been entered in the OTHER LANGUAGE EXPANSION field, PDM will default to the value entered in the OUTPATIENT EXPANSION field. If no values exist in the OUTPATIENT EXPANSION and OTHER LANGUAGE EXPANSION fields, the system will not display default values for those fields during CPRS or Outpatient Pharmacy prescription order entry processing. However, when building the SIG, Outpatient Pharmacy will default to the value the user input during order entry. See Appendix G for a list of Spanish equivalents for some of the more common medication routes. Example 1 demonstrates how to enter a new medication route. Example 1: Enter Medication Route File Select MEDICATION ROUTES NAME: SUBCUTANEOUS SC NAME: SUBCUTANEOUS// ABBREVIATION: SC// PACKAGE USE: ALL PACKAGES// OUTPATIENT EXPANSION: SUBCUTANEOUSLY// OTHER LANGUAGE EXPANSION: VIA SUBCUTANEA// IV FLAG: YES// PROMPT FOR INJ. SITE IN BCMA: DSPLY ON IVP/IVPB TAB IN BCMA? Text can be entered to edit the existing entries for a medication route, as demonstrated in Example 2 below. Since no value exists in the OTHER LANGUAGE EXPANSION database and the user did not enter a translation, the OUTPATIENT EXPANSION value will print on the patients prescription label by default. Example 2: Medication Route File Edit Select MEDICATION ROUTES NAME: SUBLINGUAL SL NAME: SUBLINGUAL// ABBREVIATION: SL// PACKAGE USE: ALL PACKAGES// OUTPATIENT EXPANSION: UNTIL DISSOLVED// UNDER THE TONGUE UNTIL DISSOLVED OTHER LANGUAGE EXPANSION: IV FLAG: PROMPT FOR INJ. SITE IN BCMA: DSPLY ON IVP/IVPB TAB IN BCMA? If the text to be replaced is more than 29 characters, the REPLACE prompt will automatically appear. Replacement text for shorter text entries may be entered after the double slashes. Some files may be set up to refuse deletions, depending on the sites File Manager setup. Example 3: Medication Route File Deletions Not Allowed Select MEDICATION ROUTES NAME: NEW INHALATION MED ROUTE EXAMPLE NIMRE NAME: NEW INHALATION MED ROUTE EXAMPLE Replace @ DELETIONS ARE NOT ALLOWED!?? Required NAME: NEW INHALATION MED ROUTE EXAMPLE Replace ... With Replace DELETIONS ARE NOT ALLOWED!?? Required NAME: NEW INHALATION MED ROUTE EXAMPLE Replace ABBREVIATION: NIMRE// PACKAGE USE: NATIONAL DRUG FILE ONLY// OUTPATIENT EXPANSION: AS NEEDED// OTHER LANGUAGE EXPANSION: IV FLAG: PROMPT FOR INJ. SITE IN BCMA: DSPLY ON IVP/IVPB TAB IN BCMA? Orderable Item Management [PSS ORDERABLE ITEM MANAGEMENT] The Orderable Item Management XE "Orderable Item Management" \b sub-menu provides an option through which the Pharmacy Orderable Items are maintained. Edit Orderable Items [PSS EDIT ORDERABLE ITEMS] The Edit Orderable Items XE "Edit Orderable Items" \b option allows the user to enter and edit data in the PHARMACY ORDERABLE ITEM file (#50.7). If a Pharmacy Orderable Item Drug Text Entry is identified at the OI-DRUG-TEXT prompt, it will be viewable during medication order entry processes through CPRS, Outpatient Pharmacy, and Inpatient Medications. Pharmacy Orderable Item defaults can be entered for selected fields. These defaults will be displayed to the user during the medication order entry processes for all applications through which medication orders can be entered. The Edit Orderable Items option allows the user to enter patient instructions in a language other than English. PDM does not translate English terms into another language; instead, it allows the user to enter a translation of a term. If a value has not been entered in the OTHER LANGUAGE INSTRUCTIONS field, PDM will default to the value entered in the PATIENT INSTRUCTIONS field. If the PATIENT INSTRUCTIONS field does not contain data for the selected orderable item, the system will not present default patient instructions to the user during CPRS or Outpatient Pharmacy prescription order processing. However, when building the SIG, Outpatient Pharmacy will default to the value the user input through backdoor Outpatient Pharmacy order entry. Example: Editing Pharmacy Orderable Items Select Orderable Item Management Option: EDIT Orderable Items This option enables you to edit Orderable Item names, Formulary status, drug text, Inactive Dates, and Synonyms. Select PHARMACY ORDERABLE ITEM NAME: IBUPROFEN 800MG TAB DISPENSE DRUG: IBUPROFEN 800MG TAB MS102 IBUPROFEN 800MG TAB is already matched to IBUPROFEN TAB Do you want to match to a different Orderable Item? NO// YES There are other Dispense Drugs with the same VA Generic Name and same Dose Form already matched to orderable items. Choose a number to match, or enter Disp. drug -> IBUPROFEN 800MG TAB 1 IBUPROFEN TAB Choose number of Orderable Item to match, or '^' to enter a new one: 1 Matching IBUPROFEN 800MG TAB To Example: Editing Pharmacy Orderable Items (continued) IBUPROFEN TAB Is this OK? YES// Match Complete! Now editing Orderable Item: IBUPROFEN TAB This Orderable Item is Formulary. This Orderable Item is marked as a Non-VA Med. Select OI-DRUG TEXT ENTRY: INACTIVE DATE: DAY (nD) or DOSE (nL) LIMIT: 7D// MED ROUTE: SCHEDULE TYPE: PRN// SCHEDULE: BID// PATIENT INSTRUCTIONS: WF// OTHER LANGUAGE INSTRUCTIONS: CON ALIMENTO Select SYNONYM: Dispense Drug/Orderable Item Maintenance [PSS MAINTAIN ORDERABLE ITEMS] The Dispense Drug/Orderable Item Maintenance XE "Dispense Drug/Orderable Item Maintenance" \b option is used for maintaining the relationship between Dispense Drugs and Pharmacy Orderable Items. Entries made at the Pharmacy Orderable Item prompts will be used by the Outpatient Pharmacy, Inpatient Medications, and CPRS packages as defaults during the medication order entry processes. If no entries are made at the MED ROUTE and SCHEDULE TYPE prompts, the software will assume the defaults of PO (oral) and CONTINUOUS, respectively. The Dispense Drug/Orderable Item Maintenance option allows the user to enter patient instructions in a language other than English. PDM does not translate English terms into another language; instead, it allows the user to enter a translation of a term. If a value has not been entered in the OTHER LANGUAGE INSTRUCTIONS field, PDM will default to the value entered in the PATIENT INSTRUCTIONS field. If the PATIENT INSTRUCTIONS field does not contain data for the selected orderable item, the system will not present default patient instructions to the user during CPRS or Outpatient Pharmacy prescription order processing. . However, when building the SIG, Outpatient Pharmacy will default to the value the user input through backdoor Outpatient Pharmacy order entry. Example: Dispense Drug/Orderable Item Maintenance Select Orderable Item Management Option: Dispense Drug/Orderable Item Maintenance This option enables you to match Dispense Drugs to an entry in the Pharmacy Orderable Item file, or create a new Pharmacy Orderable Item entry for a Dispense Drug. DISPENSE DRUG: IBUPROFEN 800MG TAB MS102 IBUPROFEN 800MG TAB is already matched to IBUPROFEN TAB Do you want to match to a different Orderable Item? NO// YES There are other Dispense Drugs with the same VA Generic Name and same Dose Form already matched to orderable items. Choose a number to match, or enter Disp. drug -> IBUPROFEN 800MG TAB 1 IBUPROFEN TAB Choose number of Orderable Item to match, or '^' to enter a new one: 1 Matching IBUPROFEN 800MG TAB to IBUPROFEN TAB Is this OK? YES// Match Complete! Now editing Orderable Item: IBUPROFEN TAB This Orderable Item is Formulary. Select OI-DRUG TEXT ENTRY: INACTIVE DATE: Example: Dispense Drug/Orderable Item Maintenance (continued) DAY (nD) or DOSE (nL) LIMIT: 7D// MED ROUTE: SCHEDULE TYPE: PRN// SCHEDULE: BID// PATIENT INSTRUCTIONS: WF// OTHER LANGUAGE INSTRUCTIONS: CON ALIMENTO Select SYNONYM: Orderable Item/Dosages Report [PSS ORDERABLE ITEM DOSAGES] The Orderable Item/Dosages Report option prints a report that displays Inpatient Medication and Outpatient Pharmacy dosages for each Pharmacy Orderable Item. These are the dosages that will display for selection through CPRS when an Orderable Item is selected through CPRS at the time an Orderable Item is selected for a medication order. Due to the length of this report, it must be queued to a printer. This option prints a report, sorted by Pharmacy Orderable Item that displays Inpatient Medication and Outpatient Pharmacy dosages for Pharmacy Orderable Items. These dosages will display for selection through CPRS when an Orderable Item is selected for a medication order. Along with each dosage that is displayed on the report, the name of the drug entry from the DRUG file (#50) that provided the dosage is displayed. Not every dosage from the DRUG file (#50) will display on this report. For example, if there are duplicate Possible Dosages for a Pharmacy Orderable Item, and there are different Dispense Units Per Dose, only the Possible Dosage with the lowest Dispense Units Per Dose will display on the report. If there are package specific Possible Dosages and Local Possible Dosages for drugs tied to the Pharmacy Orderable Item, only the Possible Dosages will display on the report because Possible Dosages always override Local Possible Dosages. In summary, this report will screen out Possible Dosages and Local Possible Dosages when appropriate, so only the dosages selectable through CPRS will display on this report. Additionally, the report will display in parenthesis the dosage, as it will appear on the Outpatient Pharmacy prescription label, if the dosage is a Possible Dosage. ----------------------------------------Screen Print Follows------------------------------------------------- Example: Orderable Item Dosages Report Select Orderable Item Management Option: ORDerable Item/Dosages Report Select one of the following: A ALL S SELECT A RANGE Print Report for (A)ll or (S)elect a Range: S// ELECT A RANGE There are entries in the Orderable Item file with leading numerics. Print report for Orderable Items with leading numerics? N// O To see items beginning with the letter 'A', enter 'A', or whichever letter you wish to see. To see items in a range, for example items starting with the letters 'G', 'H', 'I' and 'J', enter in the format 'G-J'. Select a Range: C Report will be for items starting with the letter C, and ending with items starting with the letter C. Is this correct? Y// ES DEVICE: HOME// DECSERVER Dosage report for Orderable Items from C through C PAGE: 1 ----------------------------------------------------------------------------- CAFFEINE/ERGOTAMINE TAB Inpatient Dosages: 1 TABLET ERGOTAMINE & CAFFEINE TAB 2 TABLETS ERGOTAMINE & CAFFEINE TAB Outpatient Dosages: 1 TABLET ERGOTAMINE & CAFFEINE TAB 2 TABLETS ERGOTAMINE & CAFFEINE TAB CALCITONIN INJ,SOLN Inpatient Dosages: 200UNT/1ML CALCITONIN-SALMON 400 MRC UNITS 400UNT/2ML CALCITONIN-SALMON 400 MRC UNITS Outpatient Dosages: CALCITONIN-SALMON 400 MRC UNITS CALCITRIOL CAP,ORAL Inpatient Dosages: 0.25MCG CALCITRIOL 0.25MCG CAP 0.5MCG CALCITRIOL 0.25MCG CAP Outpatient Dosages: 0.25MCG (1 CAPSULE) CALCITRIOL 0.25MCG CAP 0.5MCG (2 CAPSULES) CALCITRIOL 0.25MCG CAP CALCIUM INJ,CONC Outpatient Dosages: CALCIUM CHLORIDE 1GM/10ML INJ. Example: Orderable Item Dosages Report (continued) CALCIUM CARBONATE POWDER Outpatient Dosages: CALCIUM CARBONATE PWD CALCIUM CARBONATE/SODIUM FLUORIDE CAP,ORAL Outpatient Dosages: 1 CAPSULE FLORICAL CAPS 2 CAPSULES FLORICAL CAPS CALCIUM CHLORIDE INJ,SOLN Outpatient Dosages: CALCIUM GLUCONATE 10% INJ CALCIUM CHLORIDE INJ,CONC Outpatient Dosages: CALCIUM CHLORIDE 10% 10ML B.J. CALCIUM GLUBIONATE SYRUP Outpatient Dosages: 1 TEASPOONFUL NEO-CALGLUCON SYRUP (OZ) 2 TEASPOONFULS NEO-CALGLUCON SYRUP (OZ) 1 TABLESPOONFUL NEO-CALGLUCON SYRUP (OZ) 2 TABLESPOONFULS NEO-CALGLUCON SYRUP (OZ) 1 ML NEO-CALGLUCON SYRUP (OZ) 2 MLS NEO-CALGLUCON SYRUP (OZ) CALCIUM LACTATE POWDER Outpatient Dosages: CALCIUM LACTATE POWDER USP CAMPHOR LIQUID Outpatient Dosages: CAMPHOR SPIRITS 30ML CANDIDA ALBICANS INJ Outpatient Dosages: CANDIDA ALBICANS 1:100 INJ CANNULA, NASAL DEVICE Outpatient Dosages: CANNULA, NASAL (HUDSON) CAPTOPRIL TAB Inpatient Dosages: 25MG CAPTOPRIL 25MG TABS 50MG CAPTOPRIL 50MG TABS 100MG CAPTOPRIL 100MG TABS 200MG CAPTOPRIL 100MG TABS Outpatient Dosages: 25MG (1 TABLET) CAPTOPRIL 25MG TABS 50MG (1 TABLET) CAPTOPRIL 50MG TABS 100MG (1 TABLET) CAPTOPRIL 100MG TABS 200MG (2 TABLETS) CAPTOPRIL 100MG TABS CARBACHOL SOLN,OPH Inpatient Dosages: 1 DROP CARBACHOL 1.5% OPHT. SOL. 2 DROPS CARBACHOL 1.5% OPHT. SOL. 1 DROP CARBACHOL 0.75% OPHTH SOLUTION 2 DROPS CARBACHOL 0.75% OPHTH SOLUTION 1 DROP CARBACHOL 3% OPHTH SOLUTION 2 DROPS CARBACHOL 3% OPHTH SOLUTION Example: Orderable Item Dosages Report (continued) Outpatient Dosages: 1 DROP CARBACHOL 1.5% OPHT. SOL. 2 DROPS CARBACHOL 1.5% OPHT. SOL. 1 DROP CARBACHOL 0.75% OPHTH SOLUTION 2 DROPS CARBACHOL 0.75% OPHTH SOLUTION 1 DROP CARBACHOL 3% OPHTH SOLUTION 2 DROPS CARBACHOL 3% OPHTH SOLUTION CARBAMAZEPINE TAB,ORAL 11/13/00 CARBENICILLIN TAB Inpatient Dosages: 382MG CARBENICILLIN 382MG TAB 764MG CARBENICILLIN 382MG TAB CARBIDOPA/LEVODOPA TAB Inpatient Dosages: 1 TABLET CARBIDOPA/LEVODOPA 25/100 S.T. 2 TABLETS CARBIDOPA/LEVODOPA 25/100 S.T. 1 TABLET CARBIDOPA/LEVODOPA 25/250 S.T. 2 TABLETS CARBIDOPA/LEVODOPA 25/250 S.T. Outpatient Dosages: 1 TABLET CARBIDOPA/LEVODOPA 25/100 S.T. 2 TABLETS CARBIDOPA/LEVODOPA 25/100 S.T. 1 TABLET CARBIDOPA/LEVODOPA 25/250 S.T. 2 TABLETS CARBIDOPA/LEVODOPA 25/250 S.T. CARMUSTINE INJ,SOLN Inpatient Dosages: 100MG/1VIAL CARMUSTINE 100MG/VIAL INJ 200MG/2VIAL CARMUSTINE 100MG/VIAL INJ Outpatient Dosages: CARMUSTINE COMB.PK CARMUSTINE 100MG/VIAL INJ CAROTENE,BETA CAP,ORAL Inpatient Dosages: Select Orderable Item Management Option: Patient Instructions Report [PSS INSTRUCTIONS/ITEMS REPORT] The Patient Instructions Report option prints a report that displays Pharmacy Orderable Items, along with the expanded Patient Instructions for each Pharmacy Orderable Item. These Patient Instructions are used as default values for Outpatient Pharmacy orders entered through CPRS and Outpatient Pharmacy. This report can be printed to display all Pharmacy Orderable Items or only Orderable Items with associated Patient Instructions. Example: Patient Instructions Report Select Pharmacy Data Management Option: OR 1 Orderable Item Management 2 Orderable Item Report CHOOSE 1-2: 1 Orderable Item Management Select Orderable Item Management Option: PAtient Instructions Re port Select one of the following: A ALL S SELECT A RANGE Print Report for (A)ll or (S)elect a Range: S// ELECT A RANGE There are entries in the Orderable Item file with leading numerics. Print report for Orderable Items with leading numerics? N// O To see items beginning with the letter 'A', enter 'A', or whichever letter you wish to see. To see items in a range, for example items starting with the letters 'G', 'H', 'I' and 'J', enter in the format 'G-J'. Select a Range: N Report will be for items starting with the letter N, and ending with items starting with the letter N. Is this correct? Y// ES Should report only include Orderable Items with Patient Instructions? Y// ES DEVICE: HOME// TELNET DEVICE Instructions report for items from N through N PAGE: 1 ----------------------------------------------------------------------------- NAPROXEN TAB WITH FOOD NITROGLYCERIN TAB,SUBLINGUAL FOR CHEST PAIN-CALL PHYSICIAN IF NO RELIEF AFTER 3 DOSES End of Report. Press Return to continue: Select Orderable Item Management Option: Orderable Item Report [PSS ORDERABLE ITEM REPORT] The Orderable Item Report option lists items from the PHARMACY ORDERABLE ITEM file (#50.7), along with the associated Dispense Drugs. Due to the length of this report it must be queued to a printer. Example: Orderable Item Report Select Pharmacy Data Management Option: ORDER 1 Orderable Item Management 2 Orderable Item Report CHOOSE 1-2: 2 Orderable Item Report Select one of the following: M Drugs that are matched N Drugs that are not matched Enter M to see all the IV Solutions, IV Additives, and Dispense Drugs that are matched to an Orderable Item. Enter N to see all IV Additives, IV Solutions, and Dispense Drugs that are not matched to an Orderable Item. Enter M or N: M Drugs that are matched ** WARNING ** THIS REPORT MAY BE VERY LONG ** WARNING ** Due to the length of this report, and to avoid tying up a terminal for a long time, this report must be QUEUED to a printer! This report must be QUEUED to a printer! DEVICE: Printer 1 Requested Start Time: NOW// (JUL 18, 2001@13:59:39) -------------------------------------Report Follows---------------------------------------------- Example: Orderable Item Report (continued) ORDERABLE ITEM - DISPENSE DRUG (MATCHED REPORT) PAGE: 1 ------------------------------------------------------------------------------ (853) A-FIL CREAM,TOP (1215) Dispense Drug -> A-FIL CREAM 45GM ------------------------------------------------------------------------------ (2798) ABACAVIR(ZIAGEN) TAB (4508) Dispense Drug -> ABACAVIR (ZIAGEN) 300MG TAB UD ------------------------------------------------------------------------------ (2229) ABCIXIMAB INJ,SOLN (3912) Dispense Drug -> ABCIXIMAB (REOPRO) 2MG/ML INJ ------------------------------------------------------------------------------ (1833) ABDOMINAL PAD (25) Dispense Drug -> PAD,ABDOMINAL 7.5 X 8 STERILE (2577) Dispense Drug -> PADS ABDOMINAL 5X9 (3276) Dispense Drug -> COTTON WADDING ------------------------------------------------------------------------------ (1944) ABDOMINAL BINDER BELT (2743) Dispense Drug -> ABDOMINAL BINDER ------------------------------------------------------------------------------ (2101) ACARBOSE TAB (3764) Dispense Drug -> ACARBOSE (PRECOSE) 50MG TAB (3765) Dispense Drug -> ACARBOSE (PRECOSE) 25MG TAB ------------------------------------------------------------------------------ (1) ACEBUTOLOL CAP,ORAL (577) Dispense Drug -> ACEBUTOLOL 200MG CAP (3335) Dispense Drug -> ACEBUTOLOL 400MG CAP ------------------------------------------------------------------------------ (1629) ACETAMINOPHEN TAB (263) Dispense Drug -> ACETAMINOPHEN 325MG TAB (2730) Dispense Drug -> ACETAMINOPHEN 325MG TAB UD (4429) Dispense Drug -> ZTEST ------------------------------------------------------------------------------ (2663) ACETAMINOPHEN ELIXIR (2564) Dispense Drug -> ACETAMINOPHEN LIQ 650MG/20.3ML U.D. CUP ------------------------------------------------------------------------------ (1681) ACETAMINOPHEN LIQUID,ORAL (494) Dispense Drug -> ACETAMINOPHEN LIQ 160MG/5ML 4OZ (1723) Dispense Drug -> ACETAMINOPHEN 500MG/15CC ELIXIR ------------------------------------------------------------------------------ (4) ACETAMINOPHEN SUPP,RTL (264) Dispense Drug -> ACETAMINOPHEN 650MG RTL SUPP ------------------------------------------------------------------------------ (2117) ACETAMINOPHEN/BUTALBITAL/CAFFEINE CAP,ORAL (3295) Dispense Drug -> APAP 325MG/BUTALBITAL 50MG/CAFN 40MG CAP ------------------------------------------------------------------------------ (6) ACETAMINOPHEN/CHLORZOXAZONE TAB (1808) Dispense Drug -> CHLORZOXAZONE & ACETAMINOPHEN TAB ------------------------------------------------------------------------------ (8) ACETAMINOPHEN/CODEINE TAB (341) Dispense Drug -> ACETAMINOPHEN WITH CODEINE 60MG (342) Dispense Drug -> ACETAMINOPHEN WITH CODEINE 30MG TAB (343) Dispense Drug -> ACETAMINOPHEN WITH CODEINE 15MG TAB (2029) Dispense Drug -> ACETAMIN W/CODEINE 30MG(TYLENOL#3)TAB UD ------------------------------------------------------------------------------ (7) ACETAMINOPHEN/CODEINE ELIXIR (228) Dispense Drug -> ACETAMINOPHEN AND CODEINE ELIXIR (ML) (401) Dispense Drug -> ACETAMIN W/CODEINE 30MG/12.5ML LIQ UD ------------------------------------------------------------------------------ (9) ACETAMINOPHEN/HYDROCODONE CAP,ORAL (1728) Dispense Drug -> HYDROCODONE/ACETAMINOPHEN (LORCET-HD) ------------------------------------------------------------------------------ (10) ACETAMINOPHEN/HYDROCODONE TAB (3293) Dispense Drug -> HYDROCODONE 5MG/ACETAMINOPHEN 500MG TAB (4099) Dispense Drug -> HYDROCODONE 7.5MG/ACETAMINOPHEN 750MG TB ------------------------------------------------------------------------------ (1762) ACETAMINOPHEN/HYDROCODONE LIQUID,ORAL (1572) Dispense Drug -> HYDROCODONE/ACETAMIN 2.5MG/167MG/5ML LIQ Example: Orderable Item Report (continued) ------------------------------------------------------------------------------ (2730) ACETAMINOPHEN/OXYCODONE CAP,ORAL (344) Dispense Drug -> ACETAMINOPHEN & OXYCODONE (TYLOX) CAP ------------------------------------------------------------------------------ (2614) ACETAMINOPHEN/OXYCODONE TAB (1452) Dispense Drug -> OXYCODONE /ACETAMINOPHEN (PERCOCET) TAB (1510) Dispense Drug -> ACETAMIN W/OXYCODONE 5MG(PERCOCET)TAB UD ------------------------------------------------------------------------------ (12) ACETAZOLAMIDE CAP,SA (639) Dispense Drug -> ACETAZOLAMIDE 500MG T.R.C. (2599) Dispense Drug -> ACETAZOLAMIDE 500MG CAP,SA ------------------------------------------------------------------------------ (13) ACETAZOLAMIDE INJ (640) Dispense Drug -> ACETAZOLAMIDE NA 500MG/VIL INJ ------------------------------------------------------------------------------ (14) ACETAZOLAMIDE TAB (638) Dispense Drug -> ACETAZOLAMIDE 250MG TAB ------------------------------------------------------------------------------ (2156) ACETIC ACID LIQUID (2506) Dispense Drug -> DOUCHE VAGINAL (VINEGAR) (4184) Dispense Drug -> ACETIC ACID 5% ------------------------------------------------------------------------------ (18) ACETIC ACID SOLN,OTIC (1665) Dispense Drug -> ZZACETIC ACID 2% (VOSOL) SOLN,OTIC 30ML (4113) Dispense Drug -> ACETIC ACID 2% (VOSOL) OTIC SOLN (15) ------------------------------------------------------------------------------ (17) ACETIC ACID SOLN,IRRG (675) Dispense Drug -> ACETIC ACID 0.25% SOLN,IRRG (4108) Dispense Drug -> ACETIC ACID 0.25% IRRG SOLN ------------------------------------------------------------------------------ (2201) ACETIC ACID,GLACIAL LIQUID (1185) Dispense Drug -> ACETIC ACID,GLACIAL LIQUID ------------------------------------------------------------------------------ (15) ACETIC ACID/ALUMINUM ACETATE SOLN,OTIC (1193) Dispense Drug -> DOMEBORO SOLN,OTIC ------------------------------------------------------------------------------ (16) ACETIC ACID/HYDROCORTISONE SOLN,OTIC (1881) Dispense Drug -> ZZACETIC ACID/HYDROCORT (VOSOL HC) OTIC (4112) Dispense Drug -> ACETIC ACID/HYDROCORT(VOSOL HC) OTIC(10) ------------------------------------------------------------------------------ (19) ACETOHEXAMIDE TAB (951) Dispense Drug -> ACETOHEXAMIDE 250MG TAB (952) Dispense Drug -> ACETOHEXAMIDE 500MG TAB ------------------------------------------------------------------------------ (20) ACETONE LIQUID (1292) Dispense Drug -> ACETONE 1PT ------------------------------------------------------------------------------ (21) ACETOPHENAZINE MALEATE TAB (383) Dispense Drug -> ACETOPHENAZINE MALEATE 20MG TAB ------------------------------------------------------------------------------ (22) ACETYLCHOLINE CHLORIDE SOLN,OPH (749) Dispense Drug -> ACETYLCHOLINE CL 1% SOLN,OPH (2118) ACETYLCYSTEINE 10% SOLN,OPH (225) Dispense Drug -> ACETYLCYSTEINE 10% OPH DROPS 10ML ------------------------------------------------------------------------------ (2119) ACETYLCYSTEINE 10% SOLN,INHL (173) Dispense Drug -> ACETYLCYSTEINE 10% INHL SOLN (10) ------------------------------------------------------------------------------ (23) ACETYLCYSTEINE 20% SOLN,INHL (1218) Dispense Drug -> ACETYLCYSTEINE 20% INHL SOLN (30) (1634) Dispense Drug -> ZZACETYLCYSTEINE 20% SOLN 10ML VI (4476) Dispense Drug -> ACETYLCYSTEINE 20% INHL SOLN (10) ------------------------------------------------------------------------------ (2443) ACITRETIN CAP,ORAL (4193) Dispense Drug -> ACITRETIN 25MG CAP (4317) Dispense Drug -> ACITRETIN 10MG CAP ------------------------------------------------------------------------------ (1881) ACRIVASTINE/PSEUDOEPHEDRINE CAP,ORAL (3490) Dispense Drug -> ACRIVASTINE 8/PSEUDOEPHEDRINE 60MG CAP Example: Orderable Item Report (continued) ------------------------------------------------------------------------------ (2631) ACTIVE LIFE (0227-71) POUCH (4254) Dispense Drug -> POUCH,OSTOMY,ACTIVE LIFE C#0227-71 ------------------------------------------------------------------------------ (24) ACYCLOVIR INJ (3045) Dispense Drug -> ACYCLOVIR (ZOVIRAX) 500MG INJ (43) Additive -> ACYCLOVIR (ZOVIRAX) ------------------------------------------------------------------------------ (2522) ACYCLOVIR TAB (2154) Dispense Drug -> ACYCLOVIR (ZOVIRAX) 800MG TAB (4308) Dispense Drug -> ACYCLOVIR 800MG UD TAB ------------------------------------------------------------------------------ (28) ACYCLOVIR OINT,TOP (2443) Dispense Drug -> ZZACYCLOVIR 5% (ZOVIRAX) OINT,TOP 15GM (4221) Dispense Drug -> ACYCLOVIR 5% OINTMENT (15) ------------------------------------------------------------------------------ (26) ACYCLOVIR CAP,ORAL (2600) Dispense Drug -> ACYCLOVIR (ZOVIRAX) 200MG CAPS ------------------------------------------------------------------------------ (25) ACYCLOVIR SUSP (3522) Dispense Drug -> ACYCLOVIR (ZOVIRAX) SUSP 800MG/20ML ------------------------------------------------------------------------------ (29) ADAPETTES SOLN,OPH (2271) Dispense Drug -> ADAPETTES (15ML) ------------------------------------------------------------------------------ (1945) ADAPTER MISCELLANEOUS (2676) Dispense Drug -> ADAPTER FOR URINE BAG ------------------------------------------------------------------------------ (2017) ADAPTER,JEJUNOSTOMY ADAPTER Formulary Information Report [PSS NFI] The Formulary Information Report XE "Formulary Information Report" \b option provides a listing of pertinent Pharmacy formulary information. The report is organized alphabetically by Dispense Drug but will also display the Pharmacy Orderable Item to which the Dispense Drug is matched. An N in a column indicates that the Dispense Drug is marked non-formulary at that level (Local, VISN, or National). If the Dispense Drug is restricted, an R appears in the appropriate column. The Application Package Use indicator is also displayed on the report. If the user selects to include drug text in the report, an I will appear in the appropriate column to indicate drugs for which drug text information has been identified in the DRUG file (#50). Example: Formulary Information Report Select Pharmacy Data Management Option: Formulary Information Report This report shows the dispense drugs and orderable items with the formulary information associated with them. Select one of the following: A ALL S SELECT A RANGE Print Report for (A)ll or (S)elect a Range: S// ELECT A RANGE To see drugs beginning with the letter 'A', enter 'A', or whichever letter you wish to see. To see drugs in a range, for example drugs starting with the letters 'G', 'H', 'I' and 'J', enter in the format 'G-J'. Select a Range: S You have the choice to print the drug text information. If you answer "yes" to the question, you will print all the drug text information for both dispense drug and orderable items. If you answer "no", you will print only formulary designations. This report requires 132 columns. You may queue the report to print, if you wish. Include drug text information ? NO// YES Report will be for drugs starting with the letter S, and ending with drugs starting with the letter S. Is this correct? Y// ES DEVICE: HOME// ;C-VT132 TELNET DEVICE Example: Formulary Information Report (continued) Formulary Information Report for Drugs from S through S Date printed: JUN 25,2001 Page: 23 Generic Name Local Visn National Restriction Appl Drug Pkg Text Use ------------------------------------------------------------------------------------------------- STANOZOLOL 2MG UO Orderable Item: XXX TAB STERI-STRIPS O Orderable Item: STERI STRIP STERILE GLOVES O Orderable Item: STERILE GLOVE STOMA CENTERING GUIDE O Orderable Item: STOMA CENTERING GUIDE MISCELLANEOUS STOMA GUIDE STRIP SG-603 O Orderable Item: STOMA GUIDE STRIP STOMAHESIVE COVERING 4X4 5S O Orderable Item: COVERING STOMA CAP STRAP, MONTGOMERY O Orderable Item: MONTGOMERY STRAP DEVICE STREPTOKINASE 250,000 IU 6.5ML UO I Orderable Item: STREPTOKINASE INJ STREPTOKIONASE 750,000 UN INJ UO I Orderable Item: STREPTOKINASE INJ STREPTOMYCIN SULFATE 1GM INJ UO Orderable Item: STREPTOMYCIN INJ STREPTOZOTOCIN INJ,1GM,ECOG O Orderable Item: STREPTOZOTOCIN INJ SUCCINYCHOLINE 1000MG S.P. UO Orderable Item: SUCCINYLCHOLINE INJ,CONC-SOLN SUCCINYCHOLINE 20MG/ML INJ R UO Orderable Item: SUCCINYLCHOLINE INJ,SOLN SUCRALFATE 1 GM TAB UO Orderable Item: SUCRALFATE TAB SULFACETAMIDE 10% OPTH SOL 15ML UO Orderable Item: SULFACETAMIDE SOLN,OPH SULFACETAMIDE OPHTH 10% OINT UO Orderable Item: SULFACETAMIDE OINT,OPH Enter RETURN to continue or '^' to exit: Drug Text Enter/Edit [PSS EDIT TEXT] The Drug Text Enter/Edit XE "Drug Text Enter/Edit" \b option enables you to enter and/or edit entries in the DRUG TEXT file (#51.7). This file contains drug information, restrictions, and guidelines. Some entries are nationally populated by National Drug File. Drug text can be tied to a Dispense Drug in DRUG file (#50), or it can be tied to a Pharmacy Orderable Item through the PHARMACY ORDERABLE ITEM file (#50.7). Drug text tied to a Pharmacy Orderable Item is viewable when a medication is selected in Outpatient Pharmacy and Inpatient Medications, if it has been tied to the Pharmacy Orderable Item or Dispense Drug. The Drug Text Enter/Edit XE "Drug Text Enter/Edit" \b option also enables you to view or print a report, which will display the Drug Text Name, Synonyms, Drug Text, Inactive date (if inactive), and to list all drug and Pharmacy orderable items linked to it. See section 1.13, Drug Text File Report for more information. Example: Drug Text Enter/Edit Select Pharmacy Data Management Option: DRUG TEXT 1 Drug Text Enter/Edit 2 Drug Text File Report CHOOSE 1-2: 1 Drug Text Enter/Edit This option enables you to edit entries in the DRUG TEXT file. Select DRUG TEXT NAME: C 1 CELECOXIB 2 CHF II 3 COPD CHOOSE 1-3: 3 COPD There may be entries in your DRUG file and PHARMACY ORDERABLE ITEM file linked to this Drug Text Name. Editing information related to this Drug Text entry will affect the display of information related to these. Do you want to review the list of drugs and orderable items linked to this Drug Text entry? ? YES// You may queue the report to print, if you wish. DEVICE: HOME// VIRTUAL Right Margin: 80// Drug Text Report for drug text : COPD Date printed: JUL 16,2002 Page: 1 =============================================================================== PLEASE NOTE: The National Formulary Restriction Text is the original text exported with the DRUG TEXT file (#51.7) and automatically linked to the DRUG file (#50) entries based on the VA product match. No ORDERABLE ITEM file (#50.7) entries were automatically linked with DRUG TEXT file (#51.7). DRUG TEXT NAME: COPD DRUG TEXT: Refer to VA/DoD COPD treatment guidelines NATIONAL FORMULARY RESTRICTION TEXT: Refer to VA/DoD COPD treatment guidelines Example: Drug Text Enter/Edit (continued) DRUG file entries: ----------------- Enter RETURN to continue or '^' to exit: Drug Text Report for drug text: COPD Date printed: JUL 16,2002 Page: 2 =============================================================================== DIGOXIN 0.125MG C.T., THEOPHYLLINE 200MG SUS-REL TABS THEOPHYLLINE 100MG SUS-REL TABS ORDERABLE ITEM file entries: --------------------------- NONE ---------------------------------------------------------------------- End of Report. Press Return to continue: Do you want to edit the Drug Text Name? NO// IMPORTANT!! After editing the Drug Text Name OR Text, review the drugs and orderable items linked to this entry for accuracy. Do you want to edit the text for this entry? YES// TEXT: Refer to VA/DoD COPD treatment guidelines Edit? NO// Select SYNONYM: INACTIVATION DATE: Select DRUG TEXT NAME: ^ Drug Text File Report [PSS DRUG TEXT FILE REPORT] This option will display the Drug Text Name, Synonyms, Drug Text, Inactive date (if inactive), and list all drug and Pharmacy orderable items linked to it. The report is printable for one or all entries. For a list of the original entries in the DRUG TEXT file (#51.7), see Appendix B. Example: Drug Text File Report Select Pharmacy Data Management Option: DRUG TEXT FILE REPORT This report shows each selected drug text entry and lists all drugs and orderable items linked to it. Select one of the following: A ALL S SINGLE ENTRY OR RANGE Print for (A)ll or (S)elect Single Entry or Range: S// SINGLE ENTRY OR RANGE There are drugs in the drug text file with leading numerics. Print report for drug text entries with leading numerics? N// Enter a single drug text entry or to see all drug text entries beginning with the letter 'A' for example, enter 'A' or whichever letter you wish to see. To see drug text entries in a range for example starting with 'H', 'I' and 'J' enter in the format 'H-J'. Enter a single entry or select a range: C Report will be for drug text starting with C, and ending with drug text starting with C. Is this correct? Y// ES You may queue the report to print, if you wish. DEVICE: HOME// VIRTUAL Right Margin: 80// Drug Text Report for drug text from C through C Date printed: JUL 16,2002 Page: 1 =============================================================================== PLEASE NOTE: The National Formulary Restriction Text is the original text exported with the DRUG TEXT file (#51.7) and automatically linked to the DRUG file (#50) entries based on the VA product match. No ORDERABLE ITEM file (#50.7) entries were automatically linked with DRUG TEXT file (#51.7). DRUG TEXT NAME: CELECOXIB DRUG TEXT: Refer to PBM/MAP criteria for use of celecoxib NATIONAL FORMULARY RESTRICTION TEXT: DRUG file entries: ----------------- Example: Drug Text File Report (continued) CYCLOPHOSPHAMIDE 50MG C.T. Enter RETURN to continue or '^' to exit: Drug Text Report for drug text from C through C Date printed: JUL 16,2002 Page: 2 =============================================================================== ORDERABLE ITEM file entries: --------------------------- NONE ---------------------------------------------------------------------- DRUG TEXT NAME: COPD DRUG TEXT: Refer to VA/DoD COPD treatment guidelines NATIONAL FORMULARY RESTRICTION TEXT: Refer to VA/DoD COPD treatment guidelines Enter RETURN to continue or '^' to exit: Drug Text Report for drug text from C through C Date printed: JUL 16,2002 Page: 2 =============================================================================== DRUG file entries: ----------------- DIGOXIN 0.125MG C.T., THEOPHYLLINE 200MG SUS-REL TABS THEOPHYLLINE 100MG SUS-REL TABS ORDERABLE ITEM file entries: --------------------------- NONE ---------------------------------------------------------------------- End of Report. Press Return to continue: Select Pharmacy Data Management Option: Pharmacy System Parameters Edit [PSS SYS EDIT] The Pharmacy System Parameters Edit XE "Pharmacy System Parameters Edit" \b option allows the user to edit the Pharmacy System Parameters used in PDM. Example: Pharmacy System Parameters Edit Select Pharmacy Data Management Option: Pharmacy System Parameters Edit PMIS PRINTER: LASSIE PRINTER HALLWAY PMIS LANGUAGE: ? This language will be used as the default for the printing of Patient Medication Instruction Sheets (PMIS). Choose from: 1 English 2 Spanish PMIS LANGUAGE: 1 English WARNING LABEL SOURCE: ? Enter "N" for NEW to use commercial data source for warning labels. Choose from: N NEW WARNING LABEL SOURCE: N NEW CMOP WARNING LABEL SOURCE: ? Enter "N" for NEW to use commercial data source for CMOP warning labels. Choose from: N NEW CMOP WARNING LABEL SOURCE: N NEW OPAI WARNING LABEL SOURCE: ? Enter "N" for NEW to use commercial data source for OPAI warning labels. Choose from: N NEW OPAI WARNING LABEL SOURCE: N NEW Select Pharmacy Data Management Option: Standard Schedule Edit [PSS SCHEDULE EDIT] The Standard Schedule Edit \b "Standard Schedule Edit"  option allows the user to enter or edit entries in the ADMINISTRATION SCHEDULE file (#51.1). The set of times associated with the standard dosage administration schedules can be assigned, as can ward-specific administration times. This feature may be used to define the outpatient expansion to be used when the schedule is entered for an Outpatient Pharmacy medication order. Entry of a frequency in minutes allows the software to calculate the interval between dosages for Inpatient Medication orders and BCMA and is used by Outpatient Pharmacy to calculate default quantities. When the frequency is entered, a message displays telling the user, in hours, how often the administration will occur. If the schedule type is on call, the system does not require a frequency. Schedules with a frequency that is not evenly divisible into or by 24 hours are considered odd. Odd schedules are not allowed to have administration times. If the schedule type is continuous and it is an odd schedule, the system does not allow the entry of administration times. Continuous, non-odd schedules still require administration times. The Standard Schedule Edit option allows the user to enter the outpatient expansion value in a language other than English. PDM does not translate English terms into another language; instead, it allows the user to enter a translation of a term. If a value has not been entered in the OTHER LANGUAGE EXPANSION field, PDM defaults to the value entered in the OUTPATIENT EXPANSION field. If no values exist in the OUTPATIENT EXPANSION and OTHER LANGUAGE EXPANSION fields, the system will not present default values for those fields to the user during CPRS or Outpatient Pharmacy prescription order processing. However, when building the SIG, Outpatient Pharmacy will default to the value the user input through Outpatient Pharmacy backdoor order entry. See Appendix C for a list of Spanish equivalents for some of the more common administration schedules. Note: A schedule name of OTHER is not allowed. This name is used to allow building a Day-of-Week and/or admin-time schedule in CPRS. Example: Standard Schedule Edit Select Pharmacy Data Management Option: STAndard Schedule Edit Select ADMINISTRATION SCHEDULE: BID NAME: BID// OUTPATIENT EXPANSION: TWO TIMES A DAY// OTHER LANGUAGE EXPANSION: DOS VECES AL DIA TYPE OF SCHEDULE: CONTINUOUS// STANDARD ADMINISTRATION TIMES: 0900-1700// FREQUENCY (IN MINUTES): 720// Select WARD ADMINISTRATION SCHEDULE: Synonym Enter/Edit [PSS SYNONYM EDIT] The Synonym Enter/Edit XE "Synonym Enter/Edit" \b option allows the user to enter synonym information into the SYNONYM field for a selected Dispense Drug. Synonyms are used to easily identify drugs for the BCMA package and the Drug Accountability package, and to simplify medication order entry. Example 1: Creating a New Synonym Select DRUG GENERIC NAME: NAP 1 NAPROXEN 250MG S.T. MS102 N/F 09-05-00 2 NAPROXEN 375MG TAB MS102 CHOOSE 1-2: 2 NAPROXEN 375MG TAB MS102 Select SYNONYM: 018393027342// ALEVE INTENDED USE: TRADE NAME NDC CODE: Select SYNONYM: Example 2: Deleting a Synonym Select DRUG GENERIC NAME: NAP 1 NAPROXEN 250MG S.T. MS102 N/F 09-05-00 2 NAPROXEN 375MG TAB MS102 CHOOSE 1-2: 2 NAPROXEN 375MG TAB MS102 Select SYNONYM: ALEVE// @ SURE YOU WANT TO DELETE THE ENTIRE 'ALEVE' SYNONYM? Y (Yes) Select SYNONYM: 018393027342// SYNONYM: 018393027342// INTENDED USE: DRUG ACCOUNTABILITY// NDC CODE: 018393-0273-42// Select SYNONYM: Other Language Translation Setup [PSS OTHER LANGUAGE SETUP] The Other Language Translation Setup option XE "Other Language Translation Setup option" \b provides the ability to enter/edit data in the PHARMACY SYSTEM file (#59.7). This option allows sites to enter appropriate terms in another language that make up parts of the SIG when printing prescription bottle labels. If the user does not enter a translation, the English word will print. The Other Language Translation Setup option is a stand-alone option that must be assigned to the person(s) responsible for maintaining it. See Appendices C-G for lists of Spanish equivalents for some of the more common terms used for administration schedules, dosage forms, local possible dosages, medication instructions, and medication routes. Example: Other Language Translation Setup USE OF ANOTHER LANGUAGE: YES < If No is entered the remaining fields will not be prompted for> SECONDS: SEGUNDOS MINUTES: MINUTOS DAYS: DIAS WEEKS: SEMANAS HOURS: HORAS MONTHS: MESES AND: Y THEN: LUEGO EXCEPT: EXCEPTO ONE: UNA TWO: DOS THREE: TRES FOUR: CUATRO FIVE: CINCO SIX: SEIS SEVEN: SIETE EIGHT: OCHO NINE: NUEVE TEN: DIEZ ONE-HALF: MEDIA ONE-FOURTH: UN-CUARTO ONE-THIRD: UN-TERCIO TWO-THIRDS: DOS-TERCIOS THREE-FOURTHS: TRES-CUARTOS FOR: POR Controlled Substances/PKI Reports [PSS CS/PKI REPORTS] A post-installation routine for patch PSS*1*61 identifies those drugs with discrepancies between the CS FEDERAL SCHEDULE field (#19) of the VA PRODUCT file (#50.68) and DEA, SPECIAL HDLG field (#3) of the DRUG file (#50), and generates four mail messages with the following subjects to the installer and to holders of the PSNMGR keys: CS FEDERAL SCHEDULE AND DEA, SPECIAL HDLG DISCREPANCIES CONTROLLED SUBSTANCES NOT MATCHED CONTROLLED SUBSTANCES NOT SET CORRECTLY DISCREPANCY IN DEA WITHIN DRUGS TIED TO AN OI These mail messages can be used to clean up the DEA, SPECIAL HDLG code in the DRUG file (#50) where appropriate. The post-install also checks to see if the DEA, SPECIAL HDLG field (#3) of the DRUG file (#50) is null and if the drug is matched to an entry in the VA PRODUCT file (#50.68), and the CS FEDERAL SCHEDULE field (#19) of the VA PRODUCT file (#50.68) has data, then it updates the DEA, SPECIAL HDLG field (#3) of the DRUG file (#50) with the DEA, SPECIAL HDLG code mapped to corresponding CS FEDERAL SCHEDULE code. This new Controlled Substances/PKI Reports option is added to the Pharmacy Data Management menu to re-generate these post-install Mailman messages on demand. Send Entire Drug File to External Interface [PSS MASTER FILE ALL] This option sends updated information for every entry in the DRUG file (#50) to the external interface for Outpatient Pharmacy dispensing systems, using HL7 standard V. 2.4 messages. All entries are sent, regardless of how they are marked for Application Package Use. To use this option, the following items must be set up properly in the OUTPATIENT SITE file (#59): In the AUTOMATED DISPENSE field (#105), the value should be set to V. 2.4. This enables sending data through the Interface Engine using HL7 V. 2.4 standard. In the ENABLE MASTER FILE UPDATE field (#105.2), the value should be set to YES. In the DISPENSE DNS NAME field (#2006), there should be some value defined. This value sends the DNS name of the dispensing system (for example, dispensemachine1.vha.med.va.gov) to the Interface Engine, so that the Interface Engine knows where to route the HL7 messages. Example: Send Entire Drug File to External Interface Select Pharmacy Data Management Option: PSS MASTER FILE ALL Send Entire Drug File to External Interface Send Entire Drug File to External Interface Press RETURN to continue... Warning Builder XE "Warning Builder"  [PSS WARNING BUILDER] The Warning Builder option allows the user to print a copy of the old and new warning file entries. The user can choose various ways to select drugs to review which warnings will print when the flag is turned on to use the new warning label source. This option also allows the user to override the default warning labels to create a custom warning label list for the selected drug. This is accomplished by specifying a list of warning numbers from the old RX CONSULT file (#54) and/or the new commercial data source warning file. Example: Warning Builder Select Pharmacy Data Management Option: WARNING BUilder The RX CONSULT File (#54) contains local label expansions. The WARNING LABEL-ENGLISH file (#50.625) contains national label expansions in English. The WARNING LABEL-SPANISH file (#50.626) contains national label expansions in Spanish. It is important to note that RX Consult entry numbers do not correlate with the other files (i.e. Number 7 in file 54 is not included in file 50.625). Example: Warning Builder (continued) You should print a list of the current RX CONSULT file entries and the current WARNING LABEL-ENGLISH file entries. Would you like to print a list of the entries in these files? N// YES Would you like to include the Spanish translations? N// YES You may queue the report to print, if you wish. DEVICE: HOME// COMPUTER ROOM RX CONSULT file - WARNING LABEL TEXT Date printed: JAN 18,2005 Page: 1 =============================================================================== RX CONSULT NUMBER: 1 -MAY CAUSE DROWSINESS- Alcohol may intensify this effect. USE CARE when driving or when operating dangerous machinery. ---------------------------------------------------------------------- RX CONSULT NUMBER: 2 IMPORTANT: Finish all this medication unless otherwise directed by prescriber. ---------------------------------------------------------------------- RX CONSULT NUMBER: 3 Take medication on an EMPTY STOMACH 1 hour before or 2-3 hours after a meal unless otherwise directed by your doctor. ---------------------------------------------------------------------- RX CONSULT NUMBER: 4 Do not take antacids or iron preparations or eat dairy products within 1 hour of taking this medication. ---------------------------------------------------------------------- RX CONSULT NUMBER: 5 Take with plenty of WATER. ---------------------------------------------------------------------- RX CONSULT NUMBER: 6 May cause discolored urine or feces. ---------------------------------------------------------------------- RX CONSULT NUMBER: 7 It may be advisable to drink a full glass of orange juice or eat a banana daily while on this medication ---------------------------------------------------------------------- RX CONSULT NUMBER: 8 DO NOT DRINK ALCOHOLIC BEVERAGES when taking this medication. ---------------------------------------------------------------------- RX CONSULT NUMBER: 9 DO NOT TAKE non-prescription drugs without medical advice. ---------------------------------------------------------------------- Example: Warning Builder (continued) RX CONSULT NUMBER: 10 TAKE WITH FOOD OR MILK. ---------------------------------------------------------------------- RX CONSULT NUMBER: 11 Avoid prolonged exposure to SUNLIGHT and finish all this medication unless otherwise directed by prescriber. ---------------------------------------------------------------------- RX CONSULT NUMBER: 12 SHAKE WELL ---------------------------------------------------------------------- RX CONSULT NUMBER: 13 For external use ONLY. ---------------------------------------------------------------------- RX CONSULT NUMBER: 14 NOTE DOSAGE STRENGTH ---------------------------------------------------------------------- RX CONSULT NUMBER: 15 REFRIGERATE -DO NOT FREEZE ---------------------------------------------------------------------- RX CONSULT NUMBER: 16 This prescription CANNOT be refilled without a written duplicate from your physician. ---------------------------------------------------------------------- RX CONSULT NUMBER: 17 Do not use after specified date. ---------------------------------------------------------------------- RX CONSULT NUMBER: 18 THIS PRESCRIPTION CANNOT BE REFILLED. ---------------------------------------------------------------------- RX CONSULT NUMBER: 19 This is the same medication you have been getting. Color, size or shape may appear different. ---------------------------------------------------------------------- RX CONSULT NUMBER: 20 CAUTION: Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed. Spanish translation: PRECAUCION: La ley federal prohibe la transferencia de este medicamento a otro paciente para el que no fue recetado. ---------------------------------------------------------------------- End of Rx Consult file Report. Press Return to continue: WARNING LABEL-ENGLISH file - WARNING LABEL TEXT Date printed: JAN 18,2005 Page: 1 =============================================================================== Example: Warning Builder (continued) WARNING LABEL-ENGLISH NUMBER: 1 May cause drowsiness. Alcohol may intensify this effect. Use care when operating a car or dangerous machines. Spanish translation: Puede causar somnolencia. El alcohol puede intensificar este efecto. Tenga cuidado cuando conduzca vehiculos automotores u opere maquinaria peligrosa. ---------------------------------------------------------------------- WARNING LABEL-ENGLISH NUMBER: 2 Important: Finish all this medication unless otherwise directed by prescriber. Spanish translation: Importante: Acabe todo este medicamento a menos que quien le escriba la receta le indique lo contrario. ---------------------------------------------------------------------- WARNING LABEL-ENGLISH NUMBER: 3 Take medication on an empty stomach one hour before or two to three hours after a meal unless otherwise directed by your doctor. Spanish translation: Tome este medicamento con el estmago vaco una hora antes o dos a tres horas despus de comer, a menos que su mdico le indique lo contrario. ---------------------------------------------------------------------- WARNING LABEL-ENGLISH NUMBER: 4 Do not take dairy products, antacids, or iron preparations within one hour of this medication. Spanish translation: Una hora antes de tomar este medicamento y hasta una hora despus de tomarlo, no tome productos lcteos, anticidos, o preparados de hierro. ---------------------------------------------------------------------- WARNING LABEL-ENGLISH NUMBER: 5 Medication should be taken with plenty of water. Spanish translation: Debe tomar este medicamento con mucha agua. ---------------------------------------------------------------------- . . . This will print all warning labels in the commercial data sources warning file. (To save space, only the first five warning labels are displayed in this example.) Select one of the following to display drugs that match that criteria to examine or edit their drug warnings: 1. Drug has WARNING LABEL filled in but there are no FDB warnings for the drug 2. Drug has WARNING LABEL numbers higher than 20 3. Select by range of drug names 4. Drug has more than 5 warning labels 5. Drugs containing specific WARNING LABEL number 6. Drug has WARNING LABEL that does not map to new data source 7. Drugs containing specific new data source warning number 8. Drugs containing gender-specific warnings 9. Drugs with warning mapping, but drug doesn't contain "mapped to" number Example: Warning Builder (continued) Enter selection: // 4 GREATER THAN 5 WARNINGS Exclude drugs with NEW WARNING LABEL LIST filled in? Y// ES NOTE: Only the first 5 warnings will print on the yellow auxillary labels. Do you want to see the warning text for all warnings? Y// ES Warnings (>5) that won't print and won't be sent to CMOP will be marked with a "*" on the following screens. Current Warning labels for ACETAMINOPHEN AND CODEINE 30MG Labels will print in the order in which they appear for local and CMOP fills: 1N May cause drowsiness. Alcohol may intensify this effect. Use care when operating a car or dangerous machines. 62N May cause dizziness 45N Taking more of this medication than recommended may cause serious breathing problems. 8N Do not drink alcoholic beverages when taking this medication. 20 CAUTION: Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed. *66N This medicine contains ACETAMINOPHEN.Taking more ACETAMINOPHEN than recommended may cause serious liver problems. *70N Do not take other ACETAMINOPHEN containing products at the same time without first checking with your doctor. Check all medicine labels carefully. *14N Obtain medical advice before taking non-prescription drugs as some may affect the action of this medication. Pharmacy fill card display: DRUG WARNING 1N,62N,45N,8N,20,66N,70N,14N NOTE: Because the NEW WARNING LABEL LIST field is empty, the warnings above are the warnings that our national data source distributes for this drug. Would you like to edit this list of warnings? N// O Current Warning labels for ALPRAZOLAM 0.25MG TABS Labels will print in the order in which they appear for local and CMOP fills: 1N May cause drowsiness. Alcohol may intensify this effect. Use care when operating a car or dangerous machines. 82N Warning: Do not use if you are pregnant, suspect that you are pregnant, or while breastfeeding. Consult your doctor or pharmacist. 71N Do not eat grapefruit or drink grapefruit juice at any time while taking this medication. 14N Obtain medical advice before taking non-prescription drugs as some may affect the action of this medication. 20 CAUTION: Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed. *94N Herbal/dietary supplement products may interact with this medication. Discuss any such product with your doctor or pharmacist before taking. Pharmacy fill card display: DRUG WARNING 1N,82N,71N,14N,20,94N NOTE: Because the NEW WARNING LABEL LIST field is empty, the warnings above are the warnings that our national data source distributes for this drug. Example: Warning Builder (continued) Would you like to edit this list of warnings? N// YES NEW WARNING LABEL LIST: 1,2,3N Current Warning labels for ALPRAZOLAM 0.25MG TABS Labels will print in the order in which they appear for local and CMOP fills: 1 -MAY CAUSE DROWSINESS- Alcohol may intensify this effect. USE CARE when driving or when operating dangerous machinery. 2 IMPORTANT: Finish all this medication unless otherwise directed by prescriber. 3N Take medication on an empty stomach one hour before or two to three hours after a meal unless otherwise directed by your doctor. 20 CAUTION: Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed. Pharmacy fill card display: DRUG WARNING 1,2,3N,20 NEW WARNING LABEL LIST: 1,2,3N Would you like to edit this list of warnings? N// O Warning Mapping XE "Warning Mapping"  [PSS WARNING MAPPING] The Warning Mapping option is used to match an entry from the RX CONSULT file (#54) to the WARNING LABEL-ENGLISH file (#50.625) to aid in using the Warning Builder option to identify local warnings that do not have an equivalent entry in the commercial data source. The user can also enter a Spanish translation for an RX CONSULT file (#54) entry, if desired, but whenever possible, the commercial data sources warnings should be used. Example: Warning Mapping Select Pharmacy Data Management Option: WARNING MApping Note: Warning mapping is only used as an aid when using the warning builder. If a DRUG WARNING is defined with a warning mapping of 0, that entry will be skipped when choosing option 6 Drug has WARNING LABEL that does not map to new data source. Enter RETURN to continue or '^' to exit: CURRENT WARNING MAPPING DRUG WARNING Mapped to New data source number 1 DROWSINESS 1 2 FINISH 2 3 EMPTY STOMACH 3 4 NO DAIRY PRODUCTS 4 5 WATER 5 6 DISCOLORATION 6 7 DIURETIC K 8 NO ALCOHOL 8 9 ADVICE 9 Example: Warning Mapping (continued) 10 WITH FOOD 10 11 SUNLIGHT 11 12 SHAKE WELL 19 13 EXTERNAL 20 14 STRENGTH 15 REFRIGERATE 30 16 DUPLICATE 17 EXPIRATION DATE 18 NO REFILL 19 SAME DRUG 20 NO TRANSFER Enter a valid Rx Consult file number: 1 DROWSINESS -MAY CAUSE DROWSINESS- Alcohol may intensify this effect. USE CARE when driving or when operating dangerous machinery. Rx Consult file number 1 is mapped to WARNING LABEL-ENGLISH number 1 May cause drowsiness. Alcohol may intensify this effect. Use care when operating a car or dangerous machines. Do you want to change the mapping? N// y YES WARNING MAPPING: 1// 8 Do not drink alcoholic beverages when taking this medication. Do you want to enter/edit a Spanish translation for this entry? N// O Enter a valid Rx Consult file number: 20 NO TRANSFER CAUTION: Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed. Enter a number from WARNING LABEL-ENGLISH file to map to: : // 0 Do you want to enter/edit a Spanish translation for this entry? N// y YES SPANISH TRANSLATION: PRECAUCION: La ley federal prohibe la transferencia de este medicamento a otro paciente para el que no fue recetado. Enter a valid Rx Consult file number: Chapter Two Understanding Dosages Dosages XE "Dosages" \b are compiled by collecting information that was previously entered in various files and gathering that information to populate individual fields within the DRUG file (#50). Two types of dosages, Possible Dosages XE "Possible Dosages" \b and Local Possible Dosages XE "Local Possible Dosages" \b, are now stored in the DRUG file (#50). Explanations of what determines a Possible Dosage and a Local Possible Dosage are included below, along with diagrams to aid the user in understanding which files and fields contribute to constructing Possible Dosages and Local Possible Dosages. More detailed information on Possible Dosages and Local Possible Dosages is contained in the Pharmacy Ordering Enhancements Pharmacy Data Management Pre-Release Implementation Guide, located on the VistA Documentation Library (VDL) web page at  HYPERLINK "http://vista.med.va.gov/vdl" http://vista.med.va.gov/vdl. Possible Dosages The PROPRANOLOL TAB example in Diagram A is an example of a drug that can have Possible Dosages. Possible Dosages can be broken down into four individual fields; DISPENSE UNITS PER DOSE, DOSE, PACKAGE, and BCMA DISPENSE UNITS PER DOSE. For a drug to have Possible Dosages it must meet the following criteria. The drug must be matched to a VA PRODUCT file (#50.68) entry in National Drug File. The match in National Drug File must be an active single-ingredient product. The strength of the product must be numeric. The Dosage Form/Unit Combination of the product must be marked as convertible in the DOSAGE FORM file (#50.606). See the table below for a list of Dosage Form/Unit Combinations that will automatically be identified by the software.  The Dosage Form/Unit Combinations that have been designated as convertible for the creation of Possible Dosages are displayed in Appendix A. Possible Dosages (cont.) Possible Dosages are initially populated automatically through the use of the Auto Create Dosages option. This option identifies drugs that meet the four criteria mentioned earlier, and by utilizing fields in the VA PRODUCT file (#50.68) and the DOSAGE FORM file (#50.606), it will populate the DRUG file (#50) entry with Possible Dosage information. (Diagram A is an example of how the PROPRANOLOL HCL 20MG TAB drug entry would exist under the current file setup . Diagram A  (Diagram A The VA Product match for this drug is PROPRANOLOL HCL 20MG TAB. It is a single ingredient product with a numeric Strength (20). It has a Dosage Form of TAB and units of MG in the VA PRODUCT file (#50.68). Additionally, the non-editable multiple field called UNITS from the DOSAGE FORM file (#50.606) indicates which combination of Dosage Form and Units can be converted to Possible Dosages, assuming that the product is a single ingredient drug with a numeric strength. It also indicates the package (Inpatient Medications, Outpatient Pharmacy, or both) for which Possible Dosages can be created. So, in the first PROPRANOLOL example, the Dosage Form/Unit Combination of TAB/MG is convertible for both Inpatient Medications and Outpatient Pharmacy. The DISPENSE UNITS PER DOSE multiple of the DOSAGE FORM file (#50.606) is a non-editable field used to calculate dosages during the dosage creation process. 1, or 1 and 2, were chosen for all Dosage Forms because they require the least amount of editing in the DRUG file (#50). (See Diagram B.) Diagram B  (Diagram B Diagram B shows the drug entry with the new data. Two new fields, STRENGTH and UNIT, have been added to the DRUG file (#50). These two fields are populated with data based on the data contained in the STRENGTH and UNITS fields of the VA PRODUCT file (#50.68) match. The DOSE field of the POSSIBLE DOSAGE sub-file of the DRUG file (#50) is populated by multiplying the entry in the DISPENSE UNITS PER DOSE field of the POSSIBLE DOSAGE sub-file of DRUG file (#50) by the numeric value of the STRENGTH field in the DRUG file (#50). (DOSE=DISPENSE UNITS PER DOSE x STRENGTH) Diagram C shows what the Auto Create Dosages option could create as dosage selections for a PROPRANOLOL TAB Orderable Item when one or more drugs are matched to that Orderable Item. (See Diagram C.) Diagram C  (Diagram C In Diagram C, the PROPRANOLOL drug entries are matched to VA Products that have numeric strengths, 20 and 40, and the VA Products both have the Dosage Form/Unit Combination of TAB/MG. Since TAB/MG is marked as convertible in the DOSAGE FORM file (#50.606) for both Inpatient Medication and Outpatient Pharmacy, the new STRENGTH and UNIT fields in the DRUG file (#50) for these drugs can be populated by the software. The STRENGTH and UNITS fields of DRUG file (#50) are populated from the VA PRODUCT file (#50.68) into the DRUG file (#50). The new fields in the DRUG file (#50), DISPENSE UNITS PER DOSE, DOSE, and PACKAGE, are now populated with data. The Dispense Units Per Dose of 1 and 2 came from the new DISPENSE UNITS PER DOSE field in the DOSAGE FORM file (#50.606). When this data is carried over to the DRUG file (#50), the dose is computed by multiplying the Dispense Units Per Dose from DRUG file (#50) by the Strength from DRUG file (#50) of each drug. The PACKAGE field values of the DOSAGE FORM file (#50.606), I for Inpatient Medications and O for Outpatient Pharmacy, are also copied to the PACKAGE field of DRUG file (#50). Some of the Possible Dosages will be converted for both packages, such as the combination of TAB/MG, since this type of dosage can be ordered for Inpatient Medications and also can be converted to a patient readable Outpatient Pharmacy SIG. Other Dosage Form/Unit Combinations, such as SYRUP/MG/5ML, can only be converted for Inpatient Medications since they cannot be easily changed to an Outpatient Pharmacy readable SIG. In this example, PROPRANOLOL TAB is selected as the Orderable Item in CPRS, therefore the dose selection would be: 20MG 40MG 80MG Notice that there is only one 40MG selection for the provider, yet both the PROPRANOLOL HCL 20MG TAB drug and the PROPRANOLOL HCL 40MG TAB drug entries have doses of 40MG. In this case, the 40MG dose is associated with the PROPRANOLOL HCL 40MG TAB drug, because it has a lower Dispense Units Per Dose (1), than the Dispense Units Per Dose (2) associated with the 40MG dose for the PROPRANOLOL HCL 20MG TAB. For Possible Dosages, when the software encounters two doses that are the same, the lowest Dispense Units Per Dose will be used to determine the Dispense Drug. Additionally, another screen that is used for duplicate doses is the non-formulary screen. If there are two of the same doses, and one is formulary and the other is non-formulary, the formulary entry is the one that is used, regardless of which dose has the lower Dispense Units Per Dose value. The non-formulary drug filter is executed prior to the lowest Dispense Units Per Dose filter. So in this example, if the PROPRANOLOL HCL 40MG TAB is marked as non-formulary, and the PROPRANOLOL HCL 20MG TAB is formulary, the 40MG dosage selection would be associated with the PROPRANOLOL HCL 20MG TAB, even though it has a higher Dispense Units Per Dose (2) than the 40MG entry for PROPRANOLOL HCL 40MG TAB (1 Dispense Units Per Dose). Once the Possible Dosages have been created by the Auto Create Dosages option, doses can be deleted or added by editing the DISPENSE UNITS PER DOSE field using the Enter/Edit Dosages option. The DOSE field is automatically calculated by multiplying the DISPENSE UNITS PER DOSE field times the STRENGTH field. For example, if the PROPRANOLOL TABLET is commonly given in a 10MG dose, and there is not a Dispense Drug entry in DRUG file (#50) of PROPRANOLOL HCL 10MG TAB, a Dispense Units Per Dose of .5 can be added for the PROPRANOLOL HCL 20MG TAB, and a dose of 10MG will be created. If a dose of 60MG is sometimes given for PROPRANOLOL TAB, entering a Dispense Units Per Dose of 3 for the PROPRANOLOL HCL 20MG TAB drug will provide a 60MG dose. Similarly, if the 80MG dose is rarely given, the Dispense Units Per Dose of 2 can be deleted for the PROPRANOLOL HCL 40MG TAB drug, and the 80MG dose will be deleted. The PACKAGE field can also be edited, but this is a controlled type of edit. If the Dosage Form/Unit Combination is not marked as convertible in the DOSAGE FORM file (#50.606) for the package, then that package cannot be added as a package for that Possible Dosage. Strength can also be edited in the DRUG file (#50). If the strength is edited, then all of the doses are automatically re-calculated based on the DISPENSE UNITS PER DOSE and new STRENGTH entry. It is recommended that the strength only be edited in the rare case that the Dispense Drug must be matched to a VA Product with an inappropriate strength. (This scenario is discussed in further detail later in this document.) In summary, by adding new DISPENSE UNITS PER DOSE of .5 and 3 to the PROPRANOLOL HCL 20MG TAB entry, and by deleting the DISPENSE UNITS PER DOSE of 2 for the PROPRANOLOL HCL 40MG TAB entry, the following Possible Dosages now exist for PROPRANOLOL TAB Orderable Item. (See Diagram D.) Diagram D  (Diagram D Though the list of dosages is all that the provider will see for selection, each of the dosages is associated with a Dispense Drug. For example, if the 60MG is selected, the Dispense Units Per Dose is 3, and the drug is PROPRANOLOL HCL 20MG TAB. For Outpatient Pharmacy orders the SIG will be built in the same manner as it is today. If the 60MG is chosen, the SIG will begin with TAKE 3 TABLETS and the assigned Dispense Drug is PROPRANOLOL HCL 20MG TAB. As demonstrated in the PROPRANOLOL example, the key to populating the Possible Dosages in the DRUG file (#50) is the information that is contained in the VA PRODUCT file (#50.68) entry to which that drug is matched. Earlier diagrams also show that dosages can be added, deleted, etc., for a drug by editing the DISPENSE UNITS PER DOSE field for that drug. In addition to creating Possible Dosages for a drug by editing the DISPENSE UNITS PER DOSE field, appropriate Possible Dosages can be created by editing the STRENGTH field for a drug. When Possible Dosages are created for a drug, the strength information from the VA Product match is moved to the drug entry and stored in the STRENGTH field. The only time this data would not be accurate would be if a VA PRODUCT file (#50.68) entry with the correct strength did not exist, and a different strength of the drug had to be selected for the drugs VA Product match; however, these instances should be rare. If the desired strength does not exist for a particular drug, the functionality exists to edit the STRENGTH field in the DRUG file (#50) for that drug. Once the strength edit is completed, new Possible Dosages are created for every Dispense Units Per Dose for that drug. For example, Diagram E shows an entry in the DRUG file (#50) of METOPROLOL TARTRATE 25MG TAB. No entries with a strength of 25 exist in the VA PRODUCT file (#50.68) for that drug, so it is matched instead to a VA Product entry with a strength of 50. (See Diagram E.) Diagram E  (Diagrams E and F In Diagram E, the Possible Dosages created are 50 MG (1 tablet) and 100MG (2 tablets), but the drug is actually METOPROLOL TARTRATE 25MG TAB. These Possible Dosages were created because the strength of the VA PRODUCT file (#50.68) entry is 50. As displayed in Diagram F, the strength in the DRUG file (#50) can simply be edited from 50 to 25, and when that strength is edited, the Possible Dosages for all Dispense Units Per Dose, in this case 1 and 2, will be recalculated. (See Diagram F.) Diagram F  Local Possible Dosages (Diagram G In an earlier example using PROPRANOLOL TAB, Inpatient Medications and Outpatient Pharmacy Possible Dosages could be created for the Dispense Drugs matched to PROPRANOLOL TAB because they met all of the following four criteria. 1) The drug must be matched to a VA PRODUCT file (#50.68) entry in National Drug File. 2) The match in National Drug File must be an active single-ingredient product. 3) The strength of the product must be numeric. 4) The Dosage Form/Unit Combination of the product must be marked as convertible in the DOSAGE FORM file (#50.606). In the following example, the Orderable Item requested is TIMOLOL SOLN, OPH, which has two Dispense Drugs matched to it. Neither of these Dispense Drugs meets the four criteria for creating Possible Dosages. The two Dispense Drugs are matched to entries in the VA PRODUCT file (#50.68) as follows. (See Diagram G.) Diagram G  (Diagram G (continued) These two drugs meet the first three of the Possible Dosages criteria, but do not meet criteria number four. The Dosage Form/Unit Combination of SOLN,OPH / % is not marked as convertible in the DOSAGE FORM file (#50.606) for Inpatient Medications or for Outpatient Pharmacy. Since Possible Dosages cannot be created for these drugs, Local Possible Dosages must be created. To create Local Possible Dosages the Noun field in the DOSAGE FORM file (#50.606) is utilized. By default, all Local Possible Dosages will be marked for Inpatient Medications and/or Outpatient Pharmacy use based on the package identification of the Noun. The NOUN field already exists in the DOSAGE FORM file (#50.606). It is a multiple field, meaning that more than one Noun can be associated with each Dosage Form. Some Dosage Forms may have multiple Nouns, while other Dosage Forms may have only one Noun. For example, the Dosage Form CREAM could have the following entries in the NOUN field. LIBERALLY SMALL AMOUNT SPARINGLY THIN FILM Alternately, the Dosage Form of TAB would most likely only have one NOUN, TABLET(S). TABLET(S) In the TIMOLOL example, a review of the Dosage Form entry for SOLN,OPH, shows that the Dispense Units Per Dose of 1 and 2 are designated, and a Noun of DROP(S) is specified. If the Auto Create Dosages option is rerun with the current setup, no Possible Dosages for the two TIMOLOL drugs will be created because the drugs do not meet all four Possible Dosages criteria. Local Possible Dosages will be created of 1 DROP and 2 DROPS. If a NOUN ends in (S) or (s), such as TABLET(S) or capsule(s), the (S) or (s) will be completely dropped from the Noun when building the SIGs, as long as the Dispense Units Per Dose is 1 or less. If the Dispense Units Per Dose is greater than 1, the parenthesis around the (S) will be eliminated, creating a plural Noun, such as TABLETS. For this to happen, the Noun must precisely end in the three characters (S). Keep in mind that if an Orderable Item is selected in CPRS, and there are Possible Dosages for any of the Dispense Drugs tied to that Orderable Item, only the Possible Dosages will be returned and any Local Possible Dosages will be ignored. Local Possible Dosages will only be used when no Possible Dosages can be found for drugs tied to the selected Orderable Item and identified for use by the selected application (Inpatient Medications or Outpatient Pharmacy). In the TIMOLOL example, the Noun of DROP(S) and the Dosage Form of SOLN,OPH produces the following results. (See Diagram H.) Diagram H  Possible Dosages and Local Possible Dosages The following dosage example is of a Dispense Drug that has Possible Dosages for Inpatient Medications and Local Possible Dosages for Outpatient Pharmacy. The Dispense Drug is PROMETHAZINE HCL 25MG/5ML SYRUP. The reason Possible Dosages were created only for Inpatient Medications is because the units of MG/5ML for the SYRYP Dosage Form was only marked convertible for Inpatient Medications. Local Possible Dosages will only be used to display in the dosage list when no Possible Dosages can be found for drugs tied to the selected Orderable Item and identified for use by the selected application (Inpatient Medications or Outpatient Pharmacy). Diagram I  (Diagram I Diagram I illustrates the Possible Dosages and Local Possible Dosages that would be created for PROMETHAZINE HCL 25MG/5ML SYRUP. On the following page, Diagram J illustrates an edit of the STRENGTH field in DRUG file (#50) for a product such as PROMETHAZINE which has volume related UNITS. In the background, the software will evaluate the UNIT field in the DRUG file (#50) to determine if an adjustment in the UNIT is necessary. The software will search for the existence of a / in the UNIT field. If the UNIT field contains a /, when the strength is edited, calculations will be performed to make appropriate adjustments in the value of the UNIT. For example, the DRUG file (#50) entry may have a STRENGTH of 25 and a UNIT of MG/5ML. If the STRENGTH is edited to 12.5, the UNIT will be adjusted by the software to MG/2.5ML. When the UNIT value is adjusted, it will not display in the DRUG file (#50); however, throughout all Pharmacy and CPRS displays, the correct, adjusted unit value of the dosage will be displayed. (See Diagram J.) Diagram J  Multi-Ingredient Drugs The following are examples of multi-ingredient drugs. Since multi-ingredient drugs do not meet the criteria for creation of a Possible Dosage, Local Possible Dosages will be created based on the Noun entries in the DOSAGE FORM file (#50.606). The first example is GUAIFENESIN SYRUP WITH CODEINE 4oz. The Dosage Form of SYRUP has three Nouns, all marked for Inpatient Medications and Outpatient Pharmacy use. These Nouns are TABLESPOONFUL(S), TEASPOONFUL(S), and ML(S). The APPLICATION PACKAGE USE field of the Dispense Drug is marked for Outpatient Pharmacy use only. The Auto Create Dosages option will create the following Local Possible Dosages for the drug. (See Diagram K.) Diagram K  Chapter Three Creating the Sig Creating the Sig XE "Creating the Sig" \b Earlier versions of the Outpatient Pharmacy software allowed the SIG to be directly edited from within the Outpatient Pharmacy package. Following the release of the Pharmacy Ordering Enhancements (POE) Phase 2 project, however, which included patches PSO*7*46, OR*3*94, PSS*1*38, and PSJ*5*50, the SIG could no longer be edited as a unit. Now, instead, individual fields are populated and then concatenated to create the SIG. Although the SIG, as a unit, cannot be edited, each individual field that creates the SIG can be edited until the SIG displays as desired. Four basic types of SIGs exist: Simple Possible Dosages XE "Simple Possible Dosages" \b, Simple Local Possible Dosages XE "Simple Local Possible Dosages" \b, Complex Possible Dosages, and Complex Local Possible Dosages XE "Complex Local Possible Dosages" \b. The SIG for each of these types of dosages is created by combining fields from various PDM files. To simplify the process, each dosage can be thought of as having its own SIG formula. The key to the formulas is displayed in the following table. The formulas for creating each of the four types of SIGs follow. The following table details the symbols that will be used in the SIG tables. Table A: Formula Symbols SymbolFileSymbolFile EMBED Visio.Drawing.6 DOSAGE FORM file (#50.606) EMBED Visio.Drawing.6 MEDICATION ROUTES file (#51.2) EMBED Visio.Drawing.6 DRUG file (#50) EMBED Visio.Drawing.6 ADMINISTRATION SCHEDULE file (#51.1) or MEDICATION INSTRUCTION file (#51) EMBED Visio.Drawing.6 DRUG file (#50) EMBED Visio.Drawing.6 PHARMACY ORDERABLE ITEM file (#50.7) or Provider Comments entered with CPRS orders EMBED Visio.Drawing.6 DOSAGE FORM file (#50.606) EMBED Visio.Drawing.6 AND, THEN or EXCEPT EMBED Visio.Drawing.6 DOSAGE FORM file (#50.606) EMBED Visio.Drawing.6 HOURS, MINUTES, DAYS SIG Formulas XE "Sig Formulas (Formulas)" \b Simple Possible Dosages  EMBED Visio.Drawing.6  Simple Local Possible Dosages  EMBED Visio.Drawing.6  Complex Possible Dosages  EMBED Visio.Drawing.6  Complex Local Possible Dosages  EMBED Visio.Drawing.6  SIG Formulas Each of the four types of dosages, Simple Possible Dosages, Complex Possible Dosages, Simple Local Possible Dosages, and Complex Local Possible Dosages, can be created using the dosages respective SIG formula XE "Sig formula" \b. The formulas, along with examples of various SIGs, are explained in detail below. Simple Possible Dosages Dosages that have a numeric dosage and numeric Dispense Units Per Dose appropriate for administration are called Possible Dosages XE "Possible Dosages" \b. For a drug to have Possible Dosages, it must be a single-ingredient product that is matched to a VA PRODUCT file (#50.68) entry in the National Drug File. The National Drug File entry must have a single numeric strength and the Dosage Form/Unit Combination must be such that a numeric strength combined with the unit can be an administrable dosage selection. The formula for creating a SIG for a Simple Possible Dosage is displayed below. The charts following the formula define how various sample SIGs were created using this formula. Simple Possible Dosage Formula XE "Simple Possible Dosage Formula" \b  EMBED Visio.Drawing.6  A SIG for a Simple Possible Dosage can be created utilizing the above formula. Prior to creating a SIG, the SIG must first be broken down into each of the elements in its respective Dosage Formula. The table below outlines each element of the desired SIG. By identifying the element symbol to the right of the SIG entry, it is easy to identify which element that word or phrase represents. For example, to the right of the SIG entry, TAKE, in the table, the Verb symbol is displayed. By referencing the third column, it is apparent that Verb entries are taken from the DOSAGE FORM file (#50.606). The following tables define each element of the SIG for each of the four types of dosages, Simple Possible Dosages, Complex Possible Dosages, Simple Local Possible Dosages, and Complex Local Possible Dosages and identify which files provide each elements information. The complete SIG is displayed at the top of each table. Each part of the SIG is constructed by extracting data from a designated file within the Pharmacy software. The verb entry is derived from the DOSAGE FORM file (#50.606) entry of the Dosage Form that is associated with the Pharmacy Orderable Item. The Dispense Units Per Dose of 2 is a component of the Possible Dosage and is also provided by the software. Example: Simple Possible Dosage TAKE TWO TABLETS BY MOUTH EVERY 12 HOURS AFTER MEALSEntryElementFile TAKE  EMBED Visio.Drawing.6 DOSAGE FORM file (#50.606)2 EMBED Visio.Drawing.6 DRUG file (#50)TABLETS EMBED Visio.Drawing.6 DOSAGE FORM file (#50.606)BY EMBED Visio.Drawing.6 DOSAGE FORM file (#50.606)MOUTH EMBED Visio.Drawing.6 MEDICATION ROUTES file (#51.2)EVERY 12 HOURS EMBED Visio.Drawing.6 ADMINISTRATION SCHEDULE file (#51.1) or MEDICATION INSTRUCTION file (#51)AFTER MEALS EMBED Visio.Drawing.6 PHARMACY ORDERABLE ITEM file (#50.7) or CPRS Required elements for every Possible Dosage are the Dosage (Dispense Units Per Dose and Noun) and the schedule. Any other element may be deleted from the SIG. If a SIG contains a medication route, and that medication route is changed or deleted, a new order will be created due to the change to the MEDICATION ROUTES file (#51.2). A change to the dosage and/or schedule will also create a new order.  EMBED Word.Document.8 \s  The SIG of an order for a medication with Local Possible Dosages may contain the same elements as a Possible Dosage, except that the Local Possible Dosage replaces the Dispense Units Per Dose and Noun elements. Example: Local Possible Dosage  EMBED Word.Document.8 \s  CPRS entered provider comments may be copied into the PATIENT INSTRUCTIONS field. These Patient Instructions will then print at the end of the SIG. If Patient Instructions exist at the Pharmacy Orderable Item level, the CPRS provider will view them when the order is being entered and can select whether or not to include them as part of the order. If the provider elects to not include the Pharmacy Orderable Item Patient Instructions as a part of the order, they will not appear in the PATIENT INSTRUCTIONS field of the pending order. The following Complex Local Possible Dosage would apply to a multi-ingredient liquid product, such as Mylanta or Maalox. In this case, 1 TABLESPOONFUL was entered as a Local Possible Dosage in DRUG file (#50). ------------------------Table demonstrating Complex Local Possible Dosage Follows-----------------  EMBED Word.Document.8 \s  The following complex order for a medication with Local Possible Dosages illustrates the elements utilized to build an order for a medication to be given for a specified duration before changing the frequency of administration. The CONJUNCTION field is used to join dosing sequences for a complex order. The entries are limited to AND, THEN, or EXCEPT. AND is used for concurrent doses in a complex order, such as Take 1 tablet every morning AND take 2 tablets at bedtime. THEN is used for consecutive doses in a complex order, for example Take 2 tablets daily for one week THEN take 1 tablet daily for five days. EXCEPT can be used in a complex order to describe any dosing order that is not routine, as in Take 1 tablet every day EXCEPT take no tablets Wednesday. Example 1: Complex Local Possible Dosage  EMBED Word.Document.8 \s  Glossary XE "Glossary" \b  Administration Schedule File The ADMINISTRATION SCHEDULE file (#51.1) contains administration schedule names and standard dosage administration times. The name is a common abbreviation for an administration schedule (e.g., QID, Q4H, PRN). The administration time is entered in military time. CPRS A VistA computer software package called Computerized Patient Record System. CPRS is an application in VistA that allows the user to enter all necessary orders for a patient in different packages from a single application. Dispense Drug The Dispense Drug is pulled from DRUG file (#50) and usually has the strength attached to it (e.g., Acetaminophen 325 mg). Usually, the name alone without a strength attached is the Pharmacy Orderable Item name. Dosage Form File The DOSAGE FORM file (#50.606) contains all dosage forms and associated data that are used by Pharmacy packages and CPRS. The dosage form is used in SIG construction, default values and in the determination of the type of each dosage created for each application. Drug Electrolytes File The DRUG ELECTROLYTES file (#50.4) contains the names of anions and their cations and concentration units. Drug File The DRUG file (#50) holds the information related to each drug that can be used to fill a prescription or medication order. It is pointed to from several other files and should be handled carefully, usually only by special individuals in the Pharmacy Service. Entries are not typically deleted, but rather made inactive by entering an inactive date. Drug Interaction File The DRUG INTERACTION file (#56) is used to store DRUG-DRUG interactions. The file is sent out populated with interactions. These existing interactions cannot be deleted but their severity can be elevated. Locally defined interactions can be added. Drug Text File The DRUG TEXT file (#51.7) stores national and/or drug restrictions, guidelines, and protocols to help assure medications are being used according to defined specifications. IV Additives File The IV ADDITIVES file (#52.6) contains drugs that are used as additives in the IV room. Data entered includes drug generic name, print name, drug information, synonym(s), dispensing units, cost per unit, days for IV order, usual IV schedule, administration times, electrolytes, and quick code information. IV Solutions File The IV SOLUTIONS file (#52.7) contains drugs that are used as primary solutions in the IV room. The solution must already exist in the Drug file (#50) to be selected. Data in this file includes: drug generic name, print name, status, drug information, synonym(s), volume, and electrolytes. Local Possible Dosages Local Possible Dosages are free text dosages that are associated with drugs that do not meet all of the criteria for Possible Dosages. Medication Instruction File The MEDICATION INSTRUCTION file (#51) is used by Unit Dose and Outpatient Pharmacy. It contains the medication instruction name, Outpatient Pharmacy expansion, and intended use, as well as other fields. Medication Routes File The MEDICATION ROUTES file (#51.2) contains medication route names. The user can enter an abbreviation for each route to be used at their site. The abbreviation will most likely be the Latin abbreviation for the term. Medication Routes/Abbreviations The Medication RouteS file (#51.2) contains the medication routes and abbreviations, which are selected by each Department of Veterans Affairs Medical Centers (VAMC). The abbreviation cannot be longer than five characters to fit on labels and the Medical Administration Record (MAR). The user can add new routes and abbreviations as appropriate. National Drug File The National Drug File provides standardization of the local drug files in all VA medical facilities. Standardization includes the adoption of new drug nomenclature and drug classification and links the local drug file entries to data in the National Drug File. For drugs approved by the Food and Drug Administration (FDA), VA medical facilities have access to information concerning dosage form, strength and unit; package size and type; manufacturers trade name; and National Drug Code (NDC). The NDF software lays the foundation for sharing prescription information among medical facilities. Non-Formulary Drugs Drugs that are not available for use by all providers. Orderable Item An Orderable Item is pulled from the PHARMACY ORDERABLE ITEM file (#50.7) and usually has no strength attached to it (e.g., Acetaminophen). The name, with a strength attached, is the Dispense Drug name (e.g., Acetaminophen 325mg). Orderable Item File The ORDERABLE ITEM file (#101.43) is a CPRS file that provides the Orderable Items for selection within all Pharmacy packages. Pharmacy Orderable Items are a subset of this file. Pending Order A pending order is one that has been entered by a provider through CPRS without Pharmacy finishing the order. Once Pharmacy has finished (and verified for Unit Dose only) the order, it will become active. Pharmacy Orderable Item File The PHARMACY ORDERABLE ITEM file (#50.7) contains the Order Entry name for items that can be ordered in the Inpatient Medications and Outpatient Pharmacy packages. Possible Dosages Dosages that have a numeric dosage and numeric Dispense Units Per Dose appropriate for administration. For a drug to have possible dosages, it must be a single ingredient product that is matched to National Drug File. The National Drug File entry must have a numeric strength and the dosage form/unit combination must be such that a numeric strength combined with the unit can be an appropriate dosage selection. Prompt A point at which the system questions the user and waits for a response. Standard Schedule Standard medication administration schedules are stored in the Administration Schedule file (#51.1) and are commonly referred to as "Standard Schedules." Units Per Dose The Units Per Dose is the number of Units (tablets, capsules, etc.) to be dispensed as a dose for an order. Fractional numbers will be accepted for certain dosage forms (i.e. tablets, oral solutions, etc.). VA Drug Class Code A drug classification system used by VA that separates drugs into different categories based upon their characteristics. Some cost reports can be run for VA Drug Class Codes. VA Product File The VA PRODUCT file (#50.68). Appendix A XE "Appendix A: See Convertible Dosage Form/Unit Combinations" \b  Convertible Dosage Form/Unit Combinations XE "Convertible Dosage Form/Unit Combinations" \b Dosage Form Unit Package CAP,EC MG Both CAP,INHL MCG Both MG Both CAP,ORAL GM Both MCG Both MG Both MG/PKG Both MIC Both MIL Both MIN Both ML Both UNT Both CAP,SA MEQ Both MG Both UNT Both CAP,SPRINKLE MG Both CAP,SPRINKLE,SA MG Both DENTAL CONE MG Both DROPS,ORAL MG/0.6ML Inpatient MG/ML Inpatient UNT/ML Inpatient ELIXIR MEQ/15ML Inpatient MEQ/5ML Inpatient MG/10.15ML Inpatient MG/15ML Inpatient MG/5ML Inpatient MG/ML Inpatient EMULSION GM/15ML Inpatient UNT Inpatient ENEMA MG/60ML Inpatient ENEMA,RTL MG/5ML Inpatient FLUID EXTRACT GM/ML Inpatient GEL MCG/0.1ML Inpatient MG/2.5ML Inpatient MG/3GM Inpatient MG/5ML Inpatient MG/UNT Inpatient GRANULES GM Inpatient GM/PKT Inpatient MG Inpatient MG/5ML Inpatient GRNL,EFFERVSC MEQ/PKG Inpatient GRNL,RCNST-ORAL GM/PKG Inpatient MG/2.5ML Inpatient MG/5ML Inpatient MG/ML Inpatient MG/PKT Inpatient GUM,CHEWABLE MG Inpatient IMPLANT MG Inpatient INJ GM Inpatient GM/100ML Inpatient GM/3ML Inpatient GM/50ML Inpatient GM/BAG Inpatient GM/BTL Inpatient GM/ML Inpatient GM/VIAL Inpatient MBq/ML Inpatient MBq/VIL Inpatient MCG/0.5ML Inpatient MCG/ML Inpatient MCG/VIL Inpatient MEQ/L Inpatient MEQ/ML Inpatient MG Inpatient MG/0.2ML Inpatient MG/0.3ML Inpatient MG/0.4ML Inpatient MG/0.5ML Inpatient MG/0.5ML Inpatient MG/0.625ML Inpatient MG/0.6ML Inpatient MG/0.8ML Inpatient MG/10ML Inpatient MG/2ML Inpatient MG/5ML Inpatient MG/AMP Inpatient MG/BAG Inpatient MG/ML Inpatient MG/VIAL Inpatient MIC/VIL Inpatient MIL/ML Inpatient MIL/VIL Inpatient MILLION UNT/VIL Inpatient ML Inpatient PNU Inpatient PNU/ML Inpatient UNT Inpatient UNT/0.1ML Inpatient UNT/0.2ML Inpatient UNT/0.5ML Inpatient UNT/AMP Inpatient UNT/ML Inpatient UNT/TEST Inpatient UNT/VIL Inpatient mgI/ml Inpatient nKatU/ML Inpatient INJ (IN OIL) MG/ML Inpatient INJ,CONC MG/50ML Inpatient MG/5ML Inpatient MG/VIAL Inpatient MG/ML Inpatient INJ,CONC, W/BUF MG/ML Inpatient MG/VIAL Inpatient INJ,CONC-SOLN MEQ/ML Inpatient MG/10ML Inpatient MG/ML Inpatient INJ,FROZEN MG/ML Inpatient INJ,LYPHL GM/VIAL Inpatient MCG/VIL Inpatient MG/AMP Inpatient MG/VIAL Inpatient UNT/AMP Inpatient UNT/VIL Inpatient INJ,PWDR GM/BTL Inpatient GM/VIAL Inpatient MG Inpatient MG/VIAL Inpatient UNT/VIL Inpatient INJ,REPOSITORY MG/ML Inpatient UNT/ML Inpatient INJ,SOLN GM Inpatient GM/100ML Inpatient GM/20ML Inpatient GM/50ML Inpatient GM/AMP Inpatient GM/BAG Inpatient GM/BTL Inpatient GM/KIT Inpatient GM/ML Inpatient GM/VIAL Inpatient MCG/0.3ML Inpatient MCG/0.5ML Inpatient MCG/ML Inpatient MEQ/100ML Inpatient MEQ/50ML Inpatient MEQ/ML Inpatient MG Inpatient MG/0.3ML Inpatient MG/0.5ML Inpatient MG/0.5ML Inpatient MG/0.7ML Inpatient MG/2ML Inpatient MG/AMP Inpatient MG/INJ Inpatient MG/ML Inpatient MG/SYRINGE Inpatient MG/UNT Inpatient MG/VIAL Inpatient MIC/0.6ML Inpatient MIC/1.5ML Inpatient MIC/VIL Inpatient MIL Inpatient MIL/ML Inpatient MILLION UNT/SYR Inpatient MILLION UNT/VIL Inpatient PNU/ML Inpatient UNT Inpatient UNT/0.1ML Inpatient UNT/0.2ML Inpatient UNT/0.5ML Inpatient UNT/0.6ML Inpatient UNT/AMP Inpatient UNT/ML Inpatient UNT/TEST Inpatient UNT/VIL Inpatient VIL Inpatient mgI/ml Inpatient INJ,SOLN,SA MG/ML Inpatient INJ,SUSP GM/VIAL Inpatient MCG/ML Inpatient MG/ML Inpatient MIL/ML Inpatient MILLION UNT/VIL Inpatient UNT/0.5ML Inpatient UNT/1.2ML Inpatient UNT/ML Inpatient INJ,SUSP,SA MG Inpatient MG/ML Inpatient INJ,SUSP-DRY,SA MG Inpatient MG/VIAL Inpatient INJ/IMPLANT MG Inpatient INSERT,CONT REL MG Inpatient MG/CAP Inpatient INSERT,CONT REL,OPH MG/UNT Inpatient INSERT,VAG MG Inpatient LIQUID GM Inpatient MEQ/15ML Inpatient MG Inpatient MG/15ML Inpatient MG/5ML Inpatient MG/GTT Inpatient MG/ML Inpatient LIQUID,ORAL GM Inpatient GM/10ML Inpatient GM/UNT Inpatient MEQ/15ML Inpatient MG Inpatient MG/0.6ML Inpatient MG/15ML Inpatient MG/2.5ML Inpatient MG/4ML Inpatient MG/5ML Inpatient MG/MIN Inpatient MG/ML Inpatient UNT/0.1ML Inpatient UNT/ML Inpatient LOZENGE MCG Inpatient MG Inpatient UNT Inpatient OPHTHALMIC,CRC MG/UNT Inpatient PELLET MG Inpatient POWDER GM Inpatient GM/1.7GM Inpatient GM/5GM Inpatient GM/9GM Inpatient GM/BAG Inpatient GM/BTL Inpatient GM/CUP Inpatient GM/PKT Inpatient MG Inpatient UNT/VIL Inpatient POWDER,ORAL GM Inpatient GM/5GM Inpatient GM/CUP Inpatient GM/PKG Inpatient MG/GM Inpatient POWDER,TOP GM Inpatient UNT/GM Inpatient PWDR,EFFERVSC MEQ/PKT Inpatient PWDR,RENST-ORAL CAL/ML Inpatient GM Inpatient GM/5GM Inpatient GM/BTL Inpatient GM/PKG Inpatient GM/PKT Inpatient GM/UNT Inpatient MEQ/PKT Inpatient MG/5ML Inpatient MG/ML Inpatient MG/PKG Inpatient MG/PKT Inpatient UNT/5ML Inpatient RING,VAG MG Inpatient SOLN MG/5ML Inpatient MG/ML Inpatient MIL Inpatient MIL/ML Inpatient UNT/ML Inpatient SOLN,CONC MG/5ML Inpatient MG/ML Inpatient SOLN,INHL MG/5ML Inpatient MG/ML Inpatient SOLN,IRRG MG/ML Inpatient SOLN,NASAL MCG/SPRAY Inpatient MG/ML Inpatient UNT/SPRAY Inpatient SOLN,ORAL GM/ML Inpatient MEQ/15ML Inpatient MEQ/5ML Inpatient MG Inpatient MG/0.5ML Inpatient MG/0.5ML Inpatient MG/18.75ML Inpatient MG/20ML Inpatient MG/5ML Inpatient MG/7.5ML Inpatient MG/ML Inpatient MIL/ML Inpatient UNT/ML Inpatient SOLN,RTL MG/ML Inpatient SOLN,SPRAY,NASAL MCG/SPRAY Inpatient MG/SPRAY Inpatient UNT/ML Inpatient SUPP,RTL MG Inpatient SUPP,VAG GM Inpatient MG Inpatient SUPPOSITORY MCG Inpatient SUSP GM/5ML Inpatient GM/60ML Inpatient MG/15ML Inpatient MG/5ML Inpatient MG/ML Inpatient UNT/ML Inpatient SUSP,INTRATHECAL MG/ML Inpatient SUSP,ORAL MCG/ML Inpatient MG/15ML Inpatient MG/5ML Inpatient MG/ML Inpatient UNT/ML Inpatient SUSP,RTL GM/60ML Inpatient SYRINGE UNT Inpatient SYRUP GM/15ML Inpatient GM/5ML Inpatient MEQ/5ML Inpatient MG/15ML Inpatient MG/5ML Inpatient MG/ML Inpatient SYRUP,ORAL MG/5ML Inpatient TAB GM Both GR Both MCG Both MEQ Both MG Both MG/5ML Inpatient MG/DAY Inpatient UNT Both TAB,BUCC,SA MG Both TAB,BUCCAL MG Both TAB,CHEWABLE GM Both MG Both TAB,EC GM Both GR Both MEQ Both MG Both UNT Both TAB,EFFERVSC MEQ Both MG Both TAB,ORAL MCG Both MG Both UNT Both TAB,ORAL DISINTEGRATING MG Both TAB,RAPID DISINTEGRATE MG Both TAB,SA GM Both MEQ Both MG Both TAB,SOLUBLE MG Both TAB,SUBLINGUAL MG Both TAB,VAG MG Both UNT Both TAMPON MG Inpatient TAPE MCG/SQCM Inpatient TINCTURE MG/5ML Inpatient MG/ML Inpatient TROCHE MG Inpatient WAFER GM Inpatient MG Inpatient Appendix B XE "Appendix B: See Original Drug Text File Entries Combinations" \b  Original Drug Text File Entries Combinations XE "Original Drug Text File Entries Combinations" \b The National Formulary Restriction Text is the original text exported with the DRUG TEXT file (#51.7) and automatically linked to the Drug File entries based on the VA Product match. No Orderable Item file entries were automatically linked with the DRUG TEXT file (#51.7). DRUG TEXT file (#51.7) Entry National Formulary Restriction Text HYPERTENSION-VA/DOD Refer to VA/DoD Hypertension treatment guidelines SPINAL CORD,NEUROLOGY,REHAB RESTRICTED TO SPINAL CORD INJURY,NEUROLOGY,AND REHABILITATION HIV/AIDS Refer to HIV/AIDS TAG treatment guidelines DIABETES Refer to PBM/MAP and PBM/TAG Diabetes treatment guidelines CHF Refer to PBM/MAP CHF treatment guidelines GERD Refer to PBM/MAP GERD treatment guidelines PUD Refer to PBM/MAP PUD treatment guidelines COPD Refer to VA/DoD COPD treatment guidelines DIHYDROPYRIDINE CALCIUM ANTAGONISTS Refer to PBM/MAP criteria for use of long-acting dihydropyridine calcium antagonists HYPERLIPIDEMIA Refer to VA/DoD Hyperlipidemia treatment guidelines NEUROLOGY RESTRICTED TO NEUROLOGY SMOKING CESSATION RESTRICTED TO SMOKING CESSATION PROGRAMS BPH Refer to PBM/MAP benign Prostatic Hyperplasia treatment guidelines ATORVASTATIN Refer to PBM/MAP criteria for use of atorvastatin TROVAFLOXACIN Refer to PBM/MAP criteria for use of trovafloxacin THIAZOLIDINEDIONES Refer to PBM/MAP criteria for use of thiazolidinediones LANSOPRAZOLE Refer to PBM/MAP dosing guidelines for lansoprazole DRUG TEXT file (#51.7) Entry National Formulary Restriction Text CELECOXIB Refer to PBM/MAP criteria for use of celecoxib BECALPERMIN Refer to PBM/MAP criteria for use of becalpermin DEPRESSION Refer to PBM/MAP Depression treatment guidelines ALBUMIN Refer to PBM/MAP guidelines for use of albumin HYPERTENSION/CHF-VA/DOD-PBM/MAP Refer to VA/DoD Hypertension treatment and PBM/MAP CHF treatment guidelines HYPERTENSION/CHF/DIABETES Refer to PBM/MAP Hypertension treatment and CHF treatment guidelines and PBM/TAG Diabetes treatment guidelines HYPERTENSION-PBM/MAP Refer to PBM/MAP Hypertension treatment guidelines REVIEW Class review in progress HYPERTENSION/CHF-PBM Refer to PBM/MAP Hypertension treatment and CHF treatment guidelines ALZHEIMER'S Refer to Pharmacologic Management of Cognitive Changes in Alzheimer's Disease BPH/HYPERTENSION Refer to PBM/MAP benign Prostatic Hyperplasia treatment and Hypertension treatment guidelines Appendix C XE "Appendix C: See Administration Schedules, Spanish Translations" \b  Administration Schedules - Spanish Translations  XE "Administration Schedules, Spanish Translations" \b The Outpatient Language Modifications patch PSS*1*47 provides the functionality to print prescription labels in a language other than English. Enabling this functionality requires setting certain flags and completing several setup steps, including populating fields used for the Sig with equivalent terms in the specified other language. The following table provides Spanish equivalents for some of the more common Administration Schedules. The translations in this table may require modifications for different dialects. ADMIN SCHEDULEOUTPATIENT EXPANSIONOUTPATIENT SPANISH EXPANSIONAMDAILY IN THE MORNINGDIARIAMENTE EN LA MANANAAM-HSAT MORNING AND AT BEDTIMEEN LA MANANA Y AL ACOSTARSEAM-PMAT MORNING AND IN THE AFTERNOONEN LA MANANA Y EN LA TARDEAM-PMIMORNING AND EVENINGEN LA MANANA Y EN LA TARDEBIDTWO TIMES A DAYDOS VECES AL DIABID &HSTWO TIMES A DAY AND AT BEDTIMEDOS VECES AL DIA Y AL ACOSTARSEDAILYEVERY DAYDIARIAMENTEFR-SAFRIDAY AND SATURDAYVIERNES Y SABADOFRIDAYFRIDAYVIERNESHSAT BEDTIMEAL ACOSTARSEMO-FRMONDAY AND FRIDAYLUNES Y VIERNESMO-THMONDAY AND THURSDAYLUNES Y JUEVESMO-TUMONDAY AND TUESDAYLUNES Y MARTESMO-TU-FRMONDAY, TUESDAY, FRIDAYLUNES, MARTES Y VIERNESMO-TU-FR-SAMONDAY,TUESDAY,FRIDAY AND SATURDAYLUNES, MARTES, VIERNES Y SABADOMO-TU-TH-FR-SAMONDAY,TUESDAY,THURSDAY,FRIDAY AND SATURDAYLUNES,MARTES,JUEVES,VIERNES Y SABADOMO-TU-TH-SAMONDAY,TUESDAY,THURSDAY AND SATURDAYLUNES,MARTES,JUEVES Y SABADOMO-TU-WEMONDAY, TUESDAY, WEDNESDAYLUNES, MARTES Y MIERCOLESMO-TU-WE-THMONDAY,TUESDAY,WEDNESDAY AND THURSDAYLUNES, MARTES, MIERCOLES Y JUEVESMO-TU-WE-TH-FRMONDAY,TUESDAY,WEDNESDAY,THURSDAY AND FRIDAYLUNES, MARTES, MIERCOLES, JUEVES Y VIERNESMO-TU-WE-TH-FR-SAMONDAY THRU SATURDAYDE LUNES A SABADOMO-TU-WE-TH-SAMONDAY,TUESDAY,WEDNESDAY,THURSDAY AND SATURDAYLUNES, MARTES, MIERCOLES, JUEVES Y SABADOMO-WEMONDAY AND WEDNESDAYLUNES Y MIERCOLESMO-WE-FRMONDAY,WEDNESDAY AND FRIDAYLUNES,MIERCOLES Y VIERNESMO-WE-FRMONDAY,WEDNESDAY AND FRIDAYLUNES,MIERCOLES Y VIERNESMO-WE-FRMONDAY, WEDNESDAY AND FRIDAYLUNES,MIERCOLES Y VIERNESMO-WE-FR-SAMONDAY,WEDNESDAY,FRIDAY AND SATURDAYLUNES,MIERCOLES,VIERNES Y SABADOMO-WE-SAMONDAY, WEDNESDAY AND SATURDAYLUNES,MIERCOLES Y SABADOMO-WE-TH-FRMONDAY, WEDNESDAY,THURSDAY AND FRIDAYLUNES, MIERCOLES, JUEVES Y VIERNESMONDAYMONDAYLUNESMONTHLYMONTHLYMENSUALMENTENOWNOWAHORAONCEONCEUNA SOLA VEZONE TIMEONE-TIMEUNA SOLA VEZPC&HSAFTER MEALS AND AT BEDTIMEDESPUES DE LAS COMIDAS Y AL ACOSTARSEPMDAILY IN THE AFTERNOONDIARIAMENTE EN LA TARDEQ12HEVERY 12 HOURSCADA DOCE HORASQ12WEEKSEACH TWELVE WEEKSCADA 12 SEMANASQ15DEVERY 15 DAYSCADA 15 DIASQ1HEVERY HOURCADA HORAQ20DEVERY 20 DAYSCADA 20 DIASQ21DEVERY 21 DAYSCADA 21 DIASQ24HEVERY 24 HOURSCADA 24 HORASQ28DEVERY 28 DAYSCADA 28 DIASQ29DEVERY 29 DAYSCADA 29 DIASQ2HEVERY 2 HOURSCADA DOS HORASQ2MONTHSEVERY TWO MONTHSCADA DOS MESESQ2WEEKEVERY TWO WEEKSCADA DOS SEMANASQ30DEVERY 30 DAYSCADA 30 DIASQ30MINEVERY 30 MINUTESCADA 30 MINUTOSQ3DEVERY 3 DAYSCADA 3 DIASQ3HEVERY 3 HOURSCADA 3 HORASQ3MONTHSEVERY THREE MONTHSCADA TRES MESESQ3WEEKEVERY THREE WEEKSCADA TRES (3) SEMANASQ48HEVERY 48 HOURSCADA 48 HORASQ4DEVERY 4 DAYSCADA 4 DIASQ4HEVERY 4 HOURSCADA 4 HORASQ4WEEKEVERY FOUR WEEKSCADA CUATRO (4)SEMANASQ5DEVERY 5 DAYSCADA 5 DIASQ5MINEVERY 5 MINUTESCADA 5 MINUTOSQ6HEVERY 6 HOURSCADA 6 HORASQ72HEVERY 72 HOURSCADA 72 HORASQ7DEVERY 7 DAYSCADA 7 DIASQ8HEVERY 8 HOURSCADA 8 HORASQ96HEACH 96 HOURSCADA 96 HORASQAMEVERY MORNINGDIARIAMENTE EN LA MANANAQDDAILYDIARIAMENTEQD1300EVERY DAY AT 1:00 PMCADA DIA A LA 1:00 PMQD5FIVE TIMES A DAYCINCO VECES AL DIAQDAMEVERY MORNINGCADA MANANAQDHSDAILY AT BEDTIMEDIARIAMENTE AL ACOSTARSEQDIDAILYDIARIAMENTEQDMDDAILY AT NOONDIARIAMENTE AL MEDIODIAQDPMDAILY IN THE EVENINGDIARIAMENTE EN LA TARDEQHEVERY HOURCADA HORAQIDFOUR TIMES A DAYCUATRO VECES AL DIAQODEVERY OTHER DAYUN DIA SI Y OTRO NOQWEEKWEEKLYCADA SEMANASATURDAYSATURDAYSABADOSU-FRSUNDAY AND FRIDAYDOMINGO Y VIERNESSU-FR-SASUNDAY,FRIDAY AND SATURDAYDOMINGO ,VIERNES Y SABADOSU-MO-FRSUNDAY , MONDAY AND FRIDAYDOMINGO , LUNES Y VIERNESSU-MO-THSUNDAY,MONDAY,THURSDAYDOMINGO,LUNES Y JUEVESSU-MO-TUSUNDAY,MONDAY AND TUESDAYDOMINGO,LUNES Y MARTESSU-MO-TU-FRSUNDAY,MONDAY,TUESDAY AND FRIDAYDOMINGO,LUNES,MARTES Y VIERNESSU-MO-TU-FR-SASUNDAY,MONDAY,TUESDAY,FRIDAY,SATURDAYDOMINGO,LUNES,MARTES,VIERNES Y SABADOSU-MO-TU-SASUNDAY ,MONDAY, TUESDAY AND SATURDAYDOMINGO, LUNES,MARTES Y SABADOSU-MO-TU-TH-FRSUNDAY,MONDAY,TUESDAY,THURSDAY AND FRIDAYDOMINGO,LUNES,MARTES,JUEVES Y VIERNESSU-MO-TU-TH-FR-SASUNDAY,MONDAY,TUESDAY,THURSDAY,FRIDAY AND SATURDAYDOMINGO,LUNES,MARTES,JUEVES,VIERNES Y SABADOSU-MO-TU-TH-SASUNDAY,MONDAY,TUESDAY,THURSDAY AND SATURDAYDOMINGO,LUNES,MARTES,JUEVES Y SABADOSU-MO-TU-WE-FRSUNDAY,MONDAY,TUESDAY,WEDNESDAY,FRIDAYDOMINGO,LUNES,MARTES,MIERCOLES Y VIERNESSU-MO-TU-WE-FR-SASUNDAY,MONDAY,TUESDAY,WEDNESDAY,FRIDAY,SATURDAYDOMINGO,LUNES,MARTES,MIERCOLES,VIERNES Y SABADOSU-MO-TU-WE-THSUNDAY, MONDAY,TUESDAY,WEDNESDAY,THURSDAYDOMINGO,LUNES,MARTES,MIERCOLES Y JUEVESSU-MO-TU-WE-TH-FRSUNDAY THRU FRIDAYDE DOMIGO A VIERNESSU-MO-TU-WE-TH-SASUNDAY,MONDAY,TUESDAY,WEDNESDAY,THURSDAY,SATURDAYDOMINGO,LUNES,MARTES,MIERCOLES,JUEVES Y SABADOSU-MO-WESUNDAY,MONDAY AND WEDNESDAYDOMINGO,LUNES Y MIERCOLESSU-MO-WE-FRSUNDAY,MONDAY,WEDNESDAY AND FRIDAYDOMINGO,LUNES,MIERCOLES Y VIERNESSU-MO-WE-FR-SASUNDAY,MONDAY,WEDNESDAY,FRIDAY AND SATURDAYDOMINGO,LUNES,MIERCOLES,VIERNES Y SABADOSU-MO-WE-TH-FRSUNDAY,MONDAY,WEDNESDAY,THURSDAY AND FRIDAYDOMINGO,LUNES,MIERCOLES,JUEVES Y VIERNESSU-MO-WE-TH-FR-SASUNDAY,MONDAY AND WEDNESDAY THRU SATURDAYDOMINGO,LUNES Y DE MIERCOLES A SABADOSU-SASUNDAY AND SATURDAYDOMINGO Y SABADOSU-TH-FR-SASUNDAY ,THURSDAY , FRIDAY AND SATURDAYDOMINGO, JUEVES, VIERNES Y SABADOSU-TU-SASUNDAY , TUESDAY AND SATURDAYDOMINGO,MARTES Y SABADOSU-TU-THSUNDAY,TUESDAY,THURSDAYDOMINGO,MARTES Y JUEVESSU-TU-TH-FR-SASUNDAY,TUESDAY,THURSDAY,FRIDAY AND SATURDAYDOMINGO,MARTES,JUEVES,VIERNES Y SABADOSU-TU-TH-SASUNDAY,TUESDAY,THURSDAY AND SATURDAYDOMINGO,MARTES,JUEVES Y SABADOSU-TU-TH-SASUNDAY,TUESDAY,THURSDAY AND SATURDAYDOMINGO,MARTES,JUEVES Y SABADOSU-TU-WE-TH-FR-SASUNDAY AND TUESDAY THRU SATURDAYDOMINGO Y DE MARTES A SABADOSU-TU-WE-TH-SASUNDAY,TUESDAY,WEDNESDAY,THURSDAY AND SATURDAYDOMINGO,MARTES,MIERCOLES,JUEVES Y SABADOSU-WESUNDAY AND WEDNESDAYDOMINGO Y MIERCOLESSU-WE-FRSUNDAY,WEDNESDAY AND FRIDAYDOMINGO ,MIERCOLES Y VIERNESSUNDAYSUNDAYDOMINGOTHTHURSDAYJUEVESTH-FRTHURSDAY, FRIDAYJUEVES Y VIERNESTH-SATHURSDAY AND SATURDAYJUEVES Y SABADOTHURSDAYTHURSDAYJUEVESTIDTHREE TIMES A DAYTRES VECES AL DIATID &HSTHREE TIMES A DAY AND AT BEDTIMETRES VECES AL DIA Y AL ACOSTARSETID 1/2HR-ACTHREE TIMES A DAY, HALF HOUR BEFORE MEALSTRES VECES AL DIA, MEDIA HORA ANTES DE LAS COMIDASTID 1/2HR.AC&HSHALF HOUR BEFORE MEALS AND AT BEDTIMEMEDIA HORA ANTES DE LAS COMIDAS Y AL ACOSTARSETID 1HR-PC&HSONE HOUR AFTER MEALS AND AT BEDTIMEUNA HORA DESPUES DE LAS COMIDAS Y AL ACOSTARSETUTUESDAYMARTESTU-FRTUESDAY AND FRIDAYMARTES Y VIERNESTU-SATUESDAY AND SATURDAYMARTES Y SABADOTU-SATUESDAY AND SATURDAYMARTES Y SABADOTU-THTUESDAY AND THURSDAYMARTES Y JUEVESTU-TH-FRTUESDAY, THURSDAY AND FRIDAYMARTES, JUEVES Y VIERNESTU-TH-SATUESDAY,THURSDAY AND SATURDAYMARTES ,JUEVES Y SABADOTU-TH-SATUESDAY-THURSDAY-SATURDAYMARTES ,JUEVES Y SABADOTU-WE-FR-SATUESDAY,WEDNESDAY,FRIDAY,SATURDAYMARTES,MIERCOLES,VIERNES Y SABADOTU-WE-THTUESDAY,WEDNESDAY AND THURSDAYMARTES,MIERCOLES Y JUEVESTUESDAYTUESDAYMARTESWEWEDNESDAYMIERCOLESWE-FRWEDNESDAY AND FRIDAYMIERCOLES Y VIERNESWE-SAWEDNESDAY AND SATURDAYMIERCOLES Y SABADOWE-TH-FRWEDNESDAY, THURSDAY AND FRIDAYMIERCOLES, JUEVES Y VIERNESWE-TH-FR-SAWEDNESDAY THRU SATURDAYDE MIERCOLES A SABADOWEDNESDAYWEDNESDAYMIERCOLESWEEKLYWEEKLYSEMANALMENTE Appendix D XE "Appendix D: See Dosage Forms, Spanish Translations" \b  Dosage Forms - Spanish Translations  XE "Dosage Forms, Spanish Translations" \b The Outpatient Language Modifications patch PSS*1*47 provides the functionality to print prescription labels in a language other than English. Enabling this functionality requires setting certain flags and completing several setup steps, including populating fields used for the Sig with equivalent terms in the specified other language. The following table provides Spanish equivalents for some of the more common dosage forms. The translations in this table may require modifications for different dialects. DOSAGE FORMVERBVERB IN SPANISHPREPOSITIONPREPOSITION IN SPANISHNOUNNOUN IN SPANISHADAPTERUSEUTILIZARAS DIRECTEDSEGUN INDICADOAEROSOLUSEHACERFORPORSPRAY(S)ATOMIZACION(ES)AEROSOL,ORALINHALEHACERBYPORPUFF(S)INHALACION(ES)AEROSOL,RTLINSERTINSERTARINTOEN ELAPPLICATOR(S)APLICADOR(ES)AEROSOL,TOPAPPLYAPLICARTOPARASPRAY(S)ATOMIZACION(ES)AEROSOL,VAGAPPLYAPLICARTOEN LASPRAY(S)ATOMIZACION(ES)APPLICATORUSEUTILIZARAS DIRECTEDSEGUN INDICADOBAGUSEUTILIZARAS DIRECTEDSEGUN INDICADOBANDAGEUSEUTILIZARAS DIRECTEDSEGUN INDICADOBAR,CHEWABLECHEWMASTICARBYPORBARBARRABAR,TOPUSEUTILIZARAS DIRECTEDSEGUN INDICADOBEADS,TOPUSEUSARAS DIRECTEDSEGUN INDICADOBELTUSEUTILIZARAS DIRECTEDSEGUN INDICADOBLOCKUSEUTILIZARAS DIRECTEDSEGUN INDICADOCAP,ECTAKETOMARBYPORCAPSULE(S)CAPSULA(S)CAP,INHLUSEUSARBYPARACAPSULE(S)CAPSULA(S)CAP,ORALTAKETOMARBYPORCAPSULE(S)CAPSULA(S)CAP,SATAKETOMARBYPORCAPSULE(S)CAPSULA(S)CAP,SPRINKLETAKETOMARBYPORCAPSULE(S)CAPSULA(S)CAP,SPRINKLE,SATAKETOMARBYPORCAPSULE(S)CAPSULA(S)CONVEX INSERTUSEUTILIZARAS DIRECTEDSEGUN INDICADOCREAMAPPLYAPLICARTOENTHIN FILMUNA CAPA FINACREAM,ORALAPPLYAPLICARTOEN LATHIN FILMUNA CAPA FINACREAM,OTICAPPLYAPLICARTOENTHIN FILMUNA CAPA FINACREAM,RTLINSERTINSERTARINTOPOR ELAPPLICATORFULAPLICADOR LLENOCREAM,TOPAPPLYAPLICARTOENA THIN FILMUNA CAPA FINACREAM,VAGINSERTINSERTARINTOEN LAONE APLICATORFULUN APLICADOR LLENOCRYSTALUSEUTILIZARAS DIRECTEDSEGUN INDICADODENTAL CONEUSEUTILIZARDEVICEUSEUSARAS INDICATEDSEGUN INDICADODIAPHRAGMUSEUTILIZARAS DIRECTEDSEGUN INDICADODISKUSEUSARAS DIRECTEDSEGUN INDICADODOUCHEUSEUSARINTOEN LAAS DIRECTEDSEGUN INDICADODRAINUSEUTILIZARAS DIRECTEDSEGUN INDICADODRESSINGAPPLYAPLICARTOENAS DIRECTEDSEGUN INDICADODRESSING,TOPAPPLYAPLICARTOENAS DIRECTEDSEGUN INDICADODROPS,ORALTAKETOMARBYPORDROP(S)GOTA(S)ELIXIRTAKETOMARBYPORTEASPOONFUL(S)CUCHARADITA(S)EMULSIONTAKETOMARBYPORTEASPOONFUL(S)CUCHARADITA(S)EMULSION,TOPAPPLYAPLICARTOENAS DIRECTEDSEGUN INDICADOENEMAINSERTINSERTARINTOEN ELAS DIRECTEDSEGUN INDICADOENEMA,RTLINSERTINSERTARINTOEN ELAS DIRECTEDSEGUN INDICADOEXTRACTADMINISTERADMINISTRARML(S)MILILITROFACEPLATEUSEUTILIZARAS DIRECTEDSEGUN INDICADOFILMAPPLYAPLICAROVERSOBREAS DIRECTEDSEGUN INDICADOFILM,CONT RELAPPLYAPLICAROVERSOBREPATCHPARCHOFLANGE CAPUSEUTILIZARAS DIRECTEDSEGUN INDICADOFLUFFUSEUTILIZARAS DIRECTEDSEGUN INDICADOFLUID EXTRACTTAKETOMARBYPORML(S)MILILITRO(S)FOAM,TOPUSEUTILIZARAS DIRECTEDGASINHALEINHALARSEGUN INDICADOSEGUN INDICADOGAUZEUSEUSARGELUSEUSARTOEN LATHIN FILMCAPA FINAGEL,DENTAPPLYAPLICARFORPARAAS DIRECTEDSEGUN INDICADOGEL,NASALAPPLYAPLICARTOENAS DIRECTEDSEGUN INDICADOGEL,OPHAPPLYAPLICARTOENINCHPULGADA(S)GEL,TOPAPPLYAPLICARTOENTHIN FILMCAPA FINAGLOVEUSEUSARAS DIRECTEDSEGUN INDICADOGRAFT,TOPUSEUTILIZARAS DIRECTEDSEGUN INDICADOGRANULESUSEUSARBYPORTEASPOONFUL(S)CUCHARADITA(S)GRNL,EFFERVSCTAKETOMARTEASPOONFUL(S)CUCHARADITA(S)GRNL,RCNST-ORALTAKETOMARBYPORTEASPOONFUL(S)CUCHARADITA(S)GUM,CHEWABLECHEWMASTICARINEN LAPIECE(S)PIEZA(S)IMPLANTINJECTINYECTARAS DIRECTEDSEGUN INDICADOINHALANTUSEUSARBYPORPUFF(S)INHALACION(ES)INHALATIONSUSEUSARBYPORPUFF(S)INHALACION(ES)INHALERUSEUSARBYPORPUFF(S)INHALACION(S)INHL,NASALUSEUSARSPRAY(S)ATOMIZACION(ES)INHL,ORALUSEUSARBYPORPUFF(S)INHALACION(ES)INJADMINISTERINJECTARADMINISTRARINJ (IN OIL)INJECTINJECTARPORINJ,CONCINJECTINJECTARPORINJ,CONC, W/BUFINJECTINJECTARPORINJ,CONC-SOLNINJECTINJECTARPORINJ,FROZENINJECTINJECTARPORINJ,LYPHLINJECTINJECTARPORINJ,PWDRINJECTINJECTARPORINJ,REPOSITORYINJECTINJECTARPORINJ,SOLNINJECTINJECTARINJ,SOLN (IN OIL)INJECTINJECTARPORINJ,SOLN,LAINJECTINJECTARPORINJ,SOLN,SAINJECTINJECTARPORINJ,SUSPINJECTINJECTARPORINJ,SUSP (IN OIL)INJECTINJECTARPORINJ,SUSP,SAINJECTINJECTARPORINJ,SUSP-DRY,SAINJECTINJECTARPORINJ/IMPLANTPLACEPONERPORIMPLANT(S)IMPLANTE(S)INSERT,CONT RELINSERTINSERTARINENAS DIRECTEDSEGUN INDICADOINSERT,CONT REL,OPHINSERTINSERTARINENAS DIRECTEDSEGUN INDICADOINSERT,VAGINSERTINSERTARTOEN LAAS DIRECTEDSEGUN INDICADOIRRIGATION SETUSEUTILIZARAS DIRECTEDSEGUN INDICADOIRRIGATION SLEEVEUSEUTILIZARAS DIRECTEDSEGUN INDICADOIRRIGATORUSEUTILIZARAS DIRECTEDSEGUN INDICADOIUDINSERTINSERTARBYPOR VIAAS DIRECTEDSEGUN INDICADOJELLYAPPLYAPLICARTOENTHIN FILMUNA CAPA FINAJELLY,NASALAPPLYAPLICARINENTHIN FILMUNA CAPA FINAJELLY,TOPAPPLYAPLICARTOENTHIN FILMUNA CAPA FINAJELLY,VAGINSERTINSERTARINTODENTRO DE LAAPPLICATORFUL(S)APLICADOR LLENOKITUSEUSARAS DIRECTEDSEGUN INDICADOLANCETUSEUSARAS DIRECTEDSEGUN INDICADOLENS,HARDPLACEPONERINTOENAS DIRECTEDSEGUN INDICADOLENS,SOFTPLACEPONERINTOENAS DIRECTEDSEGUN INDICADOLINIMENTAPPLYAPLICARTOENAS DIRECTEDSEGUN INDICADOLIQUIDTAKETOMARBYPOR LATEASPOONFUL(S)CUCHARADITA(S)LIQUID(SF)TAKETOMARBYPORTEASPOONFUL(S)CUCHARADITA(S)LIQUID,AEROSOLAPPLYAPLICARFORPARASPRAY(S)ATOMIZACION(ES)LIQUID,DENTAPPLYAPLICARTOPARAAS DIRECTEDSEGUN INDICADOLIQUID,INHLUSEUTILIZARINHALATION(S)INHALACIONESLIQUID,OPHINSTILECHARFORPARADROP(S)GOTA(S)LIQUID,ORALTAKETOMARBYPORTEASPOONFUL(S)CUCHARADITA(S)LIQUID,OTICINSTILLECHARINENDROP(S)GOTA(S)LIQUID,RTLAPPLYAPLICARINENLIQUID,TOPAPPLYAPLICARTOPARAAS DIRECTEDLOTIONAPPLYAPLICARTOENAS DIRECTEDSEGUN INDICADOLOTION,TOPAPPLYAPLICARTOENAS DIRECTEDSEGUN INDICADOLOZENGEDISSOLVEDISOLVERINEN LALOZENGETABLETAMASKUSEUTILIZARAS INDICATEDSEGUN INDICADOMISCELLANEOUSUSEUSARAS DIRECTEDSEGUN INDICADOMOUTHWASHUSEUTILIZARFORPARATEASPOONFUL(S)CUCHARADITA(S)NEEDLEUSEUTILIZARAS DIRECTEDSEGUN INDICADOOILTAKETOMARBYPORTEASPOONFUL(S)CUCHARADITA(S)OIL,TOPAPPLYAPLICARFORPARAAS DIRECTEDSEGUN INDICADOOINT,DENTAPPLYAPLICARFORPARA USOTHIN FILMUNA CAPA FINAOINT,OPHAPPLYAPLICARTOATHIN FILMUNA CAPA FINAOINT,RTLINSERTINSERTARTOALONE APLICATORFULUN APLICADOR LLENOOINT,TOPAPPLYAPLICARTOPARAA THIN FILMUNA CAPA FINAOINTMENTINSERTINSERTARFORPARA USOTHIN LAYERUNA CAPA FINAOPHUSEUTILIZARDROP(S)GOTA(S)OPH IRRUSEUSETOENIRRIGATION(S)IRRIGACION(ES)OPHTHALMIC,CRCPLACEPONERINTOENTHIN FILMCAPA FINAPADUSEUTILIZARAS DIRECTEDSEGUN INDICADOPAD,TOPUSEUTILIZARAS DIRECTEDSEGUN INDICADOPASTEAPPLYAPLICARFORPARATHIN FILMUNA CAPA FINAPATCHAPPLYAPLICARTOENPATCHPARCHOPELLETINSERTINSERTARBYPORPELLET(S)BOLITA(S)PILLTAKETOMARBYPORPILL(S)PILDORA(S)POUCHUSEUTILIZARAS DIRECTEDSEGUN INDICADOPOWDERUSEUSARBYPORTEASPOONFUL(S)CUCHARADITA(S)POWDER,AEROSOLUSEUTILIZARFORPARASPRAY(S)ATOMIZACION(ES)POWDER,ORALTAKETOMARBYPORTEASPOONFUL(S)CUCHARADITA(S)POWDER,RTLDISOLVE AND INSERTDISOLVER E INSERTARBYPORENEMA(S)ENEMA(S)POWDER,SPRAYAPPLYAPLICARFORPARASPRAY(S)ATOMIZACION(ES)POWDER,TOPAPPLYAPLICARTOPARAPACKAGE(S)SOBRE(S)PUDDINGTAKETOMARBYPORTHE CONTENT OF A CANEL CONTENIDO DE UNA LATAPWDR,EFFERVSCDISOLVE AND TAKEDISOLVER Y TOMARBYPORTABLESPOONFUL(S)CUCHARADA(S)PWDR,RENST-ORALTAKETOMARBYPORTEASPOONFUL(S)CUCHARADITA(S)RING,VAGUSEUTILIZARBYPOR LAAS DIRECTEDSEGUN INDICADORINSE,ORALUSEUTILIZARFORPARATEASPOONFUL(S)CUCHARADITA(S)SETUSEUTILIZARAS DIRECTEDSEGUN INDICADOSET,INFUSIONUSEUTILIZARAS DIRECTEDSEGUN INDICADOSHAMPOOSHAMPOOLAVAR EL CABELLOAS DIRECTEDSEGUN INDICADOSOAP/DETERGENTWASH AREALAVAR AREAAS DIRECTEDSEGUN INDICADOSOLNUSEUSARBYPORSOLN,CONCTAKETOMARBYPORSOLN,INHLUSEUTILIZARIN NEBULIZER FOREN NEBULIZADOR PORMILLILITER(S)MILILITRO(S)SOLN,IRRGUSEUTILIZARFORPARASOLN,NASALUSEECHARENDROP(S)GOTA(S)SOLN,OPHINSTILLECHARDROP(S)GOTA(S)SOLN,OPH IRRGUSEUTILIZARFORPARASOLN,ORALTAKETOMARBYPORTEASPOONFUL(S)CUCHARADITA(S)SOLN,OTICINSTILLECHARINPARADROP(S)GOTA(S)SOLN,RTLINSTILLINSERTARBYPOR ELCONTENT(S)CONTENIDOSOLN,SPRAY,NASALUSEUTILIZARINENSPRAY(S)ATOMIZACION(ES)SOLN,TOPAPPLYAPLICARTOPARASPIRITUSEUTILIZARSPONGEUSEUTILIZARAS DIRECTEDSEGUN INDICADOSPRAY,TOPSPRAYROCIARFORPARAAS DIRECTEDSEGUN INDICADOSTOMA CAPUSEUTILIZARAS DIRECTEDSEGUN INDICADOSTRIPUSEUTILIZARSTRIP AS DIRECTEDTIRILLA SEGUN INDICADOSTRIP,OPHUSEUTILIZARINENSTRIP AS DIRECTEDTIRILLA SEGUN INDICADOSUPP,RTLINSERTINSERTARBYPOR ELSUPPOSITORYSUPOSITORIOSUPP,VAGINSERTINSERTARINEN LASUPPOSITORYSUPOSITORIOSUPPOSITORYINSERTINSERTARINTOENSUPPOSITORYSUPOSITORIOSUSPTAKETOMARBYPORTEASPOONFUL(S)CUCHARADITA(S)SUSP(SF)TAKETOMARBYPORTABLESPOONFUL(S)CUCHARADA(S)SUSP,INTRATHECALINJECTINJECTARBYPOR VIASUSP,OPHINSTILLECHARINENDROP(S)GOTA(S)SUSP,ORALTAKETOMARBYPORTEASPOONFUL(S)CUCHARADITA(S)SUSP,OTICINSTILLECHARINENDROP(S)GOTA(S)SUSP,RTLINSERTINSERTARINEN ELCONTENT(S)CONTENIDOSUSP,SATAKETOMARBYPORTABLESPOONFUL(S)CUCHARADA(S)SWAB,TOPAPPLYAPLICARBYENAS DIRECTEDSEGUN INDICADOSYRINGEUSEUTILIZARAS DIRECTEDSEGUN INDICADOSYRINGE/NDLUSEUTILIZARAS DIRECTEDSEGUN INDICADOSYRUPTAKETOMARBYPORTEASPOONFUL(S)CUCHARADITA(S)SYRUP,ORALTAKETOMARBYPORTABLESPOONFUL(S)CUCHARADA(S)SYRUP,SRTAKETOMARBYPORTABLESPOONFUL(S)CUCHARADA(S)TABTAKETOMARBYPORTABLET(S)TABLETA(S)TAB,BUCC,SAPLACEPONERBETWEENENTRETABLET(S)TABLETA(S)TAB,BUCCALPLACEPONERBETWEENENTRETABLET(S)TABLETA(S)TAB,CHEWABLECHEW AND SWALLOWMASTICAR Y TRAGARTABLET(S)TABLETA(S)TAB,CHEWG GUMCHEWMASTICARPIECE(S)PIEZA(S)TAB,CRTAKETOMARBYPORTABLET(S)TABLETA(S)TAB,ECTAKETOMARBYPORTABLET(S)TABLETA(S)TAB,EC (DELAYED RELEASE)TAKETOMARTABLETTABLETATAB,EC,SATAKETOMARBYPORTABLET(S)TABLETA(S)TAB,EFFERVSCDISSOLVEDISOLVERIN WATER AND TAKE BYEN AGUA Y TOMAR PORTABLET(S)TABLETA(S)TAB,EFFERVSC,TOPDISSOLVE IN WATERDISOLVER EN AGUAAND APPLY TOY APLICAR ENTABLET(S)TABLETA(S)TAB,LATAKETOMARBYPORTABLET(S)TABLETA(S)TAB,ORALTAKETOMARBYPORTABLET(S)TABLETA(S)TAB,ORAL DISINTEGRATINGPLACEPONERBYPORTABLET(S)TABLETA(S)TAB,ORAL/VAGTAB,RAPID DISINTEGRATEPLACEPONERBYPORTABLET(S)TABLETA(S)TAB,SATAKETOMARBYPORTABLET(S)TABLETA(S)TAB,SOLUBLEDISSOLVE AND APPLYDISOLVER Y APLICARINENTABLET(S)TABLETA(S)TAB,SUBLINGUALDISSOLVEDISOLVERTABLET(S)TABLETA(S)TAB,TESTUSEUSARFOR TESTINGPARA PRUEBATABLET(S)TABLETA(S)TAB,VAGINSERTINSERTARINPORTABLET(S)TABLETA(S)TAMPONINSERTINSERTARINPORAS DIRECTEDSEGUN INDICADOTAPEUSEUSARAS DIRECTEDSEGUN INDICADOTEST STRIPUSEUSARFOR TESTINGPARA PRUEBASTRIP AS DIRECTEDTIRILLA SEGUN INDICADOTINCTURETAKETOMARBYPORTINCTURE,TOPAPPLYAPLICARTOPARAAS DIRECTEDSEGUN INDICADOTROCHEDISSOLVEDISOLVERBYPORTROCHE(S)TROCISCO(S)WAFERUSEUSARAS DIRECTEDSEGUN INDICADOWAFER,TOPUSEUSARAS DIRECTEDSEGUN INDICADO Appendix E XE "Appendix E: See Local Possible Dosages, Spanish Translations" \b  Local Possible Dosages - Spanish Translations  XE "Local Possible Dosages, Spanish Translations" \b The Outpatient Language Modifications patch PSS*1*47 provides the functionality to print prescription labels in a language other than English. Enabling this functionality requires setting certain flags and completing several setup steps, including populating fields used for the Sig with equivalent terms in the specified other language. The following table provides Spanish equivalents for some of the more common local possible dosages. The translations in this table may require modifications for different dialects. LOCAL POSSIBLE DOSAGESPANISH LOCAL DOSAGE0.05 MILLILITERS0.05 MILILITROS0.1 MILLILITERS0.1 MILILITROS0.15 MILLILITERS0.15 MILILITROS0.18 MILLILITERS0.18 MILILITROS0.2 MILLILITERS0.2 MILILITROS0.25 MILLILITER0.25 MILILITRO0.3 MILLILITERS0.3 MILILITROS0.4 MILLILITER OF 120MCG/0.5ML0.4 MILILITRO DE 120MCG/0.5ML0.4 MILLILITER OF 80MCG/0.5ML0.4 MILILITRO DE 80MCG/0.5ML0.5 MILLIGRAMS0.5 MILIGRAMOS0.5 MILLILITER0.5 MILILITRO0.5 MILLILITER OF 120MCG/0.5ML0.5 MILILITRO DE 120MCG/0.5ML0.5 MILLILITER OF 150MCG/0.5ML0.5 MILILITRO DE 150MCG/0.5ML0.5 MILLILITER OF 80MCG/0.5ML0.5 MILILITRO DE 80MCG/0.5ML0.9 MILLIGRAM0.9 MILIGRAMO1 AMPULE1 AMPOLLETA1 RING AS DIRECTED1 ANILLO SEGUN INDICADO1 APPLICATORFUL1 APLICADOR LLENO1 SPRAY1 ATOMIZACION1 CAPSULE1 CAPSULA1 TABLESPOONFUL1 CUCHARADA1 TEASPOONFUL1 CUCHARADITA1 ENEMA1 ENEMA1 ENEMA AS DIRECTED1 ENEMA SEGUN INDICADO1 DROP1 GOTA1 GRAM1 GRAMO1 IMPLANT1 IMPLANTE1 PUFF1 INHALACION1 MILLIGRAM1 MILIGRAMO1 MILLILITER1 MILILITRO1 PATCH1 PARCHO1 PIECE1 PIEZA1 INCH1 PULGADA1 AS DIRECTED1 SEGUN INDICADO1 PACKET1 SOBRE1 SUPPOSITORY1 SUPOSITORIO1 TABLET1 TABLETA1 STRIP AS DIRECTED1 TIRILLA SEGUN INDICADO1 TROCHE1 TROCISCO1.2 MILLION UNITS1.2 MILLONES DE UNIDADES1.25 GRAMS1.25 GRAMOS1.25 MILLILITERS1.25 MILILITROS1.5 MILLIGRAMS1.5 MILIGRAMOS10 DROPS10 GOTAS10 MILLIGRAMS10 MILIGRAMOS10 UNITS10 UNIDADES100 MILLIGRAMS100 MILIGRAMOS1000MG1000 MILIGRAMOS1000 UNITS1000 UNIDADES10MG (0.2 MILLILITERS)10MG (0.2 MILILITROS)10MG (1 MILLILITER)10MG (1 MILILITRO)12.5 MILLIGRAMS (0.5 MILLILITER)12.5 MILIGRAMOS (0.5 MILILITRO)1200MG1200 MILIGRAMOS15 MILLIGRAMS15 MILIGRAMOS15 UNITS15 UNIDADES150000 UNITS (0.3ML)150000 UNIDADES (0.3ML)2 SPRAYS2 ATOMIZACIONES2 CAPSULES2 CAPSULAS2 TABLESPOONFULS2 CUCHARADAS2 TEASPOONFULS2 CUCHARADITAS2 DROPS2 GOTAS2 GRAMS2 GRAMOS2 PUFFS2 INHALACIONES2 MILLIGRAMS2 MILIGRAMOS2 MILLILITERS2 MILILITROS2 PIECES2 PIEZAS2 INCH2 PULGADAS2 PACKETS2 SOBRES2 TABLETS2 TABLETAS2.4 MILLION UNITS2.4 MILLONES DE UNIDADES2.5 MILLIGRAMS2.5 MILIGRAMOS2.5 MILLILITERS2.5 MILILITROS20 UNITS20 UNIDADES200 MCG(4 MU)(1ML)200 MCG(4 MU)(1ML)200 MILLIGRAMS200 MILIGRAMOS200 MILLIGRAMS200 MILIGRAMOS200 MILLIGRAMS200 MILIGRAMOS2000 UNITS2000 UNIDADES20MG (2 MILLILITERS)20MG (2 MILILITROS)25 MILLIGRAMS25 MILIGRAMOS25 UNITS25 UNIDADES250 UNITS250 UNIDADES3 CAPSULES3 CAPSULAS3 TABLESPOONFULS3 CUCHARADAS3 DROPS3 GOTAS3 MILLIGRAMS3 MILIGRAMOS3 MILLILITERS3 MILILITROS3 MILLION UNITS3 MILLONES DE UNIDADES3 TABLETS3 TABLETAS30 MILLIGRAMS30 MILIGRAMOS30 UNITS30 UNIDADES300 MILLIGRAMS300 MILIGRAMOS3000 UNITS3000 UNIDADES35 UNITS35 UNIDADES4 CAPSULES4 CAPSULAS4 TABLESPOONFULS4 CUCHARADAS4 TEASPOONFULS4 CUCHARADITAS4 LEVEL TEASPOONFULS4 CUCHARADITAS AL RAS4 DROPS4 GOTAS4 GRAMS4 GRAMOS4 MILLIGRAMS4 MILIGRAMOS4 TABLETS4 TABLETAS40 MILLIGRAMS40 MILIGRAMOS40 UNITS40 UNIDADES400 MGS (4 TEASPOONFULS)400 MGS (4 CUCHARADITAS)4000 UNITS4000 UNIDADES45 UNITS45 UNIDADES4MG (40 MILLILITERS)4MG (40 MILILITROS)5 GRAMS5 GRAMOS5 MGS (1.67 MILLILITERS)5 MGS (1.67 MILILITROS)5 MILLIGRAMS5 MILIGRAMOS5 UNITS5 UNIDADES50 MILLIGRAMS50 MILIGRAMOS50 UNITS50 UNIDADES500 UNITS500 UNIDADES5000 UNITS5000 UNIDADES6 MILLIGRAMS6 MILIGRAMOS6 MILLILITERS6 MILILITROS60 MILLIGRAMS60 MILIGRAMOS600 MGS(2 TABLESPOONFULS)600 MGS(2 CUCHARADAS)600,000 UNITS600,000 UNIDADES75 MILLIGRAMS ( 3 MILLILITERS)75 MILIGRAMOS ( 3 MILILITROS )8 TABLESPOONFULS8 CUCHARADAS8 MILLIGRAMS8 MILIGRAMOS80 MILLIGRAMS80 MILIGRAMOS80 MILLIGRAMS80 MILIGRAMOSLOCAL CARECUIDADO LOCALDISSOLVE WITH 0.7 ML STERILE WATER AND INJECT XX MLDISOLVER CON 0.7ML DE AGUA ESTERIL E INYECTAR XX MLTWO APPLICATORSFULDOS APLICADORES LLENOSTWO AND A HALF TEASPOONFULSDOS Y MEDIA CUCHARADITASTHE CONTENT OF THE BOTTLEEL CONTENIDO DE LA BOTELLATHE CONTENT OF ONE GALLONEL CONTENIDO DE UN GALONTHE CONTENT OF ONE PACKETEL CONTENIDO DE UN SOBRETHE CONTENT OF ONE AMPULEEL CONTENIDO DE UNA AMPOLLETATHE CONTENT OF ONE BOTTLEEL CONTENIDO DE UNA BOTELLATHE CONTENT OF ONE CANEL CONTENIDO DE UNA LATAHALF TEASPOONFULMEDIA CUCHARADITAHALF INCHMEDIA PULGADAHALF TABLETMEDIA TABLETAHALF MILLILITERMEDIO MILILITROAS DIRECTEDSEGUN INDICADOTHE WHOLE CONTENTTODO EL CONTENIDO1 APPLICATORUN APLICADORONE APPLICATORFULUN APLICADOR LLENOA THIN FILMUNA CAPA FINAONE AND A HALF TEASPOONFULUNA CUCHARADITA Y MEDIAA SMALL AMOUNTUNA PEQUENA CANTIDADA SMALL AMOUNTUNA PEQUENA CANTIDADONE INCHUNA PULGADA1 AS DIRECTEDUNA SEGUN INDICADOONE AND A HALF TEASPOONFULUNA Y MEDIA CUCHARADITAONE AND A HALF INCHUNA Y MEDIA PULGADA Appendix F XE "Appendix F: See Medication Instructions, Spanish Translations" \b  Medication Instructions - Spanish Translations XE "Medication Instructions, Spanish Translations" \b The Outpatient Language Modifications patch PSS*1*47 provides the functionality to print prescription labels in a language other than English. Enabling this functionality requires setting certain flags and completing several setup steps, including populating fields used for the Sig with equivalent terms in the specified other language. The following table provides Spanish equivalents for some of the more common medication instructions that can be entered in the new OTHER MEDICATION INSTRUCTIONS file. The translations in this table may require modifications for different dialects. MED INSTRUCTIONSEXPANSIONSPANISH EXPANSION828AT 8AM, 2PM AND 8PMA LAS 8AM, 2PM Y 8PM8388AM, 3PM, AND 8PM8AM, 3PM Y 8PM&LAND LUNCHY EL ALMUERZO()(AT 8AM, 3PM AND AT BEDTIME)A LAS 8AM, 3PM Y AL ACOSTARSE(12)(NOT MORE THAN 12 A DAY)(NO MAS DE 12 AL DIA)(3)(NO MORE THAN 3 A DAY)(NO MAS DE 3 AL DIA)(4)(NOT MORE THAN 4 A DAY)(NO MAS DE 4 AL DIA)(5)(NO MORE THAN 5 A DAY)(NO MAS DE 5 AL DIA)(6)(NOT MORE THAN 6 A DAY)(NO MAS DE 6 AL DIA)(8)(NOT MORE THAN 8 A DAY)(NO MAS DE 8 AL DIA)1,2HPC1 HR.BEFORE OR 2 HRS. AFTER MEALS1 HORA ANTES O 2 HORAS DESPUES DE LAS COMIDAS13HONE AND THREE HOURSUNA Y TRES HORAS13HPCONE & THREE HOURS AFTER MEALSUNA Y TRES HORAS DESPUES DE LAS COMIDAS15BB15 MINUTES BEFORE BATH15 MINUTOS ANTES DEL BANO1ATOSPRAY ONCEUNA ATOMIZACION1DINSTILL ONE DROPECHAR UNA GOTA1DAYTHE FIRST DAYEL PRIMER DIA1HACONE HOUR BEFORE MEALSUNA HORA ANTES DE LAS COMIDAS1HPC1 HOUR AFTER MEALS1 HORA DESPUES DE LAS COMIDAS1HRPCHSONE HOUR AFTER MEALS AND AT BEDTIMEUNA HORA DESPUES DE LAS COMIDAS Y AL ACOSTARSE1HSAND 1 AT BEDTIMEY UNA AL ACOSTARSE1IONE INHALATIONUNA INHALACION1PMAT 1:OO PMA LA 1:00 PM1VAT ONE TIMEDE UNA SOLA VEZ23D2-3 TIMES A DAY2-3 VECES AL DIA2ATOSPRAY TWICEDOS ATOMIZACIONES2DINSTILL 2 DROPSECHAR 2 GOTAS2DAYTHE SECOND DAYEL SEGUNDO DIA2HSAND 2 AT BEDTIMEY DOS AL ACOSTARSE2ITWO INHALATIONSDOS INHALACIONES30BBM30 MINUTES BEFORE BREAKFAST AND EVENING MEAL30 MINUTOS ANTES DEL DESAYUNO Y LA CENA30M30 MINUTES30 MINUTOS34D3-4 TIMES A DAY3-4 VECES AL DIA3DINSTILL 3 DROPSECHAR 3 GOTAS3HSAND 3 AT BEDTIMEY TRES AL ACOSTARSE3ITHREE INHALATIONSTRES INHALACIONES3PANO MORE THAN 3 DOSES PER ATTACKMAXIMO 3 DOSIS POR ATAQUE4DINSTILL 4 DROPSECHAR 4 GOTAS4HSAND FOUR AT BEDTIMEY CUATRO AL ACOSTARSE4IFOUR INHALATIONSCUATRO INHALACIONES5DINSTILL 5 DROPSECHAR 5 GOTAS5PMAT 5:00 PMA LAS 5:00 PM6PMAT 6:00 PMA LAS 6:00 PM7AMAT 7:00 AMA LAS 7:00 AM9PMAT 9:00 PMA LAS 9:00 PMA1APPLY 1 INCH TO THE CHESTAPLICAR 1 PULGADA EN EL PECHOA1PAPPLY ONE PATCHAPLICAR UN PARCHOA2APPLY 2 INCHES TO THE CHESTAPLICAR 2 PULGADAS EN EL PECHOA8AT 8PM ONLYA LAS 8:00 PM SOLAMENTEAAAVOID ALCOHOL WHILE TAKING THIS MEDICINEEVITE USO DE BEBIDAS ALCOHOLICASAAAAVOID ANTACIDS USE WITH THIS MEDICATIONEVITAR USO DE ANTIACIDOS JUNTO CON EL MEDICAMENTOABAFTER BREAKFASTDESPUES DEL DESAYUNOABMAFTER EACH BOWEL MOVEMENTDESPUES DE CADA EVACUACIONABTAT BREAKFAST TIMEA LA HORA DEL DESAYUNOACBEFORE MEALSANTES DE LAS COMIDASACDAT ONSET OF HEADACHEAL COMENZAR EL DOLOR DE CABEZAADINTO RIGHT EAREN OIDO DERECHOADAAFFECTEDAFECTADAADACIDADJUST INTAKE OF POTENTIALLY ACID ASH FOODAJUSTAR INGESTA DE ALIMENTOS ACIDOSADBASICADJUST INTAKE OF POTENTIALLY BASIC FOODAJUSTAR INGESTA DE ALIMENTOS ALCALINOSADMADMINISTERADMINISTRARADOAFFECTEDAFECTADOAESAVOID EXPOSURE TO SUNLIGHTEVITAR EXPOSICION A LA LUZ SOLARAFAFFECTED FOOTPIE AFECTADOAFAINTO AFFECTED EAREN OIDO AFECTADOAFEONTO AFFECTED EYEEN OJO AFECTADOAGFAVOID GRAPEFRUIT JUICEEVITE USO DE JUGO DE TORONJAAHAFFECTED HANDMANO AFECTADAAHSAND AT BEDTIMEY AL ACOSTARSEAIIN SELECTED AREAEN AREA INDICADAALBMAFTER EACH LOOSE BOWEL MOVEMENTDESPUES DE CADA EVACUACION BLANDAALENDROBEFORE YOU TAKE ANY FOOD,BEVERAGE OR MEDICINEANTES DE INGERIR ALIMENTO,BEBIDA O MEDICINA-AMNIN THE MORNING AND AT NOONEN LA MANANA Y AL MEDIODIAAMOXITAKE 2 TWICE A DAY AFTER BREAKFAST AND SUPPERTOME 2 VECES AL DIA DESPUES DE DESAYUNO Y CENAAOPAPPLY ONE PATCH ON AFFECTED AREAAPLICAR UN PARCHO EN AREA INDICADAAPAPPLYAPLICARAS3INSTILL THE CONTENTS OF ONE AMPUL IN THE NEBULIZERECHAR EL CONTENIDO DE UNA AMPULA EN EL NEBULIZADORASUAFTER SUPPERDESPUES DE LA COMIDAATCAROUND THE CLOCKDIA Y NOCHEAUIN BOTH EARSEN CADA OIDOAVCAFFLIMIT OR AVOID CAFFEINE INTAKEEVITE O LIMITE TOMAR CAFEAWALTERNATING WITHALTERNANDO CONBARIUMSTARTING ONCOMENZANDO ENBBBEFORE BREAKFASTANTES DEL DESAYUNOBEMBEFORE THE EVENING MEALANTES DE LA CENABID2 TIMES A DAY2 VECES AL DIABIDAPTWICE A DAY IN MORNING AND EVENING2 VECES AL DIA EN LA MANANA Y LA TARDEBIWTWO TIMES A WEEK2 VECES EN SEMANABMBETWEEN MEALSENTRE COMIDASBMHSBETWEEN MEALS AND AT BEDTIMEENTRE COMIDAS Y AL ACOSTARSEC68HEVERY 6-8 HOURSCADA 6-8 HORASCAPCAPSULECAPSULACHEVERY HOURCADA HORACLARITAKE 1 TWO TIMES A DAY AFTER BREAKFAST AND SUPPERTOME UNA 2 VECES AL DIA DESPUES DE DESAYUNO Y CENACLOTRI1DISSOLVE ONE IN MOUTH FOR 10-15 MINUTES & SWALLOWDISOLVER UNA EN LA BOCA POR 10-15 MINUTOS Y TRAGARCLOTRI2DISSOLVE TWO IN MOUTH FOR 10-15 MINUTES & SWALLOWDISOLVER DOS EN LA BOCA POR 10-15 MINUTOS Y TRAGARCNIN THE EVENINGCADA NOCHECPCHEST PAINDOLOR EN EL PECHOCSCHEW AND SWALLOWMASTICAR Y TRAGARCS1CHEW AND SWALLOW ONEMASTICAR Y TRAGAR UNACS2CHEW AND SWALLOW TWOMASTICAR Y TRAGAR DOSCTSCHANGE TASTECAMBIA SENSITIVIDAD AL GUSTODDROPGOTAD1TO SOLVE 1DISOLVER UNAD2TO SOLVE 2DISOLVER DOSD25SSDILUTE 0.25CC IN 5CC OF SALINE SOLUTIONDILUIR 0.25 CC EN 5 CC DE SOLUCION SALINAD25WDILUTE 0.25CC IN 5CC OF DISTILLED WATERDILUIR 0.25 CC EN 5 CC DE AGUA DESTILADAD34WDURING THE THIRD AND FOURTH WEEKDURANTE LA TERCERA Y CUARTA SEMANAD35SSDILUTE 0.3CC IN 5CC OF SALINE SOLUTIONDILUIR 0.3 CC EN 5 CC DE SOLUCION SALINAD35WDILUTE 0.3CC IN 5CC OF DISTILLED WATERDILUIR 0.3 CC EN 5 CC DE AGUA DESTILADAD3SSDILUTE 0.3CC IN 3CC SOD. CHLORIDEDILUIR 0.3 CC EN 3 CC DE SOLUCION SALINAD3WDILUTE 0.3CC IN 3CC DISTILLED WATERDILUIR 0.3 CC EN 3 CC DE AGUA DESTILADAD53SSDILUTE 0.5CC IN 3CC OF SALINE SOLUTIONDILUIR 0.5 CC EN 3 CC DE SOLUCION SALINAD53WDILUTE 0.5CC IN 3CC OF DISTILLED WATERDILUIR 0.5 CC EN 3 CC DE AGUA DESTILADAD5SSDILUTE 0.5CC IN 5CC OF SOD. CHLORIDEDILUIR 0.5 CC EN 5 CC DE SOLUCION SALINAD5WDILUTE 0.5CC IN 5CC OF DISTILLED WATERDILUIR 0.5 CC EN 5 CC DE AGUA DESTILADAD8AMIXED IN 8 OUNCES OF WATERDISUELTA EN 8 ONZAS DE AGUAD8JMIXED IN 8 OUNCES OF JUICEDISUELTA EN 8 ONZAS DE JUGODARIGHTDERECHADBSBEGINNING THE DAY BEFORE THE STUDYCOMENZANDO EL DIA ANTES DEL ESTUDIODC1SCONTENTS OF 1 PACKET IN 8 1/2 OZ OF WATER AND TAKEEL CONTENIDO DE UN SOBRE EN 8 1/2 ONZAS DE AGUA Y TOMARDIDISSOLVEDISOLVERDILDILUTEDDILUIDADILODILUTEDDILUIDODILOSDILUTEDDILUIDOSDILSDILUTEDDILUIDASDISDISSOLVEDDISUELTADISSDISSOLVEDDISUELTASDNCCDON'T CRUSH OR CHEWNO TRITURAR NI MASTICARDNCCSDON'T CHEW,CRUSH OR SPLITNO TRITURAR, MASTICAR NI PARTIRDORIGHTDERECHODOME1ONE TABLET DISSOLVED IN 1 LITER OF WATERDISOLVER 1 TABLETA EN 1 LITRO DE AGUADOME2ONE OR TWO TABLETS DISSOLVED IN 1 LITER OF WATERDISOLVER 1 O 2 TABLETAS EN 1 LITRO DE AGUADSMDISSOLVE SLOWLY IN THE MOUTHDISOLVER LENTAMENTE EN LA BOCADTFMUST BE DOCUMENTED ON TREATMENT FORM 10-2970CDEBE SER DOCUMENTADO EN LA FORMA DE TRATAMIENTO 10-2970CE1TAKE ONE CAN DAILYTOMAR EL CONTENIDO DE UNA LATA DIARIAMENTEE2TAKE ONE CAN TWICE A DAYTOMAR EL CONTENIDO DE UNA LATA DOS VECES AL DIAE3TAKE ONE CAN 3 TIMES A DAYTOMAR EL CONTENIDO DE UNA LATA 3 VECES AL DIAE4TAKE ONE CAN 4 TIMES A DAYTOMAR EL CONTENIDO DE UNA LATA 4 VECES AL DIAEDSPACE ALL EYE DROPS AT LEAST 5 MINUTES APARTESPACIAR LAS GOTAS AL MENOS CON 5 MINUTOS DE DIFERENCIAENEMAFOR THE STUDY OFPARA EL ESTUDIO DEEOWEVERY OTHER WEEKUNA SEMANA SI Y OTRA NOEP14MIX 1/2 CUP IN 6 OZ OF COLD WATER AND TAKEDISOLVER 1/2 TAZA EN 6OZ DE AGUA PARA TOMAREPMTO PALMSEN LA PALMA DE LAS MANOSEPPTO SOLESEN LA PLANTA DE LOS PIESEUEXTERNAL USEUSO EXTERNOEXTEXTERNALLYEXTERNAMENTEFFORPARAF10FOR TEN DAYSPOR DIEZ DIASF12FOR 12 DAYSPOR 12 DIASF14FOR 14 DAYSPOR 14 DIASF15FOR 15 DAYSPOR 15 DIASF1DFOR ONE DAYPOR UN DIAF2FOR 2 DAYSPOR 2 DIASF21FOR 21 DAYSPOR 21 DIASF28FOR 28 DAYSPOR 28 DIASF2DFOR TWO DAYSPOR DOS DIASF3FOR 3 DAYSPOR 3 DIASF3DFOR THREE DAYSPOR TRES DIASF4FOR 4 DAYSPOR 4 DIASF4WFOR 4 WEEKSPOR 4 SEMANASF5FOR FIVE DAYSPOR CINCO DIASF6FOR 6 DAYSPOR 6 DIASF60(MEDICATIONS FOR 60 DAYS)(MEDICAMENTOS PARA 60 DIAS)F7FOR 7 DAYSPOR 7 DIASF8FOR EIGHT DAYSPOR OCHO DIASF90(MEDICATIONS FOR 90 DAYS)(MEDICAMENTOS PARA 90 DIAS)FAFOR HEARTBURNPARA ACIDEZFACFOR A COLDPARA CATARROFALFOR ALLERGYPARA ALERGIAFANEFOR ANEMIAPARA ANEMIAFANXFOR ANXIETYPARA LA ANSIEDADFAPFOR ABDOMINAL PAINPARA DOLOR ABDOMINALFARFOR ARTHRITISPARA ARTRITISFASFOR ASTHMAPARA ASMAFBCTO AVOID BLOOD COAGULATIONPARA EVITAR COAGULOS EN LA SANGREFBOFROM BOTTLEDEL FRASCOFBPFOR BLOOD PRESSUREPARA LA PRESIONFBSFOR SITZ BATHPARA BANOS DE ASIENTOFCFOR COUGHPARA LA TOSFCHOLFOR CHOLESTEROLPARA COLESTEROLFCIRFOR CIRCULATIONPARA LA CIRCULACIONFCONFOR CONSTIPATIONPARA EL ESTRENIMIENTOFCPFOR CHEST PAINPARA DOLOR EN EL PECHOFDFOR DIARRHEAPARA DIARREAFDEPFOR DEPRESSIONPARA DEPRESIONFDIFOR DIZZINESSPARA MAREOSFDIABFOR DIABETESPARA DIABETESFDRYFOR DRYNESSPARA RESEQUEDADFEDFOR EDEMAPARA EDEMAFELFOR EYELIDSPARA LOS PARPADOSFENTANYLAPPLY ONE PATCH AS INDICATED EVERY 72 HOURSAPLICAR UN PARCHO EN AREA INDICADA CADA 72 HORASFFFOR FLUIDSPARA FLUIDOSFFIFOR FUNGI INFECTIONPARA INFECCION DE HONGOFGFOLLOWED BY A GLASS OF WATERSEGUIDO DE UN VASO DE AGUAFGAFOR GASTRITISPARA GASTRITISFGLAUFOR GLAUCOMAPARA GLAUCOMAFGOUTFOR GOUTPARA GOTAFHFOR HEARTPARA EL CORAZONFHAFOR HEADACHEPARA DOLOR DE CABEZAFHBPFOR HIGH BLOOD PRESSUREPARA LA PRESION ALTAFHGFOLLOWED BY 1/2 GLASS OF WATERSEGUIDO DE 1/2 VASO DE AGUAFIFOR INFECTIONPARA INFECCIONFID5 TIMES A DAY5 VECES AL DIAFIITO INJECT INSULINPARA INYECTAR INSULINAFINFOR INSOMNIAPARA INSOMNIOFINCFOR INCONTINENCEPARA INCONTINENCIAFINFECFOR INFECTIONPARA INFECCIONFINFLFOR INFLAMATIONPARA LA INFLAMACIONFIRFOR IRRITATIONPARA IRRITACIONFITFOR ITCHINGPARA PICORFJPFOR JOINT PAINPARA DOLOR EN LAS COYUNTURASFLCFOR LEG CRAMPSPARA CALAMBRES EN LAS PIERNASFLCUFOR LOCAL CARE OF THE ULCERPARA CUIDADO LOCAL DE LA ULCERAFLEDFOR LEGS EDEMAPARA EDEMA DE LAS PIERNASFLEETTHE NIGHT BEFORE THE STUDY AND 1 THE NEXT MORNINGLA NOCHE ANTES DEL ESTUDIO,UNA LA MANANA SIGUIENTEFMEFOR MEMORYPARA LA MEMORIAFMENFOR MENTAL HEALTH CONDITIONPARA CONDICION MENTALFMIGFOR MIGRAINEPARA MIGRANAFMSFOR MUSCLE SPASMPARA ESPASMO MUSCULARFNFOR NERVESPARA LOS NERVIOSFNAFOR NAUSEAPARA NAUSEAFNCFOR NASAL CONGESTIONPARA CONGESTION NASALFPFOR PAINPARA DOLORFPARKFOR PARKINSON'S DISEASEPARA PARKINSONFPFFOR PAIN AND/OR FEVERPARA DOLOR Y/O FIEBREFPMDOCUMENT ON VAF 672-241-10-97-118 PAIN FLOW SHEETDOCUMENTAR EN "VAF 672-241-10-97-118 PAIN FLOW SHEET"FPROSFOR PROSTATEPARA LA PROSTATAFPSOFOR PSORIASISPARA PSORIASISFRFOR RESTPARA DESCANSARFREFFOR REFLUXPARA EL REFLUJOFSBFOR SHORTNESS OF BREATHPARA RESPIRACION ENTRECORTADAFSEIFOR SEIZURESPARA CONVULSIONESFSIFOR SINUSPARA SINUSITISFSLFOR SLEEPPARA DORMIRFSPFOR SEVERE PAINPARA DOLOR FUERTEFSTFOR STOMACHPARA EL ESTOMAGOFSWFOR SWELLINGPARA HINCHAZONFTGFOR TRIGLYCERIDESPARA LOS TRIGLICERIDOSFTYRFOR THYROIDSPARA TIROIDESFUPFOR URINE PROTEINSPARA LAS PROTEINAS EN LA ORINAFUTFOR GLUCOSE URINE TESTINGPARA PRUEBA DE AZUCAR EN LA ORINAFVITAS VITAMIN OR SUPPLEMENTCOMO VITAMINA O SUPLEMENTOFWFOR WHEEZINGPARA PITO ASMATICOGAFOR GARGLESPARA HACER GARGARASGOLYADD LUKEWARM DRINKING WATER TO THE FILL MARK,ANADIR AGUA TIBIA HASTA LA MARCA INDICADAHHOURHORAH2DISTILLED WATERAGUA DESTILADAHSAT BEDTIMEAL ACOSTARSEIINSERTINSERTARI1JIN 1 GLASS OF JUICEEN UN VASO DE JUGOI1WIN 1 GLASS OF WATEREN UN VASO DE AGUAIALEFTIZQUIERDAIEIN EARSEN LOS OIDOSIGWIN A GLASS OF WATER OR JUICEEN UN VASO DE AGUA O JUGOIJIN JUICEEN JUGOIMINTRAMUSCULARINTRAMUSCULARIMFDOCUMENT IN VAF 672-244-12-97-11GDOCUMENTAR EN LA FORMA:VAF 672-244-12-97-11GINJINJECTINYECTARINOIN NOSTRILSEN FOSAS NASALESINSINSTILLECHARINTRONDISOLVE IN 5 ML OF DILUENT, AND INJECTDISOLVER CON 5 ML DE DILUYENTE E INYECTARIOLEFTIZQUIERDOIVFOR INTRAVENOUS USEPOR VIA INTRAVENOSAIWIN WATEREN AGUAIWJIN WATER OR JUICEEN AGUA O JUGOKWELLAPPLY TO BODY (FROM NECK DOWN),APLICAR DEL CUELLO HACIA ABAJOL8HLEAVE FOR 8 HOURS AND REMOVE WELLDEJAR POR 8 HORAS Y REMOVER BIENLANSOTAKE ONE TWICE A DAY 30 MIN BEFORE BREAKFAST AND ATOME 1 DOS VECES AL DIA 30 MIN ANTES DEL DESAYUNO Y AL ACOSTARSELCCTO WASH SCALPLAVAR CUERO CABELLUDOLEINTO LEFT EAREN OIDO IZQUIERDOLPDUSE LOW PROTEIN DIETUSE DIETA BAJA EN PROTEINASLUPRONDISSOLVE WITH 1 ML OF DILUENT AND INJECTDISOLVER CON 1 ML DE DILUYENTE E INYECTARM8WJMIXED IN 8 OUNCES OF WATER OR JUICEDISUELTA EN 8 ONZAS DE AGUA O JUGOMINMINUTESMINUTOSMOUMILLIONS OF UNITSMILLONES DE UNIDADESMP16MIX 4 LEVEL TABLESPOONS IN 8 OZ OF MILK AND TAKEMEZCLAR 4 CUCHARADAS RASAS EN 8 ONZAS DE LECHE Y TOMARMWUSE FOR MOUTH WASHUSAR PARA LAVADOS BUCALESNAT NOONAL MEDIODIANATEDO NOT LIE DOWN FOR 30 MIN. AFTER YOU TAKE ITNO SE RECUESTE POR 30 MIN DESPUES DE TOMARLONGFlush the line BEFORE and AFTER med. adm.LIMPIAR LA LINEA ANTES Y DESPUES DE LA ADMINISTRACIONNHSDO NOT TAKE AT BEDTIMENO TOME ANTES DE ACOSTARSENSNVFOR NAUSEA AND/OR VOMITINGPARA NAUSEAS Y/O VOMITOSOADONCE A DAYUNA VEZ AL DIAODONTO RIGHT EYEEN OJO DERECHOONFON FEETEN LOS PIESONRON RASHEN ERUPCIONONSON SKINEN LA PIELONSCON SCALPEN CUERO CABELLUDOOSONTO LEFT EYEEN OJO IZQUIERDOOUONTO EACH EYEEN CADA OJOPCAFTER MEALSDESPUES DE LAS COMIDASPC&HSAFTER MEALS AND AT BEDTIMEDESPUES DE LAS COMIDAS Y AL ACOSTARSEPC&HS PRNAFTER MEALS AND AT BEDTIME IF NECESSARYDESPUES DE LAS COMIDAS Y AL ACOSTARSE SI ES NECESARIOPHOSPHO(45 ML) DILUTED IN 4 OUNCES OF WATER(45 ML) DILUIDOS EN 4 ONZAS DE AGUAPLAPLACEPONERPOBY MOUTHPOR BOCAPRNAS NEEDEDCUANDO SEA NECESARIOPUDMTAKE 2 TABLESPOONS 7 TIMES A DAY (EVERY 2-4HOURS)TOMAR 2 CUCHARADAS 7 VECES AL DIA (CADA 2-4 HORAS)PUDRTAKE 3 TABLESPOONS 7 TIMES A DAY (EVERY 2-4 HOURS)TOMAR 3 CUCHARADAS 7 VECES AL DIA (CADA 2-4 HORAS)PYLORITHEN TAKE ONE DAILY FOR 15 DAYS (EMPTY STOMACH)LUEGO TOME UNA DIARIA POR 15 DIAS (ESTOMAGO VACIO)QEVERYCADAQ1-2HEVERY 1-2 HOURSCADA 1-2 HORASQ12HEVERY 12 HOURSCADA 12 HORASQ12WEVERY 12 WEEKSCADA 12 SEMANASQ15MEVERY 15 MINUTESCADA 15 MINUTOSQ2-3HEVERY 2-3 HOURSCADA 2-3 HORASQ2-4HEVERY 2-4 HOURSCADA 2-4 HORASQ2HEVERY 2 HOURSCADA 2 HORASQ2WEVERY TWO WEEKSCADA 2 SEMANASQ34HEVERY 3-4 HOURSCADA 3-4 HORASQ3DEVERY 3 DAYSCADA 3 DIASQ3HEVERY 3 HOURSCADA 3 HORASQ46HEVERY 4-6 HOURSCADA 4-6 HORASQ4DEVERY FOUR DAYSCADA 4 DIASQ4HEVERY 4 HOURSCADA 4 HORASQ5DEVERY FIVE DAYSCADA 5 DIASQ5MEVERY 5 MINUTESCADA 5 MINUTOSQ6HEVERY 6 HOURSCADA 6 HORASQ7DEVERY SEVEN DAYSCADA 7 DIASQ8HEVERY EIGHT HOURSCADA 8 HORASQAMEVERY MORNINGCADA MANANAQAMHSIN THE MORNING AND AT BEDTIMEEN LA MANANA Y AL ACOSTARSEQDDAILYDIARIAQDAMDAILY IN THE MORNINGDIARIAMENTE EN LA MANANAQDHSDAILY AT BEDTIMEDIARIAMENTE EN LA NOCHEQDMDAILYDIARIAMENTEQDPMDAILY IN THE AFTERNOONDIARIAMENTE EN LA TARDEQDSDAILYDIARIASQID4 TIMES A DAY4 VECES AL DIAQIDAC4 TIMES A DAY BEFORE MEALS & AT BEDTIME4 VECES AL DIA, ANTES DE LAS COMIDAS Y AL ACOSTARSEQIDHSFOUR TIMES A DAY AND AT BEDTIME4 VECES AL DIA Y AL ACOSTARSEQIDPCFOUR TIMES A DAY AFTER MEALS & AT BEDTIME4 VECES AL DIA DESPUES DE LAS COMIDAS Y AL ACOSTARSEQMMONTHLYCADA MESQODEVERY OTHER DAYUN DIA SI Y OTRO NOQPMEVERY AFTERNOONCADA TARDEQWEVERY WEEKCADA SEMANARIN RECTUMPOR VIA RECTALRCREPEAT CYCLE AS DIRECTEDREPETIR EL CICLO SEGUN INDICADOSALSALINE SOLUTIONSOLUCION SALINASCSUBCUTANEOUSLYPOR VIA SUBCUTANEASDON STUDY DAYEL DIA DEL ESTUDIOSENIF NEEDEDSI ES NECESARIOSFNIF NECESSARYSI FUERA NECESARIOSLUNDER THE TONGUEDEBAJO DE LA LENGUASLCUNDER TONGUE FOR CHEST PAINDEBAJO DE LA LENGUA PARA DOLOR EN EL PECHOSOTO SOAKREMOJARSODA7:00PM DAY BEFORE STUDY, 5:00AM THE DAY OF STUDY7:00PM DIA ANTES DE ESTUDIO, 5:00AM DIA DE ESTUDIOSPSPARINGLYLIGERAMENTESPRSPRAYATOMIZARSSSWISH & SWALLOWHACER BUCHES Y TRAGARSTIMMEDIATELYINMEDIATAMENTESUPSUPPOSITORYSUPOSITORIOTTAKETOMART1TAKE ONETOME UNAT1/2TAKE ONE HALFTOMAR MEDIAT1/2TABTAKE ONE HALF TABLETTOMAR MEDIA TABLETAT1/2TBLTAKE ONE HALF TABLESPOONFULTOMAR MEDIA CUCHARADAT1/4TAKE ONE QUARTERTOMAR UN CUARTOT1/4TTAKE ONE FOURTH TABLETTOMAR UN CUARTO DE TABLETAT10TAKE TENTOMAR DIEZT11/2TTAKE ONE AND A HALF TABLETTOMAR UNA Y MEDIA TABLETAT11/2TBLTAKE ONE AND A HALF TABLESPOONFULTOMAR UNA CUCHARADA Y MEDIAT12TAKE ONE OR TWOTOMAR UNA O DOST1ETAKE ONE ENVELOPETOMAR EL CONTENIDO DE UN SOBRET2TAKE TWOTOME DOST23TAKE TWO OR THREETOMAR DOS O TREST3TAKE THREETOME TREST4TAKE FOURTOME CUATROT5TAKE FIVETOME CINCOT6TAKE SIXTOME SEIST7TAKE SEVENTOME SIETET8TAKE EIGHTTOME OCHOT8WTAKE WITH 8 OZ OF WATERTOMAR CON 8 ONZAS DE AGUATAATO AFFECTED AREAEN AREA AFECTADATABTABLETTABLETATABSTABLETSTABLETASTBLTABLESPOONFULCUCHARADATBLSTABLESPOONFULSCUCHARADASTC1LTAKE CONTENT OF ONE CANTOMAR EL CONTENIDO DE UNA LATATEATEASPOONFULCUCHARADITATEASTEASPOONFULSCUCHARADITASTELYTAKE THE ENTIRE CONTENTS AS DIRECTEDTOMAR EL CONTENIDO EN 4 HORAS SEGUN INDICADOTESTOINJECT 1 ML INTRAMUSCULAR EVERY 2 WEEKSINYECTAR 1 ML INTRAMUSCULAR CADA 2 SEMANASTGENTO GENITAL AREAEN AREA GENITALTGLUIN THE GLUTEUSEN LAS NALGASTIATO INGUINAL AREAEN AREA INGUINALTID3 TIMES A DAY3 VECES AL DIATIDAC3 TIMES A DAY BEFORE MEALS3 VECES AL DIA ANTES DE LAS COMIDASTIDHS3 TIMES A DAY AND AT BEDTIME3 VECES AL DIA Y AL ACOSTARSETIDPC3 TIMES DAILY AFTER MEALS3 VECES AL DIA DESPUES DE LAS COMIDASTIWTHREE TIMES A WEEK3 VECES EN SEMANATLEXTO LOWER EXTREMITIESEN LAS EXTREMIDADES INFERIORESTLFOTO LEFT FOOTEN EL PIE IZQUIERDOTLUEXTO LOWER & UPPER EXTREMITIESEN LAS EXTREMIDADES SUPERIORES E INFERIORESTRTO RELAXPARA RELAJARSETRFOTO RIGHT FOOTEN EL PIE DERECHOTTHTO THE HANDSEN LAS MANOSTUEXTO UPPER EXTREMITIESA LAS EXTREMIDADES SUPERIORESTWTO WASHPARA LAVARTWAATO WASH AFFECTED AREAPARA LAVAR AREA AFECTADATWHTO WASH HAIRPARA LAVAR EL CABELLOUUNITUNIDADESUAHUPON ARRIVAL HOMEAL LLEGAR A LA CASAUDAS DIRECTEDSEGUN INDICADOUFBUSE FOR BATHINGUSAR PARA BANARSEUFDUSE FOR WET DRESSINGUSAR PARA COMPRESASUFIUSE FOR INHALATIONSUSAR PARA INHALACIONESUUDUSE AS DIRECTEDUSAR SEGUN INDICADOVIDEXTAKE 2 CHEWED, CRUSHED OR DISPENSED IN WATERTOME 2 MASTICADAS,MOLIDAS O DISPERSAS EN AGUAW.WITHCONWAWHILE AWAKEMIENTRAS ESTE DESPIERTOWFWITH FOODCON ALIMENTOWLWITH LUNCHCON EL ALMUERZOWMWITH MEALSCON COMIDASWMKWITH MILK OR FATTY MEALSCON LECHE O PRODUCTOS ALTOS EN GRASAWOMKWITHOUT DAIRY/IRON FORTIFIED PRODUCTSSIN PRODUCTOS QUE CONTENGA LECHE O HIERRO Appendix G XE "Appendix G: See Medication Routes, Spanish Translations" \b  Medication Routes Spanish Translations XE "Medication Routes, Spanish Translations" \b The Outpatient Language Modifications patch PSS*1*47 provides the functionality to print prescription labels in a language other than English. Enabling this functionality requires setting certain flags and completing several setup steps, including populating fields used for the Sig with equivalent terms in the specified other language. The following table provides Spanish equivalents for some of the more common medication routes. The translations in this table may require modifications for different dialects. MEDICATION ROUTEOUTPATIENT EXPANSIONSPANISH OUTPATIENT EXPANSIONBLADDER IRRIGATIONBLADDER IRRIGATIONIRRIGACION DE VEJIGABOTH EARSBOTH EARSAMBOS OIDOSBOTH EYESBOTH EYESEN AMBOS OJOSBUCCALCHEEK AND GUM UNTIL DISSOLVEDLA QUIJADA Y LA ENCIA HASTA QUE SE DISUELVACHEWABLECHEWABLEMASTICAR Y TRAGARDEEP IMDEEP INTRAMUSCULARINTRAMUSCULAR PROFUNDODENTALDENTAL USEUSO DENTALGARGLEGARGLEGARGARASGASTROSTOMYGASTROSTOMYGASTROSTOMIAGASTROSTOMY TUBEGASTROSTOMY TUBETUBO DE GASTROSTOMIAINFILTRATIONINFILTRATIONINFILTRACIONINHALATIONINHALATIONINHALACIONINHALATION NASALNASAL INHALATIONINHALATION ORALORAL INHALATIONINTRA-ARTERIALINTRA-ARTERIALVIA INTRA ARTERIALINTRA-ARTICULARINTRA-ARTICULARINTRA-ARTICULARINTRA-DYALISISINTRA-DYALISISINTRA-DYALISISINTRABURSALINTRABURSALINTRABURSALINTRACARDIACINTRACARDIACINTRACARDIACOINTRACAVITYINTRACAVITYDENTRO DE LA CAVIDADINTRADERMALINTRADERMALDENTRO DE LA PIELINTRAFOLLICULARINTRAFOLLICULARDENTRO DEL FOLICULOINTRALESIONALLOCALIZED LESIONDENTRO DE LA LESIONINTRAMUSCULARINTRAMUSCULARVIA INTRAMUSCULARINTRAOCULARINTRAOCULARDENTRO DEL OJOINTRAPERITONEALINTRAPERITONEAL USEVIA INTRAPERITONEALINTRAPLEURALINTRAPLEURALINTRAPLEURALINTRASYNOVIALINTRASYNOVIALINTRASYNOVIALINTRATHECALINTRATHECALINTRATECALINTRATHORACICINTRATHORACICDENTRO DEL TORAXINTRATRACHEALINTRATRACHEAL USEDENTRO DE LA TRAQUEAINTRAUTERINEINTRAUTERINEDENTRO DEL UTEROINTRAVENOUSFOR INTRAVENOUS USEVIA INTRAVENOSAINTRAVESICALINTRAVESICALINTRAVESICALIRRIGATIONIRRIGATIONIRRIGACIONIRRIGATION OPHTHALMICOPHTHALMIC IRRIGATIONIRRIGACION OFTAMICAIV PIGGYBACKINTRAVENOUS USEVIA INTRAVENOSAJEJUNOSTOMYJEJUNOSTOMYJEJUNOSTOMIAJEJUNOSTOMY TUBEJEJUNOSTOMY TUBETUBO DE JEJUNOSTOMIALEFT EARLEFT EAROIDO IZQUIERDOLEFT EYELEFT EYEEN OJO IZQUIERDOMOUTHWASHMOUTHWASHENJUAGUE BUCALNASALIN NOSTRILSLA NARIZNASALIN NOSTRILSLA NARIZNG TUBENASOGASTRIC TUBETUBO NASOGASTRICOOPHTHALMICFOR OPHTHALMIC USEPARA USO OFTALMICOORALMOUTHBOCAORAL INHALATIONORAL INHALATIONINHALACION ORALORAL TOPICALORAL TOPICAL USEUSO TOPICO EN LA BOCAOTICAFFECTED EARUSO OTICOPERCUTANEOUSTHROUGH THE SKINA TRAVES DE LA PIELRECTALRECTUMRECTORIGHT EARRIGHT EAROIDO DERECHORIGHT EYERIGHT EYEEN OJO DERECHOSUBCUTANEOUSSUBCUTANEOUSLYVIA SUBCUTANEASUBLINGUALUNDER THE TONGUEDEBAJO DE LA LENGUATOPICALAFFECTED AREAAREA AFECTADATRANSDERMALTRANSDERMALA TRAVES DE LA PIELTRANSURETHRALTRANSURETHRALTRANSURETRALURETHRALURETHRALURETRAVAGINALVAGINAVAGINA Index A Administration Schedules, Spanish Translations, 111 Appendix A See Convertible Dosage Form/Unit Combinations, 101 Appendix B See Original Drug Text File Entries Combinations, 109 Appendix C See Administration Schedules, Spanish Translations, 111 Appendix D See Dosage Forms, Spanish Translations, 117 Appendix E See Local Possible Dosages, Spanish Translations, 125 Appendix F See Medication Instructions, Spanish Translations, 131 Appendix G See Medication Routes, Spanish Translations, 145 Auto Create Dosages, 7 B BCMA prompts DSPLY ON IVP/IVPB TAB IN BCMA?, 33 PROMPT FOR INJ. SITE IN BCMA, 33 C CMOP Mark/Unmark (Single drug) option, 3, 5, 6 Complex Local Possible Dosages, 85 Convertible Dosage Form/Unit Combinations, 101 Creating the Sig, 85 D DEA Special Handling Code , 19a Dispense Drug/Orderable Item Maintenance, 37 Dosage Form Enter/Edit, 9 Dosage Forms, Spanish Translations, 117 Dosages, 7, 59 Drug Enter/Edit, 19 Drug Enter/Edit option, 6 Drug Interaction Management, 25 Drug Text Enter/Edit, 51 DSPLY ON IVP/IVPB TAB IN BCMA?, 33 E Edit Orderable Items, 35 Enter/Edit Dosages, 10 Enter/Edit Local Drug Interaction, 25 F Formulary Information Report, 49 G Gender-Specific Warnings, 24d Glossary, 97 I Introduction, 1 L Local Possible Dosages, 59 Local Possible Dosages, Spanish Translations, 125 Lookup into Dispense Drug File, 29 M Mail Message following completion of Auto Create Dosages, 7 Marking a CMOP Drug (Single drug), 6 Medication Instruction File Add/Edit, 31 Medication Instructions, Spanish Translations, 131 Medication Route File Enter/Edit, 33 Medication Routes, Spanish Translations, 145 Menu Options, 1 Most Common Dosages Report, 13 N Non-VA Meds, Drug Enter/Edit, b, c Noun/Dosage Form Report, 15 O Orderable Item Management, 35 Original Drug Text File Entries Combinations, 109 Other Language Translation Setup option, 57 P Pharmacy Data Management options, 3 Pharmacy System Parameters Edit, 53 Possible Dosages, 59, 89 PROMPT FOR INJ. SITE IN BCMA, 33 PSXCMOPMGR key, 5 PSXCOMPMGR key, 1 R Rerun Auto Create Dosages, 7 Review Dosages Report, 17 Revision History, i S Screen prompts, 1 Sig formula, 89 Sig Formulas (Formulas), 87 Simple Local Possible Dosages, 85 Simple Possible Dosage Formula, 89 Simple Possible Dosages, 85 Synonym Enter/Edit, 57 T Table of Contents, v U Unmarking a CMOP Drug (Single drug), 6 W Warning Builder, 58a Warning Mapping, 58f      PAGE iv Pharmacy Data Management V. 1.0 September 2001 User Manual September 2001 Pharmacy Data Management V. 1.0  PAGE iii User Manual  PAGE vi Pharmacy Data Management V. 1.0 September 2001 User Manual September 2001 Pharmacy Data Management V. 1.0  PAGE v User Manual  PAGE 12 Pharmacy Data Management V. 1.0 September 2001 User Manual September 2001 Pharmacy Data Management V. 1.0  PAGE 1 User Manual September 2001 Pharmacy Data Management V. 1.0  PAGE 11 User Manual 12b Pharmacy Data Management V. 1.0 September 2001 User Manual September 2001 Pharmacy Data Management V. 1.0 12a User Manual  PAGE 18 Pharmacy Data Management V. 1.0 September 2001 User Manual September 2001 Pharmacy Data Management V. 1.0  PAGE 17 User Manual  PAGE 20 Pharmacy Data Management V. 1.0 September 2001 User Manual September 2001 Pharmacy Data Management V. 1.0  PAGE 19 User Manual 19a Pharmacy Data Management V. 1.0 September 2001 User Manual September 2001 Pharmacy Data Management V. 1.0 19b User Manual 19c Pharmacy Data Management V. 1.0 September 2001 User Manual 19e Pharmacy Data Management V. 1.0 September 2001 User Manual September 2001 Pharmacy Data Management V. 1.0 19d User Manual  PAGE 24 Pharmacy Data Management V. 1.0 September 2001 User Manual September 2001 Pharmacy Data Management V. 1.0  PAGE 23 User Manual 24 PAGE h Pharmacy Data Management V. 1.0 September 2001 User Manual September 2001 Pharmacy Data Management V. 1.0 24 PAGE g User Manual  PAGE 52 Pharmacy Data Management V. 1.0 September 2001 User Manual September 2001 Pharmacy Data Management V. 1.0  PAGE 25 User Manual September 2001 Pharmacy Data Management V. 1.0  PAGE 27 User Manual September 2001 Pharmacy Data Management V. 1.0  PAGE 31 User Manual September 2001 Pharmacy Data Management V. 1.0  PAGE 33 User Manual September 2001 Pharmacy Data Management V. 1.0  PAGE 51 User Manual 52b Pharmacy Data Management V. 1.0 September 2001 User Manual September 2001 Pharmacy Data Management V. 1.0 52a User Manual  PAGE 56 Pharmacy Data Management V. 1.0 September 2001 User Manual September 2001 Pharmacy Data Management V. 1.0  PAGE 55 User Manual  PAGE 58 Pharmacy Data Management V. 1.0 September 2001 User Manual September 2001 Pharmacy Data Management V. 1.0  PAGE 57 User Manual 58 PAGE h Pharmacy Data Management V. 1.0 September 2001 User Manual September 2001 Pharmacy Data Management V. 1.0 58 PAGE g User Manual September 2001 Pharmacy Data Management V. 1.0  PAGE 59 User Manual  PAGE 60 Pharmacy Data Management V. 1.0 September 2001 User Manual  PAGE 86 Pharmacy Data Management V. 1.0 September 2001 User Manual September 2001 Pharmacy Data Management V. 1.0  PAGE 91 User Manual September 2001 Pharmacy Data Management V. 1.0  PAGE 85 User Manual  PAGE 88 Pharmacy Data Management V. 1.0 September 2001 User Manual September 2001 Pharmacy Data Management V. 1.0  PAGE 87 User Manual  PAGE 90 Pharmacy Data Management V. 1.0 September 2001 User Manual September 2001 Pharmacy Data Management V. 1.0  PAGE 89 User Manual PAGE 100 Pharmacy Data Management V. 1.0 September 2001 User Manual September 2001 Pharmacy Data Management V. 1.0  PAGE 99 User Manual PAGE 110 Pharmacy Data Management V. 1.0 September 2001 User Manual PAGE 109 September 2001 Pharmacy Data Management V. 1.0 User Manual  PAGE 116 Pharmacy Data Management V. 1.0 September 2001 User Manual September 2001 Pharmacy Data Management V. 1.0  PAGE 123 User Manual September 2001 Pharmacy Data Management V. 1.0  PAGE 111 User Manual  PAGE 124 Pharmacy Data Management V. 1.0 September 2001 User Manual September 2001 Pharmacy Data Management V. 1.0  PAGE 117 User Manual  PAGE 130 Pharmacy Data Management V. 1.0 September 2001 User Manual September 2001 Pharmacy Data Management V. 1.0  PAGE 129 User Manual September 2001 Pharmacy Data Management V. 1.0  PAGE 125 User Manual  PAGE 144 Pharmacy Data Management V. 1.0 September 2001 User Manual September 2001 Pharmacy Data Management V. 1.0  PAGE 143 User Manual September 2001 Pharmacy Data Management V. 1.0  PAGE 131 User Manual  PAGE 148 Pharmacy Data Management V. 1.0 September 2001 User Manual September 2001 Pharmacy Data Management V. 1.0  PAGE 147 User Manual September 2001 Pharmacy Data Management V. 1.0  PAGE 145 User Manual  PAGE 152 Pharmacy Data Management V. 1.0 September 2001 User Manual September 2001 Pharmacy Data Management V. 1.0  PAGE 151 User Manual Enter an up-arrow at the FORMULARY STATUS prompt to jump to the Select SYNONYM prompt. The CMOP Mark/Unmark (Single drug) option is displayed before the Warning Builder option in the PDM Main Menu. For documentation purposes, it is being left at the beginning of this menu.  !"./JKT\adqsuͿͿͱueYN7,jhhASeOJQJU^JmHnHuhASehe^YOJQJhASehe^Y5OJQJhASehFCJOJQJ\aJhASeh5?CJOJQJ\aJhASehe^YCJOJQJ\aJhASehe^YCJ$OJQJ\hASehe^YOJQJ\aJhASehe^YCJ0OJQJ\hASehe^Y5CJ@OJQJhASehe^Y5CJ0OJQJjhASehEU hASehe^Y$jhASehe^YCJUmHnHu!"./;JKcdefghijklmnopqrs$a$gdASe $1$$a$u    ü}k}k[PEhASeh"FCJaJhASeh5?CJaJhASehe^Y5>*OJQJ^J"hASehe^Y5>*CJOJQJ^JhASehe^Y5CJOJQJ^JhASehe^YCJaJhASehe^YCJ$OJQJ^JhASehe^YjhASehe^YU hASehe^YhASehe^YOJQJ\huR4hASeOJQJ^JhASeOJQJ^Jha0ghASeOJQJ^JhhASeOJQJ^J vttnnen !$$Ifa$!$Ifvkd,$$Ifl##   0#64 l` alp z$If$a$$a$gdASe .# ($Ifgd& kd$$IfTl44\ p$)y (0h%4 laf4p(T       : ; ? W X Z d ĩĜyyncXhASeh4YCJaJhASehv"cCJaJhASeh|CJaJ hASehKF hASeh0O hASeh] hASeh6 hASeh/D hASeh"F hASe0J"hASeh]0J"jhASehASeUhASejhASeh]U hASeh]hASehG<0J"jhASehaPDU hASehG<jhASehG<U" Y 4kd$$Ifl\ p$!0h% 4 la !$Ifgd/D !$Ifgd&  !$$Ifa$gd6 !$If^gdASe  6kd$$Ifl\ p$!0h% 4 la !$Ifgd&  !$$Ifa$gd&  !$If^gd&  ($Ifgd&       ( * 0 1 D L p ZiZi)HDo ,WeιβΧhASehe^Y6]hASehe^Y6 hASehe^YhASehe^YCJaJ hASeh<% hASehoU hASehY hASehC4 hASehgiRhASehgiRCJaJhASehFqqCJaJ hASehom hASehv"c hASeh4Y3   ( !$IfgdgiR !$$Ifa$gdgiR !$If^gdgiR ($IfgdgiR   *g_ULBB !$If !$$Ifa$ !$If^($Ifkd$$Ifl\ p$!0h% 4 la*+15>sgaWNDD !$If !$$Ifa$ !$If^!$IfkdE$$Ifl\ p$!0h% 4 lagaWWNDD !$If !$$Ifa$ !$If^!$Ifkd$$Ifl\ p$!0h% 4 lar2]WM !$If^!$Ifkd$$Ifl\ p$!0h% 4 la !$If2; TND !$If^!$Ifkd$$Ifl\ p$!0h% 4 la !$If !$$Ifa$ ]WMMD !$$Ifa$ !$If^!$IfkdQ$$Ifl\ p$!0h% 4 la !$If-xZPPPP !$If^kd$$IfTl4\ p$!y0h%4 laf4T!$If 4m/0Gkd$$IfTl4\ p$!y0h%4 laf4T!$If !$$Ifa$ !$If^068[dGkd$$IfTl4\ p$!y0h%4 laf4T !$$Ifa$ !$If^!$If!$If !h$If^hgd !$If^c]PPPC] !$h$If^ha$ !$$If^a$!$Ifkd{$$IfTl\ p$!y0h%4 laTdy&w x !!!!!!!!!7!8!9!:!F!G!H!a!b!c!d!e!f!ν}uhuZhUh heWj$#hASehe^YUjhASehe^YUhASehe^YhASehe^Y0J"aJ$'j"hASehe^Y>*B*UphhASehe^Y0J"jhASehe^Y0J"UjhASehe^YUhASehe^YCJhASehe^YjhASehe^YUhASehe^YB* phhASehe^Y6 hASehe^YhASehe^YmHsH!x `WWJD!$If !$h$If^ha$ !$$Ifa$kdB $$IfTl4\ p$0h%4 laf4Tx y  `WJJD!$If !$h$If^ha$ !$$Ifa$kd!$$IfTl4\ p$0h%4 laf4T !!g!!2"`^YWUSQQO{%gdK,kd!$$IfTl4\ p$0h%4 laf4T f!g!h!i!!!!!!!!!!!!!!!!!!!ۺ笡xlYK?KhASehe^YmHnHuhASehe^Y0J"mHnHu$jhASehe^Y0J"UmHnHuhASehe^Y5\aJheW5\!j$hASehe^Y5U\jhASehe^Y5U\hASehe^Y5\hASehe^Y0J"5\aJ$-j#hASehe^Y5>*B*U\phhASehe^Y5\hASehe^Y0J"5\jhASehe^Y0J"5U\hASehe^YaJ!!!""","-"."/"0"1"2"3"4"O"P"Q"R"U"õxkb[bGk<hASehe^Y0J"aJ$'j%hASehe^Y>*B*Uph hASehe^YhASehe^Y0J"jhASehe^Y0J"UhASehe^YmHnHuheWmHnHu&j%hASehe^YUmHnHu#jhASehe^YUmHnHuhASehe^YmHnHuhASehe^Y0J"]mHnHu$jhASehe^Y0J"UmHnHu2j$hASehe^Y>*B*UmHnHphuU"V"t"u"v""""""""""""""""""""""""""""""׷׷rdXdhASehe^YmHnHuhASehe^Y0J"mHnHu$jhASehe^Y0J"UmHnHuj&hASehe^YU'j&hASehe^Y>*B*Uph hASehe^YhASehe^Y0J"jhASehe^Y0J"U heWj&hASehe^YUjhASehe^YUhASehe^YhASehe^Y0J"aJ$hASehe^YaJ!2""";###Y$$%j%%4&&&a''1(((\))$***>+++H,,  ?"#######5#6#7#8#9#:#;#<#=#X#Y#Z#[#`#a#|#}#~#####ŹūzӹŹ`ŹūLz&j(hASehe^YUmHnHu2jm(hASehe^Y>*B*UmHnHphuheWmHnHu&j'hASehe^YUmHnHu#jhASehe^YUmHnHuhASehe^YmHnHuhASehe^YmHnHuhASehe^Y0J"mHnHu$jhASehe^Y0J"UmHnHu2jw'hASehe^Y>*B*UmHnHphu########################$$$$$$7$8$9$R$현y_2jY*hASehe^Y>*B*UmHnHphuheWmHnHu&j)hASehe^YUmHnHuhASehe^YmHnHu2jc)hASehe^Y>*B*UmHnHphuhASehe^Y0J"mHnHuhASehe^YmHnHu$jhASehe^Y0J"UmHnHu#jhASehe^YUmHnHu!R$S$T$V$W$X$Y$Z$[$v$w$x$y$~$$$$$$$$$$$$$$$$$ڼzzfڼL2jE,hASehe^Y>*B*UmHnHphu&j+hASehe^YUmHnHuhASehe^YmHnHu2jO+hASehe^Y>*B*UmHnHphuhASehe^Y0J"mHnHuhASehe^YmHnHu$jhASehe^Y0J"UmHnHuheWmHnHu#jhASehe^YUmHnHu&j*hASehe^YUmHnHu$$$$$$$%%%%%%%%%2%3%4%5%8%9%H%I%ųşӇ~w~cXOXGhASehe^YhASehe^YaJhASehe^Y0J"aJ$'j;-hASehe^Y>*B*Uph hASehe^YhASehe^Y0J"jhASehe^Y0J"UheWmHnHu&j,hASehe^YUmHnHu#jhASehe^YUmHnHuhASehe^YmHnHuhASehe^YmHnHuhASehe^Y0J"mHnHu$jhASehe^Y0J"UmHnHuI%J%c%d%e%g%h%i%j%k%l%%%%%%%%%%%%%%%%%%%%˾˵ˏxˆeWKhASehe^YmHnHuhASehe^Y0J"mHnHu$jhASehe^Y0J"UmHnHuj.hASehe^YUhASehe^YaJhASehe^Y0J"aJ$'j1.hASehe^Y>*B*Uph hASehe^YhASehe^Y0J"hASehe^Y0J"B*phjhASehe^Y0J"U heWj-hASehe^YUhASehe^YjhASehe^YU%%%%%%&&&-&.&/&1&2&3&4&5&6&Q&R&S&T&Y&Z&&&&&&&񪘪yĸ_񪘪K&j0hASehe^YUmHnHu2j0hASehe^Y>*B*UmHnHphuheWmHnHu&j/hASehe^YUmHnHu#jhASehe^YUmHnHuhASehe^YmHnHuhASehe^YmHnHu$jhASehe^Y0J"UmHnHu2j'/hASehe^Y>*B*UmHnHphuhASehe^Y0J"mHnHu&&&&&&&&&&&&&&&&&&&&&&&&&''ķwjw\jWj heWj1hASehe^YUjhASehe^YUhASehe^YhASehe^YaJhASehe^Y0J"aJ$'j1hASehe^Y>*B*Uph hASehe^YhASehe^Y0J"jhASehe^Y0J"UhASehe^YmHnHu$jhASehe^Y0J"UmHnHu#jhASehe^YUmHnHuheWmHnHu''' '!'?'@'A'Z'['\'^'_'`'a'b'c'~''''''''''''''''''''µ§ޙ~µpޙjz3hASehe^YU'j2hASehe^Y>*B*Uph hASehe^YhASehe^Y0J" heWj2hASehe^YUjhASehe^YUhASehe^YhASehe^YaJhASehe^Y0J"aJ$jhASehe^Y0J"U'j 2hASehe^Y>*B*Uph$'''''(((*(+(,(.(/(0(1(2(3(N(O(P(Q(T(U(n(o(p(((((((((µ§ޙ~µp]$jhASehe^Y0J"UmHnHujf5hASehe^YU'j4hASehe^Y>*B*Uph hASehe^YhASehe^Y0J" heWjp4hASehe^YUjhASehe^YUhASehe^YhASehe^YaJhASehe^Y0J"aJ$jhASehe^Y0J"U'j3hASehe^Y>*B*Uph!(((((((((((((((((((( ) ) ) ))):);)<)U)˸񪘪y_񪘪2j6hASehe^Y>*B*UmHnHphuheWmHnHu&j\6hASehe^YUmHnHu#jhASehe^YUmHnHuhASehe^YmHnHu$jhASehe^Y0J"UmHnHu2j5hASehe^Y>*B*UmHnHphuhASehe^YmHnHuhASehe^Y0J"mHnHuU)V)W)Y)Z)[)\)])^)y)z){)|))))))))))))))))))ڼzzfڼL2j8hASehe^Y>*B*UmHnHphu&jH8hASehe^YUmHnHuhASehe^YmHnHu2j7hASehe^Y>*B*UmHnHphuhASehe^Y0J"mHnHuhASehe^YmHnHu$jhASehe^Y0J"UmHnHuheWmHnHu#jhASehe^YUmHnHu&jR7hASehe^YUmHnHu))))******!*"*#*$*%*&*A*B*C*D*H*I*^*_*ųşӇ~w~cXOXGhASehe^YhASehe^YaJhASehe^Y0J"aJ$'j9hASehe^Y>*B*Uph hASehe^YhASehe^Y0J"jhASehe^Y0J"UheWmHnHu&j>9hASehe^YUmHnHu#jhASehe^YUmHnHuhASehe^YmHnHuhASehe^YmHnHuhASehe^Y0J"mHnHu$jhASehe^Y0J"UmHnHu_*`*y*z*{*}*~***********************+++++++++7+˹˓“˹q˓“'j;hASehe^Y>*B*Uphj*;hASehe^YUhASehe^Y0J"aJ$'j:hASehe^Y>*B*Uph hASehe^YhASehe^Y0J"hASehe^YaJjhASehe^Y0J"U heWj4:hASehe^YUhASehe^YjhASehe^YU&7+8+9+;+<+=+>+?+c+d+e++++++++++++++++++++++++, ,ɾҠҁɁyykҠj=hASehe^YUhASehe^YhASehe^Y0J"aJ$'j"=hASehe^Y>*B*UphhASehe^Y0J"j<hASehe^YU hASehe^YjhASehe^YUhASehe^YaJjhASehe^Y0J"U heWjhASehe^YUj <hASehe^YU# , , ,,,&,',(,A,B,C,E,F,G,H,I,J,e,f,g,h,l,m,,,,,,,,,,,,,,,µ§ޙ~µpޙj?hASehe^YU'j?hASehe^Y>*B*Uph hASehe^YhASehe^Y0J" heWj>hASehe^YUjhASehe^YUhASehe^YhASehe^YaJhASehe^Y0J"aJ$jhASehe^Y0J"U'j>hASehe^Y>*B*Uph$,,,,,,,,------- - -%-&-'-(-,---N-O-P-i-j-k-m-n-o-p-q-r---µ§ޙ~µpޙjuAhASehe^YU'j@hASehe^Y>*B*Uph hASehe^YhASehe^Y0J" heWj@hASehe^YUjhASehe^YUhASehe^YhASehe^YaJhASehe^Y0J"aJ$jhASehe^Y0J"U'j@hASehe^Y>*B*Uph$,-p--:...L//0u00)1s11d22R33I445 5.5/577 # !  ?-----------------.........4.5.6.7.8.9.:.;.<.W.X.µ§ޙ~µpޙjaChASehe^YU'jBhASehe^Y>*B*Uph hASehe^YhASehe^Y0J" heWjkBhASehe^YUjhASehe^YUhASehe^YhASehe^YaJhASehe^Y0J"aJ$jhASehe^Y0J"U'jAhASehe^Y>*B*Uph$X.Y.Z.^._.n.q.r.................µ§ʒ|eWL<jhASehe^Y5U\hASehe^Y5\hASehe^Y0J"5\aJ$-jDhASehe^Y5>*B*U\phhASehe^Y5\hASehe^Y0J"5\jhASehe^Y0J"5U\ heWjWDhASehe^YUjhASehe^YUhASehe^YhASehe^YaJhASehe^Y0J"aJ$jhASehe^Y0J"U'jChASehe^Y>*B*Uph..........//////*/+/,/E/F/G/I/J/K/L/ӻ~sjsbUbGUBUj heWjCFhASehe^YUjhASehe^YUhASehe^YhASehe^YaJhASehe^Y0J"aJ$'jEhASehe^Y>*B*Uph hASehe^YhASehe^Y0J"jhASehe^Y0J"UhASehe^Y5\aJjhASehe^Y0J"5U\heW5\jhASehe^Y5U\!jMEhASehe^Y5U\hASehe^Y5\L/M/N/i/j/k/l/o/p//////////////////////0000000006070úò~úòpj/HhASehe^YU'jGhASehe^Y>*B*Uph heWj9GhASehe^YUjhASehe^YUhASehe^YhASehe^YaJhASehe^Y0J"aJ$'jFhASehe^Y>*B*Uph hASehe^YhASehe^Y0J"jhASehe^Y0J"U(708090<0=0S0T0U0n0o0p0r0s0t0u0v0w00000000µ§ʒ|eWL<jhASehe^Y5U\hASehe^Y5\hASehe^Y0J"5\aJ$-jIhASehe^Y5>*B*U\phhASehe^Y5\hASehe^Y0J"5\jhASehe^Y0J"5U\ heWj%IhASehe^YUjhASehe^YUhASehe^YhASehe^YaJhASehe^Y0J"aJ$jhASehe^Y0J"U'jHhASehe^Y>*B*Uph000000000000000011 1"1#1$1&1'1(1)1ӻ~sjsbUbGUBUj heWjKhASehe^YUjhASehe^YUhASehe^YhASehe^YaJhASehe^Y0J"aJ$'jJhASehe^Y>*B*Uph hASehe^YhASehe^Y0J"jhASehe^Y0J"UhASehe^Y5\aJjhASehe^Y0J"5U\heW5\jhASehe^Y5U\!jJhASehe^Y5U\hASehe^Y5\)1*1+1F1G1H1I1Q1R1S1l1m1n1p1q1r1s1t1u1111111111111111122û~ûpjLhASehe^YU'jLhASehe^Y>*B*UphhASehe^YaJ heWjLhASehe^YUjhASehe^YUhASehe^YhASehe^Y0J"aJ$'jKhASehe^Y>*B*Uph hASehe^YhASehe^Y0J"jhASehe^Y0J"U$2 2 2A2B2C2\2]2^2a2b2c2d2e2f222222222222222222233/303˾˰ޢޙ~˾pޢޙ\'jdOhASehe^Y>*B*UphjNhASehe^YU'jnNhASehe^Y>*B*Uph hASehe^YhASehe^Y0J"hASehe^YaJ heWjMhASehe^YUjhASehe^YUhASehe^YhASehe^Y0J"aJ$jhASehe^Y0J"U'jxMhASehe^Y>*B*Uph$0313J3K3L3O3P3Q3R3S3T3o3p3q3r33333333333333333&4'4(4A4B4C4F4G4˹˓˹q˓cjQhASehe^YU'jPQhASehe^Y>*B*UphjPhASehe^YUhASehe^Y0J"aJ$'jZPhASehe^Y>*B*Uph hASehe^YhASehe^Y0J"hASehe^YaJjhASehe^Y0J"U heWjOhASehe^YUhASehe^YjhASehe^YU&G4H4I4J4K4f4g4h4i4444444444444444444445555555 5򺲥~򺲥pe]hASehe^Y5jhASehe^YUjShASehe^YU'j*B*Uph heWjRhASehe^YUjhASehe^YUhASehe^YhASehe^Y0J"aJ$'jFRhASehe^Y>*B*Uph hASehe^YhASehe^Y0J"hASehe^YaJjhASehe^Y0J"U$ 5555'5,5-56677 99:9;9\9]9^9s9t9u9w9999999999:*:f:g::̠yoޠbbZbhASehe^Y6jhASehe^YUhASehe^Y\hASehe^Y0J"\j2ThASehe^YU\jhASehe^YU\hASehe^Y\hASehe^Y;\hASehe^YB*OJQJphhASehe^YB*ph hASehe^YhASehe^Y5\hASehe^YjhASehe^Y5U\hASehe^Y5\#7v9w999:W:X::::;B;C;;;N<<<<<  ^   & F   & F  h`h & F h h^h & F  # ! ::9;A;;;\<^<i<k<|<<<<<<3=4=====>>J>K>L>>>>>>>#@*@V@@@@@@@AA쭤욍w*jhASehe^Y6CJU]mHnHuhASehe^YOJQJ^JhASehe^Y5\hASehe^YCJ8 jhASehe^YCJHhASehe^YjohASehe^YUjYhASehe^YUjThASehe^YEHUhASehe^Y5 hASehe^YjhASehe^YU+<<.=3==J>>>??S@T@U@V@@@# !   & F   & F  $ h $ & F |^`|$  ^` & F  h`h & F   h @AA{AAAAAB9BZBtBBBBCDCsCCCCD@DfDDDDDE^AA A*ABACArAsAtAyAzAAFF"GRGSGTG^G{G|G}GGGGGGGGʽzlʽzcWchASehe^Y6]^JhASehe^Y^JhASehe^Y5\mHsH hASehe^YhASehe^YCJ$OJQJ^JhASehe^YB*phhASehe^YB*EHphhASehe^YEHhASehe^YmHsHjhASehe^YUhASehe^YmHsHhASehe^Y6]mHsH$jhASehe^YCJUmHnHuhASehe^Y6]E7EzEEEE$FTFFFFF"G$GSGTGUG^GGG2I3IJJ L & F$a$1d^1 d^dGGG HHHHMMMMMMMMMMMMM N NNdNeNfNgNvNNNNNNɽɶ镣uuk^uujchASehe^YEHUhASehe^Y5CJjhASehe^Y6UhASehe^Y6hASehe^Y\jhASehe^YU\hASehe^Y\jAhASehe^YU hASehe^YhASehe^Y6]^JhASehe^Y^JhASehe^Y^JhASehe^Y6]^JhASehe^YjhASehe^YU^J" L LL4L5LtLLLL"M#M$MMMMcNdNfNPP2 $ d$d %d &d 'd N O P Q ]^ ,d^`, Pdh^h & F NNqOOOOOOP6P7PaPbPcPPPPPPPdRR*T+TITcT6U7UTUUUVUUUUUUUUUɻyypcɻchASehe^YCJOJQJhASehe^YCJ$jhASehe^YCJOJQJUhASehe^Y5CJOJQJhASehe^YCJOJQJhASehe^YCJ\hASehe^Y\jhASehe^YU\hASehe^Y5CJhASehe^YjhASehe^YUhASehe^Y6 hASehe^YhASehe^Y5&PPPPPcPdPPP'QlQmQQ RFRGRRRRRRRS;S d-D M   d # ! d $ d]^;S\S]SSSSST.TdTeTTTTT%U:UUUVUWUUU V VDVfVVVd d-D M VVVWWWXWWWWWWWWWwXxXyXXXXGZHZIZ``` & F ^   & F# ! d-D M UWWWWWWWWWWWWXXwXyXXXXXXXX?YRYSYoYpYHZkZlZżރzzppccZhASehe^YCJjhASehe^YUhASehe^Y6]hASehe^YCJhASehe^Y5CJ\hASehe^Y^JhASehe^YjhASehe^YU^JhASehe^Y6]^JhASehe^Y^JhASehe^YCJ$OJQJ^JhASehe^Y5\ hASehe^YhASehe^Y5CJOJQJhASehe^YCJOJQJlZmZZZZ/[2[v[y[[[\\&]'](]i]j]k]l]^^^__,_C_D_E_I_d_e___KcfctccfʸʸʸʱٱʱrjrhASehe^YjhASehe^YUhASehe^Y6]hASehe^YCJhASehe^Y5CJ\hASehe^Y5\hASehe^YCJ hASehe^Y"hASehe^Y5CJOJQJ\^JhASehe^YCJOJQJ^JhASehe^Y5CJ\hASehe^Y5\jhASehe^Y5U\&IZZZZ [ [M[N[~[[[[["\#\[\\\\\\\\k]l]]]# !` -D M `];^r^^^^^^^_,_D_E_aaocpcffff,g ^ ^  & F%`-D M ` -D M fgg,gVg]ggggggggggghh4h;h_hih}hhhhhhhhhhhhhh~rhhASehe^Y6]hASehe^Y5CJ\hASehe^YCJhASehe^Y5\ hASehe^Y hASehe^YB*OJQJhph.hASehe^Y5B*CJOJQJ\^Jhph(hASehe^YB*CJOJQJ^Jhph+hASehe^Y5B*CJOJQJ\^Jph%hASehe^YB*CJOJQJ^Jph#,g-g.gKgLg^gggggg h=hkhhhhhhhhhii&`^` & F# ! -DM  -DM hhiikknnnnnno]ppppiqqArIrsss8t:ttttyfyTyyTyTHyTyTyhASehe^Y5CJ\"hASehe^Y5CJOJQJ\^J$hASehe^YCJOJQJ^JmH sH hASehe^YCJOJQJ^J*hASehe^Y5CJOJQJ\^JmH sH $hASehe^YCJOJQJ^JmH sH hASehe^Y5CJ\mH sH hASehe^Y5CJ\mH sH hASehe^YCJhASehe^Y6] hASehe^YhASehe^YjhASehe^YUikknnnnn\oopXpppp.q/qiqqqqqq-r.rLrMrjr -D M &&`jrkrrrrrrsAssssss:t;tCtTtUttttttttuu&` -D M ttttttttuu,u3u6u7uEuFuuuuuuuuvBv|vv`wgwxxyyɿɮmTT0hASehe^YB*CJOJQJ^JhmH phsH .hASehe^Y5B*CJOJQJ\^Jhph(hASehe^YB*CJOJQJ^Jhph'hASehe^Y5B*CJOJQJ\ph!hASehe^YB*CJOJQJphhASehe^Y5\ hASehe^YhASehe^YCJ OJQJ^JhASehe^YCJOJQJ^J"hASehe^Y5CJOJQJ\^J u6u7u8uEuFuuuuuv@vBv|vvvvvvwLwMwiwjww  -DM -DM # ! -D M wwwwwxx xZxxxxxxx=yyyyyyyzzBzCzszzz -DM y0z`Ѓۃ -D M ۃTX„'(ԅՅ./'^` & F# !% -D M FGjkԅՅ̇ч "Ɉӈ<lђ˔4Зї̧̺̺̺̺̺̺̺̈uub$hASehe^YCJOJQJ^JmH sH $hASehe^YCJOJQJ^JmHsHhASehe^Y5CJ\$hASehe^YCJOJQJ^JmHsH$hASehe^YCJOJQJ^JmH sH "hASehe^Y5CJOJQJ\^JhASehe^YCJOJQJ^JhASehe^YCJ hASehe^YhASehe^YjhASehe^YU"/zņ4st#$lՈ׈JK( -D M (l89}IҌZ[()m:;lm -D M m:~ÐLM֑ב`a/0tu -D M ABʔ˔Sەܕ !ef34xЗї` & F -D M ї "#CD"#DE\` O^2РΤû署u_uLLL$hASehe^YCJOJQJ^JmHsH*hASehe^Y5CJOJQJ\^JmH sH $hASehe^YCJOJQJ^JmH sH "hASehe^Y5CJOJQJ\^JhASehe^YCJOJQJ^JhASehe^YCJhASehe^YCJhASehe^YjhASehe^YUhASehe^Y6]hASehe^Y5CJ\hASehe^YCJ hASehe^YhASehe^Y5\"#DEtu™ mNOuԛ՛,\ -D M '^\WX :klɞ/0`a -D M ˟̟ԟ34>lmrϠР*]^Fyz' -D M zԢ0b#$LYZcͤΤ` & F -D M Τ01OP̥ͥU]q_1ѾѨсrrrrrrcP$hASehe^YCJOJQJ^JmHsHhASehe^YCJOJQJ^JhASehe^YCJOJQJ^J"hASehe^Y5CJOJQJ\^JhASehe^YjhASehe^YUhASehe^Y6]hASehe^Y5CJ\hASehe^YCJhASehe^Y5\ hASehe^Y+hASehe^Y6B*CJOJQJ]^Jph"hASehe^Y6CJOJQJ]^J˥̥ͥ6YZ;uvE -D M '^EFmnopqKLM8E\ī-JV) -D M Vƭ./[\]ƮCTı,' -D M 1/[\`ʮDZW˴hU%e5tF3&<=@PQijȵȵȵȵȵȵȵȵzmem\hASehe^YCJhASehe^YjhASehe^YUhASehe^Y6]hASehe^YCJhASehe^Y5\hASehe^YmH sH $hASehe^YCJOJQJ^JmH sH $hASehe^YCJOJQJ^JmHsHhASehe^YCJOJQJ^JhASehe^YCJOJQJ^J hASehe^Y$hASehe^YCJOJQJ^JmH sH $kSpɴʴ˴#|d;R!>K -D M Kbɹ1NZqٻBefg0$a$ -D M &<=GHvw,-R ~gdgdgdVu x7$8$H$gdK7$8$H$*^`  & F GHvw{,-/0PQR\]gjk޷wog`Y`Y hASeh6 hASeh@hASeh@5hASehA5hASehw?5B*ph hASeh`~hASeh5B*phhASeh]5B*phhASehmHsH hASehhASehVuaJhASeh87jhASeh875UhASehK5hASeh5hASehe^Y6]hASehe^YCJ hASehe^Y">UT&'l4CDh"~gd"Hj %Qj1YZ7$8$H$ 7$8$H$gd@ & F,x7$8$H$gd@ x7$8$H$gd@~gdkZp~YZFG䧘tttttttthASehe^YCJaJhASehe^YCJ\]aJhASehe^YCJaJhASehe^Y5CJ\]aJ hASehe^Y5>*CJ\]aJ hASehAhASehA5hASehe^Y6hASehe^Y5jchASehe^YEHU hASehe^Y hASeh@ hASeh hASeh`~-xy12Z)A_gdA b b^ x & F07$8$H$37$8$H$^3` & F, 7$8$H$gdN h7$8$H$^h & F,7$8$H$ZGPQ&CD~.xh^h"#&Z[(CD.ij %ɌooohASehe^Y5CJOJQJ\hASehe^YCJOJQJhASehe^Y5CJ\hASehe^YCJhASehe^YCJPJaJhASehe^YPJhASehe^Y6]hASehe^Y6hASehe^Y5 hASehAhASehe^YH* hASehe^YhASehe^YCJ\]aJhASehe^YCJaJ+ &Aa}HtU -D M !  ! ^ Sx7$8$H$]S~3;t{"*RY\w~ CLNt&hASehe^Y5CJOJQJ\^JaJ hASehe^YCJOJQJ^JaJ*hASehe^Y5CJOJQJ\^JmH sH "hASehe^Y5CJOJQJ\^J hASehe^YCJOJQJmH sH hASehe^Y5CJOJQJ\ hASehe^YCJOJQJmHsHhASehe^YCJOJQJ-l=_| ,Z -D M 2/0~IJzNg+, -D M -D 7$8$H$M N_f +5]^dy@W`z +ĸ󧒧|i|U'hASehe^Y5B*CJOJQJ\ph%hASehe^YB*CJOJQJ^Jph+hASehe^Y5B*CJOJQJ\^Jph)hASehe^YB*CJOJQJmHphsH!hASehe^YB*CJOJQJphhASehe^Y5CJ\hASehe^Y5CJaJ hASehe^YCJOJQJ^JaJ"hASehe^Y5CJOJQJ\^JhASehe^YCJOJQJ,op4]^FGcdv?@` < -D M +1\]456>@Zb rtuv;B^㑊 hASehe^YhASehe^Y5CJaJhASehe^YCJ OJQJ*hASehe^Y5CJOJQJ\^JmH sH hASehe^YCJOJQJmH sH "hASehe^Y5CJOJQJ\^JhASehe^YCJOJQJhASehe^Y5CJOJQJ\6<=^ Y6cd @d -D M  !auvC]Ers' -D M CD #+IQem5>5>CJab 23񫤘qqqahASehe^YCJOJQJ^JhhASehe^Y5CJOJQJ\hASehe^YCJOJQJhASehe^Y5\hASehe^Y5CJaJ hASehe^YhASehe^YCJ.hASehe^Y5B*CJOJQJ\^Jhph"hASehe^Y5CJOJQJ\^J$hASehe^YCJOJQJ^JmHsHhASehe^YCJOJQJ^J&-SoAB$%?@"g -D M g'()KLab23 -DM # ! -D M 3=ITl *Ff(@t -DM   ")>E^e  '8?lstw~ ر؄؄ hASehe^YCJOJQJ^JaJ6hASehe^Y5B*CJOJQJ\^JhmH phsH 'hASehe^YCJOJQJ^JhmH sH %hASehe^Y5CJOJQJ\^JhhASehe^YCJOJQJ^Jh.hASehe^Y5B*CJOJQJ\^Jhph-La  % & S     @ A B C {     T a b -D 7$8$H$M   8 ? k z     l m n            " * ۳۬˳˳˳˳obP"hASehe^Y5CJOJQJ\^JhASehe^YCJOJQJ%hASehe^Y5CJOJQJ\^JhhASehe^Y5CJ\#hASehe^Y5CJOJQJ^JaJhASehe^Y5CJaJ hASehe^Y.hASehe^Y5B*CJOJQJ\^JhphhASehe^YCJOJQJ^Jh hASehe^YCJOJQJ^JaJ&hASehe^Y5CJOJQJ\^JaJb       m n      K   WXC( -D M   -DM -DM -D 7$8$H$M * K twx')QRU\14߽ߪߕǕǕǕǕmQǕߪ߽6hASehe^Y5B*CJOJQJ\^JhmHphsH0hASehe^YB*CJOJQJ^JhmHphsHhASehe^YB*^Jhph(hASehe^YB*CJOJQJ^Jhph%hASehe^Y5CJOJQJ\^JhhASehe^Y^Jh.hASehe^Y5B*CJOJQJ\^JhphhASehe^YCJOJQJ^Jh hASehe^YCJOJQJ^JaJCDxy*+QR67]1( -DM 1APXhCiBv,Jt+( -DM 4;ah:AnuvBJ !rtuvJMNO%,عؑؑؑؑhASehe^Y^JhhASehe^Y5CJ\"hASehe^Y5B*\^JhphhASehe^Y\^Jh%hASehe^Y5CJOJQJ\^JhhASehe^YCJOJQJ^Jh.hASehe^Y5B*CJOJQJ\^Jhph4t./NmCDx  !auv( -DM NOkl-.TZqr( -DM /6T[gno 3:JRST$%CJgn}빲~l~l~l~l~l~l~l"hASehe^Y5CJOJQJ\^JhASehe^YCJOJQJ^JhASehe^Y5\hASehe^Y5\jhASehe^Y5U\ hASehe^YhASehe^Y5B*\phhASehe^Y5CJ\.hASehe^Y5B*CJOJQJ\^Jhph(hASehe^YB*CJOJQJ^Jhph*7\o;ST-Lp6^w'# ! -DM  )1Z]   ( 0 Q /"\"o"p""""""#####$C%D%j%k%l%m%&&N'O'g'h'''񞎃yhASehe^Y5\hASehe^Y5\jhASehe^Y5U\ hASehe^YhASehe^Y^J$hASehe^YCJOJQJ^JmHsH hASehe^YCJOJQJ^JaJhASehe^YCJOJQJ"hASehe^Y5CJOJQJ\^JhASehe^YCJOJQJ^J/ Q R      !=!r!!!!!!!"."/"["\"q"""" -D M  -DM """%#&#=#W#k#######+$`$$$$$l%m%%%%&)&J&# !'( -DM J&j&k&&&&&&&'''N'O'g'h''''''(I(~((((((+( -DM '''' (({((((A)H)))))))* *:*;*N*V*r*y***********++5+=+O+W+Y+Z+++++- -(-/-H-O---.񏻏hASehe^Y5\0jhASehe^YCJOJQJU^JmHnHuhASehe^Y^J hASehe^Y"hASehe^Y5CJOJQJ\^J$hASehe^YCJOJQJ^JmHsHhASehe^Y\^JhASehe^YCJOJQJ^J8())J)K)g))))))))))**&*:*<*W*{***** H-DM ( ,-DM -DM **+?+@+Y+Z++++,,k,,,,, -0-P---...`.a.' -DM .>.?.^._.`.a.{....y//// 0050<0R0Y0n0u000000001+12151P1W1h1o1y1ɵɠɋyyyyyyyyyyɋcc*hASehe^Y5CJOJQJ\^JmH sH "hASehe^Y5CJOJQJ\^J(hASehe^YCJOJQJ^JaJmH sH (hASehe^YCJOJQJ^JaJmHsH&hASehe^Y5CJOJQJ\^JaJ hASehe^YCJOJQJ^JaJhASehe^Y5\hASehe^YjhASehe^YU hASehe^Y&a......=/x//////00=0Z0v0000131X1p11111-D 7$8$H$M y111111111114$4)4l4m444w5~5555555666L7S77IJīďIJIJIJĂvi[i[ihASehe^Y5CJOJQJhASehe^YCJOJQJhASehe^Y5CJ\hASehe^YOJQJ^J&hASehe^Y5CJOJQJ\^JaJhASehe^Y\ hASehe^Y"hASehe^Y5CJOJQJ\^J hASehe^YCJOJQJ^JaJ(hASehe^YCJOJQJ^JaJmH sH *hASehe^Y5CJOJQJ\^JmH sH 1111F2[2k2l2222&3'3T3333'4(4)4l4m4445+5?5R5'7$8$H$-D 7$8$H$M R55555566$6W66666/757Z7[7\77777 8B8g8 -D M  !7$8$H$-D 7$8$H$M 7 8^8g8z88888889&9-9p9w99999999: ::$:,:3:I:P:b:i:l:;;;<<%<=<D<f<m<<<<<<<??AA!B)BBBCCgDnDqDDDDD⻯⻧hASehe^Y6hASehe^Y5CJ\ hASehe^Y#hASehe^Y5CJOJQJmH sH hASehe^Y5CJOJQJhASehe^YCJOJQJ hASehe^YCJOJQJmH sH Bg8888889/9c9y99999:&:5:R:k:l::::;;;>;x;; -D M ;;;<(<F<o<<<<<<<D======>A>>>>>3?v??? -D M ???@@@N@@@@KALAMAAAAAA+B,B|BBBBBBB CC -D M C-CHCXCYCCCCCC DD,D-D.DoDpDqDrDDDEEFFfGgGG^ -D M DFG@HAH^H_HhIjIIIQaQnQhASehe^Y5CJOJQJhASehe^YCJOJQJhASehe^Y\hASehe^YjhASehe^YUhASehe^Y6]hASehe^Y;CJhASehe^YCJhASehe^Y5 j hASehe^YhASehe^Y5\hASehe^Y6 hASehe^Y2GG@HAHBHHHXHHHIgIhIiIjIIIJDJTJUJJJJ=KYKjKK(# !'KL LL L!LQLRLSLTLULqLLLMMMMMM!O"OOOOO' & F` & F# !%$a$(OCPDPPPPQ?QoQQQQ R*RVRWRXRRRRRSSJSSS T T/T' -D M nQQQQQQQR R"R)RARIRURWRRRRRR1SISSSSTT'T.T/T1TXTwTxT}TT5U6U`UcU]?]d]e]# !'`  & F  -D M [[[2[3[8[M[[[e]]]]]^^^^L^R^c^d^k^^^^^^^^^__8_@_Q_R_ƸƸƪƸƸƚƈƈ{n{ƸƸ^hASehe^Y5CJOJQJ\hASehe^YOJQJaJhASehe^YCJOJQJ"hASehe^Y5CJOJQJ\^JhASehe^Y5CJOJQJ\hASehe^YCJH*OJQJhASehe^Y5CJOJQJhASehe^YCJOJQJhASehe^YaJhASehe^Y6]hASehe^YCJhASehe^Y5\ hASehe^Y$e]]]]!^"^S^l^^^^^^^__A_T________a`  & F %'! -D M R_S________`` `G`H`a-aaabb.b5bcce^fgg̸̮̮̮̊{i{i{V{$hASehe^YCJOJQJ^JmH sH "hASehe^Y5CJOJQJ\^JhASehe^YCJOJQJ^JhASehe^YOJQJ^JaJhASehe^YjhASehe^YUhASehe^Y6]hASehe^Y;CJhASehe^Y5\ hASehe^YhASehe^Y5CJOJQJhASehe^YCJOJQJ"hASehe^Y5CJOJQJ\^Jaabb6bbbJccc d d>ddd&eseeeefPffffgPgg -D M x'gggh,hQhdhwhxhhh|@|O|Z|a|c|ŴsZ>Z6hASehe^Y5B*CJOJQJ\^JhmHphsH0hASehe^YB*CJOJQJ^JhmHphsH.hASehe^Y5B*CJOJQJ\^Jhph(hASehe^YB*CJOJQJ^Jhph'hASehe^Y5B*CJOJQJ\ph!hASehe^YB*CJOJQJphhASehe^Y5\hASehe^YjhASehe^YUhASehe^Y6] hASehe^YhASehe^Y;CJ!y"y{{{{||O|c|{|||||%}&}'}W}X}Y}Z}{}}}``  & F %+( -DM # !'c|r|y|{|||||||||||}$}%}&}Z}z}}}}}}ªªšªªyrhr_RrHhASehe^Y6]hASehe^YOJQJ^JhASehe^YCJhASehe^Y5\ hASehe^Y!hASehe^YB*OJQJ^JphhASehe^Y5B*^JhphhASehe^YB*\^Jhph.hASehe^Y5B*CJOJQJ\^Jhph(hASehe^YB*CJOJQJ^Jhph*hASehe^Y5B*\^JhmHphsH$hASehe^YB*^JhmHphsH}}}}  ܁݁35:XZ[{̆ȥȘȥrZrZr.hASehe^Y5B*CJOJQJ\^Jhph(hASehe^YB*CJOJQJ^JhphhASehe^Y6] hASeh3@khASeh2/B*ph!jhASeh2/B*UphhASeh3@kB*ph hASehc-hASeh2/jhASeh2/U hASehI4 hASehe^YhASehe^YjhASehe^YU}23op̆͆+[̇'(OP -D M -( -DM '# !")RYÇ̇()ʲʲʲʲnVnKD7hASehgiRB*CJph hASehe^YhASehe^YB*ph.hASehFqq5B*CJOJQJ\^Jhph+hASehFqqB*CJOJQJ\^Jhph.hASehgiR5B*CJOJQJ\^Jhph+hASehgiRB*CJOJQJ\^Jhph.hASehe^Y5B*CJOJQJ\^Jhph(hASehe^YB*CJOJQJ^Jhph"hASehe^Y5B*\^JhphhASehe^YB*^Jhph)OPoy։݉(AHJTqzԾԾԾԾԾ{cM5.hASehFqq5B*CJOJQJ\^Jhph+hASehFqqB*CJOJQJ\^Jhph.hASehgiR5B*CJOJQJ\^Jhph+hASehgiRB*CJOJQJ\^Jhph.hASehe^Y5B*CJOJQJ\^Jhph(hASehe^YB*CJOJQJ^Jhph+hASehe^Y5B*CJOJQJ\^Jph%hASehe^YB*CJOJQJ^JphhASehe^YB*phhASehe^YB*CJphމ(JTzBu0i'# ! -DM gdgiR -DM -D M 4rtah~׍؍ 0ȲȲȲȚȚȆȆȆqȲ[+hASehgiRB*CJOJQJ\^Jhph(hASehe^YB*CJOJQJ^Jhph'hASehe^Y5B*CJOJQJ\ph.hASehe^Y5B*CJOJQJ\^Jhph+hASehe^Y5B*CJOJQJ\^Jph%hASehe^YB*CJOJQJ^Jph hASehe^Y hASehgiR+hASehFqqB*CJOJQJ\^Jhph9abcd~89NijϔД'! & F.  ^# !`  & F  -DM gdgiR -D M 09Y`ad}ߎ89Nhijm{}Һҳ{l`WME:EhASehe^Y6\]hASehe^Y\hASehe^Y\aJhASehe^YCJhASehe^Y5CJ\hASehe^YCJOJQJ^JhASehe^YjhASehe^YUhASehe^Y6]hASehe^YCJOJQJ^JhASehe^Y5\ hASehe^Y.hASehFqq5B*CJOJQJ\^Jhph+hASehFqqB*CJOJQJ\^Jhph.hASehgiR5B*CJOJQJ\^Jhph}ΑϔДμykXHk>hASehe^Y\^JhASehe^YCJOJQJ^Jh%hASehe^Y5CJOJQJ\^JhhASehe^YCJOJQJ\hASehe^Y5CJOJQJ^JhASehe^YCJOJQJ\^JhASehe^YCJhASehe^YaJhASehe^Y6] hASehe^YhASehe^Y\aJhASehp\hASehe^Y\hASehe^Y6\]!jhASehe^Y6U\]hASehe^Y6\]ДW!"56st  45FG'# !-DM ( -DM orst ǘΘޘ"8?PWt{™Ù۾۾۷ۑ||||||||||lhASehe^YCJOJQJ\^J(hASehe^YB*CJOJQJ^Jhph.hASehe^Y5B*CJOJQJ\^JhphhASehe^YCJOJQJ\ hASehe^YhASehe^Y^Jh%hASehe^Y5CJOJQJ\^JhhASehe^YCJOJQJ^Jh'hASehe^YCJOJQJ^JhmHsH%%&EXYϘ#@X|™ ` & F. -DM Ù   89>fjk)-VaZi| +,-.sɻ~n[n[n[nQnhASehe^Y^Jh%hASehe^Y5CJOJQJ\^JhhASehe^YCJOJQJ^Jh"hASehe^Y5CJOJQJ\^JhASehe^YCJOJQJ^JhASehe^Y6]hASehe^Y\hASehe^YjhASehe^YU\hASehe^Y6\]hASehe^Y\hASehe^Y5hASehe^YCJ hASehe^YhASehe^Y5CJ\  ()-.`aJYZӠԠҡӡ -DM ' hh^h`h-.KQ_a{\]Σ4' 6-DM ( -DM sz\ƣͣΣ+3457UvDX߫%-ؼѰѦѦќ|h|h|h|&hASehe^Y5CJOJQJ\^JaJ hASehe^YCJOJQJ^JaJhASehe^YCJOJQJ^JhASehe^Y5\hASehe^Y6]hASehe^Y5CJ\(hASehe^YB*CJOJQJ^Jhph hASehe^YhASehe^YCJOJQJ^Jh.hASehe^Y5B*CJOJQJ\^Jhph(457Urs ǩ !9\]-D 7$8$H$M 'dd[$\$` & F.# !/0ɭL~STm¯X-D 7$8$H$M ǰQ/NPfyټڼ2 jkx۵ۙ۵۵{{۵oehASehe^Y6]hASehe^Y5CJ\(hASehe^YCJOJQJ^JaJmH sH hASehe^YCJ(hASehe^YCJOJQJ^JaJmHsH hASehe^Y hASehe^YCJOJQJ^JaJ(hASehe^YCJOJQJ^JaJmH sH hASehe^YCJOJQJ^JaJ&hASehe^Y5CJOJQJ\^JaJ&Xð OeֱPf NO7$8$H$'-D 7$8$H$M 4hδ*@4s01I_-D 7$8$H$M Ƿ/pqܸݸ;u;uUڻ-D 7$8$H$M ڻaټڼ.n:|}ƾǾھ-kl޿#h'-D 7$8$H$M MB*?@Aklmnopqrs-D 7$8$H$M stuvwgh;<=~ -D M '` & F.fh#qy/05JfglOx}cdkt<XG#T1\r̭̣}}$hASehe^YCJOJQJ^JmH sH $hASehe^YCJOJQJ^JmHsHhASehe^Y6]hASehe^YCJhASehe^Y5\hASehe^Y5CJ\ hASehe^Y"hASehe^Y5CJOJQJ\^JhASehe^YCJOJQJ^JhASehe^Y5CJ\1)*+opQ&'|}45CO -D M OPo01235Kgh/0OP~'`  & F t$a$% -D M Jyz TU}~ 89bcuv<' -D M <=j,d/X@V+Z -D M %Zz)x^|6y*yO -D M E=6#$s-R&Bw' -D M M6R\>tkA -D M .`l>u%K6rFs -D M 1\]]r"9q L$s1\' -D M Inopr4ij'# !  <`< & F `^`` $-D M a$ -D M il!SU]^_t   0 1 ] ļۭۭypļļhASehe^YCJ hASehe^YCJOJQJ^JaJ hASehe^YCJOJQJ^JaJ"hASehe^Y5CJOJQJ\^JhASehe^YCJOJQJ^JhASehe^YjhASehe^YUhASehe^Y6] hASehe^YhASehe^Y\hASehe^Y5\hASehe^Y;CJ\,ja1wCDmn -D M  STU"#>|!"-D 7$8$H$M ' -D M AB(VW>fgKtuf-D 7$8$H$M x12\^_u  > ? ] ^ '  `  & F P #$ !a$7$8$H$-D 7$8$H$M ] ^       d e         V^ 45#%&'=Z[ƺ㖟}}hASehe^Y5 hASehe^YhASehe^Y5\hASehe^YCJhASehe^YaJ"hASehe^Y5CJOJQJ\^JhASehe^Y5\^JhASehe^Y^JaJ#hASehe^Y5CJOJQJ^JaJ hASehe^YCJOJQJ^JaJhASehe^Y5CJ\1^     K L M f {      M      &'_`a(7$8$H$-D7$8$H$M 67_`vw 456Oab!-D7$8$H$M kl \]^mRS-D7$8$H$M  "#%&'=Z[(){|A('   & F !-D7$8$H$M ABde}<=l  -.^_({"*}~A"J"w"""""""""o######$$$$$$r%s%{%%xdxdx&hASehe^Y5CJOJQJ\^JaJ hASehe^YCJOJQJ^JaJ"hASehe^Y5CJOJQJ\^JhASehe^YCJOJQJ^JhASehe^YjhASehe^YUhASehe^Y6]hASehe^YCJhASehe^Y5\hASehe^YaJhASehe^Y5hASehe^Y5\^J hASehe^Y''wxY&'=R}~!'(aCDZ[i     [ \   (   !'!@!c!!!!!!"""("J"K"s"t"u"v"w""""^  `  & F # !("B#C#D#n#o####$L$w$$$$$$5%H%\%{%%%% &/&L&-D 7$8$H$M  -D M '%%'&(&.&J&K&&&& ' '@'V'W'j'k'o''''''`*,, ,",a/b/g/̻̻੢xpxibUMhASehe^Y5jhASehe^YEHU hASehAd hASehMhASehe^YjhASehe^YUhASehe^Y6]hASehe^YCJhASehe^Y5\ hASehe^Y"hASehe^Y5CJOJQJ\^J hASehe^YCJOJQJ^JaJ&hASehe^Y5CJOJQJ\^JaJhASehe^YCJOJQJ^JhASehe^Y5CJOJQJ^JL&&&&&& ' '='>'?'W'k'l'**,,`/a///`7$8$H$^``7$8$H$gdM  `$ & F `^``gdS% -D M /0 0H0I0m0n00001<1b1c1111111111333`  & F %# !( -DM 'g/0 01040I0i0l0z0000000001131:1<1Z1a1b11޶iZHZZHZ"hASehe^Y5B*\^JhphhASehe^YB*^Jhph6hASehe^Y5B*CJOJQJ\^JhmH phsH 0hASehe^YB*CJOJQJ^JhmH phsH .hASehe^Y5B*CJOJQJ\^Jhph(hASehe^YB*CJOJQJ^Jhph$hASehe^Y5B*CJOJQJph!hASehe^YB*CJOJQJphhASehe^Y5\ hASehe^Y111111112222T3W3332474G4H4R4U4_4f4w4~44444λαĐ΅uul]hASehe^YCJOJQJ^JhASehe^YCJhASehe^Y5\^JmH sH hASehe^YmH sH hASehe^Y5\^JhASehe^YjhASehe^YUhASehe^Y6]hASehe^YCJhASehe^Y5\ hASehe^Y+hASehe^Y5B*CJOJQJ\^Jph'hASehe^Y5B*CJOJQJ\ph393:3X333484S4g44444445>5y55556J6o6666# ! -D M ('44J5K555555556666A6B6I6L6f6g6n6~666666666ɶɶɶߒ߶ɶɁwpcSchASehe^Y6B*]aJphhASehe^YB*aJph hASehe^YhASehe^Y5\ hASehe^YOJQJ^JmH sH hASehe^Y5CJOJQJ\&hASehe^Y5CJOJQJ\mH sH $hASehe^YCJOJQJ^JmH sH *hASehe^Y5CJOJQJ\^JmH sH hASehe^YCJOJQJ^J"hASehe^Y5CJOJQJ\^J666699990:B:T:`:p:~:::::::::::;-D7$8$H$M '7$8$H$# !`  & F 66"7#7N8n8899999990:9:A:K:R:Z:^:g:n:p:w:|::::::::נoSoSoSoSo7hASehe^Y5B*CJOJQJ\^JaJmH phsH 1hASehe^YB*CJOJQJ^JaJmH phsH /hASehe^Y5B*CJOJQJ\^JaJph)hASehe^YB*CJOJQJ^JaJphhASehe^YB*ph hASehe^YhASehe^Y6B*]aJphhASehe^YB*aJphhASehe^Y%jhASehe^YB*UaJph :::::::::::::::; ; ;;;;#;.;3;@;I;J;U;W;X;^;k;n;o;v;;;;;;;;;;;;;==I>J>?ҦhASehe^YaJhASehe^YCJhASehe^Y5\ hASehe^Y)hASehe^YB*CJOJQJ^JaJph,hASehe^Y>*B*CJOJQJ^JaJph)hASehe^YB*CJOJQJ^JaJph/hASehe^Y5B*CJOJQJ\^JaJph3;;;$;4;J;_;w;;;;;;;;%=]=====+>I>J>? h7$8$H$^h`  & F 7$8$H$-D7$8$H$M ??@@@@AA7B8BB'C7D8DmDnDDE E&E'E(EPEfE(! & F,h^h&`` & F- 8`7$8$H$???@(@@@@@{BB!C$CCC8DmDnDDD(E7E8ENEOEPEkEzEzGGGGGxIyIIbJcJJJJJ,RRRX޹Ǡ}𠌠hASehe^YCJOJQJ^J&hASehe^Y5CJOJQJ\^JaJ hASehe^YCJOJQJ^JaJhASehe^YjhASehe^Y5UhASehe^YaJhASehe^Y5CJ\aJhASehe^Y5hASehe^Y6] hASehe^YhASehe^YCJ+fEgEyGzGGGGG HSHoHHHIXIwIxIyIIIIJJJfJgJ !7$8$H$y-D 7$8$H$M !gJJJJJJJ+K,KzKKKKKK#L?LfLLLLLM`MvMwMMM-D 7$8$H$M MMM@NVNWNwNNNO&O'OEOOOOOP(P)PPPyPPPPPQ=QQ-D 7$8$H$M QQQQQQ+R,RQRRRiRjRRRRR S.SZSSSSST%T&T !7$8$H$y7$8$H$-D 7$8$H$M &T@TTTTTTUU4U{UUUUUU9VPVQVuVVVVVDW[W\WWW-D 7$8$H$M WW X"X#XIXpXXXXX Ywiwwwwx?xdxexxxxy?ykyyyyz=z>zrzzzz!-D 7$8$H$M zzz<{q{{{{{{0|?|@||||||}:}M}N}O}}}}.~h~i~-D 7$8$H$M }}j~~~~~~~~~~~~  67 !JKt®¥wjbjjbjjbjwXwMjhASehe^YUhASehe^Y6]hASehe^YjhASehe^YUhASehe^Y5\hASehe^Y5CJ\ hASehe^Y hASehe^YCJOJQJ^JaJhASehe^YaJ&hASehe^Y5CJOJQJ\^JaJ hASehe^YCJOJQJ^JaJ(hASehe^YCJOJQJ^JaJmH sH .hASehe^Y5CJOJQJ\^JaJmH sH i~j~~~~~~~~~~~݃߃4 & F $If$If & F 0^`0# !%7$8$H$-D 7$8$H$M tuv')*CD'+,/01R[]_`acdeَô֎ւִwnִbWnjShASehe^YUhASehe^Y5CJ$\hASehe^YCJ8jhASehe^YU jhASehe^YCJ8hASehe^Y6"hASehe^Y5CJOJQJ\^JhASehe^Y5CJ\hASehe^YCJ$OJQJ^JhASehe^YaJhASehe^Y5\ hASehe^YhASehe^Y0J"jhASehe^YUjhASehe^YU"&'()*CDtmff p    7$8$H$  @@7$8$H$h^h[kdh$$Ifl$064 la$If & F $If D'()*+-/<>R]^_`bcdpq ^ȑʑԕ֕IKPUZ\ -D M  ^َÛ!4ݢ﷪ypdXhASehe^Y5CJ\hASehe^Y5CJ$\hASehe^YCJ8j}hASehe^YCJ8UhASehe^Y5\mHnHuhASehe^Y6jxhASehe^YEHUjzshASehe^YEHUhASehe^Y5 jhASehe^YCJ8j/hASehe^YUhASehe^Y5\hASehe^YCJ$OJQJ^J hASehe^YhASehe^Y6]ęřz}ܢݢ ^#$d %d &d 'd N O P Q #$d %d &d 'd N O P Q ƤǤ+-ͪΪȬɬʬˬͬ\^\ ^  ^Ȭʬˬ̬ϬӬ߭-luvyz{|ҵӵ ĺźƺܘܘ܅}uu}umahASehe^Y5CJ$\hASehe^Y\hASehe^Y]hASehe^Y6$jGhASehe^YCJUmHnHuhASehe^Y5\jD hASehe^Y5CJU\hASehe^YCJ OJQJ^JhASehe^YCJ$OJQJ^J jhASehe^YCJ8 hASehe^YhASehe^Y5CJ\jThASehe^Y5CJU\%ͬάϬЬѬҬӬݭ߭8,$If# ! & F 0^`0,-.ijklvwxy{]^ ^]kdG$$Ifl$$064 lal^_jw fg89:úĺźƺȺɺ% ^ -D M ƺǺ)½ŽƽȽ˽̽Ob퓇{pfȣ[ShASehe^Y\jhASehe^YUhASehe^Y6]jhASehe^YU jhASehe^YCJ8hASehe^Y5CJ$\j,hASehe^Y5CJ$U\hASehe^YCJ$OJQJ^JjR'hASehe^YEHUhASehe^YEHhASehe^Y5\hASehe^Y5\mHnHuhASehe^Y5CJ\ hASehe^YjUhASehe^YU )*½ýĽŽǽȽʽ˽׽ؽ ^#$d %d &d 'd N O P Q  & F 0^`0%ؽOP$a$  & F 0^`0 ^./VW  1234QRjklmnxj_xxj\hASehe^YUj^T2> hASehe^YUVjhASehe^YUj7ZhASehe^YCJUjP2> hASehe^YCJUVhASehe^YCJjhASehe^YCJUhASehe^Y5\hASehe^YjhASehe^YUhASehe^Y5\jhASehe^Y5U\hASehe^YCJ hASehe^Y%P  $If $$Ifa$h^h kdX$$IflOr% i"  20%64 lap25PQnMkd_$$IflXr% i"  0%64 la $$Ifa$$%=>?@ARSklmnshZjkU2> hASehe^YUVjphASehe^YUjS2> hASehe^YUVjlhASehe^YUj}2> hASehe^YUVjhhASehe^YUj9F> hASehe^YUVjchASehe^YUjT2> hASehe^YUVhASehe^YCJjhASehe^YUj`hASehe^YUjtS2> hASehe^YUV hASehe^Y!#$AQRoMG$Ifkdg$$Iflor% i"  0%64 la $$Ifa$o-Mkdo$$Iflr% i"  0%64 la $$Ifa$./GHIJghⲧ❎}odXhASehe^Y5CJ\jŀhASehe^YUj >> hASehe^YUVhASehe^YCJhASehe^YjhASehe^YCJUhASehe^Y5\j}hASehe^YUjp2> hASehe^YUVjlyhASehe^YUj-T2> hASehe^YUVhASehe^YCJ hASehe^YjhASehe^YUjshASehe^YU-.KfgVMMMMM $$Ifa$kd}x$$Iflxr% i"  0%64 laVTTTJ # !0^0kd$$Iflr% i"  0%64 la!>?X}q & F L^L`%$^a$0^00$d %d &d 'd -D M N O P Q ^$|^|a$0$d %d &d 'd -D M N O P Q ^ !":;<=>?WX`ayz{|}꼬uk]RFhASehe^Y5CJ\jhASehe^YUjF>> hASehe^YUVhASehe^Y5\hASehe^Y5CJ\jhASehe^YUjk>> hASehe^YUV hASehe^YjhASehe^YUhASehe^Y5CJ\mH sH hASehe^Y5\mH sH jdhASeh^}qUjj>> hASeh^}qUV hASeh^}qjhASeh^}qUhASehe^YmH sH <T,-TUWXpqrswgwjhASehe^Y5CJU\hASehe^Y5CJ\hASehe^Y:hASehe^YCJj hASehe^YU#j> hASehe^YCJUVaJjhASehe^YUhASehe^YCJOJQJ^JhASehe^YjhASehe^YUhASehe^YCJ$OJQJ^JhASehe^Y5\ hASehe^Y ;<TU  VWtuv{|} $$If`a$'h^h# ! -DM ^yyy $$If^a$xkd$$IfTl47   064 laf4p T 'uoff $$Ifa$$IfkdU$$IfTlF7= 06    4 laT    '*+CDEFGW`ayz{|}¹«š¹«{m¹«\N¹jhASehe^Y5U\!j-T2> hASehe^Y5UV\jNhASehe^Y5U\!jS2> hASehe^Y5UV\jhASehe^Y5U\!jtS2> hASehe^Y5UV\jhASehe^Y5U\hASehe^YCJhASehe^Y5\jhASehe^Y5CJU\jhASehe^Y5CJU\%jP2> hASehe^Y5CJUV\'(*GWuoff $$Ifa$$Ifkd$$IfTl!F7= 06    4 laTWX`}uoff $$Ifa$$Ifkd$$IfTlF7= 06    4 laTuoff $$Ifa$$Ifkdc$$IfTlF7= 06    4 laTuoff $$Ifa$$Ifkd$$IfTl~F7= 06    4 laT'(@ABCD{|ʳʢʋ}rʋ`UjhASeh} VU#j> hASehe^YCJUVaJjhASehe^YUj!>> hASehe^YUVhASehe^YCJjhASehe^Y5U\!jT2> hASehe^Y5UV\jhASehe^Y5U\hASehe^YCJhASehe^Y5\jghASehe^YUj_ >> hASehe^YUV hASehe^YjhASehe^YU 'Duoff $$Ifa$$IfkdQ$$IfTlF7= 06    4 laTuoff $$Ifa$$Ifkd$$IfTlF7= 06    4 laTyz{nousssssssssqss'kd2$$IfTlbF7= 06    4 laT  23^_yz{|}⳨pdZJjhASehe^Y5U\hASehe^Y5\hASehe^Y5CJ\hASehe^YCJ$OJQJ^Jj hASehe^YCJUVaJhASehe^Y5CJ\j!hASehe^YU#j> hASehe^YCJUVaJj hASehe^YU#j> hASehe^YCJUVaJ hASehe^YjhASehe^YUhASehe^Y5CJ\!23]^}~ x^x`%^[fijsw&lp»ʻ»»һ»ʻ»һһ»ʻ»ʻ»»»ʻ»$hASehe^YCJOJPJQJ^JaJ*hASehe^Y5CJOJPJQJ\^JaJhASehe^Y; hASehe^YhASehe^Y5hASehe^Y\hASehe^Y5\jhASehe^Y5U\hASehe^Y5\hASehe^Y6[\:x7$8$H$^x` x7$8$H$^xx7$8$H$^x` x^x`lnop|}XY ! xx^x` x^x`$a$ .x^x`p|Yv.!2rpLMOP[\`+ p"ɾ𶩠hASehe^YaJmHsHhASehe^YaJmH sH hASehe^YaJhASehe^Y5>*\aJhASehe^Y\hASehe^Y6]hASehe^YjhASehe^YUhASehe^Y;hASehe^Y5\ hASehe^YhASehe^Y54opOP<gBr(P  7$8$H$ x^x`Pu'\4lJ#[*  7$8$H$^  7$8$H$]  7$8$H$*b'_)Yw >\z  p7$8$H$^p  7$8$H$  7$8$H$^ * E ^ {      ) F c       4 R p       p7$8$H$^p  $ A _ |    B z    J*b Ay  7$8$H$^  7$8$H$  p7$8$H$^py!Y6nM-e E}%  7$8$H$  7$8$H$^%]=uU5lL,d   7$8$H$^ D|$\<tM- e    !D!|!!  7$8$H$^  7$8$H$!!$"\"""#<#t###$T$$$$4%f%%%&F&~&&&&'^'  7$8$H$  7$8$H$^^'''(:(q((()L)~)))*W****7+o+++,O,,,,  7$8$H$  7$8$H$^,/-g---.G....'/_///0?0w0001W111172o2 *  7$8$H$  7$8$H$  7$8$H$^"/"0 57(8>@?x??????@@:@;@h@i@@@AAAAAAGFdFeFFFwGGJJǺǺǘyhݘy hASehe^YCJOJQJ^JaJ!hASehe^Y5>*OJ QJ \^JhASehe^Y5OJ QJ \hASehe^Y5>*OJ QJ \hASehe^Y6]hASehe^YjhASehe^YU hASehe^YhASehe^YCJaJmHsHhASehe^YaJhASehe^YaJmH sH hASehe^YaJmHsH$o2223H3333%4]4445<5m5556M6666-7e777 8  7$8$H$^  7$8$H$ 8E8}8889I9|999:R::::;M;;;;<I<|<<<=E=  7$8$H$  7$8$H$^E=x===>/>c>m>>>?@?x?????@@AAA/ x!^` # !7$8$H$7$8$H$ # ! 7$8$H$  7$8$H$AA>BBBCBCsCCCLDDDD7EwEEFGFFFFG?GwG/$ x! 7$8$H$^` P7$8$H$^`PwGGtHHH9IIJJJJJ~LLLLLM$If $ d] 7$8$H$^`JJ"J%JYJZJJJJJ~LLLLLLLLMMMM黮xbxbxbWF hASehe^YCJOJQJ^JaJhASehe^YCJaJ*hASehe^Y5CJOJPJ QJ\^JaJ&hASehe^Y5CJOJQJ\^JaJhASehe^YB*EHphj|^hASehe^YEHUhASehe^YjhASehe^YU hASehe^Y)hASehe^Y6CJOJQJ]^JaJ#hASehe^YCJOJQJ^JaJ,jhASehe^YCJOJQJU^JaJMMM+MDMuooo$Ifkdc$$If4F3''' 36    2  24apMM*M+MCMDMEMJMKMdMeMMMMMMMMMMMMMMMMMMMMNNN N!N(N)NGNHNgNhNiNnNoNxNyNNNNNNNNNNNNNNNhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJ;DMEMKMeMMM3ckdve$$IfF3###36    2  24a$Ifckdd$$IfF3###36    2  24aMMMMMMMMckd4f$$IfF3###36    2  24a$IfMMMN N!N3ckdg$$IfF3###36    2  24a$Ifckdf$$IfF3###36    2  24a!N)NHNhNiNoNyNNckdnh$$IfF3###36    2  24a$IfNNNNNN3ckdi$$IfF3###36    2  24a$Ifckd,i$$IfF3###36    2  24aNNNNNNNNckdj$$IfF3###36    2  24a$IfNNNNNNNNNNNNNNN O OOOO'O(O6O7O8O=O>OPOQO_O`OaOiOjOOOOOOOOOOOOOOܼ(hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJ.NNNN OO3ckd$l$$IfF3###36    2  24a$Ifckdfk$$IfF3###36    2  24aOO(O7O8O>OQO`Ockdl$$IfF3###36    2  24a$If`OaOjOOOO3ckd^n$$IfF3###36    2  24a$Ifckdm$$IfF3###36    2  24aOOOOOO&PKPckdo$$IfF3###36    2  24a$IfOO%P&PJPKPLPWPXP|P}PPPPPPPPPPPPP Q Q-Q.Q/Q=Q>QjQkQQQQQQQQQQQQQRR8R9R:R?R@RŰŰŰŰŰhASehe^YCJaJhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH $hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJ,hASehe^YCJOJPJ QJ^JaJmH sH 2KPLPXP}PPP3ckdp$$IfF3###36    2  24a$Ifckdo$$IfF3###36    2  24aPPPPPP Q.QckdVq$$IfF3###36    2  24a$If.Q/Q>QkQQQ3ckdr$$IfF3###36    2  24a$Ifckdr$$IfF3###36    2  24aQQQQQQR9Rckds$$IfF3###36    2  24a$If9R:R@RURgRhR3ckd u$$IfF3###36    2  24a$IfckdNt$$IfF3###36    2  24a@RTRURfRgRhRpRqRRRRRRRRRRRRRRR SS'S(S)S4S5SYSZSzS{S|SSSSSSSSSSSSTTTTT!T"T'T(T)T0T1T8T9TETܼܼhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJ;hRqRRRRRRRckdu$$IfF3###36    2  24a$IfRRRS(S)S3ckdFw$$IfF3###36    2  24a$Ifckdv$$IfF3###36    2  24a)S5SZS{S|SSSSckdx$$IfF3###36    2  24a$IfSSSSTT3ckdy$$IfF3###36    2  24a$Ifckdx$$IfF3###36    2  24aTT"T(T)T1T9TFTckd>z$$IfF3###36    2  24a$IfETFTGTJTKTNTOTTTUTVTZT[T_T`TlTmTnTvTwTTTTTTTTTTTTTTTTTUU U UUUU,U-U.U6U7UHUIUXUYUZU^U_UlUmUyUzU{U~UhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJOJQJ^JaJhASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ;FTGTKTOTUTVT3ckd{$$IfF3###36    2  24a$Ifckdz$$IfF3###36    2  24aVT[T`TmTnTwTTTckdx|$$IfF3###36    2  24a$IfTTTTTT3ckd}$$IfF3###36    2  24a$Ifckd6}$$IfF3###36    2  24aTTTU UUU-Uckd~$$IfF3###36    2  24a$If-U.U7UIUYUZU3ckd.$$IfF3###36    2  24a$Ifckdp$$IfF3###36    2  24aZU_UmUzU{UUUUckd$$IfF3###36    2  24a$If~UUUUUUUUUUUUUUUUUUUUUUUUUUUUUU V VVVVV V-V.V:V;VZ?ZCZDZXZYZpZqZrZtZuZZZZZZZZZZZZZZZZZZZZZZZZZZZ[[ [ [[[[[[)[ܼhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJ;YZZZZZ&Z>Zckdj$$IfF3###36    2  24a$If>Z?ZDZYZqZrZ3ckd$$IfF3###36    2  24a$Ifckd($$IfF3###36    2  24arZuZZZZZZZckd$$IfF3###36    2  24a$IfZZZZZZ3ckd $$IfF3###36    2  24a$Ifckdb$$IfF3###36    2  24aZZZZZ[ [[ckdޝ$$IfF3###36    2  24a$If[[[*[<[=[3ckdZ$$IfF3###36    2  24a$Ifckd$$IfF3###36    2  24a)[*[;[<[=[E[F[`[a[z[{[|[[[[[[[[[[[[[[[[[\\,\-\.\9\:\Z\[\y\z\{\\\j,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJ)=[F[a[{[|[[[[ckd$$IfF3###36    2  24a$If[[[[[[3ckd$$IfF3###36    2  24a$Ifckd֠$$IfF3###36    2  24a[[\-\.\:\[\z\ckdR$$IfF3###36    2  24a$Ifz\{\\\\\3ckdΣ$$IfF3###36    2  24a$Ifckd$$IfF3###36    2  24a\\\\\\\\]]&]'](]6]7]`]a]]]]]]]]]]] ^ ^5^6^Z^[^\^j^k^^^^^^^^^^-_._ǰǰǰǰuǰuǰǰǰǰ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH $hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJ.\\]'](]7]a]]ckd$$IfF3###36    2  24a$If]]]]]]3ckd$$IfF3###36    2  24a$IfckdJ$$IfF3###36    2  24a] ^6^[^\^k^^^ckdƦ$$IfF3###36    2  24a$If^^^^._/_3ckdB$$IfF3###36    2  24a$Ifckd$$IfF3###36    2  24a._/_=_>_g_h_____________``=`>`?`G`H`c`d`}`~``````````` a a4aŴ񴡴񴡴j,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJmH sH )/_>_h______ckd$$IfF3###36    2  24a$If___`>`?`3ckd|$$IfF3###36    2  24a$Ifckd$$IfF3###36    2  24a?`H`d`~`````ckd:$$IfF3###36    2  24a$If``` a5a6a3ckd$$IfF3###36    2  24a$Ifckd$$IfF3###36    2  24a4a5a6aDaEapaqaaaaaaaaaaabbbb(b)b*b5b6b\b]b~bbbbbbbbbbbbbbbbbcɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶ(hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ(hASehe^YCJOJQJ^JaJmH sH $hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH -6aEaqaaaaaackdt$$IfF3###36    2  24a$Ifaabb)b*b3ckd$$IfF3###36    2  24a$Ifckd2$$IfF3###36    2  24a*b6b]bbbbbbckd$$IfF3###36    2  24a$Ifbbbbbb3ckd*$$IfF3###36    2  24a$Ifckdl$$IfF3###36    2  24ab c5c\c]cicccckd$$IfF3###36    2  24a$Ifc c4c5c[c\c]chcicccccccccccccdd1d2dNdOdPd^d_ddddddddddddddd e e)e*e+e1e2eŰŰŰŰŰhASehe^YCJaJhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH $hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJ,hASehe^YCJOJPJ QJ^JaJmH sH 2cccccc3ckdd$$IfF3###36    2  24a$Ifckd$$IfF3###36    2  24acd2dOdPd_dddckd"$$IfF3###36    2  24a$Ifdddddd3ckd$$IfF3###36    2  24a$Ifckd$$IfF3###36    2  24add e*e+e2e9eAeckd\$$IfF3###36    2  24a$If2e8e9e@eAeBeDeEeMeNeTeUeVe[e\eleme}e~eeeeeeeeeeeeeeeeeeeeeeeeeff8f9f:fFfGfpfqffffffff gܼܼܼhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJ;AeBeEeNeUeVe3ckdط$$IfF3###36    2  24a$Ifckd$$IfF3###36    2  24aVe\eme~eeeeeckd$$IfF3###36    2  24a$Ifeeeeee3ckd$$IfF3###36    2  24a$IfckdT$$IfF3###36    2  24aeeeeeef9fckdк$$IfF3###36    2  24a$If9f:fGfqfff3ckdL$$IfF3###36    2  24a$Ifckd$$IfF3###36    2  24afff g gg=glgckd $$IfF3###36    2  24a$If g g gggqHqIqJqRqSqWqXq]q^q`qaqdqeqoqpqzq{q|qqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqĵhASehe^YOJPJ QJ^JhASehe^YOJQJ^JhASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJGqq"q&q+q.q3q>qIqPJJJJJJJ$Ifkd$$If֞2 en!B)3 <P4 362 24aIqJqSqXq^qaqeqpq{qPJJJJJJJ$Ifkd$$If֞2 en!B)3 <P4 362 24a{q|qqqqqqqqPJJJJJJJ$Ifkd$$If֞2 en!B)3 <P4 362 24aqqqqqqqqqPJJJJJJJ$Ifkd$$If֞2 en!B)3 <P4 362 24aqqqqqrrrPF@@@@@$If !$Ifkd $$If֞2 en!B)3 <P4 362 24aqqqqqrrrrrrrr(r)r,r-r5r6r7r8r9r:rErFrTrUrVr[r\rarbrirjrlrmrorpryrzrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrss s sssss!s"shASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJRrrr)r-r6r8r:rFrJkd+$$If֞2 en!B)3 <P4 362 24a$IfFrUrVr\rbrjrmrprzrJkdK$$If֞2 en!B)3 <P4 362 24a$IfzrrrrrrrrrJkdk$$If֞2 en!B)3 <P4 362 24a$IfrrrrrrrrrJkd$$If֞2 en!B)3 <P4 362 24a$Ifrrrs sss"s0sJkd$$If֞2 en!B)3 <P4 362 24a$If"s/s0s?s@sAsJsKsPsQsXsYs[s\s^s_sjsksxsyszsssssssssssssssssssssssssssssssttt tttttttttttt!t"t%t&t*t+t,t-t.t/t;tvCvDvKvLvNvOvQvRv]v^vlvmvnvsvtvzv{vvvvvvvvvvvvvhASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJRuuuuuuuuuJkd+$$If֞2 en!B)3 <P4 362 24a$IfuuuuuuuuuJkdK$$If֞2 en!B)3 <P4 362 24a$Ifuuuvv vvv!vJkdk$$If֞2 en!B)3 <P4 362 24a$If!v0v1v>vDvLvOvRv^vJkd$$If֞2 en!B)3 <P4 362 24a$If^vmvnvtv{vvvvvJkd$$If֞2 en!B)3 <P4 362 24a$IfvvvvvvvvvJkd$$If֞2 en!B)3 <P4 362 24a$Ifvvvvvvvvvvvvvvvvvvv w w w wwwwwww w)w*w-w.w6w7w8w9w:w;wFwGwUwVwWw[w\wawbwiwjwnwowtwuwwwwwwwwwwwwwwwwwwwwwwwwwwwwwhASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJRvvvvv w wwwJkd$$If֞2 en!B)3 <P4 362 24a$Ifww w*w.w7w9w;wGwJkd $$If֞2 en!B)3 <P4 362 24a$IfGwVwWw\wbwjwowuwwJkd+$$If֞2 en!B)3 <P4 362 24a$IfwwwwwwwwwJkdK$$If֞2 en!B)3 <P4 362 24a$IfwwwwwwwwwJkdk$$If֞2 en!B)3 <P4 362 24a$Ifwwwwwwwwxxxxxxxxxx x!x/x0x1x>x?xCxDxIxJxLxMxPxQxVxWxcxdxexmxnxqxrxzx{x|x}x~xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxhASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJRwwwxxxxx!xJkd$$If֞2 en!B)3 <P4 362 24a$If!x0x1x?xDxJxMxQxWxJkd $$If֞2 en!B)3 <P4 362 24a$IfWxdxexnxrx{x}xxxJkd $$If֞2 en!B)3 <P4 362 24a$IfxxxxxxxxxJkd $$If֞2 en!B)3 <P4 362 24a$IfxxxxxxxxxJkd $$If֞2 en!B)3 <P4 362 24a$IfxxxxxxxxxJkd+$$If֞2 en!B)3 <P4 362 24a$Ifxxxxxxxxxxxxxyyyyyyyyy!y"y&y'y2y3yAyByCyLyMyRySyZy[y]y^y`yaylymy{y|y}yyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyhASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJRxyyyyy"y'y3yJkdK$$If֞2 en!B)3 <P4 362 24a$If3yByCyMySy[y^yaymyJkdk$$If֞2 en!B)3 <P4 362 24a$Ifmy|y}yyyyyyyJkd$$If֞2 en!B)3 <P4 362 24a$IfyyyyyyyyyJkd$$If֞2 en!B)3 <P4 362 24a$IfyyyyyyyyyJkd$$If֞2 en!B)3 <P4 362 24a$Ifyyyyyyz z zzzzz z!z"z#z$z%z0z1z?z@zAzIzJzMzNzRzSzUzVzYzZzhzizwzxzyzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzz{{{{{{{{{{"{#{+{,{hASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJRy z zzz!z#z%z1zJkd$$If֞2 en!B)3 <P4 362 24a$If1z@zAzJzNzSzVzZzizJkd $$If֞2 en!B)3 <P4 362 24a$IfizxzyzzzzzzzJkd+$$If֞2 en!B)3 <P4 362 24a$IfzzzzzzzzzJkdK$$If֞2 en!B)3 <P4 362 24a$Ifzzz{{{{{#{Jkdk$$If֞2 en!B)3 <P4 362 24a$If#{,{-{5{<{E{G{I{U{Jkd$$If֞2 en!B)3 <P4 362 24a$If,{-{4{5{;{<{D{E{F{G{H{I{T{U{c{d{e{m{n{q{r{v{w{y{z{}{~{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{|||| | |||||||)|*|+|4|5|8|9|=|>|$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJhASehe^YCJaJRU{d{e{n{r{w{z{~{{Jkd$$If֞2 en!B)3 <P4 362 24a$If{{{{{{{{{Jkd$$If֞2 en!B)3 <P4 362 24a$If{{{{{{{{{Jkd$$If֞2 en!B)3 <P4 362 24a$If{{{|| ||||Jkd $$If֞2 en!B)3 <P4 362 24a$If|*|+|5|9|>|A|E|M|Jkd+ $$If֞2 en!B)3 <P4 362 24a$If>|@|A|D|E|L|M|[|\|]|`|a|k|l|t|u|v|w||||||||||||||||||||||||||||||||||||||||||||||||||||| } }}}}}}}"}#}$}%}&}hASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJRM|\|]|a|l|u|w|||JkdK!$$If֞2 en!B)3 <P4 362 24a$If|||||||||Jkdk"$$If֞2 en!B)3 <P4 362 24a$If|||||||||Jkd#$$If֞2 en!B)3 <P4 362 24a$If|||||||||Jkd$$$If֞2 en!B)3 <P4 362 24a$If||| }}}}#}%}Jkd%$$If֞2 en!B)3 <P4 362 24a$If%}'}(}3}:}C}E}I}K}Jkd&$$If֞2 en!B)3 <P4 362 24a$If&}'}(}2}3}9}:}B}C}D}E}H}I}J}K}L}M}N}W}X}^}_}g}h}i}j}m}n}o}p}q}r}s}{}|}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}~ hASehe^YCJOJQJ^JaJhASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJRK}M}N}X}_}h}j}n}p}Jkd ($$If֞2 en!B)3 <P4 362 24a$Ifp}r}s}|}}}}}}Jkd+)$$If֞2 en!B)3 <P4 362 24a$If}}}}}}}}}JkdK*$$If֞2 en!B)3 <P4 362 24a$If}}}}}}}}}Jkdk+$$If֞2 en!B)3 <P4 362 24a$If}}}}}~~ ~ ~Jkd,$$If֞2 en!B)3 <P4 362 24a$If~~~~ ~ ~ ~ ~~~~~~"~#~+~,~-~.~1~2~3~4~5~6~7~B~C~I~J~R~S~T~U~X~Y~Z~[~\~]~^~f~g~m~n~v~w~x~y~|~}~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~hASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJR ~~~~#~,~.~2~4~Jkd-$$If֞2 en!B)3 <P4 362 24a$If4~6~7~C~J~S~U~Y~[~Jkd.$$If֞2 en!B)3 <P4 362 24a$If[~]~^~g~n~w~y~}~~Jkd/$$If֞2 en!B)3 <P4 362 24a$If~~~~~~~~~Jkd 1$$If֞2 en!B)3 <P4 362 24a$If~~~~~~~~~Jkd+2$$If֞2 en!B)3 <P4 362 24a$If~~~~~~~~~~~~~~~~~  )*567FGMNVWYZ\]hiwxy hASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJR~~~~~~~~~JkdK3$$If֞2 en!B)3 <P4 362 24a$If~ *Jkdk4$$If֞2 en!B)3 <P4 362 24a$If*67GNWZ]iJkd5$$If֞2 en!B)3 <P4 362 24a$IfixyJkd6$$If֞2 en!B)3 <P4 362 24a$IfJkd7$$If֞2 en!B)3 <P4 362 24a$If+Jkd8$$If֞2 en!B)3 <P4 362 24a$If*+9:;LMPQYZ[\]^ijxyzĀŀǀȀπЀۀ܀*+0189;<>?HhASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJR+:;MQZ\^jJkd :$$If֞2 en!B)3 <P4 362 24a$IfjyzJkd+;$$If֞2 en!B)3 <P4 362 24a$IfŀȀЀ܀JkdK<$$If֞2 en!B)3 <P4 362 24a$If܀Jkdk=$$If֞2 en!B)3 <P4 362 24a$If+19<?IJkd>$$If֞2 en!B)3 <P4 362 24a$IfHIVWXabghoprsuvˁ́ہ܁݁  )*89:CDIJOPTUWXcdrst}~hASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJRIWXbhpsvJkd?$$If֞2 en!B)3 <P4 362 24a$If́Jkd@$$If֞2 en!B)3 <P4 362 24a$If́܁݁JkdA$$If֞2 en!B)3 <P4 362 24a$If  *Jkd C$$If֞2 en!B)3 <P4 362 24a$If*9:DJPUXdJkd+D$$If֞2 en!B)3 <P4 362 24a$Ifdst~JkdKE$$If֞2 en!B)3 <P4 362 24a$IfĂłǂȂʂ˂ւׂ !",-1278:;>?MN\]^lmrsz{~hASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJRłȂ˂ׂJkdkF$$If֞2 en!B)3 <P4 362 24a$IfׂJkdG$$If֞2 en!B)3 <P4 362 24a$If!"-28;?NJkdH$$If֞2 en!B)3 <P4 362 24a$IfN]^ms{JkdI$$If֞2 en!B)3 <P4 362 24a$If̃JkdJ$$If֞2 en!B)3 <P4 362 24a$If˃̃ڃۃ܃ &',-0156=>EFGRSWX]^`adestńƄ̈́΄ЄфӄԄՄքׄ؄لhASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJR̃ۃ܃Jkd L$$If֞2 en!B)3 <P4 362 24a$If '-16>Jkd+M$$If֞2 en!B)3 <P4 362 24a$If>FGSX^aetJkdKN$$If֞2 en!B)3 <P4 362 24a$IftJkdkO$$If֞2 en!B)3 <P4 362 24a$IfƄ΄фԄքJkdP$$If֞2 en!B)3 <P4 362 24a$Ifք؄لJkdQ$$If֞2 en!B)3 <P4 362 24a$If  !#$/0>?@JKPQXY[\^_jkyz{…ÅąŅх҅hASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJR !$0JkdR$$If֞2 en!B)3 <P4 362 24a$If0?@KQY\_kJkdS$$If֞2 en!B)3 <P4 362 24a$Ifkz{Jkd U$$If֞2 en!B)3 <P4 362 24a$IfÅŅ҅Jkd+V$$If֞2 en!B)3 <P4 362 24a$If҅ JkdKW$$If֞2 en!B)3 <P4 362 24a$If "#&'/03489GHVWX^_bcklmnop{|ȆɆΆφֆ׆چۆ߆   !*+89:BhASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJR #'049HJkdkX$$If֞2 en!B)3 <P4 362 24a$IfHWX_clnp|JkdY$$If֞2 en!B)3 <P4 362 24a$If|JkdZ$$If֞2 en!B)3 <P4 362 24a$IfɆφ׆ۆJkd[$$If֞2 en!B)3 <P4 362 24a$If !+Jkd\$$If֞2 en!B)3 <P4 362 24a$If+9:CIQTV`Jkd ^$$If֞2 en!B)3 <P4 362 24a$IfBCHIPQSTUV_`mnowx~‡ɇʇ͇̇ч҇݇އ  +,-0145=>?@ABIJQRSZ[^_bcefhASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJR`noxJkd+_$$If֞2 en!B)3 <P4 362 24a$If‡ʇ͇҇އJkdK`$$If֞2 en!B)3 <P4 362 24a$Ifއ Jkdka$$If֞2 en!B)3 <P4 362 24a$If,-15>@BJJkdb$$If֞2 en!B)3 <P4 362 24a$IfJRS[_cfiwJkdc$$If֞2 en!B)3 <P4 362 24a$IffhivwˆÈƈLjψЈш҈ӈԈ߈ #$%*+0189<=ABKLYZ[`afgnoqrtuz{hASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJRwJkdd$$If֞2 en!B)3 <P4 362 24a$IfÈLjЈ҈ԈJkde$$If֞2 en!B)3 <P4 362 24a$If Jkd g$$If֞2 en!B)3 <P4 362 24a$If$%+19=BLJkd+h$$If֞2 en!B)3 <P4 362 24a$IfLZ[agoru{JkdKi$$If֞2 en!B)3 <P4 362 24a$If{Jkdkj$$If֞2 en!B)3 <P4 362 24a$IfʼnƉȉɉ͉̉ԉՉ߉#$&'*+9:HIJXY\]efijnowxhASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJRƉɉ͉ՉJkdk$$If֞2 en!B)3 <P4 362 24a$IfՉJkdl$$If֞2 en!B)3 <P4 362 24a$If$'+:Jkdm$$If֞2 en!B)3 <P4 362 24a$If:IJY]fjoxJkdn$$If֞2 en!B)3 <P4 362 24a$IfxJkd p$$If֞2 en!B)3 <P4 362 24a$IfĊŊƊЊъ$%,-0156>?NOPZ[`ahiklpq{|͋(hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJBŊƊъJkd+q$$If֞2 en!B)3 <P4 362 24a$If%-16?JkdKr$$If֞2 en!B)3 <P4 362 24a$If?OP[ailq|Jkdks$$If֞2 en!B)3 <P4 362 24a$If|Jkdt$$If֞2 en!B)3 <P4 362 24a$If΋ϋ݋Jkdu$$If֞2 en!B)3 <P4 362 24a$If͋΋ϋ܋݋#$%459:?@BCFGUVdefnors{|~ŒÌьҌɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶhASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH C$%5:@CGVJkdv$$If֞2 en!B)3 <P4 362 24a$IfVefos|Jkdw$$If֞2 en!B)3 <P4 362 24a$IfÌҌJkd y$$If֞2 en!B)3 <P4 362 24a$IfҌJkd+z$$If֞2 en!B)3 <P4 362 24a$If #$,-./01<=KLMTU\]mnopqr}~Ѝэҍ֍׍ڍۍߍ  hASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJR $-/1=JkdK{$$If֞2 en!B)3 <P4 362 24a$If=LMU]npr~Jkdk|$$If֞2 en!B)3 <P4 362 24a$If~Jkd}$$If֞2 en!B)3 <P4 362 24a$Ifэҍ׍ۍJkd~$$If֞2 en!B)3 <P4 362 24a$If Jkd$$If֞2 en!B)3 <P4 362 24a$If    #$45GHUVbcdmnqrz{~ĎŎʎˎ͎̎Ύώ֎׎ގߎ hASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJR   $5HVJkd$$If֞2 en!B)3 <P4 362 24a$IfVcdnr{Jkd $$If֞2 en!B)3 <P4 362 24a$IfJkd+$$If֞2 en!B)3 <P4 362 24a$IfŎˎ͎ώ׎JkdK$$If֞2 en!B)3 <P4 362 24a$If׎ߎJkdk$$If֞2 en!B)3 <P4 362 24a$If !%4Jkd$$If֞2 en!B)3 <P4 362 24a$If !$%34BCDMNUV[\^_cdklstu}~Ïď̏͏ϏЏҏӏۏ܏   $%&'()*hASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJR4CDNV\_dlJkd$$If֞2 en!B)3 <P4 362 24a$Ifltu~Jkdˈ$$If֞2 en!B)3 <P4 362 24a$Ifď͏Џӏ܏Jkd$$If֞2 en!B)3 <P4 362 24a$If܏ Jkd $$If֞2 en!B)3 <P4 362 24a$If%')+Jkd+$$If֞2 en!B)3 <P4 362 24a$If*+,-.4589ABCDEFQR`abklqrxy|}ĐŐӐԐՐڐېސߐ #$,-/023DE[\]eflhASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJR+-.59BDFRJkdK$$If֞2 en!B)3 <P4 362 24a$IfRablry}Jkdk$$If֞2 en!B)3 <P4 362 24a$IfŐJkd$$If֞2 en!B)3 <P4 362 24a$IfŐԐՐېߐJkd$$If֞2 en!B)3 <P4 362 24a$If $-03EJkdˑ$$If֞2 en!B)3 <P4 362 24a$IfE\]fmvyJkd$$If֞2 en!B)3 <P4 362 24a$IflmuvxyƑǑґӑԑߑ !#$'(67EFGOPTUZ[]^abrshASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJRǑJkd $$If֞2 en!B)3 <P4 362 24a$IfǑӑԑJkd+$$If֞2 en!B)3 <P4 362 24a$If!$(7JkdK$$If֞2 en!B)3 <P4 362 24a$If7FGPU[^bsJkdk$$If֞2 en!B)3 <P4 362 24a$IfsJkd$$If֞2 en!B)3 <P4 362 24a$If’ÒȒɒ˒̒Βϒ֒גޒߒ  $%,-235689@AHIJRSYZbcefklvwÓēhASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJRÒɒ̒ϒגJkd$$If֞2 en!B)3 <P4 362 24a$Ifגߒ Jkd˚$$If֞2 en!B)3 <P4 362 24a$If %-369AJkd$$If֞2 en!B)3 <P4 362 24a$IfAIJSZcflwJkd $$If֞2 en!B)3 <P4 362 24a$IfwJkd+$$If֞2 en!B)3 <P4 362 24a$IfēʓғՓؓJkdK$$If֞2 en!B)3 <P4 362 24a$IfēɓʓѓғԓՓדؓ     '()4589ABCDEFQR`abghlmrsuvyzƔǔӔԔՔݔޔhASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJR   Jkdk$$If֞2 en!B)3 <P4 362 24a$If()59BDFRJkd$$If֞2 en!B)3 <P4 362 24a$IfRabhmsvzJkd$$If֞2 en!B)3 <P4 362 24a$IfǔJkdˣ$$If֞2 en!B)3 <P4 362 24a$IfǔԔՔޔJkd$$If֞2 en!B)3 <P4 362 24a$If  !$%./9:;FGLMRSZ[`ajkuvwϕЕ  $%-./5hASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJR!%/Jkd $$If֞2 en!B)3 <P4 362 24a$If/:;GMS[akJkd+$$If֞2 en!B)3 <P4 362 24a$IfkvwJkdK$$If֞2 en!B)3 <P4 362 24a$IfЕJkdk$$If֞2 en!B)3 <P4 362 24a$If %Jkd$$If֞2 en!B)3 <P4 362 24a$If%./6;ADHRJkd$$If֞2 en!B)3 <P4 362 24a$If56:;@ACDGHQR\]^deijoprsvwÖĖŖΖϖӖԖٖږܖݖ  *+>(hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJDR]^ejpswJkdˬ$$If֞2 en!B)3 <P4 362 24a$IfJkd$$If֞2 en!B)3 <P4 362 24a$IfĖŖϖԖږݖJkd $$If֞2 en!B)3 <P4 362 24a$If +?IJkd+$$If֞2 en!B)3 <P4 362 24a$If>?HISTUefwxėŗʗ˗͗Ηїҗۗܗ  0167<=?@CDMNXYZfghijklźźźźźhASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJ,hASehe^YCJOJPJ QJ^JaJmH sH IITUfxJkdK$$If֞2 en!B)3 <P4 362 24a$Ifŗ˗ΗҗܗJkdk$$If֞2 en!B)3 <P4 362 24a$Ifܗ Jkd$$If֞2 en!B)3 <P4 362 24a$If 17=@DNJkd$$If֞2 en!B)3 <P4 362 24a$IfNYZgikmoqJkd˵$$If֞2 en!B)3 <P4 362 24a$IflmnopqrstŘƘȘɘ̘֘͘ט$%/01?@HIQRSTUV_`jkltuxy}~hASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJRqstJkd$$If֞2 en!B)3 <P4 362 24a$IfƘɘ͘טJkd $$If֞2 en!B)3 <P4 362 24a$Ifט%Jkd+$$If֞2 en!B)3 <P4 362 24a$If%01@IRTV`JkdK$$If֞2 en!B)3 <P4 362 24a$If`kluy~Jkdk$$If֞2 en!B)3 <P4 362 24a$IfęǙ˙ՙJkd$$If֞2 en!B)3 <P4 362 24a$IfÙęƙǙʙ˙ԙՙߙ   #$()*+,-89GHISTWX\]hitu˚̚њҚٚښ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJhASehe^YCJaJRՙ Jkd$$If֞2 en!B)3 <P4 362 24a$If  $)+-9Jkd˾$$If֞2 en!B)3 <P4 362 24a$If9HITX]iuJkd$$If֞2 en!B)3 <P4 362 24a$IfJkd $$If֞2 en!B)3 <P4 362 24a$If̚ҚښݚJkd+$$If֞2 en!B)3 <P4 362 24a$Ifښܚݚ '(345:;>?CDEFGHSTbcdmnqrvwxyz{PQ ʽʽhASehe^Y6]hASehe^YjhASehe^YU hASehe^YhASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJA(JkdK$$If֞2 en!B)3 <P4 362 24a$If(45;?DFHTJkdk$$If֞2 en!B)3 <P4 362 24a$IfTcdnrwy{Jkd$$If֞2 en!B)3 <P4 362 24a$IfR JHFHHkd$$If֞2 en!B)3 <P4 362 24a$If  [\qrȞɞʞڞ۞  ,-.=>LMN]^lmnɟʟʴʴ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJhASehe^YCJaJ*hASehe^Y5CJOJPJ QJ\^JaJ&hASehe^Y5CJOJQJ\^JaJ hASehe^YhASehe^YB*EHphjhASehe^YEHU4 [\r~lkd$$If40-''4 .62 24ap$If $ d]ɞʞ۞YPkd$$If0-##.62 24a$IfPkd$$If0-##.62 24a -YPkd$$If0-##.62 24a$IfPkd;$$If0-##.62 24a-.>MN^mYPkdK$$If0-##.62 24a$IfPkd$$If0-##.62 24amnʟYPkd$$If0-##.62 24a$IfPkd$$If0-##.62 24a$YPkd $$If0-##.62 24a$IfPkd[$$If0-##.62 24a#$%CDabc۠ܠݠ"#:;<KL]^_fgtuváġš̡͡ԡա֡ $hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJhASehe^YCJaJR$%DbcYPkdk$$If0-##.62 24a$IfPkd$$If0-##.62 24aܠݠYPkd$$If0-##.62 24a$IfPkd$$If0-##.62 24a#;YPkd+$$If0-##.62 24a$IfPkd{$$If0-##.62 24a;<L^_guYPkd$$If0-##.62 24a$IfPkd$$If0-##.62 24auvYPkd$$If0-##.62 24a$IfPkd;$$If0-##.62 24aġš͡աYPkdK$$If0-##.62 24a$IfPkd$$If0-##.62 24aա֡ YPkd$$If0-##.62 24a$IfPkd$$If0-##.62 24a !+6YPkd $$If0-##.62 24a$IfPkd[$$If0-##.62 24a !*+567=>JKLWXcdeqr}~¢ҢӢԢܢݢ  *+CDEMNXYZklhASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJR67>KLXdYPkdk$$If0-##.62 24a$IfPkd$$If0-##.62 24ader~YPkd$$If0-##.62 24a$IfPkd$$If0-##.62 24aYPkd+$$If0-##.62 24a$IfPkd{$$If0-##.62 24a¢ӢԢݢYPkd$$If0-##.62 24a$IfPkd$$If0-##.62 24a YPkd$$If0-##.62 24a$IfPkd;$$If0-##.62 24a+DENYYPkdK$$If0-##.62 24a$IfPkd$$If0-##.62 24aYZlYPkd$$If0-##.62 24a$IfPkd$$If0-##.62 24aϣޣYPkd $$If0-##.62 24a$IfPkd[$$If0-##.62 24aΣϣݣޣߣ #$%34BCDJKZ[\fgtuvʤˤ̤  $%&34ABCKLWXYmnĵĵhASehe^YOJPJ QJ^JhASehe^YOJQJ^J hASehe^YCJOJQJ^JaJhASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJGޣߣYPkdk$$If0-##.62 24a$IfPkd$$If0-##.62 24a$%4CYPkd$$If0-##.62 24a$IfPkd$$If0-##.62 24aCDK[\guYPkd+$$If0-##.62 24a$IfPkd{$$If0-##.62 24auvˤYPkd$$If0-##.62 24a$IfPkd$$If0-##.62 24aˤ̤ %YOO !$IfPkd$$If0-##.62 24a$IfPkd;$$If0-##.62 24a%&4BCLXYPkdK$$If0-##.62 24a$IfPkd$$If0-##.62 24aXYnYPkd$$If0-##.62 24a$IfPkd$$If0-##.62 24aȥɥե֥ץ !/01=>JKLYZfghpqyz{ɦʦ!"#+$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJhASehe^YCJaJRɥ֥YPkd $$If0-##.62 24a$IfPkd[$$If0-##.62 24a֥ץYPkdk$$If0-##.62 24a$IfPkd$$If0-##.62 24a!0YPkd$$If0-##.62 24a$IfPkd$$If0-##.62 24a01>KLZgYPkd+$$If0-##.62 24a$IfPkd{$$If0-##.62 24aghqz{YPkd$$If0-##.62 24a$IfPkd$$If0-##.62 24aYPkd$$If0-##.62 24a$IfPkd;$$If0-##.62 24aʦYPkdK$$If0-##.62 24a$IfPkd$$If0-##.62 24a"#,8YPkd$$If0-##.62 24a$IfPkd$$If0-##.62 24a+,789KL^_`no}~ǧȧէ֧ק&'234=>JKLVWabcstĵĵhASehe^YOJPJ QJ^JhASehe^YOJQJ^JhASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJG89L_`o~YPkd $$If0-##.62 24a$IfPkd[$$If0-##.62 24a~YPkdk$$If0-##.62 24a$IfPkd$$If0-##.62 24aȧ֧קYPkd$$If0-##.62 24a$IfPkd$$If0-##.62 24a'3YPkd+$$If0-##.62 24a$IfPkd{$$If0-##.62 24a34>KLWbYPkd$$If0-##.62 24a$IfPkd$$If0-##.62 24abctYOO !$IfPkd$$If0-##.62 24a$IfPkd;$$If0-##.62 24aɨYPkdK$$If0-##.62 24a$IfPkd$$If0-##.62 24aȨɨʨ٨ڨ#$%-.9:;IJXYZderst|}Ωϩݩީߩ   #$,-.:;GHIRS]^_lmz{hASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJRɨʨڨYPkd $$If0-##.62 24a$IfPkd$$If0-##.62 24a$%.:YPkd $$If0-##.62 24a$IfPkd[ $$If0-##.62 24a:;JYZesYPkdk $$If0-##.62 24a$IfPkd $$If0-##.62 24ast}YPkd $$If0-##.62 24a$IfPkd $$If0-##.62 24aϩީYPkd+$$If0-##.62 24a$IfPkd{$$If0-##.62 24aީߩ  YPkd$$If0-##.62 24a$IfPkd$$If0-##.62 24a$-.;HYPkd$$If0-##.62 24a$IfPkd;$$If0-##.62 24aHIS^_m{YPkdK$$If0-##.62 24a$IfPkd$$If0-##.62 24a{|ĪYPkd$$If0-##.62 24a$IfPkd$$If0-##.62 24a{|êĪŪϪЪݪުߪ  &'/01IJabcop|}~ëīūΫϫ۫ܫݫ ,-.;<IJKd$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJhASehe^YCJaJRĪŪЪުߪYPkd $$If0-##.62 24a$IfPkd[$$If0-##.62 24a '0YPkdk$$If0-##.62 24a$IfPkd$$If0-##.62 24a01Jbcp}YPkd$$If0-##.62 24a$IfPkd$$If0-##.62 24a}~YPkd+$$If0-##.62 24a$IfPkd{$$If0-##.62 24aīūϫܫYPkd$$If0-##.62 24a$IfPkd$$If0-##.62 24aܫݫYPkd$$If0-##.62 24a$IfPkd;$$If0-##.62 24a -.<JYPkdK$$If0-##.62 24a$IfPkd$$If0-##.62 24aJKe{|YPkd$$If0-##.62 24a$IfPkd$$If0-##.62 24adez{|٬ڬ۬"#012?@MNOYZghiЭѭҭ123LMghihASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJ;ڬ۬YPkd !$$If0-##.62 24a$IfPkd[ $$If0-##.62 24a#1YPkdk"$$If0-##.62 24a$IfPkd!$$If0-##.62 24a12@NOZhYPkd#$$If0-##.62 24a$IfPkd#$$If0-##.62 24ahiѭҭYPkd+%$$If0-##.62 24a$IfPkd{$$$If0-##.62 24a23MhYPkd&$$If0-##.62 24a$IfPkd%$$If0-##.62 24ahiЮYPkd'$$If0-##.62 24a$IfPkd;'$$If0-##.62 24aiϮЮѮ  #$?@AWXpqrȯɯʯٯگ*+,89EFǰǰǰǰǰܖܖܖܖܖܖhASehe^YCJaJhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH $hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJ;ЮѮ  $@YPkdK)$$If0-##.62 24a$IfPkd($$If0-##.62 24a@AXqrYPkd*$$If0-##.62 24a$IfPkd)$$If0-##.62 24aɯYPkd ,$$If0-##.62 24a$IfPkd[+$$If0-##.62 24aɯʯگYPkdk-$$If0-##.62 24a$IfPkd,$$If0-##.62 24a+,9FYPkd.$$If0-##.62 24a$IfPkd.$$If0-##.62 24aFGYlmyYPkd+0$$If0-##.62 24a$IfPkd{/$$If0-##.62 24aFGXYklmxyʰ˰߰)*<=>XYpqr VWSTʽʽʝj[6hASehe^YEHUhASehe^Y6]hASehe^YjhASehe^YU hASehe^Y$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJhASehe^YCJaJ:˰YPkd1$$If0-##.62 24a$IfPkd0$$If0-##.62 24aYPkd2$$If0-##.62 24a$IfPkd;2$$If0-##.62 24a*=>YqYPkdK4$$If0-##.62 24a$IfPkd3$$If0-##.62 24aqrXYSYWWUWWPkd5$$If0-##.62 24a$IfPkd4$$If0-##.62 24a SӴԴش[kd;$$If4F5'@' 56    2 24ap$If $ d] TҴӴԴ״ش&'(*+45BCDFGcd}fWhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH $hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJhASehe^YCJaJ*hASehe^Y5CJOJPJ QJ\^JaJ&hASehe^Y5CJOJQJ\^JaJ hASehe^YhASehe^YB*EHph"'$Ifhkd<$$IfF5###56    2 24a'(+5C$IfhkdU=$$IfF5###56    2 24aCDGd$Ifhkd>$$IfF5###56    2 24adҵӵ56JKLOPgh|}~ضٶ   012ŴŴŴŴŴŴŴŴhASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH ;$Ifhkd>$$IfF5###56    2 24aӵ$Ifhkd?$$IfF5###56    2 24a$IfhkdM@$$IfF5###56    2 24a6K$Ifhkd A$$IfF5###56    2 24aKLPh}$IfhkdA$$IfF5###56    2 24a}~$IfhkdB$$IfF5###56    2 24aٶ$IfhkdEC$$IfF5###56    2 24a  1$IfhkdD$$IfF5###56    2 24a128V~$IfhkdD$$IfF5###56    2 24a278UV}~ŷƷշַ׷ٷڷ !"78UVW[\noǰܖܖܖܖǰǰǰhASehe^YCJaJhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH $hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJ;~$IfhkdE$$IfF5###56    2 24aƷַ$Ifhkd=F$$IfF5###56    2 24aַ׷ڷ$IfhkdF$$IfF5###56    2 24a$IfhkdG$$IfF5###56    2 24a"8V$IfhkdwH$$IfF5###56    2 24aVW\o$Ifhkd5I$$IfF5###56    2 24a$IfhkdI$$IfF5###56    2 24a$IfhkdJ$$IfF5###56    2 24a$%34589CDPQRTU`apqruvιϹܹݹ޹)*+-.=>NOPUV(hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJH%4$IfhkdoK$$IfF5###56    2 24a459DQ$Ifhkd-L$$IfF5###56    2 24aQRUaq$IfhkdL$$IfF5###56    2 24aqrv$IfhkdM$$IfF5###56    2 24a$IfhkdgN$$IfF5###56    2 24aϹݹ$Ifhkd%O$$IfF5###56    2 24aݹ޹$IfhkdO$$IfF5###56    2 24a*$IfhkdP$$IfF5###56    2 24a*+.>O$Ifhkd_Q$$IfF5###56    2 24aOPV$IfhkdR$$IfF5###56    2 24aźƺǺʺ˺ںۺ #$789;<MN_`ade»ŻƻٻڻɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶhASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH Cƺ$IfhkdR$$IfF5###56    2 24aƺǺ˺ۺ$IfhkdS$$IfF5###56    2 24a$IfhkdWT$$IfF5###56    2 24a$8$IfhkdU$$IfF5###56    2 24a89<N`$IfhkdU$$IfF5###56    2 24a`ae$IfhkdV$$IfF5###56    2 24a$IfhkdOW$$IfF5###56    2 24a»ƻڻ$Ifhkd X$$IfF5###56    2 24a$IfhkdX$$IfF5###56    2 24a-;$IfhkdY$$IfF5###56    2 24a,-:;<?@JKXYZ]^hivwx{|мѼ56TUVXYde|ܼܼhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJ;;<@KY$IfhkdGZ$$IfF5###56    2 24aYZ^iw$Ifhkd[$$IfF5###56    2 24awx|$Ifhkd[$$IfF5###56    2 24a$Ifhkd\$$IfF5###56    2 24aѼ$Ifhkd?]$$IfF5###56    2 24a$Ifhkd]$$IfF5###56    2 24a6U$Ifhkd^$$IfF5###56    2 24aUVYe}$Ifhkdy_$$IfF5###56    2 24a|}~ʽ˽̽Ͻн)*+-.=>RSTWXqr˾̾,-<=>AhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJOJQJ^JaJhASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ;}~˽$Ifhkd7`$$IfF5###56    2 24a˽̽н*$Ifhkd`$$IfF5###56    2 24a*+.>S$Ifhkda$$IfF5###56    2 24aSTXr$Ifhkdqb$$IfF5###56    2 24a$Ifhkd/c$$IfF5###56    2 24a̾$Ifhkdc$$IfF5###56    2 24a$Ifhkdd$$IfF5###56    2 24a-=$Ifhkdie$$IfF5###56    2 24a=>BKT$Ifhkd'f$$IfF5###56    2 24aABJKSTU[\ۿܿ #$,-567:;UVvwxz{hASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJ;TU\$Ifhkdf$$IfF5###56    2 24aܿ$Ifhkdg$$IfF5###56    2 24a$Ifhkdah$$IfF5###56    2 24a $-6$Ifhkdi$$IfF5###56    2 24a67;Vw$Ifhkdi$$IfF5###56    2 24awx{$Ifhkdj$$IfF5###56    2 24a$IfhkdYk$$IfF5###56    2 24a$Ifhkdl$$IfF5###56    2 24a!"/0=>?BCQR`abdeuv23478RSmnotuܼܼܼܼܼhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJ;$Ifhkdl$$IfF5###56    2 24a"0>$Ifhkdm$$IfF5###56    2 24a>?CRa$IfhkdQn$$IfF5###56    2 24aabev$Ifhkdo$$IfF5###56    2 24a$Ifhkdo$$IfF5###56    2 24a3$Ifhkdp$$IfF5###56    2 24a348Sn$IfhkdIq$$IfF5###56    2 24anou$Ifhkdr$$IfF5###56    2 24a$Ifhkdr$$IfF5###56    2 24a$%,-.12de%&?@ACDTUcdeklwǰܖǰܖܖܖǰܖhASehe^YCJaJhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH $hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJ;%-$Ifhkds$$IfF5###56    2 24a-.2e$IfhkdAt$$IfF5###56    2 24a$Ifhkdt$$IfF5###56    2 24a$Ifhkdu$$IfF5###56    2 24a$Ifhkd{v$$IfF5###56    2 24a&@$Ifhkd9w$$IfF5###56    2 24a@ADUd$Ifhkdw$$IfF5###56    2 24adelx$Ifhkdx$$IfF5###56    2 24awx'(NOPSTdevwxz{hASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJ;$Ifhkdsy$$IfF5###56    2 24a$Ifhkd1z$$IfF5###56    2 24a$Ifhkdz$$IfF5###56    2 24a(O$Ifhkd{$$IfF5###56    2 24aOPTew$Ifhkdk|$$IfF5###56    2 24awx{$Ifhkd)}$$IfF5###56    2 24a$Ifhkd}$$IfF5###56    2 24a$Ifhkd~$$IfF5###56    2 24a $Ifhkdc$$IfF5###56    2 24a  )*+01bc  >?qrsuvѼѼѼhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH $hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJhASehe^YCJaJ; *$Ifhkd!$$IfF5###56    2 24a*+1c$Ifhkd߀$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a ?r$Ifhkd[$$IfF5###56    2 24arsv$Ifhkd$$IfF5###56    2 24a$Ifhkd׃$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a$IfhkdS$$IfF5###56    2 24a   !"789<=IJfghijnostuwx  23[\]abܼܼܼhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJ;  "8$Ifhkd$$IfF5###56    2 24a89=Jg$Ifhkdφ$$IfF5###56    2 24aghjot$Ifhkd$$IfF5###56    2 24atux$IfhkdK$$IfF5###56    2 24a$Ifhkd $$IfF5###56    2 24a$Ifhkdlj$$IfF5###56    2 24a 3\$Ifhkd$$IfF5###56    2 24a\]b$IfhkdC$$IfF5###56    2 24a)*QRSWXqyz!"JKLPQwxɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶ(hASehe^YCJOJQJ^JaJmHsH(hASehe^YCJOJQJ^JaJmH sH $hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH 7$Ifhkd$$IfF5###56    2 24a*R$Ifhkd$$IfF5###56    2 24aRSXz$Ifhkd}$$IfF5###56    2 24a$Ifhkd;$$IfF5###56    2 24a"K$Ifhkd$$IfF5###56    2 24aKLQx$Ifhkd$$IfF5###56    2 24a$Ifhkdu$$IfF5###56    2 24a H$Ifhkd3$$IfF5###56    2 24a GHILMgh#$VW햡햡햡hASehe^YCJaJ hASehe^YCJOJQJ^JaJhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH $hASehe^YCJOJPJ QJ^JaJ;HIMh$Ifhkd$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a$Ifhkdm$$IfF5###56    2 24a$Ifhkd+$$IfF5###56    2 24a$W$Ifhkd$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a$Ifhkde$$IfF5###56    2 24a$Ifhkd#$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a &'01267JKbcdij   ѼѼhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH $hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJhASehe^YCJaJ;$Ifhkd$$IfF5###56    2 24a$Ifhkd]$$IfF5###56    2 24a'1$Ifhkd$$IfF5###56    2 24a127Kc$Ifhkdٚ$$IfF5###56    2 24acdj$Ifhkd$$IfF5###56    2 24a$IfhkdU$$IfF5###56    2 24a $Ifhkd$$IfF5###56    2 24a  Do$Ifhkdѝ$$IfF5###56    2 24aCDnopst 23]^_abz{DEFHIuvǰǰǰǰǰǰǰǰhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH $hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJHISTUXYdersthASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJR56:FR$Ifhkd-$$IfF5###56    2 24aRSWco$Ifhkd$$IfF5###56    2 24aopt$Ifhkd$$IfF5###56    2 24a$Ifhkdg$$IfF5###56    2 24a$Ifhkd%$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a $Ifhkd_$$IfF5###56    2 24a,:$Ifhkd$$IfF5###56    2 24a:;>IT$Ifhkd۱$$IfF5###56    2 24aTUYes$Ifhkd$$IfF5###56    2 24astw$IfhkdW$$IfF5###56    2 24atvw#$%()BC^_`bcpq|}~$hASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJR$Ifhkd$$IfF5###56    2 24a$IfhkdӴ$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a$$IfhkdO$$IfF5###56    2 24a$%)C_$Ifhkd $$IfF5###56    2 24a_`cq}$Ifhkd˷$$IfF5###56    2 24a}~$Ifhkd$$IfF5###56    2 24a$IfhkdG$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a$Ifhkdú$$IfF5###56    2 24a%$Ifhkd$$IfF5###56    2 24a$%&)*78EFGJKUV_`ade()*/0?@OPQUhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJOJQJ^JaJhASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ;%&*8F$Ifhkd?$$IfF5###56    2 24aFGKV`$Ifhkd$$IfF5###56    2 24a`ae$Ifhkd$$IfF5###56    2 24a$Ifhkdy$$IfF5###56    2 24a$Ifhkd7$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a)$Ifhkd$$IfF5###56    2 24a)*0@P$Ifhkdq$$IfF5###56    2 24aPQVfz$Ifhkd/$$IfF5###56    2 24aUVefyz{&'2349:FGTUVZ[fgvwx{|hASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJ;z{$Ifhkd$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a$Ifhkdi$$IfF5###56    2 24a$Ifhkd'$$IfF5###56    2 24a'3$Ifhkd$$IfF5###56    2 24a34:GU$Ifhkd$$IfF5###56    2 24aUV[gw$Ifhkda$$IfF5###56    2 24awx|$Ifhkd$$IfF5###56    2 24a)*678;<OPghiklܼܼhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJ;$Ifhkd$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a*7$IfhkdY$$IfF5###56    2 24a78<Ph$Ifhkd$$IfF5###56    2 24ahil$Ifhkd$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a$IfhkdQ$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a $Ifhkd$$IfF5###56    2 24a !$%12FGHLMdeyz{~*+,/0<=JKLPQaܼhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJ; !%2G$Ifhkd$$IfF5###56    2 24aGHMez$IfhkdI$$IfF5###56    2 24az{$Ifhkd$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a+$IfhkdA$$IfF5###56    2 24a+,0=K$Ifhkd$$IfF5###56    2 24aKLQbu$Ifhkd$$IfF5###56    2 24aabtuv|}  567:;IJghimnhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJ;uv}$Ifhkd{$$IfF5###56    2 24a$Ifhkd9$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a 6$Ifhkds$$IfF5###56    2 24a67;Jh$Ifhkd1$$IfF5###56    2 24ahin$Ifhkd$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24aE$Ifhkdk$$IfF5###56    2 24aDEFIJTUdefjk   $%&)*>?TUVXY͸͖͖͖͖͖͖͖hASehe^YCJaJ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH $hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJhASehe^YCJaJmH sH ;EFJUe$Ifhkd)$$IfF5###56    2 24aefk$Ifhkd$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a$Ifhkdc$$IfF5###56    2 24a $Ifhkd!$$IfF5###56    2 24a  %$Ifhkd$$IfF5###56    2 24a%&*?U$Ifhkd$$IfF5###56    2 24aUVYbm$Ifhkd[$$IfF5###56    2 24aYablmnst89:?@LM]^_cdܼ܁j[hASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJ#mnt$Ifhkd$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a9$Ifhkd$$IfF5###56    2 24a9:@M^$IfhkdS$$IfF5###56    2 24a^_dr$Ifhkd$$IfF5###56    2 24adqr  "#,-;<=@AJKVWX[\kl}~hASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJR$Ifhkd$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a$IfhkdK$$IfF5###56    2 24a $Ifhkd $$IfF5###56    2 24a#-<$Ifhkd$$IfF5###56    2 24a<=AKW$Ifhkd$$IfF5###56    2 24aWX\l~$IfhkdC$$IfF5###56    2 24a~$Ifhkd$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a$Ifhkd}$$IfF5###56    2 24a$Ifhkd;$$IfF5###56    2 24a(G$Ifhkd$$IfF5###56    2 24a'(FGHKLef   =>ghijkoptuvxyǰǰܖܖܖǰܖܖhASehe^YCJaJhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH $hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJ;GHLf$Ifhkd$$IfF5###56    2 24a$Ifhkdu$$IfF5###56    2 24a$Ifhkd3$$IfF5###56    2 24a $Ifhkd$$IfF5###56    2 24a  >h$Ifhkd$$IfF5###56    2 24ahikpu$Ifhkdm$$IfF5###56    2 24auvy$Ifhkd+$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a   "#'(12356=>JKLOPlmhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJ;$Ifhkd$$IfF5###56    2 24a$Ifhkde$$IfF5###56    2 24a $Ifhkd#$$IfF5###56    2 24a #(2$Ifhkd$$IfF5###56    2 24a236>K$Ifhkd$$IfF5###56    2 24aKLPm$Ifhkd]$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a$%&)*56FGHKLSTYZ[ab  ѼѼhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH $hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJhASehe^YCJaJ;%$IfhkdU$$IfF5###56    2 24a%&*6G$Ifhkd$$IfF5###56    2 24aGHLTZ$Ifhkd$$IfF5###56    2 24aZ[b$Ifhkd$$IfF5###56    2 24a$IfhkdM$$IfF5###56    2 24a$Ifhkd $$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a -$Ifhkd$$IfF5###56    2 24a ,-.34STrstwx567:;HI^_`bcpq=>`ܼܼܼܼܼܼhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJ;-.4Ts$IfhkdE$$IfF5###56    2 24astx$Ifhkd$$IfF5###56    2 24a6$Ifhkd$$IfF5###56    2 24a67;I_$Ifhkd$$IfF5###56    2 24a_`cq$Ifhkd=$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a>a$Ifhkdw$$IfF5###56    2 24a`abefmnuvwz{&'@ABCDKLWXY]^!"89STUWɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶ(hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH ;abfnv$Ifhkd5$$IfF5###56    2 24avw{$Ifhkd$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a'A$Ifhkdo $$IfF5###56    2 24aABDLX$Ifhkd- $$IfF5###56    2 24aXY^$Ifhkd $$IfF5###56    2 24a$Ifhkd $$IfF5###56    2 24a"9T$Ifhkdg $$IfF5###56    2 24aTUXZ\$Ifhkd% $$IfF5###56    2 24aWXYZ[\]_`z{   $%-.@ABDERShASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJ;\]`{$Ifhkd $$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a$Ifhkd_$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a $Ifhkd$$IfF5###56    2 24a %.A$IfhkdW$$IfF5###56    2 24aABESd$Ifhkd$$IfF5###56    2 24aScdeghuv#$YZ[bcܼܼܼhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJ;dehv$Ifhkd$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a$IfhkdO$$IfF5###56    2 24a$Z$Ifhkd $$IfF5###56    2 24aZ[c$Ifhkd$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a$IfhkdG$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a/b$Ifhkd$$IfF5###56    2 24a./abcgh89:;<ABFGHMN]^lmnrsǰǰǰܖܖܖܖܖhASehe^YCJaJhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH $hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJ;bch$Ifhkd$$IfF5###56    2 24a9$Ifhkd?$$IfF5###56    2 24a9:<BG$Ifhkd$$IfF5###56    2 24aGHN^m$Ifhkd$$IfF5###56    2 24amns$Ifhkdy$$IfF5###56    2 24a$Ifhkd7$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a$Ifhkd$$IfF5###56    2 24a '(),-:;GHILM\]klmqr '(4569:IJUVWZ[jkyz{~hASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJR ($Ifhkdq $$IfF5###56    2 24a()-;H$Ifhkd/!$$IfF5###56    2 24aHIM]l$Ifhkd!$$IfF5###56    2 24almr$Ifhkd"$$IfF5###56    2 24a$Ifhkdi#$$IfF5###56    2 24a$Ifhkd'$$$IfF5###56    2 24a$Ifhkd$$$IfF5###56    2 24a $Ifhkd%$$IfF5###56    2 24a(5$Ifhkda&$$IfF5###56    2 24a56:JV$Ifhkd'$$IfF5###56    2 24aVW[kz$Ifhkd'$$IfF5###56    2 24az{$Ifhkd($$IfF5###56    2 24a~#$?@ACDIJPQRVWklhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJ;$IfhkdY)$$IfF5###56    2 24a$Ifhkd*$$IfF5###56    2 24a$Ifhkd*$$IfF5###56    2 24a$@$Ifhkd+$$IfF5###56    2 24a@ADJQ$IfhkdQ,$$IfF5###56    2 24aQRWl$Ifhkd-$$IfF5###56    2 24a$Ifhkd-$$IfF5###56    2 24a$Ifhkd.$$IfF5###56    2 24a  %&456;<cd BCDFGNOWXY\]lmܼܼܼܼhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJ;$IfhkdI/$$IfF5###56    2 24a $Ifhkd0$$IfF5###56    2 24a&5$Ifhkd0$$IfF5###56    2 24a56<d$Ifhkd1$$IfF5###56    2 24a$IfhkdA2$$IfF5###56    2 24aC$Ifhkd2$$IfF5###56    2 24aCDGOX$Ifhkd3$$IfF5###56    2 24aXY]m$Ifhkd{4$$IfF5###56    2 24a$Ifhkd95$$IfF5###56    2 24a)*9:;=>LM_`acdpqܼhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJ;$Ifhkd5$$IfF5###56    2 24a$Ifhkd6$$IfF5###56    2 24a$Ifhkds7$$IfF5###56    2 24a*:$Ifhkd18$$IfF5###56    2 24a:;>M`$Ifhkd8$$IfF5###56    2 24a`adq$Ifhkd9$$IfF5###56    2 24a$Ifhkdk:$$IfF5###56    2 24a$Ifhkd);$$IfF5###56    2 24a<=>@AHIPQRVW"#12hASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJ;$Ifhkd;$$IfF5###56    2 24a=$Ifhkd<$$IfF5###56    2 24a=>AIQ$Ifhkdc=$$IfF5###56    2 24aQRW$Ifhkd!>$$IfF5###56    2 24a$Ifhkd>$$IfF5###56    2 24a$Ifhkd?$$IfF5###56    2 24a$Ifhkd[@$$IfF5###56    2 24a#2$IfhkdA$$IfF5###56    2 24a237CO$IfhkdA$$IfF5###56    2 24a2367BCNOPQRVW\]^`aijrstxy&'(-.DE_`adeѼhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH $hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJhASehe^YCJaJ;OPRW]$IfhkdB$$IfF5###56    2 24a]^ajs$IfhkdSC$$IfF5###56    2 24asty$IfhkdD$$IfF5###56    2 24a$IfhkdD$$IfF5###56    2 24a$IfhkdE$$IfF5###56    2 24a'$IfhkdKF$$IfF5###56    2 24a'(.E`$Ifhkd G$$IfF5###56    2 24a`aeny$IfhkdG$$IfF5###56    2 24aemnxyz"#$'(9:XYZ\]efnopstܼܼܼhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJ;yz$IfhkdH$$IfF5###56    2 24a$IfhkdCI$$IfF5###56    2 24a#$IfhkdJ$$IfF5###56    2 24a#$(:Y$IfhkdJ$$IfF5###56    2 24aYZ]fo$Ifhkd}K$$IfF5###56    2 24aopt$Ifhkd;L$$IfF5###56    2 24a$IfhkdL$$IfF5###56    2 24a$IfhkdM$$IfF5###56    2 24a "#,-.12IJcdehiyzhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJOJQJ^JaJhASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ;$IfhkduN$$IfF5###56    2 24a$Ifhkd3O$$IfF5###56    2 24a $IfhkdO$$IfF5###56    2 24a#-$IfhkdP$$IfF5###56    2 24a-.2Jd$IfhkdmQ$$IfF5###56    2 24adeiz$Ifhkd+R$$IfF5###56    2 24a$IfhkdR$$IfF5###56    2 24a$IfhkdS$$IfF5###56    2 24a$IfhkdeT$$IfF5###56    2 24a/0145@ALMNRS_`lmnrs $%45DEFJKYZhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJ;$Ifhkd#U$$IfF5###56    2 24a0$IfhkdU$$IfF5###56    2 24a015AM$IfhkdV$$IfF5###56    2 24aMNS`m$Ifhkd]W$$IfF5###56    2 24amns$IfhkdX$$IfF5###56    2 24a$IfhkdX$$IfF5###56    2 24a %5E$IfhkdY$$IfF5###56    2 24aEFKZh$IfhkdUZ$$IfF5###56    2 24aZghilm}~89:?@YZ   ܼܼܼhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJ;him~$Ifhkd[$$IfF5###56    2 24a$Ifhkd[$$IfF5###56    2 24a$Ifhkd\$$IfF5###56    2 24a9$IfhkdM]$$IfF5###56    2 24a9:@Z$Ifhkd ^$$IfF5###56    2 24a$Ifhkd^$$IfF5###56    2 24a$Ifhkd_$$IfF5###56    2 24a $IfhkdE`$$IfF5###56    2 24a  /[$Ifhkda$$IfF5###56    2 24a ./Z[\^_ghvwx|}   '(@ABEFRShijklpǰܖܖܖܖܖܖܖhASehe^YCJaJhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH $hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJ;[\_hw$Ifhkda$$IfF5###56    2 24awx}$Ifhkdb$$IfF5###56    2 24a$Ifhkd=c$$IfF5###56    2 24a$Ifhkdc$$IfF5###56    2 24a $Ifhkdd$$IfF5###56    2 24a  (A$Ifhkdwe$$IfF5###56    2 24aABFSi$Ifhkd5f$$IfF5###56    2 24aijlqz$Ifhkdf$$IfF5###56    2 24apqyz{~12HIJMN]^qrsxyhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH hASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJ;z{$Ifhkdg$$IfF5###56    2 24a$Ifhkdoh$$IfF5###56    2 24a$Ifhkd-i$$IfF5###56    2 24a$Ifhkdi$$IfF5###56    2 24a2I$Ifhkdj$$IfF5###56    2 24aIJN^r$Ifhkdgk$$IfF5###56    2 24arsy$Ifhkd%l$$IfF5###56    2 24a$Ifhkdl$$IfF5###56    2 24a $Ifhkdm$$IfF5###56    2 24a    #$%'(23BCDFGQR]^_bc{|(4ѼѼhASehe^YB*ph hASehe^YhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH $hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJhASehe^YCJaJ.   $$Ifhkd_n$$IfF5###56    2 24a$%(3C$Ifhkdo$$IfF5###56    2 24aCDGR^$Ifhkdo$$IfF5###56    2 24a^_c|$Ifhkdp$$IfF5###56    2 24a$IfhkdWq$$IfF5###56    2 24a()*{{{$If $ d]$a$hkdr$$IfF5###56    2 24a 45FIvw/0BCWXYbclmxyz̿٫yfyfyfyfyfyfyfyfyf$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJhASehe^YCJaJ*hASehe^Y5CJOJPJ QJ\^JaJ&hASehe^Y5CJOJQJ\^JaJhASehe^YB*EHphjrhASehe^YEHU hASehe^YhASehe^Y6]hASehe^YjhASehe^YU(0CXuooo$Ifkdx$$If4F +' '' +6    2 24apXYcmyz3ckdy$$IfF +###+6    2 24a$Ifckdy$$IfF +###+6    2 24azckdz$$IfF +###+6    2 24a$If./EFGMNXYcdeklrs{|} ѼhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH $hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJhASehe^YCJaJ;3ckd|$$IfF +###+6    2 24a$IfckdI{$$IfF +###+6    2 24a/FGNYdckd|$$IfF +###+6    2 24a$Ifdels|}3ckdA~$$IfF +###+6    2 24a$Ifckd}$$IfF +###+6    2 24a}ckd~$$IfF +###+6    2 24a$If3ckd{$$IfF +###+6    2 24a$Ifckd$$IfF +###+6    2 24a$%6GIckd9$$IfF +###+6    2 24a$If#$%56FGHIJYZijklm{|  !"#/0<=JKLWXcdxyzĵhASehe^YOJPJ QJ^JhASehe^YOJQJ^JhASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJGIJZjlm3ckd$$IfF +###+6    2 24a$Ifckd$$IfF +###+6    2 24am|ckds$$IfF +###+6    2 24a$If3ckd$$IfF +###+6    2 24a$Ifckd1$$IfF +###+6    2 24a "#0=Kckd$$IfF +###+6    2 24a$IfKLXdyz3ckd)$$IfF +###+6    2 24a$Ifckdk$$IfF +###+6    2 24azckd$$IfF +###+6    2 24a$If !$If  )*;<=HITUcdetu "#01ABCPQbcwxyhASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJR 3ckdc$$IfF +###+6    2 24a$Ifckd$$IfF +###+6    2 24a*<=IUdckd!$$IfF +###+6    2 24a$Ifdeu3ckd$$IfF +###+6    2 24a$Ifckdߊ$$IfF +###+6    2 24ackd[$$IfF +###+6    2 24a$If 3ckd׍$$IfF +###+6    2 24a$Ifckd$$IfF +###+6    2 24a#1BCQcxckd$$IfF +###+6    2 24a$Ifxy3ckd$$IfF +###+6    2 24a$IfckdS$$IfF +###+6    2 24ackdϐ$$IfF +###+6    2 24a$If       5 6 K L _ ` a m n } ~                            ! 1 2 3 < = F G U V W \ ] h i q r s x y            hASehe^YCJaJ hASehe^YCJOJQJ^JaJ$hASehe^YCJOJPJ QJ^JaJR    3ckdK$$IfF +###+6    2 24a$Ifckd$$IfF +###+6    2 24a 6 L ` a n ~  ckd $$IfF +###+6    2 24a$If      3ckd$$IfF +###+6    2 24a$IfckdǓ$$IfF +###+6    2 24a        ckdC$$IfF +###+6    2 24a$If   ! 2 3 3ckd$$IfF +###+6    2 24a$Ifckd$$IfF +###+6    2 24a3 = G V W ] i r ckd}$$IfF +###+6    2 24a$Ifr s y    3ckd$$IfF +###+6    2 24a$Ifckd;$$IfF +###+6    2 24a        ckd$$IfF +###+6    2 24a$If                    - . / ; < L M b c d h i u v                   ѼhASehe^YOJQJ^JhASehe^YCJaJmH sH ,hASehe^YCJOJPJ QJ^JaJmH sH (hASehe^YCJOJQJ^JaJmH sH $hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJhASehe^YCJaJ3      3ckd3$$IfF +###+6    2 24a$Ifckdu$$IfF +###+6    2 24a   . / < M c ckd$$IfF +###+6    2 24a$Ifc d i v   3ckdm$$IfF +###+6    2 24a$Ifckd$$IfF +###+6    2 24a        ckd+$$IfF +###+6    2 24a$If     $If !$Ifckd$$IfF +###+6    2 24a                * + 9 : ; E F V W j k l s t                                   J K »hASehe^YB*ph hASehe^YhASehe^YCJaJ$hASehe^YCJOJPJ QJ^JaJ hASehe^YCJOJQJ^JaJhASehe^YOJPJ QJ^JA      3ckde$$IfF +###+6    2 24a$Ifckd$$IfF +###+6    2 24a  + : ; F W k ckd#$$IfF +###+6    2 24a$Ifk l t    3ckd$$IfF +###+6    2 24a$Ifckd$$IfF +###+6    2 24a        ckd]$$IfF +###+6    2 24a$If      3ckd٤$$IfF +###+6    2 24a$Ifckd$$IfF +###+6    2 24a      J K Q R T    {{uM $ 0 $ 1$ $ 0$a$$a$ckd$$IfF +###+6    2 24a$If K Q S T           FIJUX}<?@UVWXYȺȺȺȺȺȺȺȺȺ׏ȺhASeh2/mHnHsHuhASeh2/5mHnHuhASeh2/6]mHnHuhASeh2/\mHnHuhASeh2/5\mHnHu%hASeh2/5OJQJ\mHnHuhASeh2/mHnHuhASehe^Y5\8  JU@WYf-BDdM $ gd2/1$ $ M $ 0 $ ),-=?ABCD`d-/0FHIgiõ hASeh2/B*mHnHphuhASeh2/^JmHnHuhASeh]5\mHnHuhASeh]\mHnHu%hASeh2/5OJQJ\mHnHuhASeh2/mHnHuhASeh2/\mHnHuhASeh2/5\mHnHu00Iln&(Cv%X}1$ $ 0 $ ikmn"$%&'(@BCruv"$%TW泥泥泥泥泥ӳ泥泥泥泥ӳ泥泥泥hASehC5mHnHuhASeh2/\mHnHuhASeh2/5\mHnHu hASeh2/6\]mHnHu%hASeh2/5OJQJ\mHnHuhASeh2/mHnHuhASeh2/5mHnHu;WXz|}79:hkl*,-.>?@AB[]^_vxyhASeh2/5mHnHu%hASeh2/5OJQJ\mHnHuhASeh2/5\mHnHuhASeh2/mHnHuhASeh2/\mHnHuH}:l.@B_y.1$ $ 0 $ +-.BDEFGZ[\]^󠕍}}hybjhybUhe^Yhe^YB*phhASehe^YB*ph hASehe^YhASeh2/5mHnHuhASeh`5mHnHu%hASeh2/5OJQJ\mHnHuhASeh2/\mHnHuhASeh2/5\mHnHuhASeh2/mHnHu1.EG\^#$a$01$ $ 0 $ 2>@opvwz{  !)*0134frt DPR hKFCJheW0J2mHnHu hKF0J2jhKF0J2UhKFhybjhybUQ2?@|"#$%& 3 !H$AB ] 3 !H:$# 3 !H:$AB 3 !H$AB3 3 !H:$h]h&'()fst    33 !T$ 3 !H:$AB 3 !H$AB ] 3 !H:$ 3 !H$ ] #DQR,-./0123 3 !H:$h]h# 3 !H:$ 3 !H$ ] +34:;=>tBRV $%+,./eqsCDJKLMZbcijlmheW0J2mHnHu hKFCJhKF0J2mHnHuhKF hKF0J2jhKF0J2UR3tFSTUV# 3 !H$ ]  3 !H:$ 3 !H$h]h !"#$ers 3 !H$ ] 3 !H:$ 3 !H$h]h#N[\]^_`ab 3 !H$ ] # 3 !H:$h]h 3 !H:$ 3 !H$h]h5BCDEFGHI 3 !H:$ 3 !H:$h]h#)*0134AIxy !.69iuw  6 7 = > @ A N V W ] ^ ` a                  *!6!8!i!j!p!q!r!heW0J2mHnHu hKF0J2jhKF0J2U hKFCJhKFV"/0123456ivw  3 !H:$ 3 !H:$h]h#  B O P Q R S T U V             *!7!8!!!!# 3 !H:$r!s!!!!!!!!!!!!!!!!""%"&","-"/"0"`"l"n""""""""""""""" # #######L#X#\###################$"$#$)$*$,$-$9$:$E$F$L$M$P$Q$R$heW0J2mHnHu hKFCJhKF hKF0J2jhKF0J2UV!!!!!!!!!!!!!!!""" "!"""#"$"%"`"m"n"" 3 !H:$ 3 !H$#"""""""""""""""""# # #####L#Y# 3 !13$ !a$3 !## 3 !H:$Y#Z#[#\#############.$:$;$<$=$>$ 3$ !H:$a$ 3 !H$ 3 !W1gd} V 3 !k H$gd} V 3$ !P1a$ 3 !P1#>$?$@$A$B$C$D$E$R$$$$$$$$$$$$$$3 !H 3 !H$ 3 !H:$3 !H$h]hgd} V3&`#$#R$$$$$$$$$$$$$$$$$$%(%*%+%1%2%5%6%7%f%s%}%~%%%%%%%%%%%%%&&&&D&E&K&L&O&P&\&]&b&c&i&j&m&n&&&&&&&&&&&&&&''''7'C'E'F'u'v'|'}''heW0J2mHnHujhKF0J2UhKF hKF0J2 hKFCJV$%)%*%7%g%t%u%v%w%x%y%|%}%%%%%3&`#$ 3 !1 3 !P2] # !P1# !1#33 !$hh]h`h3&`#$ 3 !H:$3 !H:$hh]h`h%&&&&&Q&]&^&_&`&a&b&&&&&&& 3 !g28]8 3 !13 !PJ-28]8 3$ !1ABa$ 3 !1AB]# 3 ! 2 3 !g2]&&&&&&&7'D'E'F'''''''''' 3 !.8]8 3 ! 2 3 !J-]3&`#$ 3 !13 !P(28]8gd} V# 3$ !1a$''''''''''''''''''(((*(+(Z([(a(b(e(f(t(x((((((((((((((() )))?)@)F)G)J)K)Y)])))))))))))))))))))$*%*+*,*/*0*>*B*C*hybheW0J2mHnHu hKFCJhKF hKF0J2jhKF0J2UR''''()(*(+(g(u(v(w(x(((((((( 3$ !1a$ 3 !S58]8 3 ! 2 3 !4]3&`#$ 3 !13 !6028]8#())))L)Z)[)\)]))))))))) 3 !H$h]h 3$ !1a$ 3 !+8]8# 3 ! 2 3 !+]3&`#$ 3 !13 !P&28]8))))1*?*@*A*B*C***\+]+^+_+# 3 ! 23 !#+ ] 3&`#$ 3 !H:$C*******\+]+_+he^YhKF6CJ] hKFCJhKFhKFCJOJQJ^J 70&P1/R / =!"#$% D00P&P1/R / =!"#$% Dp: 00&P1/R / =!"#$% I0PcPcP&P1/R / =!"#$% Dp<PcPc&P1/R / =!"#$% <PcPc&P1/R / =!"#$% <PcPc&P1/R / =!"#$% I0PcPcP &P1/R / =!"#$% Dp <PP&P1/R / =!"#$% <PP&P1/R / =!"#$% <PP&P1/R / =!"#$% <PP&P1/R / =!"#$% I0PPP&P1/R / =!"#$% DpL00PPP&P1/R / =!"#$% DpI0PcPcP&P1/R / =!"#$% Dp<PcPc&P1/R / =!"#$% <PcPc&P1/R / =!"#$% <PcPc&P1/R / =!"#$% <PcPc&P1/R / =!"#$% <PcPc&P1/R / =!"#$% <PcPc&P1/R / =!"#$% I0PcPcP5&P1/R / =!"#$% Dp5<PcPc&P1/R / =!"#$% L00PcPcP&P1/R / =!"#$% DpE0PcPcP;&P/R / =!"#$% Dp;; 0PcPc&P/R / =!"#$% g<PcPc&P1/R / =!"#$% <PcPc&P1/R / =!"#$% <PcPc&P1/R / =!"#$% <PcPc&P1/R / =!"#$% <PcPc&P1/R / =!"#$% <PcPc&P1/R / =!"#$% <PcPc&P1/R / =!"#$% <PcPc&P1/R / =!"#$% <PcPc&P1/R / =!"#$% <PcPc&P1/R / =!"#$% <PcPc&P1/R / =!"#$% <PcPc&P1/R / =!"#$% <PcPc&P1/R / =!"#$% <PcPc&P1/R / =!"#$% <PcPc&P1/R / =!"#$% <PcPc&P1/R / =!"#$% <PcPc&P1/R / =!"#$% <PcPc&P1/R / =!"#$% <PP&P1/R / =!"#$% <PP&P1/R / =!"#$% 7 0&P1/R / =!"#$% : 0&P10/R = /!"#$% = 0 0&P10/R = /!"#$% 7 0&P1/R / =!"#$% 4&P1/R / =!"#$% 4&P1/R / =!"#$% 4&P1/R / =!"#$% 4&P1/R / =!"#$% 7 0&P1/R / =!"#$% 4&P1/R / =!"#$% 4&P1/R / =!"#$% : 0&P10/R = /!"#0$% = 0 0&P10/R = /!"#$% = 0 0&P10/R = /!" #$% = 0 0&P10/R = /!"#$% = 0 0&P10/R = /!"4 #$% = 0&P1/R :p2// =!"#$% = 0&P1/R :p2// =!"#$% = 0&P1/R :p2// =!"#$% `![9DQyj dHGKx}wO9sw*"*aE%=²bAAtzjHED-h!/x~b_o3ܹs̙9d _6 ڙ[mȿ’ ˗/-oqf>K~?bLާz"8ǫ'_)sjbrOyjJZlgJ4SeXdYe.8-3̣dM0iJgMo t:TYһ:,z_Q']E5n?P=J# }hާ/9MPiyEyqZGkxv1䚺:_sYϜOrV=azCm.9ω kNzs<B?2s9e.nnq:s?G|_yIDI3RK[9&QD[X'[";d$0Y'e|"+eLX+e̔iB$s$^#[aEZhk9rJߑZUhw`ZYk%٪$AF-#봔фK_SUJjr_fflo,*KQY%d_5fY,4$j:'餝|m@ʏZKYO-#z|wzK=hXCd䗯|TPfKa,]XQI7;| _tIiGN5ֹdOf5$ؾ%b]vףb٨V x!#aRqSApI-|o..(9|%˅ᗢxqx$((Uꈗ{&ӧԈԈ0 D?BR6 foื@y\8$R |E>Am7qI~'%/^»%8m  ~l~$ϛיg0ץ.&ܻ_ ~fٲ9c#GfnV;8N[C9FbxC|V`ϧ-%A LőԆRI4b Q#F&Oy3@x4:-4\h,hW S=KSFԍVS'G܈".rWM4 |b||Cr31dsFITNRQF(xnIK%=de */oSEH&KdTAާr;alW*$=(L׏B?=0+9"ѯ[Qx0#F}G_YZ|V]퇏#G.<]Zt"դ'%!\ 96z k[mѣ:DgԀ'QSC9>@ש;3L3ܛ}ͱP|4 u8ډ8\fq}"a,OPL<3P|D?5d<Ǜ>;2.5m Vsh~CKrIdrZ+iNdL\]øzȀ"O^z TNPIGt;uYQ  f2]3_)4N3֚4 fŘ $K_QbhUҍIg,SAҌzJC.uCQ()E](l7~.!F"KjCL."i[T!$?]"DZt*)*}`؍M롉kP,|T s4K9Z)hTR N}ОtUj Gw1qO 1ζTm1PJHjZ7-:4D֑X=/~Au|?u) ۨ~Cb]Kϣ"J~Khzc0R[ùژ;{V;r+ڇA\DrZOL0f.PBpF˹u>EWU^9u3*wRZ;9^0yīd-f!_3Y6׫`>*S[<,8] 'TkJpܫ/ ]o.K>|ݮ## aI칂ҋH4fB69| /-{PP$jgPC&2P'Л7M)yz[g:6ӉWA'npz)Mg4ġ_>٬TBv@碛dC?3 t4-. +dPPPRPREF.'іV2}:P\8Ƨ?@cWc_Hois͝3WEp\vu?3g֊8OѲ~hqмZm-on&:omj+[+i`I l %\ uBrJG0 !@Nw2lMf6te(j3J^v6\4\ppK%ﺔ̥I7gd Η c3w@?40科2$ (!+Zo"KֲPQ2.A}4\,pa.0 s7pq#yv. ᮁ[<$7xa5>WW93%:!$z+wx8m]c)ӻG{ Q`{[3>k9p/8 p%_ro0'f$ 5hwo|,&÷9aWuuqpiœqko..ifk_f joH\=mji+WMZB.t4K)SBR S=v\W=csj Slu]]k5]{:i\W-E\2EbO~ow~c#um;lcnVUPY2;maD?FڮɴQ~M1W#ZS'X)a % %2el-aJ]?Cz37GcOzIaJj{M=Ik&Mgln5-k~fn{3kb~ƽD9q'ўEܻ0WVinxmMI򺀞 aT7xHP `: Vu&2lYMfK+7z֫G?z}&U#h*?F5o;?&ҤG(dׁ97w?W1\\9yg]}˽\5WFw%5ѕChz`ADsqMOxw}-p`Ej]/%U8mvL?WD=1pf1#60-yMotmMgioMSԳCsMga-;&aڻ9i`'}ic.4 -WU^C_}an?]{ܷC{uKvLcm[b9fjF/8FnYx߬s}Lnv&{_^Ւ=6];6Ļ헅hC2Y7΂,lC,tiU uszlp<0 P}7I:8Wd(밯7S*K]*[ng NT9hpv\9CtJ՞wv E5 @/-h4FSm<RV&5~}InFKKYVχRȵ"*-͎\+ruKMt63]*ՒS7e:wdPRyraE)T>2٭ɅWL.XMCk]aql<ϊ HN/\ 2K{Dc|[ʈӽî>Ji-|P*_\)L$;4E_'0^6wu;tYշT#OR(ǯ/ixgˁ-A:-ʙVޓ\@ W^[;[)W{a7y _"2q1;m 4{4J5Ո1וRn/.(˧pS`X"֪%Ԡlw O` R'S@,WS5re-מ«Ch[ʈFb5d7w_a"٭j\sS->2s GoMBA+vEaW⠖>'VdjD/TU`oDv*2:O#uӔ–*@llNΔs59Jcct FUƲezKdA ć5Rʬ--'psuxlP.Ӌwe~&￸`(ݲ\iRY{;W|Pm PwmbSAY2^]$'vz(^/eYP*+kс` !oE ' vH5|4lNΨ^>cnscXUfDW&C(%8ͻ7TX>wdFn A̒~Pz+6Oژt?9uS`o%RCDZ._FB=D!%' |v@#X9/Bi7 7V.?UWfOk~n([-rߐٕ8{M//gK]0vfڷ5IןL{Jŧ.j;*j<vGF YR&ӽ~N0tk~Y (sQpt, L_3}aSND?0?O[ѩY5[d0j-[S7o,%i7iH%9uSn L$s&)}f9@lҙ>w47'gv ?D&&6k y._\X\X }X끎fJ#UpZOB3sf̀4<ۙ+q0;r^˫̧fUX9uˤn%nGRlW|"-UZ)=:eKԻ_ʬg6Z_)֍͹TyS,!J#l9Ab{4vGIbYXヲ'ًf,Xجx)M:nHx'dl0eeׯ*yv:1Q1)>.[RↂlN ҙŇ!? [Ҁ~BvivK:Ucg;4R93*zZ#-V9(3iy0IZ9+wi[ZJto Ŧo*_ӗhrHJs|.>qdj*l̲Wuᦀ%ujG;_i7uƾ,~ՙ"|>B7&RG*MYz?(_<_4ΗގHCŧ&G7/Fԙeׯ:*\&qA]{;8V9~?m>JĉVGH+3_"RmPlM*hS(fG.C_Azl8RA^|ͦ_,?b4j\Xأmd7lcC'BoRkDiMYtJo._+сH6ԢʈI|APwޅ/>whEOGHU2:'kՕJ4 ȵ26KJoI3}W2-4X+w3e??xVq E7 Ξm̢x3e{su׻*s?gfNBc/>n=?^o6-ѽ~QJ}}]fL!4 8YeuFfS&}]eD[́%2#'f2qH: 6J< -;\c'r"ncO8M)x$v$_ʵdA7 e?Jn]<8}UK{o[,'񟪳 yYavaX#'"-kSΫC!~)WʼS(3٭'rUM+E#!kGWPVᦀY|CC% ˣ6#Dpd{!lkY>%x+w:svGCxPcBf(ǧ,fJyF^mӝw-w 3q#ߘP)i9pmf$bgjXy(p! ~5 XUWG*YʬCi5A`ƼFZȞn`i5"Xlh8[sN`hrq&!fssPzʬ*j]q#>V  ."EtfC򍟗jXh_ $D`Sك"&]l-6n,~ lHWl`Dww4p:lx#8 6g7NQ_i$~ F^|ә4^?pzI#ĠxqCU܀Hx%x<܃#i8i$~* g&l܆7Hx8#6[g|]s4^?p-J#7>N gfYBdj~P+8&62IxV5,6xpLljZlA%xqLlq ^?Qj/jH-mA1yAMSKi$~P8)6CZI<@ 7p6d:; ^?ݺi$pAx lpi x'揶x'ŦUui$~UA, U`!$ֆ鈪~H§>An dHG9xV}he?3"|Brd)l0^r]>^0v&dqfkq쨫^K@Ut٫/د!6&/#l\`& X>qA؉9|•x 7O%|"( !* ٬G<6qAsOX͎qfjTqUFBy6gYz7P4OV&zul㙨mbja݁-Ҷ`Nf >Bb/?R>.LbOFNpe&gQ9 LE6Wp";Ix![JO'.sf+nnYjr׼NuGi !yI(Vp>i{yLY$^L޸3~,T̓;*TjTP#"U֫bP_J_>2\vɹJ&AeC쑗op*Pa*1ڛ#o87K[D>%Zeܠ]o -m\%Xoi}=+{HS2My̎ U]xEYJ'|LBfP*?m:T~`$v'f)Ns#?j`!oP>,OJq\).ڀ23htK%E7,ʝM48c 6栞{cIOHkqhWyPsԻ**Is^ULź\{D/q8)bpr\Cz ?z pZ_6H{M;L&Ԛh6q*bZyj\ů3z+{ҍ."Ddh pq  s bA*Key 24Security key graphic"`2:[9DQyAZ`![9DQyj dHGKx}wO9sw*"*aE%=²bAAtzjHED-h!/x~b_o3ܹs̙9d _6 ڙ[mȿ’ ˗/-oqf>K~?bLާz"8ǫ'_)sjbrOyjJZlgJ4SeXdYe.8-3̣dM0iJgMo t:TYһ:,z_Q']E5n?P=J# }hާ/9MPiyEyqZGkxv1䚺:_sYϜOrV=azCm.9ω kNzs<B?2s9e.nnq:s?G|_yIDI3RK[9&QD[X'[";d$0Y'e|"+eLX+e̔iB$s$^#[aEZhk9rJߑZUhw`ZYk%٪$AF-#봔фK_SUJjr_fflo,*KQY%d_5fY,4$j:'餝|m@ʏZKYO-#z|wzK=hXCd䗯|TPfKa,]XQI7;| _tIiGN5ֹdOf5$ؾ%b]vףb٨V x!#aRqSApI-|o..(9|%˅ᗢxqx$((Uꈗ{&ӧԈԈ0 D?BR6 foื@y\8$R |E>Am7qI~'%/^»%8m  ~l~$ϛיg0ץ.&ܻ_ ~fٲ9c#GfnV;8N[C9FbxC|V`ϧ-%A LőԆRI4b Q#F&Oy3@x4:-4\h,hW S=KSFԍVS'G܈".rWM4 |b||Cr31dsFITNRQF(xnIK%=de */oSEH&KdTAާr;alW*$=(L׏B?=0+9"ѯ[Qx0#F}G_YZ|V]퇏#G.<]Zt"դ'%!\ 96z k[mѣ:DgԀ'QSC9>@ש;3L3ܛ}ͱP|4 u8ډ8\fq}"a,OPL<3P|D?5d<Ǜ>;2.5m Vsh~CKrIdrZ+iNdL\]øzȀ"O^z TNPIGt;uYQ  f2]3_)4N3֚4 fŘ $K_QbhUҍIg,SAҌzJC.uCQ()E](l7~.!F"KjCL."i[T!$?]"DZt*)*}`؍M롉kP,|T s4K9Z)hTR N}ОtUj Gw1qO 1ζTm1PJHjZ7-:4D֑X=/~Au|?u) ۨ~Cb]Kϣ"J~Khzc0R[ùژ;{V;r+ڇA\DrZOL0f.PBpF˹u>EWU^9u3*wRZ;9^0yīd-f!_3Y6׫`>*S[<,8] 'TkJpܫ/ ]o.K>|ݮ## aI칂ҋH4fB69| /-{PP$jgPC&2P'Л7M)yz[g:6ӉWA'npz)Mg4ġ_>٬TBv@碛dC?3 t4-. +dPPPRPREF.'іV2}:P\8Ƨ?@cWc_Hois͝3WEp\vu?3g֊8OѲ~hqмZm-on&:omj+[+i`I l %\ uBrJG0 !@Nw2lMf6te(j3J^v6\4\ppK%ﺔ̥I7gd Η c3w@?40科2$ (!+Zo"KֲPQ2.A}4\,pa.0 s7pq#yv. ᮁ[<$7xa5>WW93%:!$z+wx8m]c)ӻG{ Q`{[3>k9p/8 p%_ro0'f$ 5hwo|,&÷9aWuuqpiœqko..ifk_f joH\=mji+WMZB.t4K)SBR S=v\W=csj Slu]]k5]{:i\W-E\2EbO~ow~c#um;lcnVUPY2;maD?FڮɴQ~M1W#ZS'X)a % %2el-aJ]?Cz37GcOzIaJj{M=Ik&Mgln5-k~fn{3kb~ƽD9q'ўEܻ0WVinxmMI򺀞 aT7xHP `: Vu&2lYMfK+7z֫G?z}&U#h*?F5o;?&ҤG(dׁ97w?W1\\9yg]}˽\5WFw%5ѕChz`ADsqMOxw}-p`Ej]/%U8mvL?WD=1pf1#60-yMotmMgioMSԳCsMga-;&aڻ9i`'}ic.4 -WU^C_}an?]{ܷC{uKvLcm[b9fjF/8FnYx߬s}Lnv&{_^Ւ=6];6Ļ헅hC2Y7΂,lC,tiU uszlp<0 P}7I:8Wd(밯7S*K]*[ng NT9hpv\K~?bLާz"8ǫ'_)sjbrOyjJZlgJ4SeXdYe.8-3̣dM0iJgMo t:TYһ:,z_Q']E5n?P=J# }hާ/9MPiyEyqZGkxv1䚺:_sYϜOrV=azCm.9ω kNzs<B?2s9e.nnq:s?G|_yIDI3RK[9&QD[X'[";d$0Y'e|"+eLX+e̔iB$s$^#[aEZhk9rJߑZUhw`ZYk%٪$AF-#봔фK_SUJjr_fflo,*KQY%d_5fY,4$j:'餝|m@ʏZKYO-#z|wzK=hXCd䗯|TPfKa,]XQI7;| _tIiGN5ֹdOf5$ؾ%b]vףb٨V x!#aRqSApI-|o..(9|%˅ᗢxqx$((Uꈗ{&ӧԈԈ0 D?BR6 foื@y\8$R |E>Am7qI~'%/^»%8m  ~l~$ϛיg0ץ.&ܻ_ ~fٲ9c#GfnV;8N[C9FbxC|V`ϧ-%A LőԆRI4b Q#F&Oy3@x4:-4\h,hW S=KSFԍVS'G܈".rWM4 |b||Cr31dsFITNRQF(xnIK%=de */oSEH&KdTAާr;alW*$=(L׏B?=0+9"ѯ[Qx0#F}G_YZ|V]퇏#G.<]Zt"դ'%!\ 96z k[mѣ:DgԀ'QSC9>@ש;3L3ܛ}ͱP|4 u8ډ8\fq}"a,OPL<3P|D?5d<Ǜ>;2.5m Vsh~CKrIdrZ+iNdL\]øzȀ"O^z TNPIGt;uYQ  f2]3_)4N3֚4 fŘ $K_QbhUҍIg,SAҌzJC.uCQ()E](l7~.!F"KjCL."i[T!$?]"DZt*)*}`؍M롉kP,|T s4K9Z)hTR N}ОtUj Gw1qO 1ζTm1PJHjZ7-:4D֑X=/~Au|?u) ۨ~Cb]Kϣ"J~Khzc0R[ùژ;{V;r+ڇA\DrZOL0f.PBpF˹u>EWU^9u3*wRZ;9^0yīd-f!_3Y6׫`>*S[<,8] 'TkJpܫ/ ]o.K>|ݮ## aI칂ҋH4fB69| /-{PP$jgPC&2P'Л7M)yz[g:6ӉWA'npz)Mg4ġ_>٬TBv@碛dC?3 t4-. +dPPPRPREF.'іV2}:P\8Ƨ?@cWc_Hois͝3WEp\vu?3g֊8OѲ~hqмZm-on&:omj+[+i`I l %\ uBrJG0 !@Nw2lMf6te(j3J^v6\4\ppK%ﺔ̥I7gd Η c3w@?40科2$ (!+Zo"KֲPQ2.A}4\,pa.0 s7pq#yv. ᮁ[<$7xa5>WW93%:!$z+wx8m]c)ӻG{ Q`{[3>k9p/8 p%_ro0'f$ 5hwo|,&÷9aWuuqpiœqko..ifk_f joH\=mji+WMZB.t4K)SBR S=v\W=csj Slu]]k5]{:i\W-E\2EbO~ow~c#um;lcnVUPY2;maD?FڮɴQ~M1W#ZS'X)a % %2el-aJ]?Cz37GcOzIaJj{M=Ik&Mgln5-k~fn{3kb~ƽD9q'ўEܻ0WVinxmMI򺀞 aT7xHP `: Vu&2lYMfK+7z֫G?z}&U#h*?F5o;?&ҤG(dׁ97w?W1\\9yg]}˽\5WFw%5ѕChz`ADsqMOxw}-p`Ej]/%U8mvL?WD=1pf1#60-yMotmMgioMSԳCsMga-;&aڻ9i`'}ic.4 -WU^C_}an?]{ܷC{uKvLcm[b9fjF/8FnYx߬s}Lnv&{_^Ւ=6];6Ļ헅hC2Y7΂,lC,tiU uszlp<0 P}7I:8Wd(밯7S*K]*[ng NT9hpv\K~?bLާz"8ǫ'_)sjbrOyjJZlgJ4SeXdYe.8-3̣dM0iJgMo t:TYһ:,z_Q']E5n?P=J# }hާ/9MPiyEyqZGkxv1䚺:_sYϜOrV=azCm.9ω kNzs<B?2s9e.nnq:s?G|_yIDI3RK[9&QD[X'[";d$0Y'e|"+eLX+e̔iB$s$^#[aEZhk9rJߑZUhw`ZYk%٪$AF-#봔фK_SUJjr_fflo,*KQY%d_5fY,4$j:'餝|m@ʏZKYO-#z|wzK=hXCd䗯|TPfKa,]XQI7;| _tIiGN5ֹdOf5$ؾ%b]vףb٨V x!#aRqSApI-|o..(9|%˅ᗢxqx$((Uꈗ{&ӧԈԈ0 D?BR6 foื@y\8$R |E>Am7qI~'%/^»%8m  ~l~$ϛיg0ץ.&ܻ_ ~fٲ9c#GfnV;8N[C9FbxC|V`ϧ-%A LőԆRI4b Q#F&Oy3@x4:-4\h,hW S=KSFԍVS'G܈".rWM4 |b||Cr31dsFITNRQF(xnIK%=de */oSEH&KdTAާr;alW*$=(L׏B?=0+9"ѯ[Qx0#F}G_YZ|V]퇏#G.<]Zt"դ'%!\ 96z k[mѣ:DgԀ'QSC9>@ש;3L3ܛ}ͱP|4 u8ډ8\fq}"a,OPL<3P|D?5d<Ǜ>;2.5m Vsh~CKrIdrZ+iNdL\]øzȀ"O^z TNPIGt;uYQ  f2]3_)4N3֚4 fŘ $K_QbhUҍIg,SAҌzJC.uCQ()E](l7~.!F"KjCL."i[T!$?]"DZt*)*}`؍M롉kP,|T s4K9Z)hTR N}ОtUj Gw1qO 1ζTm1PJHjZ7-:4D֑X=/~Au|?u) ۨ~Cb]Kϣ"J~Khzc0R[ùژ;{V;r+ڇA\DrZOL0f.PBpF˹u>EWU^9u3*wRZ;9^0yīd-f!_3Y6׫`>*S[<,8] 'TkJpܫ/ ]o.K>|ݮ## aI칂ҋH4fB69| /-{PP$jgPC&2P'Л7M)yz[g:6ӉWA'npz)Mg4ġ_>٬TBv@碛dC?3 t4-. +dPPPRPREF.'іV2}:P\8Ƨ?@cWc_Hois͝3WEp\vu?3g֊8OѲ~hqмZm-on&:omj+[+i`I l %\ uBrJG0 !@Nw2lMf6te(j3J^v6\4\ppK%ﺔ̥I7gd Η c3w@?40科2$ (!+Zo"KֲPQ2.A}4\,pa.0 s7pq#yv. ᮁ[<$7xa5>WW93%:!$z+wx8m]c)ӻG{ Q`{[3>k9p/8 p%_ro0'f$ 5hwo|,&÷9aWuuqpiœqko..ifk_f joH\=mji+WMZB.t4K)SBR S=v\W=csj Slu]]k5]{:i\W-E\2EbO~ow~c#um;lcnVUPY2;maD?FڮɴQ~M1W#ZS'X)a % %2el-aJ]?Cz37GcOzIaJj{M=Ik&Mgln5-k~fn{3kb~ƽD9q'ўEܻ0WVinxmMI򺀞 aT7xHP `: Vu&2lYMfK+7z֫G?z}&U#h*?F5o;?&ҤG(dׁ97w?W1\\9yg]}˽\5WFw%5ѕChz`ADsqMOxw}-p`Ej]/%U8mvL?WD=1pf1#60-yMotmMgioMSԳCsMga-;&aڻ9i`'}ic.4 -WU^C_}an?]{ܷC{uKvLcm[b9fjF/8FnYx߬s}Lnv&{_^Ւ=6];6Ļ헅hC2Y7΂,lC,tiU uszlp<0 P}7I:8Wd(밯7S*K]*[ng NT9hpv\A, `!$ֆ鈪~H§>An dHG9xV}he?3"|Brd)l0^r]>^0v&dqfkq쨫^K@Ut٫/د!6&/#l\`& X>qA؉9|•x 7O%|"( !* ٬G<6qAsOX͎qfjTqUFBy6gYz7P4OV&zul㙨mbja݁-Ҷ`Nf >Bb/?R>.LbOFNpe&gQ9 LE6Wp";Ix![JO'.sf+nnYjr׼NuGi !yI(Vp>i{yLY$^L޸3~,T̓;*TjTP#"U֫bP_J_>2\vɹJ&AeC쑗op*Pa*1ڛ#o87K[D>%Zeܠ]o -m\%Xoi}=+{HS2My̎ U]xEYJ'|LBfP*?m:T~`$v'f)Ns#?j`!oP>,OJq\).ڀ23htK%E7,ʝM48c 6栞{cIOHkqhWyPsԻ**Is^ULź\{D/q8)bpr\Cz ?z pZ_6H{M;L&Ԛh6q*bZyj\ů3z+{ҍ..DdHll  s XAPencil 07Note graphic"`2Pֆ鈪~H§>A, `!$ֆ鈪~H§>An dHG9xV}he?3"|Brd)l0^r]>^0v&dqfkq쨫^K@Ut٫/د!6&/#l\`& X>qA؉9|•x 7O%|"( !* ٬G<6qAsOX͎qfjTqUFBy6gYz7P4OV&zul㙨mbja݁-Ҷ`Nf >Bb/?R>.LbOFNpe&gQ9 LE6Wp";Ix![JO'.sf+nnYjr׼NuGi !yI(Vp>i{yLY$^L޸3~,T̓;*TjTP#"U֫bP_J_>2\vɹJ&AeC쑗op*Pa*1ڛ#o87K[D>%Zeܠ]o -m\%Xoi}=+{HS2My̎ U]xEYJ'|LBfP*?m:T~`$v'f)Ns#?j`!oP>,OJq\).ڀ23htK%E7,ʝM48c 6栞{cIOHkqhWyPsԻ**Is^ULź\{D/q8)bpr\Cz ?z pZ_6H{M;L&Ԛh6q*bZyj\ů3z+{ҍ..DdHll  s XAPencil 07Note graphic"`2Pֆ鈪~H§>A, գ`!$ֆ鈪~H§>An dHG9xV}he?3"|Brd)l0^r]>^0v&dqfkq쨫^K@Ut٫/د!6&/#l\`& X>qA؉9|•x 7O%|"( !* ٬G<6qAsOX͎qfjTqUFBy6gYz7P4OV&zul㙨mbja݁-Ҷ`Nf >Bb/?R>.LbOFNpe&gQ9 LE6Wp";Ix![JO'.sf+nnYjr׼NuGi !yI(Vp>i{yLY$^L޸3~,T̓;*TjTP#"U֫bP_J_>2\vɹJ&AeC쑗op*Pa*1ڛ#o87K[D>%Zeܠ]o -m\%Xoi}=+{HS2My̎ U]xEYJ'|LBfP*?m:T~`$v'f)Ns#?j`!oP>,OJq\).ڀ23htK%E7,ʝM48c 6栞{cIOHkqhWyPsԻ**Is^ULź\{D/q8)bpr\Cz ?z pZ_6H{M;L&Ԛh6q*bZyj\ů3z+{ҍ.DyK yK 8http://vista.med.va.gov/vdl}$$If!vh5h%#vh%:V l0654l=Dd-&WU   S `A$PROP Diagram 1Diagram A graphic"`b<cs-ˤ0TN޹b<+nZ<cs-ˤ0TN޹PNG  IHDR q!$PLTE3Mf::WWuu3J` w(/7>FMUl"Dfƪ3"J1`@wO^n}Ҍ"Df׈33GG\\pp)Rz"31J@`Ow^n}"Df3M"f+3<DMUh|:Wu3Pm33MMff3Mf"+3<DMUh:|Wu3"J1`@wO^n}Ҍ"Df̈ת33MMff:Wu3(P7mETbq3Mf3Uw--DD[[qq3&M3f@MYfs:WuȒׯ33MMff:Wu3M&f3@MYfs:WuD#bKGDH cmPPJCmp0712Hs8IDATx^ rmzn-q W5fÀ$=@=@=@XqX7:7ha|3CWx?K?0.W=`Uxء~5wV y( Ǎ:>>L˱.8|,|cmF6:{qi,9h=%5}`j؞mJ.sOQVlhySΧA8sDmG*iCij[cp" 9%}7l?&{3MOpv*EOӧQG$h7gn ]_m׮M{m,}fzBoEtstډ;:}Ҷp{oame V.* ^]8ArpQ]- *u0y^ZlLPږ2.`t_[ۮҸeא!g\yoP4E+S !_XZ j\n rÎK9f殒$L!~/rn%_Jకn[t2u؊SQ+el򴢭vVvӍt>B d-*ޅ=VMy yS:6WS`;:`{ip^^M^2Nu=_fzW$Ods[{WL9<;xŋ l7J4$4 Va5/̢`]4qnʸgfapt:48zQb Nih89T%4[{ˣkfa8~?@os`Y9zS*"Lt/f^0) 0Û`ZpK*fsmhxOsb"I9٘B#P iTd_kX K1r` ls!&<qiAPvx E62SZ&iw\Ѕ$;=Nazܙtu3c'扟+w{~KӾߐƢ woǴi)0;m.nqwۈ]1`xw7 wuTXDM]1ߡq>8m ,i!A?Ai=oi3k#-L4츪KB.i{2rC8z<7PQ.{ [\rReI5])D zl+5{.{aLϷ>pA?od˦HC krSf7 4DLb }yfxoy3 5iw|BX<[ޝgk48LVlzݧw/; *73b.XShh Y$|8!EaG $ /?f. iᶥ_2YAD˙h* ў<٦\L/1SlP46n{{1 O+&g^#$ 6MMXs`ɉ_YDC*c,NP55r|Riv~l/98ũZ+[jT]t?l'>w!Yg -JC -{e#hp)N'[{UISա ) %{~FMU Kf4tt% lHNq3I'k;/ziUdTeiq`H<-Dc, C/2M2wa4rUCx7DQ+hM9'4HpMvLV@DpS|as[-YFBC9o,ZI' oӥ5Cx݅;x5(fR Ko;tp BnSAyj&UG[׺JZ{x 2Ik!9 u+tB T),m).&t"њuY¤`kAڼ̔# i꽠4M+%ܹ#$x{јy(WΝ5#zO̩NIAI&QWKL%4]5уm~ r'[}u4~l]r"r&Gdʤd`bߠh"R>)z y\h,-vj8!W^Xa*CY&$xи@ק\r (Hi> QHPtn FSW$4Ҍ"idu4crv򞘿l,7@S'd4$=QGh`lIt]r -ݮNɜƧpeɰ݄u&˨hd:R Z1b 4T8u7Ls4D"O4F٨f2qR 7H4ؽ\Rg=`nwj?%iUo"?6Xnmzt$QҌ E'md3H ×t܉}xlm=PtoECz6 < ~!4:'xy0B2Ip̹RCC]/J=Esm>fY! qsH/c󣘌lDV'E՞V7`( X]o)>4?m& 6np kN4~V4D׀o:8`v@hpi \RMTDp$VtEzx4@H0XY4[]Hs;awHUD:<ЛɼvO7ڍN[@
!4x<'4oj-f`E<Љ9$IM +8`u<Љ՟op; !x7 bey}VH0}1ip% JiL)/@s%z8``fix8`~st48q$>/h.v*, {Ÿ4zJ8`ZMoÂLbEp$6u}Uā4s q^-KTOߥ{Ҁ%`L[7br8`zCM~pb 8`Tw*:4|4.mܙ*T=Oq J}CыfܽJ>L÷O, A۔B&4#nYV b~seu 8 iw@ |4l-(,ED|T8Np$vRuuŁ4h& qZ ~@85 05Q>IJo%)}RLɀiޯ'J!y28LKyq ,u6 _G[4?zV&|Tpe4 8`z݊piYS 06߮cف4+| p=&Sx >i(()8`Q4OÇ# % 0-vad4- 0}X濲uЪAlJ/Faq6SŘ6Z6F.O )4{4`ˆpN0)O?`|$  8`F_4 6 qiA#Ұyi}0bt:' <ciC8`j6@T2s8`F01*jqJS]׉qI  `}4i Uעw 0MsX-}8(}JA2Z 4.{r1k{Zi ZgjG\dŁ4h# S@4h`08HCpբ85 [r&|T߅i,ā4Fā4i%`L.c"iZǟ"]v=H"/yk9Hi@<ۮi,S 3viH00b8H]S sV" P&3^  8` ua6p P3^ 8` ua>up P&4^ 8` uaFUp P4^KE4gKdi]+@Hsp ̀r}ϋ GH @ -07\k%Ӡ\*}nsq q  _bnx{v @ف47*9|37;;yl@ wҠo0! wҠ ! *wҠ 3[c6U/Ł4Jw@5f ZwҠ /ikn 8 ֵq9%žoPvk/s ? {n AΧ :?]Z͛o`b{b4g+%0tX|Zs[5]s̫=+iV]ޥvIqD<ϟE7HӪK wωC/݁?V}7TFPk Lj>GýSZ 3ޣ=n3$}1:2誅;,@ViU0>4ү" M==}hh겙*# m1 /iU6 P sJ# 0㩒iKc<A1oC w'4"H.<8]Ĭiܥ4Ҡ1# Ƴ@# 0Ip Pؘ w4#ƕ+x H4] 8$bECŒ'4@!cn܅?i"F wƏ@]7(brjtr PH.aH1 7~E4@0~~4H[s*uZRCzeeu=V*EDw5yrS4U-0%-U r4ئZHTg=i?f=>{.˔&&͑&n,T}ip?f@jK7fho5Ja }a@:Bxh((iqCko~?O'sJ=<4oo%#n +<~ԙ24q-zPnpM6;30=ߴCwFpmonoqKÞZӇ|Cqjkly{= /ixhv PH#q PH&q PH6p PHFp PHVƣp PHVƣnY" P$ ^ȳƃp PHvcp PH䮆Cixixiָ?iظ;iڸ7iܸ3i޸/i+iø'pRe3P#4@GH=q[H1q?H1q7H1q/H1q4i"F w3i"F wu4i"F w4i"F wu5i"F w5ni"F wu6ni"h(ݦ Ɓ4@q 7Ɓ4@# Ł4@# G4@# 7Ł4@# Fā4@# 7ā4@# I(br f8(br(V8(br0F8(br868(br@&8(bM{kr}8(rP8(brX8(br`8(br`h(brh8(brp8(brx{8(brƷp P o9Ki H1zH1!jH1)ZH1Kb]4ƕ8(rsu8(br׃U8(brד58(bͶȱk.J(rף8(br׳8i1i"F w=m@Yoq8I[i@evp H H)l!3 AK`Mi@FobK%s,05 .PAi J Ai/N-(/Ji&OƯIup$xRa]vO"q͎ݏ)2~;lP |3!\Hl4(γb,ba:k;T<ϊѰ_`v& ZgWU>I~x̤a>{TpDG^Ӱ>jSi)r}[8C<Jʛ ^z $iR@.p!%jR:J~_V8Ez~MD.>y=bHA݅3HZҀkRH/= ECmǁ4@q &6@]3γ(brH1kn#wшc=@@[ۦ8$f lH3Ҁx 1 c3/; pKL#H58-D4z4}ޱ[H>AWYzH>nAwY:H>nA𧻓YA7 Ԏ@Ա jWpǁ4#GԮziPG4]JA9oҠiPꭆ37hCGziP4]Z v~dQoFmáQUkWC֎>~8|`Hp~ 8Pl`R;&^8 B6 A7gX;\5# /\ohCLHW"i([7ֱqzM@;0p߀f kw-/baCiB;h4Zt"0p4Nn`5u? OKWܔ]Ŧ*oV 6iTVkA7q0zﳇ?dHSy;sil|Q_Ed_p o7[h\ӪhսGv>Q5 '4HN)!G0U:E4Rs#@O*my Np"φ8VIB!CH]+SʰUGBet9YpcpS]秫 h0itiɔY,iLRA=fb=VMܐҠA*RZ[v񳲆-#JOmuoiMhuWBaWuxj6]U[qJGr68(1\9:P%ʜSq'!vvǩ# 9 "Hp /vU34W$~Zɥ4} Ƭޝu0pPg hp@Ug.4Tg_\qMa1`r.0Yl=K./k%0P6Aâ0D~B|xT}@j9ϐVZs7ˉ%3oPnDWqҠ(2 >9VZs8,e Ec ixk|EC >0k^Pn퐆Zi% 8I N1  Kw`Ji9.qBn0 1}*d=xH a=.pDJKV>a4ûiPh·}߃*\~C9ZvL+) w{gIë@;[ JnO,k?3qy~4%ߧUz\>04w-a1>> y~ki˶_wt毿Whh01#hs2%+dPѐa+!5)}oc?ٛliġ혲Z}N0n3k'Kx_0`]s,:~c~ތ{̿۾;\]9j% TP2sCCW }>*hRCR4̧R4D8tA16Վ4HHCQ EMg p &5TT" Ӊ!Bm?V;rŐѠ0E/4tSݬ48b?*x_03q!$l# ˶S` 4t48e~Nt!9vS[N=Z@ ?P` A! =ڷ [7Ł𦬽abv-7L>ҩ*6, @>@4:*i@H>3,VE\- {.7H9J{CU4D0,s oo>А`.N7ٓm]Ԗ{r_opmzgeB our1i)u޻7xt"uOm&#`%U@i) )ҿSOr^[™p̽c@K vVY+y ܴgB4$]Kym9(4n)]jpX(9 {Se4OܰR4IMz?2K_AJPTvh8R4 ޔ`xX$9007L>Ma@a,$ix}p{%hHxXa@^'IC Ɂ44몺M!'{SjV؟ΗO9lI0p:Mw Lm^54KVI1 HC(ل+AxWeK *v5~\,ܰʵChDC*H.)Q9Mp_78ߘL3GeRiJiV4A9B+c[:r`J鴙CH1v4Y /wɕߴJ \qyPbnmIA:jߐwz1ҹ_5 o!:chȾrN h=9)NA.cW2r,HhEX\4~i#"^ڙhHc24DQ|BS~gpɚo0 L6{y0!wѓ(uD7P EEEjfvCMi!xfuK$Ynsq iZC;, }K8 Eh/SYv!hL(,7DwdOM!ݧIó"4L3RGJZ8i1>+!#$ Cr/ 4BHÇܠ 6sM17J\)-Ni ;WJ`/4[Ć?߰UD}I aP=e|6=Q}T:Z!\SoGn uhJ4!t(!Q17nιyf iPie}hp!#Aħ4@\мmIQ{i$ipr_%/sǃ@ i ^:444 ; -kEBrB2o`Q% 먽44 χ9"FOWJa1;" % su4׋1XrҰ~ێd 'ZE[J+3'ۺ%27<4؝P8#6F:n+rC"RZG-Fҟ( [D?wh&B61ul?ӐaRZT75q8)92q͔$ 7eh4Ny7< }Hâr94σf{"OABsC²xNU,z \F =EddU^GwĽH}ty}iا *v-:%O\D*ZŢ? th2?z $7D53Q e0I*Z/c ^lAfN۾?ICC' X9NJ$ %s4bIJZ8i(Œ4qCݻ_ѐ~.{̵u}4$jU][IXYI`EyN"7H]FH# n~^L_.i]x>4$aU|B3 1 㕒+§b۪SWfqI|ChH0 fh8ّ{.:v|hhEjrCCC|HCPa,n?훷=یsy/+  tPF`S˩% ǁ+VJrS!@V"caof$ v.,|*i{ +, qR]Ԗ{\@sJ*p(hIVٙ:Z:YAoY sz+aјJ.7ܣAQ[~F'f#nK[]D1 ΰG2͇Mvb9W]xS-,@+ve|'T[lEBH\w.$t';S4 ޚö- ^D;0C^E39i-I20;ȞX gS>] )͡hCC~>B_[eP@k˕<@JUumRxHCɷ-Wi(VյJ~ %֪\?<ZUז+y4|[rx?TOvU``HCAu"" u~{i OoIiKO4'7W۵4|e]/9BpzMח+i s)ސjoln,wnK" i I(!5z(Nٹ4ސXQ\#GCݷI偋pN7ϼ; vNn V!ݤap7 oP[Uxzos>tVoWwGGqY|joi: V|ѭ-뚷\ߛ![s7]{qm5߮#qvm4y*ڍYMMFEcHE ~}=dX#mXi}-f6ʹ5օ[ {[yJ;ĩـw,ޑFsW3i9z/Z~wy09<OmjWڎdh5ZZ0?3Z|mGAT8Bk7?m a{ɦ}jD Sz)cy'ʺ3 tSlX:$.9C>Uw7LfafzgnnSmKkW-]=e]#"56ih'Gx}JMݩQQR鐀ܧz ތuzmFMUl"Dfƪ3"J1`@wO^n}Ҍ"Df׈33GG\\pp)Rz"31J@`Ow^n}"Df3M"f+3<DMUh|:Wu3Pm33MMff3Mf"+3<DMUh:|Wu3"J1`@wO^n}Ҍ"Df̈ת33MMff:Wu3(P7mETbq3Mf3Uw--DD[[qq3&M3f@MYfs:WuȒׯ33MMff:Wu3M&f3@MYfs:Wu愗;bKGDH cmPPJCmp0712HsCIDATx^츭'zyw-1`HjTW R*oxx< -끦iEj@rxzjQՂájb9ș>P^g6_NILwV[2hAWLGPPìe^d wD,60IWK= "chvGñW u8,HZ!jGh0Njr]V&=48~!ӎT]俫>Wsqt*T˵ͭ)=AYמ<=>=ZcnhЃd&X⧀Hrb:Ter?Sꕍ s6!/u12dRB)Gs,G& FJ i9{%(L'a}eQ48 Ql&+8Ì2{>=k^_L^Ei_%uxZ7Mъtwc?_0~:׿ftH20skA Wtynƭ#Ⳛ95UNr@(Ne'^s!@{ozK@H_`յ$ٚﮒoޣe_ Jq6$omICfL`+7s<^ vi?~+D }?O\HմYXh蕁]ck*q 5ѤYڒ>;Ct1a>oٳ^svmkS٣rs+UM]/|i.Z=Si`Yjh] t7D2bxgr3 `%ӠK*U'Sט;ֶxȁ jrT:p؀uh4 rP~'4 4şQN7t:6gu~㎻ݩ=S-޶ӧΠ6-S]+~mSW??.zTZX|`0h@8*:ZuG4L3|G[NMGM/De.6]+տ<h <L=z7QߵkP=z~?!pVqr4sbw QFv{RfŬ48wM@?S73l>WBhU+-Xq649}plVJvSE7Zt4.λ]gY>/n?p)M*h` ^>4|6Tltg7Y6gkO6VNʬC*hј|~ldL\f껱ᚦgG`E!T{U4a1f;:DC8Pcplj!VY|hpygjA)$VXݡMW[## QL!?O UN1.4kOu4dUבѥw2N`_!KoACl"hйWZNCtJQYq10!/o^籩 NOvW<i/KBap d4oW( OC4Pp[\=( a cbC >Nռa!}?qwLW;+ʯ7shpCկ_y w,o@7 XݒjO{**my vB2/4'X&x T$rL_czJdJ䞒` V;EXl0il(Jf4\i.~:OIIΨPu劬eQ0,6y߲46W%<Nޠ 2K<շ'^OW9i5a_BnO.hL(YK[{Lx%*hZa1iV oͨ11fn+2S[ T:bwr=G#]W=d46 h6ѳ@0@ѠrOGfɷ&4/V| nC`F1 u.I%^ju֕6 .leg';{ ~j:m2=$NH~ Zi0+8=Y]Ym%ŗr5 &E{ýk2hi9i0ЍIRlBd|*ɐۚ30Ip@lpe(PMk4;b}5KcopG:"c_ҪkIЧ4 ,D& *irș{LZZ̒IKjmP 4kTeBhn/Hױ43f>Hfnqy#wMRbW? ,m%!hPNAJCJu+Xb4 FOXnǛ )i4̍f^:3qs \dtsAef&l$dT"4]LWjk=F]m93wlv,eĕLJJ dlv a.l#M(y zD-nܹ~VG|WyicE;Ɓ!cM!# 8.XX̶Quxd% C$z%Rl`KF! $2ZPq.S iP5{}z^Wq6 C62.G: N4 )PkF>kƥVb.e9 c}RlRG)Ycϭ ~e{S'P ŘUŗ mw9T@ACFک5C=Eu J1ޑRѧ\l4Zy>ѕ/DýKe"Fv@„-*2TD 0?T=3M꺪Fx"N8.]4YO]=xlȣ좿|ªP3Ο{;IJG.B]i}G>NׁLItST*͚ N> #Vk[@o&Z Z"1n2B}7v[*SȌٿD:6lBC@KRLGw4@{g0s˔tev.m 6/-n# W&u7Aׇ,9{ l+6 6mDT( 6Ոn6X˅&[e#7XS7U0 :;bcU dJNs*wmKzSNpi5n#y3D'AXKR].<%=QjL\`4]zЭ=R 9 Ny2~0KO#|Ć_-ϧ!'2 ^|E9Ȕ!,5B( ^m (3fv=4;ơ- 1)Qņ1@T0h Bi E2!h 25܃PD֗YV!,8oH2MŏfIDKMwh؅g* LDw/_4lChB+:]h%i: XD]av.9&s{~ڶ_͋|9~zpV7'o./wf+ݪhiҐFwMA=\h6~zk QT$4NZ{y&cqP)DO_+k]Dl9Txhaa8b4(FPDi<^PSlq,@Iکa4\$6]xа hsFhQg#4D&WhoEEZE~EhX4)pJyd0 ԫǫ n8^]  ~NÚ,̠&Μ &_̬Zbٜ4J^;ȗҔvI xT|tnAu(Ewi(;U+P47Qɓr)2\!_蕎nac}%I)`3 ƛ&`y-;?Rs11 -hn,̍ jfd^) xLEM/ ܦK,7f ڢ*RλIcb̐8 <`0nO#~ Lrt`cadY$Sڂ'h`@ FAP .\^_Z ˟I2mnnQ~l OdžMXOv4YLR}ϓueC[)Z\Ŷz2 kڝ# z[CI~uz, ۰0?+ֿYQٳBHEŪc lSzn#Du8D r+5/֟a#&̔ lVNvfݜ `Ocӯ˔(,wzd/l8󷯘24l8˖sISOņX 2hU"@I ۱zǎۮ { y~iؒQ4jUBq-Cik%AtgfӰ) hhSJ< Kö,vIM))( hw& hkTy4lh%z#A]ݷY *QYѰ= a{xfpFl8hhz#>`a%h]y!,,ACfFu}%="])J4&s(_~ѱ |W^s{GSbQ,,Eb~צ]/\0A濷tٗ_s_+Gcq,G`i0@VΘZ5@l*-H˜LH-Mߎ  >ͭң@C3Phha-6|i<@10iBP4 3džB86| .6| ᠠG[, ȔhpXz$͔hHp. e~#_;"b rML$,}p< ؠ`z%߮ZcOEgPs̄WH$bT+ eoZ%?hlP*opPYCН ˆkR唽0Ե+@֮;[\_hAN%#!¡Ƃn` YSkpDʆB׼,W H RNlP]k פ$H|6#` dc*3<|3yzD5GvORAN?Ewݹr,O~ZI \]αHlC ͪ&=& 3A4L 6Ka$ 6)>L $"#^i0nlu4 !dH/2Gۋ 0Iw 4V4$1:sXQ&4r{~84|J@h ! _ /Zg 6| Ć3Q@,4zçPAl&J4$uk^$: h Pd4Ht `G'j4|IpgvE> bbç,h !)ӃL|GOL3 zy/ާb94)`< |08T~2< P |p86 6F26$}p߯XfUނqԓq%&ss[rQ>C*C1i/|A_4d6%4GjR?CvԋJ)S)ؘrt񿛞sh8~*:4b#h zR@Cq- j!}3OC!;eIz@)sOǑ 7_8Yc 9Q1'UX7g Tv˨@hh͙e@h8S- E7g Le44€3^44跥}~R糝 tO*b|sߟw\ߖ.Im 8SZZ֍ p\,'ktž>Ȕ糽 ݶvO*b|w)=gZ.?)ggdI+4glF@&:}m4lХmJ5 &4lgYGG[׶À]3|*4YZ FL[`:m4g'?P@ój[5! ZBGذ:%CXayhqգL~~ҟ?E5)okl iH{~>v-a7ǽ1hI5jKJ6ª)@HES]k_@yR`+h'( nwע0(]c9<4;A~2վκwP&  4<"Ip8 ^bҺn\dRyW68e>@C`.ajhrp+ȝ^! VĆ'uzhjg08 w%`XpOiZzBWɓ] W w=< fyg4x`' Fj^cuI?)zi{|{61VHT<0|`aDh8zMNRX!@?ffѿ{3ȕji+W=*1Ym kuJ7" *Zh&h#mځx;dɔ!6U< 62<>ureR4lZĆ`b4>7/;:z k +>DhPU:b]5- 4q秷OJ5ذZgwΣ,=r-s_ihmo--?O'qp /uv!ي[~hXYavן{o9>AH; Hl/~G^ r^F!^4A䦽@hK3{}]/9y{>HC ʥv h@l a/-h 3Wݠ4ؙ /HwR{4 6 Ձа|w4ڸ:63cBu3=fkAhK3{ @L}U7h {)vfoFCiw`  * g^x E6uߩGt/3? eauHc@EvBxIOjW|:iHޙfVu'r-O#KB `^Dҿِ\j\+%Pq^ {`wh,]J^]L;ˡ-ޯ$a!/L=OVPxߑ)m(.hh}DR;bB;+TRQzh l&B4Qd6nĆ)ڲRN0EX[VNĆAR:!0HJT3Πa=)ɚ[B̀|טva@4^hПڧh4q{ S^LAUk_/ͥ>5(6@cFIM#4m+r܏T 9z*:{|ӠEԞ)/jh8+Mr]-4| .NORKctA4X hOLF3)Sj'-4A4hX@+wa. v#{-oBCꛩ3c});_B))d`.:!f=dZ* *ySi*숨/Ƹi*ڍ!jhpwLEx vA)ʥv&z`* =jʥv:{4x>\j7~P4Lÿ*Z8:**-1P"ATR;4j DCsq36RK햘etBshzOh%UN6 Z`e^t"f*UԮ3h=o !UnFO8hAj?-UԮO}GP>)x9QHrk\jW3}4PeF>փ7rq0PQ 齳A[NHT-V>:L/A a 62x0J̓-3с$]vM8@7 D- fɓ S[ U`E[يITRvPu"yy'%8STR;Hl#t9Р 2%#qјDSH3 uzW{i'<8!5O0hm,2%Xv0]f4MUpLfc4hH`M{ x:6nAL?Pa"hlP]4JRt? >h`h Kn( 7ݳ[p "$IU.7Ui!uJ ϒ|-7ň g%?Xƃ,ͤ*O?6>Ⱥ_\) LDOs݇e'UnL8a(R;Qe0ZҐ#tʥvaݿRK{{HRKMdECiݕOTRU&xD(Docn\j'ShYWtgJ(~BU:ym(^ op6!wTҿ}mM%)hXEoc U~T{BL P*m.A2-븲#4aߗvL4! 4\_kL㯂}4kwfts4/Nylm#Ӑ}G ]vgQ-ACyLE!Ԏ[4R;Qe0ZkРsA .wed#A|@C,SrOi'!5_jҼ,By(kt7~9@C>Uf\))Yap$`b÷^:4G2%*bZB[x`삞~q} 4hpʓ2Q1tL p~`9G;A}y`jӲU9CM\qyy9f@6ʥvi]}wG~p-z y! = 8@wovů7R&u]y%kԮX,7h:xuZqkþ`= ab4&}F'v{џTtЇ}* vjmct"`0BdBrs.H=p za)xFrt"`4BlʥvfaչRKZr/x4xN\jœVЪ h7̑7j;>jԵOi4CuW#]vIj Ū,1%ߒ?EH_Xr9oh"r͖OSK;Q%RZX3L^ \L{*ڝ'GTCnZkVl\$O?o/c@Cʥvk缡U|U8h~V4c{#U<<*n zxly/%+ka $0=ɓ=?4_ḲA721C Ln4@hP﫚HBc 5r.L>$6hIKq[\̕׼x" WKIK?EFI_Lһ7V ˤ?%E742U5 HjwH>3*C[vYn5fw" lߐW\rgt@h^}- Τ4 C i? 282?57x*ņ$ /]vc < P9~B+3o_߉g"d_|60Vl?aBT$ Wi'EKVt) TRoyoтo*mou4o)>7Z@ەzwNTu4ڝG؀p@Ct,@Ánh 9h ʺqH44Jb4(!(p@Ct,@Ánh 9XH÷os>-L6 z 4?ř"6/?}xi<Ճb S:P ʺqH44Jb~x NI@͜;$4+u"4|hh\Ćs];2Ps]D ݍh8Q1Kgz OrEi?yijTyGz 2p3@osߟh@؜~v ^&)^NuܡD8T4hpSZ)JxyJ''vеf3]?$]?gѤs30" i%m)s~Ln6?6Mm*tNLv6?5Սm,vKa.Rm]:r:܎iOVӦi{-unY8;=D *>h;]KK'z˾s?54+l;"˫fCy1S(6tru[>"+V#F7WFj&v7[wێoUqC>;".JP1]l"]]|Ӱ)C+{bhv<6V:  p'ޅ9k/Og fpYkuktak6.掏6=YdLʟm'S˸n4kl FLMU=0HsU;Я1)^3mtxǧlP)<<2xxxPq]]IENDB`CDd-LWV   S ^A$PROPRANOLOL 3Diagram C graphic"` bB< _U~B/nB< _U~PNG  IHDR H=1*PLTE'3Mf::WWuu3J` w(/7>FMUl"Dfƪ3"J1`@wO^n}Ҍ"Df׈33GG\\pp)Rz"31J@`Ow^n}"Df3M"f+3<DMUh|:Wu3Pm33MMff3Mf"+3<DMUh:|Wu3"J1`@wO^n}Ҍ"Df̈ת33MMff:Wu3(P7mETbq3Mf3Uw--DD[[qq3&M3f@MYfs:WuȒׯ33MMff:Wu3M&f3@MYfs:WuibKGDH cmPPJCmp0712Hs?WIDATx^흋*KTFh{* |d\.K%p \.K%p \.K%p \.K%p .???g*X\0NKi6 8 jsL] >h HlJ'eE׍RhӅeuJôkFibm>]5drkiq$h$6硇L40e\WE!й5Ѱk_ 1- 8=z iO40 G i`p0kU] qP!1:d߬&`.!:;iF9G 7|ͮ\13KˋTK,ʄ϶-KU4d3?R(!pu#HNast) `fW˪Ӊp$+d6WC V aB̃9w[JG> oFLg&hs驏9NCso3 dMi(ܡp"l֮çBrPnr]Gb BGK8nea,Gƒϟ4&ҀƋ8A, wƌ?7|Z ǎ}S0С4zA{\-4@v y?dON©:4<3닶_tY~br ildzj#\&4p{\Y4dJ; ۸kr; /̨jE98 ZLw; LRKgBq j+۪'AJ뱦9 }Øx hx;U>o ,^a[[5yÂֵ['݃p'uu;oa#N&6좨}3Z1pP'I!g JH羷; ]8%vl͞ k݋vq9k.O>hhk0=yͺ, T9V(ݞ3"=L4U q48 ϙ@MkJ}ÀYfyӆc2& bL+VVDtÈZi`v)Y$-ȒsȲ!pB$8 %ؚƖs2^(>bq) 挖]F,X}+۪aż"~}>~XrDSD$,cWyט$(`J6hl3 Np6 >YlHV/hJ)h`mˢ1(|0&7mncofsbt H ~#!M|I6o`smH*i00΅UJ? +Uu qMiOض2t֜הD֔)!)tVⱢY* d d_M5p8dg&qAq1"c|-|♘1WBTVs7D5PCNC$V[i>' ]KA؈bd*JVņE7HB2R8U[h8Eg1YJ_!"~o7`D R@ BoFÕ^_ LEW!tOz4 sY.`D%g>oAKEJP?O ƠSsE1@fBJgz BF!3VY? 2@i u#h'k"$X\MDiR5 IkJ0w!~ؤ!/QIL1#&@XMb kF4LI̳/pX^ Ub!hzA(.i R l2R3\ ])AZ-}v S|$ҢQZL1m,JF< W&W4M\`֙ѱb҆kJ%ilu(*|; ylFufa@ ^n!"K4R !\;k V2v*Nh(0"mlV-Z-!ŝd-BR& Xm.hm T40s9JC4DbD 4>}.pLLfbUL*d}xTgN?JVU@Di, wrfʲ*v6pNfUpʌ|:QغOlՊihh% "{$:4,Ji!3Y?-=ZA QK7C T6Eo"{%JN}_,nʟ;4sF>7|B%Ѿ ;݆LR` ٶP/& 'h ų9KqP.%^S*If[ nom㣅[Fy/ X50/y1o57r7U76흢ݍӔXFJN~_VwۋFC>lJ\[X] lUIOK%~R^ Rրa7Шp Sܨ8zi$n* 3>xu1򻎔:B/Q>^4 ˪!a)]hD6P^u֔R,PO# e-܅RhpNÃuibMjWPןS~n]B[F3'@`}% QHzrj\+ #vf]8ޞ%Gs`VaIgc$T;oJKTk'4s6-ЀQZEULjO+4u_MiPٜDiLqޟ7(#|䓠+Nv; JEHׇ4P\S#IGfCHI8mXy"ia櫔1iO62uސ]uN|ăIa61qlU~wg $_a 1rYeTV4IH}TӲ*jcV(,Kgi: 7Y#v)-!(x@IJvE#Zn+Hu ҫTۄ'f(@v ^!//v6ctMI޲\sr7˺-!a C0mC{NC& )hhxnoWV&*vy^!-`ͦ4rJӎH{oPPAC _BUk|y'|NCΎT888pk9ߘr߀㩢/Ni~k!^Jf>td՞B%!A۴K{Woє wx|Ri]ѝe1`S,C/y5FA#q!Y5!!5!V5&ԜmDCZPoKCWeDѰ.Ch\\ ht+iC~[VJa.#%[sr7̱$(i*Η &vtWpX9T]qsJ4̍[ipL4M{pl WrY"SsXqpl"2N ~Է#Otcf9 &eaU;'- sg8 2G72)M֧Izb4|ڎ4`BbN}; m*vmINCG;9 yțM6Hy<~9I:B3 j󆬤8 6xh@N#+BE;(?Ƕs08o+/%]vB%qn}pM: &U30MYAZ2*{ #Ly41J4o)+ a_ AL'+0 ֞fWVNGc*._Q=VwlMɤ̗4 ;p*bi=.1t4DeU6fv%rIca! iq0B` 4Sw"%mլNC4n2l,L5ŬG@4 &y4ʘhC=5@I!hh -4`/a;&O}b`&1-.aMF6#u8Y{hͳXi8)&[D+:|E+~/P1uiЦ"roU_af!]^V}BN0_j)HSN-Min%me`[5VZkM)g KDlT4fo_q`Ӧ`17,#>NQNYY:g^U%9ByWNN;rZ aJʝWĎe 8w\#^pNðfdp\HtUq܁ p^U@nǪV]?o`ǶC^A'·RٕVo. Cgup-F|*{8 ҵeW49Q] %aRj֐Go+:iIrz%rn&@~7*-3 |:C h{T]M^=] |/:_YKa}4[uc{_hեGdNM-4%|@WzB n: m: m]!Z(dÔ&z*iPLJ5v}m}2o(׬]Vk Ħ94 MbysG]L\ @ OR4EJ'(EHIhA!$0àlU7Vlb\ 6t`/wk?33Sw~EJ<޼GC_;ihmUʟљeb\Yf+ѰH_|6ɔ+U܄/V;0*YNPRzO0+.΄:4$tChUN+" y9Xr^[vFE6숃& }Zc:ƶBvj]4|A.4QX9* h8>c9 V ?`-]Db{S]a->>;p]SR}dS`PSlOf7ΰ]Oz &'fנ4q(H dVPQySBVw9;v?JpcRhMY kY#͌)BFh "㬕9 zgTqϕ0AבRq\viAK6ևZ/M7iUFOK !0yÏFJ3 DCB!֐Q﷔4|&~h(>^O˂4㽚},ZV!z?Jx=miY^f  UUi ^4m^4\8瘈Wh}d7'H)!,%80ԡy\Q'Ԅ9rfѠ9huYe EJ3d0 \p)4SAEeUZ!C.4tz [ֳWv7 #ih`YEG7Nzy* 7=DFPc 4<*{ko0iX*hCaWhK4̱yʟӞv),JF) +oMȓ08 mѤ|Me3 5&8E}սYyCݳhM6_Saϕ DFArmW{͓hA^~bStX!+GO4ܰƱ94</E[qͰ4G3Oѽi 3 j% v~vOmT8cL4ϥ HJJq6ݦR1>!N*ŏqME7q" 4Z4TMTAqV{j/p"okOh{wH;7ڐBJAe;6\&ļ!рa gweаz' isbwT2aLn(mZe$~ttg*aDj)OY~) 4ďKLBPkN4bkR3boi)*UMId~n0]gB^liB~d|}s; 6^o5T1!`&r6mpVnצM.?ڴgZ]6}l[+kӦM~kvmoܮM>\~6۵iӇ&r6mpVnצM{?{@?%Vg4VGG]t$!?nЏe*W ! j_Qp?3*& ؂օs.! u{-0/8tf߽_`\8~8| p ~ cxam{_ 2``hd?CS?B͟ma-O#}~Ap9M[cJʎa6 0F+gKZ34ԓ wD*MxCkkjRMe1?!ðSLKcYB:1/ i|-: dzQsN$z*4Tc]`nz N4'CzoHXUpo}ܱbJkK;bށD(*~ @-{!{Hwll,# R? mGCXQD;#Ʊ4ĭ9~p 7O yvBA٫_ZS:D҈Ti-cW XD2XS?HiXdCɞ6 wJ-UzXiy[[g Uسѣnsw+ cvi"%&&Lh"`Qsp,5EraOxp8}^W88 z9R lK/bW+L~2 ⴮kJ=JpNC Ks,$i}ȖbwU-UG:NMF`ܞ'i9 6rl{%w98 6}8 6`Ӈ`K+JNMNM~/8 4Q$Xb3[ZK#J^\;vgfܓ&rqpljIC4yx5C'a X5Xz휦c?KCy]iM=DV xiPi쪉]ic !ID/.nT|Kv6ShN)Ry,GJUpNCE{i51W/̿t ImrZ1406h %R:O{pNCig@ @ {QiTOSxߓ&s qg'$4h@ld ^~`"FĬL1`6`:j %&`ߘi86+44~Nd$O1OB 2Zp" ;)>Tɠz31UG]U]49 Q'zq9",5 5_ XmAD#CӠI`%?!ԫ5s׾@+a LŔzF,ylDbfѥXTPGLgS187* XYp+ d4Pô%[PfߜBxwa"dPzR0 0T8( 0l#P\ XaC86 pX kr*A"^Amw-H=jS6 3ơi09ZH)ĉHII00ii0/3EJ7\ shGJd1i1ƊH)!?!Nr@dN l2 ޡ-98 m9)%?:34q8dfB9 d',G;tdaw3f!Ki-RjA;u0͓[35M )`J35XV4BI %F6e-lO%V F]l.!0s|'# f5;`:@?HAl34hHI LqI?6P,›J9 \74i@Az_yzE> 7.i*F4}JF5܋7SߤA+Yi0`ڕY4WqE80pcAw _T}zмS܄b.Q~b#~~AY!cT\B!$ ~BdT4P]1 Ig+8H6 p8ѐ/JIŸ)؝̼%064hUv* iH774p i !MpO$ܽ^ ts`Q>W m ᶅpamwyb Hg*imi0T'-5,KKoCv7cf_\,R&6F/.N+Y/. @9i>?wxtFy9c1V)Eظ^V(9DOt4粼)2$=.wucGiS͡!-q-L0phsXhd^t \jfhE.ضr[/ҥ}Ȝi4pŇ=h{݅v0+ 䑋Qx sV_JW5C4fa8NpPG4c%fq[=|~jߐNn FOwIC$Dk4'oP1>}W.Qj8b%)9 zux)E2VʷҐfj""1 1* 4sC/%~c4}=JR? -`Ўk?LCi&=n%: +"7D1KOEA7b2h;'ѠS\SV# |~TL@7 z156|A)zE/NsO)uI0JI%MQ?)}S8'וr$wU #N/]Q4'ƜyCzؤ_Cݣ/PXfR֕Ž30`t|/j!t;CB4?MdAү:;ץꮼaɌ٭R4p(+E?PgTm\fbpbSvs^rYӐϤO27&ٹ.)j(XKxaK$sH| @N4YJg}6A?/A [ Тt_:iX,Vb`+r!$Prgsb(T ~XI߹SvEJݪ0oӍOӄ"hHx@wZt+#L8%m+=m 4V)AuACI,zW4= Jz|:8 h7Sx󆘾4i XI U lL bQYSJהL`+WOM,lSM̒Aѐ*pCTDh}9 AxL|f.Sӻ~!nUhXIɜN +)44(ACt*ttrZ>UJJ*: *1mIJM-: Mmpu౒FNFJ[pAJ %: !mIJ M: cIq)߃kihhM?ǟM*[ִ4E}@{wi0cmpwaLaԢ,6аz9z,%hi?Lۓ'hïQ~a8qH4 'a<<4]V;~.C@ecTb4dń;uJ0yE"fq@AC*"j *mʝ3zn;q}و5BDCa&]r ghH tQ!YX6&302ƈs>oh{߄~|McYp, q ɷ@9ҦyaO1C*; MqoY!Ű *SzU(i4Xy_++i؛MM ^@&\9B ԋ\Ez)B{4Titfvr{FhM&. *e쑘P!"%>C4mͤ!&ÃceO E`FG44Lj!4Ҝ0$6NF46\AshoCNʬti!Q o?n}CzR_Hk!JynE&;xtiyt1V^LNKCFC1a.25Yq7V5_ZjbF|}@NE- =Z  -rAV_BpZ4\P8 R>7i/J,jkh{ݻfv?XA 6FñXVLU9 슕 4ГmyWN]}2 =8hy"t2\ x4-1@`AM:Ng<0xb_Sj)t|e1~JJR9]AExΖ1,Wf7c%+6&eH :v$h$?2=27NY#VڸO*u$x!4vY@ X4{Tfbߦxg:ˊ)> f_Р:3fbA>y$I4d!GJ7P݄{p 0menGCrU'/aNˮ|C+V:`8mMi6Lm;l)p^S3NLZzIC=sm,q9N4+ؕxh%=-[/s48-}C; B 3i ?*9 wdmJ3io: OZuh(J wwߞ(ixBOѤCo*9 OYiq8ixJCAC>v4% M8?4i/'Bר}z 5 CQ럶V!#= -)ok YI&=}y편o G~qP>):|C4N>ni C]C4|23axUq2$ׯ&B0Ē2{6,E |&''P6 冂Iv4Pw S#J{4t겢z)'?$Ҁ^ J4m 8 זP>qݧimIC!ca4ĩC![o[(t:RrN:K G"¼!M0gH4[m qIC!6[Q hH F(4[h580ww`rѰ5,:3M\·o#Ւv9S=6V')F HECP$gbސ/?e7/dllݦ\C6spP-ul͆yacQWkJ4F+ `h}}C. it ̡ [P*ɽHDJdq2,m:p4p Fl|WB5oKm h])zL m/ƣ>vP7zKSU`AXj(\#O_&ݖdMgi6}xu1a' 'X- /l6JwUlhtSwumxViW2q^D9 :X@mߔtM!&O)р i4HI0bBH4h.Ts"%4.Ӡ3DkS=DCI~Q%ϠA.-S҃>=(|AȪߖʢ5Lh`(sYz 7.TN^ RDfN瑒:;ץIg,n[mjl%ZM!7eV{ߏ0PR ҥ^hȞ` O[pXt4: ]FPL! v;޵ތ4D.d&A`:u֢w\m=_RJA5|8ڇq?M([XR!R4R.) %0qڑ1j4D Q{pA0o@e=]7 fڃO筰bʼ$4Z$y\q]̢qz-MDD5޲L9M[ o:&bD{?7dcN ٔfҩL~VN:KO'4qFO igi،eO[ kh U[4աj/$Ի% [r&4y|]Inmp!\{aHgDyN;rֱ!lWle,q߰& 8Ow̧anL~Le{t6{hnk7g/هKeK߀ہAҘAbr LoVy9 Ȱ!mmdNǡ[M-nmwK{2l:uy1Onqrf'׷Uqmn՝0&EۛY}){`VY% n-lhۍPKjXii~CA-1-+O׳Š QhMi*}>t@keE[Mz>x5 tc=s߭@g".Il;ӝ*ہZaTo22E^ȆXiƆ &ϔ ++aL}%-]!ܷ{~s{.!W\.$I@ A, s`!$ֆ鈪~H§>An dHG9xV}he?3"|Brd)l0^r]>^0v&dqfkq쨫^K@Ut٫/د!6&/#l\`& X>qA؉9|•x 7O%|"( !* ٬G<6qAsOX͎qfjTqUFBy6gYz7P4OV&zul㙨mbja݁-Ҷ`Nf >Bb/?R>.LbOFNpe&gQ9 LE6Wp";Ix![JO'.sf+nnYjr׼NuGi !yI(Vp>i{yLY$^L޸3~,T̓;*TjTP#"U֫bP_J_>2\vɹJ&AeC쑗op*Pa*1ڛ#o87K[D>%Zeܠ]o -m\%Xoi}=+{HS2My̎ U]xEYJ'|LBfP*?m:T~`$v'f)Ns#?j`!oP>,OJq\).ڀ23htK%E7,ʝM48c 6栞{cIOHkqhWyPsԻ**Is^ULź\{D/q8)bpr\Cz ?z pZ_6H{M;L&Ԛh6q*bZyj\ů3z+{ҍ..DdHll   s XAPencil 07Note graphic"` 2Pֆ鈪~H§>A, x`!$ֆ鈪~H§>An dHG9xV}he?3"|Brd)l0^r]>^0v&dqfkq쨫^K@Ut٫/د!6&/#l\`& X>qA؉9|•x 7O%|"( !* ٬G<6qAsOX͎qfjTqUFBy6gYz7P4OV&zul㙨mbja݁-Ҷ`Nf >Bb/?R>.LbOFNpe&gQ9 LE6Wp";Ix![JO'.sf+nnYjr׼NuGi !yI(Vp>i{yLY$^L޸3~,T̓;*TjTP#"U֫bP_J_>2\vɹJ&AeC쑗op*Pa*1ڛ#o87K[D>%Zeܠ]o -m\%Xoi}=+{HS2My̎ U]xEYJ'|LBfP*?m:T~`$v'f)Ns#?j`!oP>,OJq\).ڀ23htK%E7,ʝM48c 6栞{cIOHkqhWyPsԻ**Is^ULź\{D/q8)bpr\Cz ?z pZ_6H{M;L&Ԛh6q*bZyj\ů3z+{ҍ.~LDd- MN  S XA$PROP FINALDiagram D graphic"` bKDTϚr _|K~ntKDTϚr _PNG  IHDR #v PLTE'3Mf::WWuu3J` w(/7>FMUl"Dfƪ3"J1`@wO^n}Ҍ"Df׈33GG\\pp)Rz"31J@`Ow^n}"Df3M"f+3<DMUh|:Wu3Pm33MMff3Mf"+3<DMUh:|Wu3"J1`@wO^n}Ҍ"Df̈ת33MMff:Wu3(P7mETbq3Mf3Uw--DD[[qq3&M3f@MYfs:WuȒׯ33MMff:Wu3M&f3@MYfs:WuibKGDH cmPPJCmp0712HsGIDATx^](L_Vht_UQ5p \L k5p吀rP{VNͼ8bzH^ECpz?߬ՀufѤ vpyS@ľV| BØ+x<{(DU>r'UטgjCy[>:ElX<]b\ yFX Њ4leށC -U4DЎ?,аqDszxx ֡?8+\ ahb{>UgK0O4`'b%=a}+ǫ" } Os%(F7}rv"@P0!Ϗo8T7#6(A8ǍS@HPL KR(y#8\yg$AóAg8Ҍ>S)9ky ,_ 7y4b ^U)Ӕp[V:M? 4JȻoqth@tH8. [14 w>0I"6a:~8bo(6j 9&~ѐsA!A3rx6Sr4E=CCf8Fhbghj Z~ ?j.b_MPpp4χ{V,t4ﺕ _C#<e>3hgl\2xF&K+l-4UtBC7t͆0$H^v4<Ѐ,⪫{c=,`wm>FGuGh%(%P[AlcT\8,]51ϩWl2Z{y 'QUp[H42Z ǿ.zcFYrB 4 +élp,!-apVq4 z0, 2vHSahR8 g.$t|15mZ3ΔdP4 E$wנ?,H{hE=}?~z]N, S/ihϲ}ݐ< ϔxtJYHh9tɩ ]p%4(B(Fk -Q)*gN?,% $J3?CV95B*$9+iXBL>Y˨Zg~ DLȔE2`;mSlQ֜ TO 6IJ,)3kGdt[4 hHa`p<` VZ_8{Y>,N0IfFIӫ%˒/?DheXƖuTo dv*h:'NxdKKȕ+ &Svd9,6Kn TҫoGa!kQ@ܣn*w6C*Z:[S"ZVOR8 ߍ"# TѠRϩϛp)BkdJxo@6 nѠzTOd9im l@FOۄ8DX"/ Uw_+84dž~T6*hH#(a_b! :vlSBB3Xc _<4mrv΀/tr d1=%fxݷB:FIKeBCT&qhud5q\!r[tB8pC!L !#ӣs ţΎLPhG1}qbh PS& 0[`52N5( H3_+Le 9{Wo;h`DǧM<4h@ d̅3S&9s~s$y 4lz)2"QbB]9Ļ }5! r{aM@Nq(^X)4uJabHH%Y\}R)NUd%ȈN0m:߱$VW̓ĪRBl87%Scv3 1|/ooiUӀ" 0dͯpQH1V3%+]źG(ɼff>q4q J$ ["[r4PȎ@!-i븹AȔ{6FޑZGCSɩ#:6gA<>Ŵqͤ(x{h_ʋNsT A,j wi@Ćt xN{f5hhT7ç5X9ySbn7>I'5fS묎Ii53XPTe,KhRv[5x w fhNl8jvsP؉:ek4.z SC :)w# 7 \#ԸhzJTc036gzA1̓5j#14<ԑLQ/h0҆U'i=,WyyNɿ~R2vEp` W=Ê*Щ-huX LN~HY~C}-N-)YG{;NԹRꆎůx(a>K0@s_L)HA?Vg2#HN+ۑmZ{Ff{l[%05_cZH~X$e@1'!D TtlB [v?#FTzkq>E+4$4icQD¤ϐvIU l*! !l@ݐh *82>#b $g 00Cx~&ŖVӸ961v47SC5a$-lDIa{KGb#|pԯoiُ8isJSx@CtkwF-5q4XR3!4rܹS0} 0p*cE {8,B@u[9< B_NҏEף+kk/=ۤ q‡ y yG8ݔNo剓{}X?;-aЫLMj]籡EChvkLV6KGCJ8uJ GjACm:&Utl# #S@0\גk*kGh%~46šEXOoo9f7Aݸ{\Tt VR) dKمx/&z2vN\"mY{"y%ziGXx6@+T\iC?Ld 8>5,8]#u.}Ai"5ϫ;_-V`{1utPW\:\Ǟ_Gf CH8xB<Ŗ['AMR"zAhK,`CŴBFe6 x#%sOs2#!(Kn"dIew8K6 WqzaBKvw4h@ʏ B(HhbL>64#:RS@î X4I%z3Q0h8_HohР!: <6 2XHA#GJp~d~j0у+goؕxD ! ̅L#._PW>ZYGA'CR^{ PA=_WfU;놘BUA! (ftISl55Ve>uJ|6x J1&}:f-;蚲66Aoq x 4TW)Xxi+y)@JKHޑxRXРDk:f dI⦖طHf賥  iPK>ƽlhU*uly@Nj(_ SwPGլʄ bUn-k98zLZ;b!ӉlSgs{|\_a 'FRUc[1b BO,`cАrЀX\34h՞1@| qX[ãrChUx^pzlxaP֥w 블 *ko0A ~inċ6_h֨}o}f#Gr}|L˹7fk1S٣E* ߻$y`ߴZ.-l8*XW>2{^0wOo2n/GNOSBE DB$ /6Y>$βNQ!9$U-ykߖoSXJup{,EJ0L3D;dhh9|C3[߭)ѦsoSۢF$ֲY j-w'F]^EY ]%MՎػ-4"V Sr4,A|  {Ćh{Y!us@1N̎MP%)[GU \/Hi_ACuWao8@aɓA[ϭh8~ kW.TͰQJ -X*۽Ie؊>- bԡe7&co;h$KI/р*RkRl!}Fѐ޳2zHy?s^EBGJhgKm0HG( LwNԧd!`!4 JS0 5OqQr| ?% &jd &% uC400s0A=,D|-J>'I)!HAdJPզ#hPBn/CT7T9ޠKJ,>µ~8og[$o/QD݃ CHJ|1,9uh"~D~ɔJ]}'&Uh隄N̜%hr.)q (*-Gd)zʫ,5D{Ќբ8%=h\)b$»r܆WB%{( ^UM +(C+>wPC:%W=hd;D]hH X6^Ο2@-z_T.p'Wj DQ;]U0T ћ,U%+g%J[S>*{*4#K*Cc1JԠHKl |XCCGʑ0]U0 `>> G_Z7@F?9ԪoCD0 |*ғ5[*@Aa<NVERe=.<4(lZS8B^'\&B-4 %`И?G+}>L,G$ AkJS[y;KHp0PS|31i.DuYJ' :kV<(=@8:,C ȱ@ KGliFyFKW4u4pr}gpj*¡_kh#hDYGCFfGE`ɝ 4=RxD{>}Mڥy Rd$UH$8BqKiJ[ku 4SV X`8Awr:vaТp.xO1CJz 2,D8htúqh2j^m5kO Lp$0 |ĕz藄2Ax?a 4t4`v#F8 ؘ>ZOPs5[y(kdhGBz< "jdf&t4$ h|ш6Ur49]K8ȃ4℆M:" ;hmϟbSGCS72+PR < gٴ-2yH1 A[>g ;ٗH*Xap kp:BTg|5ErDдl|P!(B/tęGۢ|/ =iȬ8s _&4W,@tdž4_rh&j:4 uռ2'[z1*!'8%&BIȧ&c@h:vM|C#񪀕2II>rXyY8($ yޙEϤH籡*[zѐo1!J2ˎbW<1(=CC8U1#1Kh𺡆Lw(uQQp P|RȲޔ U4tqگ!]1iW0Cy Ut;Q *0u'p&~Fh(ř/Dfz]vA?\4iV+7,2w?T fh`[/26b^0)A-QĆߔ)EfbCfLD:׮QLӉ%K4s Gl-QIFpH9j&ņTI:ΙUf2@õN~+ ҇Oޝi5{h dp62KSlg)zz48A+0I*ĆKスE}NGC, GQEڛaL#ofU͞u$jD0 "\PN$.yߓ,r@mdZ38Dg6<d'4mnD):̖sHgx>` P%Ӵ{W@񏺄&X (]4 wghcxs.lmxy [,4q=6,@,-P7? xk;)[k}t05b1A!mPy!$4Li Փs̼bD#Dl.;:4^ g m:bB `~P9h$ōnpL w o!MKK4Be#QQF2ɺ)gJtzW ],gG<4X"d3U3הh5:fu,L)DܖL i$jQ4p*΢fdž -ӟoMCC\x`M)thPG{807ʏ4&҉#BCpQ ;_V ف(H "|DcT2形O<%TP '4z8!ch  iWQjh„KהQ_ }vgJTewGS┟:Ibl+8{@{n6MHy"T}KEX?y1:/sgJU;K˞~ɴNpذ24uDcw[^/ ^I@ 4kWs%cnj7Xa=i >c#j$3Gq98fhuֳZ0Aю Jd( :l( *ð`(  ^I[`͉Jh0V,vECydnG>q+`pG:10RKmNuO%zB7jF=ŁfLԌJs˰yxН5 +%c. vo3 Jv˰}|qmxi(>'ۮP֭[s4t[⍆VD6eƧD#y> p9#2'#w@2zL 'АI)b_گ A;C?9t CAD f鯠$"AXt< v#H?|*-uhh3k44I^W E"dq ^i*si\ 9=2BC .CYjq NO;h`h13./])/ꄆT7P,-[fZɴM@ g8C H$Źۮ *ݿOtoN3de)!* ٛTRFC> Y׽8,&i na1t̴M,Kk4 3]9ڬ G{`Xa#t=i6 QoA9h Ia )vhP] X:6җ =OfA}sȏvz QV7 =rL6(6+ 'q4q6uy|QՆsaXECyUr\!ɫ yRVǣ;pt웚8Ryt}ЖG [@dȟLw+C4p_'?$D0p #s*[=Tgр?Q# GC+\Ѐ.j[B4t5!P/op% E1B]*&bˑTzYƢ[iEdʀܽ8p! d{9!n3ƫSr"Yv? h@Iq`&z^gJ Ac99ꂃL, >ܐH%] vK9f8C!/D _n0@n{ V"ނ~ yPٚ3[,N%2Ĺs8h,3G V߫z QjsY,{mb 4Ѡ!w+V>$)ݽBhp44Ғ w44)+ ~0.7ٳJ|s+Tedj/LL T ڢr9q^Վ{Nuez |h]IʵSJR;{t@rU*Au @@[ <+'x>;z4( z_vh%p\8t48ƽY4x3rDt5hp4|yhHGCѪӫq_ڟh`7R1!ՀKN<6Ghw@$%gJ惡vb<G&vtĆtSP2HҚD_a.hxA)fJ-o - Y 7W6u4(6gJX`-4ܝamP7z7`gH yGð VBC}JooIiNǑ;% ay5\J`ō9(sni t8m_()?-ȻzY"FF>(SUhH<F: 4IBܡ|<_0.J9(օ-ұ'q6j Y7$iibۓXr"ڼ! W>/Δ Jt,)nD JyeZƱ]=#5D9)=er4d VkCHEd` BؐwR9?!](`:S5J/LW:W Mh/ 1 ))FpuqHf?k++"4&dže-2eEi+Z̅:q*bFP +RIQUǎqSRsaTuhXżUS2mǑVDu׆L Bmf8okc(hXZ c2-ǡ)vVJVLBz59f.{%[A:G Y&EL ցa=Fi ,ʿl}t0lCzDd-ge  S \A$METOPROLOL 1Diagram E graphic"`b>דJ ӫ µvݷ=n=דJ ӫ µvݷPNG  IHDR  SPLTELJ3Mf::WWuu3J` w(/7>FMUl"Dfƪ3"J1`@wO^n}Ҍ"Df׈33GG\\pp)Rz"31J@`Ow^n}"Df3M"f+3<DMUh|:Wu3Pm33MMff3Mf"+3<DMUh:|Wu3"J1`@wO^n}Ҍ"Df̈ת33MMff:Wu3(P7mETbq3Mf3Uw--DD[[qq3&M3f@MYfs:WuȒׯ33MMff:Wu3M&f3@MYfs:Wun?bKGDH cmPPJCmp0712Hs:gIDATx^]n)srהA1cUb`K_jZ@-m?}X?z^Ws "5=z Ƌ~}+?7wޖ稤7(X/iޕ1l1icl VomxN32'?V;ofϾ$ A#%wIpi%~32<  8=5ǎ9(\\r d@@Dyh8avzuJut%9cfys"K:Y`u}]ac'(%m F5Yb.c ᳡")O +rU bP=?pސ!"?9D0Ժc5ݚI'bAOno1d_%B|H:)i>@!U=Il4.FM"BRʪFv Y.T7[6Q8)=aL a1) #6{n 18hc V2u|5*e?>Ć!\Pe{"OGbݾJ]_:fŧl\_uUp~C/ ÅrmX.7WgS7Hv> ߳k}a:,t.;֍Rtr~F_vkaylXOh۰vBɾ{|1*Hpۀ fl7^͆BCKq\ 7~0᦭3!ej^!6ymhJCe r/[S2%Yo4pIW߇zY8K09K{ZbeG䶊p&U`XuT8>"-o]φ~GtA'p~wJ~vܾQ )ի\ aV@4{Qcv`z^Mh1fC^ ^Cdݪdoº YˆSzT&nrQ:HA7TrJphO!va&t0_xJpꬋ 0!3xH甜R6\>ur&t,-"[fJpTe&t ; a { gul[`=4yC`os->Y)96쉏&ə* sAeXiZhc8:1H&-(x xf 9u ᑓ@Ƅ"lرL3i BxM)4VT* a ""TWk9dT|4}l'ufdHObCOa?ω uL!ou0ِh4 HM$$U.b2Ak`0&1LJ8k_0-w~UЩC$ mr~[1> `<Fi̔6Dp:|O1Ql(RF^l`:Cݨ+:Tcx?R D<&DN{GSjX` qE<60N!J vV2o @ S"3|Gl!&*PRt3%;"L@AIE H ɀ{N6N`6GRB " ?t&`Z8T[bC`cB0{%pL.cT4s?g`ER%Sӆ~tP60베F6~R6#VB6D* zpX0 L2b ņ~m~DC*I(sEAs3I+gJ}lԪ$@IqÓ*kMG]FJJi V6qY?VЛ68gn 7w !ʆfR,+ TjtRĭo`F]}ϳȲ@Ђ QY1XoQNYlCQ:k;\FUt2%@ji$ d@_ ^+bC0iB[n`:*E7yXT tE5*;u$]^PF?֔ /Eا!s-\~wpRՆd ـ }2 6Q|MDg~"zN'fCZ^y'K* VoU${S9 ۰&і v0KyeCB2#~o ~(GO-l1o6H H=,l豦>} A`^f?}zT-s7_p.lqgCn3ց/\zVɆ*w{tƫ{HlBLˋ&D=} g#ʆ[`9pO5yxG7$iSuvzVКuK(,⃐"؎6 E"6@o<,W/Az I6HR '> 64oS{)D>@&D>tP6GkJ-J:ΔBl >^FneC69 덚l >` R`9;3Q6T!0. ^ HdgjlpI%FcJ*UHh~/-H(Ya5OTM_  Hh 2%y 4K:R&e Pj^2ZP$f WXLɳ!z(l``PDDa9`~O0WXS6=7Y<hB'],_And`WF{5jߖ) !\2cO iq`ѐ |/bbR"mncjiE*[]`0TalXĚXv YN2c (W q6YaDΎ(D@zr"&Kv^\v/lsmb7.fiywJ1SmŔ |{!lփlGA!>ޅ7hɍC8[|Wc}lId Sᥱ#z]LaW6@hҨD[lCi8!*$) cOϢɄۍ)GȄ/csD)ِJ7!8_d u8P6Jjj?t`k_,7I3u>KLc+9 &}:*$gqԵ1J/"4) IScRcC̆kqB2=!ۛ&(xMb ۻȌ2s Tl8gI W<Hkpx+B z0()z0jBBo#l mcǤj`jO.h73ϻW@$FbTffJ26-x@~& QD5Axm$S G($^UW3:od,7o+2QD8E6Myaښ͔$2Zc9 {)tw Qd/Ľ (T]}D)dS6T'z2%iJ׷Yol 0Havs&ie&fv1I7,]~_S6L4z뛢+U6H]i*cj³v#bmKo=ض"`VYIpP]h\ pK.GV삻EHK8C3r#SU#eCD-)ZJe \]A엎NqВ*:\yS$LH䔻w[T v%yl~ե ->l`I6s/;K3lAClDF ,D:V6L44ZDnl$y JdЮdu@*GT@~{vTZހ v X)F͔A@7eC'"l[eR Ё#ΒWDِfJ,49qKF6G*W6(Y邉Ll+fCҋLPgdJk'C>mĆT@-[oԽeԯl۳Y\\ɠplN ع\:yaC{ VmF7Q׸W6KSu قkg32?VwMi;tXV$Z%2%eC&4[: twlV81l  q%VאSW6?( z\]Hb7zfJA&\5gT74vpCPE Z6h*R ۇaJl`; (,/ ޗ(M >g0!tQ6Cؐ  "6TM Bʆ5HF o3ivj=VqSDl(G~^6=Żo-cݽNQ&s9}Lh BDZA0f(621o0ge]:YfZc^꧈!xYa<6@S'S3eaRzu|v@ABDฒ.^W. $ECIwQpІU*@s#ty4YVƆ9OhWgJbg>O橢ZT >5 Y156(̆((eJʆ!τ9`Ң"̄c6izDWDِ΢;.Y\ 2gȠm"j(hAs D4YeŒL!2(7\ta,С#"a>yr,:0W/8}Lx;SGa6:. oKw4R)eCiC+M7m5^ [ݍ:uZeCɞ(cC暤':6  ^>T6㋛0ؠaܓʆq.傄 V^G (d8[6A)KN 9+l924I4AИ*A jse9gUgrAaΩ.0Z nfؠAyN1araϭ"E spa]k ؠa ,+Z/qrAԲAeʆyٻI$AU)&WjtrAΦ S+UurAʞz ,S&0etK4s Cסloc FWly k|lXcVt0bʆk=! \zp~cʆͽfpW{[[ٰp lX⦐ cO߮,7B|߭<[q.AٰʆfpTD; /֤O |߫N^UvWʆ.M-mS6L8V(TKuYaF66ӎYC$e UEf~)2Syʆ'SKSTt9 _9i?^лKUvk95 ig"w1sҩ{NpnϧׇL?5܍%m hϰXG04Vgձ~'e<0\իzo %fFV;Iy#9s0mS6,Q̌4wIZg5&Q<`dmÝ -PrIu_q]8H!FPM0ǚV^1H 0h\섂dQ%]lcQ3$n>BXQE dpA3%S$Dtb pĆХnpS{5sj>SR6tXu"ʆ'4$;p5s9l honkwEGe#/H`S_VWTK-lI6\s븟#N [hNgRʆv@ mc ȕ~cPENhSdhNcCK)m@ uyuӨY,3=-nZ536n eMKVאؙ56 A0;3%S%elFܗ៧Gelx yajpjlp׼꽂 \g߀\b7>Ƚrv|_Cce|ϖ)q{nu6^l&  N# ƃx9['HWD! \߻?힌uʆ~+mP`f7w(X`TIЀ~26oޮ`AL UǮ|"P EZ哊cFeCT6,1v̘װ``&]hԉlRGs1sfKPm$w.fl'a}_m Ռ: l=ВaxE6]JRٰ]ʆ%fmD0jAVyeLO )x@ K<ڈaԂR6,aGQ6ZU^2Bʆ%P6,1h#ʆQ +XfzZHٰʆ%fmD0jAVyeLO )x@ٰ̣(F-*l`i!e(yeèY ,3=-lXe36l e Km9_pv+U~(t.fլgݭNlVӠ [;㻀 AEs5p" J򭲁eQl»469NfNii6d )Oϵt󤲡mŦU6plZjHN vA̮ 'RP\̜Yfs݇p2|q(3)~.fլÓ=<#EәeeCB"!x/:Cv̹{yb Y6{pÓ~o=؉M4?3jRlM^b\x]$lXdf ccV60 a K<ڈaԂR6,aGQ6ZU^2Bʆ%P6,1h#ʆQ +XfzZHٰrl[Wɻ(AYWO̹5;yf lp',P[ sBҴ(.fլſe%`;kj?7%n-У9W?O+#ƆϜ5DDti11A6@H&s![ie{Ą?~>]NϓG n>fK+xE 0gcCĆhE&:3jF؀ShPdU̹x\HbJP)V6Lepa|JWXRɢ^hea NlyépMi-ϙrf˝٥˔ʌ AX `3B]S:+udn:w=WQCzl(Ịٰ(F-*l`i!ĕνr.fl ʹlˆ,nb\͸@]"' '乘9W%(6!s1sf\.ێ [K2b\͖H 6vȐv,=B lnb@sjegb\͸@]"wt%sӳ%GOXo'=3jFd7(laLdCqZ( (Y_:3jn6dbC ѝlAx{!O*!..<b\͖H3y\e˓2li-p.fՌ %rlVIN<l9Or#ym K@F:pݢf a/΢v46|cNHjCT(YaU6|*Q;-)ũ " K(Li H>HslbNWXW!tP>h3&B/R;JHXY^In]*?78Wǐk v u%;ND#!-SSZ9o[Ata/ gdAl"ګދ ٫JU{5 l|H9ƹ#蹚vlp|Ȯ0C3f:3j6d̏on.mӝs5t=`MPCDb\͖;Pxvƹ9W@ߖ 73s1sfK^klݫ}<6#ȣb\j]z~ IJ59y$J/?;\̜R[ÆEn ?{Eppk083jV{<l $9Wh5 ~TeJф\TwIDJ}s1sf5.= 1ᯪ'hs.f=3jƞfCĻ[tQ Ht.fլХ痱l(-a)nll~t 7g a˝;Vڟ Ee6h^ۙyl1$!}Kgte,R46u|"Uѕ&i9csKw wOF\(9GxK~VzqgfƆվ<-9R\Z0]v76ާlNi:D>~l9Al+Ȇ9sĹ9W3e '0b| \pzf|.ܜ m83jʆ^ cJ-7l0dD@Ζ'<rbPo (kt.fl ʹܱIwF/O/GZ ě#\_]ϐA#E8lؙFo܋|%*cxWگ9(NcZl6޲S5Wo__f;x7wmM݌M[׷jۍQW`TɍvnҍU:=ŗ6e=j ]N[׽׶mWﯵpǻ6YU6[{b 9: teWԫSԜ+^$+-'veϯvR[jI]^-oՀ8ҪBI-o+s,9P'@tDbAUR z,\;[}IENDB`=Dd-li  S \A $METOPROLOL 2Diagram F graphic"`b<TGm< n<TGmPNG  IHDR !;&+PLTEg3Mf::WWuu3J` w(/7>FMUl"Dfƪ3"J1`@wO^n}Ҍ"Df׈33GG\\pp)Rz"31J@`Ow^n}"Df3M"f+3<DMUh|:Wu3Pm33MMff3Mf"+3<DMUh:|Wu3"J1`@wO^n}Ҍ"Df̈ת33MMff:Wu3(P7mETbq3Mf3Uw--DD[[qq3&M3f@MYfs:WuȒׯ33MMff:Wu3M&f3@MYfs:Wu~-hbKGDH cmPPJCmp0712Hs97IDATx^흋(n;L$l )LZqя>k_+ +0]?}? =?,7h@h)#ϛ: Mi_ihP4DMahd$_PvN|B Ol%OܟEfw7Vs$@C5ɫ;hPpn /u*p$ Džu|^zjɣh oh =lC k<\V Qˎ>_x G%<N IϠT_&YB ij P4)mS4LrMJ$I#VNpnN@[g<{ߏOXpHuBqD'Zv(OY\# S?]?^h88=3m-^)ˢ=j4hT\is- GM739d0m 8b|ZN(XXw#￝>Ӱeїzܞ Fii ,Wрp2LHnz4tQZE8 ߠ^J4+?7j뢯tk k)D"Ajm ;<[]>!sM)7v~1[G7 hE _ww}.uK^Pv.G35k]ٷ= ]\QǑ!G{1Խ} i ipf 3rWǯTIa-:BjACx1]JiO$A J4EH /̇eMr2 / T4@+1 fHm1Vij4"}1 6 28eP\ߐR,Z}O4@ ?Bk-Gi?QF `KW1[^\6pOr1ByݙVrRd%sECZKRRYn> qK<&ϝh•ff/+NY;3s0.v˳)`D+H <SхJ ֧5.bD:r 8bV5d #03L;;)ŠcLoL)[YPGJ|nJ1V]'Vf楛GC-~ܿz K͆P0H4@)"37at/;S`JѤ/ .DZ0j/:?ՐrR<|*N O* Hbn, ?\w<ɸ߿sxN*'dVAE4D_)<ëͽNBN3⚼S~2␹Yc(:#ޝ&xLI}fj= $FBLm6%0{Ҕ|IH e&лD$=&PB` MЅ}+)%Ȥn m*hsZĈq}|d@t ?6t })RksCe1S6+hl$įB:@9T-oؔTsX7E7ʔi&K@|# =셫F4&]̅ã "5vwl^  eǯ$7$.0#@'8ThF}|O(6$2dRt:=~9K.ϔʠ͚!OcWKe T IYpNژҐB(8Uh?F4iBvxQX+  |9Ml&b[@ &DC#=dha2 H䀌kC]ڈOX=Q?ډ".BG4a0@ivċv3n h|7&q4&^<6jXOñvK>d:{&q i %TiA2Z7=isQiYOCAu)L=LiKJ U\BJii8fqR2 :dkmL, |GN!֣)N퐏MChJFz7\ւzO).L#yBz k^0~g$Qf%DO7@7 [ҡO?K92bB)`/i0V5zB'a,z1}8J! yk'T*TZd Xx1MzŲY_f4xKqD.- sC\>epI姅6ߗŹʸk79 M饴֧]# FxW4zi_C%/f./cquЌ>K8:6EaZYQx?C<,Ûx 0i% /+A^<OH` a:+uh#[гN(v]qbP[j@P 2e3 ko r-nqHVCRB!r'?& 8bf vH͔94\uy5ȍ9આ%!4R5_4EƀNJ9vu>_0x1B; VJ=(nE 19@L=~lvJtbq/3.`=6 iuy-u"~+4QđFF^p%qGS\#j<8 FuJŞ6 gwo"z!sÞ&ȍS: 9vUdtVY( LBo UՐM#x))-oEL}eOxrokp}(93B-L(o뒆@lc?}ng4@K=W#Zh^i1Nު2# 9"<)c5":v3$S+,( .7qZm|W`$ҷ)BN^e6R_gjnpL4=|2E ܕ=^X( so7x޺vdG]-[2iNûƣb̳Q`|tP:iK]*G5);Xc#/ν+NQ3R[47 LuQ7VFqZ,BjdEK_ \>*oIe՚#v ʧZat-?JThTNC}irвJ\Np B$7zp&PX>J]Q혶Mq1c@ y1ɧ"ƝNVNP¸Ri$]!m* f4eDLh6$EspM.i 5j4rCtBCAdqn*Cq4ilv,7@P\)Ŵq!i9 2i C9YeFxn PptØ;PH 3bpX8 osl&m^?\Ҿ*8 [<@78 |FExt 'KH 9S$da4HT$FX Vti'ZIUFXӠV MVA)lЫrN"EB44(4(z+/]yUi%m.Hx[cGc`q(#x*}? dŲC4j45ez^ m8 zHxI;ܔ_M?7 \@~ha: ]LHF0i %7LKiH3t{ l*XqEBC0^$wG4 ;,.JW#1 IqP/#$a_26 "4g\C9cXih bc|56F"Ydb&gwg;!PT^Hmߡ+%7]}C "Ia %y4DӔKd% \ziR՜=fDG,2)=]vXI% 8 l] ;Irqzb4(.W*Z:}l--`ީy0^h Kk98EIòxZ% atQ H9\iWJEꙠ-\W RT[A1 4$b(L4u W0neD!:4vx%.F42Usp&-Ɂkb龜xA0x>C,IDXŊpQvHp`|ꔄKY+Enڕ1b~am9 i)]cYuA@&40 ,qQ~B=?]ۨ{حND㜀;5jiQɘv}Kq hNÐ(k44%zi\qZ `M\ikiwr_fٓ^7b$SW<90U4%+4VJ^QIMNZD2t-ݟ4ȴ{`4__3r|j,h;`RbH}Nјp:ֈ1 Pu! 4~bHV4 ZNV_>l$[qFqSyCNXO5o78 FS]tiss aįqV+ў.}XxμсͥR Ai5 yB1\*Bsz8z+/瞆-~Jɀ`8 |’]}Hga#C|pnpYn` 8֊9٪jx_26] ?. gkR^H1ZVii/i-qzb0s]{#XowOiֱqLJP?~UGE;0at74f} ##uS5 _T)y2_)m/pKO~>TGҫ!q~ i6{ ]Ţ=đuuZQ6#V{(?Z^qYG#Vi nMpy*qLP>ܰ+*j+J-IKND% jDArX+,d!^w iP44 6t`S$&U{3ѫfR;rxdTh$m.IZ%)԰ЀIDt Fq0[2> >*VJFC,"v F`g?Ӟj+Q|ε͝P6myrh P;<T1D=ו OMNb$ۦb#8 UHPi ΊA8cm6 A4;(CA%4¤1 v}Քc b4TZ]a 8uLmU6(w/?uGP0a,A}JZsDS|pK:U-Xx>a2ޱoJQ;Nx e8 =ec'C24졁|ΆC^Yj֤V#E~wEu0HshH7c̅ T  oT^HF.&Ш !~E@{f^[&ɊU9gMo8}msE^UM]ݫ܀iXIܶ>ȷ{n&4$Dklh5קWJQrMCuO =O/ig0D^K5u3; ˂B0Ca na%I0W*!@3IJ?2HuLo/](`@յ]̰8He50KշO-[U= A YC ?Όx{{RB̚LjQx2VNmd~~)`J+'akE4"W 2Iq!Dd2 D7KzmHslھQ tLFCTF`4hh}v:4t2|(F*ՔG̗Vҝ`yqظ~:ϋuGoA,{nhn042bo 0)mstc3(ۋkӼXP_)Jwiq#F!3`ni0T\8b_!WcGI AbņO4p %{zlߏ:Nj0Ѻ(_psX$@AApXFktt$.`Ɯ!O#[i.bsI󒁔l$@eK1<ѳ1=>&1 o,j݌~_ <*$: A/l0CiHuOC 7\JI2%ZV[)ѵ ޷F0 xqQp9 c*v6 2K: uAJ#xfWGLLq~&~^_9s̋Mh$Na1o =u =-2NCJ(nxXOgaw$hfHhMYz iז^-6G9s2f:/U7mۿiC8& {H<}KkϵKz~1vAmZMEއWݴ; ZpqO]fNMH z%]t^2w,0$4"`gWѦY0DƹhpwY= a0i0r^Ew48 ; bΪ_$Y4X9K[ŝ[=vA``4^i^S+48 *T4PոΒ_$Ksj[iN`/4LֲZN`-i&]Ŕ0Z4Lת4H΂zTYa B̻: `d a- 0A &Bתv; R<#a"[:mAzaC%jb} ov~8 W`A/_:iBU}vno{g yƷuA:kyv4,Z ;Hr3wSd7**ӰQGQ?vЛIw*W?GL>Wa ]y#t˙;Ю߅AG#ɒ_ ~$a"л(=oUeLt35>0яzlZ~%K' g;hdsDt{۶Ӱ&jj{v$=!pf|l .apkBUح=S-<D$OqEWUh6-Q3l cTgY U->NPXCm+#0m$yWBdzv q=)p^Gٞ{ X#h0BsCK!o FWtIXz]vX2'D{\4IXRqtK[@lAVW= Qƅ-Us0E/VJ xԩvg~iQc⨺R;,//Bw@EÆ -E <; }: ݩ A0TXg 3H4w =Ҍ҈z.BL})B/ze]hXO -Rޅ^$H3>H#)ʺ 2AZ Hf|FSub=eꃴHyz# (B+zi."GAQOQօV"]EB44 )SEʻЋiiD=EY?Q}S }'=  HOmiAZڧ-Jb) ;:Fݿ{h (- b:;tp.c?w9N,ez iBw"XaP;Wd5kuk0 -~B"7|K3rfa 5\H|4-o]3\ϧ:l.JWY4|<5lE80y_098 `AFqv;y(PmSHC ǁ~iІu}FMNEC>l>(;IBcD#=i(4k*9\J*m7/y˟BG8+3xL =4^h_h?-78 v4iy[<8 gf&` ״l7/&njWv,; miUNYnS݈JIg4,JCt"44,hiX$H3NÈzRRӰHya#8 #): 2u)4,zaD=EYA!SN"坆EB44(4(ziXӰHfeXO: w =Ҍ0Ӡ)SaN"GqFSub=e4,R^OC,q'GUQx7jCxYV3ʁ\j>CL8:lg^_h+gt~. ?ڢ iyC $k; -̠BaqjE*rk8sn?gjn4M$<8 vXpwa=DW;9:WNC{F&hC:1_)Fi0v%4&#=h",h!7;Rkqiޮx SJ&4֘m/.B*^8)uP.,GC8cewf3)!6NhwI Y4xV3QA(ԓfN"EB44(4(ziXӰHfeXO: w =Ҍ0Ӡ)Sa4 g#n|E A ة@V4HGi*5h7JCVU4TJ<a(L!0\& ; BFͦ+ܠ4AX% pw6E*ʝ8pK )UmΫa* ۜ TAՐ- C 7R_1g4PR! dï>tSȿiHh+guraS0/wt4Gihkdb1ucs@7~UmN\IzC^6t4V3C: UV3]ùӰHfeXO: w =Ҍ0Ӡ)SaN"GqFSub=e4,RiX$H3NÈzNBLE!}&Ob"Z2ʙZܚ qB0B=UUmL/iFCY]'tO7͗ UmΫ9Sjx4Hi*5hgE,z-Ƿ4TX"ti UjΒ;w>+S eVܼNâq <7d4dE4|yʙEՌ q IA.io0>B[VΌ64`J`uJpi0rRV +ɯNӰ(BhP/[L@ +7|<:2qE̛aRJ7d;3XZ}A ~{m߬hx[M[9Hq<:;.ެq֎ӰV|%Ӡly aN"GqFSub=e4,RiX$H3NÈzNBLE; iiQOQiPӰHya#8 #): 2u)4,zaD=EYA!SN"坆EB44(4(ziXӰHfeXO: w =Ҍ0Ӡ)SaN"GqFSub=e4,RiX$H3NÈzNBLE; iiQOQiPӰHya#8 #): 2u)4,zaD=EY% ?MoB(b϶ : C?' HY)s3]V3!|PEC6&H4V|0ԎZ S6]4\ulBg,5hV3OE] |*/р& w݌,8Um`3ZoM4|Dvi}:n98zm isJ,۰o >ɍ4M}12%3n='uNi8 gr`WJqc]]qWA> oPp}D`ЕRr!ihňi[ov* HL+ߦ. >3/6x7 P:~"82zZúR{+gZ#{f$9Y>d8$ߎqe[V<;Uo@[9xhXHַh+gD<:qM*}wixiofCo֑!ҢAr =Ҍ0Ӡ)SaN"GqFSi⼒wV۽ɮS[ E/ʙEu5cA~oD wm@[9 M0 qaK Y]Xtޤ* 9wy m@[938SϢADAica*9T8E: -_#K7 ai8>X!q5x ,3XeC 0A{UmL/9N懺#UQLI9he\07 ӭUei vJ0Ž 4E8 ⢨8S זD;b-|VάZ\Sjʙ5׊ЧRN"EB44(4(ziXӰHfeXO: w =Ҍ0Ӡ)SaN"GqFS'VDױ%X6>?-sTGo^WͻvV3\nzECقޕF y2 nj'"kUmW4xOC@PŽI4餡qV3\nڠ}p?3b&uĘ|ͯh>9l@[9< *i`8̠:]ϭh+gTK<4Bv ޭ% Yuɶ Y4a vÁ.ѐL(֏(|e7)Cg+>[9 eco[P@-/˻!X]ϔC3mi[?a-!rWJI-},9?@^eTT!avʙ7 iwl*0`QU Z% kuqy14Ǣ?{y#ggtW47v[ViX$ӰHfeXO: w =Ҍ0lz+ɷrFwc惡m.XӰ[7F;b[Ζ4=E%8 ,vYfл895%5:4 '/ѰRǥ cC\kɄC=aGk\ZNgRyАO;D.Ca0ʥ3=(nGԮkSV!O;wj=9  /e+ ^][coRWwC=o 宔^~MJَݓC[qv[4NH1}ΤUly5|/czra}-ׂkU'dwΗK}ՎQЫ|sNCGST~# m(, vsWWОOi]9vZ5ąh{:}1n/S-\;ݚ+pvb5{-)͠.eƼU2 -zED-:Ssx]PcAVΔ ,xr ۮL% SU@]yj]c>xu+f'9opޠqFYIENDB`$$Ifl!vh5$#v$:V l065$4algDd3-  S lA *$TIMOLOL SOLN phase 1Diagram G graphic"`bf=Z&##fGnf=Z&##PNG  IHDRv &PLTEg3Mf::WWuu3J` w(/7>FMUl"Dfƪ3"J1`@wO^n}Ҍ"Df׈33GG\\pp)Rz"31J@`Ow^n}"Df3M"f+3<DMUh|:Wu3Pm33MMff3Mf"+3<DMUh:|Wu3"J1`@wO^n}Ҍ"Df̈ת33MMff:Wu3(P7mETbq3Mf3Uw--DD[[qq3&M3f@MYfs:WuȒׯ33MMff:Wu3M&f3@MYfs:WuetbKGDH cmPPJCmp0712Hsc0IDATx^흉(+gN7zk`$"_UX~/Z@-P jZ@-0wsTZov|"^Z{=xm5liOognƶzٟͷ.=0c v~^' 5$Qʰ 0feDd#ߥ|m:fr~c7/Sĕ_e G !$i_\BT~_Ŗys}e|5| W&Lwv8tt1T j7J4vr ro-~hEI]E⌊ FA(4q'/D2 qngm!7q^@ /`BU ޸ʠА|+qv  .c>_uJ,tj vI;dĺ}'Vf2M!6=J/Qqn2\AތBMPDMystRV>;וBOX .w-a; W30|P+T;>/fśǸ/rЩ*}湀L 8(`{:/c=vuϕbW-vR q$=֑ءtKrl_vpΈEN{/fpF&b}6PvSlgγ 0ɍnG ~_̨A+]k8;66RNˎ:PSkc @sS'|gCqď4(wG-@l\YWuf5N0L?S_OzStD Ye+Hwː]B3ͦZó¿A}>9Y-"+:Bװ@e-pd5h?1$Ѐ!LEi"Mxiד+4E')vKeC$]xUwi0/ndV lw_y;bPsԔDb-voSJX&4sWx_ha.LD%Tc%efΥݡVcXELŎ0rΕ#c`"=\ =*WFV^wB#._cCWA4yqaq(vWYfғ'!/MKNv]]DP/Py}؉#\v]~E9tRհ[+۬QFH;>; !lR>Q!3v|(vBf(UFD:Qa\jXbv|(vJQnj*o;ai)q(vs)vđbǵB5N(z)Qe6" zT#"IVn)?R"@lHP."`SB.}s;nf~ h-D"-6wq%*t>kP}I6Elc $>oΥ􇢠Jh{?ܴƻ3l0vhR;[w6wo ؕ~ zM.`Sx>RςaSz;vRG.cׯN`~:6El&vh6$0ޗ:k]T6ElV] 6vRbrwΦ-жŴ<3}lFr h Tnl4ZlkO@WӍb 4R1<Ŏo-Ŧ-hYTҔAIB-\~NT(q)b <#i ni|Jĝ`1O߷bShaW*{l(W9v[:T(q)b <_J 퀻,]Uփ͆R]BM[aL vZ֗VIaa֦=y wʾ i wMd?ͥN+? T|@!<;Z_YE#Ulbw J+Vt?햃$!`i@6bQx[kΔrk ($M󊢘~e/J\ \o/qVOSAhDǓΑ쾌 aEwDp1U;zU$)G}@-znrĆ=.b'7f;Nmؙ݉lL!«8sU^ 2.]2__bG-Ƕi7Zb1+ݡـt֜1iH]ns%Ӛ>CvsLy& q@ _^7[R5dꢱXW&oת8A ,PCZyAfP}+~ (j7ܙ6TcGm"b}ܝ,1N34;f} .oĤtǮN=p zF#:~=u^zd#B÷`}ɹކU\ru,mN#u ^!?¼d:jO,QCa ʰa}ƆBYE5=aص.u]ZE{[61ݙ֡>P_IHv|FfXS=ޮ^?(v8pGF+NsBھ7!ZC7ϓB hJ/1`. A6ex c{TvɢFPveJرX_g7avusk [`tgJuX`Svik[K)b i]t*B0=ݾKv9ҴVT"~nO*6El]|G`PD[M[`ÆǷ"nO*6El](eFnO*6El]4.HaR&(Ut.bSHAaRWɦ-ڡq* E)qeΰ-)Jwp[dSxȘRj;8"!%!E*ɦ-&!E*َeo,̦-pUiDJi'N6El_-(R!]l 7Rwx0sPꂝb&fneͣE*3(hc3&{UnP.}h( Qabf TQаw&l/`:gw:ӴMPm>RX#AGk ;8گAEP?4NR8;2< 0㾳{ee;xYخ4ȍv)nocga=F3g▿c عk6Pf1n_Rm^3=;ԳF׵ kbcgRvI+[:PMV1nG vgs7;W;ܹ6oeHneϱPF1nOnnvkuq c@qhm=޹DNt7;FanN~ܦTb*O$R!Tcwr7s vqQv2Y)I ,` ab7(ûCdƇ~\/l.'k<}:qh7(i_lF`W]wb7mG{|P{VQ`wN+ć;n:vT$Ub7_ /ݽ~raӝbGKI^tbpZ(sLH{!؞\bn Ylyip\k`r}U/¹ܱ7`I,^߸As5[[(o-+&Fn*wk*X "Tau1芚pW-Kex;N+ܱ)b 7'o47 ٍi};K:sxǦ-@|JT~\r6Po]V*v]"3vq{=?Il ~Ko,UqN2f) \![:,fxAteK1+Tݩ 1[w_6vLN+(ɹuXyUnNeܷ8^Ȑt27]L<߱$;,/s̘:r,@e*]:mQRL;Oa-u¦sTx~t.Asَ`EV!NJND2:LHtCZwdԟ5]e0`"{ryO ﻳciŮ"Ȕ#Cf7J0w߃׋P3i3DbtwNكP|vT:dDVC+)v84wWݹtؽcwӰ{S*;N⊦S]ӕL[\kuJCSHw]۬sJ1Ss:)v3s1QNuNwL~)v$)twL촓IB;iuNwN{ھǝf;Y'۝;Ŏxwլm>S~b*OmC9'Թ͇wlgu e.+q3[R,)cn&Yl!H(>1qv[`DH18/vLz;;"jt | "&vk7;1]^lg;dAIAsZ7,F$nG->1qv[`DHmʑ_.p혊wޱQ r]WV0[8r< :*Fzb qRw>-VvYl"U#i"[vrnY7Zc;-0"wҡ B[vVaS "P[10Lg1Eh-Eܩcۏ;@>;ݴ "6.vkS,_a$ۭYS<nLyaV銅~~\+vMV`3E;ukwY[ݠОwlg&|=*u^͹2xMNcezwlU2ڷ uz(gwCk 11an&Yl pV I.ޢH8cSg8b[5X'9FܔMl4c;-pʔ +۵ۇ;6ElSCiWa:;ݍt̎ h>*lg>nb7*ޱ)b (vHnjM4Ylsu'k#sM ЌMwlgN93e_,Wm{;6ElC]il7'ݩc8. Ul4v=ԈG)v Tn&"@F&A&wS9fOPwlgj7{=!QF-}/ [GlGzM[f|.?Y%y5N昱];lg)哓2cSxNc;>Ɂe髅݄59 };`|N*/ :fUoQ ;}Yfv{# v[z'TN=y[讍pF:f]Qrb Fg;ٔuۨwl#a؍NwCO*;5uĮsmJwQk,f)b Ա?k` \`78 s@cj-wlg0] NAcx`ӢKg ԬlX7͸.0;ҁ]{Øc]󲶕ܱx٘Ka7z9Yl1ܑbs2ʝ:Fuܱ(;ZS6"fn_6cSjwl72ݩcên&Yl8Ibwnm]"^hN]Y3cS˜ n`/S3Kc;-0i1Qbct3ǝ:fcWpv[`1RsqGv~]dSϬ[ͶdcSlbdaN3,毚fs)v;6El=_]QWm /Yl8Fbw* v욖St29Q^cGi5c;-`ZZH*v:k՜M[kc;nSdS0LHw6\ϵ1!ƻ:.;ɀQcXGpv[PP2#1U>ƕSwl/Hwf;xo@a:8L "mCiS^ݧMle*vabT7ɦ-tWacrw #b x/q]fy;YYl7sNfb.ӝb?sǦ-Wf:cWp ,O )<|ZM[ /إOǎN83$"CYlpM,r3O|}S>ĥcS#`GN«Kޱ)b #cW<v[`16ծmAFrǦK^^%;v{ޚû.vSNK#nQc{rʁqL툇iH,3E03ҋ5'َFzT7M[x@UL,"RhN2h՜M[[obv48mUnjwcAYl%ح ;QtYCc;-բm搁1cS .C`^/Uo?;b H3y6Zo;Rl7'M.Gȼ)}wgׅMۍ§[πnX<^qh9vlw"bya- VmS.QK' *Z5g;`?$M&.t;'w$ޱE.>%ٯ|WT^dl؝DUcmu;"v|krvoTxׅ]qǷRB07\ˮRΙRBha)؞(~mJךּZ~%Jwk24͢n3qYؕ#bw̱ع5T(%7 R=R] = ֒ rwS%pkk\ 7+v‚A~;1P7fja4J៦sOzN;X٪Lw u Ն 4/MqKq^yv`mѦ]'1 Y=2m.CR:6ux6beԍz]u >%d.MqJiee',e lHbw`Xu/ݨ&OIOh)vRx׏gUV".6w(rw7M;=4-dx%]'vcdCC]7=;ԆͦE6nf7vn!`tiFxT'9N$t{(vLӞP`w;&QrӤfU;r1fzt4SpgW#8Lvaڮf~:s\ gtT:j3JkYMw3- cNoQob7%/k%s'W}b[c䋢`wYlGLTNf-7`gKy/us<#r7;kbO]E;I cő7INvb7Č)!u3WN;oyc`gRX:0ؽw^Ȋ)v#ҥرuPv7S{ϝw4۽獑57SF:].nw\?j1S^tتûA})}b767ָ(Z=C0diaSR%aW= {cGDKW#N4.G_% $6*McG9bJ{T!b4۝>:ֹ&,Ŏsׁ/؉.ogN6S6$G֤wl x:#x'k,73sgDݻ:\\_a?\mb2-f?Q(v2I ;;usſkuRR#r |rv`0c.v/rn\o]v?H `X805PD!"Kء]mA nD48c`;#.d7]2V /ܟ( lo)LCX?dI/0qNt&s 4r;%Dⅅ2gyʰSHN$_,)4SgiK=n_Nf$qѶG[ۑm*pGΦiQCv.9AS*nhzY2OMO>3.i{h٨i/\s\'/%Iqɱ(t~Qj *7!u:b+nѰL!O(z${3b>h\.|drYr#r DۘaMu3IͦX魆-@&3_y}0% $a7'ZcNݰ(OQԹ瓝gå;'uDǫC>%i_N-ʺPl^'t^)a_xچ=;1;Nsg&; e6vKn ~*;,gK5v2:dy9npo.]5obݳ 8 МdxNW R8i's*CUbHMVӝb74ķTwjg-Iۨ`g>kP4^~U @fZgُ%JtmmK4O|5(v'3+rn&nL\qR]9[_-` nwL\7:^b78`'Ow w+o]WcP5[O~e륓%,q*S쎀f@#/v;wrXR`'N&Vhd-# v1G xi3A4Q[qdfk[bg-fn]~z];KuBP{U-(Ps;|lIIX v4 /)~yDp殆;dBGPO:]y^QװC67eCS؎򮲦NLj+6Z=~ŧi]]L;v ʍ`gZ&\1l;~5 #?"qIs?M HwUM__\mm]Ѐ~9pc,:@Y/SG"v&;aݿ6Zjݿ˯_ǽq팝B_e.J&Cxf)';y/S՘B4$c?^\?V_5WE!(vc]n{p lOfn|®Knb' kYy&wKKd+}Dl'ej'*%.NT6 n]" `LS!GbS얝 zd0.[َ+*RE;%.O=pwQv)vx>r63Klt EhqQ2cse ob`uɮ]uRGSXaߢV`8Hf-߈5ܧN|/sRE;EuVt,t5bw|NiحU(eҝf;+Mx&Pls$Nx\fFI;ꚠ̹>Rw{Ɉ &cw//ÎF]M4%ug8*+7'yϥjFa\CK}լ|D;J~HW)zw_xYHaKbY^aJy5:C&Řn(i-`_˔ #SQC삝 oRѩa $gcw)f4Ab7Tf:Cb7V&:Eb7V&zDopcZmѨG=Kd0-;hVyIbwySfaǥnvĠb,c2ul̷4mXN-*vSAb7{*U&WuOr)vl.?ݝ3eOC(]ω%L.W/v25.niM:ەBVb%a{['>2 ެ>^Ȱ+o =ܐAJ[.N+Z _mtnC=(9ГzRhC^Vftv RR+a(SbOΦ/jH\WKaw O#ˆ'X*Kv&ٹ潯 #/«:Qjn~Td8b -Į>?Ok`/GT%j(Iw0XKG2КVr#k|siGva/hnGxFmnd;2ϾR성|ZnW XHM?Uvn ڿf"4Hft@ϓ|# ȽLv]6۸HP@_0Ty;1vR]ulؑc+ֹHi&f,k$ǒBվ/3E;bU Bw\ ΃-zm\wo΅ަQ,i!UU72a:n5d}9* ;MǞ|Kb OEQ2Ih!%>%߬vlWykvqij/?AݐÓmќ]1 }wRנS3{1ߖKN7+|>>^ oPn v 7BBv'UvP|NsM˲]D́Uv_hOp, ϝwڝT>dw#0]޻JR 퍑瞴Cˇhۺ3<`%**| 55i.ݯgep2t%%.۵#%0nxd=/ǎx@mn.i]˷7y8TAhFޝ0g )`d=VIns1jmR[b0O`|de;AOuJzKhO=v~1&@aٮuxws zNu%H*cؙ71C!| T*"im^Pr𨴤] #:ܱeisK\/vu;/Β8{'C𩱖⎁..HFqaC2IdW(=d8,R֖hkErCP] YqCTգn;SZd {qBv`M5P,P/Aᄆh5Y M)vq+rEV&P.V59EpG3N:w(v[؅ٳDʀ;%31( ֪m7 Bȣ/~ΨYmmj<$N=)jUD*x*cgis<Вbw_@H̏vkrCN/\y(%1pαՐ*$Ķ7+QIC, VakubfNx4 nתԳi*A|\4wK]ְUx#Z)1wK? [3}oih'[⇹Ύ+Aѕ+5 ݅JĢ1븅ڗl8#"~`_b3<\&VB춵& S6qĂf(v LBJ)vxQM71Ŏj)vPM71Ŏj)vPM71Ŏj)vPM71Ŏj)vPM71뿨6.9=_=3ʸ[{[)]ԙ U|s0vɽ]}]ooðS;v.=]##v/'(?Pu>rN^݄c`{<5 (|p>Gv7=vع#JP$Nv(;?jd;8kF@M޴u2lU{+({>$h۽>,)y'gs!{{9}&vywE({'B*D8>K9ng]\%Nf0܃v y{̛N]|A;C¹(k $vN?=`W+#M^Jz凭Iɳ bBi ek]zDBWY?\nG9o;cs[Э\n"&خlJ;d J'3-wbF{2y5i,ۥTkbWЅGOyΈvԎ:ЗKa' ܳe?qlx$$=%OۆՏM3O~D9Q!|Z(?%+aO%|QtM`, 54/:d>^BmbQбHtpݲ1y/mM{ǧVsr_D-Ť؅NYYk[\ O%0wL㓢-\aLQC-yI-َqփyخ>L iֈ-O놂x[6mAM4q{fŮ+xB~B7vwlw1VnCM@}+ߨ\b#'O s)ds;4MwYCqȇnxt2Qc,ˆ+v >< vW4մ}N;n bvhll񊺽2~f;@}Jv؆5!d?vсvOQX)FKwpӝdKZPЁܟ6@M iP }>bWc2{jc{^ܒ+Lh9vvnqt؂v1){;Rr,0;_k`<+#g; ([.6vwWY9vNv oc;o9?le'= xLMdTKcRа¤)} yR ZXk^m%Ů?o!S,b [8%l}?ǯϘYċO늡+y ܺʾf;|Y>E +xG?LEڂݓ v,JaB*/|P'v553f]74!HJD]vqD UL)AJ%)]ښ8Ksg1/-ՅR28yy) ۇV0B][ZO;3-'7{owp+ N]^94{ `8 !bWKO:w,6n#[3hCX@([u8db獛ܠ>UՊ@hQ.`:1}HEN"O ɜ.V6<v2f]BVWP)nQf}K,ڋE[k˜?/n{(iB(vU\p:dr4 j Hk(vkBIzۥ؍iƻ+8N]_bQ캽5ZPmQ>J9S辙\RlgKS^5 VS;rGb[ɫ4(vC8Bb7ŠBS~'4 )Lpb7ΖRMS&4 s(= V:Ůvs$ 9К4u-2 Qk~Q n #\VNWyM4!p4';vM/*P$ E>BȨS{ZcB'.vmxw4uwkLkao>uG95Nz+vm>F /tK t*ff^#+"`|b:={Q)f+1" /uk~_J|7 8v[םe!ڡ?J.+OuÐ ؅H%Yh`⮊$GB!EYg; .:~!ݱ l^p\z$ie<`y)SڪeXod?%h#F(> TM}2v6d\{]lSd&+F}{'ab|ޥ`>|8!b P#' v0[8cf >cW]b[jkn֝*F(> T$ձS*8Q9%v'aW^dg3i_8/.Ǘ8!b4M2v~nNr _d id`P%n"v8.C}IGe,+}%%!n,J; CFK@Yp#عer])e\9]HaTn\Liv&$T6+Jh](:vj}ZW)x6n=@-tU)v\Ȝv2aE^hAn#F[6tGlRbئ n+h)vQdgPS&;b+Lw<d5 /34-͋ zmr#g|eD.cniϷkV[ "ߏt9sȅxDxE|[Rݢ}(*`g: {(v@#oǣG MV 4 oID!PR t 쉝y8^˓THƒ4XBc;Hɛ7 !%zbȺ @rs nT)yaWRj3XB+a>3\1t%?1xmٙLΦܬnv6c,ܧBn+;e4fPxڂ#f2P5$ l]iΥg Y@ ]HȍP>-1bF{)W>Ysn jKl-󘮻|iu>قg;|c;rha;LYRîyfa;KNȒתKَ,ZrvNz| D}mV> |(v;}FyGJȍPcZmq;`1%E0I]0j .-pV?'Y{ LJ0] j[-^1ku4:۶Tr#_|_^;S0XCٮ2aYs'OY̝s&!Ѥ=OIf{6; wSEIKعgNȍP|q}yu/a{an3,`J\;?8 9-mIJsv]|SPg =U<.0]m!]K102J8vlحWJSM{*#+, Xs 'LWB`ݽytv;.&dIccamU*( #ncWSCSMgx;:{6)_ $w5hr#_{^;{aT-ЅRz0B&y@{V#:l;3N9Ӕ|l绐h_NfcnouhD*vꀂ%+-حc]Bnۘ+mf!7Bm Qq6f(v۸YȍP|3|ECm,F(!6nr# _n7 ochbŷ1W4DBnۘ+mf!7Bm Qq6f]zGAJ~o1_oٕ,W=2,]ŻB8dWv&l;^UȍPm'XPݱzD6حMv6c[y/(Ԭl ];v'p:#F(1ZT#H Ȧ 2sHnql'? F;݌H>hK?[4b]+Ĵ?لcdqtxSjO6a9 L[;ᜈPe"-,٥*vf@ͥ Lr#'5Q ؅g!Tm dYQ#:>;ΞеH8)>rN9&Z؅vr'xa3M yVib3D$4)vGmB-F & Evwmɴ?P!Yp]oJʏ9 B@YNLG6Yvfa.BA$7u$liX*ʴLb/>#0ҳdSGb'W'P&ؕkV1oΟ=<\I74rODjY Sw,v\%נx,;vw=p@h^tX 2v j5dʡkXtZQvn7ɝ}}mW)r/(_M}qb7I?ꋽ:LiGXt^bW䶥%!2:V*uԫ2KZ#YԼd1h-kgG{ʔj,3g[b7N(Cҳ谿Zdw ;ŪNb;uɲw)emPOXeYZ݂-lPv !Ջ(qcRPnWVY;\9!tazL |ۧKRTI%--*ei[vNzc]omj| 6~!,d&V0Џ+-0* QSϋ[hZה>oⰦͦ<,6Vж=UcU Ady|fՇ8rHe[4iFvG[{փ}"8K9>G9#HyIP jZ@-P jZ@-P jZ@-P jZ@-P jZ@-P jZ@-P jZ@-P jZ@-P jZ@-P jZ@-P jZ@- Ҩ\;IENDB`wDdy;-fg  S hA &$TIMOLOL SOLN finalDiagram H graphic"`bwBvnvBPNG  IHDR QtPLTE'3Mf::WWuu3J` w(/7>FMUl"Dfƪ3"J1`@wO^n}Ҍ"Df׈33GG\\pp)Rz"31J@`Ow^n}"Df3M"f+3<DMUh|:Wu3Pm33MMff3Mf"+3<DMUh:|Wu3"J1`@wO^n}Ҍ"Df̈ת33MMff:Wu3(P7mETbq3Mf3Uw--DD[[qq3&M3f@MYfs:WuȒׯ33MMff:Wu3M&f3@MYfs:Wu>bKGDH cmPPJCmp0712HsshIDATx^흋*rΎD{U'A' |ɿ@h 4 B@h 4> i;Fx^#]{^Kуi Ч>ntOEn>5iKd>ni]hqP׾£9߻6{NAZ}g=#=zG}@^||} Fx^}8@oL~pcQv ;IZ־[Ae3_ywONU`?HwzG[69h ; v>g@3x`!Svy~ל(riQOw X `iTF-BzJkIzjb}6࿎bo OFk(俌oyۮUA&ߌ6/V6Zw]wp Cfq5X3COL࿆RYG'__<~9%an[=BҰ 6ʥTתlҐH> sV]j}w pYdz$"QRKA\=msY q̌%LQ+3CJ @n7 睹Dg> m2Cg bbga3M)z ){E*7qG\oO"fg#>{c2-i?@ۗ{yVm!*o+cAIaL sq1tUBYKqU퀁vs_o^~6>+RF}.ЂRO@|0?e"g< Wrh1Z>Y S~=$Z{xlǩRȅԭ)>z`u,36F*S@,Dj%!T [΄;#!WPE+=C U܃ϩ/sq My 'uy㡿ig}:E@8)N^Ek([Ăl!v P.4_HF]${⣉ J=.sM}=@gQ33e}J["ҩ->U>C‡AM*(`ôg|*[b}Es>?==\xD{t36;YnsR0WGr+(CpOOS!PL Gus_ho&g6WW>Ub|:4@Gy>4%YbNX.KE$C+Wr݂&Hxy5hHHSP~ "1Tl0TtD6|% j)HYKr21}jx_liE$ cG؇ygiw!B1YL,3R?Kep-/yFMѯBRhZ(5ͪ]r/Nj4v][%7\f')>hY߲BBg}M8n/xϓ/^K-zS.ɩRuEOԩr ɍ9ឦ%xO\$Մފ{˺g++UKz7FyHW 4rl>'܋C`rO*Ӽ|>ԟ3#ad8J&'#JL"4ΐJyJ`npآtoٛo |ngrO@`"@sQ,NahG![+B ;w7oYC6^ccj6wQ |wWR=% 3@'o 7*^- ^=!˦i:{ ?~w9ww-}U-as9}G[fkc9;>}?nm-%ny!w>znw˸9 ] a~2TnLTq珍*j-~j:^Yx 50h]]c֔أ1 ri`HduyڹͅʼnSTZ?j1=8eȜb ra`PE?q4FCQՄoKZpVhyhq\~]r9ϗ~9.o16+k5z;+x{tz (,ѷ!h`p%F9pvt&q s%z cL*. l{.Ɣ8h⢚ FzQl6uޖBUE)qШAE6;h*xkX󤍙lssӍ۟a]8+tql;M3c~n}%cT|*mHc{/? ttrbt=Ȁ gt# '*U8xl5?"d>k亞%Ipɟ;L;Lᯉ؃P;#~^UNݝG\{nUY;p֚T|'s%sx_.ɉ{ʬgMYDFv"Kei #  ű4ƻ&xCZFd|Z5ttU/꫎t޵;|"ܟP)G"i#qz-RGv,3 t'o=5(NJI|pveV 0ȧR=,9m E0({@cU@?1k8 Q)t'դܱ10x!U خI' vЮrn az= W=<3k2Ŗ^Q]Vj_=[{7OS;'fHx 3uPpW}SᲔ2FHԙ+9QԵcc:dmxLo"5TؘiDj883?Nb(ϕBqhZx/)\W#"k=Vi;Hn4@5[QbUk:5hjK4db>P̪<ʉ ,%$6V\_’- `/p$kOӉP"0v}X=?WyHFv {I8,)N T{!`l ǽ9xO*8|^=6Śr1ƾ4 аo{оM=$2c\C-w43 g ^*gt]e?EL5[lwZey1k5h S~TUjmZ,1YXC:}j¨{SHI]f-<' 铫AKPЄ`?ԫpюA" cnݪ9*͏Ӗg׽dܧTߔKu?U7_aU֊z-euEWY7lQ\?xo>@[]D}tvZSP)@RY;N )$8cblO ӈu~M@q{>/@撩S >mqV~k.wuOӀž!ItWL~0VFi042_=r^դ !5OMZB,kD}(RT"P)+*iWRҪ?eX϶-:@IQ9 t7oÃmY$H3Y`r ü\ߧ;C&"{9}&Irt)݊sM8W!ЯwEw!j4ܛt^ܵ4?ߧK}{g]ߏ$ފpj w0 os{{~# u~ȹ"&DleON ܈dZ孈D"uVmuXL;N@";pו)4\xPn+^ͽ܃]wV˚?V$Ѳ8:N㭈DO`docx+EfpoDܸ/G OQsoޥ['N*D%Ke䤢Rp:JNqQI, l C$ӒVP gN<+8 UcF "xi `ܤ"H:iji>{4@IbxOC]}:z>[6tgEhiQ{LaJ"_m[ZyY8X((ƺ9"+P~WDY-nnנɪMMc][ c~nHS/{#5ʀk]FvQ'.o2͙qOlAKI/g,ۙ^'7 Uh\3U=Fp'63;5kqgB@&ЬI%y~6Mk_|_EN쪹AԐګMҌ؝Y=c,Fm['|Rlɽ{db%WϡdP>NderOs(0,E})\p5Ywˬ1.RN}M,'X^3؛i. 1_-tW谋1;""T9PV>z}>}C{-BI=] {of_@gtgy>Z~ឬOv 2Ӕ$u~U:ܠs˛Qj˵ s0@B,sJwf:U$n@UB_q&11)k}(J9~(N\x?WԜjodEdD%;x*Uspނdsta2=o:k]sydZQY}}Vk}plqs?fpW~8@WuN 69-8t;Xޠ03٩qes`|Wp_[V%sOuQx' m|:W+ aRJW<֡z,Z}UK!^3Ԅ/iEprp_^pO_AV9Q7ohm3a>jQ7#`ܗ)#=eOUDZI>3p}zZv 3p=PNsr"ޛL47iBr/ٯF>/!7&[=K Innr*[2d3m͘e#iELs9TDpi +Kb%~ܧ~`_d >z>})ҷ1RW 2waTy~&kE8 Vw7rx"*ܣXOuw:K/@B*34AW]&e=^!྇ܫ`Yեk]T$CSKW>-ܮh~! `":J4aAg^[)!M9[ǜP7:rʐuA9o{d8J$gk3t ,g4}yྚ` m8/Ҹ/y]OH?L";ѐXq5?^| |e-]8-RC]_}1λ=WhKh"*yz"6&4nv] ?}R<'a_@+dP6P6R=ǸþD{=6=jVΗ?WZ0{|Ye {xp/I~1;>o'r:Bɑ!= UNB6ΓGl7aN+=F(?+% oEh /KAmdp?'9elވ ^Q>1ZR#r)!k*m=Y6ghN=2|{p!p/$?Co|m{Y hW# M s6K=& >Ln@ۣ)@5j //,u#Ŧi=,ybjqMi'vD5sB\Ƈkot_Ol/d=(y>/4OmHD\ .d\]@c}`ۋh /g KP?U=q?:G3"{c9'sQB{ٙMmz"1 7;M7Ճ 6枕`]SDFwPk{p`F+E{3Z)"wvp;JVXS\d훂J> |n<+ՒEʊ%q/'>GXn{o~=+[iY=Rp?b;Y=R {xs(-Iqѩ<%zrY{8V*Hypok_ WzTncy~vs#s)Ò{ǙQY-Ur_,uVN==yuݙ2{ĻIsqЩSAc9Y`} xo*bYl2q{ 6hϹOg +[#?Hb$fٙM>HD^Kų~ۋr^"6E~X3.jKVIJk<OH$ܳ%|l'2J-E=s'NdQ勉g/}Hs,:d)HcR@G\C؟sOfz˘q&(>S_:<kx"Bi7WL"[)z_a՝ka7 BM= mc/}R.9o^Y$svVFձ^ d7(4 &sX{ El;5cc - ?hA}p`F+E{3Z)"wvp;JVfRDp>w0"{m;h;hA}p`F+E{3Z)"wvp;JVfR/pѧq~%mjvDtSdA}1JUn,h>G&%_;]bRJ/rࣗT`ˆ" }q nn^ޫȸǵ~YFs2s=]^{ %.]Yub_bxU|\@p?dۣ.0B!ң̙:O] 5=.߉Gh7,!-z1=.O0wnj;mѾXJ i,yŶ:P̤S֔^ ȱo Q5Zr]N$sHwx79u\w^Gbi+{F"}Y:(|fm=orTf1Ic>K˸RIZ1 qDV[h_s> 9ȋ|R;y{ϠzO~ո.FSx~[}4߂{L( $9=&\P;͆YshFai\|}U7$e9aJ3-iO #[#g#3k{7؏^ y>Qd#{};<1]Tlb"{ZmW\8k:'0H^I!EA ^ǙZ5=I<@v4I`Zl=y飱h-Ӣd~qZA*2!Q%;*&q0Tn:K5OS@V+5˸Ǿ:%4 g1w"$^zGJ8\Dܳ"fT:ѡu˴0m>6}p_Vʢ:Sj*Ԓg@7Y㉦XG9J3E!O:kF͙|݌jTP{anz!jr䞥0$S4dS)dk->uʪ<~nVd1hp?ZExܣ*#*J 9Ap9?JE6sny:dTDj"-0q&9F ԫ9{ bx@Kx>ӞL~X/h1xOtL‘{& ӌCP%\LxUJ_(GDѸcдC;g"'8@X=VHW.I aA>SDh[ ٹYxJ3&:`1 swh\D &o{zC > =N_8eGIs'szTŰҹ2x?ُ~`d=wX"?eJ9~խ<Bib%CecG9 j|rׄ{[̽GXYǤܪeQ^z@b};SdۻbBG+:3'Put7C6 ("w'Qe~D$^b\onaE<1[ftԸ;(s;[& lSU;U8n`ߒ4Z'KQ9ՃަR;aX"vQDkq1k#p؃rtOonL=h}3sRP-l}af1waP#"QHNp0{"a\>pڗ }{t([-sWeMcYqcp"\BVr5Ȫ}b;72>̮RF5ﯼ s=:;{5fMAc7iy*lp{¼ݚ')c|/n. coq_m&c@|WGh]j+8+,=$mB;؄ Z"b̤g~)qc B`D*mLt:UOVtg<ʽH51=|~~xݬ 6"&{D>=BW؃CVfR'm3R=m?}=Q 8ި[ł[[Xx+oo, m庩ZG{x{,Wvhͧ{?=㞽7~s5nK? XL옭/!.}DfqV m.9cJ|t.:FQw l6'>C]CȽl{@cJhh*=vXc&3Z4t|h\VT5cy|)qݫcl:FS|)1u\{f.1%7owг1]i%sՃv߫qχ݄&ƭhm1˯,Ḯ;aO^}y'EG-}s;} :4~MpGO&G}z 5}0v0PrM؃&zp[}pۈV ~yZ1a6m w"w?+"^~dܺ8+ϋz0DFTLIS'Ze096`uqou?W,h9/9Ӊ K|9|0D_>?1O/jڇR>[S Y;/W<@s[ Kꛮ -F˖jȭi_X٘Uw{OppY>|<?Ns'iF$?+SP]Ίq_e &ު(7{a`#8 A }f{ZESg9M.Nq×=.I^&K7A/f̞doQ?W\oc-/2r wq;̦.lҋ},侞o7mU9PEt)Z1pO'nU"VE VLg^ʢPjtp i{-C>Y6?KO?[ ܥ LW%%ȤN[RUiYm/ԦOS5bD}:.9y'ɟnKGt\r׮JqH<ƻBƎ?[nЅN-1]%&qJ~Jn/7vrk?rU5:L*p +OIDW;(c*ڄ{1C7džH-qf֧asoOY,Z_/+%ix@׀ LjpE1 cP3yxT* rmU(5W(Uܓ߾_oCҺd^܍|9ϽypoFY]˩̕L1<ʋG̽:wP6}bM'ΆM3`^ݟ .Ӗ?Uƅ{1~uENa~{FU~=p=o&+t9 R8M Lq?ϳiȍWXN3{^Z?ADq_&rR`#ݗ]{o2/}9Q*ڤ++_}`m(}7HV[_8UBGk=ޚ;xˆ5> 7Sܹ/OZUhzgަKss>128ghQQ=VXhPoipoVp_r51?Ga}-:.]z,_N˚2aG߉>le*7gp$0{BCP@pK=%vK^' w :~Ӊ5Fֆj][OJ{_1Ͳ0!k J+ ?]>0_dpI\=ylyXlp2Vr{{ҿBFp][4@p߯gj;[ 2[f 0K>o73,o3L5o?Ee y[f- _4S]^k%js<ߗfh==^pä)nԿ$:|o؂>}=W{ ?9ibd؇u8/ ͒ÉOFwf) _ <9TMm: /oqj^@MgneE U$ƥ. j̹:Ga!q"OV3M(-9>s鐆O ,\OJ9@ VBbF[͋kJ0l2 ,?N{ 9Q>?j!e|J?U*LO-ձP)-__Bb֑y^x %j )ؖWH5OYueoO*E@PTe^@~)TWlSg8@ͣ yh'.D^ubi ﴺه6U'wׂ3?E`4Gjʁ7^%VC>7Q~k. ')hTF3Q.?5W]%"^R )?0^Im5{LOj/}7Kb 3YFÔ_l(t =ԕG0P;˙Z1enLxUC bMH5}yF:6ӫr_PvVtG_ǧkNV{{ج #sg067]쑨K0qc_}1J@O yj"+]/,c)ښ)E]Ė3HH" [h*I7'}Z^؝q>g>}qQW>fEѸ RTNUDT[>l\s?OH2{GDSsp(}ϐ?t[8,Zzh#+MP4Z6,= bʏpؗONj>bϒEO .K2[MIg(_'?G9?iǎ"saB;(:w7sz>p^fLO'^_SvP"]O bD l=`_bi6y~py?%"υL.`)upNǹD4RټzG7څz^<~F }pWvv~Ws~5m^+ߡڎ.-lMFl9gF̾QFUǭf E[ /L [xW>(w0qM84":4 N>#fYELqb~):M@ ྃ)b0dŌ7 )gԄ *n2QMj4*h {·@Л5Fv,]6{H!>0¨\򖿧֮&},TdK*/ 9&^14ݰK{fR{c -H?#!JeÐ8$Gd^Ý^Dk CW5>x/$>/x?h˫qODOdQ,k|lq Qͭo}p86rqîsK~5|?؇7=~dCxckn4ܿ묪} ˍјAa4^b={ִDDpqIDpl%w_tfRDp>w0"{m;h;hA}p`F+E{3Z)"wvp;JVfRDp>w0"{m;h;hA}p`F+E{3Z)"wvp;JVfRDp>w0"{m;h;hA}p`F+Ehÿc+w^|jTFr&XǻWIt?7ղCS&WB=%PڡLw5+Eq~bEi^V 9Z.xd? >_ C[%ɤ#eҍ$ q`՘98[\dTRv^Ipo54 Q! p~s$M>LKG!! mc#GfopO%9WM3\ 5 дe{) ld6xoqO0>/Z`lqO]sxQPϿBo@|ϣՃNS݄|{*q9|锲TH;ރ,s L+v9's5I.񒿔ǓpӜe0W} %r(#Q!5R@~1 R4Z]ܧ==r'WzAdG!;[S4 f,.4Byx],eikQb[yR\ MREb'-ϥnȃ^͉4IZQ,ZyR?ݯ $`wWfR4(|PM5#7}=>AΏ`.lqT65CD0OxT?˽%̴c B0j #l 3'V{z9^1e3_s9B9c<=jxC|7|zG#@bӊa%%Cܗ9daMHsK<wتy \nJL앥}yr'cygر^; T=Z>LEeV@g)֦ F!R)|<5br<8%g/`ן独# [\=y<D# dz:؈JiKۃϩ}; aF|Da%L!GCEUzуPd1k}ƞ*nB7Q D%}+BUTx0)=nZ{r1$_%{ JaC,3NVEbgqVxU1>J''$( LPr,v;̎+$]pˀwGQIbJ, jޡDľn3rj1]+͂LD^ D՘R>hA}p`F+E{3Z)"wvp;JVXʽ~I.57(zYU}pjP-wH5X [c-Lܹm7px{$ݙNz<*ӈ~ʹE}u~0.֮1PK_Y㥗r:Els tYXGIJ"?Fr/)=S>*}BvPppV:q/ ]H.6fKྪ݅3*x_~Cp_K1//UVrvxS~wu߰KY}FxYIXhc)8;(qe > *.+Kj$F^WyR.Ea9}%"hj?&q7ct:mv  X}:@VB P9"i7?>_OdS?@;se8Y/WLKH:_ &py|x%08[R("Ry\ȽA%ds}F&rֳr-dPaG%Kp?nPnUYYmm-Lhh^g]ACbʯ#7%R ؓ,04HXnmie--l^ L2h ?;04KY*F9U)=jI'Y,Dr%ahf_ýGR^oMܧ|LO̿p1ҺNZO{'K)â\nF=܏5G j |pۦ v0=oqi@qE?y(Xp?{VQP ˜m_\r/ x'ӕྒྷȣd:{:<7< SxWZ^?;,01XI㭺@{;DдPT }aޠ>Z IbO|KE:4 #bx_?lƘm*<=}+*T^xZ⪘L*}7>Sl F]̈́H Ϸ2X-5Ws_gs"atNHvpoPZ`_p?{Xscˢx_vpO+Z]UV6O5{ R`ous}&ho=vWG".ݯWrp| ^70?lλ9gՏؖ=z[,ы/Bĕ N #ދ+xtqʮ:37y_nE2 _Jsɨ20'5ۢ$w*Q${q?Mi*0O>ߴ|%@^@ãLuJU'YL/@ ۔4G2`BZ'|*$fj_x K~ʣ4 DhU(/e@~/\f^ٔ,l{2GFjQ-17:^okj~M.R.qheC 6ߘ Ú7e|1LMp^n6*C1QڛLyS% hz4Jb5ýzO/i>>{ǧj<7bpoT?㡄ʽV:Q'RIvYbq{FE=^̉T6UBB2˫jyGE?7ipoT Ih!b,!`Ė}^}Y4jr'!KufOH!Է `9-[g6ެ p:q1R_@\Oʨ+o ވqߎD{-j;nu_^!;O>m=Yօ{$S3}d#j̃ { Fٜz}ObCFbۊn[x8U)gr=YFnyvΥbI/?ZK4TV0K\SS[)'ì疵gэy yy>ےi_+=~ף/^^U1}';efzYW7L: B&.!v;%p r%;  p3Ʊg_ྟι qO6hS42?Nb+9iHܯp_8f+w"LbD+O)}P`Y>߰ EϤxE'zzz4 h .-v3o䣹ߞ0s?(w=9(xSV÷OE[q9#؟-6Kܷsqmkwz>>-:KBx_(O?ϴNz=yYg>LjKgSǒֿAb#lGu-4Ş^̠ʽpfE7 nƁZ`'{l|{ 䃽t av=z-ޞmh>](;j!` W bϥa)/̩Mdm؋uRp"?Lw54"Ǻ-5}ڷLwp[d2s_O8s譇{OFL[oB>Fe.}ڇ{RwqVb'ق{lm sP%FE}zܗ{>)96Q?395}=O {h()3O_ϕޟ{v]Qf|'zP!-s[p^ x:^FSr_= 1ܷcTM-[½N݈fIܧ (Fy%*{;c7Xr2[kgp{|jޯ'*M"%m?XLټ^?>gߙ]z J?s/說R@&vHr%τ,4{RV~\Ubu_4_}y[^${EJ/\9k2ZϽ5̷hwUrٛV#Ǿczk[>b?sL_Ͻ3 ̛<Oogx/_yir?5 -xy兞{R<ЫX?kut#~{&U:^V#?ܛlooRUPp(msW*{fMOV/FgOsT\w0XbE,Պ]cz36U?]M{tЁԣ"Fp{M5_ӸWθ'Y)H$dA(T80:!t]ckzka1MuJ$}oܯgҩ=:o }+UKtAUV"1P[>0y̥WxjQ9I!H2WW-p_b8~JxF-m~BSQg x~jͷ]xɢp:=8C[9b? w m*%NEi_Pޔ*vx^+=AZ %I cDsV;g_U]: tF T.堯׆tz0tF FltZ CX-UN>e|kH3u絊QQǧ*1˥n`! Հ vQZJ:{=뎑{mN;Ӎʴ+ r~{>cREs1h +Iϸ'1q/2O8R/Aw0"{m;h;hA}p`F+E{3Z)"wvp;JVfRDp>w0"{m;h;hA}p`F+Ev[hwI=;e&o>*-%r@ħ?|bN]x~ =?@V55<Qj+ʹ<uNt^ >y}腃xW>RV :gdq:'0H^g'3 jz/Z2~FO"3|G5P8O &yTYrP)lhFf){h0㟯~{S"Z—Rp.ojtXɔޚ<10$Rp%MU8:!7oHW;&f󂁉q܄_ʒ8qYlZո8eRWC{TUU@vH*#+egH2)_ 0VD*@qtT%<"i( wx~扉x*7KL> 0ME E\JZX. .p$Z؏sz| "'7jj2EJ`/8LS:6{]4}ӏށ>+{e^HL^uda#^'Khkf,WR} ܛ'&KUr-O"s#x,h?#9t߾~2Vȥ|lhFWSu?ZKW^ܭygoQ&dmp>}]0^ J=Ǔ!L1Ș L*d{t J& %rsw/qe#@g?z5-ˈIgy'w/9fOqKDs_ *貵~{bC̈́{彃هll1eFf{h+{eFw*_*ΔEXf\ v{_s/܃ \l]]_ufC@O&+>Bh;sC ZP=V|BV*/sžw$7iAٶW]^Ӽ7~QG ts.;y{y>,n”)<-Iw@g}9ǥB, [n l;gD2#^-RSܨ#o ҩtzj\Sr/H"A:=b1|\Zz𖉟~Z'Q8UMv!Hn ^Iʎ2_҄_dpH[5sNB 8k-n^Ѝ< vqOPQ=[<K^H< (!ryu{M`bpH{6(t{M<]}lYU=<ASFP5B]zD }Cē; Etwb\dzipoNs9޽~sk9ӗZ:j iA}p`F+E{3Z)"wvp;JVfRDp>w0"{m;h;hA}p`F+En'6B{AQEͬpGUX=V!k tJ~pzd;Sm!{<1 Z(*3?|p?C3d.D/pM?Ȁ^<T[dPJǵ )=ZmQ:I{P&J'Տy,Zx/jf jԶdO) |o= %%kǫ@ {߷|pyqoٻBV݃2~Aqd>y? ~ |S1 zeyܯ6~G[}Zw'0s_~v.:ia%}+|gܓJX/TJY=ksib FxryuNmK.1"$uq禰_?aH%Dm ~AAX/jf;F[5VKRZ="2A4X@r*;cWO{kŽaݵ`^8-_|E|*|}.5P }joL_Yӻv7{ԝq_i?jۦ@'j.me]JpKE;TT[t"|lv7+NO=3{V<!p)"u|pdF%P9?4ƞ?oy_vojo_Q7Un k_﷉!{p VZp߭p_wp5{a/.Uv,Ͽ7un]q]ULV%/wԶc[}Ux.>P}E`6p?pqEYم{I&VҷX9ٸgZ J<ߠ/x;X-FԬ?p>]#9WR}RIuTIg |:8DYZM57UQzQW<` Í?S=a+lܷΙ2Y,CyO2b*}ހEYAKqĂH,:‘a;1vrܗH/EgYɐ23͹4:M E5ɽrz7ZqOMHʻl47jpoPE6¶Q#S/aUЗ{ Jڢ*Ng?e>`ҘjpoW: ¢D xr<'^re VEoW`m[I.t=v2AKAI[q^)ԓ|ty?'WW2O$7kpoPEOẽxPO60Gh&1+[9 E `-BdO{oΒȽvA.-jEe6 b7k#$Ļ%(*Oր#SJZFglC8Lc}oR{(=\Ε|-FDit}-`[6/UTIOIY};pOA릧r4AM Jڢ+ڏ_֑C/ 7 )GKc t{ Jڢ3[ :Z<b7Uޠޠ-i Jڢȷs_sU-N)ٯލZPpe^v9Epev97󳶂y7r_-knj0 {? t9WRpYXp˹㾺_?{ۿbIz\EEX~.w`oڤO( W{4* 6dKA=j&Y>=ܟ2}p?Sw/^L)]7,[^m'?~ ajz+KS;}+Gﲡ~P]V{Ou}p?h^ܳ75=;6[m=c/b^wh>"t c?n} ='qŎG*Olr I|܃obFR"YHj?g:I 'ŘXߏm}~ pw.wSdAqO~Hϯ߼.X7WWr/.٭Mg gHSx{kz$e+jҜ4Rgr_i)$ ŰX7uqysGKNe装sFڸGC!͠,کkMBP!NV2\srOȣSg>侀==ɼP]Y Kp?f?l&UeljY?Eu"SYSFǸYW{%5>^SOp?L&r/=,V&,@D1]x2P]^`~tImL{D7sehp/~#ޏ)n-P>_7O+wEޤNdc}oҪ|EܧjW6'?7_poRӜB^{N?sy^-j{\+^&YgZ9 M MjSh6>jtb_O]H5+}=9^ӝN^"6n'6 |=XCGffkA2^9tR0Jb r,:~$qcNGmMIoߧ{9h!9]=+xY#mtfW)S#W}s$=xqRb-Qܳ~TJhrt0j=bbJݫ"Hł2K4QYD2WG}!=ڽ& ' Buz$\>KAwr'-Tpo2(15:BCRl$ eo1cdD=xh%掠;@,~DkO/(!+y3J;ܿ=j@e!%.F.{V)'۬~ ivg{nZ0I̘:y۽*S[^AmWsb^nQ|nn{L Zi撝'̹C=xgu7-0P?="_٘W0SS};˔D:Xu뙘xoRze%V4!摯$pQ)R)P. 8oEpҖ.xQ i! /FO.ro~ T)7_?ԙlX;q-=]l2joEWu"PWl#A4Al= ՝ d+}AjMЌ?vRAv+%c@`RH5tkt] #0L ,B'NR,LH}}pn'M0q M%Osc=L=V'yA len07 A4v#%N賌7k,ai+>'(_dp=>?AoܿbƂ{id^aQe.}L׸Cw7n=OD .qKZU3tp/3񘘐k=n#=]cܔ =ε𰪉2(尢΃ayb}iqU[czz YҢZbz"n =V-25*Q|h-T<25EkSZRX)-LiTf&l_3Ug~)KqCc |cVb: k*,TiK 7$WC_m}}4t{FŽ}PO5M.|FGkWxG=F5LDVե]5`pV5 &1ߠYE,Go~{ AI]̞7E%>e|>A$r0vyT|CE*b:-Ox4*7۰ S uF0>.@T]*+aKXtGc#;Pa'>U Wi`h¶j YTTzºyF'5ґ_[-S+@`/8F#,{H~JOl?/6<~CA>s TDYP~r~sc_FA, '`!$ֆ鈪~H§>An dHG9xV}he?3"|Brd)l0^r]>^0v&dqfkq쨫^K@Ut٫/د!6&/#l\`& X>qA؉9|•x 7O%|"( !* ٬G<6qAsOX͎qfjTqUFBy6gYz7P4OV&zul㙨mbja݁-Ҷ`Nf >Bb/?R>.LbOFNpe&gQ9 LE6Wp";Ix![JO'.sf+nnYjr׼NuGi !yI(Vp>i{yLY$^L޸3~,T̓;*TjTP#"U֫bP_J_>2\vɹJ&AeC쑗op*Pa*1ڛ#o87K[D>%Zeܠ]o -m\%Xoi}=+{HS2My̎ U]xEYJ'|LBfP*?m:T~`$v'f)Ns#?j`!oP>,OJq\).ڀ23htK%E7,ʝM48c 6栞{cIOHkqhWyPsԻ**Is^ULź\{D/q8)bpr\Cz ?z pZ_6H{M;L&Ԛh6q*bZyj\ů3z+{ҍ.~Dd9-{{  S RA $SYRUP 2Diagram I graphic"`b}TUpU},n}TUpUPNG  IHDR JlPLTE3Mf::WWuu3J` w(/7>FMUl"Dfƪ3"J1`@wO^n}Ҍ"Df׈33GG\\pp)Rz"31J@`Ow^n}"Df3M"f+3<DMUh|:Wu3Pm33MMff3Mf"+3<DMUh:|Wu3"J1`@wO^n}Ҍ"Df̈ת33MMff:Wu3(P7mETbq3Mf3Uw--DD[[qq3&M3f@MYfs:WuȒׯ33MMff:Wu3M&f3@MYfs:WumbKGDH cmPPJCmp0712HszIDATx^흉:Iߵ~ͶIIEث[k5p \׀k5j 3jp]ߤs?|Z|,k`E* 8_eNk5u yC4 *q҃+蚱=_={ݙrpl]HT13Ԩ^(ag,˞}Z)uHJ 1u#+`u] ?zUw4-E EjYli@|G?cnPD ~jE';'t]I\qj)HCM;*W2e d4k5yQ#s|oWyaSJ١# OpCOo?)|, ؑ\!hA>JW:u&vZj溓v*߅Xi;h )?Ѝi0t`.wQ]O{-X3E+C3Q NO\i7ŵsP)9|֏z^ʒ} Q( @GR/ 曰ގj>;DA\DՀk;|-ևrv;rOǣ Dp[ 6F`}(XSNLªS5`67پ*h}wΚR-c.GL[N)RkHuܰ-~:޶6*H>WKHBsCsMP]F[r(}fzn*!Z dтdzP~NT1Fxc5BVuTz}XUQ}rώ:N9 븻l׎;f:yp3Hc/-]SuhMU9+V{(2G}8 x wڼվKN/{mj, XۨA:Iw5{]HR 3%i)d0\$ KO::c㟀h(e`ul85-2 R 9j k:9C@flg-~]?ը&_5Xώ5Iw@?G*#v@|IQ)𩯭r%iE6`q@U6C/:\$O;̶̧UFm%㪋``yZitkI!>\[tXh kRϡ<[$ @ g>zōunFr ku+/CN\X_%z[Ux+*/?4?(Z戂XHTAaGa9pXo엟f4(!õmyS1ipևR8+`zծ;xJvFQ Y79>aJye5z^" hÆa^.6k^g ~$ CNlW39cݦ7թh)2G;> o 1ii]XwWo@܃X ?:d*t6ZuJ>\Ϯ6GLcꭔiÂ5A)X#4OZ .]dO~!JzCwK #YSoUHg^hk'zS.ӒamG-GOhoV?q/"|!pD9-{j]H|?1&LB$Vib>B ܛձ.Tecݮ;١[ l2QCPձGoRXWj;puWPs׳6n_0H/nѺf=[nuo?_ovnX ჺv+rUhBPv4m;~gTCZ]A WYJ‡u}-ԂnpURP ܙvinܓ ^Y'& 7g3c=52c=RޖՀc#ʱ6+X_7XQ?sh77Pu6 .[ ֋µc VtXr裊i/%[ӎ4P@e4Ụͬ -/2-pں2X ׎o[݉cL2U|G*M5ұCpe=>TK/ 篿}B]]/mVIML`u7|p8c<7NV|J,p|.ucz-xTNOeA_5qD_u$m.K-?Jj3UT8֝\? ײv{J1֡73X1Z5ժ:køH 0*ɣ}jK%v؟}'=3?z k 7kRL MP{uN8(ung`mÑH>N'6Z6ʐCJX۵!׺`z!MөWamKyPMpJ.MfjTIk`W@b7XE`-T,7W)M%Y4$[(qDgLkzvzjV^[YdvDY댎 dNd9@I3>5RM~*O}넻T_*Q/7R`ToWn1X&LO35vYR+U,]iߝԝXHe:j5dj8H J^Q[ ~Q44`ΆSlw|lڤ6Ś(!|m}65W+<kȓْW*c-ygV}jS(yz9cYLh^"/&,DzX-M4@P'Kk .;rPvpc%ldsvB hJevN8rķR%]xamy)+#}], |OQ#j&pxWGh]w% ։mcM&IB ]qaS77s75u:$6Xe0ZhPDhvJf:t6;dߤaҁ>XI NÏ<'$-)2wՅDu!rZÂYb$_FcCˮ1|o:֮/XQ.%E"{cIgY)CUx׮k:֝&}RZ0,G>|h5N.m;s׷2^[h\ttM;kǺ_n$VHJvL+h3:;p9qB`[ԱvgÊ#l|ȱF ZZwEIx"AmU=f&X?:tm{'ᱲ09J-X3D׮Xڃuyҭzts[z?_z֚m_qa9P+jhᓵ|jj@J0 x“8I4Jwb;c2"\ֺ~sizӯ)&(:fbt GBsi).E8Zr5DgInusfJ\s2S cR*GkjYi֡zz0+t`ӣ5R,\I")bd8cfL/UK3ScP<-hrJhUSkW3j 9֣ƜJza/a/Řg@.u9IUН9c=kvB װI\$F~T0[(\c=s<|#04 "њ%˥en5mkz3A)(Wq (Om;{ Mӕ?ikf }ff}Rg#G-yRpR+yeܱ.vBjow_AzM3c]l[^ w_AzMߗxV޹CG.HG7Rֶ - F+D {ġ|-XT["؛*"gČN;lY5ybQxC[ɽ{ CĘ s:>52}.Ec}[E9&Nz<=6Y8C3Whvp%za'=|Set׋lOIEψ1;39JѺkT;&74RX I&OV/|eNk@BDB>9M3_r2<r06wp,:c=P4U5>Z QU;C)ԩ|$H΅md#R?~āmquVЬy(*^'%h,^TX_FLP2Ѽ-/h|A|sZDR-U3RL$"3I,$u0#8h.Ιf+uk4Ў5&cL ;1BxeAb"ifNͪ('0wx[u0D7:V[n X-ڴc0f HvRuȞrYX?Jyj Fyov3f2 ]edY_e\c!c-kfkIbN?4:sz%j֭'2Yv9s{H56I%&Kzwb-ɶ1 ]UedV Y22ѝI_SsfO/CeN$[[WYg=2@|O07GmZh>nҶnz1ijɹ(N&j}{ i6NOxS量SRu͒a#lh*|ٰcB'XcP3XOбާwWh>GF9CT}qzX?w"ù~ ?Oۿ0dn'jOzrKH: KUi:SzI 6 bm^E)E^*[X4dLȸ]nQwv2jo|0S5 ״>F빷&9I׍j!g\E(m;֣4U;VX.c\+:`ykVǺImWuO#4I-k'Frv띬^z8:I~{ΣTt=,lyC^MuO-cku涮7khl^qu_u}2ɧ'/QX7vl1X-bv1XrGǿr%!_poPBJ=Zwp.˖5] Ú9Ce֭]p,{uWSY},z|ŭֺ/X=Zwʎue(KP(ٸa뿃<Ɇce]+;]9:c =&B]Bcez*wjȱIn#n6ѬoZ-.@eǺ'[fXKH;]Fʎu 0S&&Z Xa]q{Kt^&  71Du-:Q[[dU]BzvmȱLj𚍳٠,\kۺٖxG.YٱK5Ϻͻ,>FMq%'ԷkuerXs j5lgKhm-]@w#np,bעXJ~d+3&fN6k?򔵕ޭ7c轢KyޤU5\XǺX_5$R {+ȷz<&;vpU\Aǚor&4$':N6ܬ멢ڱsپ]'u^ a>McF'rk}Ób|V˭ +/Wo3rUu~ kJi8s\3N1OEs.6t[X1]ٲ88Rd= : [wD$0yu~yuh]rbivK3:7SFo۩-Vu^w83 :Xk@*VYix,xRsZJJ3ܔ5A2'΁/Ou9ǺXe+X3lpi}ƃZk]l9(i!]XG9c Uƫ2Xkr8Pr0}buĭnE1L Bڔ߱ns5k̡ǜ/oٔE[C1I8}P;*ڵ5M)ܽf uOQG*~;D.%q4V\8mVk<'Xܝ\ 5S5)`vu>uuTp#7b# C' xRvj;kV= ?1 ֘ DY^ڱ.串jWxv$ & O,/X+c~MZ6%jTYi%˱Ra+$|~k)7,O6J; [4T3i<IfY ߼ޤ$` dqcۆXcj`ތ1 DCq~ 83ZԦc]&/ԠǺAic8cdxW[7ԿXC؁/EhҲds#H&Hw׵X/5Yz륊?nT ̱~Hsu7nR8O{Q"ES7Z}hob^,Gczz;zs\s_ҳcDЉcZ?؟c)EhWtXвñ^k 1choGP޾UDz::Uhǚ_V]_aᤕ)h/:ԧڏ )Wj` J.+a.o̪ɆG=ӱ~T:o~C! ;Tnj٪FV5P亪m4\BoAXO慷>"ת*^a4y"w;~"]XG>P'kx̷^ŗHG@4Xhm:XGc? T&&ߗ_ &l6ajdMi^[spyzBhk3K$\C,; h-i/pY=6Plq*tvx(mg|7z}- \K1!4ùnG|i/h*[5~< } ^r)+oΕ?ECs+ăiSVa-| {/2ydX)c]cieK=YEB^pY1@[o>2.z S'+CTWNT_9mXWt0hdrUr zj&2 'ڊWL+G ּ)6gkSW=XL7Xҁ޵5S9쑈u*ce_*[~E[G(n)Zc-ח _p y* ,<׺̏%ŠxkZe!]ȡIL'1-_#c]+[( 0CFPGY_R$sؤit}<55b-Ig$,%6awQc YE9p~A AݵNnlWlhaπl'{sF}Ij> $ȸ!n&њSZW"|:@dՉ\2=+ArNZ1hǺBY_XkX4SEt4.Je5{܂jƈ~3eVXW( bM)FeЎ543k%̄o&ZseZN~W:oK pI8' 꺎Ah3vŬgi*!2^+dh]/,Zu SϹf,sMik<>cIMҝ\GȔqkњ5Vu i>g'T>Y[gy5_S:h2 t*h]/,Z$ꖀM#M\LSh~^mY=I]$I2SVmjqՊ!]a},79dSǣ۹$J4=(lYqq ^ Bq2@VQ~.kYJnQhAwqwH3Xl\Ͱ *ӷ+$ik?|96+ல1eI!ܙ\"x!T!UG㉇Yo)2 X+djZBlEj2+ 5|ɵsymM+}E17w4 T$a|i95)Fgޣi\ްc\w] >k57HjCdE4@|/NBp8n-;vak׃ϋ]5N{5eXN X_GkʧՇvk5V.k\qLfy_ MuN-yLV76};M͡:4ܛ#@6옃:+J]nnf_QֽwQ^Xw\#'IX$yKo0!O 9HzFio0MS0 r炵/'HMֺ;OVoXcmh -.Ҁ8dU5z} &xs6k !)O& \ThP ڛ6hرogѕlњak}QxzpK5U^[l 5D@.$_%5X..M1֒x(VR2S eP7(/Ag mZ6=úor$(aj`#zqXn8m (xzhWS 3N˰&w0~~EnZi[?9M3(Ӊ y7 *l('EH,|D. EU!n+)=6tcP1cT c[e8,+LpxH[0> k[8* Lv$d$F ֽ2k`QװܾK4j`-Hk&DC'UڙukZRká7%͚Q*})u7_$ArrAXfĚ~4oPw6Bs&t.vX7x"Ew^R]XK`{RJA5sύYg7HU*5Ї5XXA#Fh"=ftά-vR imǚKYwLb!M1ou:ٍ=n5]u'҄$kh]~֤1|F[7Wt9j6qbt !3?c9ٹ:zyqIXLs9EXO(}kX-рcDvrl+ v7b=})=ZJGñvGўm8{eTcp/j؏cV1u P$zuՂ^N^B=w0V\nݱ~s3k~%&zY۵!{\Z(n-Vά5X7wv>Ǵq m`j̚Śun{?BU-mBGQw!p=J2ޙ k(\VawݟDwfߕţuٿq̚Z^u2$!:6ǺKwj+?;k갰~+֟a-['ׁG7J ܮgjݗTN!Ma7X KÊѓ[O8QNLQU) WIKW9D#u̬ҎmxI?> ֆbmŠ1;OIB 9жLj<04~Ϗx@C9m fwcmKH./4Yb0¯Dk)7&MiWR#k z#Iud9C2oLt%:\HAOqqiTo{P;ՂdÍzgcMTT$X]ǺN_E(H= &H5a23/q)^'/%5-;۫i)1~X7ޒ!{I[ZTf(ѺkƝY/*?Ó7֑d6ϦwI(+70Q>ةݩ*yQ'cW-7zʣ^M5`b*la䍼- QlGfTgX-Ac7QӨş&I&OPXXTFT40^IIJ&|v,X+k$4֙tt9wΑtsj.*ZYH4Ôcu3 Zdu/4Sf-_ bheONz&س^dj: tpk9^M[tlj>: fo|v(Gt6\30S fmr%|DJ޸`cn<ҟ)ܣߥMYr4ހQ@\ 4u3v:d.4f֡{ZVߪeᡂk쿏.IVfKhL$\wfMn,1롓vlzh7`Baͱ\Mhˬh[a 3Hu1˜VKtSNwhGz #@;4ߒm=?O^:k3UM~.I6w,oT-`Vh%X/~ԵB+ }L:mRM?J%c֥z9RsuOI\EoɈU,QZĮ3j,}:AJ'Sp_sS{Ac(ZaZ"I=o֪y@Yȡ$=p[1up c}g ]%" 2ցkǺ'.͋zO]'0uV]%^98X;Yl1- uRVռvG췵%7*ZwЎu"\1)Z/߫~~{ l_cw"VF9K",GoGg|#̱ YJ | $j#b70`gj>_^$JxHZ}8e`1C;LQEjyStGJ]@˕QL a[p$7@0DUzgfcZ~gPug aƁ+js?8L _kDmiz6!q~/5fgآ)n槕6ܜؿP1za)Cz`(%\a&|$aNYbSZ1e{l²1"| s7#h9ׯ򖠯f3z~67]P^I=eՆr^ZKާ 䂚H25tx/W(1xʸvǽНf3rZnJI/0峼viެB}ZmÎY !M+:#cYAϡ;|>E~r Og,ih@rRNCkflr X$wOӧWYڸD-)_΃ykp[58Sy;F,Lj6P>oIuz; "?ϝ51=KPg!MOdso$|HP`=:#7ZV249}W>^XOb(ԍo&Pʻk aNwf;dܝwZ%-/|HR)%JSYv3KkY8+qzG_iѺAjG~9>st'AIB8׾~ bZ'@-`k-< JeU׹2}U=s9uUv7"c]w]3Sɛ/$|s7Bon{̶x񵍬i̦ݗI 릴c]'ʵ-tZ˱_S5mݔXjrmXj#0/ Hxa>"17oc쁺j: v>9cԛ5m~vm٥J҃xdNf.8.380솵[5YuFsR;5ӒB5vp6؊E?UI?q<RXp08eEIǯRgm[EA`gj!/L0igwM'i>Qc= Ƕփj$Q/7Y`.exց?3$6r9+ k1|2S,j eIέsǂ8Xc%48+N4ὢhH}Qȇ6*#Nq͋~j)Xꦷփup,HTJ"QH)8gjgV~E]b Dk U HD&ѱ5L3Ս=Z±b-搃;ޝXN5T">Œw 5i߱bš#(ZrIs*4ks>碵Is iȍdش5=ZOpaMb-,8fcL#'aYSس.f6]a`r y*kSp8F`mOe(-2\nS>HDB;8 gXg!7$R %Q:SQڷHƔӈc='44kb>k^a'iz2pX؞p M3uZ +EA ڒ$ >[wqkEvѺE_# =aX[KG@|pֱvczLޝ$a9hb-ָ+ѺM:}_iP|W|/]XXGαM͹>FBSN0L9-Jqcx 75X'ufCP:4RSбn7c/uqNj14Zj.ze:Rρ/EW9ǺE}_p&$=XEz`UF54\F X5Žuc}~OY/GHc%"WqF[55Gk*XFBZ^^zI*bb;uIXK(b4dM1rN>8bm'xڌA3ǃXK~da-ua1fy4P"Yws@6L˓҈h]rg in-X/Sʎi=qJ`iazuG ur#;,XS=9lT|YZv';$lo&5I:]/ɱ^ r74JHu܂cfXYXM7Ykxnbֺcwapsz<[2[ֆS}jz]\*ٲr2UkLM6UZi}9u@X+A`"*kLSЦJibD>tDg@26 /]z%:W׼F7&S\#k*?1nz~ou.ox1iU].\9lw82lњ YH?Q=xS5uY鹅Zߔk+ShE:~~W* 嬞c]htsW>g5wVLmoVM5tS*@-f,N“Pñ.5lah}Pʪ~WXc3'rN5/BKkOEUC/,{_ؑUdL lX[D ?ây={0u9.+-(4g:@:i^:kJwׅ#Q$ "n8DNBK 9t8E-FK9%\`(S-5k3mX@gN" ^vy%T#@/ *Ac}CqD1q,gX==hqx:h2ҳD}M&hN f,.McB 2Z}̌iۻQBs$ LIR+jw#yyZMDԞЕb~'ًV^uFh a&3bqLӞmV~vn" ̶볘{e"d6K8qJm|X+ u660H̘>LHP)F:I[Тn-OJ;reL4 ;Ҕcm?PT>y^[\9p"_F*兘ܬq}>Q9Fmz0wXCn:Kvy(DkxZw3㙴mT{Q$ַ[f(AEɮ 'Ǩ]37CUv 1֬i])O,^ oTY& M4{Zk dt0 t;C+[ǭUn lz :uY8h^@ɻj+[ǭQַzcXo-~VKԻc=I/iֱ~tmo1+Z<(ǺXUo*XZeut ʟ׵c=Oohٱ~etUU2'ƱJʱ.V՛ :oxY:ݠEz#<(cuXZv`jj}U[fG=y믤Gokzc=Ix!=EQ7XGρTůn |?UpC%7M:5Uƥ5)}4L]ËdZg(O§xӍ:֧;࿟Bt*HKܰif ?0STNXDÁL; Xuf_D-5x ZPpA]:Ǭhf34xHf^+͝B2 f1c@`zۉ3/(a׊=St$ZSy|V(k~5Gvprbabi'{vGĈ_uT. ` >b+7c*Ǻ>ZW71GV9kN59TKfEx a rBc:T`m>9$6KXc]5+;]_Ek06V6Ƽ;!X%{7~)|8Z)Y<-6N5edEM[7'q-v g d2nuH/putG'H %|dBNWib^Xj ֧T9rʒ/NrN ,ݜG%,V2^–R.|YlA&w- w ?߯Dzm,b&Yp= fP r3cѺ[&LJq:}e [7h ֠,8reVU/?Aa+c=qEpLq`p5Oz@&J#Xuv=Nt Ź`mWDcomi=z:IU)z};8_Ҏn5ktEZ}/ ޸={%Z3ֹ};El+46ZwX'dްM%Ɩkn!<ְq>۵5CfǺԘ bc:X;d[rLuF==Y[x9m$zj:Xg̱gmXKy%7~rybA[+rj2|S5ngIu+,5pV7fju'bNwe/5C}l(Ñ{\T~ʪpT==guPg<,%XDuL!2hXdw$̮+ +KG$!JjuLЈut1J38J6;mp0u*k/<kyK'gKq:QWYuX[Uub}#f%Dh']dPLIG*.A/rXBH;vڮvdN¹3zW8kLΉ IFo.vvIG# HR}έ'%t/TΤf5ֱ2XOTsMoق"AcCXv;_iA9ŪzS'.}7xmj{eT+lz;,ȣRu̱^=qKTu_^ݱ~;_iAap|SfݰRWR?WWz4mX3 nq᜵4U[eveXukt֐z<2߻ZNS,c:6 fF FYumh-ĕ,kxa2I3@ܣ7<ШF"jH6ʷEHKX ryx{-qQg !ܣU \, 3A"!b-\bI=ֳ$ @1{ku2`֩2*`͌Wt WEξ Ʒ:| Ofn9~\&@ D𐰮iVD:gb4fn'X%$Qߎu c2EixN-"ZG!b͠2A?+F#:ɋɋa/j"PNLpS!7|Y͜qbqV6<#| 2mJyE8rX1ОX'ut@V,ָŃjDŽ=ۧDkJRP1%&o)q~ +kkq0+qhWNGRϰe7њ P.FyNk}h2#mF/M.^Г9Cb?ckl!IDkmCm)K#l5Nm5όUYu::"6qevD$\bXE; kH9w8%_ 9f4\K25B8z tV/:PXDZkR$Hm5yՖY}JeT "x9J7XSF+,LVa=ܺ[6xu%ϰ6LM<=ve;$XVO h$ 3 y:2DsG,#2QSVµ^A(0|ԤD0qt+ Wuጓ~G!˱xHO6=Sz*-amwњC&M8-rn`Tz9&w&Z&$j21S6:Etۆ+x -J&R.STtɳ6bV5sʸ7"̅Pd}|65N 7 U5mjljc]Y56YCvúIx=: Oh~Bz[ ı6Xh";:WZױJʱ.V՛ >6-32 b/HO.83'"ظ?)5H2O U hB݋|5q}[TtH7X وuzH܎u$ 1֒eia/KMUljJZǺJ]_W ȱ#_ ѱJ;_iA9ŪzSAM/c=^Xo`EpTy}CˎT-c]X9y0WxPuTб~X-:A?kznвc+UXW*a}E #NP& c=-i,ORIcIoXbM_Mmh>Lt<2$XN%h]puu(Q9zH:ypUG'ij{0kZS}&o:yu%ֹ%d;(Pg} ԙ#|먿mRұjrWh*VͥmҴAWcضVu lF ^' ؠ2"( WI%Q=O0|#|;P e&#SZcr?8Ds6A8^RjZ4ǹ kIALP9!TtiQp-mb6}bm~Y!&+\Ǻ47V O'?[25 ::RSj@8Omk'n9kyIK}k}iֶV*0K"E,)t^n K/ju+~so\w:@ISͮ(ūU^h|kSZf0! 9z@>-@S^\ˤ9 u[(0\@aB=l {%dRi\MsS>Iay)B樗曠+xv+9( Uvi//wgiWSAi#0sZM)b.!faF@A~gj!^fh / nLnEoL榉#tn.+D]*[ ;@TZB~Kf ^u\aƠ #~׺B%堮çQX=߷$|3*ıPV5O,)3aEF!=p "БIn!`-ګr B3sN4&4m4[ok ո3, !kGkZJ4ֽ0$,NL`> :>8X܀ּ:Lۃ} q.+o %G\c=3C Qǘq/mY0?bϜ$"֎e%#͢OFAcEXϟ%S>XC ^8_̄{5D?9 H1֌M*a{$Y'蜒!׊P(8EoV_]7i-wѦᮬu]Ls'aܓ\O7Ĭoa(#S~sd/.ڮ(Vkl5j@}mr:1_]U? Tjj5zU^Q u7YM]6K}Z}$X8jn` 떄z+4\ py5SeCDMGXf::̥Ӆw#`ʹ|jsf_WI?Ru__:?K“nǺZXW_l81W𕃪v2[k}M_*Q>XKrKE~8 Y$ wLM yY#TF` XwSRHqnFSc벎8]^у-7a?ںy3/-!q{5\xswY,(e'[Ʊ\kMX@fZf,bż?R*Im|:"js- Yyu+Tyc@īwڇ X$r(Gj%,vUKF 4#5xkv*PxXgcxs^~֤WOܵA?sҐnXl1b},ymr+փ~LtP뚘7'1Kg9jgi)lw34PnVEekO'&p7(Ѕp.|J >k˔MԼWzF5f5ļ3}W5~Zj筳ͼd5f֝vCh5=x4f}@uDqj2YoU_i^7WxPnbUM/:}/3:^ַخfM,c侶\ΠܤZcVZMJpUU]uտJciZ2DZ77ո?+cÍMuK˘zO˱Nm~Z-8߃hHnů1;^Dwjl]uTb*U2K.m<kU^!Ǻ/`i=ݱ.qD/3RXG |<]vmh-&g.ue4jfܮm}c;" }IKMnUNuƿ inY_$n}ZG4u;֭zX'.8;Єuop9ւe7ool/Ts"z2sЍtowK:!_] kZN6_9%:|Ni©EgPma~tbYaRF˱>y??  ̏&^tu/G=2bݬB|e 'Cop}n*1ֺ1?cȆ.Sr;lQU{Go>w(w2N l &áӐ7=fj ОR*pjc ._Es~=g]\>׀k5p \׀k5p \׀k5p \׀k5p \׀k5p \׀k5p \׀k5p \׀k5p \׀k5p \׀k5p \׀k5p \׀k5p \׀k5p \׀k5p \׀k5p \׀k5p \׀k5p \׀k5p \׀k5p \׀k5p \׀k5p \׀k5Я0dgIENDB`SDd-"  S PA $Prom12Diagram J graphic"`bRn{* a5R[nRn{* a5PNG  IHDR PXxOPLTE3Mf::WWuu3J` w(/7>FMUl"Dfƪ3"J1`@wO^n}Ҍ"Df׈33GG\\pp)Rz"31J@`Ow^n}"Df3M"f+3<DMUh|:Wu3Pm33MMff3Mf"+3<DMUh:|Wu3"J1`@wO^n}Ҍ"Df̈ת33MMff:Wu3(P7mETbq3Mf3Uw--DD[[qq3&M3f@MYfs:WuȒׯ33MMff:Wu3M&f3@MYfs:WumbKGDH cmPPJCmp0712HsOIDATx^]*n)~k%͵`t=U6!F`n[-0uiߥcg_=[`: ylx("s,lcG 80އ98бtVBUJz^%@#V{Dκ |SeVwevZkи,DuZ[ذҿ(}2p-l@SLZs" KDMϝ lcLy+29:פP+_4HAm/pj%? mtJ eo3T!p7M|x$ +pzbeɀ3ωAJ ^ #8Z ;~Yv󆈰;.iBXl ."nT{]:E UY[ J\eUɆH 'Q$Ka"ՉFL(!@J+Fܽd@ڮذ3?"Obga~?KI;/r{nW?7I- TRCq')sM:qI1=~P,Q) k'TlRf6d6ބ+;+ @{%=Ttj eĆ?~ }DeȰ4עAwdgZn(N:21VWl~֧zU@= 籀F_o860^U<=3#1ΆqJ9 d0~%6 obC^|8y_.pE:ᰮF^ ij}f .vZnwA!`Ox!\l:<7ob.q sy* (y gwʾak@IQ$*|G_;(ya \AJ"0 !GaOPaCD1mu7LaC{[3gû<26:o`g@65kJC-p#P;;{a?P_{[ '{}A#)gbqal#RD'kSЬ1 }ì[NKN{϶l-/:oYkHNT>. d?yX\59ݻΆody^ (>1DWKs6dΊ5p6kE!`]XV Zdcr|Q0V0u0X5dtFbeOwI|ɳ&/N(#.+aau.Jfb*|m.[\%UPG9Y d>NʲA675 hˮH"U۠l(aUlWsc#ԌpݾZ Ԗ2 Ӽr9dtkg1{yl0ںllHl/4ӊH/gRP'#V@4sPcҢR6nRsѭU۠qX[mZNiLVyļB!q6A2DqLJe|!+CIrYnGUӨ_Tbz–= r'ЈF,-Lz;9- ZRܙ/Mɻ'PBj.q&Rp9}0qu zal販5L?WFYA4l`HAؤ|$d#$l:mD|k l*j2PhN'6 .1; IGːf6l@Ԛ n/d#.X"{7xCoW`6ղh(3\ۙglHM Ɓ{@k<@f@[Q0!F#VB3ts:MLSfqP"WHcaIIG[ >_2֥}-i`+$):' M w[n W[H%["Vث V\ՏgC/6!I#ܐPx?@!Az5%#Nfw6d,PG` lG&)<0)'Ѧ\`P77-AagCD ]c{6MM?U1$ W? Tq=o9LB26F [`)DL,̵vU4/;$N$[==oka%C;UӁ&zzdU- (^QhO)""Lh ӣ~yl ! t6ЅI W .rw`G&Ioy >]r00wT]HH4aCLKK:hU'y9 2RkG5؀xl8  87!]Vr6 /cX]% ֘%F`d!p&aQ&Rr06k/d 7!MPG؀@a/DHG2U zѣަzɘ7w&T}u$` -bp?tde-,(G7;GlFE-p zijЪ@vi!^JV@ 8q~ l,=OqD2OFzqelUбL0B&~_ K_bPwq6i\*]>8YIUiv}tal AӮwUY6w/$y&rTh(;bh:iMlbY69"h6<!(uoA!I4.\T\?&%gDOc<7UYtM]\9G}$Qy {|al1ɔ/`L*!,D~UP~juR^=тe1L݉)`U.J '4R,9Q"<}ۉgC]?t.bbC$ 8̋c +lD$UO7J.&7<>2 {l9@B«;i/Žr/я!,XG.e(Eر]kJ%ox|G w(l ۊo9&.~}e [!g19pыh ΢Kh6`hDŽp?¦ϕr6( wVidz3n:(lQ68-_M( 9?ϣߚd##%.78 nRk:v"٠o'&]NhJ/Vli'L$3OCuN_cCrD2 cٷ9fQLlwh5Άph9fc蟫 *!L'stWf{X`WJ=@;Ns(6L!L;փ- 8Va3ʆH$6&DË-j5?,bn|f!" 0bgH׬`rfod<ȏe3If_he# )n8oblC$6 'G lPZ-gH$wmn/٠=a*a%bO\#* ,E gDTQx31MWX7T:J Ӈ*;,96kz^+B|IY& ӉeEUtE4Hf.g".n?uuC^ŭl8iVoSS8w @8/$)6,'bFJ{?M8CD pI2IJ5e*4{Qշe*VAtN^3 `Ĺxa|hBP0JXe cS= -ѩX *RjQ\#S!sqmKv+ d‡ * EcV8<6;@c+@h*?2-d'4a5]p:,$AzޣJ~Os0`_LLԾ:GkTg#ec𘡐6kQ; "oH7:GE.cDlUL$u!F$cI+(OZgY)a!O?H6d0Ά?]iR:LU?#lX Slj΢0%lk IS {oXkgTˮ a9 R:s0U*a| &9Lf+H vezHxϭ?r)/YTKÃynk8lf NKc>XZP-:aEA<x'ڛ80bWԵ 4Ap4f6`hOW67C5Uv`2Bc<@yKT aU[}xw:߀ #?h XA/~z{[h +ps f *Nɣ>w+. _- gƬbyx Mw ~k <^>Ά&5BFa*Yǒm9*oI*VQl@hzOKkҝ [7<6!dѸJWoYa=55FΆ]V< -A=|G-{[Y;k{;:Qh8۰aKuKBh-|&I =|GCaq64kVag,KNljN0gR[9s6bZΆw6,1Pgè;̶a ֨f% K:*47,xʞpdJ<" %ꀱ9 ~EQ7:U6*F0Ay:][B%A ]h¹f+6)a\9OaLbl h);%3 Ci ̯ 4W/S`CkVË%*R;>@/bf(CWT$#[{7Q-t8 ,F._ Qsd2 zEU^M`8ifC|4jY.S!0!(^ 1he%dɡjJu9l`+y,֊{OŒ)`C7| m p]A0T`.Gwu1hEqo R6a5З D&[aj lEEp(O-#%aMDp6H߀C$  ^'\ET\n5w oH3tkʫ.Ғ%QM H)@ 5t s@*Ere_-P&NJJ)xTA,] e%IJPBtҙ NVB\y;Ϯ)q@Y QXIx0cs$36|̭^#: `z)lڟ Z}edei$7,I53&p(,ҳ)OqҲQ1uiJTOLMZ`4XH#oNuC$‰͏.Y-&{Ab,|N8OMFXJe) ZBߚw6hɪ*on)lPndeh{:[*vo O 51u~R:!%T֯k-M=IXK;[| L8. ZPx]I`Cs] d-"Pձ F9!:#hlQ@y j M4 E--Vp`fC1,aLq#FG5B9,BCoġ jZdC7Wq,cefY`1vG:{uɳ|'q=6(P-F!W7ZG x؀LrRf&]"Ci-&2H?B{T-aq Fy[X7莦ֱrԦfGc-#̒l`35g xg6)' )k`6j@5ClؠIgJC !L` -$b*~1H\ysdl|X !|L0ԇ~ <zw/v;0=@ۃ52L/vn阩hNLȤǏz,Zxbc#H%>.=7j\64; Ml.#ņSsqo; Ilђؾ31ͻ4| m:Ad6~4A/גD$WX[/vjZoH }"D!?l(0vZƻ7\YN)鰈^^ p~G=O[0E@ E41wÆpVw lI^tm is6Xeh iqՔ )"RV:Wi[)ɂ jxy3ll.-GƄLl9oS UDd֔>vi=4[א(A tk;Atv Fk:PeC{ِѧ:OvFݮP2ܮv6̶I^(jP}j]E wY]g-lF 5 -Ɇpy١s 6N$M:S#ұ0ȄφͶO15@dž&Ҿ?k%K򏱄NwI0#n;%ydhCT]5V'(6?: |#q:~ӆ;ݪ6IFgz5?h3]@;s\U{`Z6 ܠscqlUn64oG݈blЪqTh_ rJKڴ m*·SY̆6Y4 }0lbu j 8(D #VX lWY4ֱљ˵>۟!D lh1jt3"7L: ?Ɋ 6ZL.= dlвX 2Gp7Bq ̈-I['9_ECo\gvjkN2).g6i ]?;e-:iF@vN$#%Lndk!fv;¼8j9iB L,FP+4}QfBϞĆEdäXiv֚Ws8 p|s@-6d . soxwLŋ `bؠI6y3HZQgLj &3_eE (\D: ;T0hJI66+EF7"*u6/]{aR@ũ3ָQdu6 -`x4aM'L _<|EGR{dm$R;i Vt&Oi(@ɞ2'q9e+op6|T&6>?7L' vSiSf<...x `#^=죁bCX VW-ݹ%;HeՓޅk>nu87 "fg 0<Iͣf0R? } @7)1>,aiB,< :KǍc|aCL+w`zspkh:kt ,p9`Cɱ(6RWlߒ6G+Lv0/I6KeWə{]c+ ΃N`sȀOMNfP U+,{d^jWgA?U 쏔B^\t a2Dܐ][ ;OAeZƁ,6=R_l= އxZlOɹ0{iߐ'ȕ6I>+eD|/]#Fϙ@Dvï@3pM{8 %=>3nٰg{g$.[P+#؈AfI­[,OwnI^&(E>i``Õs8s.җ`'f?@_?wΛB)*~|ReO6jF想f" Ė`|BWJߥ l&C:ǾJv#aю<{A g-n$t&u A!IDfPݾ;or\U?_gC?Jg#|7-oiTq_sp6xZYaWc7lA /$Zz_ f?\?Xp w&p$ԟ?WA3nMh6.-4d9!^Iq _¯1AlA 3y@6/` wr6xZY4Dנ q 4}j?`u!I}` y/">̆g4bߧ*BgF.kslhD_Kds6,F_cXy Aϱ5RUctY2=Oa wFaCϪlxxtil2[Z0ɐwy>tA[XyoQl3?6苐2y"  / 5ark}ZvJ_#C dC==zxWp: JӘ _P)XpTe 8j&dd⺖JU6@y;f \S@2Za7Y kAyi*F0$?ʆs S0~<>!*RY2T*# Jh_CJ u; n1MqL2EAD@C|Wp)KȁnMc+MjlXi{n6)Ȳ$\dDӂ)'kQ Rq "%!Aq 4Y|xRa#CN][bnߠSh?H5&.fe ᾡ#e7{'4R!t- kK=seXƄ\! Pl*,Q+6 +li0ᄀK>c"i$m牌]V#I%6L2f1z4ych]bq[Osxz5|[o;#dDU ޏx @QĢװ|bNwX;Y4h_nNX ,$:KɃk^]V<!o 7,&TCEfkoA )S7!:'I|GDa5 b9H)/S+6lWf 6p6ZlK{&4l`" mjl0ig~[Lł7,6pxgCk9 a]+R ֨f% K:*0ju6g[-z͏,,ޱrM(X>SdXF epBЫ@w_EV8 yZـdcIBBr$Hy9bpy=lYGWq w(b \٠B!S4a8LF]KVc8w efܦ*8X@nE'M~d 5TjԈp+q"&Lؠ{A}Wih[ΆR =8OcS"E ՑCqH ^ͭvX, .S mibmel>P) q1Ъ #.(bVH$B?\=]ުn%ߟ)o\hug4f6m2C;fyfd#S,*ӟ֚ju򃪼>3C>eR?ͻo0jg{Fښ^ÁDɕ;#ʋǺ3iti{2Oƻ1|;G6p|Gt)?>;F˩M>ug[ƆCHwb wcXwwl Ãl6ail8b"T/) x 6guqMΜ1^/e i07*ŏcݙ4LcCLA rY~ >άQ^-g$ rMV&cݩu)b4RNrjLͱR!ʢc߀ϣ8lZjjIlY4&<絒fauǺSgp69SrVv6أP#aeZ|AgH@(ɂ@?n,noj@TTs6XL qʏ ,*_'e;Dl}be.(T`SB ԗR ! ?2{I0 l4J>+×NML)'Ʃ"#y3 u78q23dk"8aBu֎VX`f((i\iI~{[=7D3~k%'Z%6d Ds>JEJc""gp.p, |5&CsY4%%q~q @GebRÐ)K(ʹ>I8ɳAi+⾡7Kt0ATJ 2&1#;DsEkJD!C+,#$5f"ߑra~Xa% p5!lBLvRoPٲgӊ!~dU:`r^0)(,@H7}C jMIˢ_DD̟W<_DJ4# Ȗ)d 5`X/ak߀Q†xE@|*"871oTiJ$$ y>8r\Ά΁j0 r/X~..}ugFq6ZpI}gքdC#uO>u§w6bw1-q|MM\>#gh/]QkI}clt2C" bA} a Q|'gB6}!q"6DÝp>L^`LUMIo!RV43 ЛkםW[pYu0Sv,t'3Zp>ƩE[,VjaCff611$5dA !B%p6s ea**E/kmlf3hdgC8OS= p)bJ9lCads {@7h&i`Vj`S;GJ,ed LjpLR4"N!*aD |zST=Tiu04t}d)s#B4W}So7į!36 -/&lQEJZFƆF.= 6?BEG`̫-8o.H($#0ִ1naÚwfLbEqva;36!+U }v'~)aҴb p6<##mQȑr62,Ά[^kPВ;ٰi&Wv6nQ%%8XJ72vG%V5X,Pc?dN} >-h x$\3pόEB.[bkimJǺ[ h ',VK}čMDBg-rΆG[ C) Xyq;ѡ OP$T?GKt5~  0B" odw:^:6{Jg2a.Il$(G'ʖɾ)P7l3"<`CyO)l+Z%Ϗy0,M/;h3cif w6$l΢r!^r!drX1]! 24(td",:|!"δXNk0-lx;3w˾ wcN6x5]U VKm-1Wv9am/$;n1{QgCBK;uTaԂ] ]f[]ٰYΆ[^kPВΆ%fl`W}gCVWr6GJXQgCF+bw¾21 ڏƳJ|L)s_S 1&٦ :8&\16dZRzTI9 o~k(G O| fJ6| O7DzM9ΌoF s/ɋr!^obi #_Шw͡үAkJMje63fh{ϥ H !ɲa;3n_S!9<Ύg$ Qo=Y/h#~ $轚.=v}p6BaY-df)^JdAxKr2F=2 B-@p6X4Q2\ #Bɳ:aM'35@OBWrЖt%iP<`:2{Ke-Vd1} bY%[: VO6gKd(FJ P[ yXn5K2m΁qjϾk ;s6; Fgg4kJ!pߐE6z oΆl47R Y= Vp.HIiwgN lmݸPP2NߙݸkpOm! sΌbzAcg ow K?/:v6\,-8Od|*˗-pmvO8qVNPbTe2Ӗ ?̸gl6N_bsZ7FJX{r >?#n B-fF}XjZr;ĬB}XF-UeՕr$o8>?qvuoԙ[n)kG-Psy҆Qov-göqli0,zC P†f3|`-{h"} ljC-%,klx$ .]sd/jZoNga xΆ>ԔWzgNlHwgÇؕ 6}wf4-1خA1heU\]M=lK7tqB"SB lh~gg+|ƗE< fgSqV|F ݍ >z-"NSe =nm m/v6lɖƾ"be-ОN&u{O02>:Lk|x 6Tܭ=d=[ocj=Mtc:n>mCn]hix U ƺxM7f~c;<  Fp܋O2dIxњjXwy c%@0cf̂]/\Km \ݮM'tQ,@|lݚxA47>d9Yhe9盨e$=n[-p n[-p D|*T3IENDB`4ZDd-t"  S ZA$Multi Out 1Diagram K graphic"`bTY_L6JnfH0Yn(Y_L6JnfHPNG  IHDR LLPLTE3Mf::WWuu3J` w(/7>FMUl"Dfƪ3"J1`@wO^n}Ҍ"Df׈33GG\\pp)Rz"31J@`Ow^n}"Df3M"f+3<DMUh|:Wu3Pm33MMff3Mf"+3<DMUh:|Wu3"J1`@wO^n}Ҍ"Df̈ת33MMff:Wu3(P7mETbq3Mf3Uw--DD[[qq3&M3f@MYfs:WuȒׯ33MMff:Wu3M&f3@MYfs:Wu\xߧbKGDH cmPPJCmp0712HsUIDATx^䨎r?MB]a ! 7q \/iE2Py#إ-=:3ݝj`VV?۽Vό*6\ aaP7ܙKe^.4*]a7ol oYke4EػH]!?a1,n۽fRhυB&F Al$d,݂ȧGLA?c8laB ztng _zh_C0kIՂ7Cw"^p">w@4tTEw_HlK vQ^ӧǐ°xxPUd_?Ym]MM<<`H g D5c$0` ǥ$P{q'pm?@v=CFW/v{ծzׁ.P[w_vWp6k"C0rithU[cO;L%t|ov"}/vh(e -h'l4b@OZYY4J(W#%zT> DWnꁷcXmN+o-86, #4dhsx`MV*(nr ,A $Zb0||tp/^B3X߅/ꪸH&p}w6+={o882udSWy.l14Ĵr\'T ?SpMS@Q=p]TI.1-CA 4P:>^4u: 4`<Ď4NP1zu irqwKTKӂQa4~>2u)C%j!;6|b/9`T\y6 ~t+ BCקÇbL -ҳh Pd^NC!L"e_ blPW2bwx ?T/Q0qFCn :wo`h GAUv@#eo*t֎o mbZNI҃:X67iC1THc| Po'!sTơ'I 4#b Qbű0kN/_0As<۩ll8nV<(z6/?3 ߺos_Ťnãh_@go4RKD \tT"!xᗧ98 Z[ϋ6ym245ϫ-iZzuãh ]B"πvӰFMq~r~1Z/0PsY|P iJ&Hlsg8 ;a: &_xGifJgdB>~oI4<2JiL%H jtM4aj31A &0Ia"$NÃ,hIHiDE6RAF8|P-p (*RI6TeOgfWY_Z^ dh\%Nao܁@ Eev]-,}k[ Q Wyeu4c%y3JO-t.;xU[hgi,iXe+g KwxS=ldaMkC5ٝq?/ջ-[3ZME3?NVۖӰZM7do5$nih圆:X9 :[P#\iAӂӸ:o5&{a׿V즻o1pgNCA|_:q_! *<CTK4QfxgP/T[v4h(mv4ѓDP㋚Lp !ܖ#Ko4Ohв墉2C'>>ppiX}[do@&dk@'e埻5%ulJJ 1"!WL݇NX6-ȱ@,&)n vl1~coRZ(Vy "+1#ЇKh4D4XHi03x;`͟rL>!%hJӐˢNLK` L^lpIXtuw34!gh8U޳=dH}|k"W %Yvk^}GvP 'wNE7$4(iם(5C iPf{Ua˵NC\hh0TBtKj9B_#vV;K VYO?ewO>dJ3AnH:e˯ ^\uDlt٥+ [IWf0iW率H02!w,!*R mҢ(K'v>fH !А/s k.Ua{sU7SGiHbLXOݧ%)0c7uu8SqjiBDNQhGJ lʿNЮWN#%q; ף>zKgfm!1SRceE{Qpp7 *~ [BԠȧk7 kcVlά9K,(*HiqBp`5iAz8uzo&z|RW&"Ґ˝Z {idB$IKưhEQdL$8eoxH{(|.`G.tܖnF^h)CO.yo8!ҭ')5U勍(:J: ?մudŢ&cp`#/0|E%[>`)@ #,p""..&ƃY"6! QWC>)E_$4\5l4m{0ݧ1׍MZ>ԃV&u}!h;/Ѡ?EX+qgY:=F2B+lMUY "3*hE~Iu6{LnM-a:W sViKХ ; Wiڴ4ܢZNCMC[; [:+iP}aHm+9 54ܢZNCMC[giࣽc6xMM_H.uMi 8aFXPcCI^zZv{`G$1 T{w˿nGB^;9yyGS%WpP5h|xՁR0}<#"!?O1bvajE%G?X. ɜiP16qeVD-L5A۩!c#Z\9Y V+v|٠8Y|FDJu@lyQ!.3^v̆8Cc#-wVƹyה4ЀX6:Vyf@lhgFe$&>}ӠNèWѠ2H uX~l<ʮ9N|H ,箈b۶-!ZZ(ўqBT :Ih 1 ƂSGi@e_-9cVqkcv}{ h8)eH_ڏ3kf}C'|>fhৌŠ%o=j1Ih֎jUJ>쀷о7ĈmE: j [GmAguq m~5;J1:4Ԉe@EyUIҪm Ay'I%X5ixfb9C6}C?e D=)I˔ʶJ MP>J7GJ,x 4P"#ui9R"2+E8 + RYNå^cpA瀇8¾:rq7e#:U-IJlH6w8#夀6$Y WJY @RCT/y]}i-4ovܷ{4@9ޭ\M#mi.Ӏ4Gd J;)5K=!OUӶ%a@^E4p1"e^ZCn/&z3 wFr曪Ӏ;lz) t uwvMe*q3F>5c0߱-^wFru^Ghp}]$d-j*_H-Ie1x"CLҝP߀0@sbw[dd}RWT u@b ЛUKf;vPGY4<3k>%?tu!,#%o`t& 1:l~Cf"&뼺( WcҰ鸋m;cU Am4;64N3@;Ǡh }g$Md1^s@NN/vb=0}̚ӰGNC ^zYsikrUXήKx{a]W KotD=V.XQk4P !aTk-IW{^8ټ虂M!w4 EFd;,g*v2G}#յ"`nzyæ!#no>r)dxO _ish1K==ﬨRk-lW[n=}76?K؆SXDՇK[akgo6 !] \0 P%239NäǪҰh 5KyoRA4d!M-v(r&m4L/~_ê60%|X@)q$f'}ì)PgImmr,v-Y_57p)ZG2ݔ  P P MȤ!ց %{Ħbo^841l/hl$t--Sm5rb@'TXx d,нqc; _i{`j@"D/5զu}ވ"٠(:(;O[54@@ϮZ \afe |F2SuVT:f3u LԊZ L%ʄE2@Cș +Pf ajҥ&k1E@Ex[Zq_Y Gɠ ѳ!#,2biX>\yO)7~Nj0`D]{|K6`@f<PlcL^O+S@a$ұ{ iE}6R"{g.@ѐ|| /fjjK0dPԮ: jUWodЅJ aLG.0Zk%Erŏ[%*%ՍM<6 Z0D_da֧NI 4V $T|4`+ 54}zZ\ETC !VwHBHpFX;h|(z\k0YY0"T"onNG4'Al'7)e7lK~bDŽ[$?آڭQY=%mUA [{ZxѝH5NME 3vа04^f K 0lE5 !Rl}*kS"% p#o>J P`U<j6 蝶 XBL3 [6j쥡lr 'mVA\3#iېGjDarH3Ցdm:H+ z//Uü#06,@?tkXa-Vzx 5S^a\QHdkar$f ylЪK9 snQ{Q-ם-j4jp0ݕwnQ{Q-ם-j4jp0ݕH 54 mY n4lQkMP-ם)x3[zQ Z/OƗV۪pכ,Pwti?N-n0HQN4; O2ɾ<6N3sܷb7'h2w5 ׂp$i'U7 {eW>zh(g7JyKU9( T- %T(9AebkjZg+@6C^aU >I%6i A}.  #hS0[>V>j=dنR7K4<\6T7* ᖜ 46}jYH`^7@@&_Ҽ+8TZ-rE ZbsfST[І X?!0$)%x#R}aݴzi {j mA /l1FBO~Tve BT,*‰NX~ XN2LOETNbԆɃY. D.ta: ;*Ayzq,tUQd2^r6Pl4{( 8!Ie(PaGLky!c[L#> emHV ޳8*iWz fៀ![WU GiN9|[5q+, =Ja7{ M=m(H9E̅p˴8 ֨PЖ4@vBKK*pmyKɉ6L:QwFjw hoD>W'o{*`+ n+kdž3]EF0-8 KwFjw m C?pBmK7Al]4MziSyzDt"iA_4rq@CP CZuhT!gB`\TƮ%=Eod2r*-i S_{OEn9SN-ygƂNHHi `f&=u2#``Hc,e32U6ҰPYpY9(8 pM~9 WilA%sR%-;q P!w 難y'iX9KO﹀-Q(i]:=3јs1MUr@+*j*7kVOġ:2{fyC}h` QtPHV Ph4 2oA)zP(xVH|B5:5Xi5 0svQc/WCBq O Czl!WjAC~'cyk ,I9I R Ml!&Ne㨙2t  atjkAYt `(W=!zOqp7fyvSJ@ /,:wZ4=0Է%# 3:v\ʸxBPa˲JNf L;`(R6xdB4| ʭ 4JjV pS[׮%9ICIh`4( \;=P(ֈp՝@s!1 )*)XNt"d!VbiHttM wFr O r U`!UCI!(> !@]k k H[9+d 2L1GITHH>5nZ tCGlm4w"G5@]&/AJo2P 7Xu]V5 jitMģ`>E-X'N]kx[Q&9}-I'4TCV@1P`9C4.lj7 ; WH%t73 5YͅOQӠ@H4+CXw=ңK;[)ヮ#{/BCKS7\AapFC~{ at)\uZҜF &5T6Wiksh9ǂjA#3*YiޠcR%P@1 &NbpSȰ^Jja-v ,U ؒW,<)죥r#m+Ka/U`0bVigBAIk۶F4(5dr)V.̚${l\ 8b6Z>~/,ոC K^!Y^4PVYfGnwA5q׈b@j0'jüV!1^ĕ/P9 FDCk:u?ߠK%OICUhXȦzF){@{I kلtZڟ=' A*| !eu # DWKlٚ,M5ma{$8 \O6'mz*ivM̛򺎵ẒuzljI"uU{o?7EZծُ_qaQGMogվ-ytSZGwkQ`hau `pPq #Cɟ1quФ205O2-% 4}~-^:JJr;>Н?=nr"n Z4-nի5Цܜ|:{"-^Rj~hIy2ۦe1FwaEYto?" =FMz|Ҥ_0rHi# X+_3 6s)Jb7J*pohet>^Nj7EMmY< ڻ b IsM<$4{Q"/&Ct8qq/@ִ%}*i>CC&/cqv lZph{eLvG rB6EjH\Zw4VRDmomޠn߫M0ODK|E,pѠ%45r5! Џݱ}QҎ*rVmʂўvhA!1ij*%&,F{`mZrK:-;t b&8C8#%`_N櫦yy;̻SfeZYlKߡ!TdvN@qJ$`o!v#:2q-7AY *L<2`xzr#a2xkb "DJiЛAQ+MƀVnUh' jC: tGfjz%3@ pȥWi LРEN6'v)/Fdn``X!XB,ӎ_Bv%QD4Tx% _Tw#sI<}6$ԗ|C*.P~XQ}j7۩7F܁8 A7zf է7Hʥ(l(߀k[hst jo'<LrA5F֧Ec:D+~. $"E7#0[R u4˺;}^V]e$tpi)١{lڋ_oY*]W{G_oB;.ǧbm67udH\ 1ק>-ب[FCDW sNBҬ,zL^TM4z3M;ju6IyW)vro>zEl}S42ɧj Ã4I?ة[tuaNÅʖj{ sֶ74lWqڳ, EeqV,$N!PPO'I̗UP*G+_^4*ߣMø_> :)|F"T -'W}WhQ]R"'2ΥԧI %LWVuͷK4k֮N6qOb ؉.`$-e:OiWm{2[8/¿؟ 3]v`4֦-F 14;hq"Fm(/104RLJvlSh jXg=ʩ0BXr!ɂN5e| ʊ}&cvMQj:o_ 4l֌r{-aupgY&h%^Rg7aV/fh8_K~:C1x{Hk, bg2j}ٱKgf@鳣 Na8LmV*3Z9 B₪H6SW4lԮWKm) \7&.PVďpCXaA/@)v#'O+u`b64QWl 9ptQL7}U: E^AC AB:!apQB B$_u5[LHsLC8 #}C;âgf#߳ }LEP>̿X4 Sm+4PnCo{fv* ?mvOi7ùMQfVhQD'S"*!9RQ1|ُh+mEwѠrֹOpUqݾ 74PD\P^ 6ZP9G[ՑOx-n7YV0CKo4o c{Nhx# }>P0+Ǡ2R+jQ0~Q1E!X+s&:م V ذH/epp  voi (9o5AjA?DJ z}QVJ4KG2:|4٣!' spJiXJS`$?.(V8P)Z*4y[iDK>h27W~G>o5+衍L(Is*OHʤ3TCUC2!:^ .t,gVtd`}UE׳85VicOi T.A ޅ`ʟdB}53h}.mTW+4HuV(NФpo!FV ~O ^35 5^ҵG/\ ઠΆqA]=ZA@)8 : !d G'* m 䐪s.()$m:o3 6s`mr#Wq\DoheR |FkĿ7Bh׊xaA(E%Vn[\M7ڎ+YMk9Ker" @]tF`] n?ehpœ4vGW# ֽ5o$6,Qb\z((O) &\ytF@!MϢ^ZdtS^ZMqSve[ _ W@GOjL#R} yu!6$S`TbUr o]6 >ItL `%Xl4_L'  vG y^"n`*DNu{}dEW}M)qH"Fְ; RuA/;OԂH Рo~"%HH>!]N)R1.u69mi iH>f5O+ k2y'q\e,Z;'+@7B1,i8SN+Պ:h6N'hYX U#ȃUΈiVb'#Rm-ӟOCHJ&MfEP1RSϢ12ˈb#5 -nb;jl7K&a~nm "JeR7-#ia/T -hӏ;O(V NCԯuJA-M.u&)7lknʄP! !$ ?ɿiLĆZR؉=%clJ(РU Q):xIHS/PVWl^LQ \Me`s#Ɵ!9vRD YZ3PN"9+g)ڏF4P~nyohPRl]V T|)[غ ރ3mD1R 9U5+sW^Yچje-|VB)졘g LQO!MսY>7hPԙwtܲ5B3X/ *li ~70_0=.L=4dЀb$&obh8 nɻ5p /r@HʺN ZevC >DE7b?j 庘EqroYFB&j VipaO wH Y"sf?O+ b9qvIhD~:Ҙ=NGJ2[FDMRP4o[Em AQ}Xōv6@_4%ߠo"%ݡ7gc1AņyKs]43=2% iț|)hMha߮Usl3J*[)m E | u.cRVi}^siA+iix:45T+W |4Y>0>vN.nn_/h9؎xk p4гAM`Ͱո#2n+cM &[m&֪tPx< , SØOɮi0J9 jCi@)m]7nohOpCOr+ג&p hH'44W룡Q@, c?Cj)>R(WN(ߧ>7jK%6xdZyW16)Z 4/sM|2(F&OrrqPJ5VCp(@T!ol^m-ZE::;msZL>?Cc|ӽ4dO" PHC[QI7)cLU4#q`u[*8 4HV1l߂=´ECCA&'&ZݰTFSK,:njj'CoCǘY` |\چۥ *aC@ۖH'pyrV4B k4(?\fp41.*w'+*'NӰU%4pc<Lꨘh@;ٲZ)DJ=740kmzC9aR"iȿZ3v@)EQw#tLjp+M=4Pߘ4H|Bv@@oum)ӰB2~:A`6{ D!ҭ NèmA4 ߠB>or);Ц9Sju͖EC 4؝"6x&(RG#Z4tlE4 2q|ť界hZj F.h[޴+DQG C=YQiXn34t7Bm4dujriآYNì; Cj]iح|ujriآYNì; Cj]iحanPNÐf+oNքAntW?^u~u%*XJ2< xj:)dj)yeI>3vb RduaJ}^y "R'1T)qfu%^YVk/ &Rr2Y-|T&nʀyGJ 44(i}4tw7({,|* q) 8(.Oihi :y i0I/p/,z48 "V̒>+P."p~ݔ1 &A?$b~$Nü^RD!FVSv} 2n L4a 5 Og(`) C'"S2qt\θJYLxgfLi7P7a[&$Gokt $Gw*R[[6g9ߠ#zmZs $y,oHU637 ِGJCjDJ:N2ʌUxrfKZk-7h˜j7OkNq=v7%o<ȹtnujriآYNì; Cj]iح|ujr|/65½uǒGvjx@O`SZJN,=cN3ս8 lrNë?^gt_z4HB޼e?-=hLQkbN>3i(HYQn,z#Lid421YmYkyn6jTs}cK_.hp~4b( L1o boHk`1 F&B}ï6# yLJ|خ5V4- [ŷFs=5D9.L$fFJ}ndhK裋G^#0\A 6Ap S~ӰKr[iP0JYG)~F,wԧWy~ku%4bmA2LdܻoE Hg5LN˹>^1= ) k)NTH FIxѤFڲ`볕Lc1kz.N*# ~F ӎi48,N`t-h!Շ| [z3NxBehjD5Sz/[Ihxih0|œd:tVh[^+? Gh\K!R a ܋# ѫW#R +$@ìHђaJxl,4 KKGrfODQ`oO۪)~WrNT{jίӰVMΔf,,sf -@MOgD͋֩GmSVm-37ն'`y%F5㝿T?CmW<)Z?'B\ة/75 qv^ %,TfUk[ \~h'h@iU\׃OUvM_v|&Qܡ4]{Z^ІO%VDxQ 7Yq`>[[gջU˅b]Oü+sG-*W^nKnlwD>g̟ ? yr?g=ݶ>h>$׀k5p \׀k5p \׀k5p \׀k5p \׀k5p \׀k5p \׀k5p \׀k5p \׀k5p \׀k9TIENDB`^$$If!vh5 5i55" 5 #v #vi#v#v" #v :V lO 20%65 5i55" 5 / 4p2Dd /  6  3 A?22 w7h:# {Z`! w7h:# xWxT=OA};6NрJDa>%$H Be A)ӥM'] $*A$fo(AIXogvvvv (@  (:?-' ?j$2gs,h~X rSi=]kO,,\E`xC{uaF}q{&>':i]g=ί"elOdS>9pG=ӗ^\  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~                           ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~  l    Root Entry Fr̪U rData [UWordDocumentObjectPool, T˪Ur̪U_1043484840F˪U˪UOle CompObjqObjInfo  $%&'()*+,-./012345689:;<=>AEFGHIJKLMNOPQRSTUVWYZ[\]^_bfghijklmnopqrstuvwxy{|}~ FMicrosoft Visio DrawingVISIO 6.0 ShapesVisio.Drawing.69qOh+'0HPht vhaisbcostekVisioDocument +VisioInformation"SummaryInformation(  DocumentSummaryInformation8Visio (TM) Drawing +Lls*Rl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1U#J:DT1EW-hTT<* /Ub bO0zGz?@8@H2!kWb*U  +$PL/^&9^$? { Ak^&,,'%/v&& * 1y   )P? 2   U U12?k9aBBHEHEHEHEHEHEH@?>?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*gL9QOF$B_XKPcu jU8g'P!//*[mvǏُH}E0 TҙS-?Qcuχϙϫ);M_q߃ߕߧ߹߂ 2DVhzێb֯ *<N`rӘa#5GYk} 1CUgyՖ*!//(/:/L/^/p////////??$?6?H?Z?l?~?Ֆa?????? O@O-O?OQOcOuOUbbO1a6feOOOO__&_8_J_\_ҙ~________o o2oDoVoU oooooo,>Әia_q%7hcJxoj|ď֏ ASewџnasͯ߯0BTfxҿefB5GYk}ϡϳ-&8J\n߀ߒ߶I Y,1CUgy(:L^p'K$6HZl~9 -@?QcuBCh9!nkV3" bz@`nc/&`&/8/J/\/n%ib{/MvQ3/////??%?7?I?[?m?=G`P!=KBTfx,V/Pbt(:/^pj?@|?1!$6^DlMOumц >mKUrq!Wbqy[ja@OROfYNxYOOOOO/0% //0-VxQ$__FX|uAI!__oo%o7oIoL#F/a/j/5/////?O??'?9?K?)?????7:7H_Z_dOvO_____*=OL`{ޓՌ);f%tj|ğ֟蟜 !3b!HZ"d¯ԯ@RdҚ"4%7jǿٿ!3@!EŃx7I[m﵏Ǐ?? O2FLHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IP Ul4,&'?`/b? <A-43 7"AU~@*<N`@  FR @4(U~@*<N`@ RUFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HI ;V?-  _`߅pl`ul`u kw{sg_'Regular octagon, or eight-sided shape.b?贁N? 4 HDB $# ?h-(>TT9 EAUA@ ? Q6 mu` o?u j>Z--200`0A0(2@2T^h0r|>U5 L{/!4$5 `7Copyright 1999 Visio Corporation. All Y"s reserved.`d _Sba.chm!#22421PBd9 l> >Ud]!!(<* Z#A|rvPph.b31,1e g2(:S425$a?a! Ҁ?1E5Y6gq4bH3x81| N5%O7I71x?:?=3A1@IZ&Ax;87:U\S7I]:U; >tRTD%^RTEa^UQq5:^[ QY6[@$n[Q_HZq^QzD1QjeO_0_Sa<nU }e^}en}D%e,n}E~cq5~6Y|ev~cP{8ޏyA( ~Verbi$5/G/DD W'28AUl4,&'?`/bC? U A-37;U2@̔7LRH<( U2E7 RUlL|@?$)RD <U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)$LT *o8&Q- H*)=PEQy//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowOctagonWhite fillvisAecIsTech?nicalWallBuildingROOM BindingROOM Line StyleNet Thin lineNet NormalOctagon.5_34`~ Ed e>- fUG$M UZP9jP 9jP9jP9jܪP9jP9jP9jn"9j4`&9jL`*9jd`.9j|`2TKk`69j`:9j`>k`B9jԪ`F9j`J9j oN9j$pRTk`V9j!BRv&LJU,NlRUVZݫ^b<*fjǻEnw.,UUD7Ulp'3˭ʤݫW˭ҹQx{˭ڹ$OIiO7O湪UdO깪|OUO򹪤O%OOOK!*yH`'Q x'4'T10^!fxRp! ! j9`"#[%&'()*+T!-./01256789J:;m=U>?@ABC3eFUHIJKTMNOUPQRSUVWX*YZ[EU]^_`Еabc !efghiJjkmUnopqХrsWuvwxyzR{}~UЀЁЂЩЅІЇЈЉЊЋTiЍЎЏUБВГeЕЖЗИ*ЙКЛAUОПРЕТУХЦЧШЩJЪЫЭUЯабХгkQежзийкRлноUЩQqǪiUzU U UUU!U34Ul4,&'?`/bK? (bC-3')A$Ul4, Lz)A-D37"A_*<N@L-) MRVgdpq7uH<( H<( _*<NE* RVgpq \{zN  g"4FX(-@(P y @gn:]R>,k _lo_qq&yu!Bty;> DO` E8Ȯ, a$ '=fSNf)f 1 f=vl`2e NV<5( F?^dFDf!*KC=U5dG |J!pmG DGDxwt U EMF<X XVISIODrawing  {x  &% % V@wt T&&R&rTruRu&T% (   % RL Arial% Td"CV_AA"CLTVerb  ՜.+,D՜.+,@HP\h t   PagesMastersPage-1Octagon8_VPID_PREVIEWS_VPID_ALTERNATENAMES_PID_LINKBASE? A  FMicrosoft Visio DrawingVISI_1043485790F T˪U T˪UOle CompObj qObjInfo!O 6.0 ShapesVisio.Drawing.69qOh+'0HPht vhaisbcostekGx~Pk  EMFX XVIVisioDocument +VisioInformation""SummaryInformation(#DocumentSummaryInformation87Visio (TM) Drawing +M%*Rl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1U#J:DT1EW-hTT<* /Ub bO0zGz?@8@H2!kWb*U  +$PL/^&9^$? { Ak^&,,'%/v&& * 1y   )P? 2   U U12?k9aBBHEHEHEHEHEHEH@?>?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*gL9QOF$B_XKPcu jU8g'P!//*[mvǏُH}E0 TҙS-?Qcuχϙϫ);M_q߃ߕߧ߹߂ 2DVhzێb֯ *<N`rӘa#5GYk} 1CUgyՖ*!//(/:/L/^/p////////??$?6?H?Z?l?~?Ֆa?????? O@O-O?OQOcOuOUbbO1a6feOOOO__&_8_J_\_ҙ~________o o2oDoVoU oooooo,>Әia_q%7hcJxoj|ď֏ ASewџnasͯ߯0BTfxҿefB5GYk}ϡϳ-&8J\n߀ߒ߶I Y,1CUgy(:L^p'K$6HZl~9 -@?QcuBCh9!nkV3" bz@`nc/&`&/8/J/\/n%ib{/MvQ3/////??%?7?I?[?m?=G`P!=KBTfx,V/Pbt(:/^pj?@|?1!$6^DlMOumц >mKUrq!Wbqy[ja@OROfYNxYOOOOO/0% //0-VxQ$__FX|uAI!__oo%o7oIoL#F/a/j/5/////?O??'?9?K?)?????7:7H_Z_dOvO_____*=OL`{ޓՌ);f%tj|ğ֟蟜 !3b!HZ"d¯ԯ@RdҚ"4%7jǿٿ!3@!EŃx7I[m﵏Ǐ?? O2FLHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPUl4,D#?_,? A-$3 7U *<N`r@BR @4(U *<N`r@ߘ RUFDfP h> /T6DUI@A?I BP(?3H$- b]b--rx@l^bf>M,,D'^fO - b, , 'eZYUHu F .LYcuZo^SLRepresents an actor reference.mb߿??PQ࿤p= ף??3㿕HD" # "=h#-$>T #T3 AOAU@?=@?@u߽?P6 )i8VYAEDA@@#u` *'.8BhPZ`u#j Ub >U5 gL{5!5 A`7Copyright 1999 Visio Corporation. All _"s reserved.`j _D88.chm!#2]0 l>0>Udd!!P #w a2U50` 9`fC"`e1De 2#(  O?si?e113???%G1 7@<Oa?9ME)2RO;rABC#(^actorReferenceiVA!aPIE9 3~'2qcPӼ? &bVq(^/\:5!?lOrISsQU__f+OnQ&%^]oeoooxGQ3ULYoopOorHl'-ER  [F Z8#<[r? YQ-'aRx-OD+y->|?,- _( ?4S$RU++@D\'+Wi{Ա9wS  UPxP4FDTey  ahnm qT^UID#?I_,??-I?*?QcO@?^[qu`Fuae@u UHq%Pʕ$w!p/////{!w!x$iD!w!#p!N? "1a$ E?@?@`{eW5;?!H-#00b/(<53Q2-?Q?w!l"10qU"1q5 aD!G1>&A%*U?@ABCt !eFUHIJKoAMNOPQJRS1aUUVWXYZ[!]^_`abc!efghijRk/!mnUopqrs!uvwxyz{3}~TYU*S!GUGGGGGG1GGGGGJGGGGGUGGGG४G૟GGபGGGGRG1GGGUGGGG੻aGGG࿪GGGGTGGGGUGGGiUzU U UUU!U34Ul4,D#?_,K? v(bC-47A$Ul4, \+)A-T397"A_*<N@t( MRVgp;)7uH<( H<( _*<NE) RVg|qq <{zN  g"4FX(mӆ?@(XLίy @tP:]R} Q 4𴯮q&R!BP;> DOwE8O_ a$|^k 'TqTQN$xf)f 1{$f=`2y V<l( F?rGDC=5*|J!QY DSIODrawing  T  &% % V0~PN|N|N% (   % RL Arial% T%g7AA% L`Outpatient     T8iJAA8 L`Expansion   ՜.+,D՜.+,@HP\h t   PagesMastersPage-1Actor reference8_VPID_PREVIEWS_VPID_ALTERNATENAMES_PID_LINKBASE A _1043485556DF˪U˪UOle ?CompObj@qObjInfoB FMicrosoft Visio DrawingVISIO 6.0 ShapesVisio.Drawing.69qOh+'0HPht vhaisbcostekGxVisioDocument ,VisioInformation"CSummaryInformation(DDocumentSummaryInformation8XVisio (TM) Drawing ,4G9+yRl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1U#J:DT1EW-hTT<* /Ub bO0zGz?@8@H2!kWb*U  +$PL/^&9^$? { Ak^&,,'%/v&& * 1y   )P? 2   U U12?k9aBBHEHEHEHEHEHEH@?>?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*gL9QOF$B_XKPcu jU8g'P!//*[mvǏُH}E0 TҙS-?Qcuχϙϫ);M_q߃ߕߧ߹߂ 2DVhzێb֯ *<N`rӘa#5GYk} 1CUgyՖ*!//(/:/L/^/p////////??$?6?H?Z?l?~?Ֆa?????? O@O-O?OQOcOuOUbbO1a6feOOOO__&_8_J_\_ҙ~________o o2oDoVoU oooooo,>Әia_q%7hcJxoj|ď֏ ASewџnasͯ߯0BTfxҿefB5GYk}ϡϳ-&8J\n߀ߒ߶I Y,1CUgy(:L^p'K$6HZl~9 -@?QcuBCh9!nkV3" bz@`nc/&`&/8/J/\/n%ib{/MvQ3/////??%?7?I?[?m?=G`P!=KBTfx,V/Pbt(:/^pj?@|?1!$6^DlMOumц >mKUrq!Wbqy[ja@OROfYNxYOOOOO/0% //0-VxQ$__FX|uAI!__oo%o7oIoL#F/a/j/5/////?O??'?9?K?)?????7:7H_Z_dOvO_____*=OL`{ޓՌ);f%tj|ğ֟蟜 !3b!HZ"d¯ԯ@RdҚ"4%7jǿٿ!3@!EŃx7I[m﵏Ǐ?? O2FLHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPUl4,춰 -?`/b? A-3 7"AUV6@ FRUFDfP h$T PUUBmUA@ ?I? 3xO@7IyIfBo?вsUP  /e Z.$ H" S?!{)19AI?dp]qi} Aw:npqA9pwwA9pwpiEquilateral triangle.b?? ߿ $t@ ?<?紁N;3HDB t# ih0>T@dE=M AkUA@??A߻?Q6 L,A >M A JuM` ?[y&y0y:@u` UJS>#JU0O贁NKk?<@MJdO@ܼ@ L LP6 @?FS@U%%F@))@H""oKJ%{X1]45 `7Copyright 1999 Visio Corporation. All 2s reserved.J`0_Sba.chm!#22416Aida?lJ*,>Ud6ZV$(s=?)ǹ<$$b# X"yB:V/ K;EA%;D]2׳뽿HH?!:ͳ?OARM%2pO;JrA RSq(^!(M%9M\Me2AO-QVD}Ho *oFTO`c5WD`18WoiDYebW_`c%@neNooO[jJ(?kF8Hl'-h !OyaGEWszF${#V? TyPavuooD+_~poB?ԃoP@4(UV6@` R(n?S#Rtyv++@dvSD,'m,ij UPxP4FDTey  ahnm qT^UI -?I`/b??-I?*?QcO@?^[qu`Fuae@u HqPǕ$p/////{!{!$iD! N?@ D!G1,G1G1D!ahE ?@ = ףp?@b7?@<03?@aA?Q 56D79C89EG2 q@?OF<k?A|!H-kA(#00/(< ?Q?Dispense Units/DoseCi8xD<'2=R<D^8=`glA$7U??HQaD! CeaDÓ-2Xe65ce&5dlD%oq4D!(QTD!D)i0)MEq<u%Qh}u-+Jxw,}~66xj2/D/V+dG!3qZ$?p!`pk @<HEUl4,춰 -?`/bC? R A-,\7;U2@db7MRH<( U2E7 RUlLpPqA@?d%)RD4r;U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)$LT *o8&Q- H*)=PEQy//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowTriangleWhite fillvisAecIsTech?nicalWallBuildingROOM BindingROOM Line StyleNet Thin lineNet NormalTriangle.2_3,89 E<C N- YTGq} 9~Uqc 4qUc Lqc dqUc |qc qUc qc qUc qc qd :)$7)<7()T75)l7B)7O)7\)7i)v)7)!7);W,)U7\UDt)j<)U$ < T l  [+  !:̟ !:= !: !:$S0!:!:S0B!:S0F!: >J!:RS0Ni;+@R!:4+@V!:D+@Z;+@^!:d+@b!:t+@fT;+@j!:+@n!:+@r/K+@v!:J+@zE;?r!:PSKP!:LPTKP!:|P!:+@KP!:P!;P;PE;@4 3;P[AX !:,Dj {;`>!:Ki;5`ISK5`s[5`W;z5`;M KR5`֍;`!:`I!;`3;`W;`!:`'kN[[s[Ti;\a[_ gpkz` kz4pkzLpkz\pkzpkzaT{p"kzlp&kzDe*kzbW.kzd2kzU|6kz:kzU>kzBkzUFkz-Jkz5Nkz fP@kz$πVUπZkzU?@ABCA!eFUH*IJKUMNOPQRSiUVWXYJZ[/!]U^_`aХbcefghijRk{mnUopqrЩsS!uvwxyz{T}~UЁЂЃ5᪁ЅІЇЈ*ЉЊЋuqUЎЏАЕВГЕЖЗИЙJКЛНUПРСХУсХЦЧШЩЪRЫAЭЮUабвЩежзийклTGнопUŁƁǁ*ɁʁiUzU U UUU!U34Ul4,춰 -?`/bK? )UbC-37A$Ul4, d?*A-\3M7"A_*<N@4) LRVgO*7uH<( H<( _*<NE* RVgq R{zN  g"4FX(y5q@(ᐖy @Pu:]RQ xq& S!Bܖ[;>COE8O^p X$D '*tfQNrKx)T1Tx 1_4s_x=uy`20NV< zu F?*GDl5 C=?!5*+J!D3 Y  EMFX XVISIODrawing    &% % V,~M~~% (   % RL Arial Whp@{ % T|#ayvAA#aL\Dispense   TyAAy L`Units/Dose    ՜.+,D՜.+,@HP\h t   PagesMastersPage-1 Triangle8_VPID_PREVIEWS_VPID_ALTERNATENAMES_PID_LINKBASE A _1043485842F˪U˪UOle `CompObj aqObjInfoc FMicrosoft Visio DrawingVISIO 6.0 ShapesVisio.Drawing.69qOh+'0HPht vhaisbcostekVisioDocument" ,VisioInformation"dSummaryInformation(!#eDocumentSummaryInformation8z            (  ,          ! " # $ % & ' ) * + - . E I 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D F G H J K c f M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b d e g j k l m n o p q r s t u v w x y z { | } ~  Visio (TM) Drawing  ,T*|Rl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1U#J:DT1EW-hTT<* /Ub bO0zGz?@8@H2!kWb*U  +$PL/^&9^$? { Ak^&,,'%/v&& * 1y   )P? 2   U U12?k9aBBHEHEHEHEHEHEH@?>?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*gL9QOF$B_XKPcu jU8g'P!//*[mvǏُH}E0 TҙS-?Qcuχϙϫ);M_q߃ߕߧ߹߂ 2DVhzێb֯ *<N`rӘa#5GYk} 1CUgyՖ*!//(/:/L/^/p////////??$?6?H?Z?l?~?Ֆa?????? O@O-O?OQOcOuOUbbO1a6feOOOO__&_8_J_\_ҙ~________o o2oDoVoU oooooo,>Әia_q%7hcJxoj|ď֏ ASewџnasͯ߯0BTfxҿefB5GYk}ϡϳ-&8J\n߀ߒ߶I Y,1CUgy(:L^p'K$6HZl~9 -@?QcuBCh9!nkV3" bz@`nc/&`&/8/J/\/n%ib{/MvQ3/////??%?7?I?[?m?=G`P!=KBTfx,V/Pbt(:/^pj?@|?1!$6^DlMOumц >mKUrq!Wbqy[ja@OROfYNxYOOOOO/0% //0-VxQ$__FX|uAI!__oo%o7oIoL#F/a/j/5/////?O??'?9?K?)?????7:7H_Z_dOvO_____*=OL`{ޓՌ);f%tj|ğ֟蟜 !3b!HZ"d¯ԯ@RdҚ"4%7jǿٿ!3@!EŃx7I[m﵏Ǐ?? O2FLHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPUl4,@Wd?$y"? @A- 3 7"A_vV*<N`r&8@ FR@4(_vV*<N`r&8@\ RUFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HC 5Vo?)> pp/quupwj  lpysopi`;Generic circle with text and connection points.b?贁NE?4 HDD # =hZ,>THYY9 mAUA? Q6 u` ?u ~YA|XA44 4> !bJfvq >!E"q06DNX l>U5 L@d($%9%#APE&L#%%%?P6 @RL# L#  7p  #2 ' JB{%#145 `7Copyright 1999 Visio Corporation. All 2s reservedo.`0_Sba.chm!#22426+l>(>Ud#1E (!(Z$ B$bW :?- vUG$M U MK MX we ,r D \ t    ͙ ʙ ;xG!SLUd 4U|Ui-y< 5U P\ Tt X \* ` d[+ h l+zSp+A0tA0Ix+A0|+A0+RA0+ "A0A0+A0i!;A0{,@D@JA0+@%l@7+@+@@I+@T+@@@/K@$Q|`+PTPSKPPTKPPe PKPUPZP ZS}" Z,PZUPZDPZUTPZdP"ZUtP&ZP*ZUP.ZP2ZP6[P:ZĪP>ZPBZ~FZ4`JJZL`Nk`RZ|`VKk`ZZ*`^Z`bk`UfZ`jZ`MnZ &Z$pvk`zZ?@ABC3eFUHIJRKMNUOPQRSUVWXYZ[TE]^_U`abc !efgh*ijkUmnopЕqrsWuvwxyJz{}U~ЀЁХЃЅІЇЈЉЊRЋiЍЎUАБВЩeЕЖЗИЙКЛTAНОПUСТУѪХЦЧШ*ЩЪЫUЮЯаЕвгkQежзийJклнUпХQqƪiUzU U UUU!U34Ul4,@Wd?$y"K? C(bC- A_U)A$Ul4, $)}A-7 "A_*<N@l@[) ORVgtq8uH<( H<( _*<NE@8* RVgEq {zN  g"4FX(e?@( ί0y XQ:]R}COE8OCtY v*$ }'dvRfRNxf)zf 1L{f=`2uKNV?:`2BBHEHEHEHEHEHEHEH@$%O9F7AOY@; A*sVsVAgLTkY 1 W_W__ !`#ku4lb6Pu`kW 4l 4l %Y?:?-\ *#!+|tKf*2|2|2|2wG)QUoTMeEttA%_8BOTOfOxOO??O?7 ܻuW+? sU42 T*PbtφϘϪ(:L^p߂߂O߳ 1C@Ugb{.);M_xa"4FX 0Bzas//'/9/K/]/o/////////?#?zaB?T?f?x????????OBOUbb7OQV.e_OqOOOOOOOO_wk#_5_G_Y_k_}______L__UlAoSoeowoooooooxa(:L^p cwo!3EWi{Ï٦ .@Rdvk}*B'Ck#bz@.`c.`/%b /=QN3L/^/p////////??7?Pbtί(:L^p݇Z;ɼٿِ>.@*[m߅3O'Nk P2Ǎq?߃?\.?o AqT$$$'9K]ڊ䐾伩jPPj|xԕIWؙ&V03E)0<kDB!ߵ V /ASew+=Oa/09K]o?!?%LHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55H!winspoolHP LaserJet 5Si_742029_IP0Ul4,zLp?Dc) ? |2!}A-0'7"AUV6@1)GRUFDfP h$T PUUBmUA@ ?I? 3xO@7IyIfBo?вsUP  /e Z.$ H" S?!{)19AI?dp]qi} Aw:npqA9pwwA9pwpiEquilateral triangle.b?? ߿ $t@ ?<?紁N;3HDB t# ih0>T@dE=M AkUA@??A߻?Q6 L,A >M A JuM` ?[y&y0y:@u` UJS>#JU0O贁NKk?<@MJdO@ܼ@ L LP6 @?FS@U%%F@))@H""oKJ%{X1]45 `7Copyright 1999 Visio Corporation. All 2s reserved.J`0_Sba.chm!#22416Aida?lJ*,>Ud6ZV$(s=?)ǹ<$$b# X"yB:V/ K;EA%;D]2׳뽿HH?!:ͳ?OARM%2pO;JrA RSq(^!(M%9M\Me2AO-QVD}Ho *oFTO`c5WD`18WoiDYebW_`c%@neNooO[jJ(?kF8Hlh !OyaGEWszF#<s? mWakoD+oB?\ooP@4(UV6@42{ R(n?1p#R,+@SDD' ,ij UPxP4FDTe]@y  ahZ- ^TUIzLp?IDc_) ?? I?*?QcS@?^ua`u$ eu G{!D!e "u)D%@?@?@J7?@O*g?5H5??/18! L.&6.&62U66666#0Q 3-%// d/U1H<p$1CɭRCa(D1)A1!i$5/G/D '2qGPQA1DiQ [B1a`Q/`Q]%QAUD-YaE90:x?@?Pp?d?@.%ef]K?Q !t\A ]tE0Vbt!abMozUme\mmevgzkچ05E m=Ac#gc4heAO-O?C&@/^A<ߩߏ̟9KH~﷟۟1DLocalPossibleDosage@`Q!3EWrcNSh()Ul4,zLp?Dc) K? 1A-07;U2@407LRH<( U2E0 7 RUlL oz@?)RD7<U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)LT *o8&Q- H*)=PEQy//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowvisAecIsTech?nicalTriangleTriangle.6Triangle.18_,34s E} J- ;G; W,qUc Dqc \qUc tqc qc qd q q! q. ; %H 4%U L%b d%o |%| % % %J ;%y˨X,T* M*\*lV)[*; m+%[*[*[*m+[*#[ ? 2R[ B[*d )F[&"" 0 fPx!1m*E[  !"#$%&'() *+U^U U UUUl4,zLp?Dc) K? 37 KC-$37AUl4, 5 A-37"A_*<N@2 KRVgq7uH<( H<( _*<NE2`! RVgmq \{zN  g"4FX(Ga ?@(g:bίy @D:]R}< lq&|!BC; >EOtDo9OWW$'6fO|Ndf)f 1f=1`2ĕJV<- 7F?HNFDzJNC= !N|J!NPht vhaisbcostekGx] EMF!X XVISIODrawing    &% % V,o~nAn~n% (   &% % V, ~K~~% (   % RL Arial% Tl:N\]AA:NLXLocal  T|0^dmAA0^L\Possible   Tp3oa~AA3oLXDosage  ՜.+,D՜.+,@HP\h t   PagesMastersPage-1 Triangle8_VPID_PREVIEWS_VPID_ALTERNATENAMES_PID_LINKBASE A  FMicrosoft Visio DrawingVISI_1043496375<\.F˪U˪UOle CompObj-0qObjInfoO 6.0 ShapesVisio.Drawing.69qOh+'0DHPht vhaisbcostekGxqv EMFX XVIVisioDocument/2/ x*VisioInformation"SummaryInformation(13tDocumentSummaryInformation8Visio (TM) Drawing x* (Rl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1U#J:DT1EW-hTT<* /Ub bO0zGz?@8@H2!kWb*U  +$PL/^&9^$? { Ak^&,,'%/v&& * 1y   )P? 2   U U12?k9aBBHEHEHEHEHEHEH@?>?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*gL9QOF$B_XKPcu jU8g'P!//*[mvǏُH}E0 TҙS-?Qcuχϙϫ);M_q߃ߕߧ߹߂ 2DVhzێb֯ *<N`rӘa#5GYk} 1CUgyՖ*!//(/:/L/^/p////////??$?6?H?Z?l?~?Ֆa?????? O@O-O?OQOcOuOUbbO1a6feOOOO__&_8_J_\_ҙ~________o o2oDoVoU oooooo,>Әia_q%7hcJxoj|ď֏ ASewџnasͯ߯0BTfxҿefB5GYk}ϡϳ-&8J\n߀ߒ߶I Y,1CUgy(:L^p'K$6HZl~9 -@?QcuBCh9!nkV3" bz@`nc/&`&/8/J/\/n%ib{/MvQ3/////??%?7?I?[?m?=G`P!=KBTfx,V/Pbt(:/^pj?@|?1!$6^DlMOumц >mKUrq!Wbqy[ja@OROfYNxYOOOOO/0% //0-VxQ$__FX|uAI!__oo%o7oIoL#F/a/j/5/////?O??'?9?K?)?????7:7H_Z_dOvO_____*=OL`{ޓՌ);f%tj|ğ֟蟜 !3b!HZ"d¯ԯ@RdҚ"4%7jǿٿ!3@!EŃx7I[m﵏Ǐ?? O2FLHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPUFDfP h$T PUUBmUA@ ?I? 3xO@7IyIfBo?вsUP  /e Z.$ H"N @X(:H?_hz  ww "Square.b?贁N? 4 HDD $# =h-(>TTE=kUA@ ? uQ6 u` ?u B6> 00A0(2s@sJsT>d=$5 h9 L]{ !$5 `7Copyright 1999 Visio Corporation. All 4"s reserved.`? _Sba.chm!#224_17l>0>Udd!!  T '"<hb 261 g,s724  =?M1Y?r?91M1E;6=H=5P2?;rA IBOCq,B^35/\ @F"AC "3AP?LOe?#7A)[8B_T_OxY)___f_.eAE_oo_LHl'-i !OyaGE WszFK#\WKb? t 6UDek>os+C?o%?5doVUl4,&'?xj? `aA-3g7"AU2@Ii7FR@4(U2@I7 R(nSLfP@?I=RD4KOi{ UPxP4FDTey  ahnm qT^UI&'?Ixj??-I?*?QcO@?^[qu`Fuae@u HqPƕ$p//@///{!6 kD!"1N? 5a$ @E?@0<ˊ?@xA|035?Q #00b/!H-(<<-?Q?l"10qU"1q59aD!G1>\A*U6;[Q^5CSD%*^[HG1_8Zq^G1,QG1UOAUW8_(aE4k_Xo_m4eoo`lwn6o`lD%n A(4atient Instructions+/orProvider Co;mmpsiT5/G/ D '2UBUl4,&'?xjC? NU A-37;U2@"7LRH<( U2E47 RUlLrXO@U?%n)RDs;U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)$LT *o8&Q- H*)=PEQy//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowSquareWhite fillvisAecIsTech?nicalWallBuildingROOM BindingROOM Line StyleNet Thin lineNet NormalSquare.1_34P ET U>- VUG$M1 UTMULc lMYc MUfc Msc MUc Mc M՚c Mc WWc ,c UDc \c Utc c d )ʃ;6XG@!Q0L\d`*4d*h*|l*p*t҃*YW*< TX *\ U*t * U* * [+ * ž+ZƑ+A0J*A0ε+A0+A0+A0+ޒ A0A0+A0!;A0*_[),@U JD@ JA0U J\@ Jl@U J|@ J@U J@ J@U$ J@( J@, J@0/K@4 J$\8 J<*P< JTP@SKPD JPHKPL JPP J PTTKPX JP\ J5P` J]" KPh/KPlKPpT[Pt JdPx JtP|=[P J*P JPa[P[P JP JP J^ J4` JL`k`eK`Kk`K` JR`k` J`K`s[_IKp̥k`[pkpeKp$kpKpKpKkp5{`Ik?k?k2?eK?&*?U??U ??M,at@t $J(,50b@U4q8Tq<@qD qHqLQqPccHPuX\ `d-h$lQp-qEtud$`|c-QceH`u!! !!-! !RӋ!!cfhpLTȋl̋UЋ-؋܋<*ǻEcg.,UDTZUl1p'@ʜDʴH̚LhpP䪭T$OX?@*ABC3w]FUHIJKMNOPQRRSUVUWXYZЩ[E]^_`abcT !efgUhijkmnop*qrsWUuvwxЕyz{}~ЀЁJЂЃЅUЇЈЉХЋiЍЎЏАБВRГkЕЖUИЙКЩНОПРСТУT{ХЦЧUЩЪЫЭЮЯа*бвгkQUжзиЕклнопJQqU9EUzU U UUU!U34Ul4,&'?xjK? iH'bC-`7A$Ul4, d'A-\3 ( A_*<N@,`' MRVg (6uH<( H<( _*<NEt`( RVgq {zN  g"4FX(Pm?@(PoίГy @0:]R>D8 _<_yq&d!u!Bߴi;>COxE8Ot?U$O'ԏN,t TT)\TU 1T=$`2UV F?C(GDl5 C=55 J!D 5  SIODrawing  ur  &% % V0qnlolol% (   % RL Arial% TxS)AAL\Patient    T +f=AA + LdInstructions     Td+>GPAA+>LT+/or    T|QYcAAQL\Provider     T|dbvAAdL\Comments    ՜.+,D՜.+,@HP\h t   PagesMastersPage-1Square8_VPID_PREVIEWS_VPID_ALTERNATENAMES_PID_LINKBASE[@ A  FMicrosoft Visio DrawingVISIO 6.0 ShapesVisio.Drawing.69q_10434856916F˪U˪UOle CompObj58qObjInfoOh+'0HPht vhaisbcostekG8x EMF0X XVISIODrawing  VisioDocument7:L @,VisioInformation"SummaryInformation(9;DocumentSummaryInformation8Visio (TM) Drawing @,tT*yRl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1U#J:DT1EW-hTT<* /Ub bO0zGz?@8@H2!kWb*U  +$PL/^&9^$? { Ak^&,,'%/v&& * 1y   )P? 2   U U12?k9aBBHEHEHEHEHEHEH@?>?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*gL9QOF$B_XKPcu jU8g'P!//*[mvǏُH}E0 TҙS-?Qcuχϙϫ);M_q߃ߕߧ߹߂ 2DVhzێb֯ *<N`rӘa#5GYk} 1CUgyՖ*!//(/:/L/^/p////////??$?6?H?Z?l?~?Ֆa?????? O@O-O?OQOcOuOUbbO1a6feOOOO__&_8_J_\_ҙ~________o o2oDoVoU oooooo,>Әia_q%7hcJxoj|ď֏ ASewџnasͯ߯0BTfxҿefB5GYk}ϡϳ-&8J\n߀ߒ߶I Y,1CUgy(:L^p'K$6HZl~9 -@?QcuBCh9!nkV3" bz@`nc/&`&/8/J/\/n%ib{/MvQ3/////??%?7?I?[?m?=G`P!=KBTfx,V/Pbt(:/^pj?@|?1!$6^DlMOumц >mKUrq!Wbqy[ja@OROfYNxYOOOOO/0% //0-VxQ$__FX|uAI!__oo%o7oIoL#F/a/j/5/////?O??'?9?K?)?????7:7H_Z_dOvO_____*=OL`{ޓՌ);f%tj|ğ֟蟜 !3b!HZ"d¯ԯ@RdҚ"4%7jǿٿ!3@!EŃx7I[m﵏Ǐ?? O2FLHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPUl4, X ?`/b? }A- 7"AUzZ*<@  GR@4(UzZ*<@ RUFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HC 5Vۀ {?"o./? ?pdofk| w{P}|shlwwwxnVpo]Pp'Regular pentagon, or five-sided shape.b返??lDK\wX}W鿰6??,̪]ơ%HDB $# ?h-(>TT9  AUA@A%??AmDK\w?Q6 u` ?u` i%kL>+000A0U(2}@}J}T}^>d@ @+B{!#$5 `7Copyright 1999 Visio Corporation. All H"s reserved.`S _Sba.chm!#22418lQ4>Ud}!!!Z hb93& 2g}U2<"£A f"0&8Ď@Y?@3 i3k1E: 4k (и?%99f5i8<*2|5fuN?2Se?2Z@ 4LW7%93:eiH?$2 ?5rA BCq!0^d!E/*\D 끁s,x#?eA`F+"A~%9\~DG;?oQo?uo|]x?_o??jZ&eNo+?=;Hl'-}i !OyaGE!szF#_d@ ģZ)0?fkoaD+$KoV?5o(n?4wTR🬞|++W@D'+W̢SX UPxP4FDTey  ahnm qT^UI X ?I`/b??-I?*?QcO@?^[qu`Fuae@u aHqPŕ$ap//@///{!ax$@iD!"1_D!N? 53a$ E( ?@*tF?@b7?@<03?@\w?]Q #00/!H-(<9?Q?l4qU9!AA=;5G1R"1>\A65.US@GCFT.U^J̿GSD%.U'+&GSG1*YG!?e\(q5._@Vq80 "1q5OSa~_5^0LG%Wa<ce^|omce^omce^<mD%ce]^Em Uce^iA(qNoun!iT5/G/ D^ '2BUl4, X ?`/bC? U A-$37;U2@7LRH<( U2E_7 RUlL<{@?@RDl;U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)$LT *o8&Q- H*)=PEQy//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowPentagonWhite fillvisAecIsTech?nicalWallBuildingROOM BindingROOM Line StyleNet Thin lineNet NormalPentagon.3_3$` E< - lSGM_ 4MUcLMc UdM,c |M9c UMFc MSc M`c mmc zc Tc tc c c c c վc nc ґc c le  L!$T(|,U04fAE*IX\DoTU {$   [+ I+  ,pS+/0/0U/0/0} qU40L0 7r7*,0i;0͟;0Jl0+0[+*0Ŀ0E;0I+0i;0_s@I+@;@+V@\@JUl@ J|@ JU@J@JU܅@J@J_ t!J$]PU%J<]P)JL]PI-K]P1K]P5KR]P9[]P=J]PA[]PEJ]PIT+[]PMJ]PQJ]PUO[uYJY`]J,Y`aTs[Y`eJTY`iJUdY`mJtY`qJUY`uJY`y[*Y`}JY`'kY`}Jv]kz1pKxkRUp[UpJUpEkz8'kp9kzpO[{a[ps[p[pJJpkpkp[pkp'kp#{|]kٷkpJ4$[kkiKJD}@$k kS 0JQM Q~PQ$Q̇Q:PQ쇀Q|T^PQݐ%QݐE)uP1QSLPQl79QU7=Q7A7E7IQ<$`Q\QuUTϛYQ]Ra󛣠eQiQ3q2c`Q`QUi}QiQ# pQiI)ϛ_zpQ4QH8McRQdMQ Q,QDQQURQU$!n)ԟ(P8 LP 4+! l+% L+) ڌ+- ڤ+1 ڼ+5 ̪+9 += +A X $I?@AJBC!eFUWHIJKMNOPQRSTUVWUXYZ[A]^_`*abcUefghЕijkmnopqJrs!uUvwxyХz{}~ЀЁЂRЃ5ЅІUЈЉЊЩ3ЍЎЏАБВГT/!ЕЖЗUЙКЛ!НОПР*СТУсUЦЧШЕЪЫe!ЭЮЯабJвгA!еUзийХлGнопRŁƁUǁȁɁʁiUzU U UUU!U34Ul4, X ?`/bK? )bC-| 7A$Ul4, )A-37"A_*<N@) LRVg$q7uH<( H<( _*<NE\[* RVgthq 6{zN  g"4FX(1u}?@(2~ίЂy Pu:]R\Q Tq&V!B1;> DO` Eͯ8OCzW S$r '>yf>Nf}),f 1f=l`21kpNVF˪U˪UOle CompObj=@qObjInfoVisioDocument?Bi 9VisioInformation"SummaryInformation(ACDocumentSummaryInformation8   Visio (TM) Drawing 9R8Rl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1U#J:DT1EW-hTT<* /Ub bO0zGz?@8@H2!kWb*U  +$PL/^&9^$? { Ak^&,,'%/v&& * 1y   )P? 2   U U12?k9aBBHEHEHEHEHEHEH@?>?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*gL9QOF$B_XKPcu jU8g'P!//*[mvǏُH}E0 TҙS-?Qcuχϙϫ);M_q߃ߕߧ߹߂ 2DVhzێb֯ *<N`rӘa#5GYk} 1CUgyՖ*!//(/:/L/^/p////////??$?6?H?Z?l?~?Ֆa?????? O@O-O?OQOcOuOUbbO1a6feOOOO__&_8_J_\_ҙ~________o o2oDoVoU oooooo,>Әia_q%7hcJxoj|ď֏ ASewџnasͯ߯0BTfxҿefB5GYk}ϡϳ-&8J\n߀ߒ߶I Y,1CUgy(:L^p'K$6HZl~9 -@?QcuBCh9!nkV3" bz@`nc/&`&/8/J/\/n%ib{/MvQ3/////??%?7?I?[?m?=G`P!=KBTfx,V/Pbt(:/^pj?@|?1!$6^DlMOumц >mKUrq!Wbqy[ja@OROfYNxYOOOOO/0% //0-VxQ$__FX|uAI!__oo%o7oIoL#F/a/j/5/////?O??'?9?K?)?????7:7H_Z_dOvO_____*=OL`{ޓՌ);f%tj|ğ֟蟜 !3b!HZ"d¯ԯ@RdҚ"4%7jǿٿ!3@!EŃx7I[m﵏Ǐ?? O2FLHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPU.4UUUl4,  贁N[??O'CA,7"A_.*<N`r@.oCR@4(_.*<N`r@Lo RUFDfP h RTBUUUIo:mW?Im?I?x Q2eqYkT Go 2w <"2vOr`Network>]`f Xd|8e#*--$` ?>? jq  x1xxllxƬ 11xRy  ylKRepresents a token-ring network layout. Glue control h?andlesmputers.ubؿ?9io6ؿ3?78j|?53tV?DUGDF  !P# h>4/T6DU@"۟~j?s?Py D,!444444 ",,NXblvu` ?"u"),UH" L@"bKp!{Q#!$W+d`Vis_SBN.chm!#22306A`7Copyright 2000 io Corporation. All "s reserved.t' #0XQ)H### Q#8`T,G%Z1e#!]t=%J 3H1H%4CP#&Z7A3A-TConnect To Network ?DeviceYBH%fOxO&OO6OO86OO5_,_6G_Y_D3T1YBt5T2YB V3YB1XA4YB*1^h!^ _7_t!X5YB[6YB1Xu7YB_o45C^o!^A1^`^k1^tQ^)bZSh}3^t3Z"#w$%}pt11]ut1t9 ?@t3T[$2pUb#)+%4#93*!Va"b4" qO`{_Eo @!N!X!b@!l!v!DNXblvD@NXb lvᒀsH%3?@3PČԏ茏3+ t"Ur:s#äs%4ELBČ)'E쳯ů׭54KE ČD֮954 Č l*!,>ڪ,t3B(\ Č ΀93ڪ5ЅѼ8ߩ" Č uV43T߱׭E41ߢ Č 0ewdd]95OH%Dȏ77! @ 7A` Token_Ringm*1`]WGHuS1$"H"/<2 I92V,_1_12pR4}t2RRE(tuS% Ru0d` Manufacturer3`R02b3A Enter the m name0%sgu2`Prod=u.Numb !W`pnnv05>|uxa Pars#!  95}ugqmDescrip!)(#d|'c5kA/S&7 oAssesk"`a2ID.5q/S&ua SerialR?q s33"UgO?S&ud$|aLoca-?lD.U?R'u>ha0JTpaaMU@Qo?@?P @+tQ` ?tTU'U'0'RaQux~u1bA@U EKT~`0Ri'%!N$-`7Copyright 2000 Visio Corporation. All s"s reserved.T  9 BzgAU@?@??@w?P6 @t`  ?t 8M>^ ]l^pFuX^{lvub_A@i>U `0i'%!NN5  `7Copyright 2000 Visio Corporation. All s"s reserved. ,#Bdb'=O#$+l>(>Ud% ( RWf 1|2| 7(o4  #? ?:?:31Eo?? OrA  CKO]O6xO4!:%^Token-ringH'-[ !OyaGEĐF~#t[K @ }GV?~f4.D+W/;?GojP--N_V("?q@R++-D#+Wi{ e!;S  UPxP4FDTey  ahj TqUI N?I??I?*?Qc`2@?qu`&u o <Mw!w! `Network `" (e5/G/P !GqP,41!>?P?b?t???11b!53? 1 a$ !) !yt'@ {FvrF?1 621 CF@D!-8Dw! #0# /UH<4!uS(KXe3PE>]?U?H1!p4:Q80W:Q:Y'U7E11[{"߿UeORVe2#_eBa<]/?@Cfoxf?dkr@>aom5k`o!AbkpHb@c1Joe`_oqooboXeEn43Dmsot`LgmD6Q3T1.$1T!<I "%r2B""r4L:RY f2uQddf/Q6291_=:Qd#o5j:Q !OP.J5љOIEm{{@QQ@OOA _SlDHU'UUuc1KX5Nԡٕ@(7M_q˿sta"4FXjσuϨt1 AS7Ir1hzߌߞosr>a /ASo߉l:QOo,luQ!auQi2c>a= !5_G_4qg{A^1_bUConjunc?tioni///_X#ZP'2rqAS[ iA;Mٕv w@Q yF c$5&+ (Q/U24UUUl4,  贁N?? _'+C-_T7AU2@TP'7JRH<( U2EP+(7 RUlLwߐ"r'w@?v (RDx8;U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)$LT *o8&Q- H*)=PEQy//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowWhite fillvisAecIsTech?nicalWallBuildingROOM BindingROOM Line StyleNet Thin lineNet NormalToken-ringManufacturerProductNumberPartNumberProductDescriptionAssetNumberSerialNumberLocationRoomDepartment_3 ) zEU T)- |)G c ăc D_*d \}  U$, <9 UTF lS U` m Uz _ mU 4m LmU dmȫ )իm߫^!mm|jmm+m7* U7*4W 7 W 7*dW 7*W #7 U|W >7*W B7*W F7*W J+ }N7* R7*_t V7*0Z7*0^7*$b+S0f7*D*S0j7*\S0n;S0)r+0v7 %7S0)7 fS0+S07*S07+S03;+@T+@7*@I+7*a@7*,a@7*?@ABCeFUHIJRKMNUOPQRS7UVWXYZ[Ts]s^s_sU`sasbscsesfsgsh*sisjsksUmsnsospsqsrss1susvswsxsyJszs{s}sU~sssss!ssssssRs+1sssUsssssssssssT3ssssUssssssss*ssssUsssssssssssJss!ssUsssss !ssƪsssssiUzU U UUU!U34Ul4, 贁N?? DY_d6bC-_U7A$Ul4, U7A-3$7"A_*<N@CO E8Ou"l$J̏"'}W(S>N?@ABCDEGHIJKLMPTUVWXYZ[^bcdefghilpqrstuvwx{Oh+'0HPht vhaisbcostekGxbBL EMFX XVISIODrawingHP  d &% % W$J2bJJJb2W$b2bTbTb2W$b222b2W$bz2zb2W$bb2bb2W$Jb2Jb2W$2b22b2% (  &% % Vx2b224$:CN[iv$2@LVv^ib[bN^CV:L4@22% (   % RL Arial?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*gL9QOF$B_XKPcu jU8g'P!//*[mvǏُH}E0 TҙS-?Qcuχϙϫ);M_q߃ߕߧ߹߂ 2DVhzێb֯ *<N`rӘa#5GYk} 1CUgyՖ*!//(/:/L/^/p////////??$?6?H?Z?l?~?Ֆa?????? O@O-O?OQOcOuOUbbO1a6feOOOO__&_8_J_\_ҙ~________o o2oDoVoU oooooo,>Әia_q%7hcJxoj|ď֏ ASewџnasͯ߯0BTfxҿefB5GYk}ϡϳ-&8J\n߀ߒ߶I Y,1CUgy(:L^p'K$6HZl~9 -@?QcuBCh9!nkV3" bz@`nc/&`&/8/J/\/n%ib{/MvQ3/////??%?7?I?[?m?=G`P!=KBTfx,V/Pbt(:/^pj?@|?1!$6^DlMOumц >mKUrq!Wbqy[ja@OROfYNxYOOOOO/0% //0-VxQ$__FX|uAI!__oo%o7oIoL#F/a/j/5/////?O??'?9?K?)?????7:7H_Z_dOvO_____*=OL`{ޓՌ);f%tj|ğ֟蟜 !3b!HZ"d¯ԯ@RdҚ"4%7jǿٿ!3@!EŃx7I[m﵏Ǐ?? O2FLHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPUl4,?`/b? ̒A-3 7"AUl*<N@ FR@4(Ul*<N@| RUFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HG 9V?o)>  `r/`wpw> ȳpke{rpgTHYY9 mAUA? @ ?Q6 u` ?Mu ~YYA|XA44 4> !bJfvqQ >!"q06DNX lL>U5 LO@%#A?AE^?AL#l%u%?P6 @*  L#&H   " ' ]{%#W1\!\!5 `7Copyright 1999 Visio Corporation. All 2s reserved.`0_Sba.chm!#22427Bd(,*9 l>(>Ud!E (!(ZU$ B$bW*G g3?TU^7X q^?1,~Q?1(?1H_B#0ZX1va<oUole_oln+tcD%kYehA(~Qrepositioni<45/G/xD '2AUl4,?`/bC? ~U A-37;U2@47LRH<( U2E7 RUlLym@?Dz)RD{<U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)$LT *o8&Q- H*)=PEQy//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowEllipseWhite fillvisAecIsTech?nicalWallBuildingROOM BindingROOM Line StyleNet Thin lineNet NormalEllipse.4_3t0d En y- 8SGM 9Uqc U4qc Lqc Udqc |qc Քqc qd q q q, :9 $7F <7S T7` l7m 7z 7 737xA6U77;W4MU ,3 T3 u3 3 3 U3 *\S0UB*tS0F*<3 UJ S0S fS0`*3 dT; h*S0l*S0p+>tJ*S0x++@|*%,+@;+@++@{;+@*l+@T;+@*+@/K+@*+@*+@*+@*O?SK'Pi;'P{;'P;'PJ*+@/K'Pĵ*'P3;'P̵* KF E;PSKD؟;P+P$s[P;P KPi;L*TY`+Y`[M3]k`*`Uj̏`j` j`jNj4RIk pk p j\ p$jS(j$Up,kUp0T5{Up4jtUp8jUDUp?@ABCs1eFUHIJKTMNOUPQRSiUVWX*YZ[1]U]]^]_]`]Еa]b]c]e]f]g]h]iJ]j]kM]m]Un]o]p]q]Хr]s1]u]v]w]x]y]zR]{]}]~]U]Ѐ]Ё]Ђ]Щ9]Ѕ]І]Ї]Ј]Љ]Њ]ЋT9A]Ѝ]Ў]Џ]U]Б]В]Г]Е]Ж]З]И*]Й]К]Л]U]О]П]Р]Е]Т]У]]Х]Ц]Ч]Ш]ЩJ]Ъ]Ы]Э]U]Я]а]б]Х]г]е]ж]з]и]й]кR]лա]н]о]U]]]]Щ]]]Ǫ]]]]iUzU U UUU!U34Ul4,?`/bK? ((bC-3)A$Ul4, k)A-3y7"A_*<N@ܒ) MRVg{q7uH<( H<( _*<NE$) RVg*r G{zN  g"4FX(`w@(翪vy Xq:]R| 4rq}&t!BL;>COE8OywV a$x 'C%fQ|N |vfz)1~f 1yf=`218NV<( F{?FDTw*="R=5VG C!_G DGxt{U EMFX XVISIODrawing  x  &% % Vt<1 &#2 C Ugy &1<GR\dkyogrUrCo2k#d\ RG<% (   % RL ArialpqfqrfrsfstgtuguvgvwhwxhxyhyziefbfgbghchicijciTzz% TC_AAC LdPreposition   ՜.+,D՜.+,@HP\h t   PagesMastersPage-1Ellipse8_VPID_PREVIEWS_VPID_ALTERNATENAMESh_PID_LINKBASE? A _1043493119NF˪U˪UOle 0CompObjMP1qObjInfo3 FMicrosoft Visio DrawingVISIO 6.0 ShapesVisio.Drawing.69qOh+'0HPht vhaisbcostekVisioDocumentOR A-VisioInformation"4SummaryInformation(QS5@DocumentSummaryInformation8FVisio (TM) Drawing A- Y+Rl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1U#J:DT1EW-hTT<* /Ub bO0zGz?@8@H2!kWb*U  +$PL/^&9^$? { Ak^&,,'%/v&& * 1y   )P? 2   U U12?k9aBBHEHEHEHEHEHEH@?>?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*gL9QOF$B_XKPcu jU8g'P!//*[mvǏُH}E0 TҙS-?Qcuχϙϫ);M_q߃ߕߧ߹߂ 2DVhzێb֯ *<N`rӘa#5GYk} 1CUgyՖ*!//(/:/L/^/p////////??$?6?H?Z?l?~?Ֆa?????? O@O-O?OQOcOuOUbbO1a6feOOOO__&_8_J_\_ҙ~________o o2oDoVoU oooooo,>Әia_q%7hcJxoj|ď֏ ASewџnasͯ߯0BTfxҿefB5GYk}ϡϳ-&8J\n߀ߒ߶I Y,1CUgy(:L^p'K$6HZl~9 -@?QcuBCh9!nkV3" bz@`nc/&`&/8/J/\/n%ib{/MvQ3/////??%?7?I?[?m?=G`P!=KBTfx,V/Pbt(:/^pj?@|?1!$6^DlMOumц >mKUrq!Wbqy[ja@OROfYNxYOOOOO/0% //0-VxQ$__FX|uAI!__oo%o7oIoL#F/a/j/5/////?O??'?9?K?)?????7:7H_Z_dOvO_____*=OL`{ޓՌ);f%tj|ğ֟蟜 !3b!HZ"d¯ԯ@RdҚ"4%7jǿٿ!3@!EŃx7I[m﵏Ǐ?? O2FLHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPUl4,`/b?Ȓ_,? ̴A-3 7"A_h -?Qcu@);M@IJ  FR@4(_h -?Qcu@);M@| RUFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ! Hu 7~???0𫏆=@FwnmmhZ[L7Double arrow with 60-degreheads. HDB # ?hZ4>THYY9 dA[UA? u?P6 -u `u b_u  @"! FhWuk` tu.AdV8bM>ڲ@!$U'P"_/q%'i-/ 7$#5 L!# 7 6 BdH*%#/ Hh?Q6 u{%6{`("u?"F&`Qps-8R? WI@ 偌!6Q(-DT! @u@{$#AD5 `7Copyright 1999 Visio Corporation. All Bs reserved.h`@_Sba.chm!#224398B!$Cu tNs!OR U\l>Ud0@ Yi \!(Z$*L/S!4b?GQ b#Ib(3$$*3Ey‚7ʱRrB-db&`_aEojp= ףpՃoOR.ccb>$$?M˰iORD3eoeE9m |g`o'W6$*6a23(o_a|M:hz|%a_aQivQe&sbebQ2lm?l^Rgoyf?oQuo؅A &jdTAha9 G7(حN@fQB?bZބۀ!(! [?2vB@z?JVQ&999Y9Q9SIQ?IgRmb?п贁N8i/6??Hl'-s !Oya GE_6szF4 w#_K? Ab$noD Yoo/P+D?_(|?SLRY++@D ,'+Wi{ /ASeSf UPxP4FDTey  ahnm qT^UI`/b?IȒ_,??-I?*?QcO@?^[qu`Fuae@u U%Hq%P̕$w!p/////{!w! x$iD!"1#D!|53_"10"1q5"aD!E?@ڶڶ?坊& /~8K~05!H-5N?OQA(fEJ<4#005DB(8w!K_C ?Q=w!d5/G/AQLXz?@Gz?N@\_l^ x$U1 a aP 91"1 m$ iC CeVPEcnRdUeh0kUnkq5kFeQacnUcYaoXcp!fuaaFjX!Durationi8__ T'28k㨀PPUl4,`/b?Ȓ_,C? U A-37;U2@47LRH<( U2EV7 RUlL|[D@?7wRDc;U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)$LT *o8&Q- H*)=PEQy//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowWhite fillvisAecIsTech?nicalWallBuildingROOM BindingROOM Line StyleNet Thin lineNet Normal60 degree double_3L EΪ )- OG# _ 4R_ufL_$ Ud_1 |_> U_K _X U_e _r _ U $% <% T% %$ % % %% t Q !M? T$$(,l04*8GK,WOU UjL nd Ur| v z ~[+ ܟ SA0\A0UtA0A0A0+A0 A0fA0A03;Ѩn+0D0TW;00i;0%+0+0T;00[+0000/K'@+@S 8*@Z@UZ@ Z@UZ@Z$@UZ@Z@M ZӖZ,PU(ZDP,ZP0Z\P4[P8Z|P<ZP@T=[PDZPHZ%PLa[PP[PTZܷPXZ W\Z4``ZUL`dZd`hk*`lZ`pKk`UtZij`xZ`|k`Z`*Z`s[&Z?@*ABCAWFwHIJKMNOPQRRSWUVUWXwYwZw[a1w]w^w_w`wawbwcTwewfwgwUhwiwjwkA!wmwnwowp*wqwrwswUuwvwwwxwywzw{w}w~wwwJww/!wwUwwwww1wwwwwwRwwwwUwwwwewwwwwwwTGwwwwUwww{wwww*wwwAwUwwwwwwwwwwwwJwwe!wwUwwwwwyaE%UzU U UUU!U34Ul4,`/b?Ȓ_,K? ̻*bC-|r7A$Ul4, *A-37"A_*<N@ܴx* MRVg|q7uH<( H<( _*<NE$R+ RVgħ_q W{zN  g"4FX(G:?@(Z;ίPy @:]R}[ \q&$]!B;> DO E8Oh0x$~0',xTNO[x)_^x }1_x= `}2n"V<* F? +(!DlWl5 C=ń55 J!5 DGdxP  EMF\X XVISIODrawing  T  &% % VHP *ii~*iNi66N*% (   % RL Arial\\^\^z{^{|^|}^}~^~^^^__`ab^n}}o% T|0cEAA0L\Duration    ՜.+,D՜.+,@HP\h t   PagesMastersPage-160 degree double8_VPID_PREVIEWS_VPID_ALTERNATENAMES(_PID_LINKBASE A  FMicrosoft Visio DrawingVISI_1044253872VF˪U˪UOle NCompObjUXOqObjInfoQO 6.0 ShapesVisio.Drawing.69q՜.+,D՜.+,d @HP\h t   PagesMastersPage-1Square Triangle PentagonEllipseOctaVisioDocumentWZ aVisioInformation"RSummaryInformation(Y[ 0,DocumentSummaryInformation8S Visio (TM) Drawing aH b`Rl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1U&J:DT1EW-hTT<* /Ub bO0zGz?@8@H2!kWb*U  +$PL/^&9^$? { Ak^&,,'%/v&& * 1y   )P? 2   U U12?k9aBBHEHEHEHEHEHEH@?>?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*Pbt߆ߘ߼#5GYk}b4?Qcua&8J\n /"4FXj|Q!//+/=/O/a/s////////??'?9?K?]?o????a???? OO0OBOTOfOxOOOUbbOXa]feOO__)_;_M___q________o#o5o0GoYoko}oU&oooo /ASea(:L^cqoǏُ!3E(hzŸԟ .@Я*EWi{ÿտ όf8i\nπϒϤ϶T);M_q߃ߕߧ߹p3ǀSFXj|+=OasNr'9K]o 9 0BTfxBC`!k}3I bz@6` /'c//A&`M/_/q//%b/)MQ3///??(?:?L?^?p???"dGoPo be3oo}_oooooo&8J\_VC94O*O -?Qcu͏ߏ'9K]ccU<犯"/ΟF//:/!щqfxү,>Pbtο@_ jK[CuU՞ϰϬҔЅaa3vO贁NkߖFa`27qZ?Yka?\.? pQA6k6߻H k+6;CjԕaI^g030|kPewȈ$ !%7dri{ /AS}/w+=Oa???'9A1K]DM*Oѭ e.KUqH)Wq[=ۑagOyOYuğYOOOOOV0%!/3/E/ W-}QK_mϣ(A(I1oo(o:oLo^opo s#m///5/////O(O*?P?????Ga^o__OO_____-?VQ=v.s#{.峑PbLǟٟ!3sHZb=!o"důׯ //gyI[L^$6HZg!lŪ(:ɏ^p9܏ $?OGOYJ#qٿ 1߀C __-_iȉX@R_ba QJ_+Չ/ڜ,5 ,5,0$Zl~r?? 2??h8LHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPUFDfP h$T PUUBmUA@ ?I? 3xO@7IyIfBo?вsUP  /e Z.$ H"N @X(:H?_hz  ww "Square.b?贁N? 4 HDD $# =h-(>TTE=kUA@ ? uQ6 u` ?u B6> 00A0(2s@sJsT>d=$5 h9 L]{ !$5 `7Copyright 1999 Visio Corporation. All 4"s reserved.`? _Sba.chm!#224_17l>0>Udd!!  T '"<hb 261 g,s724  =?M1Y?r?91M1E;6=H=5P2?;rA IBOCq,B^35/\ @F"AC "3AP?LOe?#7A)[8B_T_OxY)___f_.eAE_oo_LHlu-i !OyaGE WszFT #\ b? WDekos+ o%? DoV_  '*4 AUFDfP h$T PUUBmUA@ ?I? 3xO@7IyIfBo?вsUP  /e Z.$ H" S?!{)19AI?dp]qi} Aw:npqA9pwwA9pwpiEquilateral triangle.b?? ߿ $t@ ?<?紁N;3HDB t# ih0>T@dE=M AkUA@??A߻?Q6 L,A >M A JuM` ?[y&y0y:@u` UJS>#JU0O贁NKk?<@MJdO@ܼ@ L LP6 @?FS@U%%F@))@H""oKJ%{X1]45 `7Copyright 1999 Visio Corporation. All 2s reserved.J`0_Sba.chm!#22416Aida?lJ*,>Ud6ZV$(s=?)ǹ<$$b# X"yB:V/ K;EA%;D]2׳뽿HH?!:ͳ?OARM%2pO;JrA RSq(^!(M%9M\Me2AO-QVD}Ho *oFTO`c5WD`18WoiDYebW_`c%@neNooO[jJ(?kF8Hl-h !OyaGEWszF4$ f#) 5? # /akNoD+L( OoB?*7 oPUl4, eG%@o^? |A <A-t3B7"AUl4, eG%@o^? @ A-37"AUl4, eG%@o^? A A-37"AUl4, eG%@o^? A &A-$3,7"A Ul4, eG%@o^? A tA-3z7"AUl4, eG%@o^? B A-$37Ul4, eG%@o^? U A-37"A_vV@@ DFR| A >) B ;[.` C |q|/D qB@(: UFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HC 5Vۀ {?"o./? ?pdofk| w{P}|shlwwwxnVpo]Pp'Regular pentagon, or five-sided shape.b返??lDK\wX}W鿰6??,̪]ơ%HDB $# ?h-(>TT9  AUA@A%??AmDK\w?Q6 u` ?u` i%kL>+000A0U(2}@}J}T}^>d@ @+B{!#$5 `7Copyright 1999 Visio Corporation. All H"s reserved.`S _Sba.chm!#22418lQ4>Ud}!!!Z hb93& 2g}U2<"£A f"0&8Ď@Y?@3 i3k1E: 4k (и?%99f5i8<*2|5fuN?2Se?2Z@ 4LW7%93:eiH?$2 ?5rA BCq!0^d!E/*\D 끁s,x#?eA`F+"A~%9\~DG;?oQo?uo|]x?_o??jZ&eNo+?=;Hl'-}i !OyaGE!szFĺ #$_e s@ D s 0?f|koaD+/ oV?_1 oUFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HG 9V?o)>  `r/`wpw> ȳpke{rpgTHYY9 mAUA? @ ?Q6 u` ?Mu ~YYA|XA44 4> !bJfvqQ >!"q06DNX lL>U5 LO@%#A?AE^?AL#l%u%?P6 @*  L#&H   " ' ]{%#W1\!\!5 `7Copyright 1999 Visio Corporation. All 2s reserved.`0_Sba.chm!#22427Bd(,*9 l>(>Ud!E (!(ZU$ B$bW* /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HI ;V?-  _`߅pl`ul`u kw{sg_'Regular octagon, or eight-sided shape.b?贁N? 4 HDB $# ?h-(>TT9 EAUA@ ? Q6 mu` o?u j>Z--200`0A0(2@2T^h0r|>U5 L{/!4$5 `7Copyright 1999 Visio Corporation. All Y"s reserved.`d _Sba.chm!#22421PBd9 l> >Ud]!!(<* Z#A|rvPph.b31,1e g2(:S425$a?a! Ҁ?1E5Y6gq4bH3x81| N5%O7I71x?:?=3A1@IZ) C ;D[_ 4D ;) F ܃$|6) E UFDfP h> /T6DUI@A?I BP(?3H$- b]b--rx@l^bf>M,,D'^fO - b, , 'eZYUHu F .LYcuZo^SLRepresents an actor reference.mb߿??PQ࿤p= ף??3㿕HD" # "=h#-$>T #T3 AOAU@?=@?@u߽?P6 )i8VYAEDA@@#u` *'.8BhPZ`u#j Ub >U5 gL{5!5 A`7Copyright 1999 Visio Corporation. All _"s reserved.`j _D88.chm!#2]0 l>0>Udd!!P #w a2U50` 9`fC"`e1De 2#(  O?si?e113???%G1 7@<Oa?9ME)2RO;rABC#(^actorReferenceiVA!aPIE9 3~'2qcPӼ? &bVq(^/\:5!?lOrISsQU__f+OnQ&%^]oeoooxGQ3ULYoopOorHlER  [F| b08# h1r? , ]'a\ 2D}+ >? @UFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HC 5Vo?)> pp/quupwj  lpysopi`;Generic circle with text and connection points.b?贁NE?4 HDD # =hZ,>THYY9 mAUA? Q6 u` ?u ~YA|XA44 4> !bJfvq >!E"q06DNX l>U5 L@d($%9%#APE&L#%%%?P6 @RL# L#  7p  #2 ' JB{%#145 `7Copyright 1999 Visio Corporation. All 2s reservedo.`0_Sba.chm!#22426+l>(>Ud#1E (!(Z$ B$bW :?" S:,wR5 | UPxP4FDTe]@y  ahZ- ^TUI eG%@I_o^?? I?*?QcS@?^ua`u$ eu GH~&kD!</ P%] !$ @ ! "a$@@ ?@<ˊ?@xOA|O0I3P5w?Q ^t LN?{2t!216-?57@_[PW57gclZޒ0#0/QH-E(<<[?/l^ !0^U! %9 !D!!>+A%EI6 [5 ^R5SD%NX[!j_Zq$!,Q!UOA$Wa8_QPEk.XVo.meWo`o/l5FnR6o/lD%nooA(4atient Instructions+/orProvider CwommepsiD5/G/4 '2Ur 1!a, "//q__q !a#?U@_{eE?@`?@b7?@xPCЀʃ?@a„l?~:EF-(տ? PC? CPo? UrEd܆Žڈ{!2 qА?ϟPCk?A|C5%O1u?OC=OT \OnOaFqS{Dispense Units/DoserUPHtst)<~8ㅰVAEiBt_IOOcDÓ-2/]]܆Ӆ9_a&5df]ϯR'qpqyI_v(.ok%üQ 1qok-+Jx\tߴo2} j$d#*7!3HAfG?p!` kPI&! !/$E#5///??(<ί=" @@`wa0ʏ܆\#8_eG i%?I[O%mk !ERsBIπGݿ←:]S@GC>$^J/]f]'+&/]]G!?4Y8ưUGoOOMU@_5^LG%o>m/Lk$?kg?okp?-U߹߾?EzѧNoun(Luz%*<ϩ\w׿rY@4?@7?@!`nSuUذOTFQ # " R;uh gdpUhkP7:[?@BPeYe߬?K]jLM 4A W_7I#h6.U8"n\ \ g3?tՕuv~Wҥ5'e5&/ux?/lZ/Ϗ@?yK?5{U O&$HPrepositio3OEOWOiO{OOD/O,OOOvR)N) I[&?x8r%\S7͟L; >tLָ-ƸWۧ 1ګ7%R)ϙf%ߖQ۠xu#x`fxi?ڬP *<yՓ)u#= !KVerb۟ퟀ#5SU rr__)lxcU?@`{e0/#tj@ /X߽Z 3"t j`#县 !٨̿޿jЇG2 q70?6?H6c3g? * AX$IT: `6y1vQt :QW%~/,/.8=OFeAO@?{fEG wS3(8za0+W_8_D)__3a_ B›Outpatient Expansؐ from MEDICATION ROUTE file (#51.2)Ưد,U!KUb?boow,)7AhgjN;;d' f!#y$u?`jPkp} X X%/1Qa\Y!oiѬ+= X )+P eG@@p@2?@k (E%$%.$gQ+7(QuJi06(#bu!mMKQL!LƖږ߁a%&R'F&FUƖBږږ**T>>RRUffzz5e؄L4\_e dpozU)IJ4ǽU)!4E)ڑ4)߁4e)Ĝa45)4dz)ہ4)+Q4)4%4%ȳ4ǫe)TA4ɺX_7ƪہк+Qќa@1іѐ@F@AoHA1oRA5O_F'U /U@,!@@??@㍦ί=sS[Im%圶?QS/e)eGx/ RۮU/ *./ e//@XEV@Px?@#)'߿R$ E/ ?3}?TA6 A`4?1A5s2_+UO)O l.X8$R M_{E &G5,3 5E1_Oj__oR5/_/e/-+ /4oڑOhSchedu`fffۏ폋o'd5YQ19Q1`5Q1ӅoooT3eE?@)q?@vB?@(qU|EERZqasFǟy lP7 CECQ [[Axx)n{ r0A7°@C|7o[a\1 ŸU !b*WBHIC~daS(7e~FHoGEmounEoow~a`57noZo~a7ooTn1[+8+H2U?g?y??;լ;u???? OO.O@OROdEЯ=䲢@@vENOOOOOO;A6'_ ;\STc_u________oo)oqoά o.AKe$6lɿ 2DYk}ŏ׏]LrYQ@@8,>Pbt qş IIAVNY%7I[mǯ%7It3i{ÿտ2 hewω ϭϿ7 0BTfxߊ`I"f$6H z9/c OOAVNY$6 /ASe6@O~OasO UTDMR. JflU"*̑&*3 ?I* /Ki UZ** +0!;0*L0ת*d0*|0J*40+0*U0*0+0*0*0+0*S*}JO JoK{KK/K}J#K'J?+KP/KO{3Ko7K;K}?JCJG[K\O[OSK_WK[K{_Kclgs[`kKo[/sK?w'l}{JoJl[JtolKK/KW[o[[{KKs[[K?K\K/L\\|s[۷l{s[[|K]lL|KwTKQ Q?{Q_Q_<QtUQQ}#QL'Q+ϛ/Q3Q7Q;Q/?Qd\CQ{GQKᛋOQlS;W󛣠[Q}_QcQ%gkQ}oQsQU$EwQDE{_REEQUEQREQ0EO簷REQ簿Q簽)Q,A[A$AקAQA\A UJA UA$p'T&74U;L?ʄUCdGʤЕKʼOwASJWE[# cgLvЕ|Вx*Р+Ю'5+ J/۪oUlo VFo?@ABCOFHIJKTMNOP;@jQWUXYZ[]^_`*abcUefghijk!mnopqJrsuUvwxyz{'A}~RUTǑUQ*oUJURU!ϪT7aUU U UUU!U34UUl4,! eG%@o^K? P ^C-3_A$Ul4, 6 h_A-3v7"A_*<N@4P _ JRVgR xq7uH<( H<( _*<NEP _ RVg[ `r ${zN  g"4FX(\y ?@(\ίy o :]R>C  _D _l q&I u!BL;>REƯOC8OJ $ ? @ A B C D E F G H I J K L M N O R U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~  Oh+'0,HPht vhaisbcostekGT+xi EMFL+X XVISIODrawing    % RL ArialKw ###%KKKKKKKKK%### . J  % TTImAAILP+  % TTLpAALLP+  RL Arial !svKKF&%JPL[]rN#KIuN  KKN#% TTRUdyAARULP+  RL Arial %%.-  K# #%%  #II#II#%%M$##Q$! !Q!% TTX|AAXLP+  RL Arial3"6"[[00=[Y%%?##[H^^,,,MM^^^^^,M,M^^H% TT{X|AA{XLP+c   &% % V4~>3}f}3>% (  % RL Arial:V:W:Y:T;V;W;Y;BADAFAJAOATAUAVAWAYAACAGVGAOKOROTOVOWOYOAQ TATLTOTRTAUBUQURU VAVDVLVOVRV AWDWLWOWRWOX YAYDYLYOYRYFaPaTaVK% TdV\rAAVLTNoun  RL Arialvavbvdvevnvovrv vAwTwawdwlwowswexoxAyKyLyTyWyaybycydyeyhylymynyoypyry ,.Ltf ,.Ltf???--ia% TTzImAAzILP+   &% % V0xwww% ( % ( % ( RL Arial}rkggkr7}RR7gL1$(($}`E- S Arial????????????????????????-  -- 2 aY Conjunct% ( RL Arial -C l?????????????????????????-C Arial?????????????????????????- -C Arial???????)% (  % RL Arial- -$[f[- d Arial?????????????????????????- --d Arial?????????????????????????- -% Tx"4AA"L\Patient    T5GAA5 LdInstructions     TdI[AAILT+/or    T|\nAA\L\Provider     T|oAAoL\Comments      &% % V,q~}r}}% ( % ( % (  % RL Arial% T|_tAA_L\Dispense   TwAAw L`Units/Dose      &% % VK~G<1' -:'C1I<JGIRC]:g-ov z}}zvog]RG% ( % (  % RL Arial% TN4jAAN LdPreposition     &% % V@t~ S$0]$}S}s]s0S% ( RL Arial% (  % RL Arial% Td!NUjAA!NLTVerb    &% % V0s(rtqq)t)tq% ( % ( RL Arial% ( RL Arial% ( RL Arial% ( % (  % RL Arial% T:HAA: L`Outpatient   TIWAAILhExpansion from   TXfAAX L`MEDICATION    T{jxAA{jLpROUTE file (#51.2)    &% % Vt}G9 ,!!/=KXc!l,r9sGrUlaclXuKz=|/z!ul aUG% (  % RL Arial% T|B`TAABL\Schedule    TUegAAU L`Expansion   gonActor referenceCircle8_VPID_PREVIEWS_VPID_ALTERNATENAMES_PID_LINKBASE  A  FMicrosoft Visio DrawingVISIO 6.0 ShapesVisio.Drawing.69q_1044277894l$^F˪U˪UOle \CompObj]`]qObjInfo_VisioDocument_b :NVisioInformation"`SummaryInformation(ac< ('DocumentSummaryInformation8aVisio (TM) Drawing :N L}Rl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1TJDT1EWP-hTT<U*U U =/Ub b酸0zGz?@8H2!kWbU%U  +PL/^&9^$? { Ak^&,",'%/v&Q&  1y   )? 2    J12?k9aUBBHEHEHEUHEHEHEH@?>?:`2BBHEHEHEHEHEHEHEH@$%O9F7AOY@; A*sVsVAgLTkY 1 W_W__ !`#ku4lb6Pu`kW 4l 4l %Y?:?-\ *#!+|tKf*2|2|2|2wG)QUoTMeEttA%_8BOTOfOxOO??O?7 ܻuW+? sU42 T*PbtφϘϪ(:L^p߂߂O߳ 1C@Ugb{.);M_xa"4FX 0Bzas//'/9/K/]/o/////////?#?zaB?T?f?x????????OBOUbb7OQV.e_OqOOOOOOOO_wk#_5_G_Y_k_}______L__UlAoSoeowoooooooxa(:L^p cwo!3EWi{Ï٦ .@Rdvk}*B'Ck#bz@.`c.`/%b /=QN3L/^/p////////??7?Pbtί(:L^p݇Z;ɼٿِ>.@*[m߅3O'Nk P2Ǎq?߃?\.?o AqT$$$'9K]ڊ䐾伩jPPj|xԕIWؙ&V03E)0<kDB!ߵ V /ASew+=Oa/09K]o?!?%LHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55H!winspoolHP LaserJet 5Si_742029_IP0Ul4,] #@Dc) ? !}A-d'7"AUl4,] #@Dc) ? )pAJ-,3v7"AUl4,] #@Dc) ? 5A-37"A Ul4,] #@Dc) ? D0 A-T37!Ul4,] #@Dc) ?  XA-3^7"A*Ul4,] #@Dc) ? D A-<37"AU@<_)GR1_x;D?DI;F?B?m`qbURU  !'*4UFDfP h$T PUUBmUA@ ?I? 3xO@7IyIfBo?вsUP  /e Z.$ H" S?!{)19AI?dp]qi} Aw:npqA9pwwA9pwpiEquilateral triangle.b?? ߿ $t@ ?<?紁N;3HDB t# ih0>T@dE=M AkUA@??A߻?Q6 L,A >M A JuM` ?[y&y0y:@u` UJS>#JU0O贁NKk?<@MJdO@ܼ@ L LP6 @?FS@U%%F@))@H""oKJ%{X1]45 `7Copyright 1999 Visio Corporation. All 2s reserved.J`0_Sba.chm!#22416Aida?lJ*,>Ud6ZV$(s=?)ǹ<$$b# X"yB:V/ K;EA%;D]2׳뽿HH?!:ͳ?OARM%2pO;JrA RSq(^!(M%9M\Me2AO-QVD}Ho *oFTO`c5WD`18WoiDYebW_`c%@neNooO[jJ(?kF8Hl'h !OyaGEWszF x#,G? GAa `oD+L aoB?7oPUFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HG 9V?o)>  `r/`wpw> ȳpke{rpgTHYY9 mAUA? @ ?Q6 u` ?Mu ~YYA|XA44 4> !bJfvqQ >!"q06DNX lL>U5 LO@%#A?AE^?AL#l%u%?P6 @*  L#&H   " ' ]{%#W1\!\!5 `7Copyright 1999 Visio Corporation. All 2s reserved.`0_Sba.chm!#22427Bd(,*9 l>(>Ud!E (!(ZU$ B$bW* /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HI ;V?-  _`߅pl`ul`u kw{sg_'Regular octagon, or eight-sided shape.b?贁N? 4 HDB $# ?h-(>TT9 EAUA@ ? Q6 mu` o?u j>Z--200`0A0(2@2T^h0r|>U5 L{/!4$5 `7Copyright 1999 Visio Corporation. All Y"s reserved.`d _Sba.chm!#22421PBd9 l> >Ud]!!(<* Z#A|rvPph.b31,1e g2(:S425$a?a! Ҁ?1E5Y6gq4bH3x81| N5%O7I71x?:?=3A1@IZ /T6DUI@A?I BP(?3H$- b]b--rx@l^bf>M,,D'^fO - b, , 'eZYUHu F .LYcuZo^SLRepresents an actor reference.mb߿??PQ࿤p= ף??3㿕HD" # "=h#-$>T #T3 AOAU@?=@?@u߽?P6 )i8VYAEDA@@#u` *'.8BhPZ`u#j Ub >U5 gL{5!5 A`7Copyright 1999 Visio Corporation. All _"s reserved.`j _D88.chm!#2]0 l>0>Udd!!P #w a2U50` 9`fC"`e1De 2#(  O?si?e113???%G1 7@<Oa?9ME)2RO;rABC#(^actorReferenceiVA!aPIE9 3~'2qcPӼ? &bVq(^/\:5!?lOrISsQU__f+OnQ&%^]oeoooxGQ3ULYoopOorHlER  [F4_A"8#LlGTr? \Q*T'akTOD+eT>?o$UFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HC 5Vo?)> pp/quupwj  lpysopi`;Generic circle with text and connection points.b?贁NE?4 HDD # =hZ,>THYY9 mAUA? Q6 u` ?u ~YA|XA44 4> !bJfvq >!E"q06DNX l>U5 L@d($%9%#APE&L#%%%?P6 @RL# L#  7p  #2 ' JB{%#145 `7Copyright 1999 Visio Corporation. All 2s reservedo.`0_Sba.chm!#22426+l>(>Ud#1E (!(Z$ B$bW :?TTE=kUA@ ? uQ6 u` ?u B6> 00A0(2s@sJsT>d=$5 h9 L]{ !$5 `7Copyright 1999 Visio Corporation. All 4"s reserved.`? _Sba.chm!#224_17l>0>Udd!!  T '"<hb 261 g,s724  =?M1Y?r?91M1E;6=H=5P2?;rA IBOCq,B^35/\ @F"AC "3AP?LOe?#7A)[8B_T_OxY)___f_.eAE_oo_LHlui !OyaGE WszFH,# V-b?} @]Dek.t+CK%?J5&V@4(@4(@4(@4(@4(@4(U@_1 R1; ,; d9; mF; ,S;_( ?VR J.B< SE; GS !SX&S.,t B_|0SD}'`1J/ UPxP4FDTe]@y  ahZ- ^TUI] #@IDc_) ?? I?*?QcS@?^ua`u$ ePu GHD!#kD!3w!|)AG.D% !$ ! "Z @@Λ?@qǿq?@L0ǻqG5?@K1q?f?/1!tw! d߹8Rä5t!2?}Ƥ57Ʋ\SѤ57qi11%Y#FH-"L#0Ql0^UAA a !D!>Uf{2{2-UI6_58_ 8U^d3;p__UIQD%^_%__IQA__o_ p!+Ci$5/G/|kD '2Ur_A!aA, "aA/Ea//?F#9Odk!@@P*gF0<ˊ?@xA|psu?Q = xK? qZp? TH%?8_A0<kOfO/A)PbtB88n //)/;/M/_/q//~آII/#/4hv//??+?=?O?a?s????__+_?VOOzOKO]OȌOOOOJcnڏG_Y_k_}________o!o3oEoWoio?ܝ_{eE?@Λޙ`bj:ooookc oNsE ?qi~&v0Ɓ#5Gɟ:(L_i߃BTߊ @,>PbGA䅡٣3A˺ե({ûIa^A.@@PeJ7?@Ob\-j|u5 |; 3ɿ 80 8H"# TUPp\Ure{ʨȒ`@~uŃ;()AF2Uz ~,S!Q3#եz@[dxW= @@x/h?@N05"5?Q,)mXzE N _ mjDQy cO00 -Ϫœ;Ed.5T74@M_.Ngj 5EAP $<S!}OwF?/S!'/1@65;ؖ`<0-< g3?3TBU#^,7m_'qڤ,Qp70FWbXFXao59oKlbe_|oKlbnGodbkPYKhQPreposition/ /hW/i$zx///)ݯ/0p8?@\l;?@ Ā=?K}ZRd? 5M@~? ? "??pXݲ??.DTGOYOkLȟCO뗒EDqɒřόvS!O _-sx8@Dž:U\?S7Ս^; >tfyC姂3饮:ѱ~+奄ShݫzE~US!sDqeS!zI8JoүCIo-Mύo%{"o%{I %{p(7@Ec&9dž)`&S@ֈ"VrxVerb\; 8{ A ##5S//O\'Bƺ@@7qN0: ?@k`n*0l!J $' 1;}? ‰ c; on큿?fx82G,s=$??H%At TMeG GEbaDY9S\nl+ +ĭ&䯨kE+V{B(%iF&?a'y=+2QI?/؊?@qg(F?uBOutpatient Expansp from MEDICATION ROUTE file (#51.2)0asU$BOOGR 7NGj(XXd66p_!3R+q&vD+U?,`B(k*_<_(( XA%e9KCo//\%U@D.+J@@P?@ί=ĀS[Im%ec '% ,+4 7VY 5׶. \sU@g8EuV t@Px?@# suŦXM՟XAgo/ \6ug88lpl M_{@g?'Na,W̡Na{լ/4/?z Z??kN?/~ʯ(ߴ ԯ?Schedu5@F__~OM NaDHoZo͙{Հoo)eoU@0:xp?POp?`.]KD ]tE6{½MOozP{j{zk`pq'5u=RR@*q5&39Tb yǟˏݏ14Dy`0)Ƥ&/31Q7,S-/CU/-); <_);:·xb7j|C7-a1)o1!jo*9K`r220y?@ϭϿr]tq3J2DVhzߌߞ0T1?<=16HZl~? 2cVhCgO O.pOR=_,ALocalPossibleDosagea(rųqG*qߴ*mqimdKN__gHI 4A] @@Dc) ?@rY"@@P*gee*Vu$! s3p&ru !1x1A IQ ) 0ԟ $ f" 0:!fx!1JE^! !"#T%%&'U()*+U^U U UUUl4,] #@Dc) K? % 'KV7C-3r7AUl4, KA- 37"A_*<N@T xK LRVg̽q7uH<( H<( _*<NE QL RVg^q {zN  g"4FX(n ?@(}ίy T :]R}|  ,q& !Bo|!; >GOdXWEo9O 1ե$LO2' MEVN$ ) 2n`!s1IVV<K F? L(!DWk5 C= !5 J!i5 D՜.+,D՜.+,V@HP\h t   PagesMastersPage-1 TriangleEllipseOctagonActor referenceCircleSquare8_VPID_PREVIEWS_VPID_ALTERNATOh+'0&HPht vhaisbcostekGL&x~^] EMFD&X XVISIODrawing    % RL Arial% TTHlAAHLP+  % TTKoAAKLP+  RL Arial% TTKoAAKLP+  RL Arial% TTK"oAAKLP+  RL Arial% TTzHlAAzHLP+   &% % VrD:0$'/ =M^n~ '0:DNW`g~mnp^qMp=m/g$`WND% (  % RL Arial% T2I[AA2I LdPreposition      &% % V@t} S%0\%|S|s\s0S% (  % RL Arial,,,,,,y,,,,,cccccccHccc,c,, . : ; D,F,J,O,P,Q,T,U,V,W,Y,e, f,r,v,w,y,T-V-W-r-D.FJ.O.P.Q.T.U.V.W.Y.e.f.r.v.w.y.TD% Td'LOaAA'LLTVerb     &% % Vr<.!  !.<JVajoqojaVJ<% ( RL ArialuVuWuYubumunuAvavbvdvevnvrv vAwTwawdwewlwowswexoxAyKyLyTyWyaybycydyeyhylymynyoypyry ,.Ltf ,.Ltf  % ( RL Arial} "&*.26:>BFJNRVZ^bfjnrvz~h|% (  % % T|7IAA7L\Schedule    TJ\AAJ L`Expansion     &% % V,onnn% (   &% % V,~}}}% ( % ( % ( RL ArialPAL @A|@  074GLHL@"% (  % RL Arial"&*.26:>BJNRVZ^bfjnrvz~|% TlN]AANLXLocal  T|^mAA^L\Possible   Tpn}AAnLXDosage    &% % V0( u)tt))t% ( % ( RL Arial } "&*.26:>BFJNRVZ^bfjnrvz~|% ( RL Arial% (  % RL Arial% TxCw1AACL\Patient    T03EAA03 LdInstructions     TdOFkXAAOFLT+/or    T|=Y}kAA=YL\Provider     T|4l~AA4lL\Comments      &% % V0xrqwqwq% ( % ( % ( RL Arial6engine font ``):344S6% ( % (  % RL Arial^989 6 f6 8 J7 .8 5 4 $7 p7 67% T7hEAA7LtOutpatient Expansion   TG_UAAGLlfrom MEDICATION     TY^gAAYLpROUTE file (#51.2)  ENAMES_PID_LINKBASE A  FMicrosoft Visio DrawingVISIO 6.0 ShapesVisio.Drawing.69q՜.+,D՜.+,_1044278213fF˪U˪UOle jCompObjehkqObjInfomVisioDocumentgjT yVisioInformation"nSummaryInformation(ik /DocumentSummaryInformation8oD   " Visio (TM) Drawing y !ZxRl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1U&J:DT1EW-hTT<* /Ub bO0zGz?@8@H2!kWb*U  +$PL/^&9^$? { Ak^&,,'%/v&& * 1y   )P? 2   U U12?k9aBBHEHEHEHEHEHEH@?>?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*Pbt߆ߘ߼#5GYk}b4?Qcua&8J\n /"4FXj|Q!//+/=/O/a/s////////??'?9?K?]?o????a???? OO0OBOTOfOxOOOUbbOXa]feOO__)_;_M___q________o#o5o0GoYoko}oU&oooo /ASea(:L^cqoǏُ!3E(hzŸԟ .@Я*EWi{ÿտ όf8i\nπϒϤ϶T);M_q߃ߕߧ߹p3ǀSFXj|+=OasNr'9K]o 9 0BTfxBC`!k}3I bz@6` /'c//A&`M/_/q//%b/)MQ3///??(?:?L?^?p???"dGoPo be3oo}_oooooo&8J\_VC94O*O -?Qcu͏ߏ'9K]ccU<犯"/ΟF//:/!щqfxү,>Pbtο@_ jK[CuU՞ϰϬҔЅaa3vO贁NkߖFa`27qZ?Yka?\.? pQA6k6߻H k+6;CjԕaI^g030|kPewȈ$ !%7dri{ /AS}/w+=Oa???'9A1K]DM*Oѭ e.KUqH)Wq[=ۑagOyOYuğYOOOOOV0%!/3/E/ W-}QK_mϣ(A(I1oo(o:oLo^opo s#m///5/////O(O*?P?????Ga^o__OO_____-?VQ=v.s#{.峑PbLǟٟ!3sHZb=!o"důׯ //gyI[L^$6HZg!lŪ(:ɏ^p9܏ $?OGOYJ#qٿ 1߀C __-_iȉX@R_ba QJ_+Չ/ڜ,5 ,5,0$Zl~r?? 2??h8LHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPUFDfP h$T PUUBmUA@ ?I? 3xO@7IyIfBo?вsUP  /e Z.$ H"N @X(:H?_hz  ww "Square.b?贁N? 4 HDD $# =h-(>TTE=kUA@ ? uQ6 u` ?u B6> 00A0(2s@sJsT>d=$5 h9 L]{ !$5 `7Copyright 1999 Visio Corporation. All 4"s reserved.`? _Sba.chm!#224_17l>0>Udd!!  T '"<hb 261 g,s724  =?M1Y?r?91M1E;6=H=5P2?;rA IBOCq,B^35/\ @F"AC "3AP?LOe?#7A)[8B_T_OxY)___f_.eAE_oo_LHl-i !OyaGE WszF # b?  WDekos+ o%?\jYDoVy   '4 A*N[UFDfP h$T PUUBmUA@ ?I? 3xO@7IyIfBo?вsUP  /e Z.$ H" S?!{)19AI?dp]qi} Aw:npqA9pwwA9pwpiEquilateral triangle.b?? ߿ $t@ ?<?紁N;3HDB t# ih0>T@dE=M AkUA@??A߻?Q6 L,A >M A JuM` ?[y&y0y:@u` UJS>#JU0O贁NKk?<@MJdO@ܼ@ L LP6 @?FS@U%%F@))@H""oKJ%{X1]45 `7Copyright 1999 Visio Corporation. All 2s reserved.J`0_Sba.chm!#22416Aida?lJ*,>Ud6ZV$(s=?)ǹ<$$b# X"yB:V/ K;EA%;D]2׳뽿HH?!:ͳ?OARM%2pO;JrA RSq(^!(M%9M\Me2AO-QVD}Ho *oFTO`c5WD`18WoiDYebW_`c%@neNooO[jJ(?kF8Hl'-h !OyaGEWszFtW q#4\ @? G:}aV YoD+|[ ZoB?oq oPUl4,f? '<%@,5? "HA- 3N7"AUl4,f? '<%@,5? "AJ-$37"AUl4,f? '<%@,5? D"A-<37"AUl4,f? '<%@,5? \"0A-T367"A Ul4,f? '<%@,5? t"~A-l37"AUl4,f? '<%@,5? $"}A-"7Ul4,f? '<%@,5? #A- 3"7"AUl4,f? '<%@,5? #_jA-%$3p7"AUUl4,f? '<%@,5K? #UC-37A_@D"PFR| <"D l" [8` \"q>"q>'9$` |"r[C-/#[LqUFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HC 5Vۀ {?"o./? ?pdofk| w{P}|shlwwwxnVpo]Pp'Regular pentagon, or five-sided shape.b返??lDK\wX}W鿰6??,̪]ơ%HDB $# ?h-(>TT9  AUA@A%??AmDK\w?Q6 u` ?u` i%kL>+000A0U(2}@}J}T}^>d@ @+B{!#$5 `7Copyright 1999 Visio Corporation. All H"s reserved.`S _Sba.chm!#22418lQ4>Ud}!!!Z hb93& 2g}U2<"£A f"0&8Ď@Y?@3 i3k1E: 4k (и?%99f5i8<*2|5fuN?2Se?2Z@ 4LW7%93:eiH?$2 ?5rA BCq!0^d!E/*\D 끁s,x#?eA`F+"A~%9\~DG;?oQo?uo|]x?_o??jZ&eNo+?=;Hlu-}i !OyaGE!szF #_ O @ dZ!0?ft oaD+,/ oV?_4 oUFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HG 9V?o)>  `r/`wpw> ȳpke{rpgTHYY9 mAUA? @ ?Q6 u` ?Mu ~YYA|XA44 4> !bJfvqQ >!"q06DNX lL>U5 LO@%#A?AE^?AL#l%u%?P6 @*  L#&H   " ' ]{%#W1\!\!5 `7Copyright 1999 Visio Corporation. All 2s reserved.`0_Sba.chm!#22427Bd(,*9 l>(>Ud!E (!(ZU$ B$bW* /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HI ;V?-  _`߅pl`ul`u kw{sg_'Regular octagon, or eight-sided shape.b?贁N? 4 HDB $# ?h-(>TT9 EAUA@ ? Q6 mu` o?u j>Z--200`0A0(2@2T^h0r|>U5 L{/!4$5 `7Copyright 1999 Visio Corporation. All Y"s reserved.`d _Sba.chm!#22421PBd9 l> >Ud]!!(<* Z#A|rvPph.b31,1e g2(:S425$a?a! Ҁ?1E5Y6gq4bH3x81| N5%O7I71x?:?=3A1@IZ) ";"_ [;) "$6) 4"_ ĂW~) #mUFDfP h> /T6DUI@A?I BP(?3H$- b]b--rx@l^bf>M,,D'^fO - b, , 'eZYUHu F .LYcuZo^SLRepresents an actor reference.mb߿??PQ࿤p= ף??3㿕HD" # "=h#-$>T #T3 AOAU@?=@?@u߽?P6 )i8VYAEDA@@#u` *'.8BhPZ`u#j Ub >U5 gL{5!5 A`7Copyright 1999 Visio Corporation. All _"s reserved.`j _D88.chm!#2]0 l>0>Udd!!P #w a2U50` 9`fC"`e1De 2#(  O?si?e113???%G1 7@<Oa?9ME)2RO;rABC#(^actorReferenceiVA!aPIE9 3~'2qcPӼ? &bVq(^/\:5!?lOrISsQU__f+OnQ&%^]oeoooxGQ3ULYoopOorHlER  [F!s18#D"y2r? U!]'a!3V+/!>?_\!QUFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HC 5Vo?)> pp/quupwj  lpysopi`;Generic circle with text and connection points.b?贁NE?4 HDD # =hZ,>THYY9 mAUA? Q6 u` ?u ~YA|XA44 4> !bJfvq >!E"q06DNX l>U5 L@d($%9%#APE&L#%%%?P6 @RL# L#  7p  #2 ' JB{%#145 `7Copyright 1999 Visio Corporation. All 2s reservedo.`0_Sba.chm!#22426+l>(>Ud#1E (!(Z$ B$bW :? /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ! Hu 7~???0𫏆=@FwnmmhZ[L7Double arrow with 60-degreheads. HDB # ?hZ4>THYY9 dA[UA? u?P6 -u `u b_u  @"! FhWuk` tu.AdV8bM>ڲ@!$U'P"_/q%'i-/ 7$#5 L!# 7 6 BdH*%#/ Hh?Q6 u{%6{`("u?"F&`Qps-8R? WI@ 偌!6Q(-DT! @u@{$#AD5 `7Copyright 1999 Visio Corporation. All Bs reserved.h`@_Sba.chm!#224398B!$Cu tNs!OR U\l>Ud0@ Yi \!(Z$*L/S!4b?GQ b#Ib(3$$*3Ey‚7ʱRrB-db&`_aEojp= ףpՃoOR.ccb>$$?M˰iORD3eoeE9m |g`o'W6$*6a23(o_a|M:hz|%a_aQivQe&sbebQ2lm?l^Rgoyf?oQuo؅A &jdTAha9 G7(حN@fQB?bZބۀ!(! [?2vB@z?JVQ&999Y9Q9SIQ?IgRmb?п贁N8i/6??Hlus !Oya GE_6szF&;w#*<? '0=-aL W]oDo)^o/P+,A4?UFDfP h-RTUUUA@ ?I? 3h d  eqYk QHoP@Rw >2O` Flowchart}}` >?< -> \it `0Represents any microform. ape.bol.H D  %# =hj8>T YY>zAUA@ ? Q.6 ~A+<F ZZ [u`h_?`  $@8V`zSu U" , '>  Ԓ>z!}bzU%r# "rg&"#9&u`uY`"u`J2z@|&Un1s45 `Vis_Smis.chm!#23300`7Copyright 1999 0io Corporation. All 2s reserved.#3U5 /LW1]h7 309:#z3g#h30O贁Nk?<)@9#F"U:%8%Fl>BYUdv\17(gh3z?"#b"%$ jbt"t\8IS@_Z]'%zVV`86!F/R2c'P&0"B/jT  //'ayZ6fJo\c"^UgWoBcQBE3oR_zA(qalEA#oUPmo[`nohu,>qb)bEA_w?f8jR0svPomTPAaG+R%T:"_2) 27(sFn5n1CA"`Cost63,Enter the c] associated withois procgess03B`@_5-CE_3OUDu3*3 jd {ofstep05{šH` Resour0:jnumbmpeople0quirցtosmte^task0dA^9 Ge:v?FFBVL S$sj^g/w$rb#cVjvr)q(^!ˍYAFI&FF>A-:%@]$6 E#._5OS{ύZY!jTcU5ltπqUTBEan1k8n1J:@R` %Propertiz\:30Setoustome selecshape0W[@jRb W1?Q_5߉B&CTA:"7(m9#?EQttRr#FiV߯tD'2qbBϢbؿ?8i6? 4 Hl9  !OyaEhFT3"ZB#7"%C? 2"].ak]DjLY]P+6"I%?(  S!1@B!,V /?"R!l $/"q!߂*w4//DY"0e"\!6/ /AS"?"b;P"? A"1"IU  UPxP4FDTe]@y  ah TP^UIf? '<%@I⿥,5??I?*?QcW^Y2@?[u`F ""ua)o%uH!!a` Flowchart `$ !eU/g/!;G‹&!i! )171g? !`1,`1`1!a%X?@b 5?@Shc2?@g1ߝtE?@vMdѻ?Q t!)1 3ɿ?5Bt>!@BKr_LE;GLVgLEUGEL@EFDDGC!HE-12q P?_V<?A|-(#0QŞ!(B<71_[?j?71 Dispense Units/Dosei8/ T 'T~l=d7U??Pea@aĥ _SaـdBLeF Ese&԰|@eoq4@aQ@@a@ii0ME q<~uZAv x1 ukc!\wt ~( F~ j/@ov+d\W*7!3Hq&XTG?#!kLP<_U!&?<O2_5A  a$ =?@w0?@RC >?@6Q£߬Ff/L@7/5M /yLO [fO C%ĀO ڳ@# #'#qOQ<\_<WL{sQ_yXaqd⁾goU ifע-ע=-y^ťo'꥔ϭή+hy^߁9q5^@{Y" g+(f`alo~dU"jՌcOQ!'߄?<O2`?r?@RdOf?U@j"n\$@@9D\??@%WA} ?@@֕AJ%O7Ki2G y4 ҌN O,sQdl_^OQ[__TQ_p a /ooCE}Cf R5z?of [ &P/LQ/Z/;/H/,%.//S%3kPatient Instruction +/or Provider Comm_0s(b(:Lyodw77 'Hr @@߳gO&@HkP٫IECeDx@{ 0< ]8E PV2PUUXENtDED@?d^d2?@^V4SpSǦFt 7T a!o"4l a^GbmOe,E 8NtLPLW )`tdenGS6ex"?(/Jk/?={ /Py/k5?<P9reposij1??????y)?瞕O.O@Or"WEB֣PP?@rv `VkOBcް_ ҟ<#"_<_ :gY_k___ oTl`聀mџ>> oo@ 6UzQpk L5&C19Y+m-ɀL"=bh0puC@ Rؿ꿷vߢ1+nt+α﷏+ukA^{+z; M;Verb,>Pbtr;7 Gbaß՟ <$@@ *u@Y?@^N |?@pDK\w&_ ψ!/ů L~߯ TUQ Z,>PAYVT/-Ze4ggSyըߺ);+ə@fa*œ3炅͏lͶ^{Hh;8?ov WZy  /vsU@E:v,x}>~OF>O>>__>G_>_nqqAnB^&CnóKfEnFn%&n9  !!55IIggqqB kUUU%%CC6v-$*!eJ`Wiן;!- *d d TqЈai@jEvv ў&Uv5av5ўv}aevgў%vqў-vўFrarNrўevўVrўQra^rv%q(rC yWFLj$ 1!5!5Ŋ!{!}aĊ!gc̊!Ԋ!%gсo0qgoooiŸЌ&U@,tM3]~?@BG4?@ف0303?Qewy.YpO  &Fv )Bq 155lZ@XP=!)CطEԙt&U /Ag._ck)0gфk7z?џϏᏏ5 }a1<66 1TU^7Uo-1,Wfi-1"Wh"o:oeJk-]i}a{iRSchedu?I[mSq22 <Q_M߉@MXMŁa$N[3M4Vށ`0?@RC >?@6Qt*}ƀIϺ= /yO [/O z;IO #6Oc@~Qp)<fIsO^RLAOz XgQS5VqwTTW1W5o4_UYZzK74\ /v@exvX/R v/ Lϸ! #+@5M_qU;Ѷȏڏ"4FXw`>@l~Ɵ؟8GT뚎1K[mǯٯ!ϑiοÿտ:D^/όeR+=ATfxߊߜ߮X " -?Qcu7HC/) ؽ1AF~6 /ASew/Al+OasO*_O`_yO_O]or//(/:/L/^/p//X @@"j_///// ??.?@? )U󮫪vc8J.8QF??????OO'O9OKO]O___O _O._8O_v__Y_k_ȟ4_"_ oo1oCoUogoyoAooooooo /@@0jLMyWc"=`xrypf9o , " z*5GYk}ŏ׏Yk}Cg̟ߝ%쟣^߂IǯٯB?2B\=IoeyщBכQcہqȹE,Н@@ ~~O  ?P#Gv|~2׈Ȏ@@@{ Y;@@OZ޸@` #mH *$c c~ B2!ς& ~QJk,x4 u<r tNTzs&(8d/?dcu?x!LXz?@Gz ?sN@?8y2JFmqߪ@ C Ȃzپ563> 24%5RkTbM3N;eվ551VOhFь1OA@ 531O83FO6E1?::%JDurationV^//rqC+=OasͿYQuchp@c!3EW]UnwU͕MQ v|;/-?>cuߞ?H_ jfp憐Aʈeݏmp(Lw܏/AS____!e_o o2oDoVohozooԵnucl"@1V`oo Vv- ψ!/G l&W;a`á"Ɲ -?QcӟFV&@\Z{ߍT ߌ8ߥ&8(Repeat as Needed) 2DVh_~̯ޯ&nP#@@HLooz$6_D c)q{vy;M_qσϧϹ_qIϏ|5/>q}/E//C/` mFDIY11vT`@CE|,{7DQ5FT 4TP K'kSU]CoQ9c xzݿj~ r^ V@58'=((1NFAW3GTAF0 R28Tw `0(8{311oa_M1m1~4|oɝ+JTխd2ֺd "dQ1UAa8Conjunctionm2Tv???? 2d$'a0TUA?0606O|$fcxX2qq|TUA9vQ)bX26t]ĘW(u𡄂uVǀ]q@]ۏ{5\y|tT%J)rc&!BqtTa{tTy$A]?Q>j )uL֯ %E_U:UUUl4,f? '<%@,5K? d"e1C-"_fAU2@,"f7ORH<( U2Et"f7 RUlL!KN!e@?$!lfwRD,!;U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)$LU-T *o6.-;)-'T)8</!=D!D!>t!t!? !!@!!A11C4141E d1d1&118&Q - H*)=OB&Md1QOOLGuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowSquareTrianglePentagonEllipseOctagonWhite fillvisAecIsTech?nicalWallBuildingActor referenceSquare.8CircleEllipse.11Octagon.12Actor reference.13ROOM BindingROOM Line StyleNet Thin lineNet NormalCircle.22Pentagon.3Triangle.260 degree doubleYellow fillMarketing Normal 3Flow NormalMicroformCostDurationResourcesAntiScale_3t.#h E /# )- DR)G\)U t)U)c )Uc )c )id ) 0#! 4. L; dH |U b o | 1# $ < TRʽdԽI0 Vj)̑% *f% u}I*2#*% 1i 9%*4i =%*li A% XLi \%*i `%*i d%*i h%*Ԫi l%*i p%*3#t%*0x+0|+0%*L0+0+0+0+0% T;'07*0%*_4#%*$0I+0W;0%*Ud0%*|0µ+0%*0%*0+0%+0J%*0+0%*0;5#$;@+@W;@IK@/K@%*e@eK@k)U@aZ@ aZU@aZ@aZ_ 6#aZPUaZ4PaZLPU"aZ\P&aZlPU*aZ|P.aZPU2aZP6aZPU:aZP>aZ̷PBs[PFaZPJaZ7#NaZ`RaZ,`VaZDR`Z[`^aZt`b'k`faZ`j$]k`nok`rs[`Iv[`z[`~kO8#kpaZ_B$ᛵF󛵠JEN>`)EV;EZME^)b*UE{ᐮ*cᚤE0Ep'Eٺ?#UE$ժ?@ABCaOFwHIJRKMNUOPQRS}UVWXYZ[TQ]^_U`abcefghT_% aPᐵop*qrsCUuvwxyz{}~JѡUॊ'ѡRGQUਜ਼ѡࠡࡡࢡTॡডৡU੡ડoAୡ஡௡*ౡಡѡUඡ෡มມ]ѡཪྡ࿡J¡ášUơǡȡɡʡ͡ΪϡСѡRӭա֡סa;UU U UUU!U34UUl4,!f? '<%@,5K? _#vC-T#wA$Ul4, "awA- 3o7"A_*<N@ #w JRVg"qq7uH<( H<( _*<NE|#w RVg"q {zN  g"4FX(r ?@(ίpy 8!!:]R}T!  !"q&!!BC#;>G_O?dXEO!J$l_!~K'?<!f~N|S! g})U! 1^!unw,"`2.#_nVLXdl#r*t3r;lBdHXMLO>O2M'HB;3% ( % (  % RL Arial  p]lAA]LXDosage   &% %% T(6gCAA(6 LdPreposition   &% % V@ HQ 3!<P3PG<G!3% (  % RL Arial% T| ;FJAA ;L\Schedule   TKH% Td34BAA3LTVerb    &% % V0ONNN% ( % (  % RL Arial% T -AA L`Outpatient  T-:AA- L`Expansion  T:GAA:Llfrom MEDICATION   TFSAAFLpROUTE file (#51.2)   &% % Vx" x`#7%+* 2<GS^hp u+w7uBpMhV^\S_G_<\2V*M%B#7% ( % ( % ( RL ArialDd% (  % % T|23fAAA23L\Schedule  T/AiOAA/A L`Expansion  RL Arial% TTM6_ZAAM6LP+  % TT6ZAA6LP+  RL ArialtGn@% TTx6ZAAx6LP+  RL Arial% TT 8\AA 8LP+  RL Arial% TTz7[AAz7LP+   &% % VH W 2%% 1U>>V2% ( % (  % RL Arial% T|6DAA6L\Duration   RL Arialn% TT7[AA7LP+ % ( RL Arial% (  RL Arial% TW-<AAW- L`(Repeat as   Tx_=LAA_=L\Needed)  % (  RL Arial% TT<`AA<LP+   &% % Vh SVO(2= HRROHK=I2K(OTUTO% ( % (  % % T5LDAA5 LdConjunction  % (  RL Arial% TT7[AA7LP+ D@HP\h t   PagesMasters  Page-1Square Triangle PentagonEllipseOctagonActor referenceCircle60 degree double Microform8_VPID_PREVIEWS_VPID_ALTERNATENAMESl_PID_LINKBASEJ@ A  FMicrosoft Visio DrawingVISIO 6.0 ShapesVisio.Drawing.69q՜.+,D՜.+,z6@HP\h t _1044255558T}nF˪U˪UOle yCompObjmpzqObjInfo|VisioDocumentor rVisioInformation"}SummaryInformation(qs -DocumentSummaryInformation8~6Visio (TM) Drawing rz qRl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1U&J:DT1EW-hTT<* /Ub bO0zGz?@8@H2!kWb*U  +$PL/^&9^$? { Ak^&,,'%/v&& * 1y   )P? 2   U U12?k9aBBHEHEHEHEHEHEH@?>?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*Pbt߆ߘ߼#5GYk}b4?Qcua&8J\n /"4FXj|Q!//+/=/O/a/s////////??'?9?K?]?o????a???? OO0OBOTOfOxOOOUbbOXa]feOO__)_;_M___q________o#o5o0GoYoko}oU&oooo /ASea(:L^cqoǏُ!3E(hzŸԟ .@Я*EWi{ÿտ όf8i\nπϒϤ϶T);M_q߃ߕߧ߹p3ǀSFXj|+=OasNr'9K]o 9 0BTfxBC`!k}3I bz@6` /'c//A&`M/_/q//%b/)MQ3///??(?:?L?^?p???"dGoPo be3oo}_oooooo&8J\_VC94O*O -?Qcu͏ߏ'9K]ccU<犯"/ΟF//:/!щqfxү,>Pbtο@_ jK[CuU՞ϰϬҔЅaa3vO贁NkߖFa`27qZ?Yka?\.? pQA6k6߻H k+6;CjԕaI^g030|kPewȈ$ !%7dri{ /AS}/w+=Oa???'9A1K]DM*Oѭ e.KUqH)Wq[=ۑagOyOYuğYOOOOOV0%!/3/E/ W-}QK_mϣ(A(I1oo(o:oLo^opo s#m///5/////O(O*?P?????Ga^o__OO_____-?VQ=v.s#{.峑PbLǟٟ!3sHZb=!o"důׯ //gyI[L^$6HZg!lŪ(:ɏ^p9܏ $?OGOYJ#qٿ 1߀C __-_iȉX@R_ba QJ_+Չ/ڜ,5 ,5,0$Zl~r?? 2??h8LHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPUFDfP h$T PUUBmUA@ ?I? 3xO@7IyIfBo?вsUP  /e Z.$ H"N @X(:H?_hz  ww "Square.b?贁N? 4 HDD $# =h-(>TTE=kUA@ ? uQ6 u` ?u B6> 00A0(2s@sJsT>d=$5 h9 L]{ !$5 `7Copyright 1999 Visio Corporation. All 4"s reserved.`? _Sba.chm!#224_17l>0>Udd!!  T '"<hb 261 g,s724  =?M1Y?r?91M1E;6=H=5P2?;rA IBOCq,B^35/\ @F"AC "3AP?LOe?#7A)[8B_T_OxY)___f_.eAE_oo_LHl'-i !OyaGE WszF̀ #< b? Lt De\qW os+_ o%?4 DoVl  ' 4ANUFDfP h$T PUUBmUA@ ?I? 3xO@7IyIfBo?вsUP  /e Z.$ H" S?!{)19AI?dp]qi} Aw:npqA9pwwA9pwpiEquilateral triangle.b?? ߿ $t@ ?<?紁N;3HDB t# ih0>T@dE=M AkUA@??A߻?Q6 L,A >M A JuM` ?[y&y0y:@u` UJS>#JU0O贁NKk?<@MJdO@ܼ@ L LP6 @?FS@U%%F@))@H""oKJ%{X1]45 `7Copyright 1999 Visio Corporation. All 2s reserved.J`0_Sba.chm!#22416Aida?lJ*,>Ud6ZV$(s=?)ǹ<$$b# X"yB:V/ K;EA%;D]2׳뽿HH?!:ͳ?OARM%2pO;JrA RSq(^!(M%9M\Me2AO-QVD}Ho *oFTO`c5WD`18WoiDYebW_`c%@neNooO[jJ(?kF8Hluh !OyaGEWszF9n#- =? 87a 1uVoD+_4:WoB?KoPUl4,Q%@Bc) ? p GA- 3M7"AUl4,Q%@Bc) ? p A-$37"AUl4,Q%@Bc) ? p A-,37"A Ul4,Q%@Bc) ? p 1A-t377"AUl4,Q%@Bc) ? p A-37Ul4,Q%@Bc) ? Lq }A-p 7"AUl4,Q%@Bc) ? dq A-\3"7"AUUl4,Q%@Bc) K? jUC-43~7A_@| OFR| t |L) ;Dm9<^` B(: q ՃGuW$* _\u mLq@4(@4(@4(@4(@4(@4(@4(@4(_@ X R|  e|L) l r;2 ;) m$6) D >q !~)  !mUFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HG 9V?o)>  `r/`wpw> ȳpke{rpgTHYY9 mAUA? @ ?Q6 u` ?Mu ~YYA|XA44 4> !bJfvqQ >!"q06DNX lL>U5 LO@%#A?AE^?AL#l%u%?P6 @*  L#&H   " ' ]{%#W1\!\!5 `7Copyright 1999 Visio Corporation. All 2s reserved.`0_Sba.chm!#22427Bd(,*9 l>(>Ud!E (!(ZU$ B$bW* /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HI ;V?-  _`߅pl`ul`u kw{sg_'Regular octagon, or eight-sided shape.b?贁N? 4 HDB $# ?h-(>TT9 EAUA@ ? Q6 mu` o?u j>Z--200`0A0(2@2T^h0r|>U5 L{/!4$5 `7Copyright 1999 Visio Corporation. All Y"s reserved.`d _Sba.chm!#22421PBd9 l> >Ud]!!(<* Z#A|rvPph.b31,1e g2(:S425$a?a! Ҁ?1E5Y6gq4bH3x81| N5%O7I71x?:?=3A1@IZ ToKAyoPUFDfP h> /T6DUI@A?I BP(?3H$- b]b--rx@l^bf>M,,D'^fO - b, , 'eZYUHu F .LYcuZo^SLRepresents an actor reference.mb߿??PQ࿤p= ף??3㿕HD" # "=h#-$>T #T3 AOAU@?=@?@u߽?P6 )i8VYAEDA@@#u` *'.8BhPZ`u#j Ub >U5 gL{5!5 A`7Copyright 1999 Visio Corporation. All _"s reserved.`j _D88.chm!#2]0 l>0>Udd!!P #w a2U50` 9`fC"`e1De 2#(  O?si?e113???%G1 7@<Oa?9ME)2RO;rABC#(^actorReferenceiVA!aPIE9 3~'2qcPӼ? &bVq(^/\:5!?lOrISsQU__f+OnQ&%^]oeoooxGQ3ULYoopOorHl'ER  [F /+8# 5,r? G]'a ]ODK/ ]>?$  - UFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HC 5Vo?)> pp/quupwj  lpysopi`;Generic circle with text and connection points.b?贁NE?4 HDD # =hZ,>THYY9 mAUA? Q6 u` ?u ~YA|XA44 4> !bJfvq >!E"q06DNX l>U5 L@d($%9%#APE&L#%%%?P6 @RL# L#  7p  #2 ' JB{%#145 `7Copyright 1999 Visio Corporation. All 2s reservedo.`0_Sba.chm!#22426+l>(>Ud#1E (!(Z$ B$bW :? /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ! Hu 7~???0𫏆=@FwnmmhZ[L7Double arrow with 60-degreheads. HDB # ?hZ4>THYY9 dA[UA? u?P6 -u `u b_u  @"! FhWuk` tu.AdV8bM>ڲ@!$U'P"_/q%'i-/ 7$#5 L!# 7 6 BdH*%#/ Hh?Q6 u{%6{`("u?"F&`Qps-8R? WI@ 偌!6Q(-DT! @u@{$#AD5 `7Copyright 1999 Visio Corporation. All Bs reserved.h`@_Sba.chm!#224398B!$Cu tNs!OR U\l>Ud0@ Yi \!(Z$*L/S!4b?GQ b#Ib(3$$*3Ey‚7ʱRrB-db&`_aEojp= ףpՃoOR.ccb>$$?M˰iORD3eoeE9m |g`o'W6$*6a23(o_a|M:hz|%a_aQivQe&sbebQ2lm?l^Rgoyf?oQuo؅A &jdTAha9 G7(حN@fQB?bZބۀ!(! [?2vB@z?JVQ&999Y9Q9SIQ?IgRmb?п贁N8i/6??Hl's !Oya GE_6szF 5w# !W6? 4 ]-a 7Do /P5+YK;h?UFDfP h-RTUUUA@ ?I? 3h d  eqYk QHoP@Rw >2O` Flowchart}}` >?< -> \it `0Represents any microform. ape.bol.H D  %# =hj8>T YY>zAUA@ ? Q.6 ~A+<F ZZ [u`h_?`  $@8V`zSu U" , '>  Ԓ>z!}bzU%r# "rg&"#9&u`uY`"u`J2z@|&Un1s45 `Vis_Smis.chm!#23300`7Copyright 1999 0io Corporation. All 2s reserved.#3U5 /LW1]h7 309:#z3g#h30O贁Nk?<)@9#F"U:%8%Fl>BYUdv\17(gh3z?"#b"%$ jbt"t\8IS@_Z]'%zVV`86!F/R2c'P&0"B/jT  //'ayZ6fJo\c"^UgWoBcQBE3oR_zA(qalEA#oUPmo[`nohu,>qb)bEA_w?f8jR0svPomTPAaG+R%T:"_2) 27(sFn5n1CA"`Cost63,Enter the c] associated withois procgess03B`@_5-CE_3OUDu3*3 jd {ofstep05{šH` Resour0:jnumbmpeople0quirցtosmte^task0dA^9 Ge:v?FFBVL S$sj^g/w$rb#cVjvr)q(^!ˍYAFI&FF>A-:%@]$6 E#._5OS{ύZY!jTcU5ltπqUTBEan1k8n1J:@R` %Propertiz\:30Setoustome selecshape0W[@jRb W1?Q_5߉B&CTA:"7(m9#?EQttRr#FiV߯tD'2qbBϢbؿ?8i6? 4 Hlu9  !OyaEhF&!<#6!K? !e=.a_!!o}DT*!oP+-!C%?(Lv S 4:B!3/? "RD,]}eF 6%/"4 *," /*<N<  5 l ;"$#!C  UPxP4FDTe]@y  ah TP^UIQ%@IBc) ??I?*?Qc^*e@?u` "&"ua)o%AuEH!S!a` Flowchart +`$ !eU/Dg/!G&"!$i! "71;1|;1!(!)a-?@9_ <03?@E61?Q t!! ]tE?1Bt>!q!71?<2R\?n?(^U9a$ Y?U@.jLߤ/$@@?@@zrv '"O4E)1 ?۸׳HKTXl abKTTCrt|KT.H@A<O_!W3_E_WT n__U71aT71^Y];1__owfثImjo˪&5ǯnW__Yo/j ˿$P{%.ϔquWΫϽx3atient Instruction +/or Provider Comm3sr;1 2HD'Q! n?<D1A q@ď֏&X^@WcO`Wc"=͍jFf/H@7/Iґ` &_z <1生 |.# #$'#['Q<<ALnOǘXQfx [Ϭ-=-HY~ț0Hk#WHeѩ"%+r5fxߊ߮UT"ս!);M_\q%b "@|T~ر=Aaa w yϞyaF&,qQ_6t(:O09O3_1:R_d_+_nƣ__|_O_o!(Repeat as Needed)@ //-/?/;r>[+ Tfq||% deIiewx@@1\5w%?@B<0su9K b-? 6wc? +FW? __@Pq1ICDHEv3uGt@(30 …E0̓O6CA OOϟ TqBؒ9d@~qZwBkIO4lu DH8v|| ^B{w'3}Oſ '9oޯz?^A"qϧǿ ۖ$reposi>Y߸ooooQ&[+!.t=Oasy///zq?@Dzpr逖Ճwqzcγ) 3VC {ң] Rw@GO 05ݖG^Da!5{ Dw@IGݐݐkПkO߀a-YXȓtRK\+6js\jG-QC)ТQa*єIs دR ٿ5.(/b/%//L+/ϲ= kVerbM_qσϕϧT1T1,>P߿|@.@@$O?@WH?@XBN抲 +O70 -| - iQO,>Pbtw1T1*H BT1{,A𱋔{1,A,E7s!3>bC@|fE@kUo o?Bze@Vfm&YKkfLCo9?~69Outpatient ExpansJ from MEDICATION ROUTE file (#51.2)g?y????0rq#'_sADKsA8OJO\OnO`j~ #@@qWcOWc"=ٕ╽1n(E6A+> aAVU6qAX6qQ(56aAR6?qA56SqA6gqA67AA32qA2qA e6(q23A2A6Ao_N!WW1\ + a\ 8qԌ\ RaQ̣!\ q rpA_97AUNO`O lH[U@?@1?@-?@98-פq ?]tEuMoz:ur}]tu3JQE]J0V`|i\ B="/ Y&w"#2i"T!b۵`5l3fUgUVR0?@K9Beٯe??T!&I}!cWr_p,a#U?2d \VV' Istu~W~umRu FZᏉ >%dm@ yeb(Schedule ExpansionKOOOO5CE|ɥ1ש@1U1%$hWЊ{Ho?@DhkPXcOJ6QGl w&ဥ///)ґ/ NA'o ݟ>*8?PniܵvqI34:^inoL*lUKU1zy1OUUyRDǠ@TW'n8ߨ]߆zwߥץ'JW'ߌ@DeIA++8OOasU3'ү,>P,jL@dvп+m)'>Sewωϛϭwa߅2٘јi[* ; z2#UF5Sո^BTEUEa]n[][6U[Q)o;f_Qwo`EScQ_HS>oVekQPoZ2E;BDurationNV%OOrqvU:UUUl4,Q%@Bc) K? ^U1C-t37AU2@ _7LRH<( U2E< k_7 RUlL ,E ^@?4 L_RD x;U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)$L)T *o.)P)- !!4!4!d!d!o)o!!!A !!$1$18D#Q - H*)=?2=TEQ?OQOcLGuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowSquareTriangleEllipseOctagonWhite fillvisAecIsTech?nicalWallBuildingActor referenceSquare.8CircleEllipse.11Octagon.12Actor reference.13Triangle.6ROOM BindingROOM Line StyleNet Thin lineNet NormalTriangle.18Circle.2260 degree doubleYellow fillMarketing Normal 3Flow NormalMicroformCostDurationResourcesAntiScale_3$P!Ma ElW D_!b- lR;mG;U ;U;c ;խc ;c `W!c 4c U|c c լc Ĺbd ܹ" a!/$I<@${}#{1I5{k{jk{kh@{Mjl@#{q qjkq{MJjqkq{qcm4 #{$ 1ѥkIϛk1qcn$`#{${1kIϛk}{o`e*p`%Tq`%tE %E%w&%<3%Ul32(%>E?r0%>0x!N%p'Uհ]ٺTհl%U4հIհ%հ%հ%հ%հ%Dհ%հ%y!ٻT%4ȑLU%\%Utٺ fT: ڼ 3z L} ST| la#e۪O' ԛ+ ڄO/ ,33 I~T0 -G Цx  $Y <] |a ڔe i* ڬmې@ UUDooIo ǜo \oeoT=ooeo д7T f,#D#S gv10L!f`xp!m 񔱨v !"P#TP%P&P'PU(P)P*P+1P-P.P/P0P1P2PP5P6P7P8P9JP:P;P=PU>P?P@PAPBPCOFHPIPJPKT!PMPNPOPUPPQPRPS{PUPVPWPX*PYPZP[APU]P^P_P`P `j% KhPiPjPkPmPnPoPpPqJPrPsPuPUvPwPxPyPzP{P}P~PPPPRPPPPUPPPPPPPPPPPT5PPPPUPPPQPPPP*PPPPUPPPPPPYPPPPPJPP1PPUPPPPP'PPPPPPRPQPPPUPPPP˽qPPPϪPPPPTPPPPaUU U UUU!U34UUl4,!Q%@Bc) K? _(QoC-_| 7A$Ul4,   pA-37"A_*<N@ o IRVg, p7uH<( H<( _*<NE|"p RVg q "{zN  g"4FX(Œ @(S۪` y @ v :]R>,q  ՄԾ q}&u !B\!;>GOF_8ODz DD$~ k#E'$_N ) 1 uP`2_!g0V< Go F? ! SpGl 5 B=55 C"!5 Oh+'0,HPht vhaisbcostekG<,xli EMF4, X XVISIODrawingd  p  &% % V0`___% (   % RL Arial^^^^,M,M^^M,,,,r,HHMHMMMc,MMm,BBBc     H c,,,,,,y,,,,cccccccHccccc,c,, . : ;T% Tx(5AA(L\Patiente  T5BAA5 LdInstructionL  TBOAAB Lh+/or ProviderY  T|O\AAOL\Comments    &% % VF\7.% (4=%C.E7CA=I4Q(VZ [ZVQIA7% (  % RL Arial% T<6NAA< LdPreposition      &% % V@S` ;(H_;_RHR(;% (  % RL Arial% Td=<OAA=LTVerb     &% % V0\_]^^]]^% ( RL Arial% (  % % T(7AA( L`Outpatient   T8GAA8 L`Expansion  TfHWAAfHLlfrom MEDICATIONT       TgXgAAgXLpROUTE file (#51.2)    &% % V,`ZYaYY% (   &% % V,hfeiee% ( RL Arial#% XXM `'(V 8Sh(ArialArial% ( RL Arialc60e~Ƅ ,,M.c!.S u~Qi-Ƅ4 d22dN2PostScriptHelveticaHelvetica-Bold'..J<% (  % RL ArialJ3333 .3.A..*  0.*SS7S**.SS.N7.....=.00=!03..EEE3<<<<<<S7777<<AAAAA0A<<<<773......J3% Tl=LAA=LXLocal,  T|M\AAML\Possible   Tp]lAA]LXDosage    &% % VxVl?2' "/;FN'S2U?SKNWF`;g/k"kg `WK?% (  % RL ArialewlwowswexoxAyKyLyTyWyaybydyeyhylymynyoypyry ,.Ltf ,.LtfSSƄƄƄ'ƄƄƄM% T| ;FJAA ;L\Schedule   TKHZAAK L`ExpansionM  RL Arial,,,,,y,,,,,cccccccHccc,c,#% XXM `'(% TTYHklAAYHLP+  % TTHlAAHLP+I % (  % TTIB[fAAIBLP+  RL ArialdN2PostScriptHelveticaHelvetica-Bold'..J< 0..........0003Q<<<<73A<.<3E<A7A<73<7N7730.3.3.33.J3333 .3.A..*  0% TTBfAABLP+J  RL ArialTLTOTRTAUBUQURU VAVDVLVOV WAWDWLWOWRWOX YAYDYLYOYRYFaPaTaVaWaYavayarcddrddKePeTeVeWeYefge xeyeze agggrgchckblcllKoPoToVr% TTW>ibAAW>LP+r   &% % VHmZ n5))5YBBYn5% ( % ( % (  % % T|9HAA9L\Duration   RL ArialrgchckblcllKoPoToVoWoYoforovowoyorqTrrrssrtAuJuKuTuVuWuYubumunuAvavbvdvevnvovrv vAwTwwdwewlwowswexoxAyKyLyTyWyaybycyy % TT@dAA@LP+ RL Arial,M,,yMMHM,,,,,,,,MMHHHcc ,cA  ccMMH,M,c,c,Mcc,ycccc,M, ,,H^^^,,,MM^^^^% (  RL Arial    H c,,,,,,y,,,,,cccccccHccccc,c,% TH1@AAH1 L`(Repeat as   TxPAPAAPAL\Needed)  % (  RL Arial~Qi-4 d22dN2PostScriptHelveticaHelvetica-Bold         % TT?cAA?LP+   &% % VhDZS#.9CCS9O.M#OSXYXS% ( % (  % RL ArialO.P.Q.T.U.V.W.Y.e.f.r.v.w.T:V:W:Y:T;V;W;Y;BADAFAJAOAPATAUAVAWAYAACAGVGAOKOROTOVOWOYOAQ TTLTOTRTAUBUQURU VAVDVLVOVRV WAWY% T9=HAA9 LdConjunctiong    PagesMasters Page-1Square TriangleEllipseOctagonActor referenceCircle60 degree double Microform8_VPID_PREVIEWS_VPID_ALTERNATENAMESi_PID_LINKBASE A #                         ! j i % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T V W X Y Z [ \ ] ^ _ ` a b c d e f g h m n o p q r s t u v w x y z { | } ~  _1053423354xF˪U˪UOle PRINTuw ?CompObjq#j   &" WMFC J /xb#j EMF/ X VISIODrawing  5  % RL8 ArialHP LaserJet 5SiwqXX@MS% TTUU@UU@LP+u  RL8 Arial% TTx  UU@UU@x LP+u  RL8 Arial@% TTUU@UU@LP+u  RL8 Arial0% TTf)UU@UU@f)LP+u  RL8 Arial`p% TT):UU@UU@)LP+u   &% % V4(n #5Aa A#% (  % RLj Arial (*#~'#~S\% Td !UU@UU@ !LTNounl\\\ % (  RL8 Arial(+#~/#~C:GRAM FILES\NETWORK ASSOCIATES\VIRUSSCAN\VSHWIN32.EXE% TTzUU@UU@LP+SSu   &% % V0Pa]n]n]% ( % ( % ( RL ArialC:\PROGRAM FILES\NETWORK ASSOCIATES\VIRUSSCAN\CANX.EXE~% ( RL Arial(G#~#~C:\W% (  % RL Arial(#~#~39C:\WINDOWS\SYSTEM\SPOOL3EXE% TxL>UU@UU@L\PatientC8!8=!  TSUU@UU@S LdInstructions=8!'=8!==8  TdI.UU@UU@ILT+/or:='  T|CpUU@UU@CL\ProviderC'=8=8'  T|UU@UU@L\CommentsH=YY8=!8   &% % V,]P#P% ( % ( RL Arialh˃V% (  % RL Arial% T|XUU@UU@XL\DispenseT!AGAGAA  TabUU@UU@a L`Units/DoseTG!'A!TGAA   &% % VH agK    j& O8 4M f   7 b } v q nH nw q v } * S z )4:OHjRXZXRH:0)Kd }   z S *    w H     b 7      f }M d8 K& 0    % (  % RLj Arial  &%% V,##% (   % R Arial% T  UU@UU@  LdPrepositiond:S\\S*2*\\   &% % V@a nn#4#KK4n% ( RLj ArialTsj@j@ `Units/DoseTG!'A!TGAA  4 "--% &WMFC/(  % RLj Arial-2 XDispenseT!AGAGAA2  Units/DoseTG!'A!TGAA--'&' 2 sH 2-"2 A L aDRUG file (#50)<7 % Td$UU@UU@LTVerbdS:\   &% % V08@E33EE% ( % ( % ( RL Arial- "-s-- !H- "-HLHH-- !8L- "-% ( RL Arial   -- !- "--- !o- "-oo-- % ( RL Arial- "- --2 U/oaTABLETSCHCCCB8 2 Uoa 1aH&Ln.  % (  % RL Arial EMF0XVISIODrawingd  t5  &% % V4^##A% T!sUU@UU@! L`OutpatientA33..3  TUU@UU@LhExpansion form7.3.3.333 J  T;UU@UU@ L`MEDICATIONE7<<<3A<  TMUU@UU@M LdROUTES file<A<377.  Tx9?UU@UU@9L\(#51.2)....   &% % Vf=zY 8/E_z{ uDsgu{ (BXl|8Yz&|GlfXB( g D   z_E/f G&% ( % ( % (  % RL Arial\ \ ` -- !\ - "-\ \ \ ` -'- "% T|d!UU@UU@dL\ScheduleC8=8==8  TF@}UU@UU@F L`ExpansionC8=8=8==   4.- Arial- 2 +u Arial- 2 x +u Arial?- 2 +u Arial??- 2 )f+u Arial???- 2 )+u--$#5Aa A#-- Arial??- 2 ! Nounl\\\"Systemj>2``'-  ArialI?????????- 2 +u- -$]n]n]- - - d Arial???????????????????????-d Arial--d Arial-2 PatientC8!8=!2 S Instructions=8!'=8!==8 2 I+/or:='2 CProviderC'=8=8'2 CommentsH=YY8=!8-- $P#P-- u Arial--u Arial-2 XDispenseT!AGAGAA2 a Units/DoseTG!'A!TGAA--$K    j& O8 4M f   7 b } v q nH nw q v } * S z )4:OHjRXZXRH:0)Kd }   z S *    w H     b 7      f }M d8 K& 0    -- Arial  &%-2  Prepositiond:S\\S*2*\\- -$ nn#4#KK4n-  ArialT????????? - - Ariali??????T!AGAGAAA- 2 VerbdS:\- -$E33EE- - - S Ariali ??"i?????-S Arial????????iji -S Ariali ??"i?????--S Arial??????X-2 ! OutpatientA33..32 Expansion form7.3.3.333 J2  MEDICATIONE7<<<3A<2 M ROUTES file<A<377.2 9(#51.2)....--~$=zY 8/E_z{ uDsgu{ (BXl|8Yz&|GlfXB( g D   z_E/f G&--  - -d Arial????????iji -2 dScheduleC8=8==82 F ExpansionC8=8=8== FMicrosoft Visio DrawingVISIO 6.0 ShapesVisio.Drawing.69q՜.+,D՜.+,d @HP\h t   PagesMastersPageObjInfovzVisioDocument$ 2`VisioInformation"y{SummaryInformation(|U &Visio (TM) Drawing 2`H^Rl !fffMMM333$ $ UO8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1U#J:DT1EW-hTT<* /Ub bO0zGz?@8@H2!kWb*U  +$PL/^&9^$? { Ak^&,,'%/v&& * 1y   )P? 2   U U12?k9aBBHEHEHEHEHEHEH@?>?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*gL9QOF$B_XKPcu jU8g'P!//*[mvǏُH}E0 TҙS-?Qcuχϙϫ);M_q߃ߕߧ߹߂ 2DVhzێb֯ *<N`rӘa#5GYk} 1CUgyՖ*!//(/:/L/^/p////////??$?6?H?Z?l?~?Ֆa?????? O@O-O?OQOcOuOUbbO1a6feOOOO__&_8_J_\_ҙ~________o o2oDoVoU oooooo,>Әia_q%7hcJxoj|ď֏ ASewџnasͯ߯0BTfxҿefB5GYk}ϡϳ-&8J\n߀ߒ߶I Y,1CUgy(:L^p'K$6HZl~9 -@?QcuBCh9!nkV3" bz@`nc/&`&/8/J/\/n%ib{/MvQ3/////??%?7?I?[?m?=G`P!=KBTfx,V/Pbt(:/^pj?@|?1!$6^DlMOumц >mKUrq!Wbqy[ja@OROfYNxYOOOOO/0% //0-VxQ$__FX|uAI!__oo%o7oIoL#F/a/j/5/////?O??'?9?K?)?????7:7H_Z_dOvO_____*=OL`{ޓՌ);f%tj|ğ֟蟜 !3b!HZ"d¯ԯ@RdҚ"4%7jǿٿ!3@!EŃx7I[m﵏Ǐ?? O2FLHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPUFDfP h$T PUUBmUA@ ?I? 3xO@7IyIfBo?вsUP  /e Z.$ H"N @X(:H?_hz  ww "Square.b?贁N? 4 HDD $# =h-(>TTE=kUA@ ? uQ6 u` ?u B6> 00A0(2s@sJsT>d=$5 h9 L]{ !$5 `7Copyright 1999 Visio Corporation. All 4"s reserved.`? _Sba.chm!#224_17l>0>Udd!!  T '"<hb 261 g,s724  =?M1Y?r?91M1E;6=H=5P2?;rA IBOCq,B^35/\ @F"AC "3AP?LOe?#7A)[8B_T_OxY)___f_.eAE_oo_LHlu-i !OyaGE WszF4#$KbB |6W@ekU>os+k?o%akdoV_  '*4 AUFDfP h$T PUUBmUA@ ?I? 3xO@7IyIfBo?вsUP  /e Z.$ H" S?!{)19AI?dp]qi} Aw:npqA9pwwA9pwpiEquilateral triangle.b?? ߿ $t@ ?<?紁N;3HDB t# ih0>T@dE=M AkUA@??A߻?Q6 L,A >M A JuM` ?[y&y0y:@u` UJS>#JU0O贁NKk?<@MJdO@ܼ@ L LP6 @?FS@U%%F@))@H""oKJ%{X1]45 `7Copyright 1999 Visio Corporation. All 2s reserved.J`0_Sba.chm!#22416Aida?lJ*,>Ud6ZV$(s=?)ǹ<$$b# X"yB:V/ K;EA%;D]2׳뽿HH?!:ͳ?OARM%2pO;JrA RSq(^!(M%9M\Me2AO-QVD}Ho *oFTO`c5WD`18WoiDYebW_`c%@neNooO[jJ(?kF8Hl-h !OyaGEWszF#SB _Makulo@+_moBa4oPUl4, eK U%@`/b? [}A-a7"AUl4, eK U%@`/b? tA-l37"AUl4, eK U%@`/b? AJ-$37"AUl4, eK U%@`/b? DA-3J7"A Ul4, eK U%@`/b? A-37"AUl4, eK U%@`/b? TA-d37Ul4, eK U%@`/b? |.A-t347"A_vV@,cGRT F D?<QL_>mq_B(: 6UFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HC 5Vۀ {?"o./? ?pdofk| w{P}|shlwwwxnVpo]Pp'Regular pentagon, or five-sided shape.b返??lDK\wX}W鿰6??,̪]ơ%HDB $# ?h-(>TT9  AUA@A%??AmDK\w?Q6 u` ?u` i%kL>+000A0U(2}@}J}T}^>d@ @+B{!#$5 `7Copyright 1999 Visio Corporation. All H"s reserved.`S _Sba.chm!#22418lQ4>Ud}!!!Z hb93& 2g}U2<"£A f"0&8Ď@Y?@3 i3k1E: 4k (и?%99f5i8<*2|5fuN?2Se?2Z@ 4LW7%93:eiH?$2 ?5rA BCq!0^d!E/*\D 끁s,x#?eA`F+"A~%9\~DG;?oQo?uo|]x?_o??jZ&eNo+?=;Hl'-}i !OyaGE!szF#oB ,ZO0d\kyoa@+dkoVs̾k# UFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HG 9V?o)>  `r/`wpw> ȳpke{rpgTHYY9 mAUA? @ ?Q6 u` ?Mu ~YYA|XA44 4> !bJfvqQ >!"q06DNX lL>U5 LO@%#A?AE^?AL#l%u%?P6 @*  L#&H   " ' ]{%#W1\!\!5 `7Copyright 1999 Visio Corporation. All 2s reserved.`0_Sba.chm!#22427Bd(,*9 l>(>Ud!E (!(ZU$ B$bW* /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HI ;V?-  _`߅pl`ul`u kw{sg_'Regular octagon, or eight-sided shape.b?贁N? 4 HDB $# ?h-(>TT9 EAUA@ ? Q6 mu` o?u j>Z--200`0A0(2@2T^h0r|>U5 L{/!4$5 `7Copyright 1999 Visio Corporation. All Y"s reserved.`d _Sba.chm!#22421PBd9 l> >Ud]!!(<* Z#A|rvPph.b31,1e g2(:S425$a?a! Ҁ?1E5Y6gq4bH3x81| N5%O7I71x?:?=3A1@IZ* dUFDfP h> /T6DUI@A?I BP(?3H$- b]b--rx@l^bf>M,,D'^fO - b, , 'eZYUHu F .LYcuZo^SLRepresents an actor reference.mb߿??PQ࿤p= ף??3㿕HD" # "=h#-$>T #T3 AOAU@?=@?@u߽?P6 )i8VYAEDA@@#u` *'.8BhPZ`u#j Ub >U5 gL{5!5 A`7Copyright 1999 Visio Corporation. All _"s reserved.`j _D88.chm!#2]0 l>0>Udd!!P #w a2U50` 9`fC"`e1De 2#(  O?si?e113???%G1 7@<Oa?9ME)2RO;rABC#(^actorReferenceiVA!aPIE9 3~'2qcPӼ? &bVq(^/\:5!?lOrISsQU__f+OnQ&%^]oeoooxGQ3ULYoopOorHlER  [F /8#0rB  1'ak1oO@+ 2Ro>atpo UFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HC 5Vo?)> pp/quupwj  lpysopi`;Generic circle with text and connection points.b?贁NE?4 HDD # =hZ,>THYY9 mAUA? Q6 u` ?u ~YA|XA44 4> !bJfvq >!E"q06DNX l>U5 L@d($%9%#APE&L#%%%?P6 @RL# L#  7p  #2 ' JB{%#145 `7Copyright 1999 Visio Corporation. All 2s reservedo.`0_Sba.chm!#22426+l>(>Ud#1E (!(Z$ B$bW :?+AEI6 [5 ^R5SD%NX[H!j_Zq$!,Q!UOA$Wa8_QPEk.XVo.meWo`o/l5FnR6o/lD%nooA(4atient Instructions+/orProvider Co;mmepsiD5/G/4 'W2Ur1!a, "//q__q !a#?U@_{eE?@`?@b7?@PC<Ѐʃ?@a„l?~:EF-(? PC? CPߝo? *rEd܆ Žڈ{!2qА?ϟPC?A|C5%O1u?OC=OT \OnOaFqS{Dispense Units/Dose@rUPHtts)<~8ㅰVAEiBt_IOOcDÓ-2/]]܆Ӆ9_a&5df]ϯR'qpqyI_v(.ok%Q 1qok-+Jx\tߴo2} j$ŕd#*!3HAfmGw?p!` AkPI &! !/$E#5///??(<ί=" @@`wa0ʏ܆\#8_eG i%?I[O%mk !ERsBIGݿ←:]S@?GC>$^J/]f]'+&/]]G!?4Y8ưUGoOOMU@_ߔ5^LG%o>m/Lk$?kg?okp?-U߾?EzѧNoun(Luz%*<ϩ\wrY@4?@?@!`nSuUذOYTFQ #" R;uhgdpUhkP7:?@BPeYe?K]jLM 4A W_7I#h6U8"n\ \ g3?tՕuv~Wҥ5'e5&/ux?/lZ/Ϗ@?yK?5{U O&$HPrepositio3OEOWOiO{OOD/O,OOOvᗑR)N) L^#x8r%\S7L; >tL姂ָ-ƸWۧ 17%R)ϙf%ߖQ۠xu#x`fxi?ڬP *<yՓ)u# !KVerb۟@#5SU r__):mS@@г]$0c0劦0c08#tj@ Q?Z j;t }uk&Mbmbۨ̿޿jЇG27q70?6?H6c3? e0%AX$T:%`6y1vQt :QW%~/&~/.8KeAO?{fEG @FY_zc5&W_8_D#__BO_ C›Outpatient Expansؐ form MEDICATION ROUTES file (#51.2)Ưد,U!Kr@2?boo w,q!jjN;;d' f!3rym$uw?`jP!kp~ X X%/1K;\Y! _iѬ,> X )+P eK U@@`/0?@k(%@D5 1%gQ+(QuJi0c3Mcu!nKK!ǖۖ1a%F&S('QAUǖBۖۖ +?U?SSgUg{{MeلL4_e dpozU*ij5*ĕ!5E*ۑ5*5e*ĝa55*5*܁5*+Q5*5&Ȑ5&ȳ5Ǭe*ĮA5ÕɺX_7ƫ܁1л+QFaȄ@ьѐʄ@˄@ѮAEK OhbA1o&ҮA5O_F'U /U@,!@@\~, ㍦ί=sS[Im%圶?QS/e)eGx/ RۮU/ *./ ̂//@XEV @Px?@# 'P+$E/ ?3}?TASA`4?NA52_+UO)O l XSq S M_{ ECGR,P RE1_8Oj_/_ooR/_3// -8+&/4oBۑOhSchedu`fff܏o^tU26s165&vn1In1}5n1ԅoȯooTPe_E?@1qqMPޓB?@0rq̪EESabtF#ǟy: l#PT CECn [[AaR*rMA7ð@D| "72xay1 U 1*gBHICap(TeFeoGEovnEoo!wa}5Tn wo/aTooqn \+e2r????;;??OO'O9OKO]OoOEЯ=䲢@@EȜN9OOOO% __XA6D_ X\pT________o"o4oFoo9'oK^hAS +=OavЏzLrYQ@@87I[mǟ q II^VkY0BTfxүBTf,P!O(υϔϦ T);M_q߃ߕߧ}I"f. /ASe z9/ OO^VkYA6(:L^p/S]O$6O~OYO#_Pbtn8~} .@Rdv.@k*`rן̟)_x\nȯڬU"UUl4, eK U%@`/bK? MC-7AU2@4M;RH<( U2E/N7 RUlL\,:*ߎM@?%NRD+<;U$ 4(%U1( O-D&U=%Q b -h"/T)T)+Uv|'g&PP)$L^)T g*of) )-A$!$!!!/!8 &Q- H*)=B?H2V=EQ??LGuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowSquareTrianglePentagonEllipseOctagonWhite fillvisAecIsTech?nicalWallBuildingActor referenceCircleROOM BindingROOM Line StyleNet Thin lineNet NormalPentagon.3Square.1Triangle.2Ellipse.4Octagon.5Actor refere?nce.7Circle.20_3O E P - -GW7- ,_UD-D_Rc U\__c t_lc U_yc _c U_c _c _c Uc c 4Uc Lc dUc |c Qd Ī"/<!FW0U,bA1fLs*Twl TcI***XԪ******* 0*0*0*$0*,0+0*<0R)D00 T00:(0:t0 :|0$:0(:0,:00:04:08:0<:0@:0D:Ī0H:0L:Ԫ0P:0T:0X:0\:0`:0d:h: 'Pl:'Pp:'Pt:$'Px:,'P|:4'P:<'PT;'P:L'P:UT'P:\'P:Ud'P:l'P;'P;'P;'P$ K'PK'P/K'PIAK'PSK'PeK'PwK'PĉK'P$K'P̭K'PпK'PIK'PK'PK'P['P[+[gp=[gp$O[gpa[gps[gp[gpS:gpzDgpzLgp zTgpz\gpzdgpzlgpztgp z|gp$zgp(zgp,zgp0zgp4zgp8zgpU?@wBCFUH*IJKEMN-0qرaUVWXGYGZG[G]G^G_G`GaGbRGcWGeGfGUgGhGiGjGkA!GmGnGoGpGqGrGsTGuGvGwGUxGyGzG{iG}G~GG*GGGAGUGGGGGGe!GGGGGJGG{GGUGGGGग़GGGGGGGRGw!GGGUGGGG੫GGG௪GGGGT/GGGGUGGGGGGGG*GGGGUGGGGGGeE UzU U UUU!U34Ul4, eK U%@`/bK? ]bC-b7A$Ul4, ]A-37"A_*<N@h] MRVglq7uH<( H<( _*<NE,B^ RVgOq E{z * g"4pFX(h@(7&1@2y JlO:]R TQU#q&T!B}DU;>WCO\7B8O̶$O*'U>[NSN|)Dg 1CǷ8/`2,UV<_\K O? ! FDy\^C=gQG J! G @Oh+'0@H`lx vhaisbcostekG%x#j EMF%X XVISIODrawing    % RL Arial% TTJnAAJLP+  % TTMqAAMLP+  RL Arial% TTSVezAASVLP+  RL Arial% TTY}AAYLP+  RL Arial% TT{Y}AA{YLP+   &% % V4?4~g~4?% (  % RL Arial% Td X]tAA XLTNoun  RL Arial% TT{JnAA{JLP+   &% % V0zxxx% ( % ( % ( RL Arial,,,,Mr,HHMHMMMc,MMm,Bc     H c,,,,,,y,,,,,cccccccHcccccc,, . : ; D,F,J,O,P,Q,T,U,,% ( RL Arialw.y.T:V:W:Y:T;V;W;Y;BADAFAOAPATAUAVAWAYAACAGVGAOKOROTOVOWOYOAQ TATLTOTRTAUBUQURU VAVDVLVVRV WAWDWLWOWRWOX YAYDYLYOYRYFad% (  % RL ArialWoYofokorovowoyorqTrrrstAuJuKuTuVuWuYubumunuAvavbvdvevnvovrv vAwTwawdwewlwowswexoxAyKyyTyWyaybycydyeyhylymynyoypyry % Tx#5AA#L\Patient    T7IAA7 LdInstructions     TdJ\AAJLT+/or    T|]oAA]L\Provider     T|pAApL\Comments      &% % V,q~s~~% ( % ( % (  % RL ArialIOgC?MSTTe4~v ,,]8w!8d u~Qi-v4 d22dN2P% T|`uAA`L\Dispense   TxAAx L`Units/Dose      &% % VMH=2( . :(D2I=KHISD^:h.pw{~~{wph^SH% ( % (  % RL ArialDAFAJAOAPATAUAVAWAYAACAGVOKOROTOVOWOYOAQ TATLTOTRTAUBUQURU VAVDVLVOVRV WAWDWLWOWRWOX YAYYLYOYRYFaPaTaVaWaYavayarcddrdde% TO5kAAO LdPrepositiont     &% % V@v T&2^&~T~t^t2T% ( RL Arial,M,,yMMHM,,,,,,,,,,MMHHHcc ,cA ccMMH,M,c,c,Mcc,yccc% (  % RL Arial88888!!:::=bHHHHC=NH8H=SCNHC=HC^CC=!!:8!8=8=8!==8Y===='8!=8N882'':###82d88!dC!d###22#8d!d8!^##C!88888!J%8::JH% Td"OVkAA"OLTVerb    &% % V0o(tqrr*q*qr% ( % (  % RL ArialWAYAACAGVGAOKOROTOVOWOYOATATLTOTRTAUBUQURU VAVDVLVOVRV WAWDWLWOWRWOX YAYDYLYOYRYFaPaTaVaaYavayarcddrddKePeTeVeWeYefege l% TI[AAI L`Outpatient     T\nAA\ L`Expansion     &% % VvH :-""/>LYd"m-r:tHrVmcdnYvL{>}/{"vnc VH% ( % ( RL ArialH^^^,,,MM^^^^^M,M^^M,,,,,Mr,HHMHMMMc,MMm,BBBc      c,,,,,,y,,,,,ccccccc% (  % % T|CaUAACL\Schedule    TVfhAAV L`Expansion   DocumentSummaryInformation8 _1044258911F˪U˪UOle CompObj~q-1Square Triangle PentagonEllipseOctagonActor referenceCircle8_VPID_PREVIEWS_VPID_ALTERNATENAMES_PID_LINKBASE A  FMicrosoft Visio DrawingVISIO 6.0 ShapesVisio.Drawing.69q    aGˑ!v=ʕ`ggq(ogM_ V.#=Q,ILlon}(Vssiʗأ\"Zk7Ky۫U_b^=#ݞgk^$nR4P_?ڨ4vV 3:Ct2YD'{u7SvveVz'R̉r\LjO}W\ Dd }|0  # A2,>_;a7]`!Y,>_;*x 'xTMkA}=QhXeADE=`X7 $YP9dvb{&xAxɃxW UUWWUWWWB?y@ I1.-4W_41@w3 6Z|N6#Vݏ09I}?sO(6"!:Y%q!RGLy{ f`=|y\)+p8?gx{dYK。γ&1}dYK;[a7h7Vq>/>\u~m[ZKGD })ͮLL}|ʁZ' ='v5*^K!?V=&&_d:a.<\/6J1ǭ\"|U}JbY-*_<pOz?%k$oOn5j_>5He 4LAs֋/)ߎ!{kd#(IMs\ \F7FI/$iCm$$If!vh5 5i55" 5 #v #vi#v#v" #v :V lX0%6,5 5i55" 5 / 4Dd  0  # A2e'Ue`N3l]/a`!Ue'Ue`N3l4c#xTjSAf?1V۴$T.ԢKc`lZpa\iЛb]SW>>ƝOPJW;3sӛ 89ϙ3W`501$ȣ%%"(\ubR#)^I|weYG$UvJ e 븇U*v3haZ:>uF`61M~כs.b\I$I%S7*'vзG#:f;m~7%k<8_-7f䢌rU Iv]erw_18p3{T04[QC?yRKz{gk-VW<=*g|lDd 0  # A2QMgJu^BEV5-4d`!%MgJu^BEV5HxUMHTQFMh1V-bhrRd2EH:a3MDUJRBM"qt* rJ@qծ;wι~rs}E?O*GgK. oL ,9 |(˂IgwmN{] 26&\H4p|}#(b2OYރ1"z^4qʲk92#S6=8.G\U^UJ]K,R8ٙCVMjxĨAUI%iwҀiC )YLKEqeRo^Jz(kj^ԴȰx$)AiN!qʔYR 2^Ƞz)M hĔ`D0$PŠ5VJǔ_9Y5.^m_Wvxẹ<N{pW}"OkL +fl=[ߑٯ7!bB._[<ߙyװ߹шvt#Nya}wjz"MCdoMtw~}ƾuy3k;FrZc}9K&G^>~'JbMv m?SlgӪ/o%͊ɉ29:`3l2x !fR5wG:={g;kRbDUځp?%w㼌vX'̯4$$If!vh5 5i55" 5 #v #vi#v#v" #v :V lo0%6,5 5i55" 5 / 4SDd 8DX0  # A2x1tNph`!x1tNpl'dqxڵUMOA~gŊj5Q7=pBmb 1x(!KXp0?acxxhLshԸ>][0yvy?D"JKIhߩy*bz)=gLQvf71B#^ CO/M!WhJYr?>cV.$iEK b胴baZ?Z?wڛŭFxX9^pg9lDԺk`ZV5;kX[OmkӺ^r1f8㉳6 0oB[8y õs--`Xus mGKEshP)9+}R">, K&z~ȃz /ɧ8BWdIsXo_&$_^yQ"ߩ}{?3/B:\ƣ9{AN RVc6w篨ړe'qK6ƍ?Dd SV6  3 A?2#AEZAvUt>Kl`!#AEZAvUt>~xUkA~3hFSQVP"XBDKJmKhBY5 l$,xRDśGśxXGYm ̛7o_9_>$ ,r8,"A_L Djm`gI[##z1H4r8lsrVsFG( c?K \yT[R0-؆]sQ m<| 5,'C4ddΨXYՇK/-jͫC#gYI;#8+N\ 1y=wk@ y*>æx=eK<\܇{§ &-ӂbPaeC{{neݸr6׀wW{ׅ+qh2?#]`؄4n,<^A~*;OݛDO?9k9ٳ^`TORf y`-h/2kο#7 ~|-?H>0,Y~\ n?Z*TgӞ[io*NY:nǽswTnN gV>2CxNanP6Z7}oywfl53yGyXq7ti&P/yR*xY-IWYު9y[Y9*#M$$If!vh5 5i55" 5 #v #vi#v#v" #v :V l0%6,5 5i55" 5 / 4Dd G0  # A2'Mn֊Ymp`!e'Mn֊Yr43xuTkA<%*a "C"3gP41! ɒaP+[`aND]  +,6y_ "psPƒ1?wQD~Qn ȍʅ9֘#YeJ~i(3gSRU<@ko1+{p,0RXok 8q2>w2q3lٚ(*w$11+{n7D7Ax. L{KXb!S[ic&R[U㑘&1w壨ْeQdZVQOmU|#} H]f"6 'loGl.F853B?~>g aѼPSYcaR'r1q5=&yx#< &qq\fZCTA-3E0.W>u8b:V} }E7qT1RcG(Ii&-tDוJZ5WQ/q;MQ!;lRYβRM0F8vI9Ϩ| յ<+PطWx3km^\ VڼaM-3E6ijLܬ͖l){$%joO9i,CA- $o`+c+լK\ym<.PΫNNt i{ یcf$K11<1-73/x~ߣ_]|LK.~lo;3%Ҟώ߲Wٵvk~03RPaA>tLBғ:|6G~/`'CĠ܃_gm iM\|[[.*_2"{wRJ)Wnp$g zVS~yO+4(.Av_k 2KVa7*V 7z/o6 t'zu5[i7(~oK })Knu5'\*J$$If!vh5 5i55" 5 #v #vi#v#v" #v :V lx0%6,5 5i55" 5 / 4Dd 0  # A2E놧"C{:Zsiy`!E놧"C{:ZsidWxTMHTQι4 @*1RlEbY Ag@DnBQ@PH+Dh&q'ƖQ}7:=swwιˀ5c}+/av4Ĺ }5n(!n8W׀B )V=t-)":u?Bsr܎OhG?z0$,XO`J08ov$ҬY{26eiĐTSP#1VZqna +0]JiCcDj(QlsgV"HS7 EA#m0cX5182sT-:,#۰l NCԓ/ѿ)vOZmK5dzdtt3i3qefIuE7t]&ƈ\۲#V+㺋]C΢A$JTa|lvKgR||N,K;yˬԏ??>>J>[dd:gX&7~{F\ֈ|`Rl!{) X[ZTv)ZK`uoL|sΜ99s*޶R@u9ޛɢQAr`3*eGt;QӺ:zXOL,Qσ,}pi,)OvQ&V64rgVB˒suzg X&,qH'C-c/9138&q0;oSimple possible dosage graphic"` 2 pBI3T  `! pBI3T<3e xmlTUe^it4Mږh..v 㶝f4-,% "č7DwȦDMjƮ=Y&ƾy{{l)C^Z۴vy5aU@߽,xɁc*|KbϿإvr֚ 㘐3$a;7*h@| vB:aona8=V yG!_ y3G0]C Yu4VA L TCbϸ\,U8B~+<?RīY@ñ5 #܏tH tH:t:]޲)C ::Nۦ=NpM .$N,4'/M_"b}65-C8۝ k7UG'cM]Q1=cСKCtt(dÙ':t:rU5t4iӡI-(byLDjҡyFӦCNg=&Pݮ"A:Z] VnAiWl(Tw-6lMd$N럅KttS]L0]>0^Lzd6Dg(@97p$v謃Y'f |njNԪQ%^ ci wt<ߑwd ~ܐ7BGa =M$3Dwn2=&],яi)}G3:6hӺ~B?LΚn~QKqlD(R+/Qˉ2Bo7~4# ?,6X|D0-6PZ]2^8Uw bŷ+ *#waԍ?7O!|Xm(?pY)Ʊw|ZQwaɤ\OE<qO!wӽ_å9bKXI-Udϛ8~E9#v+lp4QD΢gX5 Jt1eĚL0L%g>`z(KjP> FuW!0U)~7pyƬ|$<=b{%=|/kn/Ri7>j%f؂Ym$Gl! @,%D7G Gx>_̷GSNd,6XrEG'uG/;j;_30|k p$R*%ed<%c-ԧP$/]|z~y/}' ۈ&o6mkr7(ؾғrSE9\zEA+ZG~G~G~GXn&l6?#Mۉ{!2q;gh8{6!lc1ñXAw4=PuK[g.S۲;n]+mQh#MbqG>&;W/aBw;.ʡW1yIn9(7[!+{dU%yuEy =rSa+BK5"lr;خ!.,{D }}e_~ُ[n/'e!GXsf[v8+C;Ӥoq[^Ù|Ӝ@>= ipu(kM~5=j^%;uCX1 Jva箓K,Vb1e:~G+պd V\"?7Iώ%g^s%pr9*8/O~w<:yyy)d:Ι9Hl̎%pPÍȨy;BAZH$MJ#hކ*IGऴKOU)8ton^} rh0{^m|o&ݞdg=9Igӏ| ig)ml'i0zޠf Cܫto-X.的|LJy*=)>iA$AH\I*I[ -܅ -DŽv΋gggiʷaX.՝SZv\5W InDV OOxpmO|U]yc~?Wc;;?s36ܤiՖe] {vXJpXߟ𙗉f¿Dhlܸ#<=qU# .FH(#n3Inq?#c#$A+-/ >ʏZ-X5Bͬrj,~T&XC'ƥϳ VV.lU~S$#bDŘ ]\U2Q^u׆5'#k{^k= Ʈژ~̯bT:QҕQ餭?13'#p]zd}sw0ٍ>vzעI,}֐ͼ& tF(*XB$i^M;l vGׄXݘo*I.3v23YG3@W(䫿t |iZB&m1q>0q6Hwl *3=ƻ=8[j{='^Hv&kck)@93Emw. oV Cl]]͝mo[8Q(p' c$񰶶fUuU㪺uKq]crXWbط{uPMP PJ;Mݰ(q\fd".FNj^ lB&_!ұZBC9?vb %@oiaoZ Ch[Z sڭ6/#ѐP?nbiǢ;_׬} tP W:9Ug(ɭZ JAsQi2;s,|BE9îEq9ߋ1GkI힗 ;8aYXkzy9Y<e8JABD )(_̽r ud""VyW"N%mKSX!D@ &۾O3ZBxsI(`8#7&ĢG#>p.Qk´B6A46yύ|h&t#tP ^h& 5c!El)!ZP3\‘;)sm cOwHjƌh/A{D+ivD/Ӯ%T6Kh11*MgxJg틩L+ў٫@jZљhFX8mA3J/hϏ6KFe"$;Y6Txm5i46ԎTpbT*lﻈkPWuFlU^amX ckV:Cz-j-T9 V_fv:Z.)jMHj fWq+j]8 bsN, />htsii( M9j:kBxjU6%iwH*6 #p=sSnLӥ|;-6.vÎb1;~gexm8lDZ욑Gm_[Tm)Ty|k&62Z1_1Ul,ZJ0N6qoʸc n@āS\8[ Nm ;9L#n2G >jgvB6p"؀,$Ȑ&ؕr `C5GO*4TDH&B9 a= %(I(|Տb2ByeJ7"?U? ^k/|GAF GN}/iɁYb(f Y-Gsxνc,>81-}Eq>\Ͳll V2r7ՇۏGϧ: Wѹt2 $ }xӽ A'x}ϋ=CN~N{I':W◝tOD4h=uN5紷fMϗ5ZsrS:OrAPU]U^|]Sʎ.^]^|. ^\]]^7]ۚut3n⧶<[-]o{Zܿoںۼۻ݋_yG{JP\hW[htoG238+G-z&*" :7,̚)`kksC}Ĭ˖f.i\l1UhM6Z>m71Pt ̼^93SMׄ-Uv4i$,$f`<FR{gm*~e!&ydޏ=#  ΟJ#UNCD };¤Z& l&SԠ<}I !8 '5dx蹃Ũ B K/Vt*V{|Yh-Fʷ:5m͙rX)u!(R }cr EmP&, iB!/?0zaq|ǖO: bsik6@Ǫ#n" hU}I"dUb3.Lc.mǼZ/RX0 m^FsQTGѷӑ0}GgqovN.ʽóTdK}SJهy DB F\OC^Ŏ}7~=K9*yF)݋L=.g}QxdB6OKX,P.z.mL Ҫ+ =T^??]5“$=l!躴\7Ўv WGQV'W<"6V +NAzHWwU?). 'b!zD,~vCb͘nF +j`9+V<$Vm+0ö> mŶ'R#bXn# lgE;bmEAx=8+8$ڝIP.#bX:*H߈P3+ϊ8&LHwy +wL>1JEt^Nș礜.&49#UxNcT{`>(?$G{qE+ /"\ZFO>(qf)j Y,Y Y92Nr˴`?,6K(#³ [C;нwV&DPɢȔ,EJ4Mz<86@oQ4q̧iL4ű2X%R5.W|BB2<'%DFI1p'hӿtO~{إAՋ{ roq~t% ?%rOD#ä׃ɀ Iefc1Y31i1}(V{R\EaGg66/ I/2hiڡγUkm;[gγj~屶]WzV(6 J?ԺEU7[]u,6y`!nOcNsCEo)3l.iG|/߮ソvzZYE/|{j k5԰c4]n`mUX+l5$/!yZBQ[Yg)<j=AVi*F/uRn6m5:/43e+!M3rW~\{ Ykw+-WXttyUEW'G<+qZ T-Hin_4LaIf4r]4v[cm՞zRj%V+˶q#ʱKOUE؈y?|^~<ҞKBfzj(p9$&xb:ziw2KSXN9ڹ2S^gmL,+Xmda lksi:|ۚ$[uxyAIqNº:kɳg%\=բ'&] j]ݦ:J_bh"Dd ;t # C XA?@Complex possible dosage graphic"`"2D蹼/rQ(<+B Ԣ`!蹼/rQ(<+BlIr@`x[ tTEzЉ?˴J~T"ct:f#8$ *qqa%gYaj\=q!hta;[~߈gvg|TUݪ{ֽ)"DOD.{Fvί%ɺ•N0O\w8\q*' z$ Q{fxo> I,mJyo\J_2TSƣFd K.gOjsf4z A0HxZGȿ8Cq9ZBaCAC ؒ2vg]жBd@[KgIA[3PI@@e@PWtQ]/KxsGJ2w8sg ,s9! y!5aGàfEZ9$1ox_ڼI7o$ǀw]c4F'M^OcU!%;]2n- ץ("Wȃ>Oxld+#c9=/zw$!پ scjIVLI7 4ajC:RAXm^,%/; =\W-r$"BeHi)VvY/NA'o вn:Щ҇*Tm_? Cۧ4m+y< Bkal:oA3x*8o>2n4h(O*0(S{EdY70(NT|Mc}h5^$?&(a6=GVv dQ{i3љ7ioN4&ϑ_cCd1g]$,;g)Y˨5kgG4Bw_ߥ~1̟Ry4ЗM]3ti0KMWO/wO?(WO=6 brLqboADуxbb5b | !.F\k-bb=b2F&<'./bm1#A!7@OQ?%/ :U:R..t|tt䥘bY> *B]Aބn'*9%]MHSɫ>QL~ q bVm#nG|O">q'w!>!=#E7S}!>BW|nzW%/ZJK}C4$g\YI<!dΠ گ!x׈Af x 4ď?FFS#մq7ՠ4cl?3b1q1ц81ю8сXXxW ^WSD jk!?NtZw\ځqH{!y 2ܪW7WoBU-1vR7C϶Avl{ջY{3['^w?k<{3!o2~r[ i|/d3A,fեPg)Y uQW=X9 V,Cjݩ?( kK'MYT5r꺅-퐶h|]3BwAB#dЦْeu`:N[+JԑЈڏ@ю*S|^hY _:h|j!à񩔼$XhwB_:O~M'אLXIge*#j{Ϯ]`WN&k1Zlu*=6 L[o~k^ YO62`HX!Ɯ2-RLV4!{fF#W" ] +lo5 V.Nm6"l|N~Nr|陜z VHО4 ~Z. XVH[O?B?”'-aL⇩_}3{d1V:?{!/*9ݮ;J^&NY6m_yϩhIHpd;VM&q隁t)4&MwM$hv0Uۊ҉EKLۏʸ8A8<r@,ண1B`gO,YwJn U邻Te.<9@t;ܮ87/÷@z-.92υ9:o%wn+]< J$V`-rU@:[ bsu3փl)[a6ļmv ֶl-Bz}utw ~?P*([{{!xjH\=(k0[p aIk 2oe-C5 oFXpm` adXI,O?C%/5׍Cs&< Zs!eqJ!, U}SI_q mچoxXHF"Iӧ >a-O3)oӅ"ni, {Ԯբ<< +`|a]PKC0gHKs]Cvм9[s7'r %^.^g<9LwHwaHdcXX[Xo 3@DP7"Џ[5.ݑQY;ҐI+7򷠟O&yͯCQ@uvlj=4ӶҸ6к5ʟ- zs*DN'ˑr_Bʗd_"_ߊ'똾GKַh^Hw^M%c69f` W:ՙ] !6WQklAR=h!+c.Y;o em!Vd=lh Ne5x@yjy 0O [R?AAWg szw2w/[ ; 5eQC^fAj>i}*~2_ zURO.iaGzul^OS(rr?$}Ч:U9ޡ UUxet EIֽtu1N_B '=nxj<:n(:&u:x]wZ)/n=Rmvg9v9\1֟w"g)"5!Ѿ?D{g$7vr}Ag&{!柤v;B.?C߶g.En퓥3y鵼ӕIZE4k_#5(Ǘ7!Ň8ZJswm$l v;%OϛIm;{fMsg_uMVtLWҩPGp-|>:U%ۻtՙ9j;7 HRHs^yns! ?GOdxrޝBr NkEZ/w=BI)R+WtmܬэJ^61~bˣM-'IAiI@ Ҙ%FQEShuN?_fr-ߐKϢv*Di]j2?RVRMa|_'̲DhĿ9;C=7BCy6I~j Ǒx&I}tr(v1NS=.zLS άGhrD qC|ަM%d2S?QG[e- \⣗v| ;ȒuH{3-5piߗ9,)]+i%= [KGtx*} qf̸nr=(~ӟX5 HzCa1诞i'DVll,9oϏ.N$x}g_39-Kb-7e BBpPC<+ϱcgP=vT帠$Ϟ[c" , gzU5Ey-,|;XPZ{T]hgV]ښEU:ԧn9uXKB4m]W^io8Wu;_sYe'73$u I$XL"Z&Kޒ ZoBɗWJs.GdR dI+c̀2mrL0ib#?nI&qiq\wNoζЕ>ȕ((q?͝:Q,ޓߜ oK.w!Ut:11iDQH{]eI-]榧T3W,hkZz$/[x^wGeP}yr[_tJrYDd ;Zy $ C dA?LComplex local possible dosage graphic"`#2oOEfuC^2%K`!COEfuC^2%4CƓh-x[L\ǝ,obXd4G8NMl WQx`eM.lv󹦎mYn^rW*;jtJdvR >)%"-j5>3=x<W%yOߝy}3μYFiD㋉2)o8._5Lr#: X&ʉvr^/W^7ў T[Z-YM{7QϋE<j4 _Ka N>"߾ph1| uzܤgYr2pR݂ry:1nFc 6AG>uSQf/ez뚦YȣצOAv_V38 [T߲8ok< =m'2a=!&%d0K4p_>Fh Rf0ϰ/5cY9jeĠt 0 R,נälKyGT8aNέ{i)( }47D;@i'BO/lOa2xJ>G5!k UXe$M|x I %K_YR–+!mP'UtTy^Q~HVӄݹV9vNcx兮ôCz]gkθާ_nW6U®dw"^v}+)vut n]OfW&U ]K2>#J߹#]Q>,V +J&?|ʞVn0U-۠\xNa\b}L7 UΉEZsja|W5ͪɃqL`1T @7J}6HdQ!]dǸwDX p <6p1$Ց:bc!uj~JC2qWk?spOnĥfj },YЧDǑdġϤKGyMDn\|aBN}\{3B˒(ߏ|v=;'29$ߟ~27ciz  6]vqt5ʯFya" |#obŤx 4GVZ谦F"m*֛p?s8b[lb&tKFׁZMjf_ogSo0҈~ (Es orb/}c=@eh8~}ȷ,e8mPbJy/Vf紌>LJ |9B9 dAG);:wr<[Qޘ\paUb{ddcԿ\6 F~ &B'{3FrlsSbM{M /R~EAhxSM\=FsUQ訰X4 @u@l48gJT詈CBÛb.G~Σ tm.-jst}κ_߸_Rv>Z5dF(O_Du=KukD[=i'=)fY{سH_(8Vϝs?g_Qyg'_Ve/7j zݽ$6M|FT\BW`q7K-+QTx<Ԉm=z#&.|@Iǣ3J<*/7hrlqM9i 9:# s>yBQ9z{{wјY}Ts{7YYu#l{=umiaν-HN ?9qAWiLtC7+#!iv"uo5bjTFS$/m&c"#2# -P(;_A[z_5(zt裊ΔX̳%=m̝xg'kdۃ(rwʶ_JKA5_dż`rϐz"rnS`r§KEU/eq(QMX:\0"+ fWk:9PSh1V"THͱ:,/_HoM@$<FYhtF{¾phGw:-3Z,ъW! ryʠ|ɌZ2)oKɭBA)x7s܃]9*2̓2LK1+ّOȒ5^1'=: 8 bJL٨w8fJgs#>Q)hnuguxݮ`t(RifM{;d͟Sũp׷vMMuɇ:0&*q?@*w{[wɶR66<\ޮJoY`yi˜~ hr#ed55n)3ξMkϰեHLaPw5 D^ru,eg?|bϢg?'KRZ4|64g͒}mrHԪ06ge@wvr )m{EV8DTnQ:Qޏ-I +?ncjbOxJ5$~nتv %DuqOK5NH4< (i=LYsztN8"{ ֣czt=c8'{mL!a7{3b[{ g$hո֊R +dod"ԫ\~6x|Ɏ9uUv\g%3-g{sETQW_pqF9 ;Wv:WUS,LT4O %-͛OqUUKMvgX/0m[N\ k*cƪvoʨMNDd ,<_a % S nA? PSimple possible dosage formula graphic#" `$2opǰ7ͯrO`!jopǰ7ͯV438A8x: l׵ٟgwΎv(b v5 N3kڄgr(uڄ($nPhC=PCT^R'UhD"6iD!X{gfڪ3:ss?=gvdH!' "G&YpyՌ7%G@lc V5a= xvZ2 V|TФ+`!{ C#<-2A֍e|][iД3։Fн{LG0Z-[V[\. UtuG RBѯPP ɹc8X{ztNb>LGi ſXzfhe^$OQxҕP-_H%e:-2y2#oop%sܢHݑņs9po`#tоC)PRn!:GK_%C)-ƛSD0< ]A58[ӡVE|9삏FpdSMȍas%[;vDkjcd2G^E=+culw=[a+>*?Ԯ,o N.B )<}ʋ6v)ar*ps'Czx\!|n>+Bp?}B*p=^qTd0$m}+ϔ\&QJO+NEoUF!Eٕ-] =xЫ"~PD!gr#gEr el<5?g|> =Of{y°!&xl!OLU@ ]!xV9J8|d~86ś~r^ً̥V3t> _׿LS)[ŧ ۖdWSr}3[ieQ&o=W'q{u{a P&"l)̳btؙ;cQQ E3/tS8-9@}@ӽ:q74JJ>f ja^swcbٸ+ j@-ł͢wh; p@#-u縁Lw҄gwnI,q8M=]L5g}%x-O1<~UZZaO߄\{=DIsc/ڿJ&3|}Q~Ӯ뢽"6gEg!wW6@$&G4qb: ;ȧZ3WzV*,Mu(v%A4>'C&{\?ps_@3 PnZRn ,sX+`WON5=~3d2XLl8 ?Z@o{2 y{.>]F-へB"̶Qj[nyEgϓ,_2HtJ1qKe2w Zo&L!M7.Eqݽ6&&5y33ꚖP8j5߀*chsĨ(q<^ͧuƤ_-i_?a|v|FՖT7+$G%d%Ѵ=&ķ󴫝#() XOHwGOFnq3sX!=QbE4V+L}7唾=›h{0߹]ߜalG8' G;Ȓ\Yҷ3og1'QYl .k[3hT*bp%mVa};]v9lw{RFTm.t9*Gy<Òxn 0}8d,! jxgG:BWu?k;p5D-ǜ84\FևA'\0?0U, n% ʿ<1u]\2mz[,w҈ xZ޶)^m7ڨ_^1mUd^ ] -K6,G n5Z% h>5,ZB%\3"ZgD 0{Zpl%9} %ly=\fel ˇ={3\polO* <`g3l/<=PZ6))(3gW;x ow=[aKRoUjp ÿ*$R&*P_xc&6"Uzl nEzzL%/}?O[|ZvOyΓ &`KJq> &)F{Ї>pIAq%6EZU7,9MtՅ 0\~ː%yɒ>ZAeɃ B}0X0D O"mPXzupKFDˊP&wkq|3Nq8M}qς?rE}n酬?[z]gFWQ^OPL\=g?d[2nn4o(h,8z@(O%A5 -Sb6Mw)2vۙ\C-o[_j-b\YwY7y3gN_}soVrC}@){ e}N/}e({Pc,?l nǭy]-,Xu~92> %i?C-TtR _R/.nP2u Nuze/ &cL3fiqz4Io'pAVZbι}*J:[C\/G~]baV}\'`+֑K{$$If!vh5#v:V l4   065/ 4f4p T$$If!vh5=55 #v=#v#v :V l06,5=55 / ObjInfoVisioDocument -VisioInformation"SummaryInformation(`Oh+'00HPht vhaisbcostekGxQ EMF|X XVISIODrawing  MVisio (TM) Drawing -q ,zRl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1U&J:DT1EW-hTT<* /Ub bO0zGz?@8@H2!kWb*U  +$PL/^&9^$? { Ak^&,,'%/v&& * 1y   )P? 2   U U12?k9aBBHEHEHEHEHEHEH@?>?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*Pbt߆ߘ߼#5GYk}b4?Qcua&8J\n /"4FXj|Q!//+/=/O/a/s////////??'?9?K?]?o????a???? OO0OBOTOfOxOOOUbbOXa]feOO__)_;_M___q________o#o5o0GoYoko}oU&oooo /ASea(:L^cqoǏُ!3E(hzŸԟ .@Я*EWi{ÿտ όf8i\nπϒϤ϶T);M_q߃ߕߧ߹p3ǀSFXj|+=OasNr'9K]o 9 0BTfxBC`!k}3I bz@6` /'c//A&`M/_/q//%b/)MQ3///??(?:?L?^?p???"dGoPo be3oo}_oooooo&8J\_VC94O*O -?Qcu͏ߏ'9K]ccU<犯"/ΟF//:/!щqfxү,>Pbtο@_ jK[CuU՞ϰϬҔЅaa3vO贁NkߖFa`27qZ?Yka?\.? pQA6k6߻H k+6;CjԕaI^g030|kPewȈ$ !%7dri{ /AS}/w+=Oa???'9A1K]DM*Oѭ e.KUqH)Wq[=ۑagOyOYuğYOOOOOV0%!/3/E/ W-}QK_mϣ(A(I1oo(o:oLo^opo s#m///5/////O(O*?P?????Ga^o__OO_____-?VQ=v.s#{.峑PbLǟٟ!3sHZb=!o"důׯ //gyI[L^$6HZg!lŪ(:ɏ^p9܏ $?OGOYJ#qٿ 1߀C __-_iȉX@R_ba QJ_+Չ/ڜ,5 ,5,0$Zl~r?? 2??h8LHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPUl4,N!2( ?@Jz? < A-|37U *<N`r@Dq BR @4(U *<N`r@q x RUFDfP h> /T6DUI@A?I BP(?3H$- b]b--rx@l^bf>M,,D'^fO - b, , 'eZYUHu F .LYcuZo^SLRepresents an actor reference.mb߿??PQ࿤p= ף??3㿕HD" # "=h#-$>T #T3 AOAU@?=@?@u߽?P6 )i8VYAEDA@@#u` *'.8BhPZ`u#j Ub >U5 gL{5!5 A`7Copyright 1999 Visio Corporation. All _"s reserved.`j _D88.chm!#2]0 l>0>Udd!!P #w a2U50` 9`fC"`e1De 2#(  O?si?e113???%G1 7@<Oa?9ME)2RO;rABC#(^actorReferenceiVA!aPIE9 3~'2qcPӼ? &bVq(^/\:5!?lOrISsQU__f+OnQ&%^]oeoooxGQ3ULYoopOorHl'-ER  [F 8# -r2? G1b XoOD+ty!Yo>?Dz!ko_( ?p 34RD g+@D>q +W@i{l _S  UPxP4FDTey  ahnm qT^UIN!2( ?I@Jz??-I?*?QcO@?^[qu`Fuae@u U Hq%P$w!p/////{!w!x$iD!w!p!N? "1 a$ ԉEP?@D?@W՘H?@X2>?a!H-#0QKE(<w!Q2m?Q?w!)l"10qU"1q5aD!G1)>&A*U30;[Q^5CSD%*^[G1_8ZqHnAD!D)BIAUW0VVBJo$a<0eY;HoZn0noo"c 0e\okA(QOutpatient Expansion from MEDICATION ROUTE file (#51.2)iT5/G/DD '2r?qBUl4,N!2( ?@JzC? p  U A-3*7;U2@,p 07LRH<( U2Etp 7 RUlL TT @?%|)RD< ;U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)$L5T *o 8&Q- H*)=-PEQ//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowWhite fillvisAecIsTech?nicalWallBuildingActor referenceActor reference.13ROOM BindingROOM Line StyleNet Thin lineNet NormalYellow fillMarketing Normal 3Flow Normal_3 E )'- R)2G)UJ )W}ec Urc 4c ULc dc U|c c Uc ăc U܃c c _ c $Id :|O@B/KO@F:O@J:O@N:RTSK'PV:4'PZK'P^:d'Pb:RO@fK'Pj:'PIn;'Pr;'Pv K'Pz/K'P~K'PR[j :`:$`=[`:D`;`a[`T[`:t`:U`:`:U`:`kOeK`KkR`›K`:`ʓk`:`$K`s[`K`Iޥk`[`kOeKpk`KpKpdKkp5{p *pCp CpCC,CtpC\R"C&C*C.CDNCd6JC:>CBUFC`C$NCRV Z^QbC Q‚PjC|UnCrCvCzg~"X -C<C4Z`CT٠T٠C٠CU٠C٠C٠y`˫WIݫW)CUU$ߝWӋWQWCUW!*W W,ADAʴW\A#tA'ʌA+A<AUAYJUApp'A=3EЩWЋ|ЏT{ГʜЗiRЛПգ $Я<гTзl*лʄпeЕi^3ХodoDo"TZzoo ꥤoojo#<#+#/T10 fx0p!!!_0jC#W%&'(*)*+'U-./0E125U6789:;i=>?@ABCUaOFUHIJKMNOP*QRS{UUVWXYZ[]]^_`aJbckQeUfghijkmnopqrRsuvUwxyz{A}~TU*U5JUQRYUTU* Ua UU U UUU!U34UUl4,!N!2( ?@JzK? _(g*C-_ 7A$Ul4, p "+A- 307"A_*<N@ * IRVg,2+7uH<( H<( _*<NE|"+ RVg\q u{zN  g"4FX(i @( sy p~!p :]RlOt  uq&_Lv !BD;>GOFo8O_<  e=$ K0U'|fQ>N xU)!x 1 ,x=,`{2 3"*V<]* F?q!i+GD|!5 C=t5 ,J! +Y U  &% % V0IHHH% (   % RL Arial}|zywSTTjkkl% T&g!AA& L`Outpatient   T&"g1AA&" L`Expansion  T 2AAA 2Llfrom MEDICATION       TBQAABLpROUTE file (#51.2)  ՜.+,D՜.+,@HP\h t   PagesMastersPageDocumentSummaryInformation8_1044259211F˪U˪UOle CompObjq-1Actor reference8_VPID_PREVIEWS_VPID_ALTERNATENAMES_PID_LINKBASE A  FMicrosoft Visio DrawingVISIO 6.0 ShapesVisio.Drawing.69qObjInfoVisioDocument ,VisioInformation"SummaryInformation(pVisio (TM) Drawing ,t $+Rl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1U&J:DT1EW-hTT<* /Ub bO0zGz?@8@H2!kWb*U  +$PL/^&9^$? { Ak^&,,'%/v&& * 1y   )P? 2   U U12?k9aBBHEHEHEHEHEHEH@?>?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*Pbt߆ߘ߼#5GYk}b4?Qcua&8J\n /"4FXj|Q!//+/=/O/a/s////////??'?9?K?]?o????a???? OO0OBOTOfOxOOOUbbOXa]feOO__)_;_M___q________o#o5o0GoYoko}oU&oooo /ASea(:L^cqoǏُ!3E(hzŸԟ .@Я*EWi{ÿտ όf8i\nπϒϤ϶T);M_q߃ߕߧ߹p3ǀSFXj|+=OasNr'9K]o 9 0BTfxBC`!k}3I bz@6` /'c//A&`M/_/q//%b/)MQ3///??(?:?L?^?p???"dGoPo be3oo}_oooooo&8J\_VC94O*O -?Qcu͏ߏ'9K]ccU<犯"/ΟF//:/!щqfxү,>Pbtο@_ jK[CuU՞ϰϬҔЅaa3vO贁NkߖFa`27qZ?Yka?\.? pQA6k6߻H k+6;CjԕaI^g030|kPewȈ$ !%7dri{ /AS}/w+=Oa???'9A1K]DM*Oѭ e.KUqH)Wq[=ۑagOyOYuğYOOOOOV0%!/3/E/ W-}QK_mϣ(A(I1oo(o:oLo^opo s#m///5/////O(O*?P?????Ga^o__OO_____-?VQ=v.s#{.峑PbLǟٟ!3sHZb=!o"důׯ //gyI[L^$6HZg!lŪ(:ɏ^p9܏ $?OGOYJ#qٿ 1߀C __-_iȉX@R_ba QJ_+Չ/ڜ,5 ,5,0$Zl~r?? 2??h8LHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPUFDfP h$T PUUBmUA@ ?I? 3xO@7IyIfBo?вsUP  /e Z.$ H"N @X(:H?_hz  ww "Square.b?贁N? 4 HDD $# =h-(>TTE=kUA@ ? uQ6 u` ?u B6> 00A0(2s@sJsT>d=$5 h9 L]{ !$5 `7Copyright 1999 Visio Corporation. All 4"s reserved.`? _Sba.chm!#224_17l>0>Udd!!  T '"<hb 261 g,s724  =?M1Y?r?91M1E;6=H=5P2?;rA IBOCq,B^35/\ @F"AC "3AP?LOe?#7A)[8B_T_OxY)___f_.eAE_oo_LHl'-i !OyaGE WszF4 # Vb?  DeLW os+_ o%?Tq!DoVUl4,`Fr?Ir <EUA-43K7"AU2@|M R@4(U2@7 R(n S 4@?=RD,K=Si{ UPxP4FDTey  ahnm qT^UI`Fr?Ir?I?*?Qc?e@?8^nqu`MuaeuU 'HqP$w!p/////{!w!x$iD!"1#N? 53 a$ E?@q5@>7Q #0/Q!H-E(<;5O[?Q?w!l "10qU"1 q59aD!G1>\A%*U6;[Q^5CSD%*^[G1_8Zq^G1,QG1UOAUW8_(a<4k_Xo_m4eoo`lwnoo&cD%n A(3atient Instruction +/or Provider Co;mmpsiT5/G/ D '_2qJAUl4,`Fr?r W A-37;U2@47FRH<( U2EW7 RUlL$] 6 @?  8wRD4 d;U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)$L^T g*o6')-8&Q - H*)=/"&-TEQ//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowSquareWhite fillvisAecIsTech?nicalWallBuildingSquare.8ROOM BindingROOM Line StyleNet Thin lineNet NormalYellow fillMarketing Normal 3Flow Normal_3t> E ? )- D)G\)W t)"cU)0c )U=c )Jc )Wc )dc @qc AU~c $c <}c Bc Fc ,H J>c M m}c 4Oc Ld d Jt%|U$\750@g]D*_UH*! L*! }P*`T+aXCbWg*{ k*doX{ *cՎ* *e*p%+%+w%,*_k*A0}*<~*_L*dw0պ*|w0*T§ 0> 7+0E;0++@*@T+0*@+@7+@E;@*J,@J<@ J4JJL@JK KP$J(J,J0Ji4=[8=[  4u}8 4 < @ " {Du- H/ L [PT [T d7X K \ M `-dOW h T٠l |T p \ t] x^ | D_ E {a g t  f ,Rݫ ̟=u  w  x > $~ ūS SS T  UM J*Uĭp'-T 1ˤ 5, 9 =ʄOA$W EpU?p@pApBpCw!OF"H*pIpJpKpUMpNpOpPpQpRpS1pUpVpWpXpYpZp[ǒ]p^p_p`paJpbpcpepUfpgphpipjpkѫpmpnpopppqprRpsIpupvpUwpxpypzp{p}p~pppppT!ppppUpppEpppp*ppppUpppppp'ApppppJpp=1ppUpppppS!ppppppRpKApppUppppipppppp«pTqpūpƫpǫpUȫpɫpʫp˭!pͫpΫpϫp*pѫpҫp[pUիp֫p׫pa'UU U UUU!U34UUl4,!`Fr'?r t)C-ܡ 7A$Ul4, **A-387"A_*<N@L) DRVg :*7uH<( H<( _*<NE* RVg q k{zN  g"4FX(v @(H֪Ly   :]R>  _\ _dj qW&#!B1 [;>EOVD_8O_ X}$, - 'TT|N T)- T 1t: T=݁`2> V<` uj F?q q*GD1| 5 C=La +J!@kY DOh+'0@HPht vhaisbcostekGxMRLL EMFX XVISIODrawing  QQ  &% % V0MMLLLLL% (   % RL Arialdccbbwewlwowswexod% Tx;AAL\PatientT  T G+AA  LdInstructione  Td+28AA+LT+/or  T|8@EAA8L\Provider  T| EBRAA EL\Comments  ՜.+,D՜.+,@HP\h t   PagesMastersPage-1Square8DocumentSummaryInformation8_1053423587t F˪U˪UData  1Table _VPID_PREVIEWS_VPID_ALTERNATENAMES_PID_LINKBASE A   FMicrosoft Word Document MSWordDocWord.Document.89q FMicrosoft Visio DrawingVISIDd/6  3 A?22 w7h:# Dp`! w7h:# xWxT=OA};6NрJDa>%$H Be A)ӥM'] $*A$fo(AIXogvvvv (@  (:?-' ?j$2gs,h~X rSi=]kO,,\E`xC{uaF}q{&>':i]g=ί"elOdS>9pG=ӗ^\aGˑ!v=ʕ`ggq(ogM_ V.#=Q,ILlon}(Vssiʗأ\"Zk7Ky۫U_b^=#ݞgk^$nR4P_?ڨ4vV 3:Ct2YD'{u7SvveVz'R̉r\LjO}W\Dd RR0  # A2e'Ue`N3l]p`!Ue'Ue`N3l4c#xTjSAf?1V۴$T.ԢKc`lZpa\iЛb]SW>>ƝOPJW;3sӛ 89ϙ3W`501$ȣ%%"(\ubR#)^I|weYG$UvJ e 븇U*v3haZ:>uF`61M~כs.b\I$I%S7*'vзG#:f;m~7%k<8_-7f䢌rU Iv]erw_18p3{T04[QC?yRKz{gk-VW<=*g|lDdGFC0  # A2'Mn֊Ymp`!e'Mn֊Yr43xuTkA<%*a "C"3gP41! ɒaP+[`aND]  +,6y_ "psPƒ1?wQD~Qn ȍʅ9֘#YeJ~i(3gSRU<@ko1+{p,0RXok 8q2>w2q3lٚ(*w$11+{n7D7Ax. L{KXb!S[ic&R[U㑘&1w壨ْeQdZVQOmU|#} H]f"6 'loGl.F8~'JbMv m?SlgӪ/o%͊ɉ29:`3l2x !fR5wG:={g;kRbDUځp?%w㼌vX'̯4 i8@8 NormalCJ_HaJmH sH tH PP Heading 1$ & F<@&CJKH \^JaJ 88 Heading 2$ & F@&\LL Heading 3$ & F<@&CJ\^JaJFF Heading 6 & F<@&5CJ\aJ8@8 Heading 7$$@&a$5\J @J Heading 9 $$&`#$/@&a$5\<A@< Default Paragraph Font,"@, Caption 5CJ\(( TOC 1 7$8$H$&& TOC 2x]::TOC 3 $ `^` mHnHuBBBTOC 4 $ ^` mHnHu&& TOC 5 ^@a@ TOC 60@& ^05CJ\aJ>r> Style1;CJ$KHOJQJ\^JaJFF Style2 ^;CJ$KHOJQJ\^JaJz !'/45<Ytuy^_00 0 0 0000000000000000000000000000000000000004t^ <UWy::::uxSS^^__Kelly Anne Costello.C:\My Documents\POE\Simple Possible Dosage.docTh* %lT; ^`56CJOJQJo(.8^`56CJOJQJo(.^`56CJOJQJo(.p ^p`o()@  ^@ `o(()x^`o(()H^`o(()^`o(()^`o(()^`56CJOJQJo(.8^`o(.^`o(.p ^p`o()@  ^@ `o(()x^`o(()H^`o(()^`o(()^`o(()%%%ThThThTh !'/45<Ytuy^_@Zp@UnknownGzTimes New Roman5Symbol3& zArial"h5;V5;VTY<~0R2Q2TAKE 2 TABLETS BY MOUTH EVERY 12 HOURS AFTER MEALSKelly Anne CostelloEDSCompObjjObjInfoObjectPool˪U˪U_1043484840F˪U˪UOle CompObjqObjInfoVisioDocument +O 6.0 ShapesVisio.Drawing.69qOh+'0HPht vhaisbcostekGDxwt U EMF<X XVI                  3 2     ! " # $ % & ' ( ) * + , - . / 0 1 7 4 5 6 8 P Q : ; < = > ? @ A B C D E F G H I J K L M N O T R S l k V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j p m n o s t u v w x y z { | } ~  Visio (TM) Drawing +Lls*Rl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1U#J:DT1EW-hTT<* /Ub bO0zGz?@8@H2!kWb*U  +$PL/^&9^$? { Ak^&,,'%/v&& * 1y   )P? 2   U U12?k9aBBHEHEHEHEHEHEH@?>?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*gL9QOF$B_XKPcu jU8g'P!//*[mvǏُH}E0 TҙS-?Qcuχϙϫ);M_q߃ߕߧ߹߂ 2DVhzێb֯ *<N`rӘa#5GYk} 1CUgyՖ*!//(/:/L/^/p////////??$?6?H?Z?l?~?Ֆa?????? O@O-O?OQOcOuOUbbO1a6feOOOO__&_8_J_\_ҙ~________o o2oDoVoU oooooo,>Әia_q%7hcJxoj|ď֏ ASewџnasͯ߯0BTfxҿefB5GYk}ϡϳ-&8J\n߀ߒ߶I Y,1CUgy(:L^p'K$6HZl~9 -@?QcuBCh9!nkV3" bz@`nc/&`&/8/J/\/n%ib{/MvQ3/////??%?7?I?[?m?=G`P!=KBTfx,V/Pbt(:/^pj?@|?1!$6^DlMOumц >mKUrq!Wbqy[ja@OROfYNxYOOOOO/0% //0-VxQ$__FX|uAI!__oo%o7oIoL#F/a/j/5/////?O??'?9?K?)?????7:7H_Z_dOvO_____*=OL`{ޓՌ);f%tj|ğ֟蟜 !3b!HZ"d¯ԯ@RdҚ"4%7jǿٿ!3@!EŃx7I[m﵏Ǐ?? O2FLHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IP Ul4,&'?`/b? <A-43 7"AU~@*<N`@  FR @4(U~@*<N`@ RUFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HI ;V?-  _`߅pl`ul`u kw{sg_'Regular octagon, or eight-sided shape.b?贁N? 4 HDB $# ?h-(>TT9 EAUA@ ? Q6 mu` o?u j>Z--200`0A0(2@2T^h0r|>U5 L{/!4$5 `7Copyright 1999 Visio Corporation. All Y"s reserved.`d _Sba.chm!#22421PBd9 l> >Ud]!!(<* Z#A|rvPph.b31,1e g2(:S425$a?a! Ҁ?1E5Y6gq4bH3x81| N5%O7I71x?:?=3A1@IZ&Ax;87:U\S7I]:U; >tRTD%^RTEa^UQq5:^[ QY6[@$n[Q_HZq^QzD1QjeO_0_Sa<nU }e^}en}D%e,n}E~cq5~6Y|ev~cP{8ޏyA( ~Verbi$5/G/DD W'28AUl4,&'?`/bC? U A-37;U2@̔7LRH<( U2E7 RUlL|@?$)RD <U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)$LT *o8&Q- H*)=PEQy//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowOctagonWhite fillvisAecIsTech?nicalWallBuildingROOM BindingROOM Line StyleNet Thin lineNet NormalOctagon.5_34`~ Ed e>- fUG$M UZP9jP 9jP9jP9jܪP9jP9jP9jn"9j4`&9jL`*9jd`.9j|`2TKk`69j`:9j`>k`B9jԪ`F9j`J9j oN9j$pRTk`V9j!BRv&LJU,NlRUVZݫ^b<*fjǻEnw.,UUD7Ulp'3˭ʤݫW˭ҹQx{˭ڹ$OIiO7O湪UdO깪|OUO򹪤O%OOOK!*yH`'Q x'4'T10^!fxRp! ! j9`"#[%&'()*+T!-./01256789J:;m=U>?@ABC3eFUHIJKTMNOUPQRSUVWX*YZ[EU]^_`Еabc !efghiJjkmUnopqХrsWuvwxyzR{}~UЀЁЂЩЅІЇЈЉЊЋTiЍЎЏUБВГeЕЖЗИ*ЙКЛAUОПРЕТУХЦЧШЩJЪЫЭUЯабХгkQежзийкRлноUЩQqǪiUzU U UUU!U34Ul4,&'?`/bK? (bC-3')A$Ul4, Lz)A-D37"A_*<N@L-) MRVgdpq7uH<( H<( _*<NE* RVgpq \{zN  g"4FX(-@(P y @gn:]R>,k _lo_qq&yu!Bty;> DO` E8Ȯ, a$ '=fSNf)f 1 f=vl`2e NV<5( F?^dFDf!*KC=U5dG |J!pmG DVisioInformation"SummaryInformation( DocumentSummaryInformation8_1043485556F˪U˪USIODrawing  {x  &% % V@wt T&&R&rTruRu&T% (   % RL Arial% Td"CV_AA"CLTVerb  ՜.+,D՜.+,@HP\h t   PagesMastersPage     !"#$'+,-./0123456789:<=>?@ABEIJKLMNOPQRSTUVWXYZ\]^_`abeijklmnopqrstuvwxyz{|~-1Octagon8_VPID_PREVIEWS_VPID_ALTERNATENAMES_PID_LINKBASE? A  FMicrosoft Visio DrawingVISIO 6.0 ShapesVisio.Drawing.69qOle CompObjqObjInfoVisioDocument ,Visio (TM) Drawing ,4G9+yRl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1U#J:DT1EW-hTT<* /Ub bO0zGz?@8@H2!kWb*U  +$PL/^&9^$? { Ak^&,,'%/v&& * 1y   )P? 2   U U12?k9aBBHEHEHEHEHEHEH@?>?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*gL9QOF$B_XKPcu jU8g'P!//*[mvǏُH}E0 TҙS-?Qcuχϙϫ);M_q߃ߕߧ߹߂ 2DVhzێb֯ *<N`rӘa#5GYk} 1CUgyՖ*!//(/:/L/^/p////////??$?6?H?Z?l?~?Ֆa?????? O@O-O?OQOcOuOUbbO1a6feOOOO__&_8_J_\_ҙ~________o o2oDoVoU oooooo,>Әia_q%7hcJxoj|ď֏ ASewџnasͯ߯0BTfxҿefB5GYk}ϡϳ-&8J\n߀ߒ߶I Y,1CUgy(:L^p'K$6HZl~9 -@?QcuBCh9!nkV3" bz@`nc/&`&/8/J/\/n%ib{/MvQ3/////??%?7?I?[?m?=G`P!=KBTfx,V/Pbt(:/^pj?@|?1!$6^DlMOumц >mKUrq!Wbqy[ja@OROfYNxYOOOOO/0% //0-VxQ$__FX|uAI!__oo%o7oIoL#F/a/j/5/////?O??'?9?K?)?????7:7H_Z_dOvO_____*=OL`{ޓՌ);f%tj|ğ֟蟜 !3b!HZ"d¯ԯ@RdҚ"4%7jǿٿ!3@!EŃx7I[m﵏Ǐ?? O2FLHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPUl4,춰 -?`/b? A-3 7"AUV6@ FRUFDfP h$T PUUBmUA@ ?I? 3xO@7IyIfBo?вsUP  /e Z.$ H" S?!{)19AI?dp]qi} Aw:npqA9pwwA9pwpiEquilateral triangle.b?? ߿ $t@ ?<?紁N;3HDB t# ih0>T@dE=M AkUA@??A߻?Q6 L,A >M A JuM` ?[y&y0y:@u` UJS>#JU0O贁NKk?<@MJdO@ܼ@ L LP6 @?FS@U%%F@))@H""oKJ%{X1]45 `7Copyright 1999 Visio Corporation. All 2s reserved.J`0_Sba.chm!#22416Aida?lJ*,>Ud6ZV$(s=?)ǹ<$$b# X"yB:V/ K;EA%;D]2׳뽿HH?!:ͳ?OARM%2pO;JrA RSq(^!(M%9M\Me2AO-QVD}Ho *oFTO`c5WD`18WoiDYebW_`c%@neNooO[jJ(?kF8Hl'-h !OyaGEWszF${#V? TyPavuooD+_~poB?ԃoP@4(UV6@` R(n?S#Rtyv++@dvSD,'m,ij UPxP4FDTey  ahnm qT^UI -?I`/b??-I?*?QcO@?^[qu`Fuae@u HqPǕ$p/////{!{!$iD! N?@ D!G1,G1G1D!ahE ?@ = ףp?@b7?@<03?@aA?Q 56D79C89EG2 q@?OF<k?A|!H-kA(#00/(< ?Q?Dispense Units/DoseCi8xD<'2=R<D^8=`glA$7U??HQaD! CeaDÓ-2Xe65ce&5dlD%oq4D!(QTD!D)i0)MEq<u%Qh}u-+Jxw,}~66xj2/D/V+dG!3qZ$?p!`pk @<HEUl4,춰 -?`/bC? R A-,\7;U2@db7MRH<( U2E7 RUlLpPqA@?d%)RD4r;U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)$LT *o8&Q- H*)=PEQy//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowTriangleWhite fillvisAecIsTech?nicalWallBuildingROOM BindingROOM Line StyleNet Thin lineNet NormalTriangle.2_3,89 E<C N- YTGq} 9~Uqc 4qUc Lqc dqUc |qc qUc qc qUc qc qd :)$7)<7()T75)l7B)7O)7\)7i)v)7)!7);W,)U7\UDt)j<)U$ < T l  [+  !:̟ !:= !: !:$S0!:!:S0B!:S0F!: >J!:RS0Ni;+@R!:4+@V!:D+@Z;+@^!:d+@b!:t+@fT;+@j!:+@n!:+@r/K+@v!:J+@zE;?r!:PSKP!:LPTKP!:|P!:+@KP!:P!;P;PE;@4 3;P[AX !:,Dj {;`>!:Ki;5`ISK5`s[5`W;z5`;M KR5`֍;`!:`I!;`3;`W;`!:`'kN[[s[Ti;\a[_ gpkz` kz4pkzLpkz\pkzpkzaT{p"kzlp&kzDe*kzbW.kzd2kzU|6kz:kzU>kzBkzUFkz-Jkz5Nkz fP@kz$πVUπZkzU?@ABCA!eFUH*IJKUMNOPQRSiUVWXYJZ[/!]U^_`aХbcefghijRk{mnUopqrЩsS!uvwxyz{T}~UЁЂЃ5᪁ЅІЇЈ*ЉЊЋuqUЎЏАЕВГЕЖЗИЙJКЛНUПРСХУсХЦЧШЩЪRЫAЭЮUабвЩежзийклTGнопUŁƁǁ*ɁʁiUzU U UUU!U34Ul4,춰 -?`/bK? )UbC-37A$Ul4, d?*A-\3M7"A_*<N@4) LRVgO*7uH<( H<( _*<NE* RVgq R{zN  g"4FX(y5q@(ᐖy @Pu:]RQ xq& S!Bܖ[;>COE8O^p X$D '*tfQNrKx)T1Tx 1_4s_x=uy`20NV< zu F?*GDl5 C=?!5*+J!D3 Y VisioInformation"SummaryInformation( DocumentSummaryInformation8_1043485691F˪U˪UOh+'0HPht vhaisbcostekGx EMFX XVISIODrawing    &% % V,~M~~% (   % RL Arial Whp@{ % T|#ayvAA#aL\Dispense   TyAAy L`Units/Dose    ՜.+,D՜.+,@HP\h t   PagesMastersPage-1 Triangle8_VPID_PREVIEWS_VPID_ALTERNATENAMES_PID_LINKBASE A  FMicrosoft Visio DrawingVISIO 6.0 ShapesVisio.Drawing.69qOle %CompObj&qObjInfo(VisioDocument9 @,Oh+'0HPht vhaisbcostekG8x EMF0X XVISIODrawing  Visio (TM) Drawing @,tT*yRl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1U#J:DT1EW-hTT<* /Ub bO0zGz?@8@H2!kWb*U  +$PL/^&9^$? { Ak^&,,'%/v&& * 1y   )P? 2   U U12?k9aBBHEHEHEHEHEHEH@?>?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*gL9QOF$B_XKPcu jU8g'P!//*[mvǏُH}E0 TҙS-?Qcuχϙϫ);M_q߃ߕߧ߹߂ 2DVhzێb֯ *<N`rӘa#5GYk} 1CUgyՖ*!//(/:/L/^/p////////??$?6?H?Z?l?~?Ֆa?????? O@O-O?OQOcOuOUbbO1a6feOOOO__&_8_J_\_ҙ~________o o2oDoVoU oooooo,>Әia_q%7hcJxoj|ď֏ ASewџnasͯ߯0BTfxҿefB5GYk}ϡϳ-&8J\n߀ߒ߶I Y,1CUgy(:L^p'K$6HZl~9 -@?QcuBCh9!nkV3" bz@`nc/&`&/8/J/\/n%ib{/MvQ3/////??%?7?I?[?m?=G`P!=KBTfx,V/Pbt(:/^pj?@|?1!$6^DlMOumц >mKUrq!Wbqy[ja@OROfYNxYOOOOO/0% //0-VxQ$__FX|uAI!__oo%o7oIoL#F/a/j/5/////?O??'?9?K?)?????7:7H_Z_dOvO_____*=OL`{ޓՌ);f%tj|ğ֟蟜 !3b!HZ"d¯ԯ@RdҚ"4%7jǿٿ!3@!EŃx7I[m﵏Ǐ?? O2FLHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPUl4, X ?`/b? }A- 7"AUzZ*<@  GR@4(UzZ*<@ RUFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HC 5Vۀ {?"o./? ?pdofk| w{P}|shlwwwxnVpo]Pp'Regular pentagon, or five-sided shape.b返??lDK\wX}W鿰6??,̪]ơ%HDB $# ?h-(>TT9  AUA@A%??AmDK\w?Q6 u` ?u` i%kL>+000A0U(2}@}J}T}^>d@ @+B{!#$5 `7Copyright 1999 Visio Corporation. All H"s reserved.`S _Sba.chm!#22418lQ4>Ud}!!!Z hb93& 2g}U2<"£A f"0&8Ď@Y?@3 i3k1E: 4k (и?%99f5i8<*2|5fuN?2Se?2Z@ 4LW7%93:eiH?$2 ?5rA BCq!0^d!E/*\D 끁s,x#?eA`F+"A~%9\~DG;?oQo?uo|]x?_o??jZ&eNo+?=;Hl'-}i !OyaGE!szF#_d@ ģZ)0?fkoaD+$KoV?5o(n?4wTR🬞|++W@D'+W̢SX UPxP4FDTey  ahnm qT^UI X ?I`/b??-I?*?QcO@?^[qu`Fuae@u aHqPŕ$ap//@///{!ax$@iD!"1_D!N? 53a$ E( ?@*tF?@b7?@<03?@\w?]Q #00/!H-(<9?Q?l4qU9!AA=;5G1R"1>\A65.US@GCFT.U^J̿GSD%.U'+&GSG1*YG!?e\(q5._@Vq80 "1q5OSa~_5^0LG%Wa<ce^|omce^omce^<mD%ce]^Em Uce^iA(qNoun!iT5/G/ D^ '2BUl4, X ?`/bC? U A-$37;U2@7LRH<( U2E_7 RUlL<{@?@RDl;U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)$LT *o8&Q- H*)=PEQy//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowPentagonWhite fillvisAecIsTech?nicalWallBuildingROOM BindingROOM Line StyleNet Thin lineNet NormalPentagon.3_3$` E< - lSGM_ 4MUcLMc UdM,c |M9c UMFc MSc M`c mmc zc Tc tc c c c c վc nc ґc c le  L!$T(|,U04fAE*IX\DoTU {$   [+ I+  ,pS+/0/0U/0/0} qU40L0 7r7*,0i;0͟;0Jl0+0[+*0Ŀ0E;0I+0i;0_s@I+@;@+V@\@JUl@ J|@ JU@J@JU܅@J@J_ t!J$]PU%J<]P)JL]PI-K]P1K]P5KR]P9[]P=J]PA[]PEJ]PIT+[]PMJ]PQJ]PUO[uYJY`]J,Y`aTs[Y`eJTY`iJUdY`mJtY`qJUY`uJY`y[*Y`}JY`'kY`}Jv]kz1pKxkRUp[UpJUpEkz8'kp9kzpO[{a[ps[p[pJJpkpkp[pkp'kp#{|]kٷkpJ4$[kkiKJD}@$k kS 0JQM Q~PQ$Q̇Q:PQ쇀Q|T^PQݐ%QݐE)uP1QSLPQl79QU7=Q7A7E7IQ<$`Q\QuUTϛYQ]Ra󛣠eQiQ3q2c`Q`QUi}QiQ# pQiI)ϛ_zpQ4QH8McRQdMQ Q,QDQQURQU$!n)ԟ(P8 LP 4+! l+% L+) ڌ+- ڤ+1 ڼ+5 ̪+9 += +A X $I?@AJBC!eFUWHIJKMNOPQRSTUVWUXYZ[A]^_`*abcUefghЕijkmnopqJrs!uUvwxyХz{}~ЀЁЂRЃ5ЅІUЈЉЊЩ3ЍЎЏАБВГT/!ЕЖЗUЙКЛ!НОПР*СТУсUЦЧШЕЪЫe!ЭЮЯабJвгA!еUзийХлGнопRŁƁUǁȁɁʁiUzU U UUU!U34Ul4, X ?`/bK? )bC-| 7A$Ul4, )A-37"A_*<N@) LRVg$q7uH<( H<( _*<NE\[* RVgthq 6{zN  g"4FX(1u}?@(2~ίЂy Pu:]R\Q Tq&V!B1;> DO` Eͯ8OCzW S$r '>yf>Nf}),f 1f=l`21kpNV?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*gL9QOF$B_XKPcu jU8g'P!//*[mvǏُH}E0 TҙS-?Qcuχϙϫ);M_q߃ߕߧ߹߂ 2DVhzێb֯ *<N`rӘa#5GYk} 1CUgyՖ*!//(/:/L/^/p////////??$?6?H?Z?l?~?Ֆa?????? O@O-O?OQOcOuOUbbO1a6feOOOO__&_8_J_\_ҙ~________o o2oDoVoU oooooo,>Әia_q%7hcJxoj|ď֏ ASewџnasͯ߯0BTfxҿefB5GYk}ϡϳ-&8J\n߀ߒ߶I Y,1CUgy(:L^p'K$6HZl~9 -@?QcuBCh9!nkV3" bz@`nc/&`&/8/J/\/n%ib{/MvQ3/////??%?7?I?[?m?=G`P!=KBTfx,V/Pbt(:/^pj?@|?1!$6^DlMOumц >mKUrq!Wbqy[ja@OROfYNxYOOOOO/0% //0-VxQ$__FX|uAI!__oo%o7oIoL#F/a/j/5/////?O??'?9?K?)?????7:7H_Z_dOvO_____*=OL`{ޓՌ);f%tj|ğ֟蟜 !3b!HZ"d¯ԯ@RdҚ"4%7jǿٿ!3@!EŃx7I[m﵏Ǐ?? O2FLHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPUl4,?`/b? ̒A-3 7"AUl*<N@ FR@4(Ul*<N@| RUFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HG 9V?o)>  `r/`wpw> ȳpke{rpgTHYY9 mAUA? @ ?Q6 u` ?Mu ~YYA|XA44 4> !bJfvqQ >!"q06DNX lL>U5 LO@%#A?AE^?AL#l%u%?P6 @*  L#&H   " ' ]{%#W1\!\!5 `7Copyright 1999 Visio Corporation. All 2s reserved.`0_Sba.chm!#22427Bd(,*9 l>(>Ud!E (!(ZU$ B$bW*G g3?TU^7X q^?1,~Q?1(?1H_B#0ZX1va<oUole_oln+tcD%kYehA(~Qrepositioni<45/G/xD '2AUl4,?`/bC? ~U A-37;U2@47LRH<( U2E7 RUlLym@?Dz)RD{<U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)$LT *o8&Q- H*)=PEQy//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowEllipseWhite fillvisAecIsTech?nicalWallBuildingROOM BindingROOM Line StyleNet Thin lineNet NormalEllipse.4_3t0d En y- 8SGM 9Uqc U4qc Lqc Udqc |qc Քqc qd q q q, :9 $7F <7S T7` l7m 7z 7 737xA6U77;W4MU ,3 T3 u3 3 3 U3 *\S0UB*tS0F*<3 UJ S0S fS0`*3 dT; h*S0l*S0p+>tJ*S0x++@|*%,+@;+@++@{;+@*l+@T;+@*+@/K+@*+@*+@*+@*O?SK'Pi;'P{;'P;'PJ*+@/K'Pĵ*'P3;'P̵* KF E;PSKD؟;P+P$s[P;P KPi;L*TY`+Y`[M3]k`*`Uj̏`j` j`jNj4RIk pk p j\ p$jS(j$Up,kUp0T5{Up4jtUp8jUDUp?@ABCs1eFUHIJKTMNOUPQRSiUVWX*YZ[1]U]]^]_]`]Еa]b]c]e]f]g]h]iJ]j]kM]m]Un]o]p]q]Хr]s1]u]v]w]x]y]zR]{]}]~]U]Ѐ]Ё]Ђ]Щ9]Ѕ]І]Ї]Ј]Љ]Њ]ЋT9A]Ѝ]Ў]Џ]U]Б]В]Г]Е]Ж]З]И*]Й]К]Л]U]О]П]Р]Е]Т]У]]Х]Ц]Ч]Ш]ЩJ]Ъ]Ы]Э]U]Я]а]б]Х]г]е]ж]з]и]й]кR]лա]н]о]U]]]]Щ]]]Ǫ]]]]iUzU U UUU!U34Ul4,?`/bK? ((bC-3)A$Ul4, k)A-3y7"A_*<N@ܒ) MRVg{q7uH<( H<( _*<NE$) RVg*r G{zN  g"4FX(`w@(翪vy Xq:]R| 4rq}&t!BL;>COE8OywV a$x 'C%fQ|N |vfz)1~f 1yf=`218NV<( F{?FDTw*="R=5VG C!_G DVisioInformation"GSummaryInformation(HDocumentSummaryInformation8[_1043485842Fʣ˪Uʣ˪UOh+'0tHPht vhaisbcostekGxt{U EMFX XVISIODrawing  x  &% % Vt<1 &#2 C Ugy &1<GR\dkyogrUrCo2k#d\ RG<% (   % RL ArialpqfqrfrsfstgtuguvgvwhwxhxyhyziefbfgbghchicijciTzz% TC_AAC LdPreposition   ՜.+,D՜.+,@HP\h t   PagesMastersPage-1Ellipse8_VPID_PREVIEWS_VPID_ALTERNATENAMESh_PID_LINKBASE? A  FMicrosoft Visio DrawingVISIO 6.0 ShapesVisio.Drawing.69qOle cCompObjdqObjInfofVisioDocumentr ,    Visio (TM) Drawing  ,T*|Rl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1U#J:DT1EW-hTT<* /Ub bO0zGz?@8@H2!kWb*U  +$PL/^&9^$? { Ak^&,,'%/v&& * 1y   )P? 2   U U12?k9aBBHEHEHEHEHEHEH@?>?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*gL9QOF$B_XKPcu jU8g'P!//*[mvǏُH}E0 TҙS-?Qcuχϙϫ);M_q߃ߕߧ߹߂ 2DVhzێb֯ *<N`rӘa#5GYk} 1CUgyՖ*!//(/:/L/^/p////////??$?6?H?Z?l?~?Ֆa?????? O@O-O?OQOcOuOUbbO1a6feOOOO__&_8_J_\_ҙ~________o o2oDoVoU oooooo,>Әia_q%7hcJxoj|ď֏ ASewџnasͯ߯0BTfxҿefB5GYk}ϡϳ-&8J\n߀ߒ߶I Y,1CUgy(:L^p'K$6HZl~9 -@?QcuBCh9!nkV3" bz@`nc/&`&/8/J/\/n%ib{/MvQ3/////??%?7?I?[?m?=G`P!=KBTfx,V/Pbt(:/^pj?@|?1!$6^DlMOumц >mKUrq!Wbqy[ja@OROfYNxYOOOOO/0% //0-VxQ$__FX|uAI!__oo%o7oIoL#F/a/j/5/////?O??'?9?K?)?????7:7H_Z_dOvO_____*=OL`{ޓՌ);f%tj|ğ֟蟜 !3b!HZ"d¯ԯ@RdҚ"4%7jǿٿ!3@!EŃx7I[m﵏Ǐ?? O2FLHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPUl4,@Wd?$y"? @A- 3 7"A_vV*<N`r&8@ FR@4(_vV*<N`r&8@\ RUFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HC 5Vo?)> pp/quupwj  lpysopi`;Generic circle with text and connection points.b?贁NE?4 HDD # =hZ,>THYY9 mAUA? Q6 u` ?u ~YA|XA44 4> !bJfvq >!E"q06DNX l>U5 L@d($%9%#APE&L#%%%?P6 @RL# L#  7p  #2 ' JB{%#145 `7Copyright 1999 Visio Corporation. All 2s reservedo.`0_Sba.chm!#22426+l>(>Ud#1E (!(Z$ B$bW :?- vUG$M U MK MX we ,r D \ t    ͙ ʙ ;xG!SLUd 4U|Ui-y< 5U P\ Tt X \* ` d[+ h l+zSp+A0tA0Ix+A0|+A0+RA0+ "A0A0+A0i!;A0{,@D@JA0+@%l@7+@+@@I+@T+@@@/K@$Q|`+PTPSKPPTKPPe PKPUPZP ZS}" Z,PZUPZDPZUTPZdP"ZUtP&ZP*ZUP.ZP2ZP6[P:ZĪP>ZPBZ~FZ4`JJZL`Nk`RZ|`VKk`ZZ*`^Z`bk`UfZ`jZ`MnZ &Z$pvk`zZ?@ABC3eFUHIJRKMNUOPQRSUVWXYZ[TE]^_U`abc !efgh*ijkUmnopЕqrsWuvwxyJz{}U~ЀЁХЃЅІЇЈЉЊRЋiЍЎUАБВЩeЕЖЗИЙКЛTAНОПUСТУѪХЦЧШ*ЩЪЫUЮЯаЕвгkQежзийJклнUпХQqƪiUzU U UUU!U34Ul4,@Wd?$y"K? C(bC- A_U)A$Ul4, $)}A-7 "A_*<N@l@[) ORVgtq8uH<( H<( _*<NE@8* RVgEq {zN  g"4FX(e?@( ί0y XQ:]R}COE8OCtY v*$ }'dvRfRNxf)zf 1L{f=`2uKNV?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*Pbt߆ߘ߼#5GYk}b4?Qcua&8J\n /"4FXj|Q!//+/=/O/a/s////////??'?9?K?]?o????a???? OO0OBOTOfOxOOOUbbOXa]feOO__)_;_M___q________o#o5o0GoYoko}oU&oooo /ASea(:L^cqoǏُ!3E(hzŸԟ .@Я*EWi{ÿտ όf8i\nπϒϤ϶T);M_q߃ߕߧ߹p3ǀSFXj|+=OasNr'9K]o 9 0BTfxBC`!k}3I bz@6` /'c//A&`M/_/q//%b/)MQ3///??(?:?L?^?p???"dGoPo be3oo}_oooooo&8J\_VC94O*O -?Qcu͏ߏ'9K]ccU<犯"/ΟF//:/!щqfxү,>Pbtο@_ jK[CuU՞ϰϬҔЅaa3vO贁NkߖFa`27qZ?Yka?\.? pQA6k6߻H k+6;CjԕaI^g030|kPewȈ$ !%7dri{ /AS}/w+=Oa???'9A1K]DM*Oѭ e.KUqH)Wq[=ۑagOyOYuğYOOOOOV0%!/3/E/ W-}QK_mϣ(A(I1oo(o:oLo^opo s#m///5/////O(O*?P?????Ga^o__OO_____-?VQ=v.s#{.峑PbLǟٟ!3sHZb=!o"důׯ //gyI[L^$6HZg!lŪ(:ɏ^p9܏ $?OGOYJ#qٿ 1߀C __-_iȉX@R_ba QJ_+Չ/ڜ,5 ,5,0$Zl~r?? 2??h8LHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPUl4,N!2( ?@Jz? < A-|37U *<N`r@Dq BR @4(U *<N`r@q x RUFDfP h> /T6DUI@A?I BP(?3H$- b]b--rx@l^bf>M,,D'^fO - b, , 'eZYUHu F .LYcuZo^SLRepresents an actor reference.mb߿??PQ࿤p= ף??3㿕HD" # "=h#-$>T #T3 AOAU@?=@?@u߽?P6 )i8VYAEDA@@#u` *'.8BhPZ`u#j Ub >U5 gL{5!5 A`7Copyright 1999 Visio Corporation. All _"s reserved.`j _D88.chm!#2]0 l>0>Udd!!P #w a2U50` 9`fC"`e1De 2#(  O?si?e113???%G1 7@<Oa?9ME)2RO;rABC#(^actorReferenceiVA!aPIE9 3~'2qcPӼ? &bVq(^/\:5!?lOrISsQU__f+OnQ&%^]oeoooxGQ3ULYoopOorHl'-ER  [F 8# -r2? G1b XoOD+ty!Yo>?Dz!ko_( ?p 34RD g+@D>q +W@i{l _S  UPxP4FDTey  ahnm qT^UIN!2( ?I@Jz??-I?*?QcO@?^[qu`Fuae@u U Hq%P$w!p/////{!w!x$iD!w!p!N? "1 a$ ԉEP?@D?@W՘H?@X2>?a!H-#0QKE(<w!Q2m?Q?w!)l"10qU"1q5aD!G1)>&A*U30;[Q^5CSD%*^[G1_8ZqHnAD!D)BIAUW0VVBJo$a<0eY;HoZn0noo"c 0e\okA(QOutpatient Expansion from MEDICATION ROUTE file (#51.2)iT5/G/DD '2r?qBUl4,N!2( ?@JzC? p  U A-3*7;U2@,p 07LRH<( U2Etp 7 RUlL TT @?%|)RD< ;U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)$L5T *o 8&Q- H*)=-PEQ//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowWhite fillvisAecIsTech?nicalWallBuildingActor referenceActor reference.13ROOM BindingROOM Line StyleNet Thin lineNet NormalYellow fillMarketing Normal 3Flow Normal_3 E )'- R)2G)UJ )W}ec Urc 4c ULc dc U|c c Uc ăc U܃c c _ c $Id :|O@B/KO@F:O@J:O@N:RTSK'PV:4'PZK'P^:d'Pb:RO@fK'Pj:'PIn;'Pr;'Pv K'Pz/K'P~K'PR[j :`:$`=[`:D`;`a[`T[`:t`:U`:`:U`:`kOeK`KkR`›K`:`ʓk`:`$K`s[`K`Iޥk`[`kOeKpk`KpKpdKkp5{p *pCp CpCC,CtpC\R"C&C*C.CDNCd6JC:>CBUFC`C$NCRV Z^QbC Q‚PjC|UnCrCvCzg~"X -C<C4Z`CT٠T٠C٠CU٠C٠C٠y`˫WIݫW)CUU$ߝWӋWQWCUW!*W W,ADAʴW\A#tA'ʌA+A<AUAYJUApp'A=3EЩWЋ|ЏT{ГʜЗiRЛПգ $Я<гTзl*лʄпeЕi^3ХodoDo"TZzoo ꥤoojo#<#+#/T10 fx0p!!!_0jC#W%&'(*)*+'U-./0E125U6789:;i=>?@ABCUaOFUHIJKMNOP*QRS{UUVWXYZ[]]^_`aJbckQeUfghijkmnopqrRsuvUwxyz{A}~TU*U5JUQRYUTU* Ua UU U UUU!U34UUl4,!N!2( ?@JzK? _(g*C-_ 7A$Ul4, p "+A- 307"A_*<N@ * IRVg,2+7uH<( H<( _*<NE|"+ RVg\q u{zN  g"4FX(i @( sy p~!p :]RlOt  uq&_Lv !BD;>GOFo8O_<  e=$ K0U'|fQ>N xU)!x 1 ,x=,`{2 3"*V<]* F?q!i+GD|!5 C=t5 ,J! +Y UVisioInformation"SummaryInformation(`DocumentSummaryInformation8_1044259211Fʣ˪U˪U  &% % V0IHHH% (   % RL Arial}|zywSTTjkkl% T&g!AA& L`Outpatient   T&"g1AA&" L`Expansion  T 2AAA 2Llfrom MEDICATION       TBQAABLpROUTE file (#51.2)  ՜.+,D՜.+,@HP\h t   PagesMastersPage-1Actor reference8_VPID_PREVIEWS_VPID_ALTERNATENAMES_PID_LINKBASE A  FMicrosoft Visio DrawingVISIO 6.0 ShapesVisio.Drawing.69qOle CompObjqObjInfoVisioDocument ,Visio (TM) Drawing ,t $+Rl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1U&J:DT1EW-hTT<* /Ub bO0zGz?@8@H2!kWb*U  +$PL/^&9^$? { Ak^&,,'%/v&& * 1y   )P? 2   U U12?k9aBBHEHEHEHEHEHEH@?>?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*Pbt߆ߘ߼#5GYk}b4?Qcua&8J\n /"4FXj|Q!//+/=/O/a/s////////??'?9?K?]?o????a???? OO0OBOTOfOxOOOUbbOXa]feOO__)_;_M___q________o#o5o0GoYoko}oU&oooo /ASea(:L^cqoǏُ!3E(hzŸԟ .@Я*EWi{ÿտ όf8i\nπϒϤ϶T);M_q߃ߕߧ߹p3ǀSFXj|+=OasNr'9K]o 9 0BTfxBC`!k}3I bz@6` /'c//A&`M/_/q//%b/)MQ3///??(?:?L?^?p???"dGoPo be3oo}_oooooo&8J\_VC94O*O -?Qcu͏ߏ'9K]ccU<犯"/ΟF//:/!щqfxү,>Pbtο@_ jK[CuU՞ϰϬҔЅaa3vO贁NkߖFa`27qZ?Yka?\.? pQA6k6߻H k+6;CjԕaI^g030|kPewȈ$ !%7dri{ /AS}/w+=Oa???'9A1K]DM*Oѭ e.KUqH)Wq[=ۑagOyOYuğYOOOOOV0%!/3/E/ W-}QK_mϣ(A(I1oo(o:oLo^opo s#m///5/////O(O*?P?????Ga^o__OO_____-?VQ=v.s#{.峑PbLǟٟ!3sHZb=!o"důׯ //gyI[L^$6HZg!lŪ(:ɏ^p9܏ $?OGOYJ#qٿ 1߀C __-_iȉX@R_ba QJ_+Չ/ڜ,5 ,5,0$Zl~r?? 2??h8LHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPUFDfP h$T PUUBmUA@ ?I? 3xO@7IyIfBo?вsUP  /e Z.$ H"N @X(:H?_hz  ww "Square.b?贁N? 4 HDD $# =h-(>TTE=kUA@ ? uQ6 u` ?u B6> 00A0(2s@sJsT>d=$5 h9 L]{ !$5 `7Copyright 1999 Visio Corporation. All 4"s reserved.`? _Sba.chm!#224_17l>0>Udd!!  T '"<hb 261 g,s724  =?M1Y?r?91M1E;6=H=5P2?;rA IBOCq,B^35/\ @F"AC "3AP?LOe?#7A)[8B_T_OxY)___f_.eAE_oo_LHl'-i !OyaGE WszF4 # Vb?  DeLW os+_ o%?Tq!DoVUl4,`Fr?Ir <EUA-43K7"AU2@|M R@4(U2@7 R(n S 4@?=RD,K=Si{ UPxP4FDTey  ahnm qT^UI`Fr?Ir?I?*?Qc?e@?8^nqu`MuaeuU 'HqP$w!p/////{!w!x$iD!"1#N? 53 a$ E?@q5@>7Q #0/Q!H-E(<;5O[?Q?w!l "10qU"1 q59aD!G1>\A%*U6;[Q^5CSD%*^[G1_8Zq^G1,QG1UOAUW8_(a<4k_Xo_m4eoo`lwnoo&cD%n A(3atient Instruction +/or Provider Co;mmpsiT5/G/ D '_2qJAUl4,`Fr?r W A-37;U2@47FRH<( U2EW7 RUlL$] 6 @?  8wRD4 d;U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)$L^T g*o6')-8&Q - H*)=/"&-TEQ//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowSquareWhite fillvisAecIsTech?nicalWallBuildingSquare.8ROOM BindingROOM Line StyleNet Thin lineNet NormalYellow fillMarketing Normal 3Flow Normal_3t> E ? )- D)G\)W t)"cU)0c )U=c )Jc )Wc )dc @qc AU~c $c <}c Bc Fc ,H J>c M m}c 4Oc Ld d Jt%|U$\750@g]D*_UH*! L*! }P*`T+aXCbWg*{ k*doX{ *cՎ* *e*p%+%+w%,*_k*A0}*<~*_L*dw0պ*|w0*T§ 0> 7+0E;0++@*@T+0*@+@7+@E;@*J,@J<@ J4JJL@JK KP$J(J,J0Ji4=[8=[  4u}8 4 < @ " {Du- H/ L [PT [T d7X K \ M `-dOW h T٠l |T p \ t] x^ | D_ E {a g t  f ,Rݫ ̟=u  w  x > $~ ūS SS T  UM J*Uĭp'-T 1ˤ 5, 9 =ʄOA$W EpU?p@pApBpCw!OF"H*pIpJpKpUMpNpOpPpQpRpS1pUpVpWpXpYpZp[ǒ]p^p_p`paJpbpcpepUfpgphpipjpkѫpmpnpopppqprRpsIpupvpUwpxpypzp{p}p~pppppT!ppppUpppEpppp*ppppUpppppp'ApppppJpp=1ppUpppppS!ppppppRpKApppUppppipppppp«pTqpūpƫpǫpUȫpɫpʫp˭!pͫpΫpϫp*pѫpҫp[pUիp֫p׫pa'UU U UUU!U34UUl4,!`Fr'?r t)C-ܡ 7A$Ul4, **A-387"A_*<N@L) DRVg :*7uH<( H<( _*<NE* RVg q k{zN  g"4FX(v @(H֪Ly   :]R>  _\ _dj qW&#!B1 [;>EOVD_8O_ X}$, - 'TT|N T)- T 1t: T=݁`2> V<` uj F?q q*GD1| 5 C=La +J!@kY DVisioInformation"SummaryInformation(pDocumentSummaryInformation8WordDocument (Oh+'0@HPht vhaisbcostekGxMRLL EMFX XVISIODrawing  QQ  &% % V0MMLLLLL% (   % RL Arialdccbbwewlwowswexod% Tx;AAL\PatientT  T G+AA  LdInstructione  Td+28AA+LT+/or  T|8@EAA8L\Provider  T| EBRAA EL\Comments  ՜.+,D՜.+,@HP\h t   PagesMastersPage-1Square8_VPID_PREVIEWS_VPID_ALTERNATENAMES_PID_LINKBASE A  Oh+'00 <H d p | 3TAKE 2 TABLETS BY MOUTH EVERY 12 HOURS AFTER MEALSAKEKelly Anne CostelloellM bjbj== (WWl8888888l"""" .<lvL $C c282@ 88G@ @ @  88 @  @ @ :88Pj `zl" < P]0F jP@ L^8888TAKE TWO TABLETS EVERY 12 HOURSEntryElementFile TAKE  EMBED Visio.Drawing.6 DOSAGE FORM file (#50.606)TWO EMBED Visio.Drawing.6 DRUG file (#50)TABLETS EMBED Visio.Drawing.6 DOSAGE FORM file (#50.606)EVERY 12 HOURS EMBED Visio.Drawing.6 ADMINISTRATION SCHEDULE file (#51.1) or MEDICATION INSTRUCTION file (#51)Example: Simple Possible Dosage  !4:;<=UVXYtyz^_ļCJj5U\jT2> 5UV\j5U\jS2> 5UV\j5U\jtS2> 5UV\j5U\CJjP2> 5CJUV\j5CJU\ 5CJ\5\:CJ& !'/4}Psss $&PIfs$$Ifl47  6P 064 la$&P#$/If45<YtsdRR$$&P#$/Ifa$$&P#$/If$$IflF7=  6P06    4 latuysdRR$$&P#$/Ifa$$&P#$/If$$Ifl!F7=  6P06    4 lasdRR$$&P#$/Ifa$$&P#$/If$$IflF7= 6P06    4 la^sdRR$$&P#$/Ifa$$&P#$/If$$IflF7= 6P06    4 la^_sqoooooooooo$$Ifl~F7= 6P06    4 la    & 0 010 =!"#$%SummaryInformation(DocumentSummaryInformation8L_1053423631 F˪U˪UData  ell Normal.dotCEDS2SMicrosoft Word 9.0@@8@z@zT ՜.+,0 hp|  EDSR 3TAKE 2 TABLETS BY MOUTH EVERY 12 HOURS AFTER MEALS Title  FMicrosoft Word Document MSWordDocWord.Document.89q FMicrosoft Visio DrawingVISIO 6.0 ShapesVisio.Drawing.69qDd/6  3 A?22 w7h:# Dp`! w7h:# xWxT=OA};6NрJDa>%$H Be A)ӥM'] $*A$fo(AIXogvvvv (@  (:?-' ?j$2gs,h~X rSi=]kO,,\E`xC{uaF}q{&>':i]g=ί"elOdS>9pG=ӗ^\aGˑ!v=ʕ`ggq(ogM_ V.#=Q,ILlon}(Vssiʗأ\"Zk7Ky۫U_b^=#ݞgk^$nR4P_?ڨ4vV 3:Ct2YD'{u7SvveVz'R̉r\LjO}W\SDd80  # A2x1tNpp`!x1tNpl'dqxڵUMOA~gŊj5Q7=pBmb 1x(!KXp0?acxxhLshԸ>][0yvy?D"JKIhߩy*bz)=gLQvf71B#^ CO/M!WhJYr?>cV.$iEK b胴baZ?Z?wڛŭFxX9^pg9lDԺk`ZV5;kX[OmkӺ^r1f8㉳6 0oB[8y õs--`Xus mGKEshP)9+}R">, K&z~ȃz /ɧ8BWdIsXo_&$_^yQ"ߩ}{?3/B:\ƣ9{AN RVc6w篨ړe'qK6ƍ?Dd 0  # A2E놧"C{:ZsiSp`!E놧"C{:ZsidWxTMHTQι4 @*1RlEbY Ag@DnBQ@PH+Dh&q'ƖQ}7:=swwιˀ5c}+/av4Ĺ }5n(!n8W׀B )V=t-)":u?Bsr܎OhG?z0$,XO`J08ov$ҬY{26eiĐTSP#1VZqna +0]JiCcDj(QlsgV"HS7 EA#m0cX5182sT-:,#۰l NCԓ/ѿ)vOZmK5dzdtt3i3qefIuE7t]&ƈ\۲#V+㺋]C΢A$JTa|lvKgR||N,K;yˬԏ??>>J>[dd:gX&7~{1yn6~@f)dOQ tTU9N=d1".]yA C>ZǷfi1Ol2)wmP(%Q~z>m/B΋=zk4TEN67]+fws &P}WZ;0U ck"x.!b,Kߦ!qAFG).hN +ҝ9殠ţGm)e:#kk]g1 "a;~QoX\9"mǐ@1GAhZ5W6ۭ jZoZ:Y{ךj\x.nN pZhs]{xk[Be\xr~ _W{^*eS)7?]J6|;3OB&qO.XWe"d1OۥZqFI@$KŒbh927|Dd0  # A2QMgJu^BEV5- p`!%MgJu^BEV5HxUMHTQFMh1V-bhrRd2EH:a3MDUJRBM"qt* rJ@qծ;wι~rs}E?O*GgK. oL ,9 |(˂IgwmN{] 26&\H4p|}#(b2OYރ1"z^4qʲk92#S6=8.G\U^UJ]K,R8ٙCVMjxĨAUI%iwҀiC )YLKEqeRo^Jz(kj^ԴȰx$)AiN!qʔYR 2^Ƞz)M hĔ`D0$PŠ5VJǔ_9Y5.^m_Wvxẹ<N{pW}"OkL +fl=[ߑٯ7!bB._[<ߙyװ߹шvt#Nya}wjz"MCdoMtw~}ƾuy3k;FrZc}9K&G^>~'JbMv m?SlgӪ/o%͊ɉ29:`3l2x !fR5wG:={g;kRbDUځp?%w㼌vX'̯4Dd6  3 A?2#AEZAvUt>p`!#AEZAvUt>~xUkA~3hFSQVP"XBDKJmKhBY5 l$,xRDśGśxXGYm ̛7o_9_>$ ,r8,"A_L Djm`gI[##z1H4r8lsrVsFG( c?K \yT[R0-؆]sQ m<| 5,'C4ddΨXYՇK/-jͫC#gYI;#8+N\ 1y=wk@ y*>æx=eK<\܇{§ &-ӂbPaeC{{neݸr6׀wW{ׅ+qh2?#]`؄4n,<^A~*;OݛDO?9k9ٳ^`TORf y`-h/2kο#7 ~|-?H>0,Y~\ n?Z*TgӞ[io*NY:nǽswTnN gV>2CxNanP6Z7}oywfl53yGyXq7ti&P/yR*xY-IWYު9y[Y9*#M1Table CompObjjObjInfoObjectPool˪U˪U i8@8 NormalCJ_HaJmH sH tH PP Heading 1$ & F<@&CJKH \^JaJ 88 Heading 2$ & F@&\LL Heading 3$ & F<@&CJ\^JaJ22 Heading 4$@&5\FF Heading 6 & F<@&5CJ\aJ8@8 Heading 7$$@&a$5\J @J Heading 9 $$&`#$/@&a$5\<A@< Default Paragraph Font(@( TOC 1 5CJ\&& TOC 2x]::TOC 3 $ `^` mHnHuBBBTOC 4 $ ^` mHnHu&& TOC 5 ^@a@ TOC 60@& ^05CJ\aJ>r> Style1;CJ$KHOJQJ\^JaJFF Style2 ^;CJ$KHOJQJ\^JaJ-z-FGMUZ[a~<[\h+,/00@ 0@ 0@ 0@0@0@0@0@00000@0@0@0@00000000000000- Z- -az|8:h-::::::GM/<Z/LM*,,/Kelly Anne Costello7C:\My Documents\POE\Complex Local Possible Dosage 1.docKelly Anne Costello7C:\My Documents\POE\Complex Local Possible Dosage 1.docKelly Anne Costello7C:\My Documents\POE\Complex Local Possible Dosage 1.docKelly Anne Costello7C:\My Documents\POE\Complex Local Possible Dosage 1.docKelly Anne Costello7C:\My Documents\POE\Complex Local Possible Dosage 1.docKelly Anne Costello6C:\My Documents\POE\Simple Local Possible Dosage 1.docKelly Anne Costello6C:\My Documents\POE\Simple Local Possible Dosage 1.docKelly Anne Costello6C:\My Documents\POE\Simple Local Possible Dosage 1.docKelly Anne Costello6C:\My Documents\POE\Simple Local Possible Dosage 1.docKelly Anne CostelloDC:\My Documents\POE\Dosage Tables\Simple Local Possible Dosage 1.docTh* %lT; ^`56CJOJQJo(.8^`56CJOJQJo(.^`56CJOJQJo(.p ^p`o()@  ^@ `o(()x^`o(()H^`o(()^`o(()^`o(()^`56CJOJQJo(.8^`o(.^`o(.p ^p`o()@  ^@ `o(()x^`o(()H^`o(()^`o(()^`o(()%%%ThThThThFGMUZ[a~<[\h+,/@ MMZML-p@UnknownGzTimes New Roman5Symbol3& zArial"1h5;V5;VSY<0dFk2QMTAKE 2 TABLETS BY MOUTH EVERY MORNING AND TAKE 1 TABLET AT BEDTIM AS DIRECTEDKelly Anne CostelloEDS_1043484840F˪U˪UOle CompObjqObjInfoVisioDocument +VisioInformation"SummaryInformation( DocumentSummaryInformation8     +/ !"#$%&'()*,-.H0L23456789:;<=>?@ABCDEFGIJKdMiOPQRSTUVWXYZ[\]^_`abcefghjmnopqrstuvwxyz{|}~Visio (TM) Drawing +Lls*Rl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1U#J:DT1EW-hTT<* /Ub bO0zGz?@8@H2!kWb*U  +$PL/^&9^$? { Ak^&,,'%/v&& * 1y   )P? 2   U U12?k9aBBHEHEHEHEHEHEH@?>?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*gL9QOF$B_XKPcu jU8g'P!//*[mvǏُH}E0 TҙS-?Qcuχϙϫ);M_q߃ߕߧ߹߂ 2DVhzێb֯ *<N`rӘa#5GYk} 1CUgyՖ*!//(/:/L/^/p////////??$?6?H?Z?l?~?Ֆa?????? O@O-O?OQOcOuOUbbO1a6feOOOO__&_8_J_\_ҙ~________o o2oDoVoU oooooo,>Әia_q%7hcJxoj|ď֏ ASewџnasͯ߯0BTfxҿefB5GYk}ϡϳ-&8J\n߀ߒ߶I Y,1CUgy(:L^p'K$6HZl~9 -@?QcuBCh9!nkV3" bz@`nc/&`&/8/J/\/n%ib{/MvQ3/////??%?7?I?[?m?=G`P!=KBTfx,V/Pbt(:/^pj?@|?1!$6^DlMOumц >mKUrq!Wbqy[ja@OROfYNxYOOOOO/0% //0-VxQ$__FX|uAI!__oo%o7oIoL#F/a/j/5/////?O??'?9?K?)?????7:7H_Z_dOvO_____*=OL`{ޓՌ);f%tj|ğ֟蟜 !3b!HZ"d¯ԯ@RdҚ"4%7jǿٿ!3@!EŃx7I[m﵏Ǐ?? O2FLHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IP Ul4,&'?`/b? <A-43 7"AU~@*<N`@  FR @4(U~@*<N`@ RUFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HI ;V?-  _`߅pl`ul`u kw{sg_'Regular octagon, or eight-sided shape.b?贁N? 4 HDB $# ?h-(>TT9 EAUA@ ? Q6 mu` o?u j>Z--200`0A0(2@2T^h0r|>U5 L{/!4$5 `7Copyright 1999 Visio Corporation. All Y"s reserved.`d _Sba.chm!#22421PBd9 l> >Ud]!!(<* Z#A|rvPph.b31,1e g2(:S425$a?a! Ҁ?1E5Y6gq4bH3x81| N5%O7I71x?:?=3A1@IZ&Ax;87:U\S7I]:U; >tRTD%^RTEa^UQq5:^[ QY6[@$n[Q_HZq^QzD1QjeO_0_Sa<nU }e^}en}D%e,n}E~cq5~6Y|ev~cP{8ޏyA( ~Verbi$5/G/DD W'28AUl4,&'?`/bC? U A-37;U2@̔7LRH<( U2E7 RUlL|@?$)RD <U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)$LT *o8&Q- H*)=PEQy//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowOctagonWhite fillvisAecIsTech?nicalWallBuildingROOM BindingROOM Line StyleNet Thin lineNet NormalOctagon.5_34`~ Ed e>- fUG$M UZP9jP 9jP9jP9jܪP9jP9jP9jn"9j4`&9jL`*9jd`.9j|`2TKk`69j`:9j`>k`B9jԪ`F9j`J9j oN9j$pRTk`V9j!BRv&LJU,NlRUVZݫ^b<*fjǻEnw.,UUD7Ulp'3˭ʤݫW˭ҹQx{˭ڹ$OIiO7O湪UdO깪|OUO򹪤O%OOOK!*yH`'Q x'4'T10^!fxRp! ! j9`"#[%&'()*+T!-./01256789J:;m=U>?@ABC3eFUHIJKTMNOUPQRSUVWX*YZ[EU]^_`Еabc !efghiJjkmUnopqХrsWuvwxyzR{}~UЀЁЂЩЅІЇЈЉЊЋTiЍЎЏUБВГeЕЖЗИ*ЙКЛAUОПРЕТУХЦЧШЩJЪЫЭUЯабХгkQежзийкRлноUЩQqǪiUzU U UUU!U34Ul4,&'?`/bK? (bC-3')A$Ul4, Lz)A-D37"A_*<N@L-) MRVgdpq7uH<( H<( _*<NE* RVgpq \{zN  g"4FX(-@(P y @gn:]R>,k _lo_qq&yu!Bty;> DO` E8Ȯ, a$ '=fSNf)f 1 f=vl`2e NV<5( F?^dFDf!*KC=U5dG |J!pmG DOh+'0HPht vhaisbcostekGDxwt U EMF<X XVISIODrawing  {x  &% % V@wt T&&R&rTruRu&T% (   % RL Arial% Td"CV_AA"CLTVerb  ՜.+,D՜.+,@HP\h t   PagesMastersPage-1Octagon8_VPID_PREVIEWS_VPID_ALTERNATENAMES      !$()*+,-./0123456789:;=>?@ABCFJKLMNOPQRSTUVWXYZ[\]^_`abdefghijmqrstuvwxyz{|}~_PID_LINKBASE? A  FMicrosoft Visio DrawingVISIO 6.0 ShapesVisio.Drawing.69qOh+'0tH_1043485741F˪U˪UOle CompObjqObjInfoVisioDocument+VisioInformation"SummaryInformation(DocumentSummaryInformation8Visio (TM) Drawing +pe*|Rl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1U#J:DT1EW-hTT<* /Ub bO0zGz?@8@H2!kWb*U  +$PL/^&9^$? { Ak^&,,'%/v&& * 1y   )P? 2   U U12?k9aBBHEHEHEHEHEHEH@?>?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*gL9QOF$B_XKPcu jU8g'P!//*[mvǏُH}E0 TҙS-?Qcuχϙϫ);M_q߃ߕߧ߹߂ 2DVhzێb֯ *<N`rӘa#5GYk} 1CUgyՖ*!//(/:/L/^/p////////??$?6?H?Z?l?~?Ֆa?????? O@O-O?OQOcOuOUbbO1a6feOOOO__&_8_J_\_ҙ~________o o2oDoVoU oooooo,>Әia_q%7hcJxoj|ď֏ ASewџnasͯ߯0BTfxҿefB5GYk}ϡϳ-&8J\n߀ߒ߶I Y,1CUgy(:L^p'K$6HZl~9 -@?QcuBCh9!nkV3" bz@`nc/&`&/8/J/\/n%ib{/MvQ3/////??%?7?I?[?m?=G`P!=KBTfx,V/Pbt(:/^pj?@|?1!$6^DlMOumц >mKUrq!Wbqy[ja@OROfYNxYOOOOO/0% //0-VxQ$__FX|uAI!__oo%o7oIoL#F/a/j/5/////?O??'?9?K?)?????7:7H_Z_dOvO_____*=OL`{ޓՌ);f%tj|ğ֟蟜 !3b!HZ"d¯ԯ@RdҚ"4%7jǿٿ!3@!EŃx7I[m﵏Ǐ?? O2FLHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPUl4,?`/b? ̒A-3 7"AUl*<N@ FR@4(Ul*<N@| RUFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HG 9V?o)>  `r/`wpw> ȳpke{rpgTHYY9 mAUA? @ ?Q6 u` ?Mu ~YYA|XA44 4> !bJfvqQ >!"q06DNX lL>U5 LO@%#A?AE^?AL#l%u%?P6 @*  L#&H   " ' ]{%#W1\!\!5 `7Copyright 1999 Visio Corporation. All 2s reserved.`0_Sba.chm!#22427Bd(,*9 l>(>Ud!E (!(ZU$ B$bW*G g3?TU^7X q^?1,~Q?1(?1H_B#0ZX1va<oUole_oln+tcD%kYehA(~Qrepositioni<45/G/xD '2AUl4,?`/bC? ~U A-37;U2@47LRH<( U2E7 RUlLym@?Dz)RD{<U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)$LT *o8&Q- H*)=PEQy//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowEllipseWhite fillvisAecIsTech?nicalWallBuildingROOM BindingROOM Line StyleNet Thin lineNet NormalEllipse.4_3t0d En y- 8SGM 9Uqc U4qc Lqc Udqc |qc Քqc qd q q q, :9 $7F <7S T7` l7m 7z 7 737xA6U77;W4MU ,3 T3 u3 3 3 U3 *\S0UB*tS0F*<3 UJ S0S fS0`*3 dT; h*S0l*S0p+>tJ*S0x++@|*%,+@;+@++@{;+@*l+@T;+@*+@/K+@*+@*+@*+@*O?SK'Pi;'P{;'P;'PJ*+@/K'Pĵ*'P3;'P̵* KF E;PSKD؟;P+P$s[P;P KPi;L*TY`+Y`[M3]k`*`Uj̏`j` j`jNj4RIk pk p j\ p$jS(j$Up,kUp0T5{Up4jtUp8jUDUp?@ABCs1eFUHIJKTMNOUPQRSiUVWX*YZ[1]U]]^]_]`]Еa]b]c]e]f]g]h]iJ]j]kM]m]Un]o]p]q]Хr]s1]u]v]w]x]y]zR]{]}]~]U]Ѐ]Ё]Ђ]Щ9]Ѕ]І]Ї]Ј]Љ]Њ]ЋT9A]Ѝ]Ў]Џ]U]Б]В]Г]Е]Ж]З]И*]Й]К]Л]U]О]П]Р]Е]Т]У]]Х]Ц]Ч]Ш]ЩJ]Ъ]Ы]Э]U]Я]а]б]Х]г]е]ж]з]и]й]кR]лա]н]о]U]]]]Щ]]]Ǫ]]]]iUzU U UUU!U34Ul4,?`/bK? ((bC-3)A$Ul4, k)A-3y7"A_*<N@ܒ) MRVg{q7uH<( H<( _*<NE$) RVg*r G{zN  g"4FX(`w@(翪vy Xq:]R| 4rq}&t!BL;>COE8OywV a$x 'C%fQ|N |vfz)1~f 1yf=`218NV<( F{?FDTw*="R=5VG C!_G DPht vhaisbcostekGxt{U EMFX XVISIODrawing  x  &% % Vt<1 &#2 C Ugy &1<GR\dkyogrUrCo2k#d\ RG<% (   % RL ArialpqfqrfrsfstgtuguvgvwhwxhxyhyziefbfgbghchicijciTzz% TC_AAC LdPreposition   ՜.+,D՜.+,@HP\h t   PagesMastersPage-1Ellipse8_VPID_PREVIEWS_VPID_ALTERNATENAMESh_PID_LINKBASE? A  FMicrosoft Visio DrawingVISIO 6.0 ShapesVisio.Drawing.69qOh+'0H_1043485842F˪U˪UOle "CompObj#qObjInfo%VisioDocument1 ,VisioInformation"&SummaryInformation('DocumentSummaryInformation8<Visio (TM) Drawing  ,T*|Rl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1U#J:DT1EW-hTT<* /Ub bO0zGz?@8@H2!kWb*U  +$PL/^&9^$? { Ak^&,,'%/v&& * 1y   )P? 2   U U12?k9aBBHEHEHEHEHEHEH@?>?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*gL9QOF$B_XKPcu jU8g'P!//*[mvǏُH}E0 TҙS-?Qcuχϙϫ);M_q߃ߕߧ߹߂ 2DVhzێb֯ *<N`rӘa#5GYk} 1CUgyՖ*!//(/:/L/^/p////////??$?6?H?Z?l?~?Ֆa?????? O@O-O?OQOcOuOUbbO1a6feOOOO__&_8_J_\_ҙ~________o o2oDoVoU oooooo,>Әia_q%7hcJxoj|ď֏ ASewџnasͯ߯0BTfxҿefB5GYk}ϡϳ-&8J\n߀ߒ߶I Y,1CUgy(:L^p'K$6HZl~9 -@?QcuBCh9!nkV3" bz@`nc/&`&/8/J/\/n%ib{/MvQ3/////??%?7?I?[?m?=G`P!=KBTfx,V/Pbt(:/^pj?@|?1!$6^DlMOumц >mKUrq!Wbqy[ja@OROfYNxYOOOOO/0% //0-VxQ$__FX|uAI!__oo%o7oIoL#F/a/j/5/////?O??'?9?K?)?????7:7H_Z_dOvO_____*=OL`{ޓՌ);f%tj|ğ֟蟜 !3b!HZ"d¯ԯ@RdҚ"4%7jǿٿ!3@!EŃx7I[m﵏Ǐ?? O2FLHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPUl4,@Wd?$y"? @A- 3 7"A_vV*<N`r&8@ FR@4(_vV*<N`r&8@\ RUFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HC 5Vo?)> pp/quupwj  lpysopi`;Generic circle with text and connection points.b?贁NE?4 HDD # =hZ,>THYY9 mAUA? Q6 u` ?u ~YA|XA44 4> !bJfvq >!E"q06DNX l>U5 L@d($%9%#APE&L#%%%?P6 @RL# L#  7p  #2 ' JB{%#145 `7Copyright 1999 Visio Corporation. All 2s reservedo.`0_Sba.chm!#22426+l>(>Ud#1E (!(Z$ B$bW :?- vUG$M U MK MX we ,r D \ t    ͙ ʙ ;xG!SLUd 4U|Ui-y< 5U P\ Tt X \* ` d[+ h l+zSp+A0tA0Ix+A0|+A0+RA0+ "A0A0+A0i!;A0{,@D@JA0+@%l@7+@+@@I+@T+@@@/K@$Q|`+PTPSKPPTKPPe PKPUPZP ZS}" Z,PZUPZDPZUTPZdP"ZUtP&ZP*ZUP.ZP2ZP6[P:ZĪP>ZPBZ~FZ4`JJZL`Nk`RZ|`VKk`ZZ*`^Z`bk`UfZ`jZ`MnZ &Z$pvk`zZ?@ABC3eFUHIJRKMNUOPQRSUVWXYZ[TE]^_U`abc !efgh*ijkUmnopЕqrsWuvwxyJz{}U~ЀЁХЃЅІЇЈЉЊRЋiЍЎUАБВЩeЕЖЗИЙКЛTAНОПUСТУѪХЦЧШ*ЩЪЫUЮЯаЕвгkQежзийJклнUпХQqƪiUzU U UUU!U34Ul4,@Wd?$y"K? C(bC- A_U)A$Ul4, $)}A-7 "A_*<N@l@[) ORVgtq8uH<( H<( _*<NE@8* RVgEq {zN  g"4FX(e?@( ί0y XQ:]R}COE8OCtY v*$ }'dvRfRNxf)zf 1L{f=`2uKNV?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*gL9QOF$B_XKPcu jU8g'P!//*[mvǏُH}E0 TҙS-?Qcuχϙϫ);M_q߃ߕߧ߹߂ 2DVhzێb֯ *<N`rӘa#5GYk} 1CUgyՖ*!//(/:/L/^/p////////??$?6?H?Z?l?~?Ֆa?????? O@O-O?OQOcOuOUbbO1a6feOOOO__&_8_J_\_ҙ~________o o2oDoVoU oooooo,>Әia_q%7hcJxoj|ď֏ ASewџnasͯ߯0BTfxҿefB5GYk}ϡϳ-&8J\n߀ߒ߶I Y,1CUgy(:L^p'K$6HZl~9 -@?QcuBCh9!nkV3" bz@`nc/&`&/8/J/\/n%ib{/MvQ3/////??%?7?I?[?m?=G`P!=KBTfx,V/Pbt(:/^pj?@|?1!$6^DlMOumц >mKUrq!Wbqy[ja@OROfYNxYOOOOO/0% //0-VxQ$__FX|uAI!__oo%o7oIoL#F/a/j/5/////?O??'?9?K?)?????7:7H_Z_dOvO_____*=OL`{ޓՌ);f%tj|ğ֟蟜 !3b!HZ"d¯ԯ@RdҚ"4%7jǿٿ!3@!EŃx7I[m﵏Ǐ?? O2FLHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPUFDfP h$T PUUBmUA@ ?I? 3xO@7IyIfBo?вsUP  /e Z.$ H"N @X(:H?_hz  ww "Square.b?贁N? 4 HDD $# =h-(>TTE=kUA@ ? uQ6 u` ?u B6> 00A0(2s@sJsT>d=$5 h9 L]{ !$5 `7Copyright 1999 Visio Corporation. All 4"s reserved.`? _Sba.chm!#224_17l>0>Udd!!  T '"<hb 261 g,s724  =?M1Y?r?91M1E;6=H=5P2?;rA IBOCq,B^35/\ @F"AC "3AP?LOe?#7A)[8B_T_OxY)___f_.eAE_oo_LHl'-i !OyaGE WszFK#\WKb? t 6UDek>os+C?o%?5doVUl4,&'?xj? `aA-3g7"AU2@Ii7FR@4(U2@I7 R(nSLfP@?I=RD4KOi{ UPxP4FDTey  ahnm qT^UI&'?Ixj??-I?*?QcO@?^[qu`Fuae@u HqPƕ$p//@///{!6 kD!"1N? 5a$ @E?@0<ˊ?@xA|035?Q #00b/!H-(<<-?Q?l"10qU"1q59aD!G1>\A*U6;[Q^5CSD%*^[HG1_8Zq^G1,QG1UOAUW8_(aE4k_Xo_m4eoo`lwn6o`lD%n A(4atient Instructions+/orProvider Co;mmpsiT5/G/ D '2UBUl4,&'?xjC? NU A-37;U2@"7LRH<( U2E47 RUlLrXO@U?%n)RDs;U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)$LT *o8&Q- H*)=PEQy//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowSquareWhite fillvisAecIsTech?nicalWallBuildingROOM BindingROOM Line StyleNet Thin lineNet NormalSquare.1_34P ET U>- VUG$M1 UTMULc lMYc MUfc Msc MUc Mc M՚c Mc WWc ,c UDc \c Utc c d )ʃ;6XG@!Q0L\d`*4d*h*|l*p*t҃*YW*< TX *\ U*t * U* * [+ * ž+ZƑ+A0J*A0ε+A0+A0+A0+ޒ A0A0+A0!;A0*_[),@U JD@ JA0U J\@ Jl@U J|@ J@U J@ J@U$ J@( J@, J@0/K@4 J$\8 J<*P< JTP@SKPD JPHKPL JPP J PTTKPX JP\ J5P` J]" KPh/KPlKPpT[Pt JdPx JtP|=[P J*P JPa[P[P JP JP J^ J4` JL`k`eK`Kk`K` JR`k` J`K`s[_IKp̥k`[pkpeKp$kpKpKpKkp5{`Ik?k?k2?eK?&*?U??U ??M,at@t $J(,50b@U4q8Tq<@qD qHqLQqPccHPuX\ `d-h$lQp-qEtud$`|c-QceH`u!! !!-! !RӋ!!cfhpLTȋl̋UЋ-؋܋<*ǻEcg.,UDTZUl1p'@ʜDʴH̚LhpP䪭T$OX?@*ABC3w]FUHIJKMNOPQRRSUVUWXYZЩ[E]^_`abcT !efgUhijkmnop*qrsWUuvwxЕyz{}~ЀЁJЂЃЅUЇЈЉХЋiЍЎЏАБВRГkЕЖUИЙКЩНОПРСТУT{ХЦЧUЩЪЫЭЮЯа*бвгkQUжзиЕклнопJQqU9EUzU U UUU!U34Ul4,&'?xjK? iH'bC-`7A$Ul4, d'A-\3 ( A_*<N@,`' MRVg (6uH<( H<( _*<NEt`( RVgq {zN  g"4FX(Pm?@(PoίГy @0:]R>D8 _<_yq&d!u!Bߴi;>COxE8Ot?U$O'ԏN,t TT)\TU 1T=$`2UV F?C(GDl5 C=55 J!D 5  Oh+'0DHPht vhaisbcostekGxqv EMFX XVISIODrawing  ur  &% % V0qnlolol% (   % RL Arial% TxS)AAL\Patient    T +f=AA + LdInstructions     Td+>GPAA+>LT+/or    T|QYcAAQL\Provider     T|dbvAAdL\Comments    ՜.+,D՜.+,@HP\h t   PagesMastersPage-1Square8_VPID_PREVIEWS_VPID_ALTERNATENAMES_PID_LINKBASE[@ A  FMicrosoft Visio DrawingVISIO 6.0 ShapesVisio.Drawing.69q_1044258911F˪U˪UOle kCompObjlqObjInfonVisioDocumentl-VisioInformation"oSummaryInformation(p`DocumentSummaryInformation8  Visio (TM) Drawing -q ,zRl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1U&J:DT1EW-hTT<* /Ub bO0zGz?@8@H2!kWb*U  +$PL/^&9^$? { Ak^&,,'%/v&& * 1y   )P? 2   U U12?k9aBBHEHEHEHEHEHEH@?>?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*Pbt߆ߘ߼#5GYk}b4?Qcua&8J\n /"4FXj|Q!//+/=/O/a/s////////??'?9?K?]?o????a???? OO0OBOTOfOxOOOUbbOXa]feOO__)_;_M___q________o#o5o0GoYoko}oU&oooo /ASea(:L^cqoǏُ!3E(hzŸԟ .@Я*EWi{ÿտ όf8i\nπϒϤ϶T);M_q߃ߕߧ߹p3ǀSFXj|+=OasNr'9K]o 9 0BTfxBC`!k}3I bz@6` /'c//A&`M/_/q//%b/)MQ3///??(?:?L?^?p???"dGoPo be3oo}_oooooo&8J\_VC94O*O -?Qcu͏ߏ'9K]ccU<犯"/ΟF//:/!щqfxү,>Pbtο@_ jK[CuU՞ϰϬҔЅaa3vO贁NkߖFa`27qZ?Yka?\.? pQA6k6߻H k+6;CjԕaI^g030|kPewȈ$ !%7dri{ /AS}/w+=Oa???'9A1K]DM*Oѭ e.KUqH)Wq[=ۑagOyOYuğYOOOOOV0%!/3/E/ W-}QK_mϣ(A(I1oo(o:oLo^opo s#m///5/////O(O*?P?????Ga^o__OO_____-?VQ=v.s#{.峑PbLǟٟ!3sHZb=!o"důׯ //gyI[L^$6HZg!lŪ(:ɏ^p9܏ $?OGOYJ#qٿ 1߀C __-_iȉX@R_ba QJ_+Չ/ڜ,5 ,5,0$Zl~r?? 2??h8LHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPUl4,N!2( ?@Jz? < A-|37U *<N`r@Dq BR @4(U *<N`r@q x RUFDfP h> /T6DUI@A?I BP(?3H$- b]b--rx@l^bf>M,,D'^fO - b, , 'eZYUHu F .LYcuZo^SLRepresents an actor reference.mb߿??PQ࿤p= ף??3㿕HD" # "=h#-$>T #T3 AOAU@?=@?@u߽?P6 )i8VYAEDA@@#u` *'.8BhPZ`u#j Ub >U5 gL{5!5 A`7Copyright 1999 Visio Corporation. All _"s reserved.`j _D88.chm!#2]0 l>0>Udd!!P #w a2U50` 9`fC"`e1De 2#(  O?si?e113???%G1 7@<Oa?9ME)2RO;rABC#(^actorReferenceiVA!aPIE9 3~'2qcPӼ? &bVq(^/\:5!?lOrISsQU__f+OnQ&%^]oeoooxGQ3ULYoopOorHl'-ER  [F 8# -r2? G1b XoOD+ty!Yo>?Dz!ko_( ?p 34RD g+@D>q +W@i{l _S  UPxP4FDTey  ahnm qT^UIN!2( ?I@Jz??-I?*?QcO@?^[qu`Fuae@u U Hq%P$w!p/////{!w!x$iD!w!p!N? "1 a$ ԉEP?@D?@W՘H?@X2>?a!H-#0QKE(<w!Q2m?Q?w!)l"10qU"1q5aD!G1)>&A*U30;[Q^5CSD%*^[G1_8ZqHnAD!D)BIAUW0VVBJo$a<0eY;HoZn0noo"c 0e\okA(QOutpatient Expansion from MEDICATION ROUTE file (#51.2)iT5/G/DD '2r?qBUl4,N!2( ?@JzC? p  U A-3*7;U2@,p 07LRH<( U2Etp 7 RUlL TT @?%|)RD< ;U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)$L5T *o 8&Q- H*)=-PEQ//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowWhite fillvisAecIsTech?nicalWallBuildingActor referenceActor reference.13ROOM BindingROOM Line StyleNet Thin lineNet NormalYellow fillMarketing Normal 3Flow Normal_3 E )'- R)2G)UJ )W}ec Urc 4c ULc dc U|c c Uc ăc U܃c c _ c $Id :|O@B/KO@F:O@J:O@N:RTSK'PV:4'PZK'P^:d'Pb:RO@fK'Pj:'PIn;'Pr;'Pv K'Pz/K'P~K'PR[j :`:$`=[`:D`;`a[`T[`:t`:U`:`:U`:`kOeK`KkR`›K`:`ʓk`:`$K`s[`K`Iޥk`[`kOeKpk`KpKpdKkp5{p *pCp CpCC,CtpC\R"C&C*C.CDNCd6JC:>CBUFC`C$NCRV Z^QbC Q‚PjC|UnCrCvCzg~"X -C<C4Z`CT٠T٠C٠CU٠C٠C٠y`˫WIݫW)CUU$ߝWӋWQWCUW!*W W,ADAʴW\A#tA'ʌA+A<AUAYJUApp'A=3EЩWЋ|ЏT{ГʜЗiRЛПգ $Я<гTзl*лʄпeЕi^3ХodoDo"TZzoo ꥤoojo#<#+#/T10 fx0p!!!_0jC#W%&'(*)*+'U-./0E125U6789:;i=>?@ABCUaOFUHIJKMNOP*QRS{UUVWXYZ[]]^_`aJbckQeUfghijkmnopqrRsuvUwxyz{A}~TU*U5JUQRYUTU* Ua UU U UUU!U34UUl4,!N!2( ?@JzK? _(g*C-_ 7A$Ul4, p "+A- 307"A_*<N@ * IRVg,2+7uH<( H<( _*<NE|"+ RVg\q u{zN  g"4FX(i @( sy p~!p :]RlOt  uq&_Lv !BD;>GOFo8O_<  e=$ K0U'|fQ>N xU)!x 1 ,x=,`{2 3"*V<]* F?q!i+GD|!5 C=t5 ,J! +Y UOh+'00HPht vhaisbcostekGxQ EMF|X XVISIODrawing  M  &% % V0IHHH% (   % RL Arial}|zywSTTjkkl% T&g!AA& L`Outpatient   T&"g1AA&" L`Expansion  T 2AAA 2Llfrom MEDICATION       TBQAABLpROUTE file (#51.2)  ՜.+,D՜.+,@HP\h t   PagesMastersPage-1Actor reference8_VPID_PREVIEWS_VPID_ALTERNATENAMES_PID_LINKBASE A  FMicrosoft Visio DrawingVISIO 6.0 ShapesVisio.Drawing.69qOh+'0H_1044789508F˪U˪UOle CompObjqObjInfoVisioDocumentF#VisioInformation"SummaryInformation(DocumentSummaryInformation8Visio (TM) Drawing F#d!zRl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1TJDT1EWP-hTT<U*U U =/Ub b酸0zGz?@8H2!kWbU%U  +PL/^&9^$? { Ak^&,",'%/v&Q&  1y   )? 2    J12?k9aUBBHEHEHEUHEHEHEH@?>?:`2BBHEHEHEHEHEHEHEH@$%O9F7AOY@; A*sVsVAgLTkY 1 W_W__ !`#ku4lb6Pu`kW 4l 4l %Y?:?-\ *#!+|tKf*2|2|2|2wG)QUoTMeEttA%_8BOTOfOxOO??O?7 ܻuW+? sU42 T*PbtφϘϪ(:L^p߂߂O߳ 1C@Ugb{.);M_xa"4FX 0Bzas//'/9/K/]/o/////////?#?zaB?T?f?x????????OBOUbb7OQV.e_OqOOOOOOOO_wk#_5_G_Y_k_}______L__UlAoSoeowoooooooxa(:L^p cwo!3EWi{Ï٦ .@Rdvk}*B'Ck#bz@.`c.`/%b /=QN3L/^/p////////??7?Pbtί(:L^p݇Z;ɼٿِ>.@*[m߅3O'Nk P2Ǎq?߃?\.?o AqT$$$'9K]ڊ䐾伩jPPj|xԕIWؙ&V03E)0<kDB!ߵ V /ASew+=Oa/09K]o?!?%LHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55H!winspoolHP LaserJet 5Si_742029_IP0Ul4,zLp?Dc) ? |2!}A-0'7"AUV6@1)GRUFDfP h$T PUUBmUA@ ?I? 3xO@7IyIfBo?вsUP  /e Z.$ H" S?!{)19AI?dp]qi} Aw:npqA9pwwA9pwpiEquilateral triangle.b?? ߿ $t@ ?<?紁N;3HDB t# ih0>T@dE=M AkUA@??A߻?Q6 L,A >M A JuM` ?[y&y0y:@u` UJS>#JU0O贁NKk?<@MJdO@ܼ@ L LP6 @?FS@U%%F@))@H""oKJ%{X1]45 `7Copyright 1999 Visio Corporation. All 2s reserved.J`0_Sba.chm!#22416Aida?lJ*,>Ud6ZV$(s=?)ǹ<$$b# X"yB:V/ K;EA%;D]2׳뽿HH?!:ͳ?OARM%2pO;JrA RSq(^!(M%9M\Me2AO-QVD}Ho *oFTO`c5WD`18WoiDYebW_`c%@neNooO[jJ(?kF8Hlh !OyaGEWszF#<s? mWakoD+oB?\ooP@4(UV6@42{ R(n?1p#R,+@SDD' ,ij UPxP4FDTe]@y  ahZ- ^TUIzLp?IDc_) ?? I?*?QcS@?^ua`u$ eu G{!D!e "u)D%@?@?@J7?@O*g?5H5??/18! L.&6.&62U66666#0Q 3-%// d/U1H<p$1CɭRCa(D1)A1!i$5/G/D '2qGPQA1DiQ [B1a`Q/`Q]%QAUD-YaE90:x?@?Pp?d?@.%ef]K?Q !t\A ]tE0Vbt!abMozUme\mmevgzkچ05E m=Ac#gc4heAO-O?C&@/^A<ߩߏ̟9KH~﷟۟1DLocalPossibleDosage@`Q!3EWrcNSh()Ul4,zLp?Dc) K? 1A-07;U2@407LRH<( U2E0 7 RUlL oz@?)RD7<U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)LT *o8&Q- H*)=PEQy//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowvisAecIsTech?nicalTriangleTriangle.6Triangle.18_,34s E} J- ;G; W,qUc Dqc \qUc tqc qc qd q q! q. ; %H 4%U L%b d%o |%| % % %J ;%y˨X,T* M*\*lV)[*; m+%[*[*[*m+[*#[ ? 2R[ B[*d )F[&"" 0 fPx!1m*E[  !"#$%&'() *+U^U U UUUl4,zLp?Dc) K? 37 KC-$37AUl4, 5 A-37"A_*<N@2 KRVgq7uH<( H<( _*<NE2`! RVgmq \{zN  g"4FX(Ga ?@(g:bίy @D:]R}< lq&|!BC; >EOtDo9OWW$'6fO|Ndf)f 1f=1`2ĕJV<- 7F?HNFDzJNC= !N|J!NPht vhaisbcostekGx] EMF!X XVISIODrawing    &% % V,o~nAn~n% (   &% % V, ~K~~% (   % RL Arial% Tl:N\]AA:NLXLocal  T|0^dmAA0^L\Possible   Tp3oa~AA3oLXDosage  ՜.+,D՜.+,@HP\h t   PagesMastersPage-1 Triangle8_VPID_PREVIEWS_VPID_ALTERNATENAMES_PID_LINKBASE A  Oh+'0 ,8L XWordDocument(SummaryInformation(DocumentSummaryInformation8d_1056888248H  F˪U˪UM -bjbj== (WW-l>>>>>>>r    4,rKlp$ !>B>>BBB>>BBBJ:*>>` zr  0K :BRd>>>>APPLY THIN FILM TO AFFECTED AREA TWICE DAILY AFTER WASHING THOROUGHLYEntryElementFileAPPLY EMBED Visio.Drawing.6 DOSAGE FORM file (#50.606) THIN FILM EMBED Visio.Drawing.6 DRUG FILE (#50) TO EMBED Visio.Drawing.6 DOSAGE FORM file (#50.606) AFFECTED AREA EMBED Visio.Drawing.6 MEDICATION ROUTES file (#51.2)TWICE DAILY EMBED Visio.Drawing.6 ADMINISTRATION SCHEDULE file (#51.1) or MEDICATION INSTRUCTIONS file (#51)AFTER WASHING THOROUGHLY EMBED Visio.Drawing.6 ORDERABLE ITEM file (#50.7) or CPRS FGZabz{}~ 89:;<[hi} jpUj}2> UVj 5U\jT2> 5UV\ j Uj_ >> UVj5U\j-T2> 5UV\j5U\ jUj9F> UV jUCJjP2> 5CJUV\ 5CJ\j5CJU\5\:CJ1FGMUZP $&#$/Ifj$$IfTl[   064 la$If-Z[a~ztkk $$Ifa$$If$$IfTlF  0. 06    4 laztkk $$Ifa$$If$$IfTlF  0. 06    4 la<[\hztkkz,tkkztkk $$Ifa$$If$$IfTlF  0. 06    4 la +,-zltkkzi $$Ifa$$If$$IfTlF  0. 06    4 la+,-5\CJ& 0 01L, =!"#$%d    NTAKE 2 TABLETS BY MOUTH EVERY MORNING AND TAKE 1 TABLET AT BEDTIM AS DIRECTEDAAKEKelly Anne Costelloellell Normal.dotCEDS2SMicrosoft Word 9.0@@@z@zS ՜.+,04 hp|  EDSF NTAKE 2 TABLETS BY MOUTH EVERY MORNING AND TAKE 1 TABLET AT BEDTIM AS DIRECTED Title  FMicrosoft Word Document MSWordDocWord.Document.89qData "1Table CompObjjObjInfo EDd/6  3 A?22 w7h:# Dp`! w7h:# xWxT=OA};6NрJDa>%$H Be A)ӥM'] $*A$fo(AIXogvvvv (@  (:?-' ?j$2gs,h~X rSi=]kO,,\E`xC{uaF}q{&>':i]g=ί"elOdS>9pG=ӗ^\aGˑ!v=ʕ`ggq(ogM_ V.#=Q,ILlon}(Vssiʗأ\"Zk7Ky۫U_b^=#ݞgk^$nR4P_?ڨ4vV 3:Ct2YD'{u7SvveVz'R̉r\LjO}W\SDd80  # A2x1tNpp`!x1tNpl'dqxڵUMOA~gŊj5Q7=pBmb 1x(!KXp0?acxxhLshԸ>][0yvy?D"JKIhߩy*bz)=gLQvf71B#^ CO/M!WhJYr?>cV.$iEK b胴baZ?Z?wڛŭFxX9^pg9lDԺk`ZV5;kX[OmkӺ^r1f8㉳6 0oB[8y õs--`Xus mGKEshP)9+}R">, K&z~ȃz /ɧ8BWdIsXo_&$_^yQ"ߩ}{?3/B:\ƣ9{AN RVc6w篨ړe'qK6ƍ?Dd 0  # A2E놧"C{:ZsiSp`!E놧"C{:ZsidWxTMHTQι4 @*1RlEbY Ag@DnBQ@PH+Dh&q'ƖQ}7:=swwιˀ5c}+/av4Ĺ }5n(!n8W׀B )V=t-)":u?Bsr܎OhG?z0$,XO`J08ov$ҬY{26eiĐTSP#1VZqna +0]JiCcDj(QlsgV"HS7 EA#m0cX5182sT-:,#۰l NCԓ/ѿ)vOZmK5dzdtt3i3qefIuE7t]&ƈ\۲#V+㺋]C΢A$JTa|lvKgR||N,K;yˬԏ??>>J>[dd:gX&7~{1yn6~@f)dOQ tTU9N=d1".]yA C>ZǷfi1Ol2)wmP(%Q~z>m/B΋=zk4TEN67]+fws &P}WZ;0U ck"x.!b,Kߦ!qAFG).hN +ҝ9殠ţGm)e:#kk]g1 "a;~QoX\9"mǐ@1GAhZ5W6ۭ jZoZ:Y{ךj\x.nN pZhs]{xk[Be\xr~ _W{^*eS)7?]J6|;3OB&qO.XWe"d1OۥZqFI@$KŒbh927|Dd0  # A2QMgJu^BEV5- p`!%MgJu^BEV5HxUMHTQFMh1V-bhrRd2EH:a3MDUJRBM"qt* rJ@qծ;wι~rs}E?O*GgK. oL ,9 |(˂IgwmN{] 26&\H4p|}#(b2OYރ1"z^4qʲk92#S6=8.G\U^UJ]K,R8ٙCVMjxĨAUI%iwҀiC )YLKEqeRo^Jz(kj^ԴȰx$)AiN!qʔYR 2^Ƞz)M hĔ`D0$PŠ5VJǔ_9Y5.^m_Wvxẹ<N{pW}"OkL +fl=[ߑٯ7!bB._[<ߙyװ߹шvt#Nya}wjz"MCdoMtw~}ƾuy3k;FrZc}9K&G^>~'JbMv m?SlgӪ/o%͊ɉ29:`3l2x !fR5wG:={g;kRbDUځp?%w㼌vX'̯4Dd0  # A2JK]pIG &p`!K]pIG 4 xT;K\Afk\A.>F\ֈ|`Rl!{) X[ZTv)ZK`uoL|sΜ99s*޶R@u9ޛɢQAr`3*eGt;QӺ:zXOL,Qσ,}pi,)OvQ&V64rgVB˒suzg X&,qH'C-c/9138&q0;o53B?~>g aѼPSYcaR'r1q5=&yx#< &qq\fZCTA-3E0.W>u8b:V} }E7qT1RcG(Ii&-tDוJZ5WQ/q;MQ!;lRYβRM0F8vI9Ϩ| յ<+PطWx3km^\ VڼaM-3E6ijLܬ͖l){$%joO9i,CA- $o`+c+լK\ym<.PΫNNt i{ یcf$K11<1-73/x~ߣ_]|LK.~lo;3%Ҟώ߲Wٵvk~03RPaA>tLBғ:|6G~/`'CĠ܃_gm iM\|[[.*_2"{wRJ)Wnp$g zVS~yO+4(.Av_k 2KVa7*V 7z/o6 t'zu5[i7(~oK })Knu5'\*JDd/6  3 A?22 w7h:# Lp`! w7h:# xWxT=OA};6NрJDa>%$H Be A)ӥM'] $*A$fo(AIXogvvvv (@  (:?-' ?j$2gs,h~X rSi=]kO,,\E`xC{uaF}q{&>':i]g=ί"elOdS>9pG=ӗ^\aGˑ!v=ʕ`ggq(ogM_ V.#=Q,ILlon}(Vssiʗأ\"Zk7Ky۫U_b^=#ݞgk^$nR4P_?ڨ4vV 3:Ct2YD'{u7SvveVz'R̉r\LjO}W\SDd80   # A 2x1tNpp`!x1tNpl'dqxڵUMOA~gŊj5Q7=pBmb 1x(!KXp0?acxxhLshԸ>][0yvy?D"JKIhߩy*bz)=gLQvf71B#^ CO/M!WhJYr?>cV.$iEK b胴baZ?Z?wڛŭFxX9^pg9lDԺk`ZV5;kX[OmkӺ^r1f8㉳6 0oB[8y õs--`Xus mGKEshP)9+}R">, K&z~ȃz /ɧ8BWdIsXo_&$_^yQ"ߩ}{?3/B:\ƣ9{AN RVc6w篨ړe'qK6ƍ?Dd0   # A  2QMgJu^BEV5-[p`!%MgJu^BEV5HxUMHTQFMh1V-bhrRd2EH:a3MDUJRBM"qt* rJ@qծ;wι~rs}E?O*GgK. oL ,9 |(˂IgwmN{] 26&\H4p|}#(b2OYރ1"z^4qʲk92#S6=8.G\U^UJ]K,R8ٙCVMjxĨAUI%iwҀiC )YLKEqeRo^Jz(kj^ԴȰx$)AiN!qʔYR 2^Ƞz)M hĔ`D0$PŠ5VJǔ_9Y5.^m_Wvxẹ<N{pW}"OkL +fl=[ߑٯ7!bB._[<ߙyװ߹шvt#Nya}wjz"MCdoMtw~}ƾuy3k;FrZc}9K&G^>~'JbMv m?SlgӪ/o%͊ɉ29:`3l2x !fR5wG:={g;kRbDUځp?%w㼌vX'̯4 i8@8 NormalCJ_HaJmH sH tH PP Heading 1$ & F<@&CJKH \^JaJ 88 Heading 2$ & F@&\LL Heading 3$ & F<@&CJ\^JaJ22 Heading 4$@&5\FF Heading 6 & F<@&5CJ\aJ8@8 Heading 7$$@&a$5\J @J Heading 9 $$&`#$/@&a$5\<A@< Default Paragraph Font(@( TOC 1 5CJ\&@& TOC 2x]::TOC 3 $ `^` mHnHuBBBTOC 4 $ ^` mHnHu&& TOC 5 ^@a@ TOC 60@& ^05CJ\aJ>r> Style1;CJ$KHOJQJ\^JaJFF Style2 ^;CJ$KHOJQJ\^JaJ"z^_emrsx-.4Qpq+,1Ncdj ST{|}~00@ 0@ 0@ 0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@00000@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@00000000000000000000000000000000000000000000000000 rq1| x 4MO1JLj::::::::::\bNc.T]abqQSWb[[Kelly Anne Costello7C:\My Documents\POE\Complex Local Possible Dosage 1.docKelly Anne Costello7C:\My Documents\POE\Complex Local Possible Dosage 1.docKelly Anne Costello7C:\My Documents\POE\Complex Local Possible Dosage 1.docKelly Anne Costello7C:\My Documents\POE\Complex Local Possible Dosage 1.docKelly Anne Costello7C:\My Documents\POE\Complex Local Possible Dosage 1.docKelly Anne Costello7C:\My Documents\POE\Complex Local Possible Dosage 1.docKelly Anne CostellocC:\WINDOWS\Application Data\Microsoft\Word\AutoRecovery save of Complex Local Possible Dosage 1.asdKelly Anne CostelloEC:\My Documents\POE\Dosage Tables\Complex Local Possible Dosage 1.docKelly Anne CostelloFC:\My Documents\POE\Dosage Tables\2 Complex Local Possible Dosage .docKelly Anne CostelloFC:\My Documents\POE\Dosage Tables\2 Complex Local Possible Dosage .docTh* %lT; ^`56CJOJQJo(.8^`56CJOJQJo(.^`56CJOJQJo(.p ^p`o()@  ^@ `o(()x^`o(()H^`o(()^`o(()^`o(()^`56CJOJQJo(.8^`o(.^`o(.p ^p`o()@  ^@ `o(()x^`o(()H^`o(()^`o(()^`o(()%%%ThThThTh^_emrsx-.4Qpq+,1Ncdj ST@ bb"bW@UnknownG:Times New Roman5Symbol3& :Arial"hҋWFҋWFY<~0dgO2QMTAKE 2 TABLETS BY MOUTH EVERY MORNING AND TAKE 1 TABLET AT BEDTIM AS DIRECTEDKelly Anne CostelloEDSObjectPool˪U˪U_1043484840F˪U˪UOle CompObjq FMicrosoft Visio DrawingVISIO 6.0 ShapesVisio.Drawing.69qOh+'0HPht vhaisbcostekGDxwtObjInfoVisioDocument+VisioInformation"SummaryInformation( Visio (TM) Drawing +Lls*Rl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1U#J:DT1EW-hTT<* /Ub bO0zGz?@8@H2!kWb*U  +$PL/^&9^$? { Ak^&,,'%/v&& * 1y   )P? 2   U U12?k9aBBHEHEHEHEHEHEH@?>?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*gL9QOF$B_XKPcu jU8g'P!//*[mvǏُH}E0 TҙS-?Qcuχϙϫ);M_q߃ߕߧ߹߂ 2DVhzێb֯ *<N`rӘa#5GYk} 1CUgyՖ*!//(/:/L/^/p////////??$?6?H?Z?l?~?Ֆa?????? O@O-O?OQOcOuOUbbO1a6feOOOO__&_8_J_\_ҙ~________o o2oDoVoU oooooo,>Әia_q%7hcJxoj|ď֏ ASewџnasͯ߯0BTfxҿefB5GYk}ϡϳ-&8J\n߀ߒ߶I Y,1CUgy(:L^p'K$6HZl~9 -@?QcuBCh9!nkV3" bz@`nc/&`&/8/J/\/n%ib{/MvQ3/////??%?7?I?[?m?=G`P!=KBTfx,V/Pbt(:/^pj?@|?1!$6^DlMOumц >mKUrq!Wbqy[ja@OROfYNxYOOOOO/0% //0-VxQ$__FX|uAI!__oo%o7oIoL#F/a/j/5/////?O??'?9?K?)?????7:7H_Z_dOvO_____*=OL`{ޓՌ);f%tj|ğ֟蟜 !3b!HZ"d¯ԯ@RdҚ"4%7jǿٿ!3@!EŃx7I[m﵏Ǐ?? O2FLHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IP Ul4,&'?`/b? <A-43 7"AU~@*<N`@  FR @4(U~@*<N`@ RUFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HI ;V?-  _`߅pl`ul`u kw{sg_'Regular octagon, or eight-sided shape.b?贁N? 4 HDB $# ?h-(>TT9 EAUA@ ? Q6 mu` o?u j>Z--200`0A0(2@2T^h0r|>U5 L{/!4$5 `7Copyright 1999 Visio Corporation. All Y"s reserved.`d _Sba.chm!#22421PBd9 l> >Ud]!!(<* Z#A|rvPph.b31,1e g2(:S425$a?a! Ҁ?1E5Y6gq4bH3x81| N5%O7I71x?:?=3A1@IZ&Ax;87:U\S7I]:U; >tRTD%^RTEa^UQq5:^[ QY6[@$n[Q_HZq^QzD1QjeO_0_Sa<nU }e^}en}D%e,n}E~cq5~6Y|ev~cP{8ޏyA( ~Verbi$5/G/DD W'28AUl4,&'?`/bC? U A-37;U2@̔7LRH<( U2E7 RUlL|@?$)RD <U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)$LT *o8&Q- H*)=PEQy//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowOctagonWhite fillvisAecIsTech?nicalWallBuildingROOM BindingROOM Line StyleNet Thin lineNet NormalOctagon.5_34`~ Ed e>- fUG$M UZP9jP 9jP9jP9jܪP9jP9jP9jn"9j4`&9jL`*9jd`.9j|`2TKk`69j`:9j`>k`B9jԪ`F9j`J9j oN9j$pRTk`V9j!BRv&LJU,NlRUVZݫ^b<*fjǻEnw.,UUD7Ulp'3˭ʤݫW˭ҹQx{˭ڹ$OIiO7O湪UdO깪|OUO򹪤O%OOOK!*yH`'Q x'4'T10^!fxRp! ! j9`"#[%&'()*+T!-./01256789J:;m=U>?@ABC3eFUHIJKTMNOUPQRSUVWX*YZ[EU]^_`Еabc !efghiJjkmUnopqХrsWuvwxyzR{}~UЀЁЂЩЅІЇЈЉЊЋTiЍЎЏUБВГeЕЖЗИ*ЙКЛAUОПРЕТУХЦЧШЩJЪЫЭUЯабХгkQежзийкRлноUЩQqǪiUzU U UUU!U34Ul4,&'?`/bK? (bC-3')A$Ul4, Lz)A-D37"A_*<N@L-) MRVgdpq7uH<( H<( _*<NE* RVgpq \{zN  g"4FX(-@(P y @gn:]R>,k _lo_qq&yu!Bty;> DO` E8Ȯ, a$ '=fSNf)f 1 f=vl`2e NV<5( F?^dFDf!*KC=U5dG |J!pmG D U EMF<X XVISIODrawing  {x  &% % V@wt T&&R&rTruRu&T% (   % RL Arial% Td"CV_AA"CLTVerb  ՜.+,D՜.+,@HP\h t   DocumentSummaryInformation8_1043485741 %F˪U˪UOle CompObjqPagesMastersPage-1Octagon8_VPID_PREVIEWS_VPID_ALTERNATENAMES_PID_LINKBASE? A  FMicrosoft Visio DrawingVISIO 6.0 ShapesVisio.Drawing.69qObjInfoVisioDocument+VisioInformation"SummaryInformation(Oh+'0tHPht vhaisbcostekGxt{U EMFX XVISIODrawing  x   +) !"#$%&'(*,.-LO0123456789:;<=>?@ABCDEFGHIJKMNPQilSTUVWXYZ[\]^_`abcdefghjkmnqrstuvwxyz{|}~Visio (TM) Drawing +pe*|Rl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1U#J:DT1EW-hTT<* /Ub bO0zGz?@8@H2!kWb*U  +$PL/^&9^$? { Ak^&,,'%/v&& * 1y   )P? 2   U U12?k9aBBHEHEHEHEHEHEH@?>?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*gL9QOF$B_XKPcu jU8g'P!//*[mvǏُH}E0 TҙS-?Qcuχϙϫ);M_q߃ߕߧ߹߂ 2DVhzێb֯ *<N`rӘa#5GYk} 1CUgyՖ*!//(/:/L/^/p////////??$?6?H?Z?l?~?Ֆa?????? O@O-O?OQOcOuOUbbO1a6feOOOO__&_8_J_\_ҙ~________o o2oDoVoU oooooo,>Әia_q%7hcJxoj|ď֏ ASewџnasͯ߯0BTfxҿefB5GYk}ϡϳ-&8J\n߀ߒ߶I Y,1CUgy(:L^p'K$6HZl~9 -@?QcuBCh9!nkV3" bz@`nc/&`&/8/J/\/n%ib{/MvQ3/////??%?7?I?[?m?=G`P!=KBTfx,V/Pbt(:/^pj?@|?1!$6^DlMOumц >mKUrq!Wbqy[ja@OROfYNxYOOOOO/0% //0-VxQ$__FX|uAI!__oo%o7oIoL#F/a/j/5/////?O??'?9?K?)?????7:7H_Z_dOvO_____*=OL`{ޓՌ);f%tj|ğ֟蟜 !3b!HZ"d¯ԯ@RdҚ"4%7jǿٿ!3@!EŃx7I[m﵏Ǐ?? O2FLHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPUl4,?`/b? ̒A-3 7"AUl*<N@ FR@4(Ul*<N@| RUFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HG 9V?o)>  `r/`wpw> ȳpke{rpgTHYY9 mAUA? @ ?Q6 u` ?Mu ~YYA|XA44 4> !bJfvqQ >!"q06DNX lL>U5 LO@%#A?AE^?AL#l%u%?P6 @*  L#&H   " ' ]{%#W1\!\!5 `7Copyright 1999 Visio Corporation. All 2s reserved.`0_Sba.chm!#22427Bd(,*9 l>(>Ud!E (!(ZU$ B$bW*G g3?TU^7X q^?1,~Q?1(?1H_B#0ZX1va<oUole_oln+tcD%kYehA(~Qrepositioni<45/G/xD '2AUl4,?`/bC? ~U A-37;U2@47LRH<( U2E7 RUlLym@?Dz)RD{<U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)$LT *o8&Q- H*)=PEQy//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowEllipseWhite fillvisAecIsTech?nicalWallBuildingROOM BindingROOM Line StyleNet Thin lineNet NormalEllipse.4_3t0d En y- 8SGM 9Uqc U4qc Lqc Udqc |qc Քqc qd q q q, :9 $7F <7S T7` l7m 7z 7 737xA6U77;W4MU ,3 T3 u3 3 3 U3 *\S0UB*tS0F*<3 UJ S0S fS0`*3 dT; h*S0l*S0p+>tJ*S0x++@|*%,+@;+@++@{;+@*l+@T;+@*+@/K+@*+@*+@*+@*O?SK'Pi;'P{;'P;'PJ*+@/K'Pĵ*'P3;'P̵* KF E;PSKD؟;P+P$s[P;P KPi;L*TY`+Y`[M3]k`*`Uj̏`j` j`jNj4RIk pk p j\ p$jS(j$Up,kUp0T5{Up4jtUp8jUDUp?@ABCs1eFUHIJKTMNOUPQRSiUVWX*YZ[1]U]]^]_]`]Еa]b]c]e]f]g]h]iJ]j]kM]m]Un]o]p]q]Хr]s1]u]v]w]x]y]zR]{]}]~]U]Ѐ]Ё]Ђ]Щ9]Ѕ]І]Ї]Ј]Љ]Њ]ЋT9A]Ѝ]Ў]Џ]U]Б]В]Г]Е]Ж]З]И*]Й]К]Л]U]О]П]Р]Е]Т]У]]Х]Ц]Ч]Ш]ЩJ]Ъ]Ы]Э]U]Я]а]б]Х]г]е]ж]з]и]й]кR]лա]н]о]U]]]]Щ]]]Ǫ]]]]iUzU U UUU!U34Ul4,?`/bK? ((bC-3)A$Ul4, k)A-3y7"A_*<N@ܒ) MRVg{q7uH<( H<( _*<NE$) RVg*r G{zN  g"4FX(`w@(翪vy Xq:]R| 4rq}&t!BL;>COE8OywV a$x 'C%fQ|N |vfz)1~f 1yf=`218NV<( F{?FDTw*="R=5VG C!_G D  &% % Vt<1 &#2 C Ugy &1<GR\dkyogrUrCo2k#d\ RG<% (   % RL ArialpqfqrfrsfstgtuguvgvwhwxhxyhyziefbfgbghchicijciTzz% TC_AAC LdPreposition   ՜.+,D՜.+,@HP\h t   DocumentSummaryInformation8_1043485842F˪U˪UOle CompObj!q    !"#$%&)-./0123456789:;<=>?@ABCEFGHIJKNRSTUVWXYZ[\]^_`acdefghilpqrstuvwxyz{|}~PagesMastersPage-1Ellipse8_VPID_PREVIEWS_VPID_ALTERNATENAMESh_PID_LINKBASE? A  FMicrosoft Visio DrawingVISIO 6.0 ShapesVisio.Drawing.69qObjInfoVisioDocument # ,VisioInformation" SummaryInformation("$ Oh+'0HPht vhaisbcostekG8xur{ ' EMF0X XVISIODrawing  yvVisio (TM) Drawing  ,T*|Rl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1U#J:DT1EW-hTT<* /Ub bO0zGz?@8@H2!kWb*U  +$PL/^&9^$? { Ak^&,,'%/v&& * 1y   )P? 2   U U12?k9aBBHEHEHEHEHEHEH@?>?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*gL9QOF$B_XKPcu jU8g'P!//*[mvǏُH}E0 TҙS-?Qcuχϙϫ);M_q߃ߕߧ߹߂ 2DVhzێb֯ *<N`rӘa#5GYk} 1CUgyՖ*!//(/:/L/^/p////////??$?6?H?Z?l?~?Ֆa?????? O@O-O?OQOcOuOUbbO1a6feOOOO__&_8_J_\_ҙ~________o o2oDoVoU oooooo,>Әia_q%7hcJxoj|ď֏ ASewџnasͯ߯0BTfxҿefB5GYk}ϡϳ-&8J\n߀ߒ߶I Y,1CUgy(:L^p'K$6HZl~9 -@?QcuBCh9!nkV3" bz@`nc/&`&/8/J/\/n%ib{/MvQ3/////??%?7?I?[?m?=G`P!=KBTfx,V/Pbt(:/^pj?@|?1!$6^DlMOumц >mKUrq!Wbqy[ja@OROfYNxYOOOOO/0% //0-VxQ$__FX|uAI!__oo%o7oIoL#F/a/j/5/////?O??'?9?K?)?????7:7H_Z_dOvO_____*=OL`{ޓՌ);f%tj|ğ֟蟜 !3b!HZ"d¯ԯ@RdҚ"4%7jǿٿ!3@!EŃx7I[m﵏Ǐ?? O2FLHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPUl4,@Wd?$y"? @A- 3 7"A_vV*<N`r&8@ FR@4(_vV*<N`r&8@\ RUFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HC 5Vo?)> pp/quupwj  lpysopi`;Generic circle with text and connection points.b?贁NE?4 HDD # =hZ,>THYY9 mAUA? Q6 u` ?u ~YA|XA44 4> !bJfvq >!E"q06DNX l>U5 L@d($%9%#APE&L#%%%?P6 @RL# L#  7p  #2 ' JB{%#145 `7Copyright 1999 Visio Corporation. All 2s reservedo.`0_Sba.chm!#22426+l>(>Ud#1E (!(Z$ B$bW :?- vUG$M U MK MX we ,r D \ t    ͙ ʙ ;xG!SLUd 4U|Ui-y< 5U P\ Tt X \* ` d[+ h l+zSp+A0tA0Ix+A0|+A0+RA0+ "A0A0+A0i!;A0{,@D@JA0+@%l@7+@+@@I+@T+@@@/K@$Q|`+PTPSKPPTKPPe PKPUPZP ZS}" Z,PZUPZDPZUTPZdP"ZUtP&ZP*ZUP.ZP2ZP6[P:ZĪP>ZPBZ~FZ4`JJZL`Nk`RZ|`VKk`ZZ*`^Z`bk`UfZ`jZ`MnZ &Z$pvk`zZ?@ABC3eFUHIJRKMNUOPQRSUVWXYZ[TE]^_U`abc !efgh*ijkUmnopЕqrsWuvwxyJz{}U~ЀЁХЃЅІЇЈЉЊRЋiЍЎUАБВЩeЕЖЗИЙКЛTAНОПUСТУѪХЦЧШ*ЩЪЫUЮЯаЕвгkQежзийJклнUпХQqƪiUzU U UUU!U34Ul4,@Wd?$y"K? C(bC- A_U)A$Ul4, $)}A-7 "A_*<N@l@[) ORVgtq8uH<( H<( _*<NE@8* RVgEq {zN  g"4FX(e?@( ί0y XQ:]R}COE8OCtY v*$ }'dvRfRNxf)zf 1L{f=`2uKNV?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*gL9QOF$B_XKPcu jU8g'P!//*[mvǏُH}E0 TҙS-?Qcuχϙϫ);M_q߃ߕߧ߹߂ 2DVhzێb֯ *<N`rӘa#5GYk} 1CUgyՖ*!//(/:/L/^/p////////??$?6?H?Z?l?~?Ֆa?????? O@O-O?OQOcOuOUbbO1a6feOOOO__&_8_J_\_ҙ~________o o2oDoVoU oooooo,>Әia_q%7hcJxoj|ď֏ ASewџnasͯ߯0BTfxҿefB5GYk}ϡϳ-&8J\n߀ߒ߶I Y,1CUgy(:L^p'K$6HZl~9 -@?QcuBCh9!nkV3" bz@`nc/&`&/8/J/\/n%ib{/MvQ3/////??%?7?I?[?m?=G`P!=KBTfx,V/Pbt(:/^pj?@|?1!$6^DlMOumц >mKUrq!Wbqy[ja@OROfYNxYOOOOO/0% //0-VxQ$__FX|uAI!__oo%o7oIoL#F/a/j/5/////?O??'?9?K?)?????7:7H_Z_dOvO_____*=OL`{ޓՌ);f%tj|ğ֟蟜 !3b!HZ"d¯ԯ@RdҚ"4%7jǿٿ!3@!EŃx7I[m﵏Ǐ?? O2FLHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPU.4UUUl4,  贁N[??O'CA,7"A_.*<N`r@.oCR@4(_.*<N`r@Lo RUFDfP h RTBUUUIo:mW?Im?I?x Q2eqYkT Go 2w <"2vOr`Network>]`f Xd|8e#*--$` ?>? jq  x1xxllxƬ 11xRy  ylKRepresents a token-ring network layout. Glue control h?andlesmputers.ubؿ?9io6ؿ3?78j|?53tV?DUGDF  !P# h>4/T6DU@"۟~j?s?Py D,!444444 ",,NXblvu` ?"u"),UH" L@"bKp!{Q#!$W+d`Vis_SBN.chm!#22306A`7Copyright 2000 io Corporation. All "s reserved.t' #0XQ)H### Q#8`T,G%Z1e#!]t=%J 3H1H%4CP#&Z7A3A-TConnect To Network ?DeviceYBH%fOxO&OO6OO86OO5_,_6G_Y_D3T1YBt5T2YB V3YB1XA4YB*1^h!^ _7_t!X5YB[6YB1Xu7YB_o45C^o!^A1^`^k1^tQ^)bZSh}3^t3Z"#w$%}pt11]ut1t9 ?@t3T[$2pUb#)+%4#93*!Va"b4" qO`{_Eo @!N!X!b@!l!v!DNXblvD@NXb lvᒀsH%3?@3PČԏ茏3+ t"Ur:s#äs%4ELBČ)'E쳯ů׭54KE ČD֮954 Č l*!,>ڪ,t3B(\ Č ΀93ڪ5ЅѼ8ߩ" Č uV43T߱׭E41ߢ Č 0ewdd]95OH%Dȏ77! @ 7A` Token_Ringm*1`]WGHuS1$"H"/<2 I92V,_1_12pR4}t2RRE(tuS% Ru0d` Manufacturer3`R02b3A Enter the m name0%sgu2`Prod=u.Numb !W`pnnv05>|uxa Pars#!  95}ugqmDescrip!)(#d|'c5kA/S&7 oAssesk"`a2ID.5q/S&ua SerialR?q s33"UgO?S&ud$|aLoca-?lD.U?R'u>ha0JTpaaMU@Qo?@?P @+tQ` ?tTU'U'0'RaQux~u1bA@U EKT~`0Ri'%!N$-`7Copyright 2000 Visio Corporation. All s"s reserved.T  9 BzgAU@?@??@w?P6 @t`  ?t 8M>^ ]l^pFuX^{lvub_A@i>U `0i'%!NN5  `7Copyright 2000 Visio Corporation. All s"s reserved. ,#Bdb'=O#$+l>(>Ud% ( RWf 1|2| 7(o4  #? ?:?:31Eo?? OrA  CKO]O6xO4!:%^Token-ringH'-[ !OyaGEĐF~#t[K @ }GV?~f4.D+W/;?GojP--N_V("?q@R++-D#+Wi{ e!;S  UPxP4FDTey  ahj TqUI N?I??I?*?Qc`2@?qu`&u o <Mw!w! `Network `" (e5/G/P !GqP,41!>?P?b?t???11b!53? 1 a$ !) !yt'@ {FvrF?1 621 CF@D!-8Dw! #0# /UH<4!uS(KXe3PE>]?U?H1!p4:Q80W:Q:Y'U7E11[{"߿UeORVe2#_eBa<]/?@Cfoxf?dkr@>aom5k`o!AbkpHb@c1Joe`_oqooboXeEn43Dmsot`LgmD6Q3T1.$1T!<I "%r2B""r4L:RY f2uQddf/Q6291_=:Qd#o5j:Q !OP.J5љOIEm{{@QQ@OOA _SlDHU'UUuc1KX5Nԡٕ@(7M_q˿sta"4FXjσuϨt1 AS7Ir1hzߌߞosr>a /ASo߉l:QOo,luQ!auQi2c>a= !5_G_4qg{A^1_bUConjunc?tioni///_X#ZP'2rqAS[ iA;Mٕv w@Q yF c$5&+ (Q/U24UUUl4,  贁N?? _'+C-_T7AU2@TP'7JRH<( U2EP+(7 RUlLwߐ"r'w@?v (RDx8;U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)$LT *o8&Q- H*)=PEQy//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowWhite fillvisAecIsTech?nicalWallBuildingROOM BindingROOM Line StyleNet Thin lineNet NormalToken-ringManufacturerProductNumberPartNumberProductDescriptionAssetNumberSerialNumberLocationRoomDepartment_3 ) zEU T)- |)G c ăc D_*d \}  U$, <9 UTF lS U` m Uz _ mU 4m LmU dmȫ )իm߫^!mm|jmm+m7* U7*4W 7 W 7*dW 7*W #7 U|W >7*W B7*W F7*W J+ }N7* R7*_t V7*0Z7*0^7*$b+S0f7*D*S0j7*\S0n;S0)r+0v7 %7S0)7 fS0+S07*S07+S03;+@T+@7*@I+7*a@7*,a@7*?@ABCeFUHIJRKMNUOPQRS7UVWXYZ[Ts]s^s_sU`sasbscsesfsgsh*sisjsksUmsnsospsqsrss1susvswsxsyJszs{s}sU~sssss!ssssssRs+1sssUsssssssssssT3ssssUssssssss*ssssUsssssssssssJss!ssUsssss !ssƪsssssiUzU U UUU!U34Ul4, 贁N?? DY_d6bC-_U7A$Ul4, U7A-3$7"A_*<N@CO E8Ou"l$J̏"'}W(S>N?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*gL9QOF$B_XKPcu jU8g'P!//*[mvǏُH}E0 TҙS-?Qcuχϙϫ);M_q߃ߕߧ߹߂ 2DVhzێb֯ *<N`rӘa#5GYk} 1CUgyՖ*!//(/:/L/^/p////////??$?6?H?Z?l?~?Ֆa?????? O@O-O?OQOcOuOUbbO1a6feOOOO__&_8_J_\_ҙ~________o o2oDoVoU oooooo,>Әia_q%7hcJxoj|ď֏ ASewџnasͯ߯0BTfxҿefB5GYk}ϡϳ-&8J\n߀ߒ߶I Y,1CUgy(:L^p'K$6HZl~9 -@?QcuBCh9!nkV3" bz@`nc/&`&/8/J/\/n%ib{/MvQ3/////??%?7?I?[?m?=G`P!=KBTfx,V/Pbt(:/^pj?@|?1!$6^DlMOumц >mKUrq!Wbqy[ja@OROfYNxYOOOOO/0% //0-VxQ$__FX|uAI!__oo%o7oIoL#F/a/j/5/////?O??'?9?K?)?????7:7H_Z_dOvO_____*=OL`{ޓՌ);f%tj|ğ֟蟜 !3b!HZ"d¯ԯ@RdҚ"4%7jǿٿ!3@!EŃx7I[m﵏Ǐ?? O2FLHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPUl4,`/b?Ȓ_,? ̴A-3 7"A_h -?Qcu@);M@IJ  FR@4(_h -?Qcu@);M@| RUFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ! Hu 7~???0𫏆=@FwnmmhZ[L7Double arrow with 60-degreheads. HDB # ?hZ4>THYY9 dA[UA? u?P6 -u `u b_u  @"! FhWuk` tu.AdV8bM>ڲ@!$U'P"_/q%'i-/ 7$#5 L!# 7 6 BdH*%#/ Hh?Q6 u{%6{`("u?"F&`Qps-8R? WI@ 偌!6Q(-DT! @u@{$#AD5 `7Copyright 1999 Visio Corporation. All Bs reserved.h`@_Sba.chm!#224398B!$Cu tNs!OR U\l>Ud0@ Yi \!(Z$*L/S!4b?GQ b#Ib(3$$*3Ey‚7ʱRrB-db&`_aEojp= ףpՃoOR.ccb>$$?M˰iORD3eoeE9m |g`o'W6$*6a23(o_a|M:hz|%a_aQivQe&sbebQ2lm?l^Rgoyf?oQuo؅A &jdTAha9 G7(حN@fQB?bZބۀ!(! [?2vB@z?JVQ&999Y9Q9SIQ?IgRmb?п贁N8i/6??Hl'-s !Oya GE_6szF4 w#_K? Ab$noD Yoo/P+D?_(|?SLRY++@D ,'+Wi{ /ASeSf UPxP4FDTey  ahnm qT^UI`/b?IȒ_,??-I?*?QcO@?^[qu`Fuae@u U%Hq%P̕$w!p/////{!w! x$iD!"1#D!|53_"10"1q5"aD!E?@ڶڶ?坊& /~8K~05!H-5N?OQA(fEJ<4#005DB(8w!K_C ?Q=w!d5/G/AQLXz?@Gz?N@\_l^ x$U1 a aP 91"1 m$ iC CeVPEcnRdUeh0kUnkq5kFeQacnUcYaoXcp!fuaaFjX!Durationi8__ T'28k㨀PPUl4,`/b?Ȓ_,C? U A-37;U2@47LRH<( U2EV7 RUlL|[D@?7wRDc;U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)$LT *o8&Q- H*)=PEQy//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowWhite fillvisAecIsTech?nicalWallBuildingROOM BindingROOM Line StyleNet Thin lineNet Normal60 degree double_3L EΪ )- OG# _ 4R_ufL_$ Ud_1 |_> U_K _X U_e _r _ U $% <% T% %$ % % %% t Q !M? T$$(,l04*8GK,WOU UjL nd Ur| v z ~[+ ܟ SA0\A0UtA0A0A0+A0 A0fA0A03;Ѩn+0D0TW;00i;0%+0+0T;00[+0000/K'@+@S 8*@Z@UZ@ Z@UZ@Z$@UZ@Z@M ZӖZ,PU(ZDP,ZP0Z\P4[P8Z|P<ZP@T=[PDZPHZ%PLa[PP[PTZܷPXZ W\Z4``ZUL`dZd`hk*`lZ`pKk`UtZij`xZ`|k`Z`*Z`s[&Z?@*ABCAWFwHIJKMNOPQRRSWUVUWXwYwZw[a1w]w^w_w`wawbwcTwewfwgwUhwiwjwkA!wmwnwowp*wqwrwswUuwvwwwxwywzw{w}w~wwwJww/!wwUwwwww1wwwwwwRwwwwUwwwwewwwwwwwTGwwwwUwww{wwww*wwwAwUwwwwwwwwwwwwJwwe!wwUwwwwwyaE%UzU U UUU!U34Ul4,`/b?Ȓ_,K? ̻*bC-|r7A$Ul4, *A-37"A_*<N@ܴx* MRVg|q7uH<( H<( _*<NE$R+ RVgħ_q W{zN  g"4FX(G:?@(Z;ίPy @:]R}[ \q&$]!B;> DO E8Oh0x$~0',xTNO[x)_^x }1_x= `}2n"V<* F? +(!DlWl5 C=ń55 J!5 DOh+'0HPht vhaisbcostekGdxP  EMF\X XVISIODrawing  T  &% % VHP *ii~*iNi66N*% (   % RL Arial\\^\^z{^{|^|}^}~^~^^^__`ab^n}}o% T|0cEAA0L\Duration    ՜.+,D՜.+,@HP\h t   PagesMastersPage-160 degree double8_VPID_PREVIEWS_VPID_ALTEDocumentSummaryInformation8b_1044258911-=7F˪U˪UOle jCompObj69kqRNATENAMES(_PID_LINKBASE A  FMicrosoft Visio DrawingVISIO 6.0 ShapesVisio.Drawing.69qOh+'00HObjInfomVisioDocument8;p-VisioInformation"nSummaryInformation(:<o`Visio (TM) Drawing -q ,zRl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1U&J:DT1EW-hTT<* /Ub bO0zGz?@8@H2!kWb*U  +$PL/^&9^$? { Ak^&,,'%/v&& * 1y   )P? 2   U U12?k9aBBHEHEHEHEHEHEH@?>?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*Pbt߆ߘ߼#5GYk}b4?Qcua&8J\n /"4FXj|Q!//+/=/O/a/s////////??'?9?K?]?o????a???? OO0OBOTOfOxOOOUbbOXa]feOO__)_;_M___q________o#o5o0GoYoko}oU&oooo /ASea(:L^cqoǏُ!3E(hzŸԟ .@Я*EWi{ÿտ όf8i\nπϒϤ϶T);M_q߃ߕߧ߹p3ǀSFXj|+=OasNr'9K]o 9 0BTfxBC`!k}3I bz@6` /'c//A&`M/_/q//%b/)MQ3///??(?:?L?^?p???"dGoPo be3oo}_oooooo&8J\_VC94O*O -?Qcu͏ߏ'9K]ccU<犯"/ΟF//:/!щqfxү,>Pbtο@_ jK[CuU՞ϰϬҔЅaa3vO贁NkߖFa`27qZ?Yka?\.? pQA6k6߻H k+6;CjԕaI^g030|kPewȈ$ !%7dri{ /AS}/w+=Oa???'9A1K]DM*Oѭ e.KUqH)Wq[=ۑagOyOYuğYOOOOOV0%!/3/E/ W-}QK_mϣ(A(I1oo(o:oLo^opo s#m///5/////O(O*?P?????Ga^o__OO_____-?VQ=v.s#{.峑PbLǟٟ!3sHZb=!o"důׯ //gyI[L^$6HZg!lŪ(:ɏ^p9܏ $?OGOYJ#qٿ 1߀C __-_iȉX@R_ba QJ_+Չ/ڜ,5 ,5,0$Zl~r?? 2??h8LHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPUl4,N!2( ?@Jz? < A-|37U *<N`r@Dq BR @4(U *<N`r@q x RUFDfP h> /T6DUI@A?I BP(?3H$- b]b--rx@l^bf>M,,D'^fO - b, , 'eZYUHu F .LYcuZo^SLRepresents an actor reference.mb߿??PQ࿤p= ף??3㿕HD" # "=h#-$>T #T3 AOAU@?=@?@u߽?P6 )i8VYAEDA@@#u` *'.8BhPZ`u#j Ub >U5 gL{5!5 A`7Copyright 1999 Visio Corporation. All _"s reserved.`j _D88.chm!#2]0 l>0>Udd!!P #w a2U50` 9`fC"`e1De 2#(  O?si?e113???%G1 7@<Oa?9ME)2RO;rABC#(^actorReferenceiVA!aPIE9 3~'2qcPӼ? &bVq(^/\:5!?lOrISsQU__f+OnQ&%^]oeoooxGQ3ULYoopOorHl'-ER  [F 8# -r2? G1b XoOD+ty!Yo>?Dz!ko_( ?p 34RD g+@D>q +W@i{l _S  UPxP4FDTey  ahnm qT^UIN!2( ?I@Jz??-I?*?QcO@?^[qu`Fuae@u U Hq%P$w!p/////{!w!x$iD!w!p!N? "1 a$ ԉEP?@D?@W՘H?@X2>?a!H-#0QKE(<w!Q2m?Q?w!)l"10qU"1q5aD!G1)>&A*U30;[Q^5CSD%*^[G1_8ZqHnAD!D)BIAUW0VVBJo$a<0eY;HoZn0noo"c 0e\okA(QOutpatient Expansion from MEDICATION ROUTE file (#51.2)iT5/G/DD '2r?qBUl4,N!2( ?@JzC? p  U A-3*7;U2@,p 07LRH<( U2Etp 7 RUlL TT @?%|)RD< ;U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)$L5T *o 8&Q- H*)=-PEQ//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowWhite fillvisAecIsTech?nicalWallBuildingActor referenceActor reference.13ROOM BindingROOM Line StyleNet Thin lineNet NormalYellow fillMarketing Normal 3Flow Normal_3 E )'- R)2G)UJ )W}ec Urc 4c ULc dc U|c c Uc ăc U܃c c _ c $Id :|O@B/KO@F:O@J:O@N:RTSK'PV:4'PZK'P^:d'Pb:RO@fK'Pj:'PIn;'Pr;'Pv K'Pz/K'P~K'PR[j :`:$`=[`:D`;`a[`T[`:t`:U`:`:U`:`kOeK`KkR`›K`:`ʓk`:`$K`s[`K`Iޥk`[`kOeKpk`KpKpdKkp5{p *pCp CpCC,CtpC\R"C&C*C.CDNCd6JC:>CBUFC`C$NCRV Z^QbC Q‚PjC|UnCrCvCzg~"X -C<C4Z`CT٠T٠C٠CU٠C٠C٠y`˫WIݫW)CUU$ߝWӋWQWCUW!*W W,ADAʴW\A#tA'ʌA+A<AUAYJUApp'A=3EЩWЋ|ЏT{ГʜЗiRЛПգ $Я<гTзl*лʄпeЕi^3ХodoDo"TZzoo ꥤoojo#<#+#/T10 fx0p!!!_0jC#W%&'(*)*+'U-./0E125U6789:;i=>?@ABCUaOFUHIJKMNOP*QRS{UUVWXYZ[]]^_`aJbckQeUfghijkmnopqrRsuvUwxyz{A}~TU*U5JUQRYUTU* Ua UU U UUU!U34UUl4,!N!2( ?@JzK? _(g*C-_ 7A$Ul4, p "+A- 307"A_*<N@ * IRVg,2+7uH<( H<( _*<NE|"+ RVg\q u{zN  g"4FX(i @( sy p~!p :]RlOt  uq&_Lv !BD;>GOFo8O_<  e=$ K0U'|fQ>N xU)!x 1 ,x=,`{2 3"*V<]* F?q!i+GD|!5 C=t5 ,J! +Y UPht vhaisbcostekGxQ EMF|X XVISIODrawing  M  &% % V0IHHH% (   % RL Arial}|zywSTTjkkl% T&g!AA& L`Outpatient   T&"g1AA&" L`Expansion  T 2AAA 2Llfrom MEDICATION       TBQAABLpROUTE file (#51.2)  ՜.+,D՜.+,@HP\h t   PagesMastersPage-1Actor reference8_VPID_PREVIEWS_VPID_ALTERNATENAMES_PID_LINKBASE ADocumentSummaryInformation8_1044789508?F˪U˪UOle CompObj>Aq  FMicrosoft Visio DrawingVISIO 6.0 ShapesVisio.Drawing.69qOh+'0HPhtObjInfoVisioDocument@CF#VisioInformation"SummaryInformation(BDVisio (TM) Drawing F#d!zRl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1TJDT1EWP-hTT<U*U U =/Ub b酸0zGz?@8H2!kWbU%U  +PL/^&9^$? { Ak^&,",'%/v&Q&  1y   )? 2    J12?k9aUBBHEHEHEUHEHEHEH@?>?:`2BBHEHEHEHEHEHEHEH@$%O9F7AOY@; A*sVsVAgLTkY 1 W_W__ !`#ku4lb6Pu`kW 4l 4l %Y?:?-\ *#!+|tKf*2|2|2|2wG)QUoTMeEttA%_8BOTOfOxOO??O?7 ܻuW+? sU42 T*PbtφϘϪ(:L^p߂߂O߳ 1C@Ugb{.);M_xa"4FX 0Bzas//'/9/K/]/o/////////?#?zaB?T?f?x????????OBOUbb7OQV.e_OqOOOOOOOO_wk#_5_G_Y_k_}______L__UlAoSoeowoooooooxa(:L^p cwo!3EWi{Ï٦ .@Rdvk}*B'Ck#bz@.`c.`/%b /=QN3L/^/p////////??7?Pbtί(:L^p݇Z;ɼٿِ>.@*[m߅3O'Nk P2Ǎq?߃?\.?o AqT$$$'9K]ڊ䐾伩jPPj|xԕIWؙ&V03E)0<kDB!ߵ V /ASew+=Oa/09K]o?!?%LHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55H!winspoolHP LaserJet 5Si_742029_IP0Ul4,zLp?Dc) ? |2!}A-0'7"AUV6@1)GRUFDfP h$T PUUBmUA@ ?I? 3xO@7IyIfBo?вsUP  /e Z.$ H" S?!{)19AI?dp]qi} Aw:npqA9pwwA9pwpiEquilateral triangle.b?? ߿ $t@ ?<?紁N;3HDB t# ih0>T@dE=M AkUA@??A߻?Q6 L,A >M A JuM` ?[y&y0y:@u` UJS>#JU0O贁NKk?<@MJdO@ܼ@ L LP6 @?FS@U%%F@))@H""oKJ%{X1]45 `7Copyright 1999 Visio Corporation. All 2s reserved.J`0_Sba.chm!#22416Aida?lJ*,>Ud6ZV$(s=?)ǹ<$$b# X"yB:V/ K;EA%;D]2׳뽿HH?!:ͳ?OARM%2pO;JrA RSq(^!(M%9M\Me2AO-QVD}Ho *oFTO`c5WD`18WoiDYebW_`c%@neNooO[jJ(?kF8Hlh !OyaGEWszF#<s? mWakoD+oB?\ooP@4(UV6@42{ R(n?1p#R,+@SDD' ,ij UPxP4FDTe]@y  ahZ- ^TUIzLp?IDc_) ?? I?*?QcS@?^ua`u$ eu G{!D!e "u)D%@?@?@J7?@O*g?5H5??/18! L.&6.&62U66666#0Q 3-%// d/U1H<p$1CɭRCa(D1)A1!i$5/G/D '2qGPQA1DiQ [B1a`Q/`Q]%QAUD-YaE90:x?@?Pp?d?@.%ef]K?Q !t\A ]tE0Vbt!abMozUme\mmevgzkچ05E m=Ac#gc4heAO-O?C&@/^A<ߩߏ̟9KH~﷟۟1DLocalPossibleDosage@`Q!3EWrcNSh()Ul4,zLp?Dc) K? 1A-07;U2@407LRH<( U2E0 7 RUlL oz@?)RD7<U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)LT *o8&Q- H*)=PEQy//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowvisAecIsTech?nicalTriangleTriangle.6Triangle.18_,34s E} J- ;G; W,qUc Dqc \qUc tqc qc qd q q! q. ; %H 4%U L%b d%o |%| % % %J ;%y˨X,T* M*\*lV)[*; m+%[*[*[*m+[*#[ ? 2R[ B[*d )F[&"" 0 fPx!1m*E[  !"#$%&'() *+U^U U UUUl4,zLp?Dc) K? 37 KC-$37AUl4, 5 A-37"A_*<N@2 KRVgq7uH<( H<( _*<NE2`! RVgmq \{zN  g"4FX(Ga ?@(g:bίy @D:]R}< lq&|!BC; >EOtDo9OWW$'6fO|Ndf)f 1f=1`2ĕJV<- 7F?HNFDzJNC= !N|J!N vhaisbcostekGx] EMF!X XVISIODrawing    &% % V,o~nAn~n% (   &% % V, ~K~~% (   % RL Arial% Tl:N\]AA:NLXLocal  T|0^dmAA0^L\Possible   Tp3oa~AA3oLXDosage  ՜.+,D՜.+,@HP\h t   DocumentSummaryInformation8WordDocument F("SummaryInformation(GDocumentSummaryInformation8dPagesMastersPage-1 Triangle8_VPID_PREVIEWS_VPID_ALTERNATENAMES_PID_LINKBASE A  Oh+'0 ,8L Xd    M bjbj== ("WWl>>>>>>>rH H H H \ Lr5 l l l l l l l $  >l l l l l >>l l l >l >l l :>>8l ]rH $ 8|05.  v8Rd>>>>TAKE 1 TABLESPOONFUL BY MOUTH EVERY FOUR HOURS FOR 3 DAYS THEN TAKE 1 TABLESPOONFUL AS NEEDEDEntryElementFileTAKE EMBED Visio.Drawing.6 DOSAGE FORM file (#50.606) 1 TABLESPOONFUL EMBED Visio.Drawing.6 DRUG FILE (#50) BY EMBED Visio.Drawing.6 DOSAGE FORM file (#50.606) MOUTH EMBED Visio.Drawing.6 MEDICATION ROUTES file (#51.2)EVERY FOUR HOURS EMBED Visio.Drawing.6 ADMINISTRATION SCHEDULE file (#51.1) or MEDICATION INSTRUCTION file (#51)FOR 3 DAYS EMBED Visio.Drawing.6  IN DAYS, HOURS, MINUTESTHEN EMBED Visio.Drawing.6 AND, THEN, or EXCEPTTAKE  EMBED Visio.Drawing.6 DOSAGE FORM file (#50.606) 1 TABLESPOONFUL EMBED Visio.Drawing.6 DRUG FILE (#50)AS NEEDED EMBED Visio.Drawing.6 ADMINISTRATION SCHEDULE file (#51.1) or MEDICATION INSTRUCTION file (#51)Example: Complex Local Possible Dosage ^_rxy -45MNOPQp} jpUjp2> UVj 5U\jT2> 5UV\ j Uj_ >> UVj5U\j-T2> 5UV\j5U\ jUj9F> UV jUCJjP2> 5CJUV\ 5CJ\j5CJU\5\:CJ1^_emr~Pvvv $Ifq$$Ifl:d  6` 064 la$&`#$/IfrsxsdRR$$&`#$/Ifa$$&`#$/If$$IflDF_ h 6`06    4 lasdRR$$&`#$/Ifa$$&`#$/If$$IflfF_ h 6`06    4 la-.4QpqsdRRs dRRs$$&`#$/Ifa$$&`#$/If$$IflfF_ h 6`06    4 la q+,1RR$$IflfF_ h 6`06    4 la$$&`#$/Ifa$$&`#$/If +12JKLMNbcjk STǽ]j5U\jT2> 5UV\j5U\ jUj9F> UVj5CJU\jP2> 5CJUV\ 5CJ\j5CJU\CJ j>UjkU2> UV jU5\CJ&1NcdjaRaR$&`#$/If$$IflfF_ h 6`06    4 la$$&`#$/Ifa$  ST{|aRaPN$&`#$/If$$IflfF_ h 6`06    4 la$$&`#$/Ifa$|}~& 0 01/ =!"#$%NTAKE 2 TABLETS BY MOUTH EVERY MORNING AND TAKE 1 TABLET AT BEDTIM AS DIRECTEDAAKEKelly Anne Costelloellell Normal.dotCEDS2SMicrosoft Word 9.0@@@@ ՜.+,04 hp|  EDSg NTAKE 2 TABLETS BY MOUTH EVERY MORNING AND TAKE 1 TABLET AT BEDTIM AS DIRECTED Title  FMicrosoft Word Document MSWordDocWord.Document.89q FMicrosoft Visio DrawingVISI_1056889746L F˪U˪UData 1TableIKWCompObjjDd/6  3 A?22 w7h:# Dp`! w7h:# xWxT=OA};6NрJDa>%$H Be A)ӥM'] $*A$fo(AIXogvvvv (@  (:?-' ?j$2gs,h~X rSi=]kO,,\E`xC{uaF}q{&>':i]g=ί"elOdS>9pG=ӗ^\aGˑ!v=ʕ`ggq(ogM_ V.#=Q,ILlon}(Vssiʗأ\"Zk7Ky۫U_b^=#ݞgk^$nR4P_?ڨ4vV 3:Ct2YD'{u7SvveVz'R̉r\LjO}W\SDd80  # A2x1tNpp`!x1tNpl'dqxڵUMOA~gŊj5Q7=pBmb 1x(!KXp0?acxxhLshԸ>][0yvy?D"JKIhߩy*bz)=gLQvf71B#^ CO/M!WhJYr?>cV.$iEK b胴baZ?Z?wڛŭFxX9^pg9lDԺk`ZV5;kX[OmkӺ^r1f8㉳6 0oB[8y õs--`Xus mGKEshP)9+}R">, K&z~ȃz /ɧ8BWdIsXo_&$_^yQ"ߩ}{?3/B:\ƣ9{AN RVc6w篨ړe'qK6ƍ?Dd 0  # A2E놧"C{:ZsiSp`!E놧"C{:ZsidWxTMHTQι4 @*1RlEbY Ag@DnBQ@PH+Dh&q'ƖQ}7:=swwιˀ5c}+/av4Ĺ }5n(!n8W׀B )V=t-)":u?Bsr܎OhG?z0$,XO`J08ov$ҬY{26eiĐTSP#1VZqna +0]JiCcDj(QlsgV"HS7 EA#m0cX5182sT-:,#۰l NCԓ/ѿ)vOZmK5dzdtt3i3qefIuE7t]&ƈ\۲#V+㺋]C΢A$JTa|lvKgR||N,K;yˬԏ??>>J>[dd:gX&7~{1yn6~@f)dOQ tTU9N=d1".]yA C>ZǷfi1Ol2)wmP(%Q~z>m/B΋=zk4TEN67]+fws &P}WZ;0U ck"x.!b,Kߦ!qAFG).hN +ҝ9殠ţGm)e:#kk]g1 "a;~QoX\9"mǐ@1GAhZ5W6ۭ jZoZ:Y{ךj\x.nN pZhs]{xk[Be\xr~ _W{^*eS)7?]J6|;3OB&qO.XWe"d1OۥZqFI@$KŒbh927|Dd0  # A2QMgJu^BEV5- p`!%MgJu^BEV5HxUMHTQFMh1V-bhrRd2EH:a3MDUJRBM"qt* rJ@qծ;wι~rs}E?O*GgK. oL ,9 |(˂IgwmN{] 26&\H4p|}#(b2OYރ1"z^4qʲk92#S6=8.G\U^UJ]K,R8ٙCVMjxĨAUI%iwҀiC )YLKEqeRo^Jz(kj^ԴȰx$)AiN!qʔYR 2^Ƞz)M hĔ`D0$PŠ5VJǔ_9Y5.^m_Wvxẹ<N{pW}"OkL +fl=[ߑٯ7!bB._[<ߙyװ߹шvt#Nya}wjz"MCdoMtw~}ƾuy3k;FrZc}9K&G^>~'JbMv m?SlgӪ/o%͊ɉ29:`3l2x !fR5wG:={g;kRbDUځp?%w㼌vX'̯4Dd0  # A2JK]pIG &p`!K]pIG 4 xT;K\Afk\A.>F\ֈ|`Rl!{) X[ZTv)ZK`uoL|sΜ99s*޶R@u9ޛɢQAr`3*eGt;QӺ:zXOL,Qσ,}pi,)OvQ&V64rgVB˒suzg X&,qH'C-c/9138&q0;o53B?~>g aѼPSYcaR'r1q5=&yx#< &qq\fZCTA-3E0.W>u8b:V} }E7qT1RcG(Ii&-tDוJZ5WQ/q;MQ!;lRYβRM0F8vI9Ϩ| յ<+PطWx3km^\ VڼaM-3E6ijLܬ͖l){$%joO9i,CA- $o`+c+լK\ym<.PΫNNt i{ یcf$K11<1-73/x~ߣ_]|LK.~lo;3%Ҟώ߲Wٵvk~03RPaA>tLBғ:|6G~/`'CĠ܃_gm iM\|[[.*_2"{wRJ)Wnp$g zVS~yO+4(.Av_k 2KVa7*V 7z/o6 t'zu5[i7(~oK })Knu5'\*JDd/6  3 A?22 w7h:# Lp`! w7h:# xWxT=OA};6NрJDa>%$H Be A)ӥM'] $*A$fo(AIXogvvvv (@  (:?-' ?j$2gs,h~X rSi=]kO,,\E`xC{uaF}q{&>':i]g=ί"elOdS>9pG=ӗ^\aGˑ!v=ʕ`ggq(ogM_ V.#=Q,ILlon}(Vssiʗأ\"Zk7Ky۫U_b^=#ݞgk^$nR4P_?ڨ4vV 3:Ct2YD'{u7SvveVz'R̉r\LjO}W\Dd0   # A 2QMgJu^BEV5-p`!%MgJu^BEV5HxUMHTQFMh1V-bhrRd2EH:a3MDUJRBM"qt* rJ@qծ;wι~rs}E?O*GgK. oL ,9 |(˂IgwmN{] 26&\H4p|}#(b2OYރ1"z^4qʲk92#S6=8.G\U^UJ]K,R8ٙCVMjxĨAUI%iwҀiC )YLKEqeRo^Jz(kj^ԴȰx$)AiN!qʔYR 2^Ƞz)M hĔ`D0$PŠ5VJǔ_9Y5.^m_Wvxẹ<N{pW}"OkL +fl=[ߑٯ7!bB._[<ߙyװ߹шvt#Nya}wjz"MCdoMtw~}ƾuy3k;FrZc}9K&G^>~'JbMv m?SlgӪ/o%͊ɉ29:`3l2x !fR5wG:={g;kRbDUځp?%w㼌vX'̯4 i8@8 NormalCJ_HaJmH sH tH PP Heading 1$ & F<@&CJKH \^JaJ 88 Heading 2$ & F@&\LL Heading 3$ & F<@&CJ\^JaJ22 Heading 4$@&5\FF Heading 6 & F<@&5CJ\aJ8@8 Heading 7$$@&a$5\J @J Heading 9 $$&`#$/@&a$5\<A@< Default Paragraph Font(@( TOC 1 5CJ\&& TOC 2x]::TOC 3 $ `^` mHnHuBBBTOC 4 $ ^` mHnHu&& TOC 5 ^@a@ TOC 60@& ^05CJ\aJ>r> Style1;CJ$KHOJQJ\^JaJFF Style2 ^;CJ$KHOJQJ\^JaJ " zYZ`hmnt#$3Pop*+0Mabi00@ 0@ 0@ 0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@000000000@0@0@0@0000000000 m#oa t3LN 0IKi:::::::::Z`Ma`aPRV`Kelly Anne Costello7C:\My Documents\POE\Complex Local Possible Dosage 1.docKelly Anne Costello7C:\My Documents\POE\Complex Local Possible Dosage 1.docKelly Anne Costello7C:\My Documents\POE\Complex Local Possible Dosage 1.docKelly Anne Costello7C:\My Documents\POE\Complex Local Possible Dosage 1.docKelly Anne Costello7C:\My Documents\POE\Complex Local Possible Dosage 1.docKelly Anne Costello7C:\My Documents\POE\Complex Local Possible Dosage 1.docKelly Anne Costello7C:\My Documents\POE\Complex Local Possible Dosage 1.docKelly Anne CostellocC:\WINDOWS\Application Data\Microsoft\Word\AutoRecovery save of Complex Local Possible Dosage 1.asdKelly Anne CostelloEC:\My Documents\POE\Dosage Tables\Complex Local Possible Dosage 1.docKelly Anne CostelloFC:\My Documents\POE\Dosage Tables\1 Complex Local Possible Dosage .docTh* %lT; ^`56CJOJQJo(.8^`56CJOJQJo(.^`56CJOJQJo(.p ^p`o()@  ^@ `o(()x^`o(()H^`o(()^`o(()^`o(()^`56CJOJQJo(.8^`o(.^`o(.p ^p`o()@  ^@ `o(()x^`o(()H^`o(()^`o(()^`o(()%%%ThThThThYZ`hmnt#$3Pop*+0Mabi@ @UnknownG:Times New Roman5Symbol3& :Arial"hՋWFWFwY<~0dEO2QMTAKE 2 TABLETS BY MOUTH EVERY MORNING AND TAKE 1 TABLET AT BEDTIM AS DIRECTEDKelly Anne CostelloEDSObjInfoJObjectPoolV˪U˪U_1043484840PF˪U˪UOle CompObjORqObjInfoVisioDocumentQT+VisioInformation"O 6.0 ShapesVisio.Drawing.69qOh+'0HPht vhaisbcostekGDxwt U EMF<X XVIVisio (TM) Drawing +Lls*Rl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1U#J:DT1EW-hTT<* /Ub bO0zGz?@8@H2!kWb*U  +$PL/^&9^$? { Ak^&,,'%/v&& * 1y   )P? 2   U U12?k9aBBHEHEHEHEHEHEH@?>?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*gL9QOF$B_XKPcu jU8g'P!//*[mvǏُH}E0 TҙS-?Qcuχϙϫ);M_q߃ߕߧ߹߂ 2DVhzێb֯ *<N`rӘa#5GYk} 1CUgyՖ*!//(/:/L/^/p////////??$?6?H?Z?l?~?Ֆa?????? O@O-O?OQOcOuOUbbO1a6feOOOO__&_8_J_\_ҙ~________o o2oDoVoU oooooo,>Әia_q%7hcJxoj|ď֏ ASewџnasͯ߯0BTfxҿefB5GYk}ϡϳ-&8J\n߀ߒ߶I Y,1CUgy(:L^p'K$6HZl~9 -@?QcuBCh9!nkV3" bz@`nc/&`&/8/J/\/n%ib{/MvQ3/////??%?7?I?[?m?=G`P!=KBTfx,V/Pbt(:/^pj?@|?1!$6^DlMOumц >mKUrq!Wbqy[ja@OROfYNxYOOOOO/0% //0-VxQ$__FX|uAI!__oo%o7oIoL#F/a/j/5/////?O??'?9?K?)?????7:7H_Z_dOvO_____*=OL`{ޓՌ);f%tj|ğ֟蟜 !3b!HZ"d¯ԯ@RdҚ"4%7jǿٿ!3@!EŃx7I[m﵏Ǐ?? O2FLHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IP Ul4,&'?`/b? <A-43 7"AU~@*<N`@  FR @4(U~@*<N`@ RUFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HI ;V?-  _`߅pl`ul`u kw{sg_'Regular octagon, or eight-sided shape.b?贁N? 4 HDB $# ?h-(>TT9 EAUA@ ? Q6 mu` o?u j>Z--200`0A0(2@2T^h0r|>U5 L{/!4$5 `7Copyright 1999 Visio Corporation. All Y"s reserved.`d _Sba.chm!#22421PBd9 l> >Ud]!!(<* Z#A|rvPph.b31,1e g2(:S425$a?a! Ҁ?1E5Y6gq4bH3x81| N5%O7I71x?:?=3A1@IZ&Ax;87:U\S7I]:U; >tRTD%^RTEa^UQq5:^[ QY6[@$n[Q_HZq^QzD1QjeO_0_Sa<nU }e^}en}D%e,n}E~cq5~6Y|ev~cP{8ޏyA( ~Verbi$5/G/DD W'28AUl4,&'?`/bC? U A-37;U2@̔7LRH<( U2E7 RUlL|@?$)RD <U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)$LT *o8&Q- H*)=PEQy//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowOctagonWhite fillvisAecIsTech?nicalWallBuildingROOM BindingROOM Line StyleNet Thin lineNet NormalOctagon.5_34`~ Ed e>- fUG$M UZP9jP 9jP9jP9jܪP9jP9jP9jn"9j4`&9jL`*9jd`.9j|`2TKk`69j`:9j`>k`B9jԪ`F9j`J9j oN9j$pRTk`V9j!BRv&LJU,NlRUVZݫ^b<*fjǻEnw.,UUD7Ulp'3˭ʤݫW˭ҹQx{˭ڹ$OIiO7O湪UdO깪|OUO򹪤O%OOOK!*yH`'Q x'4'T10^!fxRp! ! j9`"#[%&'()*+T!-./01256789J:;m=U>?@ABC3eFUHIJKTMNOUPQRSUVWX*YZ[EU]^_`Еabc !efghiJjkmUnopqХrsWuvwxyzR{}~UЀЁЂЩЅІЇЈЉЊЋTiЍЎЏUБВГeЕЖЗИ*ЙКЛAUОПРЕТУХЦЧШЩJЪЫЭUЯабХгkQежзийкRлноUЩQqǪiUzU U UUU!U34Ul4,&'?`/bK? (bC-3')A$Ul4, Lz)A-D37"A_*<N@L-) MRVgdpq7uH<( H<( _*<NE* RVgpq \{zN  g"4FX(-@(P y @gn:]R>,k _lo_qq&yu!Bty;> DO` E8Ȯ, a$ '=fSNf)f 1 f=vl`2e NV<5( F?^dFDf!*KC=U5dG |J!pmG DSummaryInformation(SU DocumentSummaryInformation8_1043485741NfXF˪U˪UOle SIODrawing  {x  &% % V@wt T&&R&rTruRu&T% (   % RL Arial% Td"CV_AA"CLTVerb  ՜.+,D՜.+,@HP\h t   PagesMastersPage-1Octagon8_VPID_PREVIEWS_VPID_ALTERNATENAMES_PID_LINKBASE? A  FMicrosoft Visio DrawingVISIO 6.0 ShapesVisio.Drawing.69qCompObjWZqObjInfoVisioDocumentY\+VisioInformation"     ,- !"#$%&'()*+.1/02PQ456789:;<=>?@ABCDEFGHIJKLMNOURSTnmWXYZ[\]^_`abcdefghijklropquvwxyz{|}~Visio (TM) Drawing +pe*|Rl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1U#J:DT1EW-hTT<* /Ub bO0zGz?@8@H2!kWb*U  +$PL/^&9^$? { Ak^&,,'%/v&& * 1y   )P? 2   U U12?k9aBBHEHEHEHEHEHEH@?>?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*gL9QOF$B_XKPcu jU8g'P!//*[mvǏُH}E0 TҙS-?Qcuχϙϫ);M_q߃ߕߧ߹߂ 2DVhzێb֯ *<N`rӘa#5GYk} 1CUgyՖ*!//(/:/L/^/p////////??$?6?H?Z?l?~?Ֆa?????? O@O-O?OQOcOuOUbbO1a6feOOOO__&_8_J_\_ҙ~________o o2oDoVoU oooooo,>Әia_q%7hcJxoj|ď֏ ASewџnasͯ߯0BTfxҿefB5GYk}ϡϳ-&8J\n߀ߒ߶I Y,1CUgy(:L^p'K$6HZl~9 -@?QcuBCh9!nkV3" bz@`nc/&`&/8/J/\/n%ib{/MvQ3/////??%?7?I?[?m?=G`P!=KBTfx,V/Pbt(:/^pj?@|?1!$6^DlMOumц >mKUrq!Wbqy[ja@OROfYNxYOOOOO/0% //0-VxQ$__FX|uAI!__oo%o7oIoL#F/a/j/5/////?O??'?9?K?)?????7:7H_Z_dOvO_____*=OL`{ޓՌ);f%tj|ğ֟蟜 !3b!HZ"d¯ԯ@RdҚ"4%7jǿٿ!3@!EŃx7I[m﵏Ǐ?? O2FLHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPUl4,?`/b? ̒A-3 7"AUl*<N@ FR@4(Ul*<N@| RUFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HG 9V?o)>  `r/`wpw> ȳpke{rpgTHYY9 mAUA? @ ?Q6 u` ?Mu ~YYA|XA44 4> !bJfvqQ >!"q06DNX lL>U5 LO@%#A?AE^?AL#l%u%?P6 @*  L#&H   " ' ]{%#W1\!\!5 `7Copyright 1999 Visio Corporation. All 2s reserved.`0_Sba.chm!#22427Bd(,*9 l>(>Ud!E (!(ZU$ B$bW*G g3?TU^7X q^?1,~Q?1(?1H_B#0ZX1va<oUole_oln+tcD%kYehA(~Qrepositioni<45/G/xD '2AUl4,?`/bC? ~U A-37;U2@47LRH<( U2E7 RUlLym@?Dz)RD{<U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)$LT *o8&Q- H*)=PEQy//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowEllipseWhite fillvisAecIsTech?nicalWallBuildingROOM BindingROOM Line StyleNet Thin lineNet NormalEllipse.4_3t0d En y- 8SGM 9Uqc U4qc Lqc Udqc |qc Քqc qd q q q, :9 $7F <7S T7` l7m 7z 7 737xA6U77;W4MU ,3 T3 u3 3 3 U3 *\S0UB*tS0F*<3 UJ S0S fS0`*3 dT; h*S0l*S0p+>tJ*S0x++@|*%,+@;+@++@{;+@*l+@T;+@*+@/K+@*+@*+@*+@*O?SK'Pi;'P{;'P;'PJ*+@/K'Pĵ*'P3;'P̵* KF E;PSKD؟;P+P$s[P;P KPi;L*TY`+Y`[M3]k`*`Uj̏`j` j`jNj4RIk pk p j\ p$jS(j$Up,kUp0T5{Up4jtUp8jUDUp?@ABCs1eFUHIJKTMNOUPQRSiUVWX*YZ[1]U]]^]_]`]Еa]b]c]e]f]g]h]iJ]j]kM]m]Un]o]p]q]Хr]s1]u]v]w]x]y]zR]{]}]~]U]Ѐ]Ё]Ђ]Щ9]Ѕ]І]Ї]Ј]Љ]Њ]ЋT9A]Ѝ]Ў]Џ]U]Б]В]Г]Е]Ж]З]И*]Й]К]Л]U]О]П]Р]Е]Т]У]]Х]Ц]Ч]Ш]ЩJ]Ъ]Ы]Э]U]Я]а]б]Х]г]е]ж]з]и]й]кR]лա]н]о]U]]]]Щ]]]Ǫ]]]]iUzU U UUU!U34Ul4,?`/bK? ((bC-3)A$Ul4, k)A-3y7"A_*<N@ܒ) MRVg{q7uH<( H<( _*<NE$) RVg*r G{zN  g"4FX(`w@(翪vy Xq:]R| 4rq}&t!BL;>COE8OywV a$x 'C%fQ|N |vfz)1~f 1yf=`218NV<( F{?FDTw*="R=5VG C!_G DOh+'0tHPht vhaisbcostekGxt{U EMFX XVISIODrawing  x  &% %SummaryInformation([]DocumentSummaryInformation8_1043485842`F˪U˪UOle  Vt<1 &#2 C Ugy &1<GR\dkyogrUrCo2k#d\ RG<% (   % RL ArialpqfqrfrsfstgtuguvgvwhwxhxyhyziefbfgbghchicijciTzz% TC_AAC LdPreposition   ՜.+,D՜.+,@HP\h t   PagesMastersPage     !"#$%(,-./0123456789:;<=>?@ABDEFGHIJMQRSTUVWXYZ[\]^_`bcdefghkopqrstuvwxyz{|}~-1Ellipse8_VPID_PREVIEWS_VPID_ALTERNATENAMESh_PID_LINKBASE? A  FMicrosoft Visio DrawingVISIO 6.0 ShapesVisio.Drawing.69qCompObj_bqObjInfoVisioDocumentad ,VisioInformation"Visio (TM) Drawing  ,T*|Rl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1U#J:DT1EW-hTT<* /Ub bO0zGz?@8@H2!kWb*U  +$PL/^&9^$? { Ak^&,,'%/v&& * 1y   )P? 2   U U12?k9aBBHEHEHEHEHEHEH@?>?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*gL9QOF$B_XKPcu jU8g'P!//*[mvǏُH}E0 TҙS-?Qcuχϙϫ);M_q߃ߕߧ߹߂ 2DVhzێb֯ *<N`rӘa#5GYk} 1CUgyՖ*!//(/:/L/^/p////////??$?6?H?Z?l?~?Ֆa?????? O@O-O?OQOcOuOUbbO1a6feOOOO__&_8_J_\_ҙ~________o o2oDoVoU oooooo,>Әia_q%7hcJxoj|ď֏ ASewџnasͯ߯0BTfxҿefB5GYk}ϡϳ-&8J\n߀ߒ߶I Y,1CUgy(:L^p'K$6HZl~9 -@?QcuBCh9!nkV3" bz@`nc/&`&/8/J/\/n%ib{/MvQ3/////??%?7?I?[?m?=G`P!=KBTfx,V/Pbt(:/^pj?@|?1!$6^DlMOumц >mKUrq!Wbqy[ja@OROfYNxYOOOOO/0% //0-VxQ$__FX|uAI!__oo%o7oIoL#F/a/j/5/////?O??'?9?K?)?????7:7H_Z_dOvO_____*=OL`{ޓՌ);f%tj|ğ֟蟜 !3b!HZ"d¯ԯ@RdҚ"4%7jǿٿ!3@!EŃx7I[m﵏Ǐ?? O2FLHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPUl4,@Wd?$y"? @A- 3 7"A_vV*<N`r&8@ FR@4(_vV*<N`r&8@\ RUFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ HC 5Vo?)> pp/quupwj  lpysopi`;Generic circle with text and connection points.b?贁NE?4 HDD # =hZ,>THYY9 mAUA? Q6 u` ?u ~YA|XA44 4> !bJfvq >!E"q06DNX l>U5 L@d($%9%#APE&L#%%%?P6 @RL# L#  7p  #2 ' JB{%#145 `7Copyright 1999 Visio Corporation. All 2s reservedo.`0_Sba.chm!#22426+l>(>Ud#1E (!(Z$ B$bW :?- vUG$M U MK MX we ,r D \ t    ͙ ʙ ;xG!SLUd 4U|Ui-y< 5U P\ Tt X \* ` d[+ h l+zSp+A0tA0Ix+A0|+A0+RA0+ "A0A0+A0i!;A0{,@D@JA0+@%l@7+@+@@I+@T+@@@/K@$Q|`+PTPSKPPTKPPe PKPUPZP ZS}" Z,PZUPZDPZUTPZdP"ZUtP&ZP*ZUP.ZP2ZP6[P:ZĪP>ZPBZ~FZ4`JJZL`Nk`RZ|`VKk`ZZ*`^Z`bk`UfZ`jZ`MnZ &Z$pvk`zZ?@ABC3eFUHIJRKMNUOPQRSUVWXYZ[TE]^_U`abc !efgh*ijkUmnopЕqrsWuvwxyJz{}U~ЀЁХЃЅІЇЈЉЊRЋiЍЎUАБВЩeЕЖЗИЙКЛTAНОПUСТУѪХЦЧШ*ЩЪЫUЮЯаЕвгkQежзийJклнUпХQqƪiUzU U UUU!U34Ul4,@Wd?$y"K? C(bC- A_U)A$Ul4, $)}A-7 "A_*<N@l@[) ORVgtq8uH<( H<( _*<NE@8* RVgEq {zN  g"4FX(e?@( ί0y XQ:]R}COE8OCtY v*$ }'dvRfRNxf)zf 1L{f=`2uKNV?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*gL9QOF$B_XKPcu jU8g'P!//*[mvǏُH}E0 TҙS-?Qcuχϙϫ);M_q߃ߕߧ߹߂ 2DVhzێb֯ *<N`rӘa#5GYk} 1CUgyՖ*!//(/:/L/^/p////////??$?6?H?Z?l?~?Ֆa?????? O@O-O?OQOcOuOUbbO1a6feOOOO__&_8_J_\_ҙ~________o o2oDoVoU oooooo,>Әia_q%7hcJxoj|ď֏ ASewџnasͯ߯0BTfxҿefB5GYk}ϡϳ-&8J\n߀ߒ߶I Y,1CUgy(:L^p'K$6HZl~9 -@?QcuBCh9!nkV3" bz@`nc/&`&/8/J/\/n%ib{/MvQ3/////??%?7?I?[?m?=G`P!=KBTfx,V/Pbt(:/^pj?@|?1!$6^DlMOumц >mKUrq!Wbqy[ja@OROfYNxYOOOOO/0% //0-VxQ$__FX|uAI!__oo%o7oIoL#F/a/j/5/////?O??'?9?K?)?????7:7H_Z_dOvO_____*=OL`{ޓՌ);f%tj|ğ֟蟜 !3b!HZ"d¯ԯ@RdҚ"4%7jǿٿ!3@!EŃx7I[m﵏Ǐ?? O2FLHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPU.4UUUl4,  贁N[??O'CA,7"A_.*<N`r@.oCR@4(_.*<N`r@Lo RUFDfP h RTBUUUIo:mW?Im?I?x Q2eqYkT Go 2w <"2vOr`Network>]`f Xd|8e#*--$` ?>? jq  x1xxllxƬ 11xRy  ylKRepresents a token-ring network layout. Glue control h?andlesmputers.ubؿ?9io6ؿ3?78j|?53tV?DUGDF  !P# h>4/T6DU@"۟~j?s?Py D,!444444 ",,NXblvu` ?"u"),UH" L@"bKp!{Q#!$W+d`Vis_SBN.chm!#22306A`7Copyright 2000 io Corporation. All "s reserved.t' #0XQ)H### Q#8`T,G%Z1e#!]t=%J 3H1H%4CP#&Z7A3A-TConnect To Network ?DeviceYBH%fOxO&OO6OO86OO5_,_6G_Y_D3T1YBt5T2YB V3YB1XA4YB*1^h!^ _7_t!X5YB[6YB1Xu7YB_o45C^o!^A1^`^k1^tQ^)bZSh}3^t3Z"#w$%}pt11]ut1t9 ?@t3T[$2pUb#)+%4#93*!Va"b4" qO`{_Eo @!N!X!b@!l!v!DNXblvD@NXb lvᒀsH%3?@3PČԏ茏3+ t"Ur:s#äs%4ELBČ)'E쳯ů׭54KE ČD֮954 Č l*!,>ڪ,t3B(\ Č ΀93ڪ5ЅѼ8ߩ" Č uV43T߱׭E41ߢ Č 0ewdd]95OH%Dȏ77! @ 7A` Token_Ringm*1`]WGHuS1$"H"/<2 I92V,_1_12pR4}t2RRE(tuS% Ru0d` Manufacturer3`R02b3A Enter the m name0%sgu2`Prod=u.Numb !W`pnnv05>|uxa Pars#!  95}ugqmDescrip!)(#d|'c5kA/S&7 oAssesk"`a2ID.5q/S&ua SerialR?q s33"UgO?S&ud$|aLoca-?lD.U?R'u>ha0JTpaaMU@Qo?@?P @+tQ` ?tTU'U'0'RaQux~u1bA@U EKT~`0Ri'%!N$-`7Copyright 2000 Visio Corporation. All s"s reserved.T  9 BzgAU@?@??@w?P6 @t`  ?t 8M>^ ]l^pFuX^{lvub_A@i>U `0i'%!NN5  `7Copyright 2000 Visio Corporation. All s"s reserved. ,#Bdb'=O#$+l>(>Ud% ( RWf 1|2| 7(o4  #? ?:?:31Eo?? OrA  CKO]O6xO4!:%^Token-ringH'-[ !OyaGEĐF~#t[K @ }GV?~f4.D+W/;?GojP--N_V("?q@R++-D#+Wi{ e!;S  UPxP4FDTey  ahj TqUI N?I??I?*?Qc`2@?qu`&u o <Mw!w! `Network `" (e5/G/P !GqP,41!>?P?b?t???11b!53? 1 a$ !) !yt'@ {FvrF?1 621 CF@D!-8Dw! #0# /UH<4!uS(KXe3PE>]?U?H1!p4:Q80W:Q:Y'U7E11[{"߿UeORVe2#_eBa<]/?@Cfoxf?dkr@>aom5k`o!AbkpHb@c1Joe`_oqooboXeEn43Dmsot`LgmD6Q3T1.$1T!<I "%r2B""r4L:RY f2uQddf/Q6291_=:Qd#o5j:Q !OP.J5љOIEm{{@QQ@OOA _SlDHU'UUuc1KX5Nԡٕ@(7M_q˿sta"4FXjσuϨt1 AS7Ir1hzߌߞosr>a /ASo߉l:QOo,luQ!auQi2c>a= !5_G_4qg{A^1_bUConjunc?tioni///_X#ZP'2rqAS[ iA;Mٕv w@Q yF c$5&+ (Q/U24UUUl4,  贁N?? _'+C-_T7AU2@TP'7JRH<( U2EP+(7 RUlLwߐ"r'w@?v (RDx8;U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)$LT *o8&Q- H*)=PEQy//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowWhite fillvisAecIsTech?nicalWallBuildingROOM BindingROOM Line StyleNet Thin lineNet NormalToken-ringManufacturerProductNumberPartNumberProductDescriptionAssetNumberSerialNumberLocationRoomDepartment_3 ) zEU T)- |)G c ăc D_*d \}  U$, <9 UTF lS U` m Uz _ mU 4m LmU dmȫ )իm߫^!mm|jmm+m7* U7*4W 7 W 7*dW 7*W #7 U|W >7*W B7*W F7*W J+ }N7* R7*_t V7*0Z7*0^7*$b+S0f7*D*S0j7*\S0n;S0)r+0v7 %7S0)7 fS0+S07*S07+S03;+@T+@7*@I+7*a@7*,a@7*?@ABCeFUHIJRKMNUOPQRS7UVWXYZ[Ts]s^s_sU`sasbscsesfsgsh*sisjsksUmsnsospsqsrss1susvswsxsyJszs{s}sU~sssss!ssssssRs+1sssUsssssssssssT3ssssUssssssss*ssssUsssssssssssJss!ssUsssss !ssƪsssssiUzU U UUU!U34Ul4, 贁N?? DY_d6bC-_U7A$Ul4, U7A-3$7"A_*<N@CO E8Ou"l$J̏"'}W(S>N?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*gL9QOF$B_XKPcu jU8g'P!//*[mvǏُH}E0 TҙS-?Qcuχϙϫ);M_q߃ߕߧ߹߂ 2DVhzێb֯ *<N`rӘa#5GYk} 1CUgyՖ*!//(/:/L/^/p////////??$?6?H?Z?l?~?Ֆa?????? O@O-O?OQOcOuOUbbO1a6feOOOO__&_8_J_\_ҙ~________o o2oDoVoU oooooo,>Әia_q%7hcJxoj|ď֏ ASewџnasͯ߯0BTfxҿefB5GYk}ϡϳ-&8J\n߀ߒ߶I Y,1CUgy(:L^p'K$6HZl~9 -@?QcuBCh9!nkV3" bz@`nc/&`&/8/J/\/n%ib{/MvQ3/////??%?7?I?[?m?=G`P!=KBTfx,V/Pbt(:/^pj?@|?1!$6^DlMOumц >mKUrq!Wbqy[ja@OROfYNxYOOOOO/0% //0-VxQ$__FX|uAI!__oo%o7oIoL#F/a/j/5/////?O??'?9?K?)?????7:7H_Z_dOvO_____*=OL`{ޓՌ);f%tj|ğ֟蟜 !3b!HZ"d¯ԯ@RdҚ"4%7jǿٿ!3@!EŃx7I[m﵏Ǐ?? O2FLHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPUl4,`/b?Ȓ_,? ̴A-3 7"A_h -?Qcu@);M@IJ  FR@4(_h -?Qcu@);M@| RUFDfP h> /T6DUmA@ ?ۿI?Y{O1@3EEbOeZ! Hu 7~???0𫏆=@FwnmmhZ[L7Double arrow with 60-degreheads. HDB # ?hZ4>THYY9 dA[UA? u?P6 -u `u b_u  @"! FhWuk` tu.AdV8bM>ڲ@!$U'P"_/q%'i-/ 7$#5 L!# 7 6 BdH*%#/ Hh?Q6 u{%6{`("u?"F&`Qps-8R? WI@ 偌!6Q(-DT! @u@{$#AD5 `7Copyright 1999 Visio Corporation. All Bs reserved.h`@_Sba.chm!#224398B!$Cu tNs!OR U\l>Ud0@ Yi \!(Z$*L/S!4b?GQ b#Ib(3$$*3Ey‚7ʱRrB-db&`_aEojp= ףpՃoOR.ccb>$$?M˰iORD3eoeE9m |g`o'W6$*6a23(o_a|M:hz|%a_aQivQe&sbebQ2lm?l^Rgoyf?oQuo؅A &jdTAha9 G7(حN@fQB?bZބۀ!(! [?2vB@z?JVQ&999Y9Q9SIQ?IgRmb?п贁N8i/6??Hl'-s !Oya GE_6szF4 w#_K? Ab$noD Yoo/P+D?_(|?SLRY++@D ,'+Wi{ /ASeSf UPxP4FDTey  ahnm qT^UI`/b?IȒ_,??-I?*?QcO@?^[qu`Fuae@u U%Hq%P̕$w!p/////{!w! x$iD!"1#D!|53_"10"1q5"aD!E?@ڶڶ?坊& /~8K~05!H-5N?OQA(fEJ<4#005DB(8w!K_C ?Q=w!d5/G/AQLXz?@Gz?N@\_l^ x$U1 a aP 91"1 m$ iC CeVPEcnRdUeh0kUnkq5kFeQacnUcYaoXcp!fuaaFjX!Durationi8__ T'28k㨀PPUl4,`/b?Ȓ_,C? U A-37;U2@47LRH<( U2EV7 RUlL|[D@?7wRDc;U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)$LT *o8&Q- H*)=PEQy//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowWhite fillvisAecIsTech?nicalWallBuildingROOM BindingROOM Line StyleNet Thin lineNet Normal60 degree double_3L EΪ )- OG# _ 4R_ufL_$ Ud_1 |_> U_K _X U_e _r _ U $% <% T% %$ % % %% t Q !M? T$$(,l04*8GK,WOU UjL nd Ur| v z ~[+ ܟ SA0\A0UtA0A0A0+A0 A0fA0A03;Ѩn+0D0TW;00i;0%+0+0T;00[+0000/K'@+@S 8*@Z@UZ@ Z@UZ@Z$@UZ@Z@M ZӖZ,PU(ZDP,ZP0Z\P4[P8Z|P<ZP@T=[PDZPHZ%PLa[PP[PTZܷPXZ W\Z4``ZUL`dZd`hk*`lZ`pKk`UtZij`xZ`|k`Z`*Z`s[&Z?@*ABCAWFwHIJKMNOPQRRSWUVUWXwYwZw[a1w]w^w_w`wawbwcTwewfwgwUhwiwjwkA!wmwnwowp*wqwrwswUuwvwwwxwywzw{w}w~wwwJww/!wwUwwwww1wwwwwwRwwwwUwwwwewwwwwwwTGwwwwUwww{wwww*wwwAwUwwwwwwwwwwwwJwwe!wwUwwwwwyaE%UzU U UUU!U34Ul4,`/b?Ȓ_,K? ̻*bC-|r7A$Ul4, *A-37"A_*<N@ܴx* MRVg|q7uH<( H<( _*<NE$R+ RVgħ_q W{zN  g"4FX(G:?@(Z;ίPy @:]R}[ \q&$]!B;> DO E8Oh0x$~0',xTNO[x)_^x }1_x= `}2n"V<* F? +(!DlWl5 C=ń55 J!5 DSummaryInformation(suP@DocumentSummaryInformation8a_1044258911n~xF˪U˪UOle iOh+'0HPht vhaisbcostekGdxP  EMF\X XVISIODrawing  T  &% % VHP *ii~*iNi66N*% (   % RL Arial\\^\^z{^{|^|}^}~^~^^^__`ab^n}}o% T|0cEAA0L\Duration    ՜.+,D՜.+,@HP\h t   PagesMastersPage-160 degree double8_VPID_PREVIEWS_VPID_ALTERNATENAMES(_PID_LINKBASE A  FMicrosoft Visio DrawingVISIO 6.0 ShapesVisio.Drawing.69qOh+'00HPhtCompObjwzjqObjInfolVisioDocumenty|t-VisioInformation"m&!Visio (TM) Drawing -q ,zRl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1U&J:DT1EW-hTT<* /Ub bO0zGz?@8@H2!kWb*U  +$PL/^&9^$? { Ak^&,,'%/v&& * 1y   )P? 2   U U12?k9aBBHEHEHEHEHEHEH@?>?:`T2BBHEHEHEUHEHEHEHE%H@%O9 F7AOY@;P AsVsVA!gLTkY W_W__ !`#k4lb6u`kW *4l 4l %Y?P:?-\ #!+|QtKf2|2|2|I2wGQAUoTMeE$ttA%_8BOTOfOxOO??HO?7ܻXuW?YsU42 T*Pbt߆ߘ߼#5GYk}b4?Qcua&8J\n /"4FXj|Q!//+/=/O/a/s////////??'?9?K?]?o????a???? OO0OBOTOfOxOOOUbbOXa]feOO__)_;_M___q________o#o5o0GoYoko}oU&oooo /ASea(:L^cqoǏُ!3E(hzŸԟ .@Я*EWi{ÿտ όf8i\nπϒϤ϶T);M_q߃ߕߧ߹p3ǀSFXj|+=OasNr'9K]o 9 0BTfxBC`!k}3I bz@6` /'c//A&`M/_/q//%b/)MQ3///??(?:?L?^?p???"dGoPo be3oo}_oooooo&8J\_VC94O*O -?Qcu͏ߏ'9K]ccU<犯"/ΟF//:/!щqfxү,>Pbtο@_ jK[CuU՞ϰϬҔЅaa3vO贁NkߖFa`27qZ?Yka?\.? pQA6k6߻H k+6;CjԕaI^g030|kPewȈ$ !%7dri{ /AS}/w+=Oa???'9A1K]DM*Oѭ e.KUqH)Wq[=ۑagOyOYuğYOOOOOV0%!/3/E/ W-}QK_mϣ(A(I1oo(o:oLo^opo s#m///5/////O(O*?P?????Ga^o__OO_____-?VQ=v.s#{.峑PbLǟٟ!3sHZb=!o"důׯ //gyI[L^$6HZg!lŪ(:ɏ^p9܏ $?OGOYJ#qٿ 1߀C __-_iȉX@R_ba QJ_+Չ/ڜ,5 ,5,0$Zl~r?? 2??h8LHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55@!winspoolHP LaserJet 5Si_7420_29_IPUl4,N!2( ?@Jz? < A-|37U *<N`r@Dq BR @4(U *<N`r@q x RUFDfP h> /T6DUI@A?I BP(?3H$- b]b--rx@l^bf>M,,D'^fO - b, , 'eZYUHu F .LYcuZo^SLRepresents an actor reference.mb߿??PQ࿤p= ף??3㿕HD" # "=h#-$>T #T3 AOAU@?=@?@u߽?P6 )i8VYAEDA@@#u` *'.8BhPZ`u#j Ub >U5 gL{5!5 A`7Copyright 1999 Visio Corporation. All _"s reserved.`j _D88.chm!#2]0 l>0>Udd!!P #w a2U50` 9`fC"`e1De 2#(  O?si?e113???%G1 7@<Oa?9ME)2RO;rABC#(^actorReferenceiVA!aPIE9 3~'2qcPӼ? &bVq(^/\:5!?lOrISsQU__f+OnQ&%^]oeoooxGQ3ULYoopOorHl'-ER  [F 8# -r2? G1b XoOD+ty!Yo>?Dz!ko_( ?p 34RD g+@D>q +W@i{l _S  UPxP4FDTey  ahnm qT^UIN!2( ?I@Jz??-I?*?QcO@?^[qu`Fuae@u U Hq%P$w!p/////{!w!x$iD!w!p!N? "1 a$ ԉEP?@D?@W՘H?@X2>?a!H-#0QKE(<w!Q2m?Q?w!)l"10qU"1q5aD!G1)>&A*U30;[Q^5CSD%*^[G1_8ZqHnAD!D)BIAUW0VVBJo$a<0eY;HoZn0noo"c 0e\okA(QOutpatient Expansion from MEDICATION ROUTE file (#51.2)iT5/G/DD '2r?qBUl4,N!2( ?@JzC? p  U A-3*7;U2@,p 07LRH<( U2Etp 7 RUlL TT @?%|)RD< ;U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)$L5T *o 8&Q- H*)=-PEQ//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowWhite fillvisAecIsTech?nicalWallBuildingActor referenceActor reference.13ROOM BindingROOM Line StyleNet Thin lineNet NormalYellow fillMarketing Normal 3Flow Normal_3 E )'- R)2G)UJ )W}ec Urc 4c ULc dc U|c c Uc ăc U܃c c _ c $Id :|O@B/KO@F:O@J:O@N:RTSK'PV:4'PZK'P^:d'Pb:RO@fK'Pj:'PIn;'Pr;'Pv K'Pz/K'P~K'PR[j :`:$`=[`:D`;`a[`T[`:t`:U`:`:U`:`kOeK`KkR`›K`:`ʓk`:`$K`s[`K`Iޥk`[`kOeKpk`KpKpdKkp5{p *pCp CpCC,CtpC\R"C&C*C.CDNCd6JC:>CBUFC`C$NCRV Z^QbC Q‚PjC|UnCrCvCzg~"X -C<C4Z`CT٠T٠C٠CU٠C٠C٠y`˫WIݫW)CUU$ߝWӋWQWCUW!*W W,ADAʴW\A#tA'ʌA+A<AUAYJUApp'A=3EЩWЋ|ЏT{ГʜЗiRЛПգ $Я<гTзl*лʄпeЕi^3ХodoDo"TZzoo ꥤoojo#<#+#/T10 fx0p!!!_0jC#W%&'(*)*+'U-./0E125U6789:;i=>?@ABCUaOFUHIJKMNOP*QRS{UUVWXYZ[]]^_`aJbckQeUfghijkmnopqrRsuvUwxyz{A}~TU*U5JUQRYUTU* Ua UU U UUU!U34UUl4,!N!2( ?@JzK? _(g*C-_ 7A$Ul4, p "+A- 307"A_*<N@ * IRVg,2+7uH<( H<( _*<NE|"+ RVg\q u{zN  g"4FX(i @( sy p~!p :]RlOt  uq&_Lv !BD;>GOFo8O_<  e=$ K0U'|fQ>N xU)!x 1 ,x=,`{2 3"*V<]* F?q!i+GD|!5 C=t5 ,J! +Y USummaryInformation({}n`DocumentSummaryInformation8_1044789508F˪U˪UOle  vhaisbcostekGxQ EMF|X XVISIODrawing  M  &% % V0IHHH% (   % RL Arial}|zywSTTjkkl% T&g!AA& L`Outpatient   T&"g1AA&" L`Expansion  T 2AAA 2Llfrom MEDICATION       TBQAABLpROUTE file (#51.2)  ՜.+,D՜.+,@HP\h t   PagesMastersPage-1Actor reference8_VPID_PREVIEWS_VPID_ALTERNATENAMES_PID_LINKBASE A  FMicrosoft Visio DrawingVISIO 6.0 ShapesVisio.Drawing.69qOh+'0HPht vhaisbcostekCompObjqObjInfoVisioDocumentF#VisioInformation"Visio (TM) Drawing F#d!zRl !fffMMM333$ $ U8@ Td Arial@NWingdzs@m Monotype Sort+ NtSymbol5T?? Y@-1TJDT1EWP-hTT<U*U U =/Ub b酸0zGz?@8H2!kWbU%U  +PL/^&9^$? { Ak^&,",'%/v&Q&  1y   )? 2    J12?k9aUBBHEHEHEUHEHEHEH@?>?:`2BBHEHEHEHEHEHEHEH@$%O9F7AOY@; A*sVsVAgLTkY 1 W_W__ !`#ku4lb6Pu`kW 4l 4l %Y?:?-\ *#!+|tKf*2|2|2|2wG)QUoTMeEttA%_8BOTOfOxOO??O?7 ܻuW+? sU42 T*PbtφϘϪ(:L^p߂߂O߳ 1C@Ugb{.);M_xa"4FX 0Bzas//'/9/K/]/o/////////?#?zaB?T?f?x????????OBOUbb7OQV.e_OqOOOOOOOO_wk#_5_G_Y_k_}______L__UlAoSoeowoooooooxa(:L^p cwo!3EWi{Ï٦ .@Rdvk}*B'Ck#bz@.`c.`/%b /=QN3L/^/p////////??7?Pbtί(:L^p݇Z;ɼٿِ>.@*[m߅3O'Nk P2Ǎq?߃?\.?o AqT$$$'9K]ڊ䐾伩jPPj|xԕIWؙ&V03E)0<kDB!ߵ V /ASew+=Oa/09K]o?!?%LHP LaserJet 5Siw odXX6fHdzE.TdfRfd  1CUgy //-/Custom page 18/j/#B#L)2|//}//S"3/?/(55H!winspoolHP LaserJet 5Si_742029_IP0Ul4,zLp?Dc) ? |2!}A-0'7"AUV6@1)GRUFDfP h$T PUUBmUA@ ?I? 3xO@7IyIfBo?вsUP  /e Z.$ H" S?!{)19AI?dp]qi} Aw:npqA9pwwA9pwpiEquilateral triangle.b?? ߿ $t@ ?<?紁N;3HDB t# ih0>T@dE=M AkUA@??A߻?Q6 L,A >M A JuM` ?[y&y0y:@u` UJS>#JU0O贁NKk?<@MJdO@ܼ@ L LP6 @?FS@U%%F@))@H""oKJ%{X1]45 `7Copyright 1999 Visio Corporation. All 2s reserved.J`0_Sba.chm!#22416Aida?lJ*,>Ud6ZV$(s=?)ǹ<$$b# X"yB:V/ K;EA%;D]2׳뽿HH?!:ͳ?OARM%2pO;JrA RSq(^!(M%9M\Me2AO-QVD}Ho *oFTO`c5WD`18WoiDYebW_`c%@neNooO[jJ(?kF8Hlh !OyaGEWszF#<s? mWakoD+oB?\ooP@4(UV6@42{ R(n?1p#R,+@SDD' ,ij UPxP4FDTe]@y  ahZ- ^TUIzLp?IDc_) ?? I?*?QcS@?^ua`u$ eu G{!D!e "u)D%@?@?@J7?@O*g?5H5??/18! L.&6.&62U66666#0Q 3-%// d/U1H<p$1CɭRCa(D1)A1!i$5/G/D '2qGPQA1DiQ [B1a`Q/`Q]%QAUD-YaE90:x?@?Pp?d?@.%ef]K?Q !t\A ]tE0Vbt!abMozUme\mmevgzkچ05E m=Ac#gc4heAO-O?C&@/^A<ߩߏ̟9KH~﷟۟1DLocalPossibleDosage@`Q!3EWrcNSh()Ul4,zLp?Dc) K? 1A-07;U2@407LRH<( U2E0 7 RUlL oz@?)RD7<U$ 4(U1(5 *O-D&U=%QAb -h"^T))+Uv'g&JP)LT *o8&Q- H*)=PEQy//,GuideTheDocPage-1Gesture FormatVisio 90ConnectorVisio 00Visio 01Visio 02Visio 03Visio 10Visio 11Visio 12Visio 13Visio 20Visio 21Visio 22Visio 23Visio 50Visio 51Visio 52Visio 53Visio 70Visio 80BasicBasic ShadowvisAecIsTech?nicalTriangleTriangle.6Triangle.18_,34s E} J- ;G; W,qUc Dqc \qUc tqc qc qd q q! q. ; %H 4%U L%b d%o |%| % % %J ;%y˨X,T* M*\*lV)[*; m+%[*[*[*m+[*#[ ? 2R[ B[*d )F[&"" 0 fPx!1m*E[  !"#$%&'() *+U^U U UUUl4,zLp?Dc) K? 37 KC-$37AUl4, 5 A-37"A_*<N@2 KRVgq7uH<( H<( _*<NE2`! RVgmq \{zN  g"4FX(Ga ?@(g:bίy @D:]R}< lq&|!BC; >EOtDo9OWW$'6fO|Ndf)f 1f=1`2ĕJV<- 7F?HNFDzJNC= !N|J!NSummaryInformation(DocumentSummaryInformation8WordDocumentM("SummaryInformation(Gx] EMF!X XVISIODrawing    &% % V,o~nAn~n% (   &% % V, ~K~~% (   % RL Arial% Tl:N\]AA:NLXLocal  T|0^dmAA0^L\Possible   Tp3oa~AA3oLXDosage  ՜.+,D՜.+,@HP\h t   PagesMastersPage-1 Triangle8_VPID_PREVIEWS_VPID_ALTERNATENAMES_PID_LINKBASE A  Oh+'0 ,8L Xd    NTAKE 2 TABLETS BY MOUTH EVERY MORNING ANM bjbj== ("WWl>>>>>>>r((((<TrB B B B B B B $G g6>B B B B B 6 >>B B K B >B >B  B   0:>>B  0r(X  \a0 Wn :W Rd>>>>APPLY THIN FILM TO AFFECTED AREAS FOUR TIMES DAILY FOR 1 WEEK THEN APPLY DAILY AS NEEDEDEntryElementFileAPPLY EMBED Visio.Drawing.6 DOSAGE FORM file (#50.606) THIN FILM EMBED Visio.Drawing.6 DRUG FILE (#50) TO EMBED Visio.Drawing.6 DOSAGE FORM file (#50.606) AFFECTED AREAS EMBED Visio.Drawing.6 MEDICATION ROUTES file (#51.2)FOUR TIMES DAILY EMBED Visio.Drawing.6 ADMINISTRATION SCHEDULE file (#51.1) or MEDICATION INSTRUCTION file (#51)FOR 1 WEEK EMBED Visio.Drawing.6  IN DAYS, HOURS, MINUTESTHEN EMBED Visio.Drawing.6 AND, THEN or EXCEPTAPPLY  EMBED Visio.Drawing.6 DOSAGE FORM file (#50.606) DAILY AS NEEDED EMBED Visio.Drawing.6 ADMINISTRATION SCHEDULE file (#51.1) or MEDICATION INSTRUCTION file (#51) YZmtu#34LMNOPo } jpUjp2> UVj 5U\jT2> 5UV\ j Uj_ >> UVj5U\j-T2> 5UV\j5U\ jUj9F> UV jUCJjP2> 5CJUV\ 5CJ\j5CJU\5\:CJ1YZ`hmP $&#$/Ifj$$IfTld   064 la$Ifmntztkk $$Ifa$$If$$IfTlF@ hd ( 06    4 laztkk $$Ifa$$If$$IfTlF@ hd ( 06    4 la#ztkk $$Ifa$$If$$IfTlF@ hd ( 06    4 la#$3Poz0tkk $$Ifa$$If$$IfTlQF@ hd ( 06    4 laopztkk $$Ifa$$If$$IfTl F@ hd ( 06    4 la*+0Maztkkztkk $$Ifa$$If$$IfTlF@ hd ( 06    4 la*01IJKLMaijǽj5U\jT2> 5UV\j5U\j5CJU\jP2> 5CJUV\ 5CJ\j5CJU\CJ j>UjkU2> UV jU5\CJabiztkk $$Ifa$$If$$IfTlF@ hd ( 06    4 laztkk $$Ifa$$If$$IfTlF@ hd ( 06    4 lazx$$IfTlF@ hd ( 06    4 la& 0 01( =!"#$%D TAKE 1 TABLET AT BEDTIM AS DIRECTEDAAKEKelly Anne Costelloellell Normal.dotCEDS4SMicrosoft Word 9.0@F#@j;#@^[@`w ՜.+,04 hp|  EDSE NTAKE 2 TDocumentSummaryInformation8d1TableٙSummaryInformation(DocumentSummaryInformation8+ABLETS BY MOUTH EVERY MORNING AND TAKE 1 TABLET AT BEDTIM AS DIRECTED TitleOh+'0d   , 8DLT\  Normal.dotm3Microsoft Office Word@F#@ {T@U4TDd /6 & 3 A?%22 w7h:# [`! w7h:# xWxT=OA};6NрJDa>%$H Be A)ӥM'] $*A$fo(AIXogvvvv (@  (:?-' ?j$2gs,h~X rSi=]kO,,\E`xC{uaF}q{&>':i]g=ί"elOdS>9pG=ӗ^\aGˑ!v=ʕ`ggq(ogM_ V.#=Q,ILlon}(Vssiʗأ\"Zk7Ky۫U_b^=#ݞgk^$nR4P_?ڨ4vV 3:Ct2YD'{u7SvveVz'R̉r\LjO}W\$$If!vh5=55 #v=#v#v :V l!06,5=55 / 4TDd  RR0 ' # A&2e'Ue`N3l]`!Ue'Ue`N3l4c#xTjSAf?1V۴$T.ԢKc`lZpa\iЛb]SW>>ƝOPJW;3sӛ 89ϙ3W`501$ȣ%%"(\ubR#)^I|weYG$UvJ e 븇U*v3haZ:>uF`61M~כs.b\I$I%S7*'vзG#:f;m~7%k<8_-7f䢌rU Iv]erw_18p3{T04[QC?yRKz{gk-VW<=*g|l$$If!vh5=55 #v=#v#v :V l06,5=55 4TDd GFC0 ( # A'2'Mn֊Ym`!e'Mn֊Yr43xuTkA<%*a "C"3gP41! ɒaP+[`aND]  +,6y_ "psPƒ1?wQD~Qn ȍʅ9֘#YeJ~i(3gSRU<@ko1+{p,0RXok 8q2>w2q3lٚ(*w$11+{n7D7Ax. L{KXb!S[ic&R[U㑘&1w壨ْeQdZVQOmU|#} H]f"6 'loGl.F8>J>[dd:gX&7~{1yn6~@f)dOQ tTU9N=d1".]yA C>ZǷfi1Ol2)wmP(%Q~z>m/B΋=zk4TEN67]+fws &P}WZ;0U ck"x.!b,Kߦ!qAFG).hN +ҝ9殠ţGm)e:#kk]g1 "a;~QoX\9"mǐ@1GAhZ5W6ۭ jZoZ:Y{ךj\x.nN pZhs]{xk[Be\xr~ _W{^*eS)7?]J6|;3OB&qO.XWe"d1OۥZqFI@$KŒbh927|$$If!vh5=55 #v=#v#v :V l06,5=55 4TDd 6 + 3 A?*2QMgJu^BEV5-I`!%MgJu^BEV5HxUMHTQFMh1V-bhrRd2EH:a3MDUJRBM"qt* rJ@qծ;wι~rs}E?O*GgK. oL ,9 |(˂IgwmN{] 26&\H4p|}#(b2OYރ1"z^4qʲk92#S6=8.G\U^UJ]K,R8ٙCVMjxĨAUI%iwҀiC )YLKEqeRo^Jz(kj^ԴȰx$)AiN!qʔYR 2^Ƞz)M hĔ`D0$PŠ5VJǔ_9Y5.^m_Wvxẹ<N{pW}"OkL +fl=[ߑٯ7!bB._[<ߙyװ߹шvt#Nya}wjz"MCdoMtw~}ƾuy3k;FrZc}9K&G^>~'JbMv m?SlgӪ/o%͊ɉ29:`3l2x !fR5wG:={g;kRbDUځp?%w㼌vX'̯4$$If!vh5=55 #v=#v#v :V l06,5=55 4TDd 0 , # A+27^U>w 58]`!7^U>w 58] xTOA~P-a,ؐ zAR%i"بA$ YcfwAz@ Wx41޼Fߛe@˙|{yof"J|O WP< %"^'H<k|Ld=lsrvj?"ۆ _0_2`|ECί=޽7 0%z>|j@<|0h$3< lln xJYÓ0h*;;sV!x6ks&bSC<*Q8qnZBs@ZGTGas{q:{1?!4* ]+x£P%?_]ؕ R"yovJjK?"2d("V)=S yk#.7_N yDF[@ond6r/oc-pfӆ>[fu>>-R2=zSR3OӖ—qxS{EvUK,IhL,Pՙ]}$$If!vh5=55 #v=#v#v :V lb06,5=55 4TDd D%u - S XA ? :Simple Possible Dosage Table#" `,2*ƻ-B@Zc^*`!ƻ-B@Zc^\G\ `p\ȴ7x\}pT?M&&v F$5KJ X#%%,%ݡ tVڙ2jG:Ccm2U)X[mD&8j%=뽷/x7|to{睏qsKLwR8, *ɯפ T:aK]%(ڒp,}iRHvG[r(RO YEM446vY[e|t!~o [rcZ7mL.;ode*X'5tk{nxĠ i0kΖbw#xXJNaR ,m$j#EQQ2u^gr$˾ ӾÏa_DZݗߗ??rĂ~r|3Ǐ1_1!?^_aau5AX& z:rky' O{3B1P}T E& g.Nf[|(cA~XY挼[; "6f"pKn"<IYIDHluH튦84@nIXzl4@=Z <&MxLBmd(A.^ 8zm/LvO3).L4ѯt1 t"Hψ|n$j)QvˇKzZ5/ ~*~"C\ocmO|h@H~ f2cL5K oz5,8x^ [sRߣ@zKk:g62QgC4:ϞUf!<>B J|+]{u/K GdO#AHL D::IoImlnmOFPX;7 [X@T*о*V=6s<'&s}q,,oq]e3Ҟyd 3ڝ/FGzEQ2TbEl& 47vwvZ|a5 oqd6쩅KΌQs3#&NؤPf[ZLg8:B/XdɊȆd)-`"XeJg ;ij0DYAP |v\!X!{I3WBTgc Wj¦C-_-TߦX$ZosmN^7R}HT>Я.Udz$l{nZ/ݡe9.oڐ8ՆTB} F*3iZm6#l&CnZ/k, 0i}ɐW=Naq ~lGAڴ^65#X?Z ~׊A'T@Wk͝FmHWћۻќM GƘX6>TWFi#Lr!fo#9LR^b1f1) z[#HE-*S<)3œY2ŧ6l$ݏa;Sd2/cx7.}8ƫ ,f1# 1 :g)YaXlnwa?]WVΓp_4lܰ \d,Q,K]Qa,9ouRSuX.3뗲Tmdi׫~,l+e1ffa+s2Bdf31rǻ#9ٕN&;D3Xfs<:Miؒ]brKQr:JLDّdMsg٫9gCn3mlZj'30{VF(|Fi\OZOM EYma0i}& Em8~nZ7t xWm\Ur4mVͺn?XnMӲy%Y=`Я{} :~&A5Θ cgZڦ{ˁ T O5?CbM/=`:_@k"֎H}̑~vȧ2Oe̫֞#,X{ġs kϹ$Oe koLX,m_q%Ac2Obh3%ģ~BN'!6W w$yVIRu%ݯ51ye8^v邗x[<8*L}v c,ѧqz E"Й5ZG^)}Y)yh9JZ.Tz?5c}rDG/vkڄx]=ð t'6(k)MCD`G4/-#nbQjw'?^ed?e`_%X]=IMg,ǐЃ 7u/gzL@6Fe2^2Ui !RI42/l?_e6@\Zf: x?۰ن:mZַ͊Y@ Ge6@&{`^`vKo`sgJO6mWַiZ6u'9\`W=3^_.G7F0i}i˦|}# x_~ƫd &oβcPo>x~lںMoADd "E . S VA!? 8Local Possible Dosage Table#" `-2Y"D}C 8 `!Y"D}C f2 XTFx] pŕ]я=ƒ {%aajeK֟Ƈl0W2/?ߙ\g!T" .M*pu1 K!u:M˶$՚y=7(+G@o|H9h>:Owg-A<,r*3qVPoOҳ NuHK/H[ؑ }eo6-1]/B_,A%X>EŽ砽I[i+`2?o}&{w P Ď;.嬇?\ :]>Yִih1xQ[_cuFm{ֈo G-VñeZ!ŭ^CW U9w/mR}U1I\Wcڍ0ՠk6P˸q63?ko#;X s~eb?pA#.@Yy@EeB? /B%N?.3A?XM~ArHG+BCk5ҚOn@5:Oh[#ysFˤ{A~,˵(Mγ4 fܛɉ\vW3& rSlNw]fiIX]%a1KɅGư,Wr`y֜7b97髏)ϒ_^P|o*>Kxw*3ieMjoU䚥۹(brOˈS>5s=Z4Śc-J໖L8#`heѲQj,38CECS -@ixe)&iC-5-cce]Mn#ݦyjM5waWG~E;˺Ɣdy(ϽU*: L~E;˺ƔVoSy0eT;F%7Z0Col6جI_}7ZMTפIzӽ7ϑV7g8Bk`筁 O#C%Zٯ;W q>LT~أ}38rɐ+B_25fJϐ_V`0W5ceZ5hAD=8&Fk|&F>K&3ؔr>jr#B՚ɓ=t< Rb󑏁' Ɉ5ִO鞣H7v P7@\ umFP/`;XsBw y $eqyE\ \+m}D>{n?+ӌ! h!|BtSWC:-0=%63y~6JW&liJ>z֐Q :-mGlCF;zeS썭ρUCtғPtB}y%M&qf=H+ u9.߷BN+R>wL?1U wjfкqd;sQỹaOj]3[ۛ{Kˮ[z][2,G+D{%]žJ!B.cyt:2'C6:Ҷ !ţ~7}V\}} Yfx,/hEh%2â49_괷:ϙ3v}O?S9ҳIJc2yz#$S lwĉcy<\yP!p@Ug{K]2Yf(yp <Z<e9sN{<pC TV*%au%e4/S4Gu8}TAEtTاJ_}Yk稶?J_}΋9?UտvKҊmAŀCP goPk#'l%DtCmojT`P7Ĺ?py∳Xۮ%睯 9G8syKq&==jo KIM#K5uę8qGZfhcxwC!E76Syiak4w!NW~"7MKR_CZw]Qh }V44akv'krr @u0^@}/O#G9?yN !ek2:^La,Oy9Н@@_=epC3+M Q+txWЯҔ-ﬤ{ ^Zr Ֆ}{r}9^fLS K 2}/9=/vCܗXZ6a/޹z1vCԨ@DLФWdyuqW{E+mW4R6IN{@nd똼=UI_z>gو":q>&oXҗpY6N{yc%}We#J<qd >bvOŶM7bYOLv0byOeMs2b—^vv}%lPR+EGa^NC) t-|3 j/-)t+n}qN\o$tS@7}4셲v%h]7鉧c\ h_nWj\ E:@֗у:M_=*܉x5Wc8@ UE#\> TUzm5:A=Bkga4[?/z=^ʺz5oƻ!8> ǡ'xY%Lk krPGHmR'EycR )g >AI\#:GDVr5QTE>~;yz"c+^g2uS sy`(`WVKNzaXLlWا%z{;Vul(""ÿ\Zd[Wfz:*Q3>(,IpDJYUXhoug,pO*KT!YVs槺,,RyDy|c1yޒeUJ<_5{l_ŶMWeIʚ~97Ilg(=-3Qw5g2vnBo~'Z 귐nW.=ZNLϢnO^_^hώ.+h>RʎXQ?86DdH4ENch_R?j4ѻgPbE@?H.%Q5 VSV9jy (GDdqt*GA%NO=d"0$8NlGœPId4@;A:XQ]#[ _zHM& H f,y!˝D~j9I Tx-FTeeY6bXe)#KsF Ȓ Yhnjfҕ A: Ylaҵ:4طyg`-E! H=sF XWa%Qcm9@rM*瑨YY~scu xCk p2O#]? ]; : LL벲Hi5UfqTrejvS@ŶM7jYS@Lv0jyS@eMs2j)^vXvw%+~.5(G6n`C/x*iƭtoQHt;Xۛl0 !cJz$Sd7pvm7g4b7!6E 0\p ]v2vУg0J_9@Nu/^Ǔpd%ZDZ*r;DACd&/ɻ$O&sp !y?M>‡I:]l"[*rYDN1r?C#I'#pCgh<#d7j&(B֡#׫ 3{a'ܰגBAOX ԮL %9zNmAu&X( eׂjlnH/A4uSǿ(\U\.!T#yx3U'+9I[/<9d<5 Oh˟K\c˶=Qj\KxI~UЯ 5+tR 4W7h574tMƐX#Cd L2@~pVGtMW~(t9s{|--2WŒRR> F:9j+0g֔޳O9)'RRy.V9yc%} )y`y|1yc I_b 1eY"#:s87g$}gƔemJ<)jY}&b&}ukLPLvfʜ`z1vB%}74𷊿ւX2:ǁN(8KQیkxj,iЩMIȌEŦ+86qww6J~A8oc>"}ˆM1|>SbSg4>4`ӥ1n| >I%4-"v>MӏǤv4IOjHI./{Sb"^G!5Sۅ,1bT)0qnp^kNCCVQ4WkA~_naH@A%4ˁoEy4z7觛.NԦlT) PyvDLQmi xRՔ6U<֦L˹a¤Qw9y$`J l2LYPh H|=v mO2Z\)԰y="arm;|lwvGϭH/MDo-gٟ4t6鷈Zb7c#Z^ Z@*c#,^3DQ)Xn1݋aõ2k-ͷs"@vDBo{h_HwDaޢAJ!}xwvli[N.HV91y I_ te٘":qq7‘%HW)<<n}LިJҗJ ]Y6ē")eݙj#қ>m+OmTyNXdߙwݛ; =esϜ3gܙs#!Bg %mrт֕mVo f%Q2.Ggy \o>HbK0FCY9OYylile=-]vM:$fMJGjOI Ḫ"4.4nHlS5k[.VMѺk֯o]%ZӶh2|c GQ!ԣv>)=ǥpO:2Q V(С巅b/-IsxrW=)3/zRD /]~u'<)>Eqȓ"xēbJE'E8ˋFOzR1(zR, xQ-ߙ׭Smaedm&)uڬؔm궙>v;wukAFU;MtOGP_[qnÀsrvղـc~o7`/[۟|cP߇=~WZXb3Hq7*kZ/B3@xB7BA^r(|7`PXj!Q*kAEF-x\ U|U-GƼWK̭0GJˬ4&HoB-ۼ޽A Ec RjZ&;(JA_# .p~ -ԁF jF}pdٖMqoCPmD}1a|9cixskWDY[[*HG }2.'4&y9u.@` ] irE ;"YzG;>Yy m>ZenDPb ajFlGyE#F#,犖.Vڱ'x1E3_2ͤQ嚅 UbtejAUbDbgK~2w 3d㰺umKtҸiM( p*dQ"8'ؘX7a^<8;= )- o!OSZ4亄+HP>^2!%ęW`qX ZZ_-NO,j{/m~'i-}ig|+0i\J|ʒhrSֿmbS#7 T^N\4dζd.6yl-AK\lt"~ZAYA6[ԯD6!U^N9iqo??ZcM=~]Nu+7uy7VlJ_.=NbÔӣ%hE;G3Ndj '!Qw&x$ oZe|֟Z+$%jȺ7:ӉdG囁ɓఅ!Y]ݐ6@HuG$'k EώTD/0H5"ҿ@ʓntB̘TE>Rh"թ6GE%K% PT>9xPP!UOD?vn%%'%E@[udy-c|%ֆV4Jᜦb;l-fjGpr\}G䵬@"zZ_ }Fzb:CZHFb5G԰:5xx2>)ὒ@GFc%!XIk$F U3T)9 a6kجV.Ϣ$| }ɇZgXJ܃ S OV2tW>W@^xuDkcE;N>|Agv-7iv˶C~moeg!qv_9>nȟqD5g)E9F @8* +3@9 |W/P (!ri%CO2g]Pη|g'Wu>:xt%*q9jÍmQ7z{~47F<mh/.AGd&.8~LAThTfāE*/_K&amoԱm_-;ےcg[}%S9>ɷKf"~:m{g ]ŢDWĈH0^ $Az(k ½N =az2H)\$f>M_g<؇uܝ3Re bE-`P3 6P,F:@z . (ljL[ E+9,Fc:b5u_> tM^ P7j5(@=kkdwzhϥ~ Ws[LWz09/E?U-zJGAVIthT+mu*unᶶ/ũm Ft֍ uF:2ԘrDsCGfK/t44ud)  g#eIVz/.޼e݆*B)d"z ee_;:yzfQ6&w ̊Ww V3qz2By,3Rp$^ ६J$4*N"*fG"VݙmzaBFZlRGARo!Ӝ:E Mb嫳VLETG &a WgkFǔ^^D*;Sii}f~ux~ Gf B4@WMh# }KE7$ $Hv8?N^d(*)!rYMHy %OQr~4o ]C^@;>| &ףd*!P@ACvCɷ$S[s <)AA2@[>@JS h%U)J<,,q@Cz2:SX>2F)5SK1=$FG?cfC nHsdŒ4G*ib!K8yb>aZVum4 ` |_L(7K2rN3~g`0{f R N碌ק͇\XMSŢs )>[9!`Ǖ N/uD-7DG@_T0UX94)ir#Ш|gTZ UJ+U_U$27U'o + !;)s+/+u--2 ZZ_feuJJZ2/;l{ZmswҲi:vIϧe9''x<62=}lRmHDߚM@gf FL|ܒS0 .4[эoE>X)3~&vcْˡ%].a[b7Q- ,FX g =wh†$!]h:)`w+$:7;L3_!@q!"/5D;F[H!%zg"Ry )een0aBat&kr,|1NY[tv4!=;8)8wdK?o<5ʼJsCLrѺd dڽ4#І/;<.މgQb&r&+KFxƴ{媓w+Dz*LSVZ_fcq#RG$=cW)ȠeVn^N^⯼02-k@NY^fvOPǶ9}+'cgY}s_Oʬ ngw-0DZkamY(~0kBr^Q?7qG0}oOWȝ ͨ:'XoFmDp]f}6ߌmK's}a }?WXҬ YIL&)3|Gذ9i%iV+hhy'',i4Tb $n+٭xC?Q->Q ڄ7x%סqzB%TEr@l ~翀F:4XͨczW-Pc)EŸ x7xMFca$F~Adi>]I7 _14.'d'&7Gq- "S'/ǯ#f|]o/WVOǏ?~3(kDT;p#*Ç%E\\UxF|+P.C;KВT4~#S;AƇSp .)<~WP;7/a ? җ/=E uɾsߘS}'S|3J^ lA6׼ fh uhnĕg*Wڟ M̥7^kG8iTJ2b5y.0y.+y.&EE¹s_W1ts UCZ8陔^OU^"ېscjmt[9lh)<5g`lJDSU}TlҐQxf$ەk8.eHɏ_9y_آFMӵ97;p,qOۯ+VJ{ǪIXKK<`tc]u%Uy5e`eZ2]'oKrOPX[SfAKˬd:1NޘI鞠ı*oLva-ձm_v[vcg<'W9>mNnO~O[O#33h;' .n]e{?aĘ's cq Wf/ ݧCGp(a8b>r> '][ZZ_wP![֔֗w;ukHV5e qۗR/%[֒I0 aa˶7tl׷egC:vA!>$lPOޟh{Eyg;՞7+>=O'qnOO؅=!,'u=9{!{zOZO=̨ Hɱ7x/on^@s{FgDig$J&' %ZZ_MNr[U*Ҕ֗w`u!K4e kv+WW.Ғ ta]mgul׷.2:vAa>jp# bpLUC>հw;F Tk{­/}RQUimR', ƦXC+"‚̙9sə=%YsΜgfgϜH0:(iƘL 1c]Oז [CڇA^yYrb)]xO5BPyN2ACRё?ԡ/i1h@6?iMtcr(+rhŔY'd2p>g:˶)sb=D0n Jg'A}Oe/'Bؼl-wlIr>Ktܢߦ[$jO{2r|ʱ2߼0T Z?֦5rZҴr< 5%vKbK -$q{1ᆖ2{]Gٮ#~kܭ6,Q> CYJuR [_X+kYƁ8'|>k%ض| rx.M?Atgѧצ=զlyȯ3YRGgR#~]kߋcjS67`lձY~E__lwgco)'ī9>` q_"IƧ%K9kzH{Ǔ _@y bDZxoX( ԙj`Wk@hX)~4i]۟ߵ,O,)1V,8x/Ұx#([(Q/ S(fur,21]-HxuЌkЁZ^7Su <4!n?Hu]CkmN6v/ro ^=̘lB%y=9.[rz͘:2*v:No!NV֚;`o)/ě>++qy}qG$xygSgj| Wۘӷ9>)OWgW~O*OMI\`\ xny._K:;ח_>6Y<$ l^=g<~:SA)NW8HTy}ZmgI#|tA1(ۜӥlly.}>nyy*CiHqO;J棇QW!3ާd$īμoq!lh.ibðaԝQ+0-茶gyE&fjI1l:1cfZ-gGQE4g(~:0*3|#.Xu_i5K"3;‹L?A P-ہ8}rcLݘ S-7C/5\58^#4!;Bf;6wf܈ Ki g&oYW?6/Ogjym}孟 iǼ$=϶=>۶^mg{|:vf׷vA96O$n oUx> zI!\M> BL'Q#p~xVx7I;\BZ,H%#%*PFC;;Y x@Q b6Zn40<#Pk&R6Cˬ$zwØ3|Ԛ@g~`O[NmEka=@O;Oh;ex*y# aBO/!wQ줯:PGo)zD} [0b|pT^ϵ'am_Ƕ-ou̢ov_-}oE!>2? ՏQ[*j7~V!FL8HѣX ;>*?u[^o?G91YCm&P~g򭎣#_a(VIL5[*R*9׼4s+ЃcpM]uUK]cr a+bix8ZS9~뾩%l!+FKfUZsxYǴWOT8\/ d;j|79t%j%+縰@ľ1A //NIst@bI3g,n&V( N;S[3< .9n6y{芾%:Ty&]> &oT+T ѡ35y>!Rpo7QPZ<^$ݴm)c}}3m;k ؙE_Lϛ:}nS Zp2pь,Ḱ[!0bcs&`Ybk;^;5E&-=C8oψ83fװOq6trq6V'y‹ؒSW %Xk}L ^MFXD5t\Oooto! ?ôvOWc/KAKt)nv:FMOOg~z?9HHx,L?E> 7a탥t=吋 J_i5 |? %MMk`FaՁ,r3V.AfXC0@՘W|Uh>LCы>ÓǽP !19F?ݸ݄8Κ9* GN8r}4eVb5rsϵɵM^|0U^&]> &od+d!kYh)TZYYmf21F-ǻM][ *1#x'*“T Kn3AOd/ O4k6zrqʍ5&XhNsD8l{]ʿ0y HxZDH{)9ÞL]3){":, #D^aQkH`"2u]۳-c߀-4Ye+B_ZkTl4 ܟemXkW+IيHwzu ,#ߤ+.qNԜ>N3!++gcqdϘ9nd6y{'Ngiky,m}IXYhAAcЧVڪrRN\),!G<[l:< Dc 0!~rc4a-8b5=ePkƗ  Yc4gH0q>HWӝt :Z^sL Fΐv+J%dKخzw"Go\7dD: ן4Ó ]2k ?=yuT6AϑC^1O%d)&אqr*Xr䑟G{#+`Ed TFF^.H~!rp/xAdBd>I~HGryy%;A#{#dLc8 N=y"y`x['8/Ԋ6H 6tUsDR'ͤұѹѹf3њHoFk9ُ ŠF~% jkZaZWZM|[Եs_W(f.#Iq7bHU#{z\ uh[F ΍n1  U+kk 4_6r񪆚K# _]^so㱘π|q]!ຘM 6P:UCr|.9nT6ycE_aKU^&]> ^po7QTj,4Ym}C~7&o + $qo &aﹶmLӱmvv0M,vk4>Iiĥ?Y~~/?v=+ȫ4ZwE"U/|w?QwDa;߹      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~5yE_j~~ys5#.M;ӓ&DPsV(f4VVhqyq^@j7/еM^ ᪼Mxm}>7ýMޞ<᪼M&sۛR7%=\7.|۶2tlۢo{5eؙE_>os~ oHk==q2?`MU[#8d+&39׿&_27. _.E#1hģQs*R[L/?3̣@/{_DϧҲ]qb2ӮL]1L3!Cyqymq^L]1Iwy3]}]1v^&]>O{WL2po7Pwym< MV[+&( ػb6-|Gf˙zm*M}yv>O{nd3f?z-ge%}{}w,Sw`y3uWKgcD=ѷtOvޱL1i?Ǡ6{ѣoL>++c!HqϜ V4q\&JiX_f.DdHZ[ 1 s XAPencil 07Note graphic"`02Pֆ鈪~H§>A, ^`!$ֆ鈪~H§>An dHG9xV}he?3"|Brd)l0^r]>^0v&dqfkq쨫^K@Ut٫/د!6&/#l\`& X>qA؉9|•x 7O%|"( !* ٬G<6qAsOX͎qfjTqUFBy6gYz7P4OV&zul㙨mbja݁-Ҷ`Nf >Bb/?R>.LbOFNpe&gQ9 LE6Wp";Ix![JO'.sf+nnYjr׼NuGi !yI(Vp>i{yLY$^L޸3~,T̓;*TjTP#"U֫bP_J_>2\vɹJ&AeC쑗op*Pa*1ڛ#o87K[D>%Zeܠ]o -m\%Xoi}=+{HS2My̎ U]xEYJ'|LBfP*?m:T~`$v'f)Ns#?j`!oP>,OJq\).ڀ23htK%E7,ʝM48c 6栞{cIOHkqhWyPsԻ**Is^ULź\{D/q8)bpr\Cz ?z pZ_6H{M;L&Ԛh6q*bZyj\ů3z+{ҍ. $$If!vh555#v#v#v:V 4 36,5559/ /  / 2  24 p$$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 $$If!vh555#v#v#v:V 36,59/ / / /  2  24 .DdHZ[ 2 s XAPencil 07Note graphic"`12Pֆ鈪~H§>A, &`!$ֆ鈪~H§>An dHG9xV}he?3"|Brd)l0^r]>^0v&dqfkq쨫^K@Ut٫/د!6&/#l\`& X>qA؉9|•x 7O%|"( !* ٬G<6qAsOX͎qfjTqUFBy6gYz7P4OV&zul㙨mbja݁-Ҷ`Nf >Bb/?R>.LbOFNpe&gQ9 LE6Wp";Ix![JO'.sf+nnYjr׼NuGi !yI(Vp>i{yLY$^L޸3~,T̓;*TjTP#"U֫bP_J_>2\vɹJ&AeC쑗op*Pa*1ڛ#o87K[D>%Zeܠ]o -m\%Xoi}=+{HS2My̎ U]xEYJ'|LBfP*?m:T~`$v'f)Ns#?j`!oP>,OJq\).ڀ23htK%E7,ʝM48c 6栞{cIOHkqhWyPsԻ**Is^ULź\{D/q8)bpr\Cz ?z pZ_6H{M;L&Ԛh6q*bZyj\ů3z+{ҍ.$$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 4 F36,5 5<55P5545 / /  / 2 24 pFkd$$If4֞2 en!B)3 <P4  F362 24apF$$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 $$If!vh5F 535555,5N #vF #v3#v#v#v#v,#vN :V 36,5 5<55P5545 / / / /  2 24 .DdHZ[ 3 s XAPencil 07Note graphic"`22Pֆ鈪~H§>A, `!$ֆ鈪~H§>An dHG9xV}he?3"|Brd)l0^r]>^0v&dqfkq쨫^K@Ut٫/د!6&/#l\`& X>qA؉9|•x 7O%|"( !* ٬G<6qAsOX͎qfjTqUFBy6gYz7P4OV&zul㙨mbja݁-Ҷ`Nf >Bb/?R>.LbOFNpe&gQ9 LE6Wp";Ix![JO'.sf+nnYjr׼NuGi !yI(Vp>i{yLY$^L޸3~,T̓;*TjTP#"U֫bP_J_>2\vɹJ&AeC쑗op*Pa*1ڛ#o87K[D>%Zeܠ]o -m\%Xoi}=+{HS2My̎ U]xEYJ'|LBfP*?m:T~`$v'f)Ns#?j`!oP>,OJq\).ڀ23htK%E7,ʝM48c 6栞{cIOHkqhWyPsԻ**Is^ULź\{D/q8)bpr\Cz ?z pZ_6H{M;L&Ԛh6q*bZyj\ů3z+{ҍ.$$If!vh554#v#v4:V 4 .6,5549/ /  / 2 24 p$$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/       !"#$%&'()*+,-./0123456789:;<=>?@ACDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~/ / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 $$If!vh554#v#v4:V .6,59/ / / /  2 24 .DdHZ[ 4 s XAPencil 07Note graphic"`32Pֆ鈪~H§>A, 6`!$ֆ鈪~H§>An dHG9xV}he?3"|Brd)l0^r]>^0v&dqfkq쨫^K@Ut٫/د!6&/#l\`& X>qA؉9|•x 7O%|"( !* ٬G<6qAsOX͎qfjTqUFBy6gYz7P4OV&zul㙨mbja݁-Ҷ`Nf >Bb/?R>.LbOFNpe&gQ9 LE6Wp";Ix![JO'.sf+nnYjr׼NuGi !yI(Vp>i{yLY$^L޸3~,T̓;*TjTP#"U֫bP_J_>2\vɹJ&AeC쑗op*Pa*1ڛ#o87K[D>%Zeܠ]o -m\%Xoi}=+{HS2My̎ U]xEYJ'|LBfP*?m:T~`$v'f)Ns#?j`!oP>,OJq\).ڀ23htK%E7,ʝM48c 6栞{cIOHkqhWyPsԻ**Is^ULź\{D/q8)bpr\Cz ?z pZ_6H{M;L&Ԛh6q*bZyj\ů3z+{ҍ. $$If!vh55@5#v#v@#v:V 4 56,55@59/ /  / 2 24 p$$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 $$If!vh55@5#v#v@#v:V 56,59/ / / /  2 24 .DdHZ[ 5 s XAPencil 07Note graphic"`42Pֆ鈪~H§>A, s`!$ֆ鈪~H§>An dHG9xV}he?3"|Brd)l0^r]>^0v&dqfkq쨫^K@Ut٫/د!6&/#l\`& X>qA؉9|•x 7O%|"( !* ٬G<6qAsOX͎qfjTqUFBy6gYz7P4OV&zul㙨mbja݁-Ҷ`Nf >Bb/?R>.LbOFNpe&gQ9 LE6Wp";Ix![JO'.sf+nnYjr׼NuGi !yI(Vp>i{yLY$^L޸3~,T̓;*TjTP#"U֫bP_J_>2\vɹJ&AeC쑗op*Pa*1ڛ#o87K[D>%Zeܠ]o -m\%Xoi}=+{HS2My̎ U]xEYJ'|LBfP*?m:T~`$v'f)Ns#?j`!oP>,OJq\).ڀ23htK%E7,ʝM48c 6栞{cIOHkqhWyPsԻ**Is^ULź\{D/q8)bpr\Cz ?z pZ_6H{M;L&Ԛh6q*bZyj\ů3z+{ҍ. $$If!vh5 55#v #v#v:V 4 +6,5 559/ /  / 2 24 p$$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 $$If!vh5 55#v #v#v:V +6,59/ / / /  2 24 tent_Types].xmlj0Eжr(΢Iw},-j4 wP-t#bΙ{UTU^hd}㨫)*1P' ^W0)T9<l#$yi};~@(Hu* Dנz/0ǰ $ X3aZ,D0j~3߶b~i>3\`?/[G\!-Rk.sԻ..a濭?PK!֧6 _rels/.relsj0 }Q%v/C/}(h"O = C?hv=Ʌ%[xp{۵_Pѣ<1H0ORBdJE4b$q_6LR7`0̞O,En7Lib/SeеPK!kytheme/theme/themeManager.xml M @}w7c(EbˮCAǠҟ7՛K Y, e.|,H,lxɴIsQ}#Ր ֵ+!,^$j=GW)E+& 8PK!Ptheme/theme/theme1.xmlYOo6w toc'vuر-MniP@I}úama[إ4:lЯGRX^6؊>$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3ڗP 1Pm \\9Mؓ2aD];Yt\[x]}Wr|]g- eW )6-rCSj id DЇAΜIqbJ#x꺃 6k#ASh&ʌt(Q%p%m&]caSl=X\P1Mh9MVdDAaVB[݈fJíP|8 քAV^f Hn- "d>znNJ ة>b&2vKyϼD:,AGm\nziÙ.uχYC6OMf3or$5NHT[XF64T,ќM0E)`#5XY`פ;%1U٥m;R>QD DcpU'&LE/pm%]8firS4d 7y\`JnίI R3U~7+׸#m qBiDi*L69mY&iHE=(K&N!V.KeLDĕ{D vEꦚdeNƟe(MN9ߜR6&3(a/DUz<{ˊYȳV)9Z[4^n5!J?Q3eBoCM m<.vpIYfZY_p[=al-Y}Nc͙ŋ4vfavl'SA8|*u{-ߟ0%M07%<ҍPK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 +_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!Ptheme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] > Normal Indent ^41B4Style3  & F*\\@\TOC 1$ $ h@& ^hCJOJQJ^JaJmHnHu:O1B:Style15;CJ$OJQJVRV heading1,head1 & F<1$ 5^JaJ>0b> List Bullet  & FaJB6rB List Bullet 2  & F aJB7B List Bullet 3  & F!aJB8B List Bullet 4  & F"aJB9B List Bullet 5  & F#aJ>1> List Number  & F$aJB:B List Number 2  & F%aJB;B List Number 3  & F&aJB<B List Number 4  & F'aJB=B List Number 5  & F(aJHOH RevHistory $$1$a$CJ$aJHoH Table Text !((_HmH sH tH 6U@!6 Hyperlink >*B*ph8@28 Header # !CJTR@BT Body Text Indent 2$,^,`\@OR@ Blank page%$a$ B*phDC@bD Body Text Indent &`BOrB Example Heading'5CJROR Code example(-DM CJOJQJPB@P Body Text)-D M CJOJQJ^J2@2 TOC 4 *^aJTP@T Body Text 2+-DM CJOJQJ\$L@$ Date,PQ@P Body Text 3 - B*OJQJphXOX overview.^`CJOJPJ QJ^JaJ<O< Normal-TNR12/1$aJJ @J  Index 1,index0^`aJ!@  Index HeadingT1$x$d %d &d 'd N O P Q a$5OJQJ\aJ2)@!2 Page NumberCJ4 @24 Footer 3 !DZ@BD Plain Text4CJOJQJ^JaJDTRD Block Text5x]^vMbv Body Text First Indent6x-DM `CJOJQJ^J`Nar` Body Text First Indent 27hx^h`jSj Body Text Indent 38-D M ^CJOJQJ^JRR Bullet19 & F^6<B* CJaJph:: Bullet2: & Fh^hBB Bullet3; & F`^``JJ Bullet4!< & F ^`BB Bullet5= & FPP^P`P@"@ Caption >xx5CJ\aJ2?2 Closing ?^<@<  Comment Text@CJaJRYR  Document MapA-D M OJQJ^J<["< E-mail SignatureB<+2<  Endnote TextCCJaJh$Bh Envelope Address!D@ &+D/^@ OJQJ^JN%RN Envelope ReturnECJOJQJ^JaJFVaF FollowedHyperlink >*B* ph>r>  Footnote TextGCJaJ>> heading 2H1$ 5CJaJ\1\ heading 3I & F 1$@& CJOJQJ\aJXaX Heading 6 Bullet J & FCJOJ QJ ]aJ:`: HTML AddressK6]ReR HTML PreformattedLCJOJQJ^JaJ> @> Index 2M^`aJ> > Index 3N^`aJ> > Index 4O^`aJ>> Index 5P^`aJ>> Index 6Q^`aJ>> Index 7R^`aJ>> Index 8S^`aJ>> Index 9Tp^p`aJ4/R4 ListUh^h`<2b< List 2V^`aJ83r8 List 3W8^8`848 List 4X^`858 List 5Y^`BDB List ContinueZhx^hFEF List Continue 2[x^FFF List Continue 3\8x^8FGF List Continue 4]x^FHF List Continue 5^x^l- l  Macro Text"_  ` @ OJQJ^J_HmH sH tH I Message Headerg`8$d%d&d'd-DM NOPQ^8` OJQJ^J4^4 Normal (Web)a4O4 Note HeadingbF2F Paragraph1c$P1$a$CJaJ0K0 SalutationdR Section Headingke$$ & F) hd$d%d&d-D@& M NOPa$)@B*CJEHKHOJ QJ ^JaJph6@b6 Signature f^B1rBStyle2 g^5;CJ$OJQJFJF Subtitleh$<@&a$ OJQJ^JT,T Table of Authoritiesi^`L#L Table of Figuresj ^` V>V Titlek$<@&a$5CJ KHOJQJ\^JaJ H.H  TOA Headinglx5OJQJ\^J22 TOC 3 m?^?]22 TOC 5 n^aJHaH TOC 6o@& ^5CJ\aJ22 TOC 7 p^aJ22 TOC 8 q^aJ22 TOC 9 r^aJ2 xl22Tsdd$d%d&d'dNOPQ[$\$OJ PJ QJ ^J B xl23Ttdd$d%d&d'dNOPQ[$\$5OJPJ QJ\^JR xl24Tudd$d%d&d'dNOPQ[$\$CJOJPJ QJ^JaJb xl25Tvdd$d%d&d'dNOPQ[$\$5CJOJPJ QJ\^JaJFrF Bullet w & F+B* OJQJaJphH@H  Balloon TextxCJOJQJ^JaJ@j@@ Comment Subjecty5\bOb Rev History Headingzxx^CJ$OJQJ^JJ AJ  TOC Heading {^CJ$OJQJ^JjOAj Manual-body text| p@ HB*CJOJPJQJphZAZ Man-4Hdg-Num} & F1 @< B* aJph\O\ computer screen~-DM CJOJQJaJB'B Comment ReferenceCJaJPK![Coning="UTF-8" standalone="yes"?> \_#  \ -V8^?w| UDSWZud_& v)8v(~*~RdݚӤk{ʵʼ~7Bb*KR_#9D IŒN%cߔ[2y2p*h"`ܙXԚPǛB{S4s0o Y<>>@B$&&&&&&&&(*kFHHJL,moooo799;=+uwwy{ \^^`bbIKKKKKKKKMO i k k m o      Q 8 8 : : < > & ( * s s u T V X X X Z Z \ ^ C,.wy{^C(tv Y[[[[[[[[[[[[[[^u f!!U""#R$$I%%&''(U))_*7+ ,,-X..L/700)1203G4 5:AGNUlZfhty~FїΤ1kN+ * 4'.y17DnQ[R_gDvc|})0}Ùs] %g/146:?X-k}tَƺp"JMNO@RET~UWXY)[\._4ac2e ghyjmnopq"sVttuvwxy,{>|&}~~HBf͋ *lē5>lښ +{diFTd2|Awt$UaYd `WS~2eZ p4  K iWr!R$'C*_++/013456789:;<=>?@ABDEFGHIJKLMNPSUW[\_adgjmrw{ "%),015:>@COUW^ciov %+28?ELRY_flrw} !%/8CNWajt} -6@IR\eox%')*,.27:?CG  *2 0x 2",7<@E LP;SVIZ],gijruwzc~ۃ/(m\zEVK",<g3b C1t"J&(*a.1R5g8;?CGKO/TWe]agko%s!y}Д 4XڻsO<j^ A "L&/36;?fEgJMQ&TWZ^Sbf9korvzi~Dͬ,^ؽPo-'WP* y% !^',o2 8E=AwGMDMMM!NNNNO`OOKPP.QQ9RhRR)SSTFTVTTT-UZUUUUV]VVVV8WfWWW&XEXXXXYOYYYY>ZrZZZ[=[[[z\\]]^/__?``6aa*bbbccddAeVeee9fflggghnhh;iiiiTjjjm&nZnnnoPoooopPppppqIq{qqqrFrzrrr0sksssttք0k҅ H|+`އJwL{Չ:x?|VҌ=~ V׎4l܏+RŐEǑ7sג AwRǔ/k%RIܗ Nqט%`ՙ 9(T -m$;uա6dYޣCuˤ%X֥0g8~3bɨ:sީH{Ī0}ܫJ1hhЮ@ɯFqS'CK}1~ַV4Qqݹ*Oƺ8`;YwU}˽*S=T6w>a3n-@dOw*r8gt\RKH1c o^Ed5Ro:Ts$_}%F`)Pz3Uw7h Gz+Ku6hEe %Um9^<W~G hu2K%GZ-s6_avAXT\AdZb9Gm(Hl5Vz@Q5CX:`=Q2O]s'`y#Yo-d0MmEh9 [w AizIr $C^Xzd}ImKzdx    3 r    c     k     }.&3 !"Y#>$$%&'()_+ !"#$%&'()*,-.2COQRTVXYZ]^`bcefhiklnopqstuvxyz|}~     !#$&'(*+-./2346789;<=?ABDEFGHIJKLMNPQRSTVXYZ[\]_`abdefghjklmnpqrstuwxyz{|}~     !"#$&'()*,-./01345679:;<=>@ABCDFGHIJKMNOPQSTUVWXZ[\]^`abcdeghijkmnopqstuvxyz{|~     "#$&'()*+,-.012345679:;<=>?@ABDEFGHIJKLMOPQRSTUVXYZ[\]^_`bcdefghiklmnopqrsuvwxyz{|~     !"#$%&'()*+,./012345789:;<=>?ABCDEFGHJKLMNOPQSTUVWXYZ[]^_`abcdfghijklmnpqrstuvwyz{|}~      !"#$&(+-/01345689;<=>@ABDEF9Gbdeg-/02Qu689;Z}8SVWYx4Idghj.124S@[^_a + . / 1 P o !;!V!Y!Z!\!{!!!!!!!""!"""$"C"_"z"}"~""""""""##8#;#<#>#d######### $'$B$E$F$H$g$$$$$$$$%%%%'%O%j%m%n%p%%%%%%%&&5&7&8&:&Y&q&&&&&&&&&&&'+'F'I'J'L'k''''''''((((8(T(o(r(s(u(((((((()#)&)')))H)R)m)p)q)s))))))) *B*]*a*b*d*******+0+K+O+P+R+q+++++++',B,F,G,I,h,,,,,,,,----:1]1s1Jzuzz13Qjl$=?Rkm.GIg!:<`y{Wpr *CE`y{'@B{^y{_#XX X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%XX%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%̕XX::::::::::::::::::::::::::#*,BIL ,36LSV=DG\ce{BIL/69O V Y o v y   > E H   * 1 4 ; B E ^ e i CJN]dh{sz~X_c=DH^!!t!!!!!t!4!!!!!!!!4!4!4!4!4!4!!!!!!!!!!!t!!t!!!!!!!!!!!!!!!!!!!!!!t  p,2$[9DQy@H o0(  N (  VB  C D"?VB  C D"?  A*V@Key 24Security key graphic wYw M4 PL:POQP`T$`Tl)#" `?VB  C D"?VB  C D"?V   #  "?  V   #  "? \B  @ S D"?B  c DD Decorative Line"?B @ c DD Decorative Line"?B S  ?st999:"_#/| /t/p&/t/| /t/p&/t $t t #t tt L t^' _Hlt208657238 _Hlt208657239 _Hlt209949631 _Hlt210103499 _Hlt215996533 _Hlt215996534 _Hlt209949524 _Hlt210101098 _Hlt216093611 _Hlt188237377 _Hlt188237286 _Hlt188237287 _Hlt188237324 _Hlt205780524 _Hlt205780525 _Hlt129577050 _Hlt117920066 _Hlt117920067 _Hlt95197083 _Hlt148404334 _Hlt147814151 _Hlt147814152 _Hlt95131378 _Hlt96497930 _Hlt96497931 _Hlt35394715 _Hlt81300448 _Hlt83533266 _Toc95131161 _Hlt33843115 _Hlt31116277 _Hlt31116278 _Hlt31116279 _Hlt33841494 _Hlt33841495 _Hlt81300436 _Hlt83533270 _Toc95131162 _Hlt33843156 _Toc95131163 _Toc14665829 _Toc14666653 _Toc14667125 _Hlt33843827 _Hlt83533280 _Toc95131164 _Hlt81300443 _Hlt33843172 _Toc14665830 _Toc14666654 _Toc14665831 _Toc14666655 _Toc14667126 _Toc95131165 _Toc14665832 _Toc14666656 _Toc14665833 _Toc14666657 _Toc14667127 _Hlt47093804 _Toc95131166 _Hlt33843186 _Toc14665834 _Toc14666658 _Toc14665835 _Toc14666659 _Toc14667128 _Toc14665836 _Toc14666660 _Toc14667129 _Toc95131167 _Hlt33843193 _Toc14665837 _Toc14666661 _Hlt35335000 _Toc14665838 _Toc14666662 _Toc14667130 _Hlt35335016 _Hlt35335346 _Toc95131168 _Hlt33843199 _Toc14665839 _Toc14666663 _Toc14665840 _Toc14666664 _Toc14667131 _Hlt33843847 _Toc95131169 _Hlt33843205 _Toc14665841 _Toc14666665 _Toc14665842 _Toc14666666 _Toc14667132 _Toc14665843 _Toc14666667 _Toc14667133 _Hlt35335166 _Hlt35339514 _Hlt46480750 _Toc95131170 _Hlt33843210 _Toc14665844 _Toc14666668 _Toc14665845 _Toc14666669 _Toc14667134 _Toc14665846 _Toc14666670 _Toc14667135 _Toc14665847 _Toc14666671 _Toc14667136 _Toc95131171 _Hlt33843217 _Toc14665848 _Toc14666672 _Toc14665849 _Toc14666673 _Toc14667137 _Toc14665850 _Toc14666674 _Toc14667138 _Toc14665851 _Toc14666675 _Toc14667139 _Toc95131172 _Hlt33843222 _Toc14665852 _Toc14666676 _Toc204139893P131_19a _Toc14665853 _Toc14666677 _Toc14667140 _Toc14665855 _Toc14666679 _Toc14667142 _Toc95131173 _Hlt33843229 _Toc14665856 _Toc14666680 _Toc451577783 _Toc14665857 _Toc14666681 _Toc14667143 _Toc95131174 _Hlt33843240 _Toc14665858 _Toc14666682 _Toc14667144 _Toc14665859 _Toc14666683 _Toc14667145 _Toc14665860 _Toc14666684 _Toc14667146 _Toc95131175 _Hlt33843251 _Toc14665861 _Toc14666685 _Toc14667147 _Toc14665862 _Toc14666686 _Toc14667148 _Toc95131176 _Hlt33843257 _Toc14665863 _Toc14666687 _Toc14665864 _Toc14666688 _Toc14667149 _Toc14665865 _Toc14666689 _Toc14667150 _Toc14665866 _Toc14666690 _Toc14667151 _Toc95131177 _Hlt33843262 _Toc14665867 _Toc14666691 _Toc14665868 _Toc14666692 _Toc14667152 _Toc14665869 _Toc14666693 _Toc14667153 _Toc14665870 _Toc14666694 _Toc14667154 _Toc95131178 _Hlt33843267 _Toc14665871 _Toc14666695 _Hlt35335248 _Toc14665882 _Toc14666706 _Toc14667165 _Hlt33843923 _Toc95131179 _Hlt33843274 _Toc14665883 _Toc14666707 _Toc14665884 _Toc14666708 _Toc14667166 _Toc14665885 _Toc14666709 _Toc14667167 _Hlt46480779 _Toc95131180 _Hlt33843279 _Toc14665886 _Toc14666710 _Toc14665887 _Toc14666711 _Toc14667168 _Hlt33843905 _Toc95131181 _Toc14665888 _Toc14666712 _Hlt33925520 _Hlt33843992 _Toc95131182 _Hlt33843285 _Toc14665889 _Toc14666713 _Hlt35761554 _Hlt33926566 _Toc95131183 _Hlt33843293 _Toc14665890 _Toc14666714 _Toc14667169 _Toc14665891 _Toc14666715 _Toc14667170 _Toc95131184 _Hlt33843304 _Toc14665892 _Toc14666716 _Toc14667171 _Toc14665893 _Toc14666717 _Toc14667172 _Toc95131185 _Toc14665894 _Toc14666718 _Toc14667173 _Toc14665895 _Toc14666719 _Toc14667174 _Toc14665896 _Toc14666720 _Toc14667175 _Toc95131186 _Hlt33843329 _Toc14665897 _Toc14666721 _Toc14667176 _Toc14665898 _Toc14666722 _Toc14667177 _Toc14665899 _Toc14666723 _Toc14667178 _Toc95131187 _Hlt33843335 _Toc14665900 _Toc14666724 _Toc14667179 _Toc14665901 _Toc14666725 _Toc14667180 _Toc14665902 _Toc14666726 _Toc14667181 _Hlt35394962 _Toc95131188 _Hlt148404287 _Hlt33838125 _Hlt33843342 _Toc14665903 _Toc14666727 _Toc14667182 _Toc95131189 _Hlt33843367 _Toc14665904 _Toc14666728 _Toc14667183 _Toc14665905 _Toc14666729 _Toc14667184_Standard_Schedule_Edit _Toc95131190 _Hlt33843378_[PSS_SCHEDULE_EDIT] _Hlt35334843 _Hlt35334686 _Toc14665906 _Toc14666730 _Toc14667185 _Toc14665907 _Toc14666731 _Toc14667186 _Toc14665908 _Toc14666732 _Toc14667187 _Toc95131191 _Hlt33838112 _Hlt33843391 _Toc14665909 _Toc14666733 _Toc14667188 _Toc14665910 _Toc14666734 _Toc14667189 _Toc14665911 _Toc14666735 _Toc14667190 _Toc14665912 _Toc14666736 _Toc14667191 _Toc14665913 _Toc14666737 _Toc14667192 _Toc14665914 _Toc14666738 _Toc14667193 _Toc14665915 _Toc14666739 _Toc14667194 _Toc14665916 _Toc14666740 _Toc14667195 _Toc14665917 _Toc14666741 _Toc14667196 _Toc14665918 _Toc14666742 _Toc14667197 _Toc14665919 _Toc14666743 _Toc14667198 _Toc14665920 _Toc14666744 _Toc14667199 _Hlt47168260 _Hlt47168275 _Hlt47168362 _Hlt47168400 _Toc95131192 _Hlt33843397 _Hlt35335135 _Toc95131193_[PSS_CS/PKI_REPORTS] _Toc95131194 _Toc95131195 _Toc95131196 _Toc14665921 _Toc14666745 _Toc14667200 _Hlt33845057 _Toc95131197 _Hlt33845190 _Hlt33843402 _Hlt35683683 _Hlt33844208 _Hlt81280202 _Toc95131198 _Hlt33843410 _Hlt35335156 _Hlt81280207 _Toc95131199 _Hlt33843415 _Hlt33844044 _Toc14665922 _Toc14666746 _Toc14667201 _Hlt33844271 _Hlt81280211 _Toc95131200 _Hlt33843421 _Hlt33844318 _Hlt81280225 _Toc14665923 _Toc14666747 _Toc14667202 _Toc14665924 _Toc14666748 _Toc14667203 _Toc14665925 _Toc14666749 _Toc14667204 _Hlt33844441_Multi-Ingredient_Drugs _Toc95131201 _Hlt33843426 _Toc14665926 _Toc14666750 _Toc14667205 _Hlt33843825 _Hlt33845188 _Hlt81280234 _Toc95131202 _Hlt33843432 _Toc14665927 _Toc14666751 _Toc14667206 _Hlt33844387 _Hlt33844431 _Toc95131203 _Hlt33843438 _Hlt33844500 _Toc14665928 _Toc14666752 _Toc14667207 _Toc14665929 _Toc14666753 _Toc14667208 _1047380733 _1047380765 _1047721587 _1047721597 _1050139721 _1053423463 _1053423569 _1053423594 _Toc14665930 _Toc14666754 _Toc14667209 _1052118307 _1053423484 _1053423631 _1047380974 _1047380995 _1047381094 _1050140714 _1050140752 _1053331625 _1053423665 _1056888248 _1050140834 _1053423703 _1056888417 _Hlt338436      "#$%'()*5,-./012346789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijkmnopqrstuvwxyz{|}~90 _Toc14665931 _Toc14666755 _Toc14667210 _Hlt33843578 _Hlt33843744 _Hlt35394786 _Hlt47169524 _Hlt81280238 _Toc95131204 _Hlt35394905 _Hlt35394763 _Hlt35395860 _Hlt35395985 _Hlt35684408 _Toc95131205 _Hlt35684501 _Hlt35396388 _Hlt35857464 _Hlt33843449 _Toc14665932 _Toc14666756 _Toc14667211 _Hlt35336151 _Hlt33843565 _Hlt33843595 _Hlt33843742 _Hlt35336002 _Hlt35395864 _Hlt35396321 _Hlt35684413 _Toc95131206 _Toc14665933 _Toc14666757 _Toc14667212 _Hlt35684509 _Hlt35396420 _Hlt33843789 _Hlt35396065 _Hlt33843456 _Hlt33843746 _Hlt33844547 _Hlt35394278 _Hlt33848105 _Hlt35396327 _Hlt35396425 _Hlt35396728 _Toc95131207 _Hlt35396312 _Hlt35684418 _Hlt35684515 _Hlt35396118 _Hlt35395873 _Hlt35682039 _Hlt35681940 _Hlt35396456 _Hlt35681832 _Hlt35396429 _Hlt35396461 _Hlt35396734 _Toc95131208 _Hlt35684523 _Hlt35396159 _Hlt35395879 _Hlt35681942 _Hlt35396290 _Hlt35681841 _Hlt35396437 _Hlt35396467 _Hlt35396744 _Toc95131209 _Hlt35684493 _Hlt35684532 _Hlt35395888 _Hlt35681944 _Hlt35681850 _Toc95131210 _Hlt35684538 _Hlt35395894 _Hlt35681946 _Hlt35396754 _Hlt35396520 _Hlt35681858 _Hlt35681684 _Toc95131211 _Hlt35684402 _Hlt35684544 _Hlt35395901 _Hlt35681948 _Hlt35396763 _Hlt35396579 _Hlt35681866 _Hlt35396718 _Hlt33844623 _Hlt33844785 _Hlt33844845 _Hlt35395971 _Hlt35395999 _Hlt35684548 _Toc95131212 _Hlt35395942P131_149 _Hlt209949628 _Hlt81280198II@###%&& - - - ---h1h1h1r1r1V8V8V889^?^?^?^?^?^?a????OOOOOOyPyPyPyPyPPPPVVVWWWW+W,W,W%^`````````|||||}}}}}}яяяяяяҏ###000%&&^^^UDUDUDUDpDqDqDEEEEEEGGGXJXJXJ1L1L1L1LWLMMMSSSSSSS4S4S4SWWWWWWWWWWYYYdddnnnn9n:n:nsZuZuZuZuZuzu{u{uddddd}~~99NNÑÑ777TPPPx5555KKK000rrrr!!!____tuuu' ' ' ' ' ' < < wwww????@VW&_'''')))))))))))))))+++:+:+:+]+]+]+++++++,,,:,:,:,U,U,U,g,g,g,,,,......1338(=jvvvvvvvwzzzzӤӤӤɲʲʲʲ(˼˼˼˼˼˼˼}}}oooyyy}}}}}}}|N7777777777777778;8<8889BBBBBBBB B BZBZBZB[BBDbbbbcEcEcFc}ce\=W)*FFwx3KKKKKKKQT `#@@@@@@@@@ @ @ @ @ @@@@@@@@@@@@@@@@@@ @!@"@#@$@%&@'+,-(@)@.*@/@012345679:;8@<=@>?@ABCDEFG@HIJ@MNOK@L@PQ@RSUVWT@XY@Z[\]^bcd_@`@a@ef@ghijklmnopqrs@tuvwxyz{|}~@@@@@@@@@@@@@@@@@@@@@     @@@@@ @!"#()*$%&@'+@,@-./01234567@8@9:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]@^@_@`@ab@c@defghklmi@nj@o@p@q@r@st@u@v@wx@|@yz{@}@~@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@ @  @ @ @@@@@@@@@@@@ @!@@"@@@@%@#$@&@hh_###%&& - - ----i1i1i1s1s1V8V8889^?^?a?|?|?|?|????OOOOOOyPPPPPPPPWWW+W+W+W+W+WCWCW%^`````````|}}}}}&}&}}}}яяяCCC222ʝʝʝZZZ%%%%%;;/pDpDpDpDpDDDEEEEEEGGGJJJWLWLWLwLwL4M4M4MSSSSS2S2S=U=U=UWWWWWWWWWWZZZ.d.d.d9n9n9n9n9nDnDnsZuzuzuzuzuzuuud}}}}}777MNhhÑ  77TTششش///JJJJfffNNNRRRsssst' ' < < < < < < ?VVWjjjF'_'((())))))))))))+++8+8+8+W+W+W+++++++,,,7,7,7,R,R,R,f,f,f,~,~,~,,,,......13387=kvvvvvvvwzzzzӤӤ(()µ˼˼˼zzzyyy}}}}|N777777777778;8<8h8h8h8h8889BBBBBB B%BZBZBZB[BBBEbbbcEcEcFcic}ce=WԬ)FIwxKKKKKPQQQT `#(|q ( (,Q (P (lQ (  (ގ !(+ "(<. #( $(Z %(,ی &( '(((; )(1 *(F +(l1 ,(4t -(\ێ .(t܎ /( ݎ 0( 1(L 2(䐎 3(| 4(& 5(9 6(y 7( 8(< 9(d :( ;( R <(Z =(Z >(4[ ?(Ą @(d A(T B( C(؎ D(ڎ E(׎ F(ێ G(ݎ H(t I(,r J(|s K( L(L M(L N(L O( P( Q( R( S($nj T(Ր U(ds V(W(tь X(̐ Y(| Z( [(\(G ](@ ^( _( `(lҐ a(Tː b( c(t, d(֎ e(Ԑ f( g( h(_i($ j( k(L l( m(H n(L$ o(䪑 p(hq(hr(4 s(t t( u( v(L w( x(wy(wz(x{(Tx|(: }(: ~(; (D; (; (쨑 (, (l ( (쩑 ($ (d ( ( ($ ($ (d ( ( ($ (d (. (. (,/ (l/ (/ (/ (L ( ( ( (L ( ( (L((( (L((( (L((( ( (Ħ ( (D ( (ħ ( (D ( (Ĩ ( (D (T ( ( ( (T (  ww 1~~44ÃÃ;;`QQ]]f.ikk"qvvv{{1||4~~ =j1l_}iݒ++>>  ^^Qq8V@f'Gg*P2e=bU?bMr -Kl"",..33xxh(S 7`#      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~ 1~~DDӃӃEEeQQ]]f2ikk&qvvv{{5||8~~An5p„c m--AA##``Uu<Z!Dj +Kk.T6iAfYCfQv1Op&&00099{{l,W;`#  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~8*urn:schemas-microsoft-com:office:smarttagsCity9*urn:schemas-microsoft-com:office:smarttagsState9*urn:schemas-microsoft-com:office:smarttagsplace:*urn:schemas-microsoft-com:office:smarttagsStreet;*urn:schemas-microsoft-com:office:smarttagsaddress () Ge0u9}8WIh2@_ / o ;!Z!!!"""_"~"""#<###'$F$$$$%O%n%%%&8&q&&&&+'J''''(T(s((()')R)q)))B*b***0+P+++',G,,,,-o{ )4$/CMbm)s  F'Microsoft Office Word 97-2003 Document MSWordDocWord.Document.89q  ]   Title8aiu _PID_HLINKS_AdHocReviewCycleID_NewRevi4x!6AVais%0"-EQ*6}DPbnuZ f     ?!K!!!!!$"0"`# ! 77*9z999::;;^?^????'I-III J J.L?LwLLLLLLgOmOOOOORR/Sd:Bs+/&LTqs&39? T^bj [bPV 1 5 A E P T X \ h l        - : > 7 9   fjWYlpIK$(/Z=Dpx  { }     !!""$%%%&&&&''F*N***'+4+++,,,,..I/M/30@0[0_0m1q11111112222)2-2_2c22233:4>44444 5 5D5F577N8R88899:; ;;;;-;1;H;L;&<+<BBBBBCICeCiCCCCDUDUDDDIIRKYKKK_MbMMMMMMMNNPOUOSS2S2SU VWWWW[[\\]]C]G]d`l`x``gaoaaa\cgc5e:eEjJjnnDnDnOtbtctztZuZuuuyy\zaz7Az9WddW[5AәߙNPoqSVpscfɥХLO/M 38glͬ ),?f9HOY2h}Ƕٶv*~ QX5Bcn55ff ck ՜.+,D՜.+,D px  ]   Title8aiu _PID_HLINKS_AdHocReviewCycleID_NewReviewCycle_ReviewingToolsShownOnceAPw:Ahttp://vista.med.va.gov/vdlVW>http://www.va.gov/vdl87 _Toc9513121281 _Toc951312118+ _Toc951312109% _Toc951312099 _Toc951312089 _Toc951312079 _Toc951312069  _Toc951312059 _Toc951312049 _Toc951312039 _Toc951312029 _Toc951312019 _Toc951312000 _Toc951311990 _Toc951311980 _Toc951311970 _Toc951311960 _Toc951311950 _Toc951311940 _Toc951311930 _Toc951311920 _Toc951311910 _Toc951311901 _Toc95131189gvDrugTextFileReport1 _Toc951311871 _Toc951311861 _Toc951311851 _Toc951311841 _Toc951311831 _Toc951311821 _Toc951311811z _Toc95131180>t _Toc95131179>n _Toc95131178>h _Toc95131177>b _Toc95131176>\ _Toc95131175>V _Toc95131174>P _Toc95131173>J _Toc95131172>D _Toc95131171>> _Toc95131170?8 _Toc95131169?2 _Toc95131168?, _Toc95131167?& _Toc95131166?  _Toc95131165? _Toc95131164? _Toc95131163? _Toc95131162? _Toc95131161( P131_149%P P131_19a]IH [bqz&+X?@UX*-Y\$'Y\yz()wx]^{~58xy)*xy|>AQV8= ;@9=pt$%JM58qtEHrs0 BF,0Wcrr48EHaewVcu)-__MQ9 B   o    ^ l  ( ' ' = = "lq*3',pu*?'wwHK??XX))))++J-U-....3333+6/68888(=(=P=P=X@b@@@A!A]AeAAA@CECBDFDDDEEEEzFFFFGGSHXH|HH I$IIIIIKK1K7K)L?LMMMMOOOOLPTPsPxPPPQQR#RRS(S.S_SgSSSSTTTU U/U4UUUVV=VEVVVVVWW#X'XZXdXZZZZ\\G]L]^!^^^*_3_S_[_n_y_____``\`a````` aaXa_aaaaaIbcbbb3c7ccc dd3d?dddddee!e,eneteeeeef#fff8g;ggghhi iGiQiUi]iiiii)j.jjjjjjjjjkkmm!n$ndrqrrr?sTstszsssss3t=tttttttuu=u@uuu/v:vzzzz*~B~MP&)`ccf˚ۚӤӤ (,KOor))!$47QT:Clo+4S_3OklIJ">Zv )Eab &B^z(DXZvx+DF]_z|  (*EGbd35QSoq#%@B^`{} %A]y Ie)Ea}$@Ax\ g         0 L h       , H d       ( D ` |     $@\x <Xt8TGLw|$;Ws7So34ef )Ea} %A]y  9 U p      !/!K!L!}!~!!!!"":"V"r""""""#6#R#n######$2$N$O$$$$$$%.%J%f%%%%%%&&F&b&~&&&&& '&'B'^'_''"(>(Z(v((((()):)V)r))))))*6*7*n*o*****++G+H+~++++++$,@,\,x,,,,,-@-L-q-v-..J0O0"2*2U2\2222233L4Q44455H5K555662666@7w7x7799I:Y:R>V>AAXqB"C"`#333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333;qqs  (">; 0d9Ge0u9}8WIh2@_ / o ;!Z!!!"""_"~"""#<#>####'$F$$$$%O%n%%%&8&q&&&&+'J''''(T(s((()')R)q)))B*b***0+P+++',G,,,,-3C3^?^???L.LOOOOOyPPWEW``3lXl)mmqqrr t#t|(}K܇4_I_ʦǩhU%e5t;;2~z~1a>l  \pc/\{{""$$(44.5D5UDUDDDDEE IILyLNOQSS2S2S4SWWWWW>\\Q`d`bRcnnDnDnFnZuZuuuuxxdy#8Ydd9jϐ| ]s"055ffhcvTtk]\rr__' ' = = ww??XXl#$' ())))).....J3333338888 =(=(=P=P=g=SSVWjjjkk0kzzzzz+A`v˚ˤӤӤXyƲ))*ŵڹȼ5QnAR.KgW} *G`}'o3^DKEEEEEE)FiFGLHXHHHII:J5K|KKLLLlQQRR:TTTU VVV/W>WWW?XXXXY6ZZZ][i[[[\]:^G^^^ __m_aYrجGLP~88WoVeV̵е+\Vxйع48ouӺ׺2APؽ1 s ]bSXqzLQIM$j pt3_bFI erl7JinF:(Hfi  Pb4tx7b^z"U`[cch:A<Dm>WEa:Z2e1s :Z/\ycMd  3>}!gr EP +uGRfqOZ6A#.juCN+6al MX.9(hsQ\8C ( i t   ! !N!Y!!!!!3">"B"C"`#qqs>##^?^???OOOO;;RUDUDDDSS2S2SWWWWnnDnDnZuZuuudd55ffrr__' ' = = ww??XX))))....33338888(=(=P=P=jjkkzzzzӤӤ))o{ )43>$/CMbm)4x!6AVais%0"-EQ*6}DPbnuZ f     ?!K!!!!!$"0"C"`#0|ҟTp},F|~4gرl7~stT¯^Z*T9F|Jo:}|\3(t%:w`ei16\3%ăvwTRN % K~y#\3,d&2nG,$.u5%[5u c7M5;@d1.<78(5\=@KFCJES8FS}lGN^KY`L:SxIJUTtvoU\3 HX`nY{^%fa\3 xoZf_otHzo4>qBC4Qu/4 x\3z\34{Gғh~F:^`.^`.88^8`.^`. ^`OJQJo( ^`OJQJo( 88^8`OJQJo( ^`OJQJo(hh^h`. hh^h`OJQJo(*^`56CJ$OJQJo(1.^`.pLp^p`L.@ @ ^@ `.^`.L^`L.^`.^`.PLP^P`L.hh^h`CJOJQJo(hh^h`CJOJQJo(hh^h`CJOJQJo(hh^h`CJOJQJo( ^`OJQJo(o pp^p`OJ QJ o( @ @ ^@ `OJQJo( ^`OJQJo(o ^`OJ QJ o( ^`OJQJo( ^`OJQJo(o PP^P`OJ QJ o( ^`56CJo(1.2.^`.pLp^p`L.@ @ ^@ `.^`.L^`L.^`.^`.PLP^P`L. ^`56CJo(1.4.^`.pLp^p`L.@ @ ^@ `.^`.L^`L.^`.^`.PLP^P`L.hh^h`CJOJQJo( ^`56CJo(1.4.^`.pLp^p`L.@ @ ^@ `.^`.L^`L.^`.^`.PLP^P`L. ^`56CJo(1.2.3^`.pLp^p`L.@ @ ^@ `.^`.L^`L.^`.^`.PLP^P`L.^`o(.^`.pLp^p`L.@ @ ^@ `.^`.L^`L.^`.^`.PLP^P`L. ^`56CJ$OJQJo(1.^`.pLp^p`L.@ @ ^@ `.^`.L^`L.^`.^`.PLP^P`L.^`56CJ$OJQJo(1.0^`056CJOJQJo(2.pLp^p`L.@ @ ^@ `.^`.L^`L.^`.^`.PLP^P`L.8^8`56CJ$OJQJo(3.^`.pLp^p`L.@ @ ^@ `.^`.L^`L.^`.^`.PLP^P`L. ^`56CJ$OJQJo(1.^`.pLp^p`L.@ @ ^@ `.^`.L^`L.^`.^`.PLP^P`L.^`56CJo(hH1.9. ^`hH. pLp^p`LhH. @ @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PLP^P`LhH. ^`OJQJo(   ^ `OJQJo(o   ^ `OJ QJ o( xx^x`OJQJo( HH^H`OJQJo(o ^`OJ QJ o( ^`OJQJo( ^`OJQJo(o ^`OJ QJ o(hh^h`.P^`P..^`...xp^`x....  ^` .....  X ^ `X ......  ^ `....... 8^`8........ `H^``.........hhh^h`56CJ$OJQJo(.hh^`o(..h^`o(...hxp^`xo(.... h^`o( ..... h X ^ `Xo( ...... h  ^ `o(....... h8^`8o(........ h`^``o(.........h^`B*OJQJo(phh dd^d`OJQJo(oh 44^4`OJ QJ o(h   ^ `OJQJo(h   ^ `OJQJo(oh ^`OJ QJ o(h tt^t`OJQJo(h DD^D`OJQJo(oh ^`OJ QJ o(h^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJ QJ o(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJ QJ o(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJ QJ o(hHhh^h`.P8^`P..^`...xp^`x....  ^` .....  X ^ `X ......  ^ `....... 8^`8........ `H^``.........^`o()^`.pLp^p`L.@ @ ^@ `.^`.L^`L.^`.^`.PLP^P`L.hh^h`CJOJQJo(8^8`56CJ$OJQJo(2.pp^p`.@ L@ ^@ `L.^`.^`.L^`L.^`.PP^P`. L ^ `L.8^`o(.080^`0o(2.18 0 ^ `0o(2.8@ @ ^@ `.8^`.8L^`L.8^`.8^`.8PLP^P`L.hh8^h`56CJ$OJQJo(hH1.h ^`hH.h pLp^p`LhH.h @ @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PLP^P`LhH.hh^h`CJOJQJo(^`56CJ$OJQJo(1.^`.pLp^p`L.@ @ ^@ `.^`.L^`L.^`.^`.PLP^P`L. ^`56CJo(1.2.^`.pLp^p`L.@ @ ^@ `.^`.L^`L.^`.^`.PLP^P`L.h 88^8`hH.h ^`hH.h  L ^ `LhH.h   ^ `hH.h xx^x`hH.h HLH^H`LhH.h ^`hH.h ^`hH.h L^`LhH.^`56CJ$OJQJo(1.^`.pLp^p`L.@ @ ^@ `.^`.L^`L.^`.^`.PLP^P`L. ^`56CJo(1.2.^`.pLp^p`L.@ @ ^@ `.^`.L^`L.^`.^`.PLP^P`L.hh^h`CJOJQJo(hh^h`CJOJQJo( ^`56CJ$OJQJo(1.^`.pLp^p`L.@ @ ^@ `.^`.L^`L.^`.^`.PLP^P`L. X^`X56CJ$OJQJo(.0 ^`56o(1.9.pLp^p`L.@ @ ^@ `.^`.L^`L.^`.^`.PLP^P`L.1u c7i16oU4 x:}|z#faJUT$..<lGQuG,_oF4{5%[5 HX xoTR>q% ,d&M5;Ph~:SFCE~}|(t%nY%^K0{^5\=XHzoFP @P^`PCJOJQJo(s @ OJQJo(00H